Source file signed link, expires in 15 minutes
Extracted text 366
Page 1
Positioned for Profitable Growth PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 1
Page 2
Positioned for
Profitable Growth
2 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 3
Positioned for
Profitable Growth
Sanggahan Dan Batasan Tanggung Jawab
Disclaimer and Scope of Responsibility
Laporan Tahunan PT Millennium Pharmacon The 2025 Annual Report of PT Millennium
International Tbk Tahun 2025 disusun Pharmacon International Tbk has been
dengan mengacu pada ketentuan peraturan prepared in accordance with the applicable
perundang-undangan yang berlaku di laws and regulations in Indonesia, specifically
Indonesia, khususnya Peraturan Otoritas Jasa Financial Services Authority Regulation No.
Keuangan No. 29/POJK.04/2016 tentang Laporan 29/POJK.04/2016 concerning Annual Reports
Tahunan Emiten atau Perusahaan Publik serta of Issuers or Public Companies and Financial
Surat Edaran Otoritas Jasa Keuangan No. 16/ Services Authority Circular Letter No. 16/SEOJK.
SEOJK.04/2021 tentang Bentuk dan Isi Laporan 04/2021 concerning the Form and Content of
Tahunan Emiten atau Perusahaan Publik. Annual Reports of Issuers or Public Companies.
Laporan Tahunan ini memuat informasi This Annual Report contains information on the
mengenai kondisi keuangan, hasil usaha, Company’s financial condition, business results,
kebijakan strategis, rencana pengembangan strategic policies, business development plans,
usaha, proyeksi, strategi, serta tujuan projections, strategies, and objectives. A number
Perseroan. Sejumlah pernyataan dalam of statements in this report contain forward-
laporan ini mengandung pandangan looking statements based on reasonable
ke depan yang disusun berdasarkan assumptions, estimates, and projections, taking
asumsi, estimasi, serta proyeksi yang wajar into account current conditions, expected
dengan mempertimbangkan kondisi developments, and the business environment
terkini, perkembangan yang diharapkan, in which the Company operates. Therefore,
dan lingkungan usaha tempat Perseroan actual results in the future may differ from those
menjalankan kegiatan usahanya. Oleh expressed or implied in these forward-looking
karena itu, hasil aktual di masa mendatang statements, depending on business dynamics,
dapat berbeda dari yang diungkapkan atau regulatory changes, market conditions, and
tersirat dalam pernyataan prospektif tersebut, other factors beyond the Company’s control.
bergantung pada dinamika bisnis, perubahan
regulasi, kondisi pasar, dan faktor lain di luar
kendali Perseroan.
Dalam Laporan Tahunan ini, istilah “MPI” dan In this Annual Report, the terms “MPI” and “the
“Perseroan” merujuk pada PT Millennium Company” refer to PT Millennium Pharmacon
Pharmacon International Tbk. Adapun International Tbk. The use of the word “we” is
penggunaan kata “Kami” dimaksudkan intended solely for the convenience of referring
semata-mata untuk kemudahan penyebutan to the Company in general. This report is
Perseroan secara umum. Laporan ini disajikan presented in Indonesian and English, and can
dalam Bahasa Indonesia dan Bahasa Inggris, be accessed through the Company’s official
serta dapat diakses melalui situs web resmi website: www.mpi-indonesia.co.id.
Perseroan: www.mpi-indonesia.co.id.
Laporan Tahunan ini dapat dilihat dan diunduh
di website resmi MPI, yaitu
This Annual Report can be viewed and downloaded
on the official MPI website, namely
www.mpi-indonesia.co.id.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 3
Page 4
Positioned for
Profitable Growth
4 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 5
Positioned for
Profitable Growth
Penjelasan Tema
Theme Explanation
Positioned
for Profitable
Growth 2025
Sepanjang tahun 2025, PT Millennium Pharmacon Throughout 2025, PT Millenium Pharmacon International
International Tbk terus memperkuat posisinya di tengah Tbk continues to strengthen its position amidst the
dinamika industri distribusi farmasi dan alat kesehatan dynamics of the increasingly competitive pharmaceutical
yang semakin kompetitif, perubahan pola permintaan and medical device distribution industry, changing
pasar, serta tuntutan efisiensi yang kian tinggi di seluruh market demand patterns, and the growing demand for
rantai pasok. Dalam lanskap usaha yang menuntut efficiency across the entire supply chain. In a business
kecepatan respons sekaligus ketepatan pengelolaan, landscape that demands both responsiveness and
MPI memusatkan perhatian pada penguatan kualitas precise management, MPI focuses on strengthening the
pertumbuhan, dengan memastikan bahwa setiap langkah quality of growth, ensuring that every step of business
pengembangan usaha didukung oleh pengelolaan development is supported by more measured operational
operasional yang lebih terukur, struktur biaya yang lebih management, a more controlled cost structure, and an
terkendali, serta fokus yang semakin tajam pada segmen increasingly sharp focus on segments and services that
dan layanan yang memberikan kontribusi optimal contribute optimally to the Company’s performance.
terhadap kinerja Perseroan.
Arah tersebut tercermin dari upaya Perseroan untuk This direction is reflected in the Company’s efforts
membangun pertumbuhan yang tidak semata bertumpu to build growth that is not solely based on volume
pada peningkatan volume, tetapi juga pada kemampuan increases, but also on the ability to generate better
menghasilkan margin yang lebih baik, menjaga efisiensi, margins, maintain efficiency, and strengthen long-term
dan memperkuat keberlanjutan usaha dalam jangka business sustainability. MPI understands that healthy
panjang. MPI memahami bahwa pertumbuhan yang sehat growth requires a strong position in terms of distribution
memerlukan posisi yang kuat, baik dari sisi kapabilitas capabilities, service reliability, relationships with principals
distribusi, keandalan layanan, hubungan dengan and customers, and organizational readiness to respond
prinsipal dan pelanggan, maupun kesiapan organisasi to market changes. Therefore, throughout the 2025 fiscal
dalam merespons perubahan pasar. Oleh karena itu, year, the Company will continue to improve its business
sepanjang tahun buku 2025, Perseroan terus membenahi foundations to become more adaptive, selective in
fondasi bisnisnya agar semakin adaptif, selektif dalam capturing opportunities, and consistent in creating added
menangkap peluang, dan konsisten menciptakan nilai value.
tambah.
Melalui posisi yang semakin terarah, MPI menempatkan Through its increasingly focused position, MPI places
profitabilitas sebagai orientasi penting dalam setiap profitability as an important orientation in every business
pengambilan keputusan bisnis. Langkah ini menjadi decision. This step is relevant given the Company’s need
relevan seiring kebutuhan Perseroan untuk menjaga to maintain a balance between revenue expansion,
keseimbangan antara ekspansi pendapatan, efektivitas operational effectiveness, asset quality, and financial
operasional, kualitas aset, dan ketahanan keuangan. resilience. With this foundation, MPI is entering a more
Dengan pijakan tersebut, MPI bergerak memasuki fase mature growth phase, where strengthening its business
pertumbuhan yang lebih matang, di mana penguatan position will serve as the basis for generating more
posisi usaha menjadi landasan untuk menghasilkan sustainable, competitive, and valuable performance for
kinerja yang lebih berkelanjutan, kompetitif, dan bernilai all stakeholders.
bagi seluruh pemangku kepentingan.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 5
Page 6
Positioned for
Profitable Growth
Daftar Isi
Table of Contents
Sanggahan dan Batasan Tanggung Jawab
Disclaimer and Scope of Responsibility
3 Profil Direksi
76
Board of Directors Profile
Penjelasan Tema
Theme Explanation
5 Dewan Komisaris
80
Board of Commissioners
Daftar Isi
Table of Contents
6 Direksi & Tim Manajemen
82
Board of Directors & Management Team
Ikhtisar Kinerja 2025
2025 Performance Highlights 01 Kepala Cabang
Branch Manager
84
Ikhtisar Data Keuangan Penting Demografi Karyawan
10 Employee Demographics
86
Key Financial Data Highlights
Ikhtisar Kinerja Operasional Struktur dan Komposisi Pemegang Saham
14 Shareholder Structure and Composition
88
Highlights of Operating Performance
Ikhtisar Kinerja Keberlanjutan Informasi Kepemilikan Saham Perusahaan
Sustainability Overview
15 oleh Dewan Komisaris dan Direksi
Share Ownership by The Board of
89
Informasi tentang Obligasi, Sukuk atau Obligasi Konversi, Commissioners and Board of Directors
serta Pendanaan Lainnya
Information on Bonds, Sukuk or Convertible Bonds, and Other
17 Informasi Tentang Pemegang Saham Utama/Pengendali
Funding Perusahaan 90
Information Regarding Major and Controlling Shareholders
Penghentian Sementara Perdagangan Saham (Suspension)
dan/atau Penghapusan Pencatatan Saham (Delisting) Kronologi Penerbitan dan/atau Pencatatan Saham
17 Chronology of Issuance and/or Listing Of Share
91
Temporary Suspension of Stock Trading (Suspension) and/or
Delisting of Stock Listing Kronologi Penerbitan dan/atau
Penghargaan dan Sertifikasi Pencatatan Efek Lainnya 93
Awards and Certifications
18 Chronology of Issuance and/or Listing of Other Securities
Kilas Peristiwa 2025 Struktur Grup Perusahaan
19 Company Group Structure
93
Event on 2025
Entitas Anak dan Entitas Asosiasi
Laporan Manajemen 94
Management Report 02 Subsidiaries and Associations
Akuntan Publik dan Kantor Akuntan Publik
Laporan Dewan Komisaris Public Accountant and Public Accounting Firm
94
Board of Commissioners’ Report
22
Lembaga dan/atau Profesi Penunjang
Laporan Direksi Supporting Institutions/Professions
95
Board of Directors’ Report
32
Informasi Website Perusahaan
Surat Pernyataan Anggota Dewan Komisaris dan Direksi Company Website Information
96
Tentang Tanggung Jawab atas Laporan Tahunan dan
Laporan Keberlanjutan Tahun 2025 Analisis & Pembahasan Manajemen
PT Millennium Pharmacon International Tbk
48 Management Discussion& Analysis 04
Board of Commissioners’ and Board of Directors’ Statement
Regarding Responsibility for the 2025 Annual Report Tinjauan Makroekonomi
and Sustainability Report of PT Millennium Pharmacon Macroeconomic Overview
100
International Tbk
Tinjauan Industri dan Posisi Perseroan dalam Industri
Industry Overview and the Company’s Position in the Industry
101
Profil Perusahaan
Company Profile 03 Tinjauan Operasi Per Segmen Usaha
Operations Overview by Business Segment
102
Identitas dan Informasi Umum Perusahaan
Corporate Identity and General Information
52 Tinjauan Keuangan
Financial Overview
105
Riwayat Singkat Perusahaan
A Brief History of The Company
53 Kemampuan Membayar Utang dan Kolektibilitas Piutang
Debt Repayment Ability and Receivables Collectibility
111
Visi, Misi, dan Budaya Perusahaan
Vision, Mission, And Corporate Culture
55 Struktur Modal dan Kebijakan Manajemen atas Struktur
Modal
Kegiatan Usaha Capital Structure and Management Policy on Capital
113
Business Activities
57
Structure
Rantai Nilai dan Hubungan Bisnis Lainnya Ikatan Material untuk Investasi Barang Modal
Value Chain and Other Business Relationships
60 114
Material Commitments for Capital Expenditure
Perubahan yang Bersifat Signifikan Realisasi Investasi Barang Modal
Significant Changes
61 114
Realization of Capital Expenditure
Wilayah Operasional dan Informasi Jaringan Kantor Cabang Informasi dan Fakta Material yang terjadi Setelah Tanggal
Operational Area and Branch Network Information
62
Laporan Akuntan
Material Information and Facts Subsequent to the Date of the
114
Keanggotaan Pada Asosiasi
Association Membership
66 Accountant's Report
Perbandingan antara Target dan Realisasi Serta Proyeksi
Struktur Organisasi
68 untuk 1 (Satu) Tahun ke Depan
Organization Structure
Comparison between Targets and Realizations as well as
115
Profil Dewan Komisaris Projections for the Next 1 (One) Year
Board of Commissioners Profile
70
6 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 7
Positioned for
Profitable Growth
Kebijakan Dividen dan Pembagiannya Akses Informasi dan Data Perseroan
Dividend Policy and Distribution
116 Access to Company Information and Data
187
Realisasi Penggunaan Dana Hasil Penawaran Umum Kode Etik
Realization of the Use of Proceeds from Public Offering
117 Code of Conduct
188
Informasi Material Mengenai Investasi, Ekspansi, Divestasi, Kebijakan Pengungkapan Informasi Kepemilikan Saham
Penggabungan/ Peleburan Usaha, Akuisisi, Restrukturisasi Anggota Direksi dan Anggota Dewan Komisaris
Utang/Modal Policy on Disclosure of Information on Share Ownership of 190
Material Information on Investment, Expansion, Divestment,
117 Members of the Board of Directors and Members of the
Merger/Business Consolidation, Acquisition, and Debt/Capital Board of Commissioners
Restructuring
Kebijakan Pemberian Kompensasi Jangka Panjang Berbasis
Informasi Transaksi Material yang Mengandung Benturan Kinerja kepada Manajemen dan/atau Karyawan
Kepentingan dan/atau Transaksi dengan Pihak Afiliasi Policy on Performance-Based Long-Term Compensation for
191
Material Transactions Involving Conflicts of Interest and/or
118 Management and/or Employees
Transactions with Affiliated Parties
Sistem Pelaporan Pelanggaran
Perpajakan Whistleblowing System
192
Taxation
120
Kebijakan Anti Korupsi dan Anti Gratifikasi
Perubahan Peraturan Perundang-undangan yang Anti-Corruption and Anti-Gratification Policy
194
Berdampak Signifikan Terhadap Perseroan
Changes in Laws and Regulations with a Significant
120 Laporan Keberlanjutan
Impact on the Company Sustainability Report 06
Perubahan Kebijakan Akuntansi dan Dampaknya Terhadap Standar Pelaporan
Perseroan Reporting Standards
202
Changes in Accounting Policies and The Impact on the
120
Company Prinsip Pelaporan
Reporting Principles
203
Aspek Pemasaran
Marketing Aspects
121
Entitas yang dimasukan dalam Laporan
Entities Included in the Report
203
Prospek Usaha
Business Prospects
122
Periode Pelaporan, Frekuensi, dan Titik Kontak Pelaporan
Reporting Period, Frequency, and Contact Point
204
Informasi Kelangsungan Usaha
Information on Going Concern
124
Penyajian Kembali (Restatement) Informasi
Restatement of Information
204
Tata Kelola Perusahaan
Good Corporate Governance 05 Proses Penentuan Topik Material
205
Process to Determine Material Topics
Komitmen dan Kebijakan Penerapan Tata Kelola
128 Inisiatif Strategis Keberlanjutan
Commitment and Policy on Governance Implementation
Strategic Sustainability Initiatives
214
Rapat Umum Pemegang Saham
132 Tata Kelola Keberlanjutan
General Meeting of Shareholders
Sustainability Governance
218
Dewan Komisaris
138 Kinerja Ekonomi
Board of Commissioners
Economic Performance
226
Komisaris Independen
144 Kinerja Lingkungan
Independent Commissioner
Environmental Performance
230
Direksi
146 Kinerja Sosial
Board of Directors
Social Performance
240
Transparansi Informasi Dewan Komisaris dan Direksi
Verifikasi Tertulis dari Pihak Independen
Transparency of Information of the Board of Commissioners 153 Written Verification from Independent Parties
250
and Directors
Lembar Umpan Balik
Komite Audit 251
Audit Committee
159 Feedback Sheet
Tanggapan Terhadap Umpan Balik Laporan Tahun
Komite Nominasi dan Remunerasi
Nomination and Remuneration Committee
166 Sebelumnya 252
Response to Feedback Seet the Prior Year
Komite Manajemen Risiko
Risk Management Committee
170 Daftar Pengungkapan Sesuai Peraturan Otoritas Jasa
Keuangan No. 51/POJK.03/2017 Tentang Penerapan Keuangan
Organ Pendukung Direksi Berkelanjutan Bagi Lembaga Jasa Keuangan, Emiten dan
Supporting Organs of The Board of Directors
171 Perusahaan Publik
List of Disclosures in Accordance with Financial Services
253
Akuntan Publik Authority Regulation No. 51/POJK.03/2017 Regarding the
Public Accountant
179 Implementation of Sustainable Finance for Financial Services
Institutions, Issuers, and Public Companies
Sistem Pengendalian Internal
Internal Control System
181 Indeks Standar GRI
GRI Standards Index
257
Manajemen Risiko
183
Risk Management Laporan Keuangan
Perkara Hukum Financial Report 07
Legal Matters
186
Informasi Sanksi Administrasi
Administrative Sanctions
186
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 7
Page 8
Laporan Manajemen Positioned for
Management Report Profitable Growth
01
Ikhtisar
Kinerja 2025
2025 Performance
Highlights
8 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 9
Positioned for Profitable Growth PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 9
Page 10
Ikhtisar Kinerja 2025 Positioned for
2025 Performance Highlights Profitable Growth
Ikhtisar Data Keuangan Penting
Key Financial Data Highlights
(Dalam Jutaan Rupiah, kecuali dinyatakan lain)
(Expressed in Million Rupiah, unless otherwise stated)
Uraian
2025 2024 2023
Description
Laporan Laba (Rugi) dan Penghasilan Komprehensif Lain Konsolidasian
Consolidated Statements of Profit or Loss and Other Comprehensive Income
Penjualan Bersih
4.109.810 3.916.864 3.363.518
Total Net Sales
Laba Bruto
362.359 334.377 292.346
Gross Profit
Laba Usaha
113.537 96.434 105.398
Operating Profit
Laba sebelum Pajak Penghasilan
48.897 27.701 47.961
Profit Before Tax
Laba (Rugi) Tahun Berjalan/Laba yang dapat diatribusikan
38.466 16.914 33.081
Profit (Loss) for the Year/ Attributable Profit
Laba Komprehensif yang dapat Diatribusikan
35.454 7.969 21.349
Attributable Comprehensive Profit
Jumlah Saham yang Beredar
1.274 1.274 1.274
Number of Shares
Laba per Saham
30,20 13,29 25,97
Net Income per Share
Laporan Posisi Keuangan
Statements of Financial Position
Total Aset
1.960.720 1.771.857 1.639.682
Total Assets
Piutang Usaha
812.002 731.940 659.684
Trade Receivables
Persediaan
609.092 567.732 535.874
Inventory
Aset Tetap - Bersih
109.085 80.866 77.248
Fixed Assets - Net
Aset Tak Berwujud - Bersih
6.995 7.779 9.142
Intangible Assets - Net
Total Aset Lancar
1.718.942 1.563.794 1.447.652
Total Current Asset
Total Aset Tidak Lancar
241.778 208.063 192.030
Total Non-Current Asset
Total Liabilitas
1.645.317 1.489.360 1.361.969
Total Liabilities
Total Liabilitas Jangka Pendek
1.555.871 1.413.417 1.287.000
Total Current Liabilities
10 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 11
Positioned for
Profitable Growth
(Dalam Jutaan Rupiah, kecuali dinyatakan lain)
(Expressed in Million Rupiah, unless otherwise stated)
Uraian
2025 2024 2023
Description
Total Liabilitas Jangka Panjang
89.446 75.943 74.968
Total Non-Current Liabilities
Modal Kerja - Bersih
163.071 150.377 160.652
Net Working Capital
Ekuitas – Bersih
315.403 282.497 277.713
Equity- Net
Laporan Arus Kas
Statements of Cash Flow
Kas Neto (Digunakan)/Diperoleh untuk Aktivitas Operasi
88.096 (125.451) (91.653)
Net Cash (Used In)/Provided by Operating Activities
Kas Neto (Digunakan)/Diperoleh untuk Aktivitas Investasi Net Cash
(49.975) (13.921) (5.521)
(Used In)/Provided by Investing Activities
Kas Neto (Digunakan)/Diperoleh untuk Aktivitas Pendanaan
(28.751) 133.945 130.405
Net Cash (Used In)/Provided by Financing Activities
Kenaikan/(Penurunan) Neto Kas dan Bank
9.370 (5.427) 33.231
Net Increase/(Decrease) in Cash on Hand and in Banks
Kas dan Bank Awal Tahun
53.473 58.900 25.668
Cash on Hand and in Banks at Beginning of Year
Kas dan Bank Akhir Tahun
62.843 53.473 58.900
Cash on Hand and in Banks at End of Year
Rasio Keuangan
Financial Ratio
Likuiditas
Liquidity
Rasio Lancar
110% 111% 112%
Current Ratio
Acid Test Ratio
71% 70% 71%
Acid Test Ratio
Aktivitas
Activity
Perputaran Piutang
532% 563% 558%
Receivable Turnover
Perputaran Persediaan
675% 690% 628%
Inventory Turnover
Perputaran Aset Tetap
3.768% 4.843% 4.354%
Fixed Asset Turnover
Perputaran Total Aset
210% 221% 205%
Total Assets Turnover
Solvabilitas
Solvability
Rasio Liabilitas Jangka Panjang terhadap Ekuitas
28% 27% 27%
Long-Term Liabilities to Equity Ratio
Rasio Liabilitas terhadap Ekuitas
522% 527% 490%
Liabilities to Equity Ratio
Rasio Liabilitas terhadap Total Aset
84% 84% 83%
Liabilities to Asset Ratio
Debt Service
7% 6% 8%
Coverage Ratio
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 11
Page 12
Ikhtisar Kinerja 2025 Positioned for
2025 Performance Highlights Profitable Growth
(Dalam Jutaan Rupiah, kecuali dinyatakan lain)
(Expressed in Million Rupiah, unless otherwise stated)
Uraian
2025 2024 2023
Description
Profitabilitas
Profitability
Rasio Laba (Rugi) Bersih terhadap Aset
2% 1% 2%
Total Asset Return on Assets
Rasio Laba (Rugi) Bersih terhadap Ekuitas
12% 6% 12%
Return on Equity
Rasio Laba (Rugi) Bersih terhadap Investasi
0% 0% 0%
Return on Invesment
Rasio Laba (Rugi)Bersih terhadap Sales
1% 0% 1%
Return on Sales
GRAFIK IKHTISAR KINERJA KEUANGAN
FINANCIAL PERFORMANCE OVERVIEW CHART
Total Aset Total Liabilitas
Total Assets Total Liabilities
(dalam jutaan Rupiah | in million Rupiah) (dalam jutaan Rupiah | in million Rupiah)
1.960.720
1.645.317
1.489.360
1.771.857
1.361.969
1.639.682
2023 2024 2025 2023 2024 2025
Ekuitas Laba Bruto
Equity Gross Profit
(dalam jutaan Rupiah | in million Rupiah) (dalam jutaan Rupiah | in million Rupiah)
315.403
362.359
292.346
292.346
282.497
277.713
2023 2024 2025 2023 2024 2025
12 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 13
Positioned for
Profitable Growth
Laba Usaha Laba Tahun Berjalan
Operating Profit Profit for The Year
(dalam jutaan Rupiah | in million Rupiah) (dalam jutaan Rupiah | in million Rupiah)
113.537
38.466
105.398
33.081
96.434
16.914
2023 2024 2025 2023 2024 2025
Rasio Lancar Acid Test Ratio
Current Ratio Acid Test Ratio
(dalam % | in %) (dalam % | in %)
112%
111%
110%
71%
71%
70%
2023 2024 2025 2023 2024 2025
Perputaran Total Aset
Total Assets Turnover
(dalam % | in %)
221%
210%
205%
2023 2024 2025
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 13
Page 14
Ikhtisar Kinerja 2025 Positioned for
2025 Performance Highlights Profitable Growth
Ikhtisar Kinerja Operasional
Highlights of Operating Performance
Uraian
2025 2024 2023
Description
Segmen Usaha
Business Segments
Obat Resep
2.887.792 2.761.107 2.321.400
Prescription Medicine
Alat kesehatan
1.078.183 949.673 846.588
Medical Disposables
Obat non-resep
143.452 205.937 195.443
Non-prescription medicine
Lainnya
383 147 87
Others
Jumlah
4.109.810 3.916.864 3.363.518
Total
Segmen Geografis
Geographic Segments
Jawa 2.441.099 2.365.197 2.008.070
Sumatra 903.426 846.075 749.346
Kalimantan 332.020 294.381 237.040
Sulawesi 227.048 217.319 205.343
Bali & Lombok 206.217 193.892 163.719
Jumlah
4.109.810 3.916.864 3.363.518
Total
14 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 15
Positioned for
Profitable Growth
Ikhtisar Kinerja Keberlanjutan
Sustainability Overview
Uraian
2025 2024 2023
Description
Kinerja Ekonomi [OJK B.1] [201-1]
Economic Performance
Total Pendapatan dari Kegiatan Operasi dan Usaha (dalam jutaan Rupiah)
4.109.810 3.916.864 3.363.518
Total Revenues from operations and Business (in million Rupiah)
Pelibatan Pemasok Lokal (Prinsipal)
29 32 35
Involvement of Local Supplier (Principles)
Laba (Rugi) Tahun Berjalan/Laba yang dapat diatribusikan
(dalam jutaan Rupiah) 38.466 16.914 33.081
Profit (Loss) for the Year/ Attributable Profit (in million Rupiah)
Total Aset (dalam jutaan Rupiah)
1.960.720 1.771.857 1.639.682
Total Assets (in million Rupiah)
Kinerja Lingkungan [OJK B.2]
Environment Overview
Petrol
Liter 587.770,06 607.155,18 626.418,85
Gigajoules 19.268,28 20.764,71 21.423,52
Penggunaan Listrik
Energy Consumption
kWh 2.638.910 2.729.272,58 2.023.531,59
Gigajoules 9.500,08 9.825,38 7.284,71
Konsumsi Air (m3)
6.861 7.285 10.464
Water Consumption (m3)
Pelestarian Keanekaragaman Hayati (Spesies)
NA NA NA
Biodiversity Preservation (Species)
Kinerja Sosial [OJK B.3]
Social Overview
Total Karyawan (orang)
1.197 1.181 1.154
Total Employees (person)
Total Karyawan Wanita (orang)
293 282 273
Total Female Employees (person)
Turnover Pegawai (%)
1,28 1,35 1,07
Employee Turnover (%)
Dana CSR/PKBL (dalam jutaan Rupiah)
289,58 43,86 357,35
CSR/Community Development Program Budget (in million Rupiah)
Jumlah Kecelakaan Kerja (Kasus)
5 1 5
Number of Work Accidents (case)
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 15
Page 16
Ikhtisar Kinerja 2025 Positioned for
2025 Performance Highlights Profitable Growth
AKSI KORPORASI CORPORATE ACTION
Hingga akhir tahun 2025, Perseroan tidak melakukan Until the end of 2025, the Company did not conduct
aksi korporasi berupa pemecahan saham (stock split), corporate actions in the form of stock splits, reverse stock
penggabungan saham (reverse stock), saham bonus, combinations, bonus shares, changes in the nominal value
perubahan nilai nominal saham, penerbitan efek konversi of shares, issuance of convertible securities and capital
serta penambahan dan pengurangan modal. increases and decreases.
INFORMASI SAHAM STOCK INFORMATION
Tabel Ikhtisar Saham
Stock Overview Table
Harga per Saham Jumlah Saham
Volume Transaksi
Price per Share Beredar Kapitalisasi Pasar
(lembar)
(Rp) (lembar) Market
Periode Transaction
Total Capitalisation
Terendah Tertinggi Penutupan Volume
Outstanding (Rp)
Lowest Highest Closing (share)
Shares (share)
2025
Q1 116 138 126 1.274.000.000 2.514.100 160.524.000.000
Q2 114 146 127 1.274.000.000 15.940.300 161.798.000.000
Q3 125 143 137 1.274.000.000 8.079.800 174.538.000.000
Q4 132 187 155 1.274.000.000 74.415.500 197.470.000.000
2024
Q1 135 170 145 1.274.000.000 4.169.600 184.730.000.000
Q2 121 175 131 1.274.000.000 7.624.900 166.894.000.000
Q3 125 150 137 1.274.000.000 28.109.000 174.538.000.000
Q4 124 183 132 1.274.000.000 14.051.800 168.168.000.000
16 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 17
Positioned for
Profitable Growth
Informasi tentang Obligasi, Sukuk atau Obligasi
Konversi, serta Pendanaan Lainnya
Information on Bonds, Sukuk or Convertible Bonds, and
Other Funding
Hingga akhir tahun 2025, Perseroan tidak menerbitkan Until the end of 2025, the Company has never issued
obligasi, sukuk, dan obligasi konversi. bonds, sukuk, and convertible bonds.
Penghentian Sementara Perdagangan Saham
(Suspension) dan/atau Penghapusan Pencatatan
Saham (Delisting)
Temporary Suspension of Stock Trading (Suspension) and/or
Delisting of Stock Listing
Sepanjang tahun 2025, Perseroan tidak mengalami Throughout 2025, the Company did not experience
penghentian perdagangan saham sementara any suspension from the Stock Exchange so there is no
( suspension ) dari Bursa, sehingga tidak terdapat explanation regarding this matter.
penjelasan terkait hal tersebut.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 17
Page 18
Ikhtisar Kinerja 2025 Positioned for
2025 Performance Highlights Profitable Growth
Penghargaan dan Sertifikasi
Awards and Certifications
PENGHARGAAN AWARDS IN 2025
Kategori Sektor Konsumen Premier Small Cap
Category Premier Consumer Sector Small Cap
Best Stock Award 2025 25 Februari 2025
February 25, 2025
Jakarta
Kegiatan Donor Darah Rutin selama tahun 2024
Piagam Penghargaan Palang Merah Routine Blood Donation Activities throughout 2024
Indonesia (PMI)
18 Juli 2025
Certificate of Appreciation from the Indonesian July 18, 2025
Red Cross (PMI)
Semarang
SERTIFIKASI CERTIFICATION
Jenis Sertifikat Dikeluarkan Oleh
Certificate Types Issued By
CDOB – Cara Distribusi Obat yang Baik
Badan POM RI
CDOB – Good Distribution Practice for Medicines
CDAKB – Cara Distribusi Alat Kesehatan yang Baik
Badan POM RI
CDAKB – Good Distribution Practice for Medical Devices
ISO 37001 – Sistem Manajemen Anti Penyuapan BSC Mutu International
ISO 37001 – Anti-Bribery Management System Masa berlaku | Validity period: 2024 -2028
ISO 9001:2015 – Sistem Manajemen Mutu British Standard International (BSI)
ISO 9001:2015 – Quality Management System Masa berlaku | Validity period: 2025 -2028
18 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 19
Positioned for
Profitable Growth
Kilas Peristiwa 2025
Event on 2025
RAPAT KERJA NASIONAL 2025 RAPAT UMUM PEMEGANG SAHAM TAHUNAN 2025
NATIONAL WORKING MEETING 2025 2025 ANNUAL GENERAL MEETING OF SHAREHOLDERS
Tema: The Way Forward 28 Mei 2025 | May 28, 2025
Malang, 21-24 Januari 2025 Artotel Gelora Senayan Hotel, Jakarta
Theme: The Way Forward Artotel Gelora Senayan Hotel, Jakarta
Malang City, January 2- 24, 2025
PERESMIAN GEDUNG BARU (RELOKASI) CABANG DENPASAR GEDUNG BARU (RELOKASI) CABANG BEKASI RESMI BEROPERASI
INAUGURATION OF NEW BUILDING (RELOCATION) NEW BUILDING (RELOCATION) OF BEKASI BRANCH OFFICIALLY
OF DENPASAR BRANCH OPERATES
29 Juli 2025 | July 29, 2025 20 Oktober 2025 | October 20, 2025
Jl. Cargo Indah No. 10, Ubung, Denpasar Utara, Kota Denpasar Jl. Raya Kampung Setu No 28 B, Bintara Jaya, Bekasi Barat,
Jl. Cargo Indah No. 10, Ubung, North Denpasar, Denpasar City Kota Bekasi
Jl. Raya Kampung Setu No 28 B, Bintara Jaya, Bekasi Barat,
Kota Bekasi
PERESMIAN KANTOR CABANG PALU PAPARAN PUBLIK
INAUGURATION OF PALU BRANCH OFFICE PUBLIC DISCLOSURE
12 November 2025 | 12 November 2025 4 Desember 2025 | December 4, 2025
Jl. Merdeka No. 5, Talise Valangguni, Mantikulore, Kota Palu Online Meeting
Jl. Merdeka No. 5, Talise Valangguni, Mantikulore, Kota Palu Online Meeting
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 19
Page 20
Laporan Manajemen Positioned for
Management Report Profitable Growth
02
Laporan
Manajemen
Management Report
20 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 21
Positioned for Profitable Growth PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 21
Page 22
Laporan Manajemen Positioned for
Management Report Profitable Growth
Laporan Dewan Komisaris
Board of Commissioners’ Report
Joefly Joesoef Bahroeny
Komisaris Utama dan
Komisaris Independen
President Commissioner and
Independent Commissioner
22 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 23
Positioned for
Profitable Growth
Para Pemegang Saham dan Pemangku Kepentingan yang Terhormat,
Honorable Shareholders and Stakeholders,
Puji syukur kami panjatkan ke hadirat Tuhan Yang Maha We extend our gratitude to Almighty God for His
Esa, atas rahmat dan karunia-Nya, sehingga Perseroan blessings and grace, which have enabled the Company
dapat melalui tahun buku 2025 dengan menjaga arah to navigate the fiscal year 2025 while maintaining a
pertumbuhan yang berkelanjutan di tengah intensitas sustainable growth trajectory amid intensifying industry
persaingan industri yang semakin meningkat. Dalam competition. On this occasion, on behalf of the Board of
kesempatan ini, atas nama Dewan Komisaris PT Millennium Commissioners of PT Millennium Pharmacon International
Pharmacon International Tbk, kami menyampaikan Tbk, we hereby present our report on the implementation
laporan pelaksanaan fungsi pengawasan dan pemberian of our supervisory and advisory functions concerning
nasihat atas perkembangan dan pengelolaan Perseroan the development and management of the Company
sepanjang tahun buku 2025. throughout fiscal year 2025.
Dewan Komisaris mencermati dinamika eksternal The Board of Commissioners closely observed the external
yang memengaruhi industri serta faktor internal yang dynamics affecting the industry as well as the internal
menentukan ketahanan operasional Perseroan. Di factors determining the Company’s operational resilience.
tengah kompetisi yang kian ketat, Perseroan tetap Amid increasingly intense competition, the Company was
mampu mempertahankan momentum pertumbuhan, able to maintain its growth momentum, including through
termasuk melalui penguatan jangkauan layanan dengan strengthening its service coverage with the opening of
pembukaan cabang Palu yang kami pandang sebagai the Palu branch, which we consider a strategic step to
langkah strategis untuk memperluas potensi pasar pada expand market potential in the coming periods.
periode mendatang.
Dalam konteks dinamika tersebut, Dewan Komisaris In this dynamic environment, the Board of Commissioners
menempatkan pengawasan pada dua hal yang saling focused its oversight on two mutually reinforcing aspects:
menguatkan: ketepatan arah strategis dan ketahanan the appropriateness of strategic direction and the resilience
eksekusi. Sepanjang tahun 2025, pengawasan difokuskan of execution. Throughout 2025, our supervision emphasized
pada konsistensi penerapan strategi, kualitas pengelolaan the consistent implementation of strategy, the quality of
kinerja, serta penguatan tata kelola, termasuk efektivitas performance management, and the strengthening of
pengendalian internal, penerapan manajemen risiko, dan corporate governance, including the effectiveness of internal
integritas proses bisnis, agar pertumbuhan Perseroan controls, the implementation of risk management, and the
berlangsung sehat, terukur, dan berkelanjutan. integrity of business processes, to ensure that the Company’s
growth remains sound, measurable, and sustainable.
PANDANGAN DEWAN KOMISARIS THE BOARD OF COMMISSIONERS’
TERKAIT PERKEMBANGAN VIEW ON THE COMPANY’S
PERSEROAN DI TAHUN 2025 DEVELOPMENT IN 2025
Dewan Komisaris memandang bahwa sepanjang tahun The Board of Commissioners views that throughout fiscal
buku 2025 Perseroan menunjukkan perkembangan yang year 2025, the Company demonstrated constructive
konstruktif dan terarah. Di tengah meningkatnya intensitas and well-directed progress. Amid intensifying industry
kompetisi industri, Perseroan tetap mampu menjaga competition, the Company was able to maintain a
arah pertumbuhan yang berkelanjutan, tercermin dari sustainable growth trajectory, as reflected in the increase
peningkatan pendapatan dan profitabilitas dibandingkan in revenue and profitability compared to the previous year,
tahun sebelumnya sebagaimana diuraikan pada bagian as described in the financial and operational performance
kinerja keuangan dan operasional dalam Laporan section of this Annual Report. The Board of Commissioners
Tahunan ini. Dewan Komisaris menilai capaian tersebut considers these achievements to reflect the consistency
merefleksikan konsistensi Direksi dalam mengeksekusi of the Board of Directors in executing the strategy, as
strategi, serta kemampuan organisasi menjaga disiplin well as the organization’s ability to maintain operational
operasional dan kualitas layanan. discipline and service quality.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 23
Page 24
Laporan Manajemen Positioned for
Management Report Profitable Growth
Dari sisi internal, Dewan Komisaris mencermati penguatan From an internal perspective, the Board of Commissioners
jaringan distribusi melalui pembukaan cabang Palu observed the strengthening of the distribution network
sebagai langkah yang relevan untuk memperluas through the opening of the Palu branch as a relevant
jangkauan layanan dan menangkap potensi pasar di step to expand service coverage and capture market
wilayah strategis. Inisiatif ini dinilai memperkuat fondasi potential in a strategic region. This initiative is considered
pertumbuhan Perseroan, seiring meningkatnya kebutuhan to reinforce the Company’s growth foundation, in line
pelanggan atas layanan distribusi yang andal dan with the increasing customer demand for reliable and
responsif. responsive distribution services.
Dari sisi eksternal, persaingan yang semakin kompetitif From an external perspective, increasingly competitive
menuntut ketangkasan dalam menjaga mutu layanan, market conditions require agility in maintaining service
ketepatan pemenuhan permintaan, serta efisiensi quality, accuracy in fulfilling demand, and efficiency in cost
pengelolaan biaya. Dalam konteks tersebut, Dewan management. In this context, the Board of Commissioners
Komisaris menilai Perseroan mampu merespons dinamika believes that the Company has been able to respond
industri secara adaptif, menjaga kesinambungan kinerja, adaptively to industry dynamics, maintain performance
serta tetap menempatkan kepatuhan dan kehati-hatian sustainability, and consistently uphold compliance and
sebagai landasan pengambilan keputusan. prudence as the foundation of its decision-making
process.
PENILAIAN DEWAN KOMISARIS ASSESSMENT OF THE BOARD OF
TERHADAP KINERJA DIREKSI MENGENAI COMMISSIONERS ON THE PERFORMANCE
PENGELOLAAN PERSEROAN OF THE BOARD OF DIRECTORS IN
MANAGING THE COMPANY
Dewan Komisaris menilai bahwa Direksi telah The Board of Commissioners assesses that the Board
melaksanakan tugas dan tanggung jawab pengurusan of Directors has properly carried out its duties and
Perseroan sepanjang tahun buku 2025 dengan baik. responsibilities in managing the Company throughout
Penilaian ini didasarkan pada kemampuan Direksi dalam fiscal year 2025. This assessment is based on the Directors’
merumuskan dan mengeksekusi strategi yang relevan ability to formulate and execute strategies that are relevant
dengan dinamika industri, menjaga stabilitas operasional, to industry dynamics, maintain operational stability, and
serta mengarahkan organisasi untuk mempertahankan steer the organization toward sustaining long-term growth.
pertumbuhan yang berkelanjutan.
Dalam pelaksanaan pengelolaan Perseroan, Direksi In managing the Company, the Board of Directors has
mampu menjaga keseimbangan antara pencapaian been able to maintain a balance between achieving
target kinerja dan penerapan prinsip kehati-hatian, performance targets and applying prudential principles,
termasuk melalui penguatan tata kelola, kepatuhan, including through the strengthening of governance,
serta pengelolaan risiko pada aktivitas operasional. compliance, and risk management in operational
Dewan Komisaris juga mencermati efektivitas koordinasi activities. The Board of Commissioners also observed
lintas fungsi dan konsistensi tindak lanjut atas masukan the effectiveness of cross-functional coordination and
Dewan Komisaris sebagai bagian dari penguatan kualitas the consistent follow-up on the Board of Commissioners’
pengambilan keputusan manajemen. recommendations as part of enhancing the quality of
management decision-making.
Ke depan, Dewan Komisaris mendorong Direksi untuk Going forward, the Board of Commissioners encourages
terus mempertajam inisiatif peningkatan kinerja melalui the Board of Directors to further sharpen performance
penguatan kapabilitas operasional dan layanan, improvement initiatives through strengthening
peningkatan efisiensi biaya secara terukur, serta operational and service capabilities, enhancing cost
konsistensi penguatan tata kelola dan pengendalian efficiency in a measured manner, and consistently
internal agar kinerja Perseroan tetap terjaga di tengah reinforcing governance and internal controls to ensure
kompetisi yang semakin menantang. that the Company’s performance remains resilient amid
increasingly challenging competition.
24 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 25
Positioned for
Profitable Growth
PENGAWASAN DEWAN KOMISARIS SUPERVISION OF THE BOARD OF
DALAM PERUMUSAN DAN IMPLEMENTASI COMMISSIONERS IN THE FORMULATION
STRATEGI PERSEROAN AND IMPLEMENTATION OF THE
COMPANY’S STRATEGY
Sepanjang tahun buku 2025, Dewan Komisaris Throughout fiscal year 2025, the Board of Commissioners
menjalankan fungsi pengawasan atas perumusan dan carried out its supervisory function over the formulation
implementasi strategi Perseroan melalui koordinasi and implementation of the Company’s strategy through
yang terstruktur bersama Direksi. Keterlibatan Dewan structured coordination with the Board of Directors. The
Komisaris dimulai sejak tahap penelaahan rencana kerja involvement of the Board of Commissioners began at the
dan arah strategis, dengan memberikan pandangan dan stage of reviewing the work plan and strategic direction, by
rekomendasi agar strategi yang disusun Direksi tetap providing views and recommendations to ensure that the
selaras dengan prioritas pertumbuhan Perseroan, tingkat strategies formulated by the Board of Directors remained
kehati-hatian yang memadai, serta dinamika industri aligned with the Company’s growth priorities, an adequate
yang berkembang. level of prudence, and evolving industry dynamics.
Dalam pelaksanaan pengawasan, Dewan Komisaris In performing its oversight role, the Board of Commissioners
memonitor kemajuan implementasi strategi melalui rapat monitored the progress of strategy implementation
berkala bersama Direksi, termasuk pembahasan capaian through regular meetings with the Board of Directors,
kinerja dan isu-isu utama yang memerlukan perhatian including discussions on performance achievements and
manajemen. Dewan Komisaris menelaah konsistensi key issues requiring management’s attention. The Board
eksekusi strategi pada aspek-aspek yang krusial bagi of Commissioners reviewed the consistency of strategy
Perseroan, seperti penguatan jaringan distribusi, kualitas execution in aspects crucial to the Company, such as
layanan dan pemenuhan permintaan pelanggan, strengthening the distribution network, service quality
efektivitas pengelolaan biaya, serta pengendalian risiko and fulfillment of customer demand, effectiveness of cost
dan kepatuhan dalam aktivitas operasional. management, as well as risk control and compliance in
operational activities.
Berdasarkan hasil pengawasan selama tahun berjalan, Based on the results of its supervision throughout
Dewan Komisaris menilai implementasi strategi Perseroan the year, the Board of Commissioners concludes
dilaksanakan secara konsisten dan terarah. Dewan that the Company’s strategy has been implemented
Komisaris juga memastikan bahwa masukan, saran, consistently and in a well-directed manner. The Board of
dan rekomendasi yang disampaikan kepada Direksi Commissioners also ensured that the inputs, advice, and
ditindaklanjuti secara memadai, sehingga pengambilan recommendations conveyed to the Board of Directors were
keputusan strategis tetap berada pada koridor tata adequately followed up, so that strategic decision-making
kelola dan prinsip kehati-hatian, sekaligus mendukung remained within the framework of good governance and
pencapaian target kinerja Perseroan. prudential principles, while supporting the achievement
of the Company’s performance targets.
FREKUENSI DAN MEKANISME FREQUENCY AND MECHANISM
PEMBERIAN NASIHAT OLEH DEWAN FOR PROVIDING ADVICE BY THE
KOMISARIS KEPADA DIREKSI BOARD OF COMMISSIONERS TO
THE BOARD OF DIRECTORS
Dewan Komisaris memberikan nasihat, arahan, dan The Board of Commissioners provides advice, direction,
rekomendasi kepada Direksi melalui mekanisme yang and recommendations to the Board of Directors through
terstruktur dan terdokumentasi. Pemberian nasihat structured and well-documented mechanisms. Such
dilakukan terutama melalui rapat Dewan Komisaris advice is primarily delivered through meetings of the
bersama Direksi sebagai forum utama untuk membahas Board of Commissioners with the Board of Directors,
perkembangan kinerja, implementasi strategi, serta isu- which serve as the main forum to discuss performance
isu yang memerlukan perhatian manajemen. Dalam developments, strategy implementation, and issues
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 25
Page 26
Laporan Manajemen Positioned for
Management Report Profitable Growth
forum tersebut, Dewan Komisaris menyampaikan requiring management’s attention. In these forums, the
pandangan dan masukan untuk memastikan kebijakan Board of Commissioners conveys its views and inputs
dan keputusan Direksi tetap selaras dengan kepentingan to ensure that the policies and decisions of the Board of
jangka panjang Perseroan, memenuhi ketentuan dan Directors remain aligned with the Company’s long-term
perundang-undangan yang berlaku, serta prinsip tata interests, comply with prevailing laws and regulations, and
kelola perusahaan yang baik. adhere to the principles of good corporate governance.
Selain melalui rapat bersama Direksi, Dewan Komisaris In addition to joint meetings with the Board of Directors,
juga menyampaikan nasihat melalui rapat internal the Board of Commissioners also provides advice
Dewan Komisaris, koordinasi dengan komite-komite di through internal meetings of the Board of Commissioners,
bawah Dewan Komisaris, serta komunikasi resmi lainnya coordination with committees under the Board of
apabila diperlukan. Mekanisme ini memungkinkan Commissioners, and other formal communications
Dewan Komisaris memberikan respons yang tepat waktu when necessary. This mechanism enables the Board
terhadap dinamika operasional dan perkembangan of Commissioners to respond in a timely manner to
eksternal, sekaligus memastikan tindak lanjut atas operational dynamics and external developments, while
rekomendasi berjalan secara konsisten. ensuring consistent follow-up on its recommendations.
Sepanjang tahun buku 2025, Dewan Komisaris Throughout fiscal year 2025, the Board of Commissioners
menyelenggarakan 7 (tujuh) kali rapat internal Dewan held 7 (seven) internal meetings of the Board of
Komisaris dan 7 (tujuh) kali rapat Dewan Komisaris Commissioners and 7 (seven) joint meetings of the
bersama Direksi. Pokok pembahasan rapat mencakup Board of Commissioners with the Board of Directors.
antara lain evaluasi kinerja Perseroan dan pencapaian The main agenda items discussed included, among
target, pembahasan rencana kerja dan strategi others, evaluation of the Company’s performance and
Perseroan, penguatan jaringan dan pengembangan target achievements, discussion of the Company’s
pasar (termasuk pengembangan cabang/area layanan), work plans and strategies, network strengthening and
efektivitas pengelolaan biaya dan efisiensi operasional, market development (including branch and service
perkembangan penerapan tata kelola serta kepatuhan, area expansion), effectiveness of cost management and
pengendalian internal dan manajemen risiko, tindak lanjut operational efficiency, progress in the implementation
temuan/audit dan mitigasi risiko utama, serta isu-isu of governance and compliance, internal control and risk
strategis lain yang dipandang perlu untuk memastikan management, follow-up on audit findings and mitigation
kesinambungan kinerja dan ketahanan operasional of key risks, as well as other strategic issues deemed
Perseroan. necessary to ensure the sustainability of performance
and the Company’s operational resilience.
PANDANGAN ATAU TANGGAPAN VIEWS AND RESPONSES OF THE BOARD
DEWAN KOMISARIS ATAS PROSPEK OF COMMISSIONERS ON BUSINESS
USAHA DAN TANTANGAN KE DEPAN PROSPECTS AND FUTURE CHALLENGES
Dewan Komisaris memandang prospek usaha Perseroan The Board of Commissioners views the Company’s
pada tahun 2026 tetap terbuka, sejalan dengan kebutuhan business prospects in 2026 as remaining promising, in
pasar yang terus berkembang dan meningkatnya line with evolving market needs and increasing customer
tuntutan pelanggan atas layanan distribusi yang andal, demands for reliable, responsive, and efficient distribution
responsif, dan efisien. Dengan fondasi jaringan operasional services. With an operational network foundation that
yang terus diperkuat serta konsistensi pengelolaan kinerja continues to be strengthened and consistent performance
sepanjang tahun buku 2025, Dewan Komisaris menilai management throughout fiscal year 2025, the Board
Perseroan memiliki kapasitas untuk merealisasikan target of Commissioners believes that the Company has the
yang telah disusun Direksi. capacity to achieve the targets set by the Board of
Directors.
26 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 27
Positioned for
Profitable Growth
Di sisi lain, Dewan Komisaris mencermati bahwa tantangan On the other hand, the Board of Commissioners observes
pada tahun 2026 akan tetap menuntut ketangkasan dan that challenges in 2026 will continue to require agility
disiplin eksekusi. Tantangan tersebut antara lain mencakup and disciplined execution. These challenges include
meningkatnya intensitas persaingan, tekanan efisiensi intensifying competition, cost efficiency pressures across
biaya di sepanjang rantai distribusi, dinamika kebutuhan the distribution chain, evolving customer needs, and the
pelanggan, serta kebutuhan penguatan pengelolaan increasingly complex requirements for strengthening
risiko dan kepatuhan yang semakin kompleks. Oleh karena risk management and compliance. Therefore, the Board
itu, Dewan Komisaris mendorong Direksi untuk menjaga of Commissioners encourages the Board of Directors
keseimbangan antara pertumbuhan dan kehati-hatian, to maintain a balance between growth and prudence,
memperkuat efektivitas operasional, serta memastikan enhance operational effectiveness, and ensure the
penguatan tata kelola dan pengendalian internal berjalan consistent strengthening of governance and internal
konsisten. controls.
Dewan Komisaris berkomitmen untuk memberikan The Board of Commissioners is committed to providing
pengawasan yang efektif dan terarah kepada Direksi, the Board of Directors with effective and focused oversight.
memastikan strategi dan kebijakan tetap sejalan dengan This ensures that strategies and policies align with the
arah jangka panjang Perseroan, serta mendorong langkah company’s long-term direction and encourages the
mitigasi yang diperlukan agar tantangan dapat dikelola implementation of necessary mitigation measures. These
dengan baik dan kinerja tetap berkelanjutan pada tahun measures allow the Company to manage challenges
2026. properly and maintain sustainable performance in 2026.
PANDANGAN ATAU TANGGAPAN VIEWS AND RESPONSES OF THE
DEWAN KOMISARIS ATAS PENERAPAN BOARD OF COMMISSIONERS ON THE
TATA KELOLA PERUSAHAAN YANG IMPLEMENTATION OF GOOD CORPORATE
BAIK DI LINGKUP PERSEROAN GOVERNANCE WITHIN THE COMPANY
Tata kelola perusahaan yang baik bukan sekadar Good corporate governance is not merely a matter of
pemenuhan kepatuhan, tapi fondasi untuk menjaga compliance; it is the foundation for sound decision-making,
pengambilan keputusan yang tepat, ketahanan operational resilience, and strengthening stakeholder trust.
operasional, serta memperkuat kepercayaan pemangku Accordingly, the Board of Commissioners places strong
kepentingan. Karena itu, Dewan Komisaris menaruh emphasis on the consistent application of the principles
perhatian pada konsistensi penerapan prinsip integritas, of integrity, transparency, and accountability. The focus of
transparansi, dan akuntabilitas. Fokus pengawasan supervision is directed toward the effectiveness of internal
diarahkan pada efektivitas pengendalian internal, controls, the implementation of risk management, and the
penerapan manajemen risiko, serta mekanisme pelaporan violation reporting mechanism, so that the Company’s
pelanggaran, sehingga proses bisnis Perseroan berjalan business processes are conducted with adequate
dengan kehati-hatian yang memadai dan berorientasi prudence and a sustainability-oriented approach.
keberlanjutan.
Sepanjang tahun 2025, Dewan Komisaris menilai Throughout 2025, the Board of Commissioners assesses
penerapan tata kelola perusahaan yang baik di Perseroan that the implementation of good corporate governance
berjalan dengan baik dan konsisten, sejalan dengan within the Company has been carried out properly and
ketentuan Anggaran Dasar serta peraturan perundang- consistently, in accordance with the Articles of Association
undangan yang berlaku. and prevailing laws and regulations.
Perseroan telah memiliki struktur dan infrastruktur tata The Company has established an adequate governance
kelola yang memadai untuk mendukung penerapan structure and infrastructure to support the implementation
prinsip-prinsip GCG di seluruh lini organisasi. Dalam of GCG principles across all organizational levels. In its
pelaksanaannya, Dewan Komisaris terlibat aktif melalui execution, the Board of Commissioners has been actively
pemberian arahan dan rekomendasi dalam rapat involved by providing direction and recommendations
bersama Direksi, pemantauan tindak lanjut kebijakan, during joint meetings with the Board of Directors,
serta penguatan budaya kepatuhan dan integritas. monitoring policy follow-ups, and reinforcing a culture
of compliance and integrity.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 27
Page 28
Laporan Manajemen Positioned for
Management Report Profitable Growth
Dewan Komisaris mencermati penguatan pada aspek The Board of Commissioners observes enhancements
integritas dan kepatuhan, termasuk penerapan Sistem in the areas of integrity and compliance, including the
Manajemen Anti Penyuapan (SMAP) yang berpedoman implementation of the Anti-Bribery Management System
pada standar internasional ISO 37001:2016. (SMAP) in accordance with the international standard
ISO 37001:2016.
Dalam aspek pengendalian internal, Dewan Komisaris With respect to internal control, the Board of Commissioners
menilai sistem pengendalian internal Perseroan telah considers that the Company’s internal control system
berjalan cukup baik dan efektif dalam mendukung has functioned adequately and effectively in supporting
kelancaran operasional. Pelaksanaan pengendalian operational activities. The implementation of internal
internal didukung oleh Departemen Risk Management & control is supported by the Risk Management & Internal
Internal Audit dan berada dalam pengawasan Komite Audit Department and is overseen by the Risk Management
Manajemen Risiko. Committee.
Dewan Komisaris menekankan pentingnya penguatan The Board of Commissioners emphasizes the importance
pengendalian pada area-area kritis operasional agar of strengthening controls in critical operational areas
pencegahan risiko dan deteksi dini berjalan lebih efektif, to enhance risk prevention and early detection, in line
sejalan dengan meningkatnya kompleksitas bisnis dan with increasing business complexity and compliance
tuntutan kepatuhan. Selaras dengan itu, Dewan Komisaris requirements. In this regard, the Board of Commissioners
menilai penerapan manajemen risiko telah dijalankan assesses that risk management has been properly
dengan baik melalui fungsi Risk Management & Internal implemented through the Risk Management & Internal
Audit, dengan pengawasan Komite Manajemen Risiko, Audit function, under the supervision of the Risk
serta perlu terus diarahkan pada ketepatan identifikasi Management Committee, and should continue to be
risiko utama, efektivitas mitigasi, dan konsistensi directed toward accurate identification of key risks,
pemantauan secara berkala agar keputusan strategis effective mitigation measures, and consistent periodic
maupun operasional tetap berada pada tingkat kehati- monitoring to ensure that strategic and operational
hatian yang memadai. decisions remain within an appropriate level of prudence.
Dewan Komisaris juga mencermati penerapan The Board of Commissioners also observes the
Whistleblowing System (WBS) sebagai bagian dari implementation of the Whistleblowing System (WBS) as
penguatan transparansi dan integritas proses bisnis. part of strengthening transparency and the integrity of
Dewan Komisaris memberi perhatian pada aksesibilitas business processes. Attention is given to the accessibility
kanal pelaporan, kerahasiaan pelapor, serta tindak lanjut of reporting channels, the confidentiality of whistleblowers,
laporan yang objektif dan terukur. Pemantauan dilakukan and the objective and measurable follow-up of reports.
untuk memastikan sistem berjalan kredibel, disertai Monitoring is conducted to ensure that the system
dorongan penguatan sosialisasi agar kanal pelaporan operates credibly, accompanied by efforts to enhance
dipahami dan dimanfaatkan secara bertanggung jawab. awareness so that reporting channels are properly
understood and responsibly utilized.
Sepanjang tahun buku 2025, Dewan Komisaris Throughout fiscal year 2025, the Board of Commissioners
melaksanakan fungsi pengawasan atas penerapan carried out its supervisory function over the implementation
GCG melalui rapat internal Dewan Komisaris dan rapat of GCG through internal meetings of the Board of
bersama Direksi, penelaahan atas kebijakan dan laporan Commissioners and joint meetings with the Board of
manajemen, serta pemantauan tindak lanjut rekomendasi Directors, review of policies and management reports, and
dan hasil evaluasi, guna memastikan konsistensi monitoring of follow-up actions on recommendations and
penerapan GCG serta akuntabilitas pengelolaan evaluation results, to ensure consistent implementation
Perseroan. of GCG and accountability in the management of the
Company.
28 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 29
Positioned for
Profitable Growth
PENILAIAN DEWAN KOMISARIS BOARD OF COMMISSIONERS’
ATAS KINERJA KOMITE DI ASSESSMENT OF THE PERFORMANCE
BAWAH DEWAN KOMISARIS OF THE COMMITTEES UNDER THE
BOARD OF COMMISSIONERS
Dewan Komisaris menilai bahwa sepanjang tahun buku The Board of Commissioners assesses that throughout
2025 komite-komite di bawah Dewan Komisaris telah fiscal year 2025, the committees under the Board of
menjalankan fungsi dan tanggung jawabnya dengan Commissioners have properly carried out their functions
baik sesuai Piagam Komite dan rencana kerja yang and responsibilities in accordance with their respective
ditetapkan. Keberadaan komite-komite tersebut dinilai Committee Charters and established work plans. The
memberikan dukungan yang relevan bagi Dewan committees are considered to provide relevant support to
Komisaris dalam memperkuat kualitas pengawasan, the Board of Commissioners in strengthening the quality
terutama melalui penelaahan yang lebih mendalam atas of supervision, particularly through more in-depth review
isu-isu strategis dan area pengendalian yang menjadi of strategic issues and control areas of concern to the
perhatian Perseroan. Company.
Penilaian Dewan Komisaris terhadap kinerja komite In evaluating the performance of the committees, the Board
dilakukan dengan mempertimbangkan beberapa of Commissioners considered several key parameters,
parameter utama, meliputi tingkat kehadiran dan including the level of attendance and participation in
partisipasi dalam rapat, penguasaan materi dan kualitas meetings, mastery of subject matter and the quality of
masukan yang diberikan, kesanggupan menyediakan inputs provided, the ability to allocate sufficient time to
waktu untuk pemenuhan tugas dan tanggung jawab, fulfill duties and responsibilities, as well as the effectiveness
serta efektivitas pelaksanaan pemantauan dan evaluasi, of monitoring and evaluation conducted periodically
baik secara berkala maupun tahunan, atas hal-hal yang and annually within the scope of each committee’s
menjadi ruang lingkup tugas masing-masing komite. responsibilities. The Board of Commissioners also assessed
Dewan Komisaris juga menilai konsistensi komite dalam the consistency of the committees in monitoring follow-
memantau tindak lanjut atas temuan, rekomendasi, dan up actions on findings, recommendations, and issues
isu-isu yang memerlukan perhatian manajemen. requiring management’s attention.
Ke depan, Dewan Komisaris mendorong komite-komite Going forward, the Board of Commissioners encourages
untuk terus meningkatkan ketajaman analisis, menjaga the committees to improve the quality of their analysis,
independensi dan objektivitas, serta memperkuat kualitas maintain independence and objectivity, and strengthen
rekomendasi agar kontribusinya semakin efektif dalam the effectiveness of their recommendations. This will
mendukung akuntabilitas dan ketahanan pengelolaan make their contributions more effective in supporting
Perseroan. the accountability and resilience of the Company’s
management.
PENJELASAN TERKAIT PERUBAHAN EXPLANATION REGARDING CHANGES
KOMPOSISI ANGGOTA IN THE COMPOSITION OF THE
DEWAN KOMISARIS BOARD OF COMMISSIONERS
Sepanjang tahun 2025, tidak terdapat perubahan susunan Throughout 2025, there were no changes in the
Dewan Komisaris. Perubahan komposisi Dewan Komisaris composition of the Board of Commissioners. A change in
terjadi setelah berakhirnya tahun buku 2025, sebelum the composition of the Board of Commissioners occurred
Laporan Tahunan ini ditandatangani, sebagai tindak lanjut after the end of fiscal year 2025, prior to the signing of
keputusan Rapat Umum Pemegang Saham Luar Biasa this Annual Report, as a follow-up to the resolution of the
(RUPSLB) tanggal 14 Januari 2026. Berdasarkan keputusan Extraordinary General Meeting of Shareholders (EGMS)
tersebut, Bapak Dr. Imam Fathorrahman, M.M. tidak lagi held on January 14, 2026. Based on this resolution, Dr. Imam
menjabat sebagai Anggota Dewan Komisaris. Dewan Fathorrahman, M.M., no longer serves as a Member of the
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 29
Page 30
Laporan Manajemen Positioned for
Management Report Profitable Growth
Komisaris menyampaikan apresiasi atas kontribusi Bapak Board of Commissioners. The Board of Commissioners
Dr. Imam Fathorrahman, M.M. selama menjalankan tugas expresses its appreciation for the contributions of Dr. Imam
pengawasan di Perseroan. Fathorrahman, M.M., during his tenure in carrying out the
supervisory function within the Company.
Susunan Dewan Komisaris Composition of the Board of
per 31 Desember 2025 Commissioners as of December 31, 2025
1. Komisaris Utama merangkap Komisaris Independen: 1. President Commissioner concurrently serving as
Bapak Joefly Joesoef Bahroeny Independent Commissioner:
Mr. Joefly Joesoef Bahroeny
2. Komisaris Independen: 2. Independent Commissioner:
Ibu Sarah Azreen binti Abdul Samat Ms. Sarah Azreen binti Abdul Samat
3. Komisaris Independen: 3. Independent Commissioner:
Bapak Dr. Imam Fathorrahman, M.M Dr. Imam Fathorrahman, M.M.
4. Komisaris Independen: 4. Independent Commissioner:
Bapak Prof. Aman Bhakti Pulungan Prof. Aman Bhakti Pulungan
5. Komisaris: 5. Commissioner:
Bapak Dato’ Zulkifli bin Jafar Dato’ Zulkifli bin Jafar
Susunan Dewan Komisaris setelah Composition of the Board of Commissioners
RUPSLB 14 Januari 2026 after the EGMS on January 14, 2026
1. Komisaris Utama merangkap Komisaris Independen: 1. President Commissioner concurrently serving as
Bapak Joefly Joesoef Bahroeny Independent Commissioner:
Mr. Joefly Joesoef Bahroeny
2. Komisaris Independen: 2. Independent Commissioner:
Ibu Sarah Azreen binti Abdul Samat Ms. Sarah Azreen binti Abdul Samat
3. Komisaris Independen: 3. Independent Commissioner:
Bapak Prof. Aman Bhakti Pulungan Prof. Aman Bhakti Pulungan
4. Komisaris: 4. Commissioner:
Bapak Dato’ Zulkifli bin Jafar Dato’ Zulkifli bin Jafar
APRESIASI DAN PENUTUP APPRECIATION AND CLOSING
Di penghujung laporan ini, Dewan Komisaris menegaskan As we conclude this report, the Board of Commissioners
komitmen untuk menjalankan fungsi pengawasan dan reaffirms its commitment to consistently carrying out
pemberian nasihat secara konsisten, untuk memastikan its supervisory and advisory functions to ensure that
pengelolaan Perseroan tetap berada pada koridor tata the management of the Company remains within the
kelola yang baik serta berorientasi pada kesinambungan framework of good corporate governance and is oriented
kinerja jangka panjang. Konsistensi penerapan strategi toward long-term performance sustainability. The
yang telah dicanangkan dan penguatan integritas consistent implementation of the established strategy
pada proses bisnis menjadi landasan penting dalam and the strengthening of integrity in business processes
menghadapi dinamika industri dan menjaga ketahanan constitute essential foundations in addressing industry
Perseroan pada periode mendatang. dynamics and maintaining the Company’s resilience in
the coming period.
30 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 31
Positioned for
Profitable Growth
Dewan Komisaris menyampaikan apresiasi kepada The Board of Commissioners expresses its appreciation to
Direksi atas kepemimpinan dan upaya pengelolaan the Board of Directors for its leadership and management
Perseroan sepanjang tahun buku 2025, serta kepada efforts throughout fiscal year 2025, as well as to all
seluruh karyawan atas dedikasi, profesionalisme, dan employees for their dedication, professionalism, and
kontribusinya dalam menjaga kualitas layanan dan contributions in maintaining service quality and driving
mendorong pertumbuhan Perseroan. Penghargaan juga the Company’s growth. We also extend our gratitude to
kami sampaikan kepada pemegang saham, pelanggan, the shareholders, customers, principals, business partners,
principal, mitra usaha, regulator, serta seluruh pemangku regulators, and all stakeholders for their continued trust
kepentingan atas kepercayaan dan dukungan yang terus and support toward the Company.
diberikan kepada Perseroan.
Dengan dukungan seluruh pihak, Dewan Komisaris With the support of all parties, the Board of Commissioners
meyakini, Perseroan memiliki kapasitas untuk melanjutkan is confident that the Company has the capacity to further
penguatan kinerja pada tahun 2026, dengan tetap strengthen its performance in 2026, while upholding the
menjunjung tinggi prinsip integritas, transparansi, dan principles of integrity, transparency, and accountability
akuntabilitas sebagai fondasi keberlanjutan usaha. as the foundation of sustainable business continuity.
Jakarta, 16 April 2026
Jakarta, April 16, 2026
Atas nama Dewan Komisaris,
On behalf of the Board of Commissioners,
Joefly Joesoef Bahroeny
Komisaris Utama dan Komisaris Independen
President Commissioner and Independent Commissioner
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 31
Page 32
Laporan Manajemen Positioned for
Management Report Profitable Growth
Laporan Direksi
Board of Directors’ Report
Dr. Imam Fathorrahman, M.M
Direktur Utama
President Director
32 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 33
Positioned for
Profitable Growth
Para Pemegang Saham dan Pemangku Kepentingan yang Terhormat,
Honorable Shareholders and Stakeholders,
Puji syukur kami panjatkan ke hadirat Tuhan Yang We extend our gratitude to Almighty God for His blessings
Maha Esa, atas rahmat dan karunia-Nya, Perseroan and grace, which have enabled the Company to carry out
dapat menjalankan kegiatan usaha sepanjang tahun its business activities throughout 2025 while maintaining
2025 dengan tetap menjaga keberlangsungan usaha, business continuity, the quality of distribution services, and
kualitas layanan distribusi, serta pengelolaan risiko yang prudent risk management amid the evolving dynamics
terukur di tengah dinamika industri kesehatan yang terus of the healthcare industry.
berkembang.
Tahun 2025 ditandai dengan persaingan yang semakin The year 2025 was marked by increasingly intense
kompetitif, perubahan ekspektasi pelanggan, serta competition, shifting customer expectations, and
penyesuaian regulasi yang menuntut ketepatan eksekusi regulatory adjustments requiring precise execution and
dan respons yang cepat. Dalam konteks tersebut, swift response. In this context, the Board of Directors
Direksi memfokuskan upaya pada penguatan fondasi focused its efforts on strengthening the operational
operasional, mulai dari pengelolaan persediaan dan foundation, ranging from inventory management and
kualitas piutang, peningkatan efektivitas proses distribusi, receivables quality control, enhancing the effectiveness
hingga percepatan digitalisasi guna meningkatkan of distribution processes, to accelerating digitalization
akurasi, kecepatan layanan, dan efisiensi kerja. Perseroan initiatives to improve accuracy, service speed, and
juga terus menjaga tata kelola, kepatuhan, serta integritas operational efficiency. The Company also consistently
proses bisnis agar pertumbuhan yang dicapai tetap upheld governance, compliance, and the integrity of
selaras dengan prinsip kehati-hatian dan akuntabilitas. its business processes to ensure that growth achieved
remained aligned with the principles of prudence and
accountability.
Pada kesempatan yang baik ini, izinkan kami, atas nama On this occasion, on behalf of the Board of Directors, we
Direksi, menyampaikan laporan pengelolaan Perseroan hereby present the report on the management of the
selama Tahun Buku 2025. Laporan ini diharapkan dapat Company for Fiscal Year 2025. This report is intended
memberikan gambaran kepada pemegang saham to provide shareholders and stakeholders with an
dan pemangku kepentingan mengenai perkembangan overview of the Company’s developments throughout
Perseroan di sepanjang tahun, termasuk arah strategi, the year, including its strategic direction, performance
capaian kinerja, serta prioritas penguatan Perseroan ke achievements, and key priorities for strengthening the
depan. Company going forward.
PERKEMBANGAN PERSEROAN COMPANY DEVELOPMENTS IN 2025
TAHUN 2025
Sepanjang tahun 2025, Perseroan mencatatkan Throughout 2025, the Company recorded positive
kinerja yang positif dan tumbuh dibandingkan tahun performance and growth compared to 2024, despite
2024, meskipun menghadapi dinamika eksternal yang facing challenging external dynamics and increasingly
menantang serta intensitas persaingan industri yang intense industry competition.
semakin meningkat.
Dari sisi perekonomian global, pertumbuhan masih From a global economic perspective, growth remained
cenderung moderat dengan ketidakpastian yang tetap relatively moderate amid persistently high uncertainty,
tinggi, terutama terkait arah suku bunga, volatilitas particularly with respect to interest rate direction, financial
pasar keuangan, dan dinamika perdagangan. Kondisi market volatility, and trade dynamics. These conditions
ini mendorong kehati-hatian pelaku usaha dan encouraged a more cautious stance among businesses
memengaruhi biaya pendanaan, termasuk pada and affected financing costs, including within the
ekosistem kesehatan dan rantai pasoknya. healthcare ecosystem and its supply chain.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 33
Page 34
Laporan Manajemen Positioned for
Management Report Profitable Growth
Di tingkat perekonomian nasional, Indonesia tetap At the national level, Indonesia continued to demonstrate
menunjukkan pertumbuhan yang solid. Pada saat yang solid economic growth. At the same time, monetary policy
sama, dinamika kebijakan moneter dan pergerakan suku dynamics and interest rate movements shaped the
bunga membentuk konteks biaya pendanaan, perilaku context of financing costs, customer payment behavior,
pembayaran pelanggan, serta perencanaan modal and working capital planning—factors that are particularly
kerja—faktor-faktor yang relevan bagi pengelolaan bisnis relevant to the management of a distribution business.
distribusi.
Pada level industri, prospek pasar farmasi Indonesia tetap At the industry level, the outlook for Indonesia’s
terbuka sejalan dengan meningkatnya kebutuhan layanan pharmaceutical market remained favorable, in line with the
kesehatan. Namun, Perseroan juga menghadapi kompetisi increasing demand for healthcare services. Nevertheless,
yang semakin agresif, termasuk tekanan diskon di pasar the Company also faced increasingly aggressive
yang berpotensi memengaruhi margin. Selain itu, tuntutan competition, including discount pressures in the market
kepatuhan dan penyesuaian regulasi terkait distribusi that have the potential to affect margins. In addition,
serta ekosistem perizinan, beserta dinamika kebijakan compliance requirements and regulatory adjustments
TKDN, turut menambah kompleksitas operasional dan related to distribution and the licensing ecosystem, along
pasar. with developments in the Domestic Component Level
(TKDN) policy, further added to operational and market
complexity.
Sejalan dengan kondisi tersebut, tantangan eksternal In line with these conditions, the Company’s external
Perseroan pada 2025 terutama tercermin pada challenges in 2025 were primarily reflected in intensifying
persaingan industri yang semakin ketat, dinamika biaya industry competition, financing cost dynamics, and the
pendanaan, serta kebutuhan pemenuhan ketentuan need to comply with increasingly layered regulatory
kepatuhan dan regulasi yang makin berlapis. Di sisi and compliance requirements. Internally, the Company
internal, Perseroan perlu terus memperkuat kualitas continued to strengthen the quality of commercial risk and
pengelolaan risiko komersial dan modal kerja, terutama working capital management, particularly in relation to
terkait keterlambatan pembayaran outlet/pelanggan delayed payments from outlets/customers that may result
yang dapat menimbulkan ketidaksesuaian arus in mismatches between cash inflows from customers
pembayaran antara pelanggan dan prinsipal. Perseroan and payment obligations to principals. The Company
juga mengelola kebutuhan peningkatan efektivitas also addressed the need to enhance the effectiveness of
proses end-to-end agar layanan tetap andal seiring end-to-end processes to ensure reliable service delivery
bertambahnya kompleksitas operasional, sekaligus amid growing operational complexity, while maintaining
menjaga struktur biaya, termasuk dampak kenaikan UMR a prudent cost structure, including managing the impact
yang berpotensi meningkatkan beban gaji dan menekan of increases in the regional minimum wage (UMR), which
laba bersih. may raise personnel expenses and exert pressure on net
profit.
Di tengah tantangan tersebut, Perseroan tetap Amid these challenges, the Company was able to deliver
membukukan kinerja yang positif dan tumbuh positive performance and growth compared to the
dibandingkan tahun sebelumnya. Capaian ini didukung previous year. This achievement was supported by the
oleh penerapan strategi dan kebijakan strategis yang implementation of strategic initiatives and policies focused
difokuskan pada penguatan jangkauan layanan, on strengthening service coverage, improving the quality
peningkatan kualitas pengelolaan pelanggan dan of customer and inventory management, and leveraging
persediaan, serta pemanfaatan sistem untuk memperkuat systems to enhance operational process effectiveness, as
efektivitas proses operasional, yang Direksi uraikan pada further elaborated by the Board of Directors in Section II.
Bagian II.
Salah satu capaian positif yang diraih, Perseroan One of the positive achievements recorded was the
membukukan pendapatan bersih sebesar Company’s net revenue of Rp4,109,810,339,016 and profit
Rp4.109.810.339.016 dan laba tahun berjalan sebesar for the year of Rp38,466,251,197, reflecting the Company’s
Rp38.466.251.197, mencerminkan kemampuan Perseroan ability to maintain business continuity throughout 2025.
menjaga kelangsungan usaha sepanjang 2025.
34 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 35
Positioned for Profitable Growth STRATEGI DAN KEBIJAKAN STRATEGY AND STRATEGIC STRATEGIS TAHUN 2025 POLICY IN 2025 Dalam rangka menjaga kelangsungan usaha dan In order to maintain business continuity and strengthen memperkuat daya saing, Direksi menetapkan strategi competitiveness, the Board of Directors established dan kebijakan strategis tahun 2025 yang berfokus the Company’s 2025 strategic initiatives and policies pada pertumbuhan yang terarah, penguatan kualitas with a focus on well-directed growth, enhancement of pengelolaan risiko komersial, peningkatan efektivitas commercial risk management quality, improvement of operasional, serta percepatan pemanfaatan sistem operational effectiveness, and acceleration of system untuk meningkatkan akurasi dan kecepatan proses kerja. utilization to increase process accuracy and speed. These Fokus tersebut ditetapkan dengan mempertimbangkan priorities were set with due consideration to industry dinamika industri dan kebutuhan Perseroan untuk dynamics and the Company’s need to consistently memperkuat kapabilitas layanan distribusi secara strengthen its distribution service capabilities across its konsisten di seluruh jaringan. network. Pada aspek penguatan jangkauan layanan, Perseroan With respect to expanding service coverage, the Company menjalankan strategi ekspansi dan penataan jaringan, implemented network expansion and optimization salah satunya, melalui pembukaan Kantor Cabang strategies, including the opening of the Palu Branch Office, Palu yang resmi beroperasi pada November 2025, serta which officially commenced operations in November relokasi kantor cabang ke lokasi yang lebih memadai, 2025, as well as the relocation of branch offices to more yaitu Bekasi (Oktober 2025) dan Denpasar (Juli 2025). suitable premises in Bekasi (October 2025) and Denpasar Kebijakan ini diarahkan untuk memperluas cakupan (July 2025). These measures were aimed at broadening layanan, memperkuat kedekatan dengan pelanggan, service coverage, strengthening proximity to customers, dan meningkatkan kesiapan operasional pada area yang and enhancing operational readiness in areas with growth memiliki potensi pertumbuhan. potential. Sejalan dengan itu, Direksi memperkuat kebijakan In parallel, the Board of Directors reinforced its commercial pengelolaan risiko komersial melalui strategi selektif risk management policies through a more selective terhadap pelanggan guna menurunkan potensi approach toward customers to mitigate potential keterlambatan pembayaran, serta optimalisasi payment delays, as well as through inventory optimization persediaan untuk memastikan buffer stock berada pada to ensure that buffer stock levels remain appropriate— tingkat yang tepat—mendukung penjualan sekaligus supporting sales growth while maintaining working menjaga efisiensi modal kerja. Pendekatan ini menjadi capital efficiency. This approach serves as an important penopang penting agar pertumbuhan tetap berkualitas, foundation to ensure that growth remains sustainable dengan perhatian yang memadai pada kualitas piutang and of high quality, with adequate attention to receivables dan ketahanan arus kas operasional. quality and operational cash flow resilience. Pada aspek operasional, Perseroan melanjutkan agenda On the operational front, the Company continued its peningkatan efektivitas proses melalui penguatan sistem agenda of enhancing process effectiveness through dan perbaikan pengalaman pelanggan. Perseroan system strengthening and customer experience mengimplementasikan Barcoding System (APEX) untuk improvements. The Company implemented the Barcoding memperkuat akurasi dan keterlacakan pengelolaan System (APEX) to enhance accuracy and traceability in warehouse, mengembangkan e-Spesiment Customer warehouse management, developed the e-Spesiment guna memudahkan registrasi calon pelanggan Customer platform to facilitate prospective customer (pengurusan izin, submission dokumen, dan kebutuhan registration (including licensing processes, document administrasi terkait), serta menerapkan Assets submission, and related administrative requirements), and Management yang dapat diakses seluruh cabang untuk introduced an Assets Management system accessible to pengajuan kebutuhan secara real time agar proses all branches to enable real-time submission of operational pemenuhan kebutuhan operasional lebih efektif. Secara needs, thereby improving fulfillment efficiency. Overall, keseluruhan, strategi ini ditujukan untuk meningkatkan these strategies are intended to enhance service reliability, reliabilitas layanan, mempercepat proses end-to-end, accelerate end-to-end processes, and reinforce the dan memperkuat fondasi operasional Perseroan ke depan. Company’s operational foundation going forward. PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 35
Page 36
Laporan Manajemen Positioned for
Management Report Profitable Growth
PERANAN DIREKSI DALAM PERUMUSAN THE ROLE OF THE BOARD OF DIRECTORS
STRATEGI DAN KEBIJAKAN STRATEGIS IN FORMULATING STRATEGY
AND STRATEGIC POLICIES
Direksi memegang peran sentral dalam memastikan The Board of Directors plays a central role in ensuring
strategi dan kebijakan strategis Perseroan dirumuskan that the Company’s strategies and policies are relevant,
secara relevan, realistis, dan selaras dengan arah realistic, and aligned with business development goals.
pengembangan usaha. Perumusan strategi dilakukan The formulation of strategy takes into account external
dengan memerhatikan kondisi eksternal, termasuk conditions, including industry dynamics, regulatory
dinamika industri, perubahan regulasi, serta pola changes, and customer demand patterns, as well as
permintaan pelanggan, serta kesiapan internal Perseroan, the Company’s internal readiness, such as operational
seperti kapabilitas operasional, ketersediaan sumber capabilities, resource availability, and priority areas that
daya, dan prioritas penguatan yang paling berdampak have the most significant impact on business continuity
terhadap kelangsungan usaha dan kualitas layanan. and service quality.
Dalam proses perumusan, Direksi mengarahkan setiap During the formulation process, the Board of Directors
fungsi untuk menyampaikan masukan berbasis data dan instructed each department to provide data-and
pengalaman operasional, termasuk evaluasi atas capaian experience-based input. This included evaluating the
tahun sebelumnya, isu-isu yang muncul di lapangan, previous year’s achievements, addressing issues that
serta kebutuhan perbaikan pada aspek jaringan distribusi, arose in the field, and identifying areas for improvement
pengelolaan risiko komersial, dan efektivitas proses. Direksi in distribution networks, commercial risk management,
kemudian mengkonsolidasikan masukan tersebut menjadi and process effectiveness. The Board of Directors then
rancangan strategi yang terstruktur, yang diterjemahkan consolidates these inputs into a structured strategic
ke dalam program kerja dan inisiatif prioritas, mulai dari framework, translated into work programs and priority
penguatan jaringan dan kapasitas layanan, peningkatan initiatives, ranging from strengthening network coverage
kualitas pengelolaan pelanggan dan persediaan, hingga and service capacity, enhancing customer and inventory
percepatan pemanfaatan sistem guna meningkatkan management quality, to accelerating system utilization
akurasi dan kecepatan proses. to improve process accuracy and speed.
Selanjutnya, Direksi memastikan strategi dan kebijakan Subsequently, the Board of Directors ensures that
strategis yang telah ditetapkan diinternalisasi ke dalam the established strategies and strategic policies are
Rencana Kerja dan Anggaran Perusahaan (RKAP) sebagai internalized into the Company’s Work Plan and Budget
acuan target dan program tahunan. Dokumen RKAP (RKAP) as the reference for annual targets and programs.
menjadi instrumen utama untuk menjabarkan sasaran, The RKAP serves as the primary instrument to detail
indikator kinerja, kebutuhan sumber daya, serta rencana objectives, performance indicators, resource requirements,
implementasi pada tingkat unit kerja, sehingga eksekusi and implementation plans at the business unit level,
strategi dapat terarah dan terukur sepanjang tahun thereby ensuring that strategy execution remains focused
berjalan. and measurable throughout the year.
Dalam keseluruhan proses tersebut, Direksi juga Throughout this process, the Board of Directors also
menjaga komunikasi dan koordinasi dengan Dewan maintains communication and coordination with the
Komisaris untuk memperoleh arahan dan perspektif Board of Commissioners to obtain guidance and oversight
pengawasan, terutama pada area-area strategis perspectives, particularly on strategic areas affecting
yang berpengaruh terhadap keberlanjutan usaha, business sustainability, governance strengthening, and
penguatan tata kelola, serta pengelolaan risiko utama the management of the Company’s key risks. Accordingly,
Perseroan. Dengan demikian, strategi yang ditetapkan the strategies adopted are not only target-oriented but
tidak hanya berorientasi pada pencapaian target, tetapi also reinforce the Company’s foundation in responding
juga memperkuat fondasi Perseroan dalam merespons to future changes and business opportunities.
perubahan dan peluang usaha ke depan.
36 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 37
Positioned for
Profitable Growth
PROSES DIREKSI UNTUK MEMASTIKAN PROCESS UNDERTAKEN BY THE
IMPLEMENTASI STRATEGI BOARD OF DIRECTORS TO ENSURE
STRATEGY IMPLEMENTATION
Direksi memastikan strategi dan kebijakan strategis yang The Board of Directors ensures that the strategies and
telah ditetapkan pada tahun 2025 dapat dijalankan secara strategic policies established for 2025 are implemented
konsisten melalui mekanisme pengelolaan kinerja yang consistently through a structured performance
terstruktur, koordinasi lintas fungsi, serta pemantauan management mechanism, cross-functional coordination,
berkala atas indikator operasional dan keuangan. Proses and periodic monitoring of operational and financial
ini dirancang agar setiap inisiatif tidak berhenti pada indicators. This process is designed to ensure that each
perencanaan, melainkan benar-benar terimplementasi initiative moves beyond planning and is effectively
pada level operasional, baik di kantor pusat maupun di executed at the operational level, both at the head office
seluruh jaringan cabang, dengan standar kerja yang and across all branch networks, with uniform standards
seragam. of execution.
Pada tahap awal, Direksi menerjemahkan strategi At the initial stage, the Board of Directors translates the
ke dalam rencana kerja tahunan dan target-target strategy into annual work plans and operational targets,
operasional, yang kemudian diturunkan menjadi program which are subsequently cascaded into programs and
dan rencana eksekusi di tingkat unit kerja. Setiap fungsi execution plans at the business unit level. Each function
diberi mandat yang jelas, termasuk ruang lingkup is assigned a clear mandate, including scope of
pekerjaan, jadwal pelaksanaan, serta kebutuhan sumber responsibilities, implementation schedule, and required
daya yang diperlukan. Penurunan target ini penting resources. This cascading process is essential to ensure
untuk memastikan bahwa ekspansi jaringan, penguatan that network expansion, strengthened customer and
pengelolaan pelanggan dan persediaan, serta agenda inventory management, and initiatives to enhance process
peningkatan efektivitas proses melalui sistem dapat effectiveness through system utilization are carried out
berjalan dengan arah yang sama dan keterukuran yang in a coordinated and measurable manner.
memadai.
Dalam pelaksanaannya, Direksi menjalankan forum In execution, the Board of Directors conducts regular
koordinasi dan evaluasi secara berkala untuk menilai coordination and evaluation forums to assess the
progres inisiatif strategis. Forum ini menjadi wadah progress of strategic initiatives. These forums serve as
untuk membahas capaian dibandingkan rencana, platforms to review achievements against plans, identify
mengidentifikasi kendala di lapangan, serta menetapkan operational challenges, and determine corrective actions
langkah perbaikan. Evaluasi dilakukan dengan where necessary. Evaluations are based on indicators
memerhatikan indikator yang relevan dengan model relevant to the distribution business model, including sales
bisnis distribusi, antara lain capaian penjualan, kualitas performance, receivables quality and collection timeliness,
piutang dan ketepatan penerimaan, kondisi persediaan inventory levels and stock turnover, service reliability,
dan perputaran stok, reliabilitas layanan, serta efisiensi and operational cost efficiency. Through this monitoring
biaya operasional. Melalui pemantauan ini, Direksi dapat framework, the Board of Directors ensures that growth
memastikan bahwa pertumbuhan yang dicapai tidak does not compromise working capital management
mengorbankan kualitas pengelolaan modal kerja dan quality or cash flow resilience.
ketahanan arus kas.
Direksi juga menekankan penguatan pengendalian pada The Board of Directors also places strong emphasis on
area yang paling memengaruhi keberlanjutan kinerja, strengthening controls in areas that most significantly
khususnya pengelolaan risiko komersial dan kepatuhan. affect performance sustainability, particularly commercial
Sejalan dengan dinamika pasar, Direksi mendorong risk management and compliance. In response to market
penerapan selektivitas pelanggan secara lebih terarah, dynamics, the Board promotes a more disciplined and
disertai penguatan proses penagihan dan pemantauan selective customer approach, supported by strengthened
status pembayaran. Pada saat yang sama, Direksi collection processes and close monitoring of payment
memastikan pemenuhan ketentuan operasional dan status. At the same time, the Board ensures that
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 37
Page 38
Laporan Manajemen Positioned for
Management Report Profitable Growth
perizinan yang berlaku tetap menjadi perhatian utama, compliance with operational and licensing requirements
sehingga operasional Perseroan berjalan selaras dengan remains a top priority, so that the Company’s activities
standar kepatuhan yang dipersyaratkan. continue to align with applicable regulatory standards.
Untuk mendukung efektivitas eksekusi, Direksi To support effective execution, the Board of Directors
mengarahkan pemanfaatan sistem sebagai enabler promotes the use of systems as key process enablers,
proses, terutama pada aktivitas yang menuntut akurasi especially in activities requiring high accuracy and
tinggi dan keterlacakan. Penguatan sistem di area traceability. System enhancements in warehouse
gudang, administrasi pelanggan, dan pengelolaan aset/ operations, customer administration, and asset
permintaan kebutuhan cabang dioptimalkan agar proses management and branch request management are
end-to-end lebih efisien, meminimalkan kesalahan, optimized to improve end-to-end efficiency, minimize
dan meningkatkan kecepatan layanan. Direksi juga errors, and enhance service speed. The Board also
memastikan adanya koordinasi yang memadai antar ensures adequate inter-unit coordination so that
unit agar perubahan proses dan penerapan sistem di process adjustments and system implementations are
lapangan dapat diterima, dijalankan, dan menghasilkan well understood, properly executed, and able to deliver
perbaikan yang terukur. measurable improvements.
Apabila terdapat perubahan kondisi eksternal maupun Where external changes or internal constraints affect
kendala internal yang memengaruhi rencana kerja, Direksi the work plan, the Board of Directors undertakes timely
melakukan penyesuaian langkah secara tepat waktu, adjustments while maintaining alignment with the
dengan tetap menjaga prioritas strategis yang telah established strategic priorities. Through this approach,
ditetapkan. Dengan pendekatan tersebut, Perseroan the Company has been able to sustain the momentum
dapat menjaga ritme implementasi strategi sepanjang of strategy implementation throughout 2025 and lay a
2025 dan menyiapkan fondasi yang lebih kuat untuk stronger foundation for enhanced performance in the
penguatan kinerja pada tahun berikutnya. year ahead.
KINERJA PERSEROAN 2025 COMPANY PERFORMANCE IN 2025
Secara umum, Perseroan membukukan kinerja yang Overall, the Company recorded positive performance
positif sepanjang tahun 2025, tercermin dari capaian throughout 2025, as reflected in its revenue growth,
pendapatan, profitabilitas, serta posisi keuangan profitability, and maintained financial position. These
yang tetap terjaga. Capaian tersebut diraih di tengah achievements were realized amid intensifying industry
persaingan industri yang semakin ketat, dinamika biaya competition, fluctuations in financing costs, and regulatory
pendanaan, serta penyesuaian ketentuan kepatuhan and compliance adjustments that required strengthened
dan regulasi yang memerlukan penguatan pengelolaan operational and working capital management.
operasional dan modal kerja.
Pada posisi Laba (Rugi), Perseroan mencatat pendapatan In terms of profit and loss, the Company recorded net
neto sebesar Rp4,1 triliun, dengan perubahan sebesar 4,93% revenue of Rp4.1 trillion, representing a change of 4.93%
dibandingkan tahun sebelumnya. Realisasi pendapatan compared to the previous year. Revenue realization
usaha mencapai 94,91% dari target 2025. Sejalan dengan reached 94.91% of the 2025 target. In line with revenue
pergerakan pendapatan, Perseroan membukukan laba performance, the Company posted gross profit of Rp362.36
bruto sebesar Rp362,36 miliar atau 92,91% dari target, billion, equivalent to 92.91% of the target, while profit for the
sedangkan laba tahun berjalan mencapai Rp38,47 miliar, year reached Rp38.47 billion, reflecting an increase of 227%
tumbuh 227% dari tahun 2024, dan 81,14% dari target yang compared to 2024 and 81.14% of the established target.
ditetapkan.
38 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 39
Positioned for
Profitable Growth
Sementara itu, pada posisi keuangan, Perseroan From a financial position perspective, the Company
mencatat total aset sebesar Rp 1,96 triliun, atau 10,66% recorded total assets of Rp 1.96 trillion, or 10.66% compared
dibandingkan tahun 2024, dan mencapai 92,94% dari to 2024, and achieved 92.94% of the 2025 target. Total
target 2025. Total liabilitas tercatat sebesar Rp 1,65 triliun, liabilities amounted to Rp 1.64 trillion, while equity
sedangkan ekuitas meningkat menjadi Rp 315,40 miliar, increased to Rp 315.40 billion, reaching 90.88% of the
atau mencapai 90,88% dari target. Pergerakan posisi target. Movements in the financial position were primarily
keuangan tersebut dipengaruhi terutama oleh dinamika influenced by working capital dynamics, particularly trade
modal kerja, khususnya piutang usaha dan persediaan, receivables and inventories, in line with the characteristics
sejalan dengan karakteristik bisnis distribusi. of the distribution business.
Ditinjau dari segmen usaha, kontribusi terbesar terhadap By business segment, the largest contribution to the
penjualan Perseroan pada 2025 berasal dari produk obat Company’s sales in 2025 came from prescription
resep sebesar 70,27% dari total penjualan, dengan nilai pharmaceutical products, accounting for 70.27% of
penjualan Rp2,8 triliun. Kontribusi berikutnya berasal total sales, with a sales value of Rp2.8 trillion. This was
dari alat kesehatan sebesar Rp1,08 triliun (26,23%), serta followed by medical devices at Rp1.08 trillion (26.23%)
obat non-resep sebesar Rp0,1 triliun (3,49%). Komposisi ini and over-the-counter (OTC) products at Rp0.1 trillion
menggambarkan fokus utama Perseroan pada layanan (3.49%). This composition reflects the Company’s primary
distribusi produk kesehatan serta pengelolaan portofolio focus on healthcare distribution services and portfolio
yang disesuaikan dengan kebutuhan pasar. management aligned with market needs.
Berdasarkan cakupan geografis, Pulau Jawa menjadi Based on geographic coverage, Java remained the
kontributor pendapatan terbesar sebesar 59,40%, largest revenue contributor at 59.40%, followed by
disusul Sumatra sebesar 21,98%, dan wilayah lainnya Sumatra at 21.98%, and other regions at 18.62%, reflecting
sebesar 18,62%, mencerminkan sebaran pasar utama the Company’s key market distribution and the role of its
Perseroan dan peran jaringan distribusi dalam menjaga distribution network in maintaining service accessibility.
keterjangkauan layanan.
Segala pencapaian tersebut menjadi dasar bagi These achievements provide a solid foundation for the
Perseroan untuk melanjutkan penguatan kinerja pada Company to further strengthen its performance in the
periode berikutnya. coming period.
KENDALA/TANTANGAN TAHUN 2025 CHALLENGES/OBSTACLES IN 2025
DAN LANGKAH PENYELESAIANNYA AND MITIGATION MEASURES
Sepanjang tahun 2025, Perseroan menghadapi sejumlah Throughout 2025, the Company encountered several
kendala dan tantangan yang berasal dari dinamika challenges and obstacles arising from both external
eksternal maupun kebutuhan penguatan internal. Pada dynamics and the need to strengthen internal capabilities.
aspek eksternal, persaingan industri yang semakin From an external perspective, increasingly aggressive
agresif mendorong tekanan harga dan diskon yang industry competition exerted pricing pressure and
berpotensi memengaruhi margin. Di saat yang sama, intensified discount practices, which had the potential to
dinamika biaya pendanaan turut memengaruhi beban affect margins. At the same time, fluctuations in financing
keuangan Perseroan. Perseroan juga menghadapi costs contributed to higher financial expenses for the
penyesuaian ketentuan kepatuhan dan regulasi, termasuk Company. The Company also faced adjustments to
penerapan standar distribusi dan ekosistem perizinan, compliance and regulatory requirements, including the
serta dinamika kebijakan TKDN, yang menuntut kesiapan implementation of distribution standards and licensing
proses, dokumentasi, dan pengendalian operasional yang ecosystem frameworks, as well as developments in
lebih kuat. Domestic Component Level (TKDN) policies, all of which
required stronger process readiness, documentation, and
operational controls.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 39
Page 40
Laporan Manajemen Positioned for
Management Report Profitable Growth
Dari sisi pasar, tantangan yang juga relevan adalah From a market standpoint, a further relevant challenge
keterlambatan pembayaran dari outlet/pelanggan. was delayed payments from outlets/customers. This
Kondisi ini dapat menimbulkan ketidaksesuaian arus condition created potential mismatches between cash
pembayaran antara penerimaan dari pelanggan dan inflows from customers and payment obligations to
kewajiban pembayaran kepada prinsipal, sehingga principals, thereby necessitating tighter working capital
menuntut pengelolaan modal kerja yang lebih ketat management and enhanced commercial risk controls.
dan penguatan pengendalian risiko komersial. Selain In addition, increases in the Regional Minimum Wage
itu, kenaikan UMR turut meningkatkan beban gaji dan (UMR) led to higher salary expenses and posed potential
berpotensi memberikan tekanan pada laba bersih, pressure on net profit, requiring the Company to maintain
sehingga Perseroan perlu menjaga efisiensi biaya tanpa cost efficiency without compromising service quality.
mengurangi kualitas layanan.
Merespons tantangan tersebut, Direksi menempuh In response to these challenges, the Board of Directors
langkah-langkah yang terarah untuk menjaga ketahanan undertook targeted measures to safeguard performance
kinerja dan kelangsungan usaha. Pertama, Perseroan resilience and business continuity. First, the Company
memperkuat pengelolaan risiko komersial melalui strengthened commercial risk management by
penerapan selektivitas pelanggan yang lebih terstruktur, implementing a more structured customer selection
disertai pemantauan status pembayaran dan penguatan process, accompanied by close monitoring of payment
proses penagihan, agar kualitas piutang lebih terjaga. status and reinforced collection procedures, in order to
maintain the quality of receivables.
Kedua, Perseroan mengoptimalkan pengelolaan Second, the Company optimized inventory management
persediaan untuk memastikan ketersediaan stok to ensure that stock availability remained at appropriate
berada pada tingkat yang tepat, mendukung penjualan levels, supporting sales while maintaining working
sekaligus menjaga efisiensi modal kerja. Ketiga, Perseroan capital efficiency. Third, the Company continued its
melanjutkan agenda peningkatan efektivitas proses end- agenda to enhance end-to-end process effectiveness
to-end melalui pemanfaatan sistem, khususnya pada through system utilization, particularly in warehouse
aktivitas gudang dan administrasi pelanggan, untuk operations and customer administration activities, to
meningkatkan akurasi, keterlacakan, dan kecepatan improve accuracy, traceability, and service speed. Fourth,
layanan. Keempat, Perseroan memperkuat kesiapan the Company reinforced its readiness to comply with
pemenuhan ketentuan kepatuhan dan regulasi yang applicable compliance and regulatory requirements
berlaku, melalui penyelarasan proses, penguatan through process alignment, strengthened documentation,
dokumentasi, serta koordinasi lintas fungsi agar and cross-functional coordination to ensure effective
implementasi berjalan efektif. implementation.
Dengan pendekatan tersebut, Perseroan dapat menjaga Through this approach, the Company was able to
stabilitas keberlanjutan usaha di tengah tantangan maintain business sustainability and stability amid
yang ada, sekaligus menyiapkan fondasi yang lebih prevailing challenges, while laying a stronger foundation
kuat untuk penguatan kinerja pada tahun berikutnya. for performance enhancement in the following year. The
Direksi memandang bahwa pengelolaan tantangan 2025 Board of Directors views the management of challenges
menjadi pelajaran penting untuk memperkuat ketahanan in 2025 as an important learning experience to further
Perseroan, baik dari sisi kualitas pengelolaan pelanggan, strengthen the Company’s resilience, particularly in terms
kesiapan proses operasional, maupun kecepatan of customer management quality, operational process
adaptasi terhadap perubahan eksternal. readiness, and agility in adapting to external changes.
40 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 41
Positioned for Profitable Growth PROSPEK USAHA TAHUN 2026 DAN BUSINESS PROSPECTS IN 2026 AND THE ARAH PENGEMBANGAN PERSEROAN COMPANY’S DEVELOPMENT DIRECTION Direksi memandang prospek usaha Perseroan pada The Board of Directors views the Company’s business tahun 2026 tetap terbuka, sejalan dengan kebutuhan prospects for 2026 as remaining favorable, in line with layanan kesehatan yang terus meningkat serta kebutuhan the continued growth in demand for healthcare services distribusi produk farmasi dan alat kesehatan yang and the distribution of pharmaceutical and medical menuntut keandalan layanan, ketepatan pemenuhan, device products, which require reliable service, fulfillment dan kualitas pengelolaan rantai pasok. Namun demikian, accuracy, and high-quality supply chain management. Perseroan tetap mencermati dinamika eksternal yang Nevertheless, the Company continues to closely monitor dapat memengaruhi kinerja, termasuk intensitas external dynamics that may affect performance, including persaingan, perkembangan biaya pendanaan, serta the intensity of competition, developments in financing penyesuaian regulasi yang memerlukan kesiapan proses costs, and regulatory adjustments that require stronger dan kepatuhan yang lebih kuat. Dalam konteks tersebut, process readiness and compliance. In this context, Perseroan menempatkan fokus pada pertumbuhan yang the Company places emphasis on focused growth, terarah, penguatan kualitas pengelolaan risiko komersial, strengthened commercial risk management quality, and serta peningkatan efektivitas operasional sebagai enhanced operational effectiveness as the foundation for landasan pengembangan pada 2026. its development in 2026. Dalam mengoptimalkan peluang pasar, Perseroan To optimize market opportunities, the Company will akan memperkuat bisnis yang sudah berjalan melalui reinforce its existing business by improving service quality peningkatan kualitas layanan dan pendalaman kerja and deepening collaboration with current principals, while sama dengan prinsipal yang telah ada, sekaligus ensuring product availability to meet customer needs. menjaga ketersediaan produk yang mendukung At the same time, the Company targets the addition of kebutuhan pelanggan. Pada saat yang sama, Perseroan new principals to expand its portfolio, with a focus on menargetkan penambahan prinsipal baru untuk OTC products, medical devices, and consumer products, memperluas portofolio, dengan fokus pada produk OTC, thereby creating more diversified sources of growth alat kesehatan, dan produk konsumer, agar Perseroan and greater adaptability to shifts in market demand. memiliki sumber pertumbuhan yang lebih beragam serta This development direction also represents an effort to lebih adaptif terhadap pergeseran kebutuhan pasar. strengthen the Company’s position in segments with Arah pengembangan ini juga menjadi upaya untuk favorable growth prospects. memperkuat posisi Perseroan dalam segmen yang memiliki prospek pertumbuhan baik. Dari sisi jaringan distribusi, Perseroan merencanakan From a distribution network perspective, the Company pembukaan cabang baru dengan fokus pada wilayah plans to open new branches with a focus on Eastern Timur Indonesia guna memperluas cakupan layanan Indonesia to expand service coverage and enhance dan meningkatkan kedekatan dengan pelanggan pada proximity to customers in high-potential areas. This wilayah yang potensial. Pengembangan jaringan ini network expansion will be supported by strengthened akan didukung oleh penguatan infrastruktur, termasuk infrastructure, including planned investments in the rencana investasi untuk perluasan gudang pusat dan expansion of the central warehouse and branch facilities, fasilitas cabang, agar kapasitas penyimpanan, ketepatan in order to increase storage capacity, fulfillment accuracy, pemenuhan, dan kelancaran distribusi dapat semakin and distribution efficiency in line with volume growth. meningkat seiring pertumbuhan volume. Sejalan dengan agenda penguatan operasional, In line with its operational strengthening agenda, the Perseroan juga akan melanjutkan peningkatan digitalisasi Company will continue to advance the digitalization of its proses bisnis untuk memperkuat efektivitas dan kualitas business processes to enhance effectiveness and service layanan. Dalam hal ini, Perseroan mendorong peningkatan quality. In this regard, the Company seeks to increase the kontribusi PT DPAI (OLIN) sebagai enabler digital, sehingga contribution of PT DPAI (OLIN) as a digital enabler, enabling PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 41
Page 42
Laporan Manajemen Positioned for
Management Report Profitable Growth
proses end-to-end, mulai dari administrasi pelanggan, end-to-end processes—from customer administration
pengelolaan gudang, hingga dukungan operasional and warehouse management to branch operational
cabang, dapat semakin akurat, terintegrasi, dan responsif. support—to become more accurate, integrated, and
responsive.
Secara keseluruhan, arah pengembangan Perseroan Overall, the Company’s development direction in 2026 is
pada 2026 difokuskan pada penguatan kapabilitas focused on strengthening service capabilities, expanding
layanan, perluasan portofolio dan jaringan, serta its portfolio and network, and leveraging systems to
pemanfaatan sistem untuk meningkatkan efektivitas enhance operational effectiveness and the quality of
operasional dan kualitas pengelolaan modal kerja. working capital management. Through these measures,
Dengan langkah tersebut, Direksi optimistis Perseroan the Board of Directors is optimistic that the Company
dapat menjaga kelangsungan usaha, meningkatkan will be able to sustain business continuity, enhance
daya saing, dan memperkuat fondasi pertumbuhan pada competitiveness, and reinforce the foundation for growth
periode mendatang. in the coming periods.
PERKEMBANGAN PENERAPAN PROGRESS IN THE IMPLEMENTATION
TATA KELOLA PERUSAHAAN YANG OF GOOD CORPORATE GOVERNANCE
BAIK DI LINGKUP PERSEROAN WITHIN THE COMPANY
Sepanjang tahun 2025, Perseroan terus memperkuat Throughout 2025, the Company continued to strengthen
penerapan tata kelola perusahaan yang baik sebagai the implementation of Good Corporate Governance
fondasi pengelolaan usaha yang akuntabel, transparan, (GCG) as the foundation for accountable, transparent,
dan selaras dengan ketentuan yang berlaku. Penguatan and compliant business management. Governance
tata kelola diarahkan untuk memastikan proses enhancement efforts were directed toward ensuring that
pengambilan keputusan, pengendalian, serta pelaksanaan decision-making processes, controls, and the execution
kegiatan operasional berjalan secara terstruktur, terutama of operational activities were conducted in a structured
seiring meningkatnya kompleksitas bisnis distribusi dan manner, particularly in light of the increasing complexity
dinamika kepatuhan di industri kesehatan. Perseroan juga of the distribution business and the evolving compliance
melanjutkan penguatan keterbukaan informasi kepada landscape within the healthcare industry. The Company
pemangku kepentingan melalui mekanisme komunikasi also continued to enhance information disclosure
yang memadai, sejalan dengan komitmen untuk menjaga to stakeholders through adequate communication
kepercayaan pasar dan para mitra usaha. mechanisms, in line with its commitment to maintaining
market confidence and the trust of business partners.
Dalam rangka memperkuat integritas pengelolaan usaha, In strengthening the integrity of its business management,
Perseroan melanjutkan penguatan perangkat tata kelola the Company continued to reinforce its governance
(soft structure) dan infrastruktur GCG sesuai ketentuan framework (soft structure) and GCG infrastructure in
yang berlaku, termasuk pemutakhiran kebijakan dan accordance with prevailing regulations, including the
prosedur yang relevan dengan kebutuhan Perseroan. updating of policies and procedures relevant to the
Company’s needs.
Perseroan juga melanjutkan penerapan Sistem The Company also continued the implementation of its
Manajemen Anti Penyuapan (SMAP) yang mengacu Anti-Bribery Management System (ABMS), which refers
pada ISO 37001:2016 sebagai bagian dari penguatan to ISO 37001:2016, as part of its efforts to prevent bribery,
pencegahan praktik penyuapan, gratifikasi, dan bentuk gratification, and other forms of misconduct.
penyimpangan lainnya.
Direksi memandang sistem pengendalian internal The Board of Directors views the internal control
dan manajemen risiko sebagai elemen penting untuk system and risk management as essential elements in
menjaga efektivitas proses bisnis, keamanan aset, safeguarding the effectiveness of business processes,
keandalan pelaporan, serta kepatuhan. Pada 2025, Direksi asset security, reliability of reporting, and regulatory
memastikan pemantauan yang lebih intensif terhadap compliance. In 2025, the Board ensured more intensive
42 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 43
Positioned for
Profitable Growth
area-area yang paling material bagi operasional monitoring of areas most material to the Company’s
Perseroan, termasuk pengelolaan risiko komersial dan operations, including commercial risk and working capital
modal kerja, kepatuhan terhadap ketentuan distribusi, management, compliance with distribution regulations,
serta penguatan kontrol proses yang mendukung akurasi and the strengthening of process controls to support the
dan keterlacakan aktivitas operasional. accuracy and traceability of operational activities.
Perseroan juga terus berupaya memperkuat pengelolaan The Company also continued to enhance the management
Whistleblowing System (WBS) sebagai sarana pelaporan of its Whistleblowing System (WBS) as a violation reporting
pelanggaran untuk mendukung budaya integritas dan mechanism to support a stronger culture of integrity and
pengendalian yang lebih kuat. Perseroan memastikan control. The Company ensured that the WBS mechanism
mekanisme WBS dapat diakses, menjaga kerahasiaan remained accessible, safeguarded the confidentiality
pelapor, serta menerapkan proses verifikasi dan tindak of whistleblowers, and applied objective verification
lanjut secara objektif sesuai ketentuan internal. Sepanjang and follow-up processes in accordance with internal
tahun 2025, Perseroan menerima 1 (satu) laporan/ provisions. Throughout 2025, the Company received 1
pengaduan melalui WBS, dengan tindak lanjut tidak (one) reports/complaints through the WBS, with follow-up
terbukti/ditutup, disertai penguatan sosialisasi WBS actions resulting in unsubstantiated/closed, accompanied
melalui Email dan website Perseroan. by strengthened WBS socialization through Email and
Company’s website.
Upaya peningkatan berkelanjutan lanjutan lainnya, antara As part of its ongoing continuous improvement
lain, Perseroan melakukan evaluasi atas penerapan efforts, the Company conducted an evaluation of its
GCG untuk mengidentifikasi kekuatan, area perbaikan, GCG implementation to identify strengths, areas of
serta rencana tindak lanjut. Hasil evaluasi tersebut improvement, and follow-up action plans. The results of
menjadi masukan Direksi dalam menyempurnakan this evaluation served as input for the Board of Directors in
kebijakan, proses, dan pengendalian, termasuk pada refining policies, processes, and controls, including in the
aspek kepatuhan, pengelolaan risiko, serta transparansi areas of compliance, risk management, and information
informasi. Pada tahun 2025, Perseroan mencatat hasil transparency. In 2025, the Company recorded a GCG
penilaian/assessment penerapan GCG sebesar 8,7. implementation assessment score of 8.7.
Melalui penguatan tata kelola yang dilakukan sepanjang Through the governance strengthening measures
2025, Direksi meyakini Perseroan berada pada jalur undertaken throughout 2025, the Board of Directors
yang tepat untuk menjaga kualitas pengelolaan usaha, believes that the Company remains on the right path to
memperkuat keandalan operasional, serta meningkatkan maintain the quality of business management, enhance
kepercayaan pemangku kepentingan dalam mendukung operational reliability, and increase stakeholder confidence
pengembangan Perseroan ke depan. in supporting the Company’s future development.
PERUBAHAN KOMPOSISI DIREKSI CHANGES IN THE COMPOSITION
OF THE BOARD OF DIRECTORS
Sepanjang tahun buku 2025, tidak terdapat perubahan Throughout fiscal year 2025, there were no changes to
susunan Direksi Perseroan. Direksi menjalankan tugas the composition of the Company’s Board of Directors.
pengurusan dan pengelolaan Perseroan sesuai The Board of Directors carried out its management and
kewenangan dan ketentuan yang berlaku, serta oversight duties in accordance with its authority and
senantiasa berkoordinasi dengan Dewan Komisaris prevailing regulations, and consistently coordinated
dalam memastikan pelaksanaan strategi dan kebijakan with the Board of Commissioners to ensure that the
Perseroan berjalan selaras dengan arah pengembangan implementation of the Company’s strategies and policies
usaha. remained aligned with its business development direction.
Perubahan komposisi Direksi terjadi setelah berakhirnya Changes to the composition of the Board of Directors
tahun buku 2025, sebelum Laporan Tahunan ini occurred after the end of fiscal year 2025, prior to the
ditandatangani, sebagai tindak lanjut keputusan Rapat signing of this Annual Report, as a follow-up to the
Umum Pemegang Saham Luar Biasa (RUPSLB) tanggal resolution of the Extraordinary General Meeting of
14 Januari 2026. Shareholders (EGMS) held on January 14, 2026.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 43
Page 44
Laporan Manajemen Positioned for
Management Report Profitable Growth
Adapun susunan Direksi Perseroan adalah sebagai berikut: The composition of the Company’s Board of Directors is
as follows:
Susunan Direksi per 31 Desember 2025 Composition of the Board of Directors
as of December 31, 2025
1. Direktur Utama: 1. President Director:
Bapak Ahmad bin Abu Bakar Mr. Ahmad bin Abu Bakar
2. Direktur: 2. Director:
Bapak Mohamad Fazly bin Hassan Mr. Mohamad Fazly bin Hassan
Susunan Direksi setelah Composition of the Board of Directors
RUPSLB 14 Januari 2026 following the EGMS on January 14, 2026
1. Direktur Utama: 1. President Director:
Bapak Dr. Imam Fathorrahman, M.M Dr. Imam Fathorrahman, M.M
2. Direktur: 2. Director:
Bapak Mohamad Fazly bin Hassan Mr. Mohamad Fazly bin Hassan
PENERAPAN ASPEK IMPLEMENTATION OF
KEBERLANJUTAN [OJK D.1] SUSTAINABILITY ASPECTS [OJK D.1]
Keberlanjutan merupakan sebagian upaya dari Sustainability constitutes part of the Company’s efforts
menjaga kelangsungan usaha melalui keseimbangan to maintain business continuity through a balanced
kinerja ekonomi, perhatian pada dampak sosial, serta approach to economic performance, attention to social
pengelolaan aspek lingkungan yang relevan dengan impacts, and the management of environmental aspects
kegiatan operasional Perseroan. relevant to the Company’s operational activities.
Dalam konteks bisnis distribusi farmasi dan alat kesehatan, In the context of pharmaceutical and medical device
pendekatan keberlanjutan Perseroan diarahkan untuk distribution, the Company’s sustainability approach is
memastikan layanan yang andal, kepatuhan terhadap directed toward ensuring reliable services, compliance
ketentuan yang berlaku, perlindungan terhadap with applicable regulations, the protection of occupational
keselamatan dan kesehatan kerja, serta kontribusi health and safety, and measurable social contributions to
sosial yang terukur bagi masyarakat. Pengungkapan the community. The Company’s sustainability disclosures
keberlanjutan Perseroan disusun mengacu pada are prepared in reference to the Financial Services Authority
ketentuan Otoritas Jasa Keuangan mengenai penerapan (OJK) regulations concerning the implementation of
keuangan berkelanjutan bagi lembaga jasa keuangan, sustainable finance for financial services institutions,
emiten, dan perusahaan publik. issuers, and public companies.
Sepanjang tahun 2025, Direksi menempatkan isu-isu Throughout 2025, the Board of Directors integrated relevant
keberlanjutan yang relevan ke dalam pengelolaan sustainability issues into the Company’s management,
Perseroan, terutama pada area kepatuhan dan tata particularly in the areas of compliance and governance,
kelola, pengelolaan risiko operasional dan komersial, operational and commercial risk management,
ketenagakerjaan, serta efisiensi proses yang berdampak employment practices, and process efficiency impacting
pada penggunaan sumber daya. Perseroan juga resource utilization. The Company also continued to
melanjutkan penguatan proses identifikasi isu strengthen its sustainability issue identification process
keberlanjutan untuk menentukan tingkat materialitas to determine the materiality level of issues that should
isu yang perlu menjadi fokus pengelolaan dan pelaporan, become priorities in management and reporting, in line
sejalan dengan dinamika kebutuhan pemangku with evolving stakeholder expectations and industry
kepentingan dan perkembangan industri. developments.
44 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 45
Positioned for
Profitable Growth
Pada aspek sosial, Perseroan menjalankan program From a social perspective, the Company implemented
Tanggung Jawab Sosial dan Lingkungan (TJSL) sebagai Corporate Social and Environmental Responsibility (CSER)
wujud kontribusi kepada masyarakat. Sepanjang tahun programs as a form of contribution to society. Throughout
2025, Perseroan merealisasikan program TJSL dengan 2025, the Company realized CSER programs with a total
total biaya sebesar Rp289.578.205, yang diarahkan untuk expenditure of Rp289,578,205, directed toward supporting
mendukung kebutuhan sosial yang relevan dengan social needs relevant to communities surrounding the
komunitas di sekitar wilayah operasional Perseroan. Company’s operational areas.
Sementara itu, Perseroan juga melakukan evaluasi atas The Company also evaluated the effectiveness of program
efektivitas pelaksanaan program untuk memastikan implementation to ensure that the benefits delivered were
manfaatnya selaras dengan tujuan kegiatan serta aligned with the objectives of the activities and the needs
kebutuhan para penerima manfaat. of beneficiaries.
Pada aspek lingkungan, Perseroan melanjutkan inisiatif From an environmental perspective, the Company
yang relevan dengan karakter operasional distribusi, continued initiatives relevant to the characteristics of its
terutama melalui penguatan efisiensi proses dan distribution operations, particularly through strengthening
penggunaan sumber daya secara lebih optimal. Arah process efficiency and optimizing resource utilization.
ini sejalan dengan upaya Perseroan untuk meningkatkan This direction is aligned with the Company’s efforts to
efektivitas operasional sekaligus mengelola dampak enhance operational effectiveness while managing the
lingkungan yang melekat pada aktivitas pergudangan environmental impacts inherent in warehousing and
dan distribusi, sesuai ketentuan yang berlaku. distribution activities, in accordance with prevailing
regulations.
Direksi menyadari bahwa penguatan penerapan The Board of Directors recognizes that strengthening
keberlanjutan memerlukan konsistensi kebijakan, sustainability implementation requires policy consistency,
ketersediaan data, serta kesiapan proses lintas fungsi, data availability, and cross-functional process
terutama di tengah perubahan regulasi dan persaingan readiness, particularly amid evolving regulations and
industri yang terus berkembang. Karena itu, pada tahun- industry competition. Accordingly, in the coming years
tahun berikutnya Perseroan akan melanjutkan penguatan the Company will continue to enhance sustainability
pengelolaan keberlanjutan melalui peningkatan kualitas management through improving data quality and
data dan pelaporan, penyelarasan program dengan isu- reporting, aligning programs with the most relevant issues,
isu yang paling relevan, serta pengembangan inisiatif and developing initiatives that support the Company’s
yang mendukung penguatan kinerja dan kontribusi performance enhancement and sustainable contributions.
Perseroan secara berkelanjutan.
Direksi menegaskan komitmen untuk mengintegrasikan The Board of Directors reaffirms its commitment
pertimbangan keberlanjutan ke dalam pengelolaan to integrating sustainability considerations into
Perseroan, terutama melalui penguatan tata kelola, the Company’s management, particularly through
kepatuhan, pengelolaan risiko, serta peningkatan strengthening governance, compliance, risk management,
efektivitas proses yang relevan dengan operasional and process effectiveness relevant to operations. The
Perseroan. Direksi juga mencermati tantangan utama Board also acknowledges key challenges in sustainability
dalam penerapan keberlanjutan, termasuk kebutuhan implementation, including the need to improve data
penguatan kualitas data dan indikator, penyelarasan quality and indicators, align cross-functional programs,
program lintas fungsi, serta dinamika ketentuan yang and adapt to continuously evolving regulations. To this end,
terus berkembang. Untuk itu, strategi pencapaian target the strategy for achieving sustainability targets will focus
keberlanjutan akan diarahkan pada penguatan kebijakan on strengthening policies and procedures, enhancing the
dan prosedur, peningkatan kualitas pelaporan dan quality of reporting and monitoring, and developing social
pemantauan, serta pengembangan program sosial dan programs and operational initiatives most relevant to the
inisiatif operasional yang paling relevan dengan karakter Company’s business characteristics.
bisnis Perseroan.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 45
Page 46
Laporan Manajemen Positioned for
Management Report Profitable Growth
PENUTUP DAN APRESIASI CLOSING AND APPRECIATION
Tahun 2025 menjadi periode penting bagi Perseroan dalam The year 2025 marked an important period for the
menjaga kelangsungan usaha sekaligus memperkuat Company in maintaining business continuity while
fondasi pengelolaan operasional di tengah dinamika strengthening the foundation of its operational
industri yang semakin kompetitif, perubahan ketentuan management amid increasingly competitive industry
kepatuhan yang terus berkembang, serta tantangan dynamics, evolving compliance requirements, and
pengelolaan modal kerja yang menjadi karakteristik working capital management challenges inherent in
utama bisnis distribusi. Di tengah kondisi tersebut, the distribution business. Under these conditions, the
Perseroan tetap mampu membukukan kinerja yang positif Company was able to record positive performance
dan tumbuh dibandingkan tahun sebelumnya, sejalan and growth compared to the previous year, in line with
dengan penerapan strategi dan kebijakan strategis yang the implementation of targeted strategies and policies
terarah pada penguatan jaringan layanan, peningkatan focused on strengthening the service network, enhancing
kualitas pengelolaan pelanggan dan persediaan, serta the quality of customer and inventory management, and
pemanfaatan sistem untuk meningkatkan efektivitas leveraging systems to improve process effectiveness.
proses.
Memasuki tahun 2026, Direksi akan melanjutkan Entering 2026, the Board of Directors will continue the
agenda penguatan Perseroan melalui pengembangan Company’s strengthening agenda through portfolio
portofolio, perluasan jangkauan layanan pada wilayah development, expansion of service coverage in
yang potensial, peningkatan digitalisasi proses bisnis, high-potential regions, increased digitalization of
serta penguatan infrastruktur pendukung operasional. business processes, and reinforcement of operational
Seluruh agenda tersebut diarahkan untuk meningkatkan support infrastructure. These initiatives are directed
keandalan layanan, memperkuat daya saing, serta toward enhancing service reliability, strengthening
menjaga kualitas pengelolaan risiko dan kepatuhan, competitiveness, and maintaining the quality of risk
sehingga Perseroan dapat terus menciptakan nilai management and compliance, thereby enabling the
jangka panjang bagi pemegang saham dan pemangku Company to continue creating long-term value for
kepentingan. shareholders and stakeholders.
Atas nama Direksi, kami menyampaikan terima kasih On behalf of the Board of Directors, we extend our
kepada Dewan Komisaris atas arahan dan pengawasan sincere appreciation to the Board of Commissioners for
yang konstruktif sepanjang tahun 2025. Direksi juga its constructive guidance and supervision throughout
menyampaikan apresiasi kepada para pemegang 2025. The Board of Directors also conveys its gratitude
saham atas kepercayaan dan dukungan yang diberikan to the shareholders for their trust and continued support
kepada Perseroan. Kepada seluruh karyawan, kami of the Company. To all employees, we express our
menyampaikan penghargaan yang setinggi-tingginya highest appreciation for their commitment, hard work,
atas komitmen, kerja keras, dan kontribusi yang menjadi and contributions, which have been the key drivers of
penggerak utama kelancaran operasional dan capaian operational excellence and the Company’s achievements
Perseroan sepanjang tahun. throughout the year.
46 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 47
Positioned for
Profitable Growth
Direksi turut menyampaikan terima kasih kepada The Board of Directors also extends its appreciation to all
seluruh pelanggan, prinsipal, mitra usaha, regulator, customers, principals, business partners, regulators, and
serta para pemangku kepentingan lainnya atas kerja other stakeholders for the strong cooperation established.
sama yang terjalin dengan baik. Dengan dukungan dan With the support and collaboration of all parties, the Board
kolaborasi seluruh pihak, Direksi optimistis Perseroan of Directors remains optimistic that the Company will
dapat melanjutkan penguatan kinerja dan meningkatkan continue to strengthen its performance and enhance
kualitas layanan secara berkelanjutan pada tahun-tahun service quality sustainably in the years ahead.
mendatang.
Jakarta, 16 April 2026
Jakarta, April 16, 2026
Atas nama Direksi,
On behalf of the Board of Directors,
Dr. Imam Fathorrahman, M.M
Direktur Utama
President Director
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 47
Page 48
Laporan Manajemen Positioned for
Management Report Profitable Growth
Surat Pernyataan Anggota Dewan Komisaris dan Direksi
Tentang Tanggung Jawab atas Laporan Tahunan dan
Laporan Keberlanjutan Tahun 2025
PT Millennium Pharmacon International Tbk
Board of Commissioners’ and Board of Directors’ Statement
Regarding Responsibility for the 2025 Annual Report and Sustainability Report
of PT Millennium Pharmacon International Tbk
Kami yang bertanda tangan di bawah ini, menyatakan We, the undersigned, hereby declare that all information
bahwa semua informasi dalam Laporan Tahunan in the Annual Report and Sustainability Report of PT
dan Laporan Keberlanjutan PT Millennium Pharmacon Millennium Pharmacon International Tbk for 2025 has
International Tbk tahun 2025 telah dimuat secara lengkap been fully disclosed and are completely responsible for the
dan bertanggung jawab penuh atas kebenaran isi Laporan accuracy of the Company’s Annual Report & Sustainability
Tahunan & Laporan Keberlanjutan Perusahaan. Report.
Demikian pernyataan ini dibuat dengan sebenarnya. This is our declaration which has been made, truthfully.
Jakarta, 16 April 2026
Jakarta, April 16, 2026
Dewan Komisaris
Board of Commissioners
Joefly Joesoef Bahroeny
Komisaris Utama & Independen
President Commissioner & Independent
Sarah Azreen binti Abdul Samat Aman Bhakti Pulungan Dato’ Zulkifli bin Jafar
Komisaris Independen Komisaris Independen Komisaris
Independent Commissioner Independent Commissioner Commissioner
Direksi
Board of Directors
Imam Fathorrahman Mohamad Fazly bin Hassan
Direktur Utama Direktur
President Director Director
48 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 49
Positioned for
Profitable Growth
Halaman ini sengaja dikosongkan
This page is intentionally left blank
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 49
Page 50
Laporan Manajemen Positioned for
Management Report Profitable Growth
03
Profil
Perusahaan
Company Profile
50 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 51
Positioned for Profitable Growth PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 51
Page 52
Positioned for
Identitas dan Informasi Umum Perusahaan
Nama Perusahaan
Kegiatan Usaha
• •
• •
• •
• •
•
•
•
•
73,43%
9,72%
3,36%
1,86% Rp218.400.000.000
11,63%
Rp218,400,000,000
Jaringan Usaha
Rp127.400.000.000
Rp1.960.719.855.135
52 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 53
Positioned for
Profitable Growth
Riwayat Singkat Perusahaan
A Brief History of The Company
Perseroan didirikan di Jakarta pada tanggal 20 Oktober The company was founded in Jakarta on October 20, 1952,
1952 oleh Bapak Soedarpo Sastrosatomo dan Ibu Minarsih by Mr. Soedarpo Sastrosatomo and Mrs. Minarsih Soedarpo
Soedarpo Sastrosatomo Wiranatakusumah dengan nama Sastrosatomo Wiranatakusumah under the name N.V.
N.V. Perseroan Dagang (NVPD) Soedarpo Corporation. Perseroan Dagang (NVPD) Soedarpo Corporation.
Pendirian Perseroan dikukuhkan dengan akta pendirian, The establishment of the Company was confirmed by a
yaitu Akta No. 32 tertanggal 20 Oktober 1952 yang diubah deed of establishment, namely Deed No. 32 dated October
dengan Akta Perubahan No. 14 tertanggal 5 Mei 1953, dan 20, 1952, which was amended by Amendment Deed No.
telah disahkan oleh Menteri Kehakiman Republik Indonesia 14 dated May 5, 1953, and was approved by the Minister
serta diumumkan dalam Berita Negara Republik Indonesia of Justice of the Republic of Indonesia and announced
No. 56 tanggal 14 Juli 1953. in the State Gazette of the Republic of Indonesia No. 56
dated July 14, 1953.
Pada tanggal 21 Februari 1990, Perseroan melakukan On February 21, 1990, the Company adjusted its legal status
penyesuaian status badan hukum menjadi Perseroan to a Limited Liability Company, which was confirmed
Terbatas yang dikukuhkan melalui Akta No. 182 tanggal through Deed No. 182 dated February 21, 1990. The deed
21 Februari 1990. Akta tersebut dibuat oleh Raharti was drawn up by Raharti Sudjardjati, S.H., Notary in Jakarta,
Sudjardjati, S.H., Notaris di Jakarta, dan telah memperoleh and was approved by the Minister of Justice of the Republic
pengesahan dari Menteri Kehakiman Republik Indonesia of Indonesia through Decree No. C2-1252-HT-01.04. TH.90
dengan Keputusan Nomor C2-1252-HT-01.04.TH.90 tanggal dated March 7, 1990, and was announced in the State
7 Maret 1990 serta telah diumumkan dalam Berita Negara Gazette of the Republic of Indonesia No. 31 dated April 17,
Republik Indonesia No. 31 tanggal 17 April 1990 Tambahan 1990, Supplement No. 1418. Thus, the Company's official
No. 1418. Dengan demikian, nama Perseroan resmi menjadi name became PT NVPD Soedarpo Corporation.
PT NVPD Soedarpo Corporation.
Langkah strategis Perseroan berlanjut ke pasar modal. The Company's strategic steps continued into the capital
Pada tanggal 7 Mei 1990, Perseroan berhasil mencatatkan market. On May 7, 1990, the Company successfully listed
saham perdananya di Bursa Efek di Indonesia dengan its initial shares on the Indonesia Stock Exchange with the
kode saham SDPC sebanyak 3.500.000 lembar (38,46% stock code SDPC for 3,500,000 shares (38.46% of the issued
dari modal ditempatkan dan disetor penuh). Sejak saat itu, and fully paid-up capital). Since then, the Company's
nama Perseroan menjadi PT NVPD Soedarpo Corporation name has been PT NVPD Soedarpo Corporation Tbk. In its
Tbk. Dalam perkembangannya, Perseroan beberapa kali development, the Company has several times increased
melakukan peningkatan modal dasar melalui Penawaran its authorized capital through Limited Public Offerings
Umum Terbatas (PUT) yang disetujui pemegang saham, (PUT) approved by shareholders, including in 2000, 2002,
di antaranya pada tahun 2000, 2002, dan 2017. and 2017.
Memasuki milenium baru, tepatnya pada tanggal 09 Juni Entering the new millennium, precisely on June 9th
2000, Perseroan melakukan perubahan nama menjadi PT 2000, the Company changed its name to PT Millennium
Millennium Pharmacon International Tbk. Perubahan nama Pharmacon International Tbk. This name change was
ini dikukuhkan melalui akta No. 23 tanggal 09 Juni 2000. legalized through deed No. 23 dated June 09, 2000.
Pada tahun 2004, struktur kepemilikan saham mengalami In 2004, the share ownership structure underwent a
perubahan signifikan. Pharmaniaga International significant change when Pharmaniaga International
Corporation Sdn. Bhd., Malaysia, mengakuisisi 55% saham Corporation Sdn. Bhd., Malaysia, entered and acquired 55%
Perseroan. Komitmen investasi ini berlanjut pada tahun of the Company's shares. This investment commitment
2017, saat Pharmaniaga meningkatkan kepemilikannya continued in 2017, when Pharmaniaga increased its
sebesar 18,43%, sehingga total kepemilikan menjadi 73,43% ownership by 18.43%, bringing its total ownership to 73.43%
dan mengukuhkannya sebagai Pemegang Saham Utama and confirming its position as the Major Shareholder and
sekaligus Pengendali. Controller.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 53
Page 54
Profil Perusahaan Positioned for
Company Profile Profitable Growth
Pada tahun 2017 itu pula, sebagai langkah strategis In 2017, as a strategic business expansion measure, the
ekspansi usaha, Perseroan mengakuisisi 15% saham Company acquired 15% of the shares of pharmaceutical
perusahaan produsen farmasi PT Errita Pharma. Pada manufacturer PT Errita Pharma. Innovation continued
tahun 2023, Perseroan mendirikan anak usaha baru in mid-2023, when the Company established a new
bernama PT Digital Pharma Andalan Indonesia (DPAI/ subsidiary called PT Digital Pharma Andalan Indonesia
OLIN) untuk menjalankan kegiatan usaha di bidang (DPAI/OLIN) to carry out business activities in the fields
perdagangan besar & ritel, teknologi informasi, serta of wholesale & retail, information technology, and other
aktivitas penunjang lainnya. supporting activities.
Hingga akhir tahun 2025, Perseroan mengoperasikan 37 By the end of 2025, the Company had operated 37
cabang distribusi dengan dukungan 180 armada distribusi. distribution branches supported by 180 distribution fleets.
Jaringan ini melayani 22.000 outlet di seluruh Indonesia This network serves 22,000 outlets across Indonesia and
dan mendistribusikan 12.000 jenis produk dari berbagai distributes 12,000 types of products from various principals.
prinsipal.
INFORMASI PERUBAHAN NAMA INFORMATION ON CHANGES TO
DAN STATUS BADAN HUKUM THE NAME AND LEGAL STATUS
Nama dan Status Perseroan Dasar Hukum / Keterangan
Periode
Company Name and Status Legal Basis / Information
Pendirian Awal
Berdasarkan Akta No. 32 tanggal 20 Oktober 1952 dan Akta Perubahan
No. 14 tanggal 5 Mei 1953.
N.V. Perseroan Dagang (NVPD)
1952-1990
Soedarpo Corporation
Initial Establishment
Based on Deed No. 32 dated October 20, 1952 and Amendment Deed No.
14 dated May 5, 1953.
Penyesuaian Status Badan Hukum
Perubahan status dari Naamloze Vennootschap (N.V.) menjadi Perseroan
Februari 1990 –
Terbatas (PT) sesuai Akta No. 182 tanggal 21 Februari 1990.
Mei 1990
PT NVPD Soedarpo Corporation
February 1990 –
Adjustment of Legal Status
May 1990
Change of status from Naamloze Vennootschap (N.V.) to Limited Liability
Company (PT) in accordance with Deed No. 182 dated February 21, 1990.
Penawaran Umum Perdana (IPO)
Penambahan status "Tbk" seiring dengan pencatatan saham perdana
di Bursa Efek pada tanggal 7 Mei 1990.
Mei 1990 – 2000
PT NVPD Soedarpo Corporation Tbk
May 1990 – 2000
Initial Public Offering
The addition of the “Tbk” status coincided with the initial listing of shares
on the Stock Exchange on May 7, 1990.
Perubahan Identitas (Rebranding)
Perubahan nama dikukuhkan melalui akta No. 23 Tanggal 09 Juni 2000
2000-Sekarang PT Millennium Pharmacon
2000-Present International Tbk
Identity Change (Rebranding)
The name change was legalized through a deed No. 23 dated June 09, 2000
54 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 55
Positioned for
Profitable Growth
Visi, Misi, dan Budaya Perusahaan [OJK C.1]
Vision, Mission, And Corporate Culture
Visi | Vision
Menjadi Perseroan distribusi
yang paling efisien dan
efektif di Indonesia dengan
memberikan nilai tambah
kepada pelanggan dan
principal.
To become the most efficient and effective distribution
company in Indonesia by providing added value to
customers and principals
Misi | Mission
Menyediakan produk
pemeliharaan kesehatan dan
pelayanan terbaik ke seluruh
wilayah nusantara.
To provide the best health care products and services
to all regions of Indonesia.
Telaah Visi dan Misi oleh Dewan Review of Vision and Mission by the
Komisaris dan Direksi Board of Commissioners and Directors
Pada tahun 2025, Dewan Komisaris dan Direksi Perseroan In 2025, the Board of Commissioners and Directors
telah melakukan telaah terhadap visi dan misi Perseroan reviewed the Company’s vision and mission, affirming
dan menegaskan relevan dari pernyataan visi dan misi their relevance to the current situation and alignment
dengan kondisi saat ini dan kesesuaiannya dengan tujuan with the Company’s business objectives.
bisnis Perseroan.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 55
Page 56
Profil Perusahaan Positioned for
Company Profile Profitable Growth
Budaya Perusahaan | Corporate Culture
Karyawan PT Millennium Pharmacon International Employees of PT Millennium Pharmacon
Tbk percaya kepada nilai-nilai dan prinsip-prinsip International Tbk believe in values and principles
sebagai dasar keunggulan di tempat kerja. as the foundation of excellence in the workplace.
Kami bekerja sama untuk sukses dengan saling bermartabat
T
dan rasa hormat yang dapat menciptakan lingkungan yang
mendukung tujuan bersama
Team Work together for success with mutual dignity and respect that can
create an environment supporting common goals.
O
Open
Kami menghargai komunikasi yang efektif, dengan mendengarkan,
memahami, peduli, dan kasih sayang.
We value effective communication, with listening, understanding,
Communi caring, and compassion.
cation
P
Kami mencintai apa yang kami lakukan tentang keberhasilan
pelanggan, komunitas dan perusahaan.
Passion for
We love what we do about customer, community, and company
Excellence success.
I
Kita tidak akan berkompromi pada standar etika professional yang
tinggi kejujuran dan transparansi dalam semua interaksi.
Integrity and
We will not compromise on high professional ethical standards,
Honest honesty, and transparency in all interactions.
Kami menghormati, mendukung dan membangun satu sama lain
C
Caring
dan meminta bantuan jika kita membutuhkannya.
We respect, support, and build each other up and ask for help if we
need it.
56 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 57
Positioned for
Profitable Growth
Kegiatan Usaha [OJK C.4] [GRI 2-6]
Business Activities
KEGIATAN USAHA MENURUT BUSINESS ACTIVITIES ACCORDING TO
ANGGARAN DASAR TERAKHIR THE LATEST ARTICLES OF ASSOCIATION
Sesuai Pasal 3, Anggaran Dasar Perseroan, maksud dan In accordance to Article 3 of the Company’s Articles of
tujuan Perseroan ialah dalam bidang: Association, the purpose and objectives of the Company
are in the field of:
a. Perdagangan besar obat farmasi untuk manusia a. Wholesale trade of pharmaceuticals for humans
b. Perdagangan besar obat tradisional untuk manusia b. Wholesale trade of traditional medicine for humans
c. Perdagangan besar kosmetik untuk manusia c. Wholesale trade of cosmetics for humans
d. Perdagangan besar alat laboratorium, alat farmasi d. Wholesale trade of laboratory equipment,
dan alat kedokteran untuk manusia pharmaceutical equipment, and medical equipment
for humans
e. Perdagangan besar gula, coklat dan kembang gula e. Wholesale trade of sugar, chocolate, and confectionery
f. Perdagangan besar makanan dan minuman lainnya f. Wholesale trade of food and beverages
Untuk mencapai maksud dan tujuan Perseroan, Perseroan To achieve the Company's purpose and objectives, the
dapat melakukan kegiatan usaha utama dan penunjang, Company may engage in the following principal and
sebagai berikut: supporting business activities:
Kegiatan Usaha Utama Main Business Activities
a. Menjalankan usaha perdagangan besar obat farmasi a. Running a wholesale trading business of
untuk manusia, yang mencakup rumah tangga, seperti pharmaceutical drugs for humans, which includes
obat-obatan dan suplemen kesehatan untuk manusia the wholesale trading business of pharmaceutical
(kode Klasifikasi Baku Lapangan Usaha Indonesia (KBLI) drugs for household use, such as medicines and
46441). health supplements for humans (Indonesian Standard
Industrial Classification code) (KBLI) 46441).
b. Menjalankan usaha perdagangan besar obat b. Conducting wholesale trade in traditional medicines for
tradisional untuk manusia, yang mencakup usaha humans, which includes wholesale trade in traditional
perdagangan besar obat tradisional atau jamu dan medicines or herbal medicine and health supplements
suplemen kesehatan untuk manusia (kode KBLI 46442). for humans (KBLI code 46442).
c. Menjalankan usaha perdagangan besar kosmetik c. Conducting wholesale trade in cosmetics for humans,
untuk manusia, yang mencakup usaha perdagangan which includes wholesale trade in cosmetics for
besar kosmetik untuk manusia seperti parfum, sabun, humans, such as perfume, soap,powder, and others
bedak dan lainnya (kode KBLI 46443). (KBLI code 46443).
d. Menjalankan usaha perdagangan besar alat d. Running a wholesale trade business of laboratory
laboratorium, alat farmasi dan alat kedokteran untuk equipment, pharmaceutical equipment, and medical
manusia, yang mencakup usaha perdagngan besar devices for humans, which includes the wholesale trade
alat laboratorium, alat farmasi dan alat kedokteran business of laboratory equipment, pharmaceutical
untuk manusia (kode KBLI 46691). equipment, and medical devices for humans. (KBLI
code 46691).
e. Menjalankan usaha perdagangan besar gula, e. Conducting wholesale trading business of sugar,
coklat dan kembang gula yang mencakup usaha chocolate, and confectionery, which includes wholesale
perdagangan besar gula, coklat, kembang gula dan trading business of sugar, chocolate, confectionery
sediaan pemanis (kode KBLI 46331). and sweetening preparations (KBLI code 46331).
f. Menjalankan usaha perdagangan besar makanan f. Running a wholesale food and other beverage business,
dan minuman lainnya, yang mencakup usaha which includes wholesale food and other beverage
perdagangan besar makanan dan minuman lainnya, businesses, such as rice flour, tapioca flour, bakery
seperti tepung besar, tepung tapioka, premiks bakeri, premixes, caramels, processed honey, shrimp crackers
karamel, madu olahan, kerupuk udang dan lain-lain. and others. Including food for special nutritional
Termasuk pangan untuk pkeperluan gizi khusus ( untuk purposes (for infants, children, and adults), food
bayi, anak dan dewasa), bahan penolong (processing additives, processing aids, other snacks, unprocessed
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 57
Page 58
Profil Perusahaan Positioned for
Company Profile Profitable Growth
aid), makanan ringan lainnga, serelia dan produk and processed cereals and cereal-based products,
berbasis serelia yang belim diolah maupun yang telah soy beverages, ready-to-eat foods, and wholesale pet
diolah, minuman produk kedelai, makanan siap saji, food and animal feed (KBLI code 46339).
serta perdagangan besar makanan untuk hewan
piaraan dan makanan ternak (kode KBLI 46339).
Kegiatan Usaha Penunjang Supporting Business Activities
Menjalankan usaha lain yang berkaitan dan mendukung Conducting other businesses related to and supporting
kegiatan usaha utama Perseroan sesuai dengan the Company’s main business activities in accordance
peraturan perundang-undangan yang berlaku. with applicable laws and regulations.
Kegiatan Usaha yang Dijalankan Current Business Activities
Kegiatan usaha yang dijalankan saat ini oleh Perseroan The current business activities carried out by the Company
antara lain distribusi produk farmasi, suplemen makanan, include the distribution of pharmaceutical products,
dan alat kesehatan dengan cakupan seluruh Indonesia. food supplements, and medical devices with coverage
throughout Indonesia.
PRODUK DAN JASA LAYANAN PRODUCTS AND SERVICES
[OJK C.4] [GRI 2-6]
Produk Products
Produk yang ditawarkan oleh Perseroan, antara lain: Products offered by the Company are among others:
1. Obat Resep 1. Prescription Drugs
2. Obat Non-Resep 2. Non-Prescription Drugs
3. Alat Kesehatan 3. Medical Disposables
4. Barang Konsumsi 4. Consumer Goods
Jasa Services
Jasa yang ditawarkan oleh Perseroan, antara lain: Services offered by the Company are among others:
1. Penjualan dan Distribusi 1. Sales and Distribution
2. Pemasaran 2. Marketing
3. Logistik 3. Logistics
Daftar Prinsipal List of Principals
Prinsipal merupakan mitra usaha strategis bagi Principals are strategic business partners for the
keberlangsungan bisnis Perseroan. Hingga akhir tahun Company’s business continuity. By the end of 2025, the
2025, Perseroan telah menjalin kerja sama dengan 29 (dua Company has established partnerships with 29 (twenty-
puluh sembilan) prinsipal, yang terdiri dari perusahaan nine) principals, consisting of national and multinational
farmasi dan alat kesehatan berskala nasional maupun pharmaceutical and medical device companies. Through
multinasional. Melalui kemitraan ini, Perseroan dipercaya these partnerships, the Company is entrusted to distribute
untuk mendistribusikan berbagai kategori produk ke various product categories to its entire branch network
seluruh jaringan cabang di Indonesia. in Indonesia.
Berikut adalah daftar prinsipal yang bekerja sama dengan The following is a list of principals that collaborate with
Perseroan: the Company:
58 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 59
Positioned for
Profitable Growth
Nama Prinsipal Nama Prinsipal
No. No.
Principal Name Principal Name
1 PT DANPAC PHARMA 16 PT MEIJI
2 PT DIPA PHARMA 17 PT MENITI JALAN SURGA
3 PT DUALIMA INDUSTRIES 18 PT MEPROFARM
4 PT EFES DERMACOS INDONESIA 19 PT METISKA FARMA
5 PT ERRITA PHARMA 20 PT NULAB PHARMACEUTICAL INDONESIA
6 PT GLOBAL DISPOMEDIKA 21 PT NUTRIFOOD INDONESIA
7 PT GLOBAL SUCCESS CHAIN 22 PT NUTRINDO
8 PT GRACIA PH. 23 PT PHAROS IND.
9 PT GUARDIAN PH. 24 PT PROMED
10 PT KEMENANGAN VITA FARMA 25 PT RAMA EMERALD MULTI SUKSES
11 PT KINOCARE 26 PT SIMEX
12 PT LAPI LABORATORIES 27 PT STERIL MEDICAL INDONESIA
13 PT LAPI OTC 28 PT TEGUHSINDO LESTARITAMA
14 PT MARKETAMA INDAH 29 PT PT BINTANG KENCANA ANUGERAH
15 PT MEDI HOP
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 59
Page 60
Profil Perusahaan Positioned for
Company Profile Profitable Growth
Rantai Nilai dan Hubungan Bisnis Lainnya [GRI 2-6]
Value Chain and Other Business Relationships
Perseroan bergerak dalam sektor industri kesehatan dengan The Company operates in the healthcare industry sector
fokus utama pada distribusi dan perdagangan besar produk with a primary focus on the distribution and wholesale of
farmasi, suplemen makanan, serta alat kesehatan. Dalam pharmaceutical products, food supplements, and medical
ekosistem kesehatan nasional, Perseroan memegang peran devices. Within the national healthcare ecosystem, the
vital sebagai jembatan strategis yang menghubungkan Company plays a pivotal role as a strategic bridge connecting
produsen farmasi dengan fasilitas layanan kesehatan dan pharmaceutical manufacturers with healthcare facilities and
ritel, memastikan ketersediaan produk berkualitas bagi retailers, ensuring the availability of high-quality products for
masyarakat luas. the wider community.
Rantai nilai operasional Perseroan bermula dari sisi hulu The Company’s operational value chain commences upstream
melalui kemitraan strategis dengan para prinsipal selaku through strategic partnerships with principals acting as product
penyedia produk. Hingga akhir tahun 2025, Perseroan telah providers. As of the end of 2025, the Company has established
menjalin kerja sama dengan 29 (dua puluh sembilan) collaborations with 29 (twenty-nine) prominent principals,
prinsipal terkemuka, baik yang berskala nasional maupun comprising both national and multinational entities, covering
multinasional, yang mencakup produsen obat resep, obat ranges of prescription drugs (ethical), over-the-counter drugs
bebas (OTC), hingga alat kesehatan. Hubungan bisnis ini (OTC), and medical devices. These business relationships are
didasari oleh perjanjian kerja sama distribusi yang dikelola governed by professionally managed distribution agreements,
secara profesional, baik yang bersifat eksklusif maupun non- on both exclusive and non-exclusive bases.
eksklusif.
Untuk menjamin kelancaran distribusi dari prinsipal ke To ensure seamless distribution from principals to customers,
pelanggan, Perseroan menjalankan kegiatan operasional the Company executes integrated logistics and warehousing
logistik dan pergudangan yang terintegrasi serta mematuhi operations that adhere to Good Distribution Practice (GDP)
standar Cara Distribusi Obat yang Baik (CDOB). Keunggulan standards. This operational excellence is supported by a solid
operasional ini didukung oleh infrastruktur yang solid, meliputi 1 infrastructure, comprising 1 (one) central warehouse and 37
(satu) gudang pusat serta 37 (tiga puluh tujuh) kantor cabang (thirty-seven) branch offices strategically distributed across
yang tersebar strategis di berbagai pulau di Indonesia. Dalam various islands in Indonesia. In its execution, the Company
pelaksanaannya, Perseroan mengoperasikan distribusi milik operates delivery fleet units and synergizes with third-party
sendiri serta bersinergi dengan mitra logistik pihak ketiga logistics partners to ensure on-time delivery.
untuk memastikan ketepatan waktu pengiriman.
Di sisi hilir rantai nilai, jangkauan distribusi Perseroan On the downstream side of the value chain, the Company’s
mencakup segmen pasar yang luas. Produk-produk farmasi distribution coverage encompasses a broad market segment.
dan alat kesehatan disalurkan kepada lebih dari 22.000 outlet Pharmaceutical and medical device products are distributed to
pelanggan aktif. Basis pelanggan ini terdiri dari segmen over 22,000 active customer outlets. This customer base consists
institusi seperti rumah sakit pemerintah dan swasta serta of the institutional segment such as government and private
dinas kesehatan serta segmen ritel farmasi yang meliputi hospitals as well as health offices and the pharmaceutical retail
apotek, toko obat berizin, Pedagang Besar Farmasi (PBF) lain, segment, which includes pharmacies, licensed drug stores, other
serta jaringan ritel modern. Pharmaceutical Wholesalers (PBF), and modern retail networks.
Di luar rantai nilai operasional tersebut, Perseroan juga Beyond the operational value chain, the Company fosters
membina hubungan bisnis strategis lainnya yang other strategic business relationships that strengthen
memperkuat tata kelola dan keberlanjutan usaha. Hal ini governance and business sustainability. This is reflected in
tercermin dari hubungan afiliasi dengan Pharmaniaga the affiliation with Pharmaniaga International Corporation
International Corporation Sdn. Bhd. selaku pemegang saham Sdn. Bhd. as the controlling shareholder, as well as business
pengendali, serta pengembangan diversifikasi bisnis melalui diversification through its subsidiary, PT Digital Pharma
entitas anak, PT Digital Pharma Andalan Indonesia (DPAI/OLIN), Andalan Indonesia (DPAI/OLIN), which focuses on the digital
yang berfokus pada ekosistem digital. Selain itu, Perseroan ecosystem. Furthermore, the Company actively participates
berpartisipasi aktif dalam GP Farmasi Indonesia, yang menjadi in the Indonesian Pharmaceutical Association (GP Farmasi
wadah strategis dalam memantau perkembangan industri. Indonesia), which serves as a strategic platform for monitoring
industry developments.
60 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 61
Positioned for
Profitable Growth
Perubahan yang Bersifat Signifikan [OJK C.6] [GRI 2-6]
Significant Changes
Pada tahun pelaporan 2025, terdapat beberapa In the reporting year 2025, there were several significant
perubahan signifikan dalam organisasi dan rantai pasok changes in the Company’s organization and supply chain,
Perseroan, antara lain: including:
• Ekspansi Jaringan: Pembukaan kantor cabang baru • Network Expansion: The opening of a new branch
di Kota Palu yang resmi beroperasi pada 12 November office in the city of Palu, which officially commenced
2025 dengan tujuan memperluas jangkauan distribusi operations on November 12, 2025, aimed at expanding
di wilayah Sulawesi Tengah. distribution coverage in the Central Sulawesi region.
• Perseroan merelokasi gedung kantor cabang Bekasi • The Company relocated the Bekasi branch office,
yang resmi beroperasi pada 20 Oktober dan gedung which officially commenced operations on October
kantor cabang Denpasar pada 29 Juli 2025 ke lokasi 20, and the Denpasar branch office on July 29, 2025,
yang lebih besar. to larger locations.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 61
Page 62
Profil Perusahaan Positioned for
Company Profile Profitable Growth
Wilayah Operasional dan
Informasi Jaringan Kantor Cabang [OJK C.3]
Operational Area and Branch Network Information
Gudang Pusat
Central Warehouse
Kantor Cabang
Branch Office
62 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 63
Positioned for
Profitable Growth
Jabodetabek (5) Sumatra (9):
1. Jakarta I 1. Banda Aceh
2. Jakarta II 2. Medan
3. Bogor 3. Pekanbaru
4. Bekasi 4. Batam
5. Tangerang 5. Jambi
6. Palembang
Jawa (14): 7. Padang
1. Tasikmalaya 8. Bandar Lampung
2. Purwokerto 9. Pematang Siantar
3. Surabaya
4. Solo Kalimantan (4):
5. Cirebon 1. Pontianak
6. Yogyakarta 2. Banjarmasin
7. Tegal 3. Balikpapan
8. Semarang 4. Samarinda
9. Kediri
10. Bandung Sulawesi (3)
11. Sidoarjo 1. Makassar
12. Jember 2. Manado
13. Malang 3. Palu
14. Purwakarta
Bali & Lombok (2)
1. Denpasar
2. Mataram
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 63
Page 64
Profil Perusahaan Positioned for
Company Profile Profitable Growth
AKSES INFORMASI PERUSAHAAN ACCESS TO COMPANY AND
DAN KANTOR CABANG [OJK C.2] BRANCH OFFICE INFORMATION
KANTOR PUSAT
HEADQUARTER
Crown Bungur Arteri Lantai 2-4 Gudang Pusat
Jl. Sultan Iskandar Muda No. 18/Jl. Bungur No. 1 Central Warehouse
Kel. Kebayoran Lama Selatan, Kec. Kebayoran Lama, Jakarta Komplek Pergudangan PT Linsea
Selatan 12240 Jl. Tipar No. 20 Cakung, Jakarta Timur
Telp. (62-21) 2708-5961, 64/65/66
Email : investor.relation@mpi-pharmaniaga.co.id
Website : https://mpi-indonesia.co.id/
CABANG | BRANCH
JABODETABEK
Jakarta I Jakarta II
Ruko Melawai, Jl. Ciledug Raya, No.17, RT.010/RW.04, Kel. Ulujami, Jl. Panjang No. 83 HH, Jakarta Barat
Kec. Pesanggrahan, Jakarta Selatan 12250 Telp.: (021) 56952205/4
Telp.: (021) 2273-5917
Fax.: (021) 5633254
Fax.: (021) 7366-9094
Bekasi Tangerang
Jl. Raya Kampung Setu No. 28 B-2, RT 014, RW 002, Desa/Kel. Pergudangan Sinar Hati
Bintarajaya, Kec. Bekasi Barat, Kota Bekasi, Jawa Barat 17136. Jl. Sinar Hati No. 88 Blok H & I, Kel. Sukajati, Kec. Karawaci
Telp.: (021) 8855720, 8857039, 88959632 Tangerang, Banten.
Fax.: (021) 8854844 Telp.: (021) 5576 3319, 5576 3320
Fax.: (021) 557887071
Bogor
Jl Raya Pemda Pangkalan II No. 2, Kampung Tunggilis,
RT 01 RW 13, Kel Kedunghalang, Kec Bogor Utara, Kota Bogor, 16158
Telp.: (0251) 7508112, 7508113
Fax.: -
JAWA
Bandung Cirebon
Jl. Jend. Sudirman 656, Bandung Jl. Buyut No. 28 B, RT 02/RW 14, Kamp. Kutasirap Kel.
Telp.: (022) 6030371, 6034715 Pegambiran, Kec. Lemahwungkuk, Kota Cirebon.
Fax.: (022) 6045526 Telp.: (0231) 231615
Fax.: (0231) 231614
Purwokerto Semarang
Jl. KH. Ahmad Dahlan No. 15, RT.03/RW.02, Kel. Karangsari, Jl. Brigjend Sudiarto No. 446 RT.01/RW.01, Kel. Pedurungan
Kec. Kembaran, Kab. Banyumas, Purwokerto 53182 Tengah, Kec. Pedurungan, Semarang Timur 50192
Telp.: (0281) 6577843 Telp.: (024) 76606068
Yogyakarta Solo
Jl. Magelang KM 9 Dusun Mulungan Banaran No. 8, Jl. Dr.Radjiman No. 652 B, Pajang – Laweyan, Solo, 57146
Tridadi Kab. Sleman. DIY Telp.: (0271) 7066581, 739327, 739554
Telp.: (0274) 8609341
Surabaya Sidoarjo
Jl. Kalibokor Selatan No. 152, Surabaya Jl. Lingkar Timur KM-2, No 168, Desa Wadungasih,
Telp.: (031) 5026210, 5026674, 5029638 Kec. Buduran, Kab Sidoarjo, 61252
Fax.: (031) 5015003 Telp.: (031) 99726103
Fax.: (031) 99726103
Malang Kediri
Jl. Raya Karanglo No. 73 B, RT. 03/RW. 04, Desa Banjararum Jl. Masjid Al Huda No. 4, RT 01 RW 02, Ngadirejo,
Singosari, Kab. Malang, Jawa Timur Kota Kediri 64122.
Telp.: (0341) 472977, 472978 Telp.: (0354) 673188, 673189
Fax.: (0341) 411328 Fax.: (0354) 4674569
Jember Tasikmalaya
Jl. Letjen Soetoyo, No.138, RT 002/RW 003, Jl. Letkol RE Jaelani, Blok Cikurubuk Ruko, No. 3, RT. 01/RW. 13,
Kel. Kranjingan, Kec.Sumbersari, Kab. Jember, Jawa Timur Kel. Mangkubumi, Kec. Linggajaya, Tasikmalaya
Telp.: (0331) 54433104 Telp.: (0265) 311682
Fax.: (0265) 327513
64 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 65
Positioned for
Profitable Growth
Tegal Purwakarta
Jl. Industri No. 14 RT. 05/RW. 14, Kel. Panggung, Kampung Karajan, RT. 01/RW. 01, Desa Cibungur. Kec.
Kec. Tegal Timur, Kota Tegal, 52122 Bungursari, Kab. Purwakarta.
Telp.: (0283) 4536494 Telp.: (0264) 7500010
Fax.: (0283) 4531232
SUMATRA
Banda Aceh Medan
Jl. Soekarno Hatta, Dusun Aulia, Gampong Mibo, Kec. Banda Jl. Beringin No. 2 Ringroad,
Raya, Kota Banda Aceh 23238 Kel. Sunggal, Kec. Medan Sunggal, Medan.
Telp.: (0651) 73530044 Telp.: (061) 804440887, 80440888
Fax.: - Fax.: (061) 80440881
Padang Palembang
Jl. Ir Juanda No.22, Kel. Rimbo Kaluang, Jl. Soekarno Hatta No 2520, RT. 049/RW. 011, Kel Bukit Baru,
Kec. Padang Barat, Padang Kec Ilir Barat 1, Palembang, Sumatera Selatan
Telp.: (0751) 39396 Telp.: (0711) 5560018, 5260060
Fax.: (0751) 7052100 Fax.: -
Bandar Lampung Pekanbaru
Jl. Hayam Wuruk No. 45, Kel. Bumi Kedamaian, Kec. Kedamaian, Jl. Pinang No. 89, Kel. Wonorejo, Kec. Marpoyan Damai,
Bandar Lampung Kota Pekanbaru
Telp.: (0721) 242214, 476458 Telp.: (0761) 7874998
Fax.: (0721) 263191 Fax.: (0761) 7874997
Batam Jambi
Komplek Century Park Blok B No. 1 Kel. Sadai, Jl. Lingkar Selatan No. 17, RT. 26, Kel. Kenali Asam Bawah, Kec.
Kec. Bengkong, Kota Batam Kota Baru, Kota Jambi (Komplek Pergudangan JTC-Jambi)
Telp.: (0778) 477579 Telp.: (0741) 3042742
Fax.: (0778) 477576 Fax.: (0741) 7550944
Pematang Siantar
Hl Medan KM 2,8 Bo. 93A, RT. 001/RW. 001, LK 1
(belakang dealer Honda Arista), Kel. Sumber Jaya, Kec. Siantar
Martoba, Pematang Siantar, Sumatera Utara
Telp.: (0622) 7218017
KALIMANTAN
Banjarmasin Balikpapan
Jl. Pangeran Hidayatullah No. 10, RT. 015/RW. 001, Banua Anyar, Jl. Indra Kila No. 10-A, RT 28, Kel. Gunung Samarinda Baru, Kel.
Banjarmasin Balikpapan Utara, Balikpapan, Kalimantan Timur
Telp.: (0511) 6744783 Telp.: (0542) 862848
Fax.: (0511) 3269711 Fax.: (0542) 7213016
Samarinda Pontianak
Jl. Teuku Umar, RT. 35, Wilayah Pergudangan (sebrang PT Citra Jl. Puskesmas Pal 3, No. 155-156, Sui Jawi, Pontianak
Kamp Beton), Kel Karang Asem Ulu, Kec. Sungai Kunjang, Kota Telp.: (0561) 7819010, 7810447
Samarinda
Telp.:
Fax.:
BALI
Denpasar Mataram
Jl. Cargo Indah No. 10, Kel. Ubung, Kec. Denpasar Utara, Kota Komplek Pergudangan Lingkar Selatan,
Denpasar - 80116. Jl. Dr. Soejono No. 13, Blok A7, B8, B9, Kel. Dasan Cermen,
Telp.: (0361) 4749397 Kec. Sandubaya, Kota Mataram - NTB
Fax.: (0361) 265033 Telp.: (0370) 7709049
SULAWESI
Makassar Manado
Jl. Ir. Sutami No. 18 Parangloe, Kec. Tamalarea, Makassar, Jl. Maesa No. 9 Ruko No. 6 dan 7, Lingkungan 7, Kelurahan
Sulawesi Selatan Ranonunut, Kec. Paal Dua, Manado, 95129
Telp.: (0411) 855167 Telp.: (0431) 8804999
Fax.: (0411) 855162 Fax.: (0431) 8808087
Palu
Jl. Merdeka No. 05, RT 001 RW 001, Kel. Talise Valangguni, Kec.
Mantikulore, Kota Palu - Sulawesi Tengah. Kode Pos: 94118.
CP: 0858 0422 4666
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 65
Page 66
Profil Perusahaan Positioned for
Company Profile Profitable Growth
Keanggotaan Pada Asosiasi [OJK C.5] [GRI 2-28]
Association Membership
Hingga akhir tahun 2025, Perseroan berpartisipasi aktif As the end of 2025, the Company actively participates
dalam sejumlah asosiasi berskala nasional. Keikutsertaan in several national-scale associations. This membership
ini bernilai strategis sebagai sarana memantau dinamika holds strategic significance, serving as a platform to
industri, memetakan risiko dan peluang, serta mempererat monitor industry dynamics, map risks and opportunities,
relasi dengan para pemangku kepentingan. and strengthen relationships with stakeholders.
Keanggotaan pada Asosiasi
Association Membership
Nama Asosiasi Peran Skala
Name of Association Role Scale
Asosiasi Emiten Indonesia Anggota | Member Nasional | National
Gabungan Perusahaan Farmasi Indonesia (GPFI) Anggota | Member Nasional | National
Gabungan Perusahaan Alat-Alat Kesehatan dan Laboratorium
Anggota | Member Nasional | National
(GAKESLAB)
Himpunan Seminar Farmasi Distribusi (HISFARDIS) Anggota | Member Nasional | National
66 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 67
Positioned for
Profitable Growth
Halaman ini sengaja dikosongkan
This page is intentionally left blank
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 67
Page 68
Profil Perusahaan Positioned for
Company Profile Profitable Growth
Struktur Organisasi
Organization Structure
STRUKTUR ORGANISASI MPI PER 31 DESEMBER 2025
MPI ORGANIZATIONAL STRUCTURE AS OF DECEMBER 31, 2025
Director
Mohamad Fazly bin Hassan
HRGA Senior Manager FACT General Manager
Widada M. Fadhli Bin Mustafa
Acc,
Claim & Tax Treasury, Collection
MIS BOM BOM BOM
Reconcile Manager AP & Asset Manager
Manager Region 1 Region 2 Region 3
Manager Indra Manager Evy
Munajar Wijanarko Suwoto Ramang P.
Ratih Akbar S. Nurbani Herawati
Asriani
68 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 69
Positioned for
Profitable Growth
Board of Commissioners
Nomination & Remuneration
Commmittee
Risk Management Committee
President Director Audit Committee
Ahmad Bin Abu Bakar
PT Digital
Corporate Secretary
Pharma
Olga Indria Bolang
Andalan
Operational General Indonesia
Manager (OLIN)
Herly
Operational Senior Supply Chain
RMIA & Legal Senior
Manager Management Senior
Manager
Maserih Manager
Robbi Nizori
Rizki Ari Prasetyo
ISO, Business
Oper
Internal Dev,
BOM BOM ational
BOM BOM BOM Warehouse Audit Compliance
Region 4 Principal 4 Excellence
Principal 1 Principal 2 Principal 3 Manager Manager & Legal
Nasarudin Morasela Manager
Maserih Wanto Olden G.T. Vacant Aris Manager
L. W. Eko
Sulistyanto Wan Syurya
Handoko
T.D.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 69
Page 70
Profil Perusahaan Positioned for
Company Profile Profitable Growth
Profil Dewan Komisaris
Board of Commissioners Profile
PERUBAHAN KOMPOSISI CHANGES IN THE COMPOSITION OF
ANGGOTA DEWAN KOMISARIS THE BOARD OF COMMISSIONERS
PADA TAHUN BUKU 2025 IN FISCAL YEAR 2025
Sepanjang tahun 2025, komposisi anggota Dewan Throughout 2025, the composition of the Company’s Board
Komisaris Perseroan tidak mengalami perubahan. Berikut of Commissioners has remained unchanged. The following
komposisi Anggota Dewan Komisaris per 31 Desember is the composition of the Board of Commissioners as of
2025: December 31, 2025:
Komposisi Anggota Dewan Komisaris per 31 Desember 2025
Composition of the Board of Commissioners as of December 31, 2025
Nama Jabatan
Name Position
Komisaris Utama & Komisaris Independen
Joefly Joesoef Bahroeny
President Commissioner & Independent Commissioner
Komisaris
Dato’ Zulkifli bin Jafar
Commissioner
Komisaris Independen
Dr. Imam Fathorrahman, M.M
Independent Commissioner
Prof. Aman Bhakti Pulungan, MD, Paed Consultant., PhD., Komisaris Independen
FAAP., FRCPI (Hon.) Independent Commissioner
Komisaris Independen
Sarah Azreen Binti Abdul Samat
Independent Commissioner
PERUBAHAN KOMPOSISI CHANGES IN THE COMPOSITION OF
ANGGOTA DEWAN KOMISARIS THE BOARD OF COMMISSIONERS
SETELAH TAHUN BUKU 2025 AFTER FISCAL YEAR 2025
Terdapat perubahan komposisi Anggota Dewan Komisaris There has been a change in the composition of the Board of
setelah tahun buku berakhir. Perubahan komposisi Commissioners after the end of the fiscal year. The change
Anggota Dewan berdasarkan keputusan Pemegang in the composition of the Board was based on a decision by
Saham melalui RUPS Luar Biasa pada 14 Januari 2026. the Shareholders through an Extraordinary General Meeting
Berikut komposisi Anggota Direksi setelah tahun buku 2025 of Shareholders on January 14, 2026. The following is the
hingga Laporan Tahunan ini diterbitkan pada April 2026: composition of the Board of Directors after the 2025 fiscal
year until this Annual Report was published in April 2026:
Komposisi Anggota Dewan Komisaris Setelah Tahun Buku 2025
Composition of the Board of Commissioners After Fiscal Year 2025
Nama Jabatan
Name Position
Komisaris Utama & Komisaris Independen
Joefly Joesoef Bahroeny
President Commissioner & Independent Commissioner
Komisaris
Dato’ Zulkifli bin Jafar
Commissioner
Prof. Aman Bhakti Pulungan, MD, Paed Consultant., PhD., Komisaris Independen
FAAP., FRCPI (Hon.) Independent Commissioner
Komisaris Independen
Sarah Azreen Binti Abdul Samat
Independent Commissioner
70 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 71
Positioned for
Profitable Growth
Joefly Joesoef Bahroeny
Komisaris Utama & Komisaris Independen
President Commissioner & Independent Commissioner
Dasar Hukum Pengangkatan
Basis of Appointment
Diangkat pertama kali sebagai Komisaris Utama & Komisaris Independen melalui Akta Pernyataan
Keputusan Rapat No. 30 tanggal 29 April 2021
Diangkat kembali sebagai sebagai Komisaris Utama & Komisaris Independen melalui Akta
Pernyataan Keputusan Rapat No. 72 tanggal 28 April 2022
First appointed as President Commissioner & Independent Commissioner through the Deed of
Statement of Meeting Resolutions No. 30 dated April 29, 2021
Reappointed as President Commissioner & Independent Commissioner through the Deed of
Statement of Meeting Resolutions No. 72 dated April 28, 2022
Pendidikan dan/atau Sertifikasi
Education and/or Certification
• Magister Manajemen, Universitas Sumatera Utara, 1997 – 1999
• Fakultas Agribisnis Bangunan, University of New South Wales, Sydney, 1979 – 1982
• Master of Management, University of North Sumatera, 1997 – 1999
• Faculty of Building Agrobusiness, University of New South Wales, Sydney, 1979 – 1982
Pengalaman Kerja
Employment History
• President Commissioner, PT Satya Agung (Palm Oil Plantation), 2019 – Present;
• President Commissioner, PT Sisirau (Palm Oil Plantation and Mill), 2019 – Present;
• Director, PT PP London Sumatra Indonesia, Tbk, 2007 – Present;
• Honorary Consul, The Republic of Sri Lanka, 2003 – Present
• Commissioner PT Teumaron (Palm Oil Plantation), 1991 – Present;
Periode ke/Period: • President Commissioner, PT P Bahrun & Sons (Rubber Plantation), 1983 – Present;
2 (dua) • President Commissioner, PT Bahruny (Palm Oil and Rubber Plantation), 1983 – Present;
2 (second) • President Commissioner, PT BAPCO (Bahruny Plantation and Company), 1983 – Present
• Commissioner, PT Satya Agung (Palm Oil Plantation), 2005 – 2019
Usia/Age: • Commissioner, PT Sisirau (Palm Oil Plantation and Mill), 1991 – 2019;
69 tahun • President Commissioner, PT Perkebunan Nusantara (Persero) Holding, 2014 – 2017.
69 years old • President Commissioner, PT Perkebunan Nusantara III (Persero), 2013 – 2014;
• Commissioner PT PP London Sumatra Indonesia, Tbk, 2004 – 2007;
Kewarganegaraan/Nationality:
Indonesia Rangkap Jabatan
Indonesian Concurrent Position
Domisili/Domicile: • Chairman, Nomination & Remuneration Committee PT MPI Tbk
Jakarta • President Commissioner, PT Digital Pharma Andalan Indonesia
• President Commissioner, PT Bahruny
• President Commissioner, PT Sisirau
• President Commissioner, PT Bapco
Menjabat sebagai Komisaris
• President Commissioner, PT Satya Agung
Utama & Komisaris Independen
• President Commissioner, PT Pbahrun & Sons
sejak 29 April 2021
• Commissioners, PT Teumaron
Served as President
• Director PT PP London Sumatra Indonesia, Tbk
Commissioner & Independent
Commissioner since April 29, 2021
Hubungan Afiliasi
Affiliation
Beliau tidak memiliki hubungan afiliasi dengan anggota Dewan Komisaris, anggota Direksi
lainnya dan pemegang saham utama.
He has no affiliation with members of the Board of Commissioners, other members of the Board
of Directors and major shareholders.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 71
Page 72
Profil Perusahaan Positioned for
Company Profile Profitable Growth
Dato’ Zulkifli Bin Jafar
Komisaris
Commissioner
Dasar Hukum Pengangkatan
Basis of Appointment
Diangkat pertama kali sebagai Komisaris melalui Akta Pernyataan Keputusan Rapat No. 49
tanggal 29 Mei 2023.
First appointed as Commissioner through the Deed of Statement of Meeting Resolutions No.
49 May 29, 2023.
Pendidikan dan/atau Sertifikasi
Education and/or Certification
• Master of Business Administration, MAHSA University, 2025
• Oxford Programme on Negotiation, Said Business School, University of Oxford, 2025
• Circular Economy and Sustainability Strategies, Cambridge Judge Business School, University
of Cambridge, 2002
• Certified Patent Agent, 2002
• Admission to Malaysian Bar, 1997
• Advocate and Solicitor of the High Court of Malaysia,1997
• Bachelor of Law, International Islamic University Malaysia (IIUM), 1996
Pengalaman Kerja
Employment History
• Managing Director Pharmaniaga Berhad, 2024 - present
• Director University Sains Islam Malaysia (USIM) Holdings Sdn Bhd, 2023 - present
• Chairman of the Advisory Panel (Faculty of Sharia and Law), and the Investment Committee
(USIM), 2023 - present
• Member of Disciplinary Committee (USIM), 2023 - present
Periode ke/Period: • Chairman USIM Tijarah Holdings, 2023 - 2025
• Deputy Chief Executive Officer Pharmaniaga Berhad, 2023
1 (satu)
• Group Executive Director Pharmaniaga Berhad, 2022
1 (first)
• Member of the Committees (Nomination and Remuneration Committee, Audit Committee, Board
Risk Management Committee) Pharmaniaga Berhad, 2020 - 2022
Usia/Age: • Chairman of Tender Board Committee Pharmaniaga Berhad, 2020-2022
53 tahun • Chairman of ldaman Pharma Manufacturing Sdn Bhd, 2020 - 2022
53 years old • Legal Advisor Johor State Government Linked Companies (GLC), 2016 - 2019
• Director and Management member of Chartridge Conference Centre (UK) Limited, 2015 - 2021
Kewarganegaraan/Nationality: • Board of Trustee of Foundation of Research and Transformation (Prime Minister’s Office), 2015 - 2021
Malaysia • Director Aladdin Group Sdn Bhd, 2015 - 2019
Malaysian • Chairman and Director Era Universe Development Sdn Bhd, 2014 - present
• Director Songa Offshore Malaysia Sdn Bhd, 2012 - 2015
Domisili/Domicile: • Director Cooperative Commission of Malaysia, 2008 - 2010
Malaysia • Major Shareholder and Director MMA Resources Sdn Bhd, 2007 - Present
• Partner Messr Rashid Zulkifli, 2002 - 2020
• Advocate and Solicitor Messrs Raslan Loong, 1997 - 2002
• Legal Counsel Aces Sdn Bhd, 1997
Menjabat sebagai Komisaris
sejak 29 Mei 2023 Rangkap Jabatan
Served as Commissioner since Concurrent Position
May 29, 2023
• Commissioner, PT Digital Pharma Anda Ian Indonesia
• Commissioner, PT Errita Pharma
• Member of the Risk Management Committee, PT MPI Tbk
• Member of the Audit Committee, PT MPI Tbk
• Managing Director, Pharmaniaga Berhad
• Director, MMA Resource Sdn Bhd
• Director, Marsland Development Sdn Bhd
• Director, Era Universe Sdn Bhd
Hubungan Afiliasi
Affiliation
Tidak memiliki hubungan afiliasi dengan anggota Dewan Komisaris, anggota Direksi lainnya
namun memiliki hubungan afiliasi dengan pemegang saham utama.
Has no affiliation with members of the Board of Commissioners, other members of the Board
of Directors but has an affiliation with major shareholders.
72 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 73
Positioned for
Profitable Growth
Dr. Imam Fathorrahman, M.M
Komisaris Independen
Independent Commissioner
Dasar Hukum Pengangkatan
Basis of Appointment
Diangkat pertama kali sebagai Komisaris Independen Perseroan melalui Akta Pernyataan
Keputusan Rapat No. 26 tanggal 21 November 2022.
First appointed as Independent Commissioner through the Deed of Statement of Meeting
Resolutions No. 26 November 21, 2022
Pendidikan dan/atau Sertifikasi
Education and/or Certification
• Doktor Ilmu Farmasi, Universitas Airlangga, 2024
• Magister Strategic Management, Sekolah Tinggi Manajemen PPM, 2003
• Profesi Apoteker, Universitas Airlangga, 1989
• Doctor of Pharmaceutical Sciences, Airlangga University, 2024
• Master of Strategic Management, PPM College of Management, 2003
• Professional Pharmacist, Universitas Airlangga, 1989
Pengalaman Kerja
Employment History
• Independent non Executive Director Pharmaniaga Berhad, 2024 - Present
• Direktur Pemasaran & Komersial PT Kimia Farma Tbk 2021 – 2022
• Direktur Pengembangan Bisnis PT Kimia Farma Tbk, 2019 - 2021
• Direktur Utama Kimia Farma Apotek, 2011 - 2019
• Director of Marketing & Commercial of PT Kimia Farma Tbk, 2021-2022
• Director of Business Development PT Kimia Farma Tbk, 2019 – 2021
• President Director of Kimia Farma Pharmacy, 2011 - 2019
Periode ke/Period:
1 (satu) Rangkap Jabatan
1 (first) Concurrent Position
Usia/Age: • Anggota Dewan Komisaris PT Digital Pharma Andalan Indonesia
61 tahun • Anggota Dewan Komisaris PT Errita Pharma
61 years old • Anggota Komite Audit PT MPI Tbk
• Anggota Komite Nominasi dan Remunerasi PT MPI Tbk
Kewarganegaraan/Nationality: • Independent Non-Executive Director Pharmaniaga Sdn Bhd
Indonesia • Member of Board of Commissioners of PT Digital Pharma Andalan Indonesia
Indonesian • Member of Board of Commissioners of PT Errita Pharma
• Member of Audit Committee of PT MPI Tbk
Domisili/Domicile: • Member of Nomination and Remuneration Committee of PT MPI Tbk
Jakarta
Hubungan Afiliasi
Affiliation
Menjabat sebagai Komisaris Beliau tidak memiliki hubungan afiliasi dengan anggota Dewan Komisaris, anggota Direksi
Independen sejak 21 November lainnya dan pemegang saham utama.
2022 – 14 Januari 2026 He has no affiliation with members of the Board of Commissioners, other members of the Board
Served as Independent of Directors and major shareholders.
Commissioner since November
21, 2022 – January 14, 2026
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 73
Page 74
Profil Perusahaan Positioned for
Company Profile Profitable Growth
Prof. Aman Bhakti Pulungan, MD, Paed
Consultant., PhD., FAAP., FRCPI (Hon.)
Komisaris Independen
Independent Commissioner
Dasar Hukum Pengangkatan
Basis of Appointment
Diangkat pertama kali sebagai Komisaris Independen melalui Akta Pernyataan Keputusan
Rapat No. 26 tanggal 21 November 2022.
First appointed as Independent Commissioner through the Deed of Statement of Meeting
Resolutions No. 26 dated November 21, 2022.
Pendidikan, Pengalaman Kerja dan Penghargaan
Education, Employement History and Rewards
Bapak Aman B. Pulungan adalah seorang profesor pediatri, Komite Eksekutif International
Pediatric Association, konsultan senior di bidang endokrinologi pediatrik, Fakultas Kedokteran,
Universitas Indonesia, anggota NCD Child Governing Council, dan pernah menjabat sebagai
presiden Asia Pacific Pediatric Association, mantan presiden Persatuan Dokter Anak Indonesia,
dan mantan presiden Masyarakat Endokrin Pediatri Asia Pasifik (APPES). Selama 28 tahun
terakhir, beliau telah terlibat dalam banyak program diabetes di Indonesia dan kawasan. Beliau
antara lain merupakan pemimpin proyek DM Tipe 1 World Diabetes Foundation di Indonesia dan
pemimpin proyek Mengubah Diabetes pada Anak di Indonesia. Sebagai seorang klinisi dan
peneliti, beliau telah menerbitkan lebih dari 100 artikel ilmiah di berbagai jurnal internasional
dan bab buku, serta artikel populer. Dasar Pengangkatan Basis of Appointment Rangkap
Jabatan Kementerian Kesehatan Indonesia telah memberinya penghargaan sebagai salah
satu orang paling terkemuka yang terlibat aktif dalam program imunisasi nasional. Beliau
telah menerima beasiswa kehormatan dari Asosiasi Pediatri Nasional Turki atas dedikasi dan
kontribusinya terhadap kesehatan anak, beasiswa kehormatan dari Royal College of Physicians
of Ireland (RCPI), dan beasiswa kehormatan dari Indian Academy of Pediatrics. Ia juga menerima
Penghargaan Tokoh Inspiratif Republika.co.id pada tahun 2021 atas kontribusinya selama
pandemi dan Penghargaan Alumni Berprestasi Seumur Hidup dari Universitas Sumatera Utara
Periode ke/Period:
(USU) pada tahun 2023. Selanjutnya, ia juga menerima Penghargaan Tokoh Inspiratif Republika.
1 (satu) co.id Figure Award 2021 atas kiprahnya di bidang kesehatan anak selama pandemi COVID-19.
1 (first)
Aman B. Pulungan is a professor of paediatrics, Executive Committee of the International Paediatric
Usia/Age: Association, senior consultant in paediatric endocrinology, Faculty of Medicine, University of
68 tahun Indonesia, member of the NCD Child Governing Council, immediate past president of the Asia
68 years old Pacific Paediatric Association, immediate past president of the Indonesian Paediatric Society,
and past president of the Asia Pacific Paediatric Endocrine Society (APPES). For the past 28 years,
he has been involved in many programmes for diabetes in Indonesia and the region. Amongst
Kewarganegaraan/Nationality:
others, he is the project leader of the World Diabetes Foundation Type 1 DM in Indonesia and
Indonesia
the project leader of Changing Diabetes in Children in Indonesia. As a clinician and researcher,
Indonesian he has published more than 100 scientific articles in various international journals and book
chapters, as well as popular articles. The Indonesian MOH has given him an award as one of
Domisili/Domicile: the most eminent people actively involved in the national immunisation programme. He has
Jakarta received an honorary fellowship from the Turkish National Paediatric Association for his dedication
and contribution to child health, an honorary fellowship from the Royal College of Physicians
of Ireland (RCPI), and an honorary fellowship from the Indian Academy of Paediatrics. He also
received the Republika. co.id Inspirational Figure Award in 2021 for his contributions during the
Menjabat sebagai Komisaris
pandemic and a Lifetime Achievement Alumni Award from the University of North Sumatera
Independen (USU) in 2023. Furthermore, he also received the Republika.co.id Inspirational Figure Award 2021
sejak 21 November 2022 for his work in children’s health during the COVID-19 pandemic.
Served as Commissioner since
November 21, 2022
Rangkap Jabatan
Concurrent Position
• Anggota Komite Nominasi & Remunerasi PT MPI Tbk
• Anggota Komite Manajemen Risiko PT MPI Tbk
• Member of Nomination & Remuneration Committee of PT MPI Tbk
• Member of Risk Management Committee of PT MPI Tbk
Hubungan Afiliasi
Affiliation
Beliau tidak memiliki hubungan afiliasi dengan anggota Dewan Komisaris, anggota Direksi
lainnya dan pemegang saham utama.
He has no affiliation with members of the Board of Commissioners, other members of the Board
of Directors and major shareholders.
74 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 75
Positioned for
Profitable Growth
Sarah Azreen Binti Abdul Samat
Komisaris Independen
Independent Commissioner
Dasar Hukum Pengangkatan
Basis of Appointment
Diangkat pertama kali sebagai Komisaris Independen melalui Akta Pernyataan Keputusan
Rapat No. 2 tanggal 1 November 2021
Diangkat kembali sebagai sebagai Komisaris Independen Akta Pernyataan Keputusan Rapat
No, 71 tanggal 28 April 2022
First appointed as Independent Commissioner through the Deed of Statement of Meeting
Resolutions No. 2 November 1, 2021
Reappointed as President Commissioner & Independent Commissioner through the Deed of
Statement of Meeting Resolutions No. 72 dated April
Pendidikan dan/atau Sertifikasi
Education and/or Certification
• Capital Markets Services Representative’s License (CMSRL)
• Certified Practising Accountant (CPA) Australia
• Sarjana Akuntansi, University of Canberra, Australia
• Bachelor of Accounting, University of Canberra, Australia
Pengalaman Kerja
Employment History
• Independent Non-Executive Director Pharmaniaga Berhad, 2021 - present
• Executive Director of Reneuco Berhad, present;
• Executive Director, 3p Capital Advisers Sdn Bhd (an advisory firm licensed by the SC), 2018 – present;
• Director Corporate Finance Department, RHB Investment Bank Berhad, 2009 – 2018;
• Assistant Vice President Corporate Finance Department, Maybank Investment Bank Berhad,
Periode ke/Period: 2006 – 2009;
2 (Dua) • Manager Corporate Finance Department, AmMerchant Bank Berhad, 2005 – 2006;
2 (Second) • Managing Consultant Corporate Finance Department, KPMG Corporate Services Sdn Bhd, 2004;
• Assistant Manager Corporate Finance Department, Malaysian International Merchant Bankers
Usia/Age: Berhad, 2001 – 2004;
50 tahun • Senior Associate – Audit, Business, and Advisory Services, Price Waterhouse Coopers (PWC),
50 years old 1997 – 2000.
Kewarganegaraan/Nationality: Rangkap Jabatan
Malaysia Concurrent Position
Malaysian
• Ketua Komite Audit PT MPI Tbk
Domisili/Domicile: • Anggota Komite Manajemen Risiko PT MPI Tbk
Malaysia • Independent Non-Executive Director Pharmaniaga Sdn Bhd
• Executive Director, Reneuco Berhad
• Executive Director, 3p Capital Advisers Sdn. Bhd
• Chairman of Audit Committee PT MPI Tbk
Menjabat sebagai Komisaris
• Committee Member, Risk Management Committee of PT MPI Tbk
Independen
• Independent Non-Executive Director Pharmaniaga Sdn Bhd
sejak 21 November 2021
Served as Commissioner since
November 21, 2021 Hubungan Afiliasi
Affiliation
Beliau tidak memiliki hubungan afiliasi dengan anggota Dewan Komisaris, anggota Direksi
lainnya dan pemegang saham utama.
He has no affiliation with members of the Board of Commissioners, other members of the Board
of Directors and major shareholders.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 75
Page 76
Profil Perusahaan Positioned for
Company Profile Profitable Growth
Profil Direksi
Board of Directors Profile
PERUBAHAN KOMPOSISI DIREKSI CHANGES IN THE COMPOSITION
PADA TAHUN BUKU 2025 OF THE BOARD OF DIRECTORS
IN FISCAL YEAR 2025
Sepanjang tahun 2025, komposisi anggota Direksi Throughout 2025, up until the publication of this Annual
Perseroan tidak mengalami perubahan. Berikut komposisi Report in April 2026, the composition of the Company’s
Anggota Direksi per 31 Desember 2025: Board of Directors has remained unchanged.
Komposisi Anggota Direksi Per 31 Desember 2025
Composition of the Board of Directors as of December 31, 2025
Nama Jabatan
Name Position
Direktur Utama
Ahmad bin Abu Bakar
President Director
Direktur
Mohamad Fazly bin Hassan
Director
PERUBAHAN KOMPOSISI DIREKSI CHANGES IN THE COMPOSITION
SETELAH TAHUN BUKU 2025 OF THE BOARD OF DIRECTORS
AFTER FISCAL YEAR 2025
Terdapat perubahan komposisi Anggota Direksi setelah There has been a change in the composition of the Board
tahun buku berakhir. Perubahan komposisi Direksi of Directors after the end of the fiscal year. The change
berdasarkan keputusan Pemegang Saham melalui in the composition of the Board of Directors is based on
RUPS Luar Biasa pada 14 Januari 2026. Berikut komposisi the decision of the Shareholders through an Extraordinary
Anggota Direksi setelah tahun buku 2025 hingga Laporan General Meeting of Shareholders on January 14, 2026. The
Tahunan ini diterbitkan pada April 2026: following is the composition of the Board of Directors after
the 2025 fiscal year until this Annual Report was published
in April 2026:
Komposisi Anggota Direksi Setelah Tahun Buku 2025
Composition of the Board of Directors
Nama Jabatan
Name Position
Direktur Utama
Dr. Imam Fathorrahman, M.M
President Director
Direktur
Mohamad Fazly bin Hassan
Director
76 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 77
Positioned for
Profitable Growth
Ahmad bin Abu Bakar
Direktur Utama
President Director
Dasar Hukum Pengangkatan
Basis of Appointment
Diangkat pertama kali sebagai Direktur Utama melalui Akta Pernyataan Keputusan Rapat
No. 161 tanggal 16 Juli 2020
Diangkat kembali sebagai sebagai Direktur Utama melalui Akta Pernyataan Keputusan
Rapat No. 72 tangal 28 April 2022
First appointed as President Director through the Deed of Statement of Meeting Resolutions
No. 161 July 16, 2020
Reappointed as President Director through the Deed of Statement of Meeting Resolutions
No. 72 dated April 28, 2022
Pendidikan dan/atau Sertifikasi
Education and/or Certification
Bachelor of Pharmacy from Bradford University, England, 1993
Pengalaman Kerja
Employment History
• Deputy Senior Manager, Pharmaniaga Logistics Sdn Bhd, Penang, Malaysia;
• Manager, KPJ Bukit Mertajam Specialist Hospital, Penang, Malaysia, 2000;
• Pharmacy Manager, Mico Pharmacy Sdn Bhd, Alor Setar, Kedah, Malaysia, 1998;
• Quality Assurance (QA) Manager, SMP Pharmaceuticals Sdn Bhd, Sungai Petani, Kedah,
Malaysia, 1995;
• Retail Pharmacist, Guardian Pharmacy, Bangsar Shopping Complex, Kuala Lumpur, Malaysia,
Periode ke/Period: 1994;
2 (Dua) • Pre-registration Pharmacist, Lipha Pharmaceuticals, Hitchin, England, 1992;
2 (Second) • Pre-registration Pharmacist, Bradford Royal Infirmary, Bradford, England, 1990.
Usia/Age:
56 tahun Rangkap Jabatan
56 years old Concurrent Position
Komisaris PT Errita Pharma
Kewarganegaraan/Nationality:
Malaysia Commissioner at PT Errita Pharma
Malaysian
Hubungan Afiliasi
Domisili/Domicile: Affiliation
Jakarta
Beliau tidak memiliki hubungan afiliasi dengan anggota Dewan Komisaris, anggota Direksi
lainnya dan pemegang saham utama.
He has no affiliation with members of the Board of Commissioners, other members of the
Menjabat sebagai Direktur
Utama sejak 16 Juli 2020 – Board of Directors and major shareholders.
14 Januari 2026
Served as President Director
since July 16, 2020 – January
14, 2026
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 77
Page 78
Profil Perusahaan Positioned for
Company Profile Profitable Growth
Dr. Imam Fathorrahman, M.M
Direktur Utama
President Director
Dasar Hukum Pengangkatan
Basis of Appointment
Diangkat sebagai Direktur Utama Perseroan melalui Akta Pernyataan Keputusan Rapat
No. 32 tanggal 14 Januari 2026
Appointed as President Director through the Deed of Statement of Meeting Resolutions
No. 32 January 14, 2026
Pendidikan dan/atau Sertifikasi
Education and/or Certification
• Doktor Ilmu Farmasi, Universitas Airlangga, 2024
• Magister Strategic Management, Sekolah Tinggi Manajemen PPM, 2003
• Profesi Apoteker, Universitas Airlangga, 1989
• Doctor of Pharmaceutical Sciences, Airlangga University, 2024
• Master of Strategic Management, PPM College of Management, 2003
• Professional Pharmacist, Universitas Airlangga, 1989
Pengalaman Kerja
Employment History
• Independent non Executive Director Pharmaniaga Berhad, 2024 - Present
• Direktur Pemasaran & Komersial PT Kimia Farma Tbk 2021 – 2022
• Direktur Pengembangan Bisnis PT Kimia Farma Tbk, 2019 - 2021
• Direktur Utama Kimia Farma Apotek, 2011 - 2019
• Director of Marketing & Commercial of PT Kimia Farma Tbk, 2021-2022
Periode ke/Period: • Director of Business Development PT Kimia Farma Tbk, 2019 – 2021
1 (satu) • President Director of Kimia Farma Pharmacy, 2011 - 2019
1 (first)
Rangkap Jabatan
Usia/Age:
61 tahun Concurrent Position
61 years old
• Anggota Dewan Komisaris PT Digital Pharma Andalan Indonesia
• Anggota Dewan Komisaris PT Errita Pharma
Kewarganegaraan/Nationality:
Indonesia • Anggota Komite Audit PT MPI Tbk
Indonesian • Anggota Komite Nominasi dan Remunerasi PT MPI Tbk
• Independent Non-Executive Director Pharmaniaga Sdn Bhd
Domisili/Domicile: • Member of Board of Commissioners of PT Digital Pharma Andalan Indonesia
Jakarta • Member of Board of Commissioners of PT Errita Pharma
• Member of Audit Committee of PT MPI Tbk
• Member of Nomination and Remuneration Committee of PT MPI Tbk
Menjabat sebagai
Direktur Utama sejak 14 Hubungan Afiliasi
Januari 2026 Affiliation
Served as President Director
since January 14, 2026 Beliau tidak memiliki hubungan afiliasi dengan anggota Dewan Komisaris, anggota Direksi
lainnya dan pemegang saham utama.
He has no affiliation with members of the Board of Commissioners, other members of the
Board of Directors and major shareholders.
78 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 79
Positioned for
Profitable Growth
Mohamad Fazly bin Hassan
Direktur
Director
Dasar Hukum Pengangkatan
Basis of Appointment
Diangkat pertama kali sebagai Direktur melalui Akta Pernyataan Keputusan Rapat No.
161 tanggal 16 Juli 2020
Diangkat kembali sebagai sebagai Direktur melalui Akta Pernyataan Keputusan Rapat
No. 72 tangal 28 April 2022
First appointed as President Director through the Deed of Statement of Meeting Resolutions
No. 161 July 16, 2020
Reappointed as Director through the Deed of Statement of Meeting Resolutions No. 72
dated April 28, 2022
Pendidikan dan/atau Sertifikasi
Education and/or Certification
• Certified of Risk Management Officer (CRMO)
• Certified Accountant from Malaysia Institute of Accountant;
• Bachelor of Accountancy from University Technology of MARA,
Pengalaman Kerja
Employment History
• Auditor, Public Accounting Firm, 2001;
• Accountant, ACP Industries Berhad, 2003;
• Senior Manager, Group Reporting (Finance), Perseroan Otomobil Nasional Sdn Berhad,
Manufacturer of PROTON Brand Cars, 2007 – 2014;
Periode ke/Period: • Director of Finance, PT Proton Edar Indonesia, 2014.
2 (Dua)
2 (Second)
Rangkap Jabatan
Concurrent Position
Usia/Age:
51 tahun Direktur PT Digital Pharma Andalan Indonesia
51 years old
Director of PT Digital Pharma Andalan Indonesia
Kewarganegaraan/Nationality:
Malaysia Hubungan Afiliasi
Malaysian Affiliation
Beliau tidak memiliki hubungan afiliasi dengan anggota Dewan Komisaris, anggota Direksi
Domisili/Domicile:
Jakarta lainnya namun memiliki hubungan afliasi dengan pemegang saham utama.
He has no affiliation with members of the Board of Commissioners, other members of the
Board of Directors but has affiliation with major shareholders.
Menjabat sebagai Direktur
sejak 16 Juli 2020
Served as Director since July
16, 2020
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 79
Page 80
Profil Perusahaan Positioned for
Company Profile Profitable Growth
Dewan Komisaris
Board of Commissioners
Prof. Aman Bhakti Pulungan Joefly Joesoef Bahroeny
Komisaris Independen Komisaris Utama & Komisaris Independen
Independent Commissioner President Commissioner & Independent Commissioner
80 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 81
Positioned for
Profitable Growth
Dr. Imam Fathorrahman, M.M. Dato’ Zulkifli Bin Jafar Sarah Azreen Binti Abdul Samat
Komisaris Independen Komisaris Komisaris Independen
Independent Commissioner Commissioner Independent Commissioner
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 81
Page 82
Profil Perusahaan Positioned for
Company Profile Profitable Growth
Direksi & Tim Manajemen
Board of Directors & Management Team
Widada Herly Mohamad Aris Sulistiyanto Dr. Imam Fathorrahman, M.M.
Head of HRGA General Manajer Operasional Fazly bin Hassan Kepala Audit Internal Direktur Utama
Operational General Manager Direktur Head of Internal Audit President Director
Director
82 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 83
Positioned for
Profitable Growth
Ahmad bin Abu Bakar Olga Indria Bolang Robbi Nizori Mohamad Fadhli Januarto
Direktur Utama Sekertaris Perseroan Senior Manajer Risk Management Mustafa Presiden Direktur PT DPAI
President Director Corporate Secretary Risk Management Sr. Manager General Manager President Director PT DPAI
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 83
Page 84
Profil Perusahaan Positioned for
Company Profile Profitable Growth
Kepala Cabang
Branch Manager
84 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 85
Positioned for Profitable Growth PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 85
Page 86
Profil Perusahaan Positioned for
Company Profile Profitable Growth
Demografi Karyawan [OJK C.3] [GRI 2-7, 405-1]
Employee Demographics
Hingga akhir tahun 2025, jumlah karyawan Perseroan By the end of 2025, the number of employees of the
dan anak usahanya mencapai 1.197 orang karyawan, Company and its subsidiaries reached 1,197 employees,
mengalami peningkatan dibandingkan jumlah karyawan an increase compared to the number of employees in
tahun sebelumnya yang sebanyak 1.181 orang karyawan. the previous year of 1,181 employees.
Jumlah Pegawai Berdasarkan Jenis Kelamin
Total Employees by Gender
Jenis Kelamin Pertumbuhan/(Penurunan)
2025 2024
Gender Growth / (Decrease)
Pria
904 75,52% 899 76,12% 5 1%
Male
Wanita
293 24,48% 282 23,88% 11 4%
Female
Jumlah
1.197 100% 1.181 100% 16 1%
Total
Jumlah Pegawai Berdasarkan Level Jabatan
Total Employees by Position Level
Level Jabatan Pertumbuhan/(Penurunan)
2025 2024
Position Level Growth / (Decrease)
Other Staff 467 38,77% 475 39,68% 1 0%
Staff 448 37,43% 436 33,67% 12 3%
Supervisor 202 16,88% 192 19,44% 10 5%
Manager 80 5,93% 78 7,21% (7) (9%)
Jumlah
1.197 100% 1.181 100% 16 1%
Total
Jumlah Pegawai Berdasarkan Rentang Usia
Total Employees by Age Range
Rentang Usia Pertumbuhan/(Penurunan)
2025 2024
Age Range Growth / (Decrease)
> 55 tahun | years old 9 0,75% 8 0,68% 1 13%
45 - 54 tahun | years old 182 15,20% 173 14,65% 9 5%
34 - 44 tahun | years old 372 31,08% 357 30,23% 15 4%
25 - 33 tahun | years old 545 35,53% 534 45,22% 11 2%
18 - 24 tahun | years old 89 7,44% 109 9,23% (20) (18%)
Jumlah
1.197 100% 1.181 100% 16 1%
Total
86 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 87
Positioned for
Profitable Growth
Jumlah Pegawai Berdasarkan Tingkat Pendidikan
Total Employees by Education Level
Tingkat Pendidikan Pertumbuhan/(Penurunan)
2025 2024
Education Level Growth / (Decrease)
S2
7 0,58% 8 0,68% (1) (13%)
Master’s Degree
S1
531 43,94% 488 41,32% 38 8%
Bachelor’s Degree
Diploma
148 12,70% 133 11,26% 19 14%
Diploma
SMK/SMA
508 42,52% 549 46,49% (40) (7%)
Senior High School
SMP Junior High School 3 0,25% 3 0,25% 0 0%
Jumlah
1.197 100% 1.181 100% 16 1%
Total
Jumlah Pegawai Berdasarkan Status Kepegawaian
Total Employees by Employment Status
Status Kepegawaian Pertumbuhan/(Penurunan)
2025 2024
Employment Status Growth / (Decrease)
Tetap
976 82% 882 74.68% 94 11%
Permanent
Temporer
221 18% 299 25.32% (78) (28%)
Temporary
Jumlah
1.197 100% 1.181 100% 16% 1%
Total
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 87
Page 88
Profil Perusahaan Positioned for
Company Profile Profitable Growth
Struktur dan Komposisi Pemegang Saham
Shareholder Structure and Composition
Pharmaniaga International PT Danpac Pharma
Corporation Sdn Bhd PT Indolife Pensiontama
PT Ngrumat Masyarakat
Bondo Utomo Public
PT Millennium Pharmacon International Tbk
1 Januari 2025 31 Desember 2025
January 1, 2025 December 31, 2025
Pemegang Saham/
No Jumlah Lembar Persentase Jumlah Lembar Persentase
Shareholder
Saham Percentage Saham Percentage
Total Shares (%) Total Shares (%)
Pharmaniaga International
1 935.541.534 73,43% 935.541.534 73,43%
Corporation Sdn Bhd
2 PT Danpac Pharma 123.844.020 9,72% 123.844.020 9,72%
3 PT Indolife Pensiontama 42.762.830 3,36% 42.762.830 3,36%
4 PT Ngrumat Bondo Utomo 23.731.000 1,86% 23.731.000 1,86%
5 Masyarakat/Public 148.120.616 11,63% 148.120.616 11,63%
Jumlah
1.274.000.000 100,00% 1.274.000.000 100,00%
Total
RINCIAN PEMEGANG SAHAM DAN DETAILS OF SHAREHOLDERS AND
PERSENTASE KEPEMILIKAN PERCENTAGE OF OWNERSHIP
1 Januari 2025 31 Desember 2025
January 1, 2025 December 31, 2025
Pemegang Saham/
No Jumlah Lembar Persentase Jumlah Lembar Persentase
Shareholder
Saham Percentage Saham Percentage
Total Shares (%) Total Shares (%)
Pemegang Saham yang Memiliki 5% atau Lebih Saham | Shareholders with 5% or More Shares
Pharmaniaga International
1 935.541.534 73,43% 935.541.534 73,43%
Corporation Sdn Bhd
2 PT Danpac Pharma 123.844.020 9,72% 123.844.020 9,72%
Kelompok Pemegang Saham Masyarakat yang Memiliki Kurang dari 5% Saham
Group of Public Shareholders with Less than 5% of Shares
1 PT Indolife Pensiontama 42.762.830 3,36% 42.762.830 3,36%
2 PT Ngrumat Bondo Utomo 23.731.000 1,86% 23.731.000 1,86%
3 Masyarakat/Public 148.120.616 11,63% 148.120.616 11,63%
88 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 89
Positioned for
Profitable Growth
Informasi Kepemilikan Saham Perusahaan
oleh Dewan Komisaris dan Direksi
Share Ownership by The Board of
Commissioners and Board of Directors
KEBIJAKAN KEPEMILIKAN SAHAM EMPLOYEES AND/OR MANAGEMENT
OLEH KARYAWAN DAN/ATAU (ESOP/MSOP) SHARE OWNERSHIP POLICY
MANAJEMEN (ESOP/MSOP)
Hingga akhir tahun 2025, Perseroan tidak memiliki Until the end of 2025, the Company does not have a policy
kebijakan terkait kompensasi jangka panjang berbasis related to long-term performance-based compensation.
kinerja. Perseroan juga tidak melaksanakan Program The Company also does not implement the Stock Option
Opsi Kepemilikan Saham baik oleh Manajemen atau Program (MSOP) or the Employee Stock Option Program
Management Stock Option Program (MSOP) maupun (ESOP) for the provision of long-term performance-based
oleh Karyawan atau Employee Stock Option Program compensation.
(ESOP) untuk pemberian kompensasi jangka panjang
berbasis kinerja.
Sejak awal hingga akhir tahun buku 2025, tidak terdapat From the beginning to the end of the 2025 fiscal year,
anggota Dewan Komisaris maupun Direksi yang memiliki no member of the Board of Commissioners or Board of
saham Perusahaan, baik secara langsung maupun tidak Directors owned shares in the Company, either directly
langsung. or indirectly.
KEPEMILIKAN SAHAM SHARE OWNERSHIP BY CLASSIFICATION
BERDASAR KLASIFIKASI
Persentase Kepemilikan Saham
Pemegang Saham Jumlah Saham
Total Investor Percentage of Share Ownership
Shareholder Total Shares
(%)
Pemegang Saham Domestik | Domestic Shareholders
Lembaga Indonesia
38 200,821,435 15,764%
Indonesian Institutions
Perorangan Indonesia Indonesia
3.012 129.953.886 10,200%
Individuals
Pemegang Saham Asing | Foreign Shareholders
Lembaga Asing
12 130.830 0,010%
Foreign Institutions
Perorangan Asing
10 943.093.849 74,026%
Foreign Individuals
Jumlah
3.072 1.274.000.000 100%
Total
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 89
Page 90
Profil Perusahaan Positioned for
Company Profile Profitable Growth
Informasi Tentang Pemegang Saham Utama/
Pengendali Perusahaan
Information Regarding Major and Controlling Shareholders
Pemegang Saham Utama dan Pengendali Perseroan The Company’s Major and Controlling Shareholder
adalah Pharmaniaga International Corporation Sdn. is Pharmaniaga International Corporation Sdn. Bhd.
Bhd. Pharmaniaga merupakan perusahaan kesehatan Pharmaniaga was the first healthcare company in
(healthcare) pertama di Malaysia yang terdaftar pada Malaysia listed on the Main Market of Bursa Malaysia. Its
Pasar Utama (Main Market) Bursa Malaysia. Kegiatan integrated business operations encompass the entire
usahanya mencakup seluruh rantai nilai farmasi secara pharmaceutical value chain, ranging from research and
terintegrasi, mulai dari penelitian dan pengembangan, development and the manufacturing of prescription and
produksi obat resep dan obat bebas, logistik dan distribusi, over-the-counter drugs to logistics, distribution, sales,
hingga penjualan dan pemasaran. and marketing.
Pharmaniaga mengakuisisi 55% saham Perseroan Pharmaniaga acquired a 55% stake in the Company
pada tahun 2005 dan meningkatkan kepemilikannya in 2005 and increased its ownership by 18.43% in 2017.
sebesar 18,43% pada tahun 2017. Dengan demikian, per Consequently, as of December 31, 2025, Pharmaniaga
31 Desember 2025, Pharmaniaga memiliki 73,43% saham holds a 73.43% stake in the Company, serving as the Major
Perseroan dan bertindak sebagai Pemegang Saham and Controlling Shareholder.
Utama sekaligus Pengendali.
Pemegang Saham Utama dan Pengendali,
Baik Langsung Maupun Tidak Langsung, Sampai Kepada Pemilik Individu
Major and Controlling Shareholders, Direct and Indirect, up to the Individual Owner
LEMBAGA TABUNG ANGKATAN TENTERA (LTAT)
100%
BOUSTEAD HOLDING
BERHAD
35,21% 10,68%
PHARMANIAGA BERHAD
100%
PHARMANIAGA INT. CORP. SDN. BHD
73,43%
90 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 91
Positioned for Profitable Growth Kronologi Penerbitan dan/atau Pencatatan Saham Chronology of Issuance and/or Listing Of Share Perseroan mengawali pencatatan sahamnya di Bursa Efek The Company commenced its share listing on the Jakarta Jakarta dan Bursa Efek Surabaya pada tanggal 7 Mei 1990 Stock Exchange and Surabaya Stock Exchange on May sebanyak 3.500.000 lembar dengan nilai nominal Rp1.000 7, 1990, with a total of 3,500,000 shares at a par value of per saham. Pencatatan ini didasarkan pada persetujuan Rp1,000 per share. This listing was conducted pursuant Menteri Keuangan RI No. SI-090/SHM/MK.10/1990 tanggal to the approval of the Minister of Finance of the Republic 22 Maret 1990. Selanjutnya, Perseroan mencatatkan saham of Indonesia No. SI-090/SHM/MK.10/1990 dated March bonus sebanyak 4.550.000 lembar pada 17 Februari 1994, 22, 1990. Subsequently, the Company listed 4,550,000 diikuti dengan pencatatan saham pendiri sebanyak bonus shares on February 17, 1994, followed by the listing 5.600.000 lembar pada 16 Desember 1994. of 5,600,000 founders' shares on December 16, 1994. Struktur modal kembali berubah pada tahun 1999. Pada The capital structure evolved in 1999. On February 2, 1999, tanggal 2 Februari 1999, Perseroan melakukan pemecahan the Company executed a stock split, adjusting the par saham (stock split), sehingga nilai nominal menjadi Rp500 value to Rp500 per share and increasing the number per saham dan jumlah saham tercatat meningkat menjadi of listed shares to 27,300,000. Thereafter, the Company 27.300.000 lembar. Setelah itu, Perseroan membagikan distributed bonus shares in two phases, each amounting saham bonus dalam dua tahap masing-masing sebesar to 4,550,000 shares, which were listed on February 25, 4.550.000 lembar, yang dicatatkan pada tanggal 25 1999, and June 17, 1999, respectively. Consequently, the Februari 1999 dan 17 Juni 1999. Dengan demikian, total total listed shares reached 36,400,000. saham yang tercatat mencapai 36.400.000 lembar. Pada tanggal 4 Juli 2000, Perseroan melaksanakan On July 4, 2000, the Company executed Limited Public Penawaran Umum Terbatas (PUT) I dengan menerbitkan Offering I (Rights Issue I) by issuing 72,800,000 new shares 72.800.000 saham baru melalui Hak Memesan Efek Terlebih with Pre-emptive Rights, increasing the total shares to Dahulu (HMETD), sehingga total saham meningkat 109,200,000 (Bapepam Approval No. S-1345/PM/2000). menjadi 109.200.000 lembar (persetujuan Bapepam No. S-1345/PM/2000). Setahun kemudian, berdasarkan Akta No. 42 tanggal A year later, pursuant to Deed No. 42 dated May 28, 2001, 28 Mei 2001, Perseroan kembali melakukan pemecahan the Company performed another stock split to a par value saham menjadi nominal Rp100 per saham yang of Rp100 per share listed on September 3, 2001, resulting dicatatkan pada 3 September 2001, sehingga jumlah in a total of 546,000,000 shares. The Company’s capital saham menjadi 546.000.000 lembar. Modal Perseroan further increased through Limited Public Offering II (Rights kembali bertambah melalui PUT II pada tanggal 17 Juli Issue II) on July 17, 2002 (Bapepam Approval No. S-1362/ 2002 (persetujuan Bapepam No. S-1362/PM/2002) dengan PM/2002) with the issuance of 182,000,000 new shares, penerbitan 182.000.000 saham baru, menjadikan total bringing the total to 728,000,000 shares. saham sebanyak 728.000.000 lembar. Terakhir, berdasarkan persetujuan OJK No. S-443/D.04/2017, Most recently, based on OJK Approval No. S-443/D.04/2017, Perseroan melaksanakan PUT III dengan menerbitkan the Company executed Limited Public Offering III (Rights 546.000.000 saham baru yang dicatatkan di Bursa Efek Issue III) by issuing 546,000,000 new shares listed on the Indonesia pada tanggal 15 Desember 2017. Aksi korporasi Indonesia Stock Exchange on December 15, 2017. This ini menjadikan total saham ditempatkan dan disetor corporate action brought the Company's total issued penuh Perseroan mencapai 1.274.000.000 lembar dengan and fully paid-up shares to 1,274,000,000 with a par value nilai nominal Rp100 per saham. of Rp100 per share. PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 91
Page 92
Profil Perusahaan Positioned for
Company Profile Profitable Growth
Perubahan Jumlah Nama
Nilai Nominal Total Saham
Tanggal Aksi Korporasi Saham (Lembar) Bursa
Nominal Value (Lembar)
Date Corporate Action Change in Number Exchange
(Rp) Total Shares
of Shares Name
07 Mei 1990
IPO 1.000 3.500.000 3.500.000 BEJ & BES
May 07, 1990
17 Feb 1994
Saham Bonus 1.000 4.550.000 8.050.000 BEJ & BES
Feb 17, 1994
16 Des 1994
Saham Pendiri 1.000 5.600.000 13.650.000 BEJ & BES
Dec 16, 1994
02 Feb 1999
Stock Split (1:2) 500 13.650.000 27.300.000 BEJ & BES
Feb 02, 1999
24 Feb 1999
Saham Bonus I 500 4.550.000 31.850.000 BEJ & BES
Feb 24, 1999
16 Jun 1999
Saham Bonus II 500 4.550.000 36.400.000 BEJ & BES
June 16, 1999
04 Jul 2000
PUT I (HMETD) 500 72.800.000 109.200.000 BEJ & BES
Jul 04, 2000
03 Sep 2001
Stock Split (1:5) 100 436.800.000 546.000.000 BEJ & BES
Sep 03, 2001
17 Jul 2002
PUT II (HMETD) 100 182.000.000 728.000.000 BEJ & BES
Jul 17, 2002
15 Des 2017
PUT III (HMETD) 100 546.000.000 1.274.000.000 BEI
Dec 15, 2017
92 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 93
Positioned for
Profitable Growth
Kronologi Penerbitan dan/atau
Pencatatan Efek Lainnya
Chronology of Issuance and/or Listing of Other Securities
Hingga akhir tahun buku 2025, Perseroan tidak menerbitkan As of the end of the 2025 fiscal year, the Company did
atau mencatatkan efek lainnya selain saham (seperti not issue or list any securities other than shares (such as
Obligasi, Sukuk, atau Surat Utang Konversi) baik di Bursa Bonds, Sukuk, or Convertible Bonds) on the Indonesia Stock
Efek Indonesia maupun bursa efek lainnya. Oleh karena Exchange or any other stock exchanges. Consequently,
itu, tidak ada informasi terkait peringkat efek yang dapat there is no information regarding security ratings to be
disajikan. presented.
Struktur Grup Perusahaan
Company Group Structure
1,86% 3,36% 9,72% 11,63% 73,43%
1% 99% 15% 85%
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 93
Page 94
Profil Perusahaan Positioned for
Company Profile Profitable Growth
Entitas Anak dan Entitas Asosiasi
Subsidiaries and Associations
Tahun Kepemilikan
Jumlah Aset
Beroperasi Status Perseroan
Total Asset
Nama Domisili Bidang Usaha Komersial Operasi Company
(RpJuta/Rpmillion)
Name Domicile Business Line Year of Operational Ownership (%)
Commercial Status
Operation 2025 2024 2025 2024
PT Digital
Informasi &
Pharma Sudah
Komunikasi
Andalan Jakarta 2023 Beroperasi 99% 99% 1.303 2.215
Information &
Indonesia Operated
Communication
(DPAI)
Akuntan Publik dan Kantor Akuntan Publik
Public Accountant and Public Accounting Firm
Akuntan Publik
Nanda Priyatna Harahap
Public Accountant
Kantor Akuntan Publik TANUBRATA SUTANTO FAHMI BAMBANG & REKAN
Public Accounting Firm Anggota BDO International Limited/Member of BDO International Limited
Alamat Prudential Tower, Lantai 17, Jl. Jend. Sudirman Kav. 79, Jakarta, 12910 Telp: (021)
Address 57957300 Fax: (021) 57957301
Periode Penugasan Tahun buku 2025
Engagement Period Year Book 2025
Melakukan audit atas laporan keuangan Perseroan, termasuk melakukan stock
Jasa Audit yang Diberikan opname ke kantor-kantor cabang Perseroan
Audit Services Provided Conducting audits of the Company’s financial statements, including conducting
stock-taking at the Company’s branch offices.
Biaya Jasa Audit
Rp370.000.000
Audit Service Fees
Jasa Non-Audit yang Diberikan Review laporan keuangan interim
Non-Audit Services Provided Review interim financial statements
Biasa Jasa Non-Audit
Rp370.000.000
Non-Audit Service Fees
94 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 95
Positioned for
Profitable Growth
Lembaga dan/atau Profesi Penunjang
Supporting Institutions/Professions
Notaris
Notary
Nama
Dini Lastari Siburian SH
Name
Jl. Margasatwa Raya Komp. Mahkamah Agung No. 62
Pondok Labu, Cilandak
Alamat
Jakarta Selatan, 12450
Address
Telp: (021) 75903352 / 22767617
Email : notaris.dini@gmail. com
Periode Penugasan Per proyek di tahun 2025
Assignment Period Each project in 2025
Pembuat notulen dan berita acara Rapat Umum Pemegang Saham serta mengurus
Jasa yang Diberikan dokumentasi terkait.
Service Rendered To make minutes and the official report of the General Shareholders Meeting, and the
documentation concern.
Biaya
Rp25.000.000
Fee
Biro Administrasi Efek
Share Registrar
Nama
PT RAYA SAHAM REGISTRA
Name
Gedung Plaza Sentral Lantai 2
Jl. Jend.Sudirman Kav. 47-48
Alamat
Jakarta, 12930
Address
Telp: (021) 3900645, 3905920
Fax: (021) 3140185, 3900671
Periode Penugasan
2025
Assignment Period
Administrasi saham Perseroan atas data pemegang saham bulanan dan mencatat data.
Jasa yang Diberikan
To manage recording Company’s shares which is related to monthly shareholders data
Service Rendered
and recording data.
Biaya
Rp93.666.666
Fee
Kantor Jasa Kustodian Sentral dan Penyelesaian Transaksi Efek
Central Depository Services Office and Securities Transaction Settlement
Nama PT Kustodian Sentral Efek Indonesia
Name Indonesian Central Securities Depository
Gedung Bursa Efek Indonesia
Alamat Gedung 1 Lantai 5
Address Jl. Jend. Sudirman Kav. 52-53
Jakarta, 12190
Periode Penugasan
2025
Assignment Period
Jasa yang Diberikan Sebagai pendukung/ pelaksana manakala Perseroan melakukan aksi korporasi.
Service Rendered As executor/supporter when the Company carries out corporate action.
Biaya
Rp10.000.000
Fee
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 95
Page 96
Profil Perusahaan Positioned for
Company Profile Profitable Growth
Informasi Website Perusahaan
Company Website Information
Sebagai wujud komitmen terhadap prinsip keterbukaan As a commitment to the principles of information
informasi dan tata kelola perusahaan yang baik, Perseroan disclosure and Good Corporate Governance, the Company
mengelola situs web korporat yang dapat diakses melalui manages a corporate website accessible at https://www.
tautan https://www.mpi-indonesia.co.id/. Situs web ini mpi-indonesia.co.id/. This website serves as the primary
berfungsi sebagai saluran komunikasi digital utama yang digital communication channel bridging the Company
menjembatani Perseroan dengan pemegang saham, with shareholders, investors, and other stakeholders.
investor, serta pemangku kepentingan lainnya.
Situs web Perseroan dirancang dengan antarmuka yang The Company’s website is designed with a user-friendly
ramah pengguna (user-friendly) dan sistem navigasi interface and structured navigation system to facilitate
yang terstruktur untuk memudahkan pengunjung dalam visitors in accessing essential information. The content is
mengakses informasi penting. Konten di dalamnya updated periodically and is available in dual languages
diperbarui secara berkala dan tersedia dalam 2 (dua) (Indonesian and English), covering corporate profile,
bahasa (Bahasa Indonesia dan Bahasa Inggris), financial performance, governance, and recent corporate
mencakup informasi profil perusahaan, kinerja keuangan, actions.
tata kelola, hingga aksi korporasi terkini.
Pengelolaan situs web ini juga merupakan bentuk The management of this website also demonstrates the
kepatuhan Perseroan terhadap Peraturan Otoritas Jasa Company’s compliance with Financial Services Authority
Keuangan No. 8/POJK.04/2015 tentang Situs Web Emiten Regulation No. 8/POJK.04/2015 regarding the Website of
atau Perusahaan Publik. Melalui penyajian informasi yang Issuers or Public Companies. By presenting transparent,
transparan, akurat, dan tepat waktu, Perseroan berharap accurate, and timely information, the Company aims
dapat terus meningkatkan kepercayaan dan memelihara to continuously enhance trust and maintain positive
hubungan baik dengan seluruh pemangku kepentingan. relationships with all stakeholders.
96 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 97
Positioned for
Profitable Growth
Halaman ini sengaja dikosongkan
This page is intentionally left blank
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 97
Page 98
Laporan Manajemen Positioned for
Management Report Profitable Growth
04
Analisis &
Pembahasan
Manajemen
Management Discussion
& Analysis
98 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 99
Positioned for Profitable Growth PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 99
Page 100
Analisis & Pembahasan Manajemen Positioned for
Management Discussion & Analysis Profitable Growth
Tinjauan Makroekonomi
Macroeconomic Overview
Pada 2025, ekonomi global berada pada fase In 2025, the global economy was in a phase of moderate
pertumbuhan moderat di tengah proses disinflasi dan growth amid an ongoing disinflation process and
ketidakpastian kebijakan perdagangan/geopolitik. uncertainties surrounding trade and geopolitical policies.
IMF menyoroti disinflasi yang berlanjut—dengan inflasi The IMF highlighted the continued disinflation trend—with
headline global diproyeksikan turun ke 4,2% pada 2025— global headline inflation projected to decline to 4.2% in
serta risiko ketidakpastian yang dapat memengaruhi 2025—as well as risks stemming from uncertainty that
arus perdagangan dan investasi. World Bank menilai could affect trade and investment flows. The World Bank
pertumbuhan global cenderung bertahan sekitar 2,7% assessed that global growth is likely to remain around 2.7%
pada 2025–2026 dan menggarisbawahi isu “low growth” in 2025–2026 and underscored the issue of “low growth”
sebagai tantangan struktural. Bagi dunia usaha, kombinasi as a structural challenge. For businesses, the combination
pertumbuhan moderat dan risiko global tersebut biasanya of moderate growth and global risks typically results in
berdampak pada volatilitas biaya logistik, nilai tukar, dan volatility in logistics costs, exchange rates, and financing
biaya pendanaan—yang relevan bagi penguatan disiplin costs—factors that are relevant to strengthening working
modal kerja dan ketahanan rantai pasok. capital discipline and supply chain resilience.
Sementara itu, perekonomian Indonesia pada 2025 Meanwhile, Indonesia’s economy in 2025 demonstrated
menunjukkan ketahanan, dengan pertumbuhan 5,11% resilience, with growth of 5.11% (c-to-c) according to
(c-to-c) menurut BPS, meningkat dibanding 2024 Statistics Indonesia (BPS), an increase compared to 2024
(5,03%). Dari sisi produksi, Jasa Lainnya mencatat (5.03%). From the production side, Other Services recorded
pertumbuhan tertinggi 9,93%, sementara dari sisi the highest growth at 9.93%, while from the expenditure
pengeluaran Ekspor Barang dan Jasa tumbuh paling side, Exports of Goods and Services grew the highest at
tinggi 7,03%. Dalam kerangka kebijakan, Bank Indonesia 7.03%. In terms of policy, Bank Indonesia projected 2025
memprakirakan pertumbuhan 2025 pada kisaran 4,7% growth in the range of 4.7% – 5.5%, emphasizing a policy
– 5,5%, menekankan bauran kebijakan untuk menjaga mix to maintain stability and support growth. This context
stabilitas dan mendukung pertumbuhan. Konteks ini supports a baseline of domestic demand (including
mendukung baseline permintaan domestik (termasuk the healthcare sector, which tends to be defensive),
sektor kesehatan yang cenderung defensif), tetapi tetap while still requiring disciplined cost and working capital
menuntut pengelolaan biaya dan modal kerja yang management to ensure that pressures from financing
disiplin agar tekanan biaya pendanaan/logistik tidak and logistics costs do not erode margin quality.
mengurangi kualitas margin.
100 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 101
Positioned for
Profitable Growth
Tinjauan Industri dan Posisi
Perseroan dalam Industri
Industry Overview and the Company’s
Position in the Industry
Pada 2025, industri kesehatan dan rantai pasok farmasi In 2025, the healthcare industry and pharmaceutical
tetap ditopang faktor struktural (kebutuhan layanan supply chain continued to be supported by structural
kesehatan dan penguatan program preventif), tetapi factors (growing healthcare needs and the strengthening
dihadapkan pada tantangan pasokan dan efisiensi. of preventive programs), while facing supply and efficiency
Kementerian Perindustrian menargetkan pertumbuhan challenges. The Ministry of Industry targets growth in IKFT
sektor IKFT pada 2025 dan menempatkan subsektor sector in 2025 and positions the chemical–pharmaceutical
kimia–farmasi sebagai salah satu penggerak, tetapi subsector as one of the key growth drivers. However, the
ketergantungan bahan baku yang masih tinggi membuat still-high dependence on imported raw materials makes
industri sensitif terhadap volatilitas biaya, nilai tukar, dan the industry sensitive to cost volatility, exchange rate
lead time logistik. fluctuations, and logistics lead times.
Dalam lanskap tersebut, posisi MPI sebagai distributor Within this landscape, MPI’s position as a distributor is
diperkuat oleh jangkauan operasional nasional: Perseroan strengthened by its nationwide operational reach. The
mengoperasikan 37 (tiga puluh tujuh) kantor cabang yang company operates 37 (thirty-seven) branch offices
beroperasi di enam wilayah geografis dan mendukung across six geographical regions and supports product
distribusi produk ke Jawa, Bali, Lombok, Sumatra, distribution to Java, Bali, Lombok, Sumatra, Kalimantan,
Kalimantan, dan Sulawesi. Selain kekuatan jaringan, and Sulawesi. In addition to its network strength, the
Perseroan mendorong peningkatan kapabilitas eksekusi Company continues to enhance execution capabilities
melalui digitalisasi, serta rencana pembukaan cabang through the digitalization, as well as plans to open a new
baru di Palu untuk memperluas jangkauan layanan. branch in Palu to expand service coverage.
Dengan demikian, fokus daya saing MPI pada 2025 Accordingly, MPI’s competitive focus in 2025 is directed
mengarah pada penguatan ketahanan pasokan, disiplin toward strengthening supply resilience, maintaining
pengelolaan modal kerja, peningkatan service level disciplined working capital management, enhancing
distribusi, serta percepatan digitalisasi. Keempat faktor ini distribution service levels, and accelerating digitalization.
menjadi penentu kualitas kinerja dalam industri distribusi These four factors are critical performance determinants
farmasi yang semakin menuntut ketepatan pemenuhan, in an increasingly demanding pharmaceutical distribution
keterlacakan, dan efisiensi. industry, one that requires fulfillment accuracy, traceability,
and efficiency.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 101
Page 102
Analisis & Pembahasan Manajemen Positioned for
Management Discussion & Analysis Profitable Growth
Tinjauan Operasi Per Segmen Usaha
Operations Overview by Business Segment
Perseroan menyajikan analisis kinerja berdasarkan PSAK The Company presents its performance analysis in
108: Segmen Operasi. Informasi segmen disusun mengacu accordance with PSAK 108: Operating Segments. Segment
pada pelaporan internal yang digunakan manajemen information is prepared based on internal reporting used
untuk mengevaluasi kinerja masing-masing segmen by management to evaluate the performance of each
serta menentukan pengalokasian sumber daya. Sejalan segment and to determine resource allocation. In line with
dengan struktur organisasi, manajemen, dan pelaporan the organizational structure, management framework, and
keuangan internal yang berbasis kelompok produk, internal financial reporting, which are based on product
Perseroan mengelompokkan kegiatan usahanya ke dalam groups, the Company classifies its business activities into
3 (tiga) segmen. Pembagian segmen dilakukan dengan 3 (three) segments. The segmentation is determined by
mempertimbangkan karakteristik risiko dan hasil yang considering the risk and return characteristics inherent in
melekat pada tiap produk, yaitu obat resep, obat non- each product category, namely prescription drugs, non-
resep, dan alat kesehatan. prescription drugs, and medical devices.
Segmen Operasi MPI
MPI Operating Segments
Obat Resep Obat Non-Resep Alat Kesehatan
Prescription Drugs Non-prescription Drugs Medical Devices
Perseroan juga meninjau cakupan operasional dari The Company also reviews its operational coverage
perspektif sebaran jaringan dan distribusi. Dimensi from the perspective of network reach and distribution.
geografis ini penting untuk menggambarkan jangkauan This geographic dimension is important to illustrate the
layanan Perseroan dalam mendukung penyaluran obat Company’s service coverage in supporting the distribution
resep, obat non-resep, dan alat kesehatan ke berbagai of prescription drugs, non-prescription drugs, and medical
wilayah di Indonesia. devices across various regions in Indonesia.
Per 31 Desember 2025, Perseroan mengoperasikan 37 (tiga As of December 31, 2025, the Company operated 37 (thirty-
puluh tujuh) kantor cabang yang menjangkau seluruh seven) branch offices throughout Indonesia. Through
Indonesia. Melalui jaringan tersebut, produk Perseroan this network, the Company’s products are distributed to
didistribusikan ke Pulau Jawa, Bali, Lombok, Sumatra, Java, Bali, Lombok, Sumatra, Kalimantan, and Sulawesi,
Kalimantan, dan Sulawesi, sehingga Perseroan dapat enabling the Company to maintain supply continuity,
menjaga kontinuitas pasokan, kedekatan layanan kepada ensure service proximity to customers, and enhance
pelanggan, serta efektivitas distribusi pada masing- distribution effectiveness in each operational region.
masing wilayah operasional.
102 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 103
Positioned for
Profitable Growth
SEGMEN OPERASI OPERATING SEGMENTS
Kontribusi Segmen Operasi terhadap Pendapatan
Contribution of Operating Segments to Revenue
(Dalam jutaan Rupiah | in million Rupiah)
Segmen Kontribusi Kontribusi Difference Difference
2025 2024
Segment Contribution Contribution (RP) (%)
Obat Resep
2.887.792 70,27% 2.761.254 70,50% 126.921 4,60%
Prescription Drugs
Obat Non-Resep
Non-prescription 143.452 3,49% 205.937 5,26% 872.246 423,56%
Drugs
Alat Kesehatan
1.078.183 26,23% 949.673 24,25% 128.510 13,53%
Medical Devices
Total Pendapatan
4.109.810 100% 3.916.864 100,00% 192.946 4,93%
Total Revenue
Pada 2025, pendapatan Perseroan ditopang oleh 3 In 2025, the Company’s revenue was supported by 3
(tiga) segmen utama, yaitu obat resep, obat non-resep, (three) main segments, namely prescription drugs,
dan alat kesehatan dengan total pendapatan sebesar non-prescription drugs, and medical devices, with total
Rp4.109.810 juta. Kontribusi masing-masing segmen pada revenue amounting to Rp4,109,810 million. The contribution
2025 tercermin dari porsi pendapatan segmen terhadap of each segment in 2025 is reflected in the proportion of
total pendapatan, yaitu: obat resep Rp2.887.792 juta atau segment revenue to total revenue, namely: prescription
70,27%, obat non-resep Rp143.452 juta atau 3,49%, dan drugs Rp2,887,792 million or 70.27%, non-prescription drugs
alat kesehatan Rp1.078.183 juta atau 26,23%. Rp143.452 million or 3.49%, and medical devices Rp1.078.183
million or 26.23%.
Sebagai pembanding, pada 2024 total pendapatan As a comparison, in 2024 the Company’s total revenue
(penjualan neto) Perseroan tercatat Rp3.916.864 juta, (net sales) amounted to Rp3,916,864 million, with the
dengan struktur kontribusi yang didominasi segmen contribution structure dominated by the prescription
obat resep sebesar Rp2.761.254 juta (70,50%), disusul alat drugs segment at Rp2,761,254 million (70.50%), followed
kesehatan Rp949.673 juta (24,25%), dan obat non-resep by medical devices at Rp949,673 million (24.25%), and
Rp205.937 juta (5,26%). non-prescription drugs at Rp205,937 million (5.26%).
Segmen Geografis Geographic Segment
Kinerja Segmen Geografis dan Kontribusinya terhadap Penjualan
Geographic Segment Performance and Contribution to Sales
(Dalam jutaan Rupiah | in million Rupiah)
Kenaikan
2025 2024 (Penurunan)
Wilayah Increase (Decrease)
Area
Penjualan Neto Kontribusi Penjualan Neto Kontribusi
Selisih %
Net Sales Contribution Net Sales Contribution
Difference
Jawa 2.441.099 59% 2.365.196 60,38% 75.903 39%
Sumatra 903.426 22% 846.075 21,60% 57.351 30%
Kalimantan 332.020 8% 294.381 7,52% 37.639 20%
Sulawesi 227.048 6% 217.319 5,55% 9.729 5%
Bali & Lombok 206.217 5% 193.893 4,95% 12.324 6%
Jumlah
4.109.810 100,00% 3.916.864 100,00% 192.946 100%
Total
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 103
Page 104
Analisis & Pembahasan Manajemen Positioned for
Management Discussion & Analysis Profitable Growth
PENGEMBANGAN SEGMEN SEGMENT DEVELOPMENT
Perseroan secara konsisten menjalankan berbagai The Company consistently implements various programs
program dan strategi yang mencakup pengembangan and strategies that encompass business development,
usaha, peningkatan kompetensi karyawan, kontribusi employe competency enhancement, social contributions
sosial bagi masyarakat sekitar, serta inisiatif yang relevan to the surrounding community, and relevant initiatives to
untuk meningkatkan kualitas lingkungan. Implementasi improve environmental quality. The implementation of
program-program tersebut memperkuat posisi Perseroan these programs strengthens the Company’s position in
di industri farmasi nasional, sekaligus membuka ruang the national pharmaceutical industry, while also creating
bagi Perseroan untuk menangkap peluang pertumbuhan opportunities for the Company to capture growth on a
pada skala yang lebih luas. larger scale.
Dalam rangka memastikan pengelolaan Perseroan In order to ensure that the management of the Company
berjalan selaras dengan visi dan misi serta memenuhi aligns with its vision and mission and adheres to the
kaidah tata kelola Perseroan yang baik, Perseroan terus principles of good corporate governance, the Company
memperkuat penerapan GCG dan manajemen risiko. continues to strengthen the implementation of GCG and
Upaya ini dilakukan untuk menjaga kualitas pengambilan risk management. These efforts are made to maintain the
keputusan, meningkatkan efektivitas pengendalian, dan quality of decision-making, enhance control effectiveness,
memperkuat kepercayaan pemangku kepentingan. and strengthen stakeholder trust. The Company ensures
Perseroan memastikan bahwa penerapan prinsip-prinsip that the implementation of GCG principles and risk
GCG dan manajemen risiko berjalan memadai, serta management is adequate, and that business development
strategi pengembangan usaha disertai identifikasi dan strategies are accompanied by the identification and
mitigasi risiko yang relevan. mitigation of relevant risks.
Perseroan juga melakukan evaluasi atas setiap The Company also conducts evaluations of each
rencana investasi untuk memperoleh hasil kajian yang investment plan to obtain more accurate study results
lebih akurat sebagai dasar pengambilan keputusan as a basis for strategic decision-making. This approach is
strategis. Pendekatan ini ditujukan untuk memastikan aimed at ensuring that business development is directed
pengembangan usaha berjalan terarah dan memperkuat and strengthens the Company’s competitiveness in the
daya saing Perseroan pada periode mendatang. Realisasi future. The implementation of the business development
program pengembangan usaha yang dijalankan antara program includes the opening of new branch offices in
lain meliputi pembukaan kantor cabang baru di Palu, yang Palu, which expand service coverage and strengthen
memperluas cakupan layanan dan memperkuat jaringan the customer network. The Company also relocated the
pelanggan. Perseroan juga melakukan relokasi kantor Denpasar and Bekasi branch office to a larger location
cabang cabang Denpasar dan Bekasi ke lokasi yang to support increased operational capacity and added
lebih besar untuk mendukung peningkatan kapasitas operational fleets in line with the development of the
operasional, serta menambah armada operasional branch network.
sejalan dengan perkembangan jaringan cabang.
Di sisi portofolio, Perseroan menambah jumlah prinsipal On the portfolio side, the Company is adding more
untuk memperluas variasi produk dan mendukung principals to expand product variety and support sales
peningkatan penjualan. Jaringan cabang yang semakin growth. The expanding branch network also strengthens
luas turut memperkuat proposisi nilai Perseroan dalam the Company’s value proposition in building partnerships
membangun kemitraan dengan prinsipal karena with principals, as it broadens the distribution reach of
memperbesar jangkauan distribusi produk secara lebih products more evenly. To enhance process effectiveness
merata. Untuk meningkatkan efektivitas proses dan and service quality, the Company also continues to
kualitas layanan, Perseroan juga melanjutkan penguatan strengthen digitalization thru the implementation of Sales
digitalisasi melalui penerapan Sales Force Automation Force Automation (SFA) and the development of OLIN. SFA
(SFA) dan pengembangan OLIN. SFA membantu tenaga helps sales personnel receive orders via mobile devices,
penjual menerima pesanan melalui perangkat mobile making the ordering process faster and more efficient.
sehingga proses pemesanan lebih cepat dan efisien. Meanwhile, OLIN is a digital application that supports
Sementara itu, OLIN merupakan aplikasi digital yang pharmacies in managing purchase orders and inventory,
mendukung apotek dalam pengelolaan pesanan allowing for more effective purchase control and inventory
pembelian dan persediaan, sehingga kontrol pembelian management.
dan manajemen inventaris dapat dilakukan dengan lebih
efektif.
104 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 105
Positioned for
Profitable Growth
Tinjauan Keuangan
Financial Overview
Tinjauan keuangan yang diuraikan berikut mengacu The financial review described below refers to the Financial
kepada Laporan Keuangan untuk tahun yang berakhir Statements for the years ended December 31, 2025 and
tanggal 31 Desember 2025 dan 2024. Laporan Keuangan 2024. The Financial Statements have been audited by
telah diaudit oleh Kantor Akuntan Publik Tanubrata Tanubrata Sutanto Fahmi Bambang & Rekan Public
Sutanto Fahmi Bambang & Rekan dengan opini wajar Accounting Firm, which issued an unqualified opinion
dalam semua hal yang material. Posisi keuangan in all material respects. The consolidated financial
konsolidasian PT Millennium Pharmacon International Tbk position of PT Millennium Pharmacon International Tbk
dan entitas anak pada tanggal 31 Desember 2025, serta and its subsidiaries as of December 31, 2025, as well as the
kinerja keuangan dan arus kas konsolidasian untuk tahun consolidated financial performance and cash flows for
yang berakhir pada tanggal tersebut, sesuai dengan the year then ended, are in accordance with Indonesian
Standar Akuntansi Keuangan di Indonesia. Financial Accounting Standards.
LAPORAN POSISI KEUANGAN CONSOLIDATED STATEMENT
KONSOLIDASIAN OF FINANCIAL POSITION
Tabel Laporan Posisi Keuangan Konsolidasian
Consolidated Statement of Financial Position
(Dalam jutaan Rupiah | in million Rupiah)
Kenaikan (Penurunan)
Uraian Increase (Decrease)
2025 2024
Description Selisih
(%)
Difference
Aset
1.960.720 1.771.857 188.863 11%
Total Assets
Aset Lancar
1.718.942 1.563.794 155.147 11%
Current Assets
Aset Tidak Lancar
241.778 208.063 33.716 16%
Non-Current Assets
Liabilitas
1.645.317 1.489.360 155.957 10%
Total Liabilities
Liabilitas Jangka Pendek
1.555.871 1.413.417 142.454 10%
Current Liabilities
Liabilitas Jangka Panjang
89.446 75.943 13.503 18%
Non-Current Liabilities
Ekuitas
315.403 282.497 32.906 12%
Equity
Per 31 Desember 2025, total aset Perseroan meningkat As of December 31, 2025, the Company’s total assets
11% menjadi Rp1.960.720, sejalan dengan meningkatnya increased 11% to Rp1,960,720, in line with higher working
kebutuhan modal kerja pada bisnis distribusi yang masih capital needs in a distribution business that remains
didominasi aset lancar. Aset lancar naik 10% menjadi largely driven by current assets. Current assets rose 10%
Rp1.718.942, sementara aset tidak lancar tumbuh lebih to Rp1,718,942, while non-current assets grew faster at 16%
tinggi sebesar 16% menjadi Rp241.778, mencerminkan to Rp241,778, reflecting continued strengthening of the
penguatan kapasitas aset operasional. Total liabilitas Company’s operating asset base. Total liabilities increased
meningkat 10% menjadi Rp1.645.317, dengan komposisi 10% to Rp1,645,317, with the structure still heavily weighted
yang tetap didominasi liabilitas jangka pendek. toward current liabilities.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 105
Page 106
Analisis & Pembahasan Manajemen Positioned for
Management Discussion & Analysis Profitable Growth
Aset Assets
(Dalam jutaan Rupiah | in million Rupiah)
Kenaikan (Penurunan)
Uraian Increase (Decrease)
2025 2024
Description Selisih
% (YoY)
Difference
Aset Lancar
Current Assets
Kas dan bank
62.843 53.473 9.370 18%
Cash and banks
Piutang usaha
812.002 731.940 80.062 11%
Trade receivables
Piutang lain-lain
21.741 9.654 12.087 125%
Other receivables
Persediaan
609.092 567.732 41.360 7%
Inventories
Pajak dibayar di muka
206.050 193.133 12.917 7%
Prepaid tax
Biaya dibayar di muka
4.085 5.301 (1.216) (23%)
Prepaid expenses
Uang muka
3.129 2.561 568 22%
Advance payment
Jumlah Aset Lancar
1.718.942 1.563.794 155.148 10%
Total Current Assets
Aset Tidak Lancar
Non-Current Assets
Piutang lain-lain – pihak berelasi
11.100 14.400 (3.300) (23%)
Other receivables - related party
Taksiran tagihan restitusi pajak penghasilan
34.326 31.112 3.214 10%
Estimated claim for income tax refund
Aset pajak tangguhan
27.354 17.056 10.298 60%
Deferred tax assets
Penyertaan dalam bentuk saham
18.586 22.508 (3.922) (17%)
Investment in shares of stock
Aset tetap
109.085 80.866 28.219 35%
Property and equipment
Aset takberwujud
6.995 7.779 (784) (10%)
Intangible assets
Aset hak-guna
29.444 30.551 (1.107) (4%)
Right-of-use assets
Aset tidak lancar lainnya
4.888 3.791 1.097 29%
Other non-current assets
Jumlah Aset Tidak Lancar
241.778 208.063 33.715 16%
Total Non-Current Assets
JUMLAH ASET
1.960.720 1.771.857 188.863 11%
TOTAL ASSETS
Pada akhir 2025, total aset meningkat 11% menjadi As of year-end 2025, total assets increased 11% to
Rp1.960,72 miliar, terutama ditopang kenaikan aset Rp1,960.72 billion, primarily driven by a 10% rise in current
lancar 10% menjadi Rp1.718,94 miliar seiring meningkatnya assets to Rp1,718.94 billion, reflecting higher working capital
kebutuhan modal kerja. Kenaikan aset lancar terutama requirements. The increase in current assets was mainly
berasal dari piutang usaha yang naik 11% menjadi Rp812 attributable to trade receivables, which rose 11% to Rp812
miliar dan persediaan yang naik 7% menjadi Rp609,1 miliar, billion, and inventories, which increased 7% to Rp609.1
disertai peningkatan kas dan bank sebesar 18% menjadi billion, alongside a 18% increase in cash and banks to
Rp62,84 miliar. Aset tidak lancar meningkat 16% menjadi Rp62.84 billion. Non-current assets grew 16% to Rp241.78
Rp241,78 miliar, terutama didorong kenaikan aset tetap billion, largely supported by a 35% increase in property
106 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 107
Positioned for
Profitable Growth
sebesar 35% menjadi Rp109,08 miliar serta peningkatan and equipment to Rp109.08 billion and higher estimated
taksiran tagihan restitusi pajak penghasilan menjadi claims for income tax refunds to Rp34.33 billion.
Rp34,33 miliar.
Liabilitas Liabilities
(Dalam jutaan Rupiah | in million Rupiah)
Kenaikan (Penurunan)
Increase (Decrease)
2025 2024
Selisih
% (YoY)
Difference
Liabilitas Jangka Pendek
Current Liabilities
Utang bank
749.562 798.202 (48.640) (6%)
Bank loans
Utang usaha
694.449 527.590 166.859 32%
Trade payables
Utang pajak
240 114 126 110%
Tax payables
Beban akrual
19.084 18.366 (718) (4%)
Accrued expenses
Liabilitas imbalan kerja jangka pendek
5.402 4.238 1.164 27%
Short-term employee benefits liability
Utang lain
80.709 59.898 20.811 35%
Other payables
Jumlah Liabilitas Jangka Pendek
1.555.871 1.413.417 142.454 10%
Total Current Liabilities
Liabilitas Jangka Panjang
Non-Current Liabilities
Utang bank (neto bagian jatuh tempo < 1 tahun)
53.296 43.311 9.985 23%
Bank loan net of current maturities
Liabilitas sewa
- - - -
Lease liabilities
Liabilitas imbalan kerja jangka panjang
36.150 32.632 3.518 11%
Long-term employee benefits liability
Jumlah Liabilitas Jangka Panjang
89.446 75.943 13.503 18%
Total Non-Current Liabilities
JUMLAH LIABILITAS
1.645.317 1.489.360 155.957 10%
TOTAL LIABILITIES
Per 31 Desember 2025, total liabilitas meningkat 10% As of December 31, 2025, total liabilities increased 10%
menjadi Rp1.645,3 miliar, terutama didorong kenaikan to Rp1,645.3 billion, primarily driven by a 10% increase in
liabilitas jangka pendek 10% menjadi Rp1.555,88 miliar current liabilities to Rp1,555.88 billion, reflecting a 32% rise
seiring naiknya utang usaha 32% menjadi Rp694,50 miliar in trade payables to Rp694.50 billion and a 35% increase
dan utang lain 35% menjadi Rp80,71 miliar, meskipun utang in other payables to Rp80.71 billion, despite a 6% decline
bank turun 6% menjadi Rp749,56 miliar. Liabilitas jangka in bank loans to Rp749.56 billion. Non-current liabilities
panjang meningkat 18% menjadi Rp89,45 miliar, terutama increased 18% to Rp89.45 billion, mainly due to a 23%
berasal dari kenaikan utang bank (neto) 23% menjadi increase in bank loans (net of current maturities) to Rp53.3
Rp53,3 miliar dan liabilitas imbalan kerja jangka panjang billion and an 11% rise in long-term employee benefits
11% menjadi Rp36,15 miliar, serta pencatatan liabilitas sewa liabilities to Rp36.15 billion, along with the recognition of
sebesar Rp0,92 miliar. lease liabilities of Rp0.92 billion in 2025.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 107
Page 108
Analisis & Pembahasan Manajemen Positioned for
Management Discussion & Analysis Profitable Growth
Ekuitas Equity
(Dalam jutaan Rupiah | in million Rupiah)
Kenaikan (Penurunan)
Uraian Increase (Decrease)
2025 2024
Description Selisih
% (YoY)
Difference
Modal saham
127.400 127.400 0 0%
Share capital
Tambahan modal disetor
2.310 2.310 0 0%
Additional paid-in capital
Surplus revaluasi
4.203 4.203 0 0%
Revaluation surplus
Perubahan nilai wajar investasi
(27.623) (24.564) (3.059) 12%
Change fair value in investment
Saldo laba
209.135 173.166 35.969 21%
Retained earnings
Kepentingan non-pengendali
(21) (19) (3) 11%
Non-controlling interest
JUMLAH EKUITAS
315.403 282.497 32.906 12%
TOTAL EQUITY
Per 31 Desember 2025, total ekuitas meningkat 12% menjadi As of December 31, 2025, total equity increased 12% to
Rp315,4 miliar, terutama didorong kenaikan saldo laba Rp315.4 billion, primarily driven by a Rp35.97 billion increase
sebesar Rp35,97 miliar menjadi Rp209,13 miliar. in retained earnings to Rp209.13 billion.
LAPORAN LABA RUGI DAN PENGHASILAN CONSOLIDATED STATEMENTS
KOMPREHENSIF LAIN KONSOLIDASIAN OF PROFIT OR LOSS AND OTHER
COMPREHENSIVE INCOME
(Dalam jutaan Rupiah | in million Rupiah)
Kenaikan (Penurunan)
Uraian Increase (Decrease)
2025 2024
Description Selisih
% (YoY)
Difference
Penjualan
4.109.810 3.916.864 192.946 5%
Sales
Beban pokok penjualan
(3.747.451) (3.582.487) (164.964) (5%)
Cost of goods sold
Laba bruto
362.359 334.377 27.982 8%
Gross Profit
Beban penjualan
(65.591) (65.548) (42) 0%
Selling expenses
Beban umum dan administrasi
(169.305) (160.643) (8.662) 5%
General and administrative expenses
Pendapatan operasi lain
1.256 3.712 (2.456) (66%)
Other operating income
Beban operasi lain
(15.182) (15.464) 282 (2%)
Other operating expenses
Laba usaha
113.537 96.434 17.103 18%
Operating Profit
Pendapatan keuangan
290 59 231 392%
Finance income
Biaya keuangan
(64.930) (68.791) 3.861 (6%)
Finance costs
108 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 109
Positioned for
Profitable Growth
(Dalam jutaan Rupiah | in million Rupiah)
Kenaikan (Penurunan)
Uraian Increase (Decrease)
2025 2024
Description Selisih
% (YoY)
Difference
Laba sebelum pajak penghasilan
48.897 27.701 21.196 77%
Profit before income tax
Jumlah beban pajak penghasilan
(10.431) (10.787) (3.536) (3%)
Total Income tax expenses
Laba tahun berjalan
38.466 16.914 21.552 127%
Profit for the year
Rugi komprehensif lain tahun berjalan, setelah pajak
3.012 (8.946) 5.934 (66%)
Other comprehensive loss for the year, net of tax
Jumlah penghasilan komprehensif tahun berjalan
35.454 7.969 27.486 345%
Total comprehensive income for the year
Laba per Saham (rupiah penuh)
30,20 13,29 16,91 127%
Earnings per Share (full amount)
Penjualan Sales
Pada 2025, Penjualan meningkat 5% menjadi Rp4.109,81 In 2025, Sales increased 5% to Rp4,109.81 billion, up from
miliar dari Rp3.916,86 miliar pada tahun sebelumnya. Rp3,916.86 billion in the prior year. This increase indicates
Kenaikan ini menunjukkan aktivitas penjualan tetap that sales activity continued to grow despite intense
bertambah di tengah persaingan yang ketat. competition.
Laba bruto Gross Profit
Laba bruto meningkat 8% menjadi Rp362,36 miliar dari Gross Profit rose 8% to Rp362.36 billion, compared with
Rp334,38 miliar pada tahun sebelumnya. Sejalan dengan Rp334.38 billion in the prior year. Accordingly, gross profit
itu, marjin laba bruto membaik dari sekitar 8,54% pada margin improved from approximately 8.54% in 2024
2024 menjadi sekitar 8,82% pada 2025, menunjukkan to approximately 8.82% in 2025, indicating a modest
kualitas marjin yang sedikit lebih baik meskipun Beban improvement in margin quality even as Cost of goods
pokok penjualan meningkat. sold increased.
Laba usaha Operating Profit
Laba usaha meningkat 18% menjadi Rp113,54 miliar dari Operating Profit increased 18% to Rp113.54 billion, up from
Rp96,43 miliar pada tahun sebelumnya. Peningkatan Rp96.43 billion in the prior year. This improvement occurred
ini terjadi walaupun Beban penjualan naik dan Beban even though Selling expenses increased and General and
umum dan administrasi naik 5%, karena Beban operasi administrative expenses increased 5%, supported by a
lain menurun 2%, sehingga tekanan beban operasi dapat 2% decline in Other operating expenses, which helped
lebih terkendali. contain overall operating cost pressure.
Biaya keuangan Finance costs
Biaya keuangan menurun 6% menjadi Rp64,93 miliar dari Finance costs declined 6% to Rp64.93 billion, compared
Rp68,79 miliar pada tahun sebelumnya. Penurunan biaya with Rp68.79 billion in the prior year. The reduction in
keuangan ini membantu memperkuat kinerja setelah finance costs contributed to stronger performance after
mempertimbangkan beban pendanaan. considering funding-related expenses.
Laba sebelum pajak penghasilan Profit before income tax
Laba sebelum pajak penghasilan mencapai Rp48,90 miliar Profit before income tax reached Rp48.90 billion in 2025, an
pada 2025, meningkat 77% dibandingkan Rp27,70 miliar 77% increase from Rp27.70 billion in 2024. The improvement
pada 2024. Perbaikan ini sejalan dengan peningkatan was in line with higher Operating Profit and lower Finance
Laba usaha serta penurunan Biaya keuangan. costs.
Jumlah beban pajak penghasilan Total Income tax expenses
Jumlah beban pajak penghasilan turun 3% menjadi The total income tax expenses decreased by 3% to IDR
Rp10,43 miliar dari Rp10,79 miliar pada tahun sebelumnya. 10.43 billion from IDR 10.79 billion in the previous year.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 109
Page 110
Analisis & Pembahasan Manajemen Positioned for
Management Discussion & Analysis Profitable Growth
Laba tahun berjalan Profit for the year
Laba tahun berjalan meningkat 127% menjadi Rp38,47 Profit for the year increased 127% to Rp38.47 billion,
miliar dari Rp16,91 miliar pada tahun sebelumnya. compared with Rp16.91 billion in the prior year. The
Peningkatan ini didorong oleh kenaikan Laba bruto dan improvement was supported by higher Gross Profit and
Laba usaha, serta dukungan penurunan Biaya keuangan. Operating Profit, along with lower Finance costs.
Jumlah penghasilan komprehensif tahun Total comprehensive income for the year
berjalan
Jumlah penghasilan komprehensif tahun berjalan Total comprehensive income for the year increased 345%
meningkat 345% menjadi Rp35,45 miliar dari Rp7,97 to Rp35.45 billion, up from Rp7.97 billion in the prior year.
miliar pada tahun sebelumnya. Perbaikan ini terutama This improvement primarily reflected higher Profit for the
dipengaruhi kenaikan Laba tahun berjalan dan year and a recovery in Other comprehensive loss for the
membaiknya Rugi komprehensif lain tahun berjalan, year, net of tax.
setelah pajak.
Laba per Saham Earnings per Share (full amount)
Laba per Saham meningkat 127% menjadi Rp30,20 Earnings per Share (full amount) increased 127% to Rp30.20,
dari Rp13,29 pada tahun sebelumnya, sejalan dengan up from Rp13.29 in the prior year, in line with the increase
peningkatan Laba tahun berjalan. in Profit for the year.
110 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 111
Positioned for
Profitable Growth
Kemampuan Membayar Utang
dan Kolektibilitas Piutang
Debt Repayment Ability and
Receivables Collectibility
KEMAMPUAN MEMBAYAR UTANG DEBT REPAYMENT ABILITY
Kemampuan Perseroan dalam memenuhi seluruh The Company’s ability to fulfill all obligations, both long-
kewajiban baik kewajiban jangka panjang maupun jangka term and short-term liabilities, is measured through
pendek diukur melalui beberapa rasio antara lain rasio several ratios, including liquidity ratios and solvency ratios.
likuiditas dan rasio solvabilitas. Rasio likuiditas digunakan Liquidity ratios are used to measure the Company’s ability
untuk mengukur kemampuan melunasi kewajiban jangka to settle short-term liabilities, while the solvency ratio is
pendek, sedangkan rasio solvabilitas digunakan untuk used to measure the ability to meet all obligations.
mengukur kemampuan memenuhi seluruh kewajiban.
Rasio Selisih
2025 2024 % (YoY)
Ratio Difference
Rasio Likuiditas
Liquidity Ratio
Rasio Lancar
110% 111% 1 1%
Current Ratio
Rasio Cepat
71% 70% 1 1%
Acid Test Ratio
Rasio Solvabilitas
Solvency Ratio
Rasio Liabilitas terhadap Ekuitas
522% 527% (5) (1%)
Liabilities to Equity Ratio
Rasio Liabilitas Jangka Panjang terhadap
Ekuitas 28% 27% 1 5%
Non-Current Liabilities to Equity Ratio
Rasio Liabilitas terhadap Aset
84% 84% 0 0%
Liabilities to Assets Ratio
Rasio Utang Berbunga terhadap Ekuitas
(Rasio Gear)
255% 298% (43) (15%)
Interest Bearing Debt to Equity Ratio
(Gearing Ratio)
Likuiditas Liquidity
Rasio Lancar (Current Ratio) Current Ratio
Rasio Lancar pada tahun 2025 tercatat sebesar 110%, The Current Ratio in 2025 was recorded at 110%, slightly
sedikit menurun dari 111% pada tahun 2024, tetapi tetap lower than 111% in 2024, yet still indicates that the Company
menunjukkan kemampuan Perseroan dalam memenuhi maintained a relatively stable ability to meet its short-
kewajiban jangka pendek pada level yang relatif stabil. term obligations.
Rasio Cepat (Quick Ratio/Acid-Test Ratio) Quick Ratio (Acid-Test Ratio)
Rasio Cepat meningkat tipis menjadi 71% dari 70%. Kenaikan The Quick Ratio increased slightly to 71% from 70%. This
ini mengindikasikan kemampuan memenuhi kewajiban improvement suggests a modest strengthening in the
lancar dengan aset paling likuid sedikit membaik. Company’s ability to cover current obligations using its
most liquid assets.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 111
Page 112
Analisis & Pembahasan Manajemen Positioned for
Management Discussion & Analysis Profitable Growth
Solvabilitas dan Leverage Solvency and Leverage
Rasio Liabilitas terhadap Ekuitas (Liabilities to Liabilities to Equity Ratio
Equity Ratio)
Rasio Liabilitas terhadap Ekuitas turun menjadi 522% dari The Liabilities to Equity Ratio declined to 522% from 527%,
527%, menunjukkan leverage menurun terbatas seiring indicating a modest reduction in leverage in line with
penguatan ekuitas. stronger equity.
Rasio Liabilitas Jangka Panjang terhadap Ekuitas Non-Current Liabilities to Equity Ratio
Rasio Liabilitas Jangka Panjang terhadap Ekuitas The Non-Current Liabilities to Equity Ratio increased to
meningkat menjadi 28% dari 27%, mencerminkan porsi 28% from 27%, reflecting a slightly higher proportion of
liabilitas jangka panjang terhadap ekuitas yang sedikit non-current liabilities relative to equity.
meningkat.
Rasio Liabilitas terhadap Aset Liabilities to Assets Ratio
Rasio Liabilitas terhadap Aset tetap 84%, yang The Liabilities to Assets Ratio remained at 84%, indicating
menunjukkan proporsi liabilitas terhadap aset tidak that the share of liabilities relative to total assets did not
berubah secara material. change materially.
Rasio Utang Berbunga terhadap Ekuitas Interest Bearing Debt to Equity Ratio (Gearing Ratio)
Rasio Utang Berbunga terhadap Ekuitas turun menjadi The Interest Bearing Debt to Equity Ratio (Gearing Ratio)
255% dari 298%, mengindikasikan tekanan utang berbunga decreased to 255% from 298%, indicating reduced interest-
relatif terhadap ekuitas berkurang. bearing debt pressure relative to equity.
TINGKAT KOLEKTIBILITAS PIUTANG RECEIVABLES COLLECTIBILITY
Kolektibilitas piutang pada tahun 2025 masih menghadapi Receivables collectibility in 2025 remains challenging,
tantangan, terutama dipengaruhi oleh siklus kredit primarily impacted by extended credit cycles in the
yang lebih panjang pada sektor pemerintah, yang terus government sector, which continue to affect overall
mempengaruhi konversi kas secara keseluruhan. Hal ini cash conversion. This is partially mitigated by improved
sebagian diimbangi dengan peningkatan penagihan dari collections from the private sector. The Company continues
sektor swasta. Perseroan terus memantau piutangnya to closely monitor its receivables through regular ageing
dengan cermat melalui peninjauan umur piutang secara reviews and strengthened collection efforts, supported
teratur dan penguatan upaya penagihan, didukung by ongoing risk assessments to proactively manage and
oleh penilaian risiko berkelanjutan untuk secara proaktif mitigate credit risk exposure.
mengelola dan memitigasi eksposur risiko kredit.
112 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 113
Positioned for
Profitable Growth
Struktur Modal dan Kebijakan Manajemen
atas Struktur Modal
Capital Structure and Management Policy on Capital Structure
KEBIJAKAN STRUKTUR MODAL CAPITAL STRUCTURE POLICY AND
DAN DASAR PEMILIHAN BASIS FOR DETERMINATION
Perseroan mengelola struktur modal secara cermat untuk The Company carefully manages its capital structure
menjaga kelangsungan usaha dalam jangka panjang, to maintain long-term business continuity, support
mendukung kebutuhan pendanaan kegiatan usaha, serta business funding needs, and maintain financial health.
memelihara kesehatan keuangan. Dalam menetapkan In determining its capital structure policy, the Company
kebijakan struktur modal, Perseroan mempertimbangkan considers economic prospects, business growth potential,
prospek ekonomi, potensi pertumbuhan bisnis, dukungan capital support from shareholders, and healthy capital
permodalan dari pemegang saham, serta target rasio ratio targets. Through balanced management of liabilities
permodalan yang sehat. Melalui pengelolaan komposisi and equity, the Company strives to maintain funding
liabilitas dan ekuitas yang seimbang, Perseroan flexibility, support sustainable business growth, and
berupaya menjaga fleksibilitas pendanaan, mendukung comply with applicable loan covenants.
pertumbuhan usaha secara berkelanjutan, serta
memenuhi ketentuan covenant pinjaman yang berlaku.
RINCIAN STRUKTUR MODAL
Capital Structure Details
Kenaikan (Penurunan)
2025 2024
Instrumen Increase (Decrease)
Instrument Rp Juta Kontribusi Rp Juta Kontribusi Selisih
%
Rp Million Contribution Rp Million Contribution Difference
Liabilitas Jangka
Pendek 1.555.871 79,35% 1.413.417 79,77% 142.454 10%
Current Liabilities
Liabilitas Jangka
Panjang 89.446 4,56% 75.943 4,29% 13.503 18%
Non-Current Liabilities
Jumlah Liabilitas
1.645.317 83,91% 1.489.360 84,06% 155.957 10%
Total Liabilities
Jumlah Ekuitas
315.403 16,09% 282.497 15,94% 32.906 12%
Total Equity
Jumlah Liabilitas dan
Ekuitas 1.960.720 100,00% 1.771.857 100,00% 188.863 11%
Total Liabilities and Equity
Pada tahun 2025, jumlah liabilitas Perseroan meningkat In 2025, the Company’s liabilities increased by 10% to
10% menjadi Rp1.645.317 juta, terutama ditopang oleh Rp1,645,317 million, mainly supported by a 10% increase
kenaikan liabilitas jangka pendek sebesar 10% menjadi in short-term liabilities to Rp1,555,871 million. Long-term
Rp1.555.871 juta. Liabilitas jangka panjang juga meningkat liabilities also increased by 18% to Rp89,446 million.
18% menjadi Rp89.446 juta. Sementara itu, jumlah ekuitas Meanwhile, equity rose 12% to Rp315,403 million. Overall,
naik 12% menjadi Rp315.403 juta. Secara umum, struktur the Company’s funding structure is still dominated by
pendanaan Perseroan masih didominasi oleh liabilitas, liabilities, although equity also showed an increase
meskipun ekuitas juga menunjukkan peningkatan compared to the previous year.
dibandingkan tahun sebelumnya.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 113
Page 114
Analisis & Pembahasan Manajemen Positioned for
Management Discussion & Analysis Profitable Growth
Ikatan Material untuk Investasi Barang Modal
Material Commitments for Capital Expenditure
Sepanjang tahun 2025, Perseroan tidak memiliki ikatan Throughout 2025, the Company had no material
yang material untuk investasi barang modal. commitments for capital expenditure.
Realisasi Investasi Barang Modal
Realization of Capital Expenditure
Kenaikan (Penurunan)
Jenis Barang Modal Increase (Decrease)
2025 2024
Type of Capital Expenditure Selisih
%
Difference
Hak atas tanah
0 0 0 0%
Landrights
Bangunan
262 0 262 100%
Building
Renovasi bangunan
138 672 (534) -79%
Buildings renovation
Perbaikan sewa
315 2.558 (2.243) 31%
Leasehold improvements
Kendaraan
929 513 416 81%
Vehicles
Peralatan kantor
2.227 1.848 379 21%
Office equipment
Peralatan teknik
1.472 1.478 (6) -0.41%
Technical equipment
Aset dalam penyelesaian – bangunan
32.416 7.090 25.326 357%
Contruction in progress - Buildings
Jumlah
37.759 14.159 23.600 100%
Total
Informasi dan Fakta Material yang terjadi
Setelah Tanggal Laporan Akuntan
Material Information and Facts Subsequent to the Date of
the Accountant's Report
Pada tahun 2025 tidak terdapat informasi atau fakta In 2025, there were no material information or facts that
material yang terjadi setelah tanggal laporan akuntan, occurred after the accountant’s report date, so there is no
sehingga tidak terdapat informasi mengenai dampaknya information regarding their impact on future performance
terhadap kinerja dan risiko usaha di masa mendatang. and business risks.
114 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 115
Positioned for
Profitable Growth
Perbandingan antara Target dan Realisasi Serta
Proyeksi untuk 1 (Satu) Tahun ke Depan
Comparison between Targets and Realizations as well as
Projections for the Next 1 (One) Year
Pada tahun buku 2025, Peseroan telah menetapkan In the fiscal year 2025, the Company has set several targets
sejumlah target yang hendak dicapai yang dituangkan to be achieved, which are outlined in the Company’s Work
dalam Rencana Kerja dan Anggaran Perseroan (RKAP) Plan and Budget (RKAP) 2024. The comparison of the
2024. Perbandingan pencapaian beberapa target yang achievement of several set targets with the realization in
ditetapkan dengan realisasi tahun buku 2025 adalah the fiscal year 2025 is as follows:
sebagai berikut:
(Dalam jutaan Rupiah | in million Rupiah)
Target RKAP
Pencapaian RKAP Kenaikan
2025 Realisasi 2025 Realisasi 2024
Uraian RKAP (Penurunan)
RKAP 2025 2025 Realization 2024 Realization
Description Achievement Increase (Decrease)
Target
(a) (b) (c) (b/a) (b−c)/c
Pendapatan Usaha
4.329.993 4.109.810 3.916.864 94.91% 4.93%
Operating Revenues
Laba Bruto
390.000 362.358 334.377 92.91% 8.37%
Gross Profit
Laba (Rugi) Tahun
Berjalan
45.168 38.466 16.914 85.16% 127,42%
Profit (Loss) for the
year
Struktur Modal
828 352,62 652 42,56% -45,94%
Capital Structure
Pendapatan terealisasi sebesar Rp4.109,81 miliar atau Revenue reached Rp4,109.81 billion or 94.91% of the target,
mencapai 94,91% dari target, serta meningkat 4,93% and increased by 4.93% compared to 2024. Gross profit
dibandingkan tahun 2024. Laba bruto tercatat sebesar was recorded at Rp362.36 billion, or 92.91% of the target,
Rp362,36 miliar, atau 92,91% dari target, dan tumbuh 8,37% and grew by 8.37% compared to the previous year. Profit
dibandingkan tahun sebelumnya. Laba tahun berjalan for the year reached Rp38.47 billion or 85.16% of the target,
mencapai Rp38,47 miliar atau 85,16% dari target, tetapi but increased significantly by 127.42% compared to the
meningkat signifikan sebesar 127,42% dibandingkan realization in 2024. Thus, the Company continues to
realisasi tahun 2024. Dengan demikian, Perseroan tetap record growth in key performance indicators, although
mencatatkan pertumbuhan pada indikator kinerja utama, the effectiveness of achieving the RKAP target still needs
meskipun efektivitas pencapaian terhadap target RKAP to be improved.
masih perlu terus ditingkatkan.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 115
Page 116
Analisis & Pembahasan Manajemen Positioned for
Management Discussion & Analysis Profitable Growth
PROYEKSI SATU TAHUN KE DEPAN ONE YEAR PROJECTION
Realisasi
Target
Uraian RKAP 2025 Selisih
RKAP 2025 %
Description RKAP 2025 Difference
RKAP 2025 Target
Realization
Pendapatan Usaha
4.329.992 4.520.151 190.158 4%
Operating Revenues
Laba Bruto
390.000 401.765 11.765 3%
Gross Profit
Laba (Rugi) Tahun Berjalan
45.168 55.759 10.591 23%
Profit (Loss) for the year
Struktur Modal
352,62 828,51 -475,89 (57,44%)
Capital Structure
Kebijakan Dividen dan Pembagiannya
Dividend Policy and Distribution
Dasar kebijakan pembagian dividen Perseroan mengacu The basis for the Company’s dividend distribution policy
pada Undang-undang No. 40 Tahun 2007 tentang refers to Law No. 40 of 2007 concerning Limited Liability
Perseroan Terbatas, di mana pembagian dividen dilakukan Companies, whereby dividend distribution is carried
berdasarkan keputusan Rapat Umum Pemegang Saham out based on a resolution of the General Meeting of
(RUPS). Perseroan diperkenankan membagikan dividen Shareholders (GMS). The Company may distribute
interim sepanjang diperbolehkan oleh Anggaran Dasar interim dividends to the extent permitted by its Articles
dan tidak menyebabkan aset bersih Perseroan menjadi of Association and provided that such distribution does
lebih rendah dari modal ditempatkan dan disetor penuh not cause the Company’s net assets to fall below its
serta cadangan wajib. Perseroan juga dapat membagikan issued and fully paid-up capital and statutory reserves.
dividen kas/tunai pada tahun ketika Perseroan mencatat The Company may also distribute cash dividends in a
saldo laba positif. Apabila keputusan pembagian dividen year when it records a positive retained earnings balance.
telah ditetapkan, dividen dibayarkan dalam Rupiah, Once a dividend distribution is approved, dividends are
dan tidak terdapat negative covenant yang dapat paid in Rupiah, and there are no negative covenants that
menghambat Perseroan melakukan pembagian dividen would restrict the Company from distributing dividends
kepada pemegang saham. to shareholders.
Sebagai implementasi kebijakan tersebut, berdasarkan As an implementation of this policy, based on the
keputusan RUPS Tahunan Perseroan untuk tahun buku Company’s Annual GMS resolution for the 2024 fiscal year,
2024, Perseroan membagikan dividen tunai untuk the Company distributed cash dividends for the fiscal year
tahun buku yang berakhir 31 Desember 2024 sebesar ending December 31, 2024, amounting to Rp2,548,000,000
Rp2.548.000.000 atau 15% dari laba bersih, sehingga setiap or 15% of net profit, so that each share received a cash
saham memperoleh dividen tunai sebesar Rp2,00 dengan dividend of Rp2.00, taking into account the applicable
memperhatikan ketentuan perpajakan yang berlaku. tax provisions.
PEMBAGIAN DAN PEMBAYARAN DIVIDEND DISTRIBUTION AND
DIVIDEN TAHUN 2023 HINGGA 2025 PAYMENT 2023-2025
Dividen per
Dividen Kas
Tahun Persentase Dividen Lembar Saham
Tanggal Dibagikan (Rp juta)
Tahun Pembagian Divide terhadap Laba Bersih (Rp/lembar)
Pembayaran Cash Dividends
(Distribution Year) (Dividend Dividend Payout Ratio Dividend per
(Payout Date) Distributed (Rp
Year) to Net Profit Share (Rp/share)
million)
2 Juli 2025
2025 2024 15% 2.548 2,00
July 2, 2024
4 Juli 2024
2024 2023 9,62% 3.185 2,50
July 4, 2024
28 Juni 2023
2023 2022 10,42% 2.548 2,00
June 28, 2023
116 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 117
Positioned for
Profitable Growth
Realisasi Penggunaan Dana Hasil Penawaran Umum
Realization of the Use of Proceeds from Public Offering
Pada tahun 2025, Perseroan tidak melakukan Penawaran In 2025, the Company did not conduct any Public
Umum, sehingga tidak terdapat informasi mengenai Offering therefore there is no information regarding the
total perolehan dana, rencana penggunaan dana, saldo total proceeds obtained, the planned use of proceeds,
dana, dan tanggal persetujuan RUPS atas perubahan the remaining balance of funds, or the date of the GMS
penggunaan dana hasil penawaran umum. approval for any changes in the use of proceeds from a
public offering.
Informasi Material Mengenai Investasi, Ekspansi,
Divestasi, Penggabungan/ Peleburan Usaha,
Akuisisi, Restrukturisasi Utang/Modal
Material Information on Investment, Expansion, Divestment,
Merger/Business Consolidation, Acquisition, and Debt/Capital
Restructuring
Sepanjang tahun buku 2025, Perseroan tidak melakukan Throughout the 2025 fiscal year, the Company did not
aksi korporasi yang bersifat material, termasuk investasi, undertake any material corporate actions, including
ekspansi, divestasi, penggabungan atau peleburan usaha, investments, expansions, divestitures, mergers or
akuisisi, serta restrukturisasi utang dan modal. consolidations, acquisitions, or debt and capital
restructuring.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 117
Page 118
Analisis & Pembahasan Manajemen Positioned for
Management Discussion & Analysis Profitable Growth
Informasi Transaksi Material yang
Mengandung Benturan Kepentingan dan/atau
Transaksi dengan Pihak Afiliasi
Material Transactions Involving Conflicts of Interest and/or
Transactions with Affiliated Parties
TRANSAKSI MATERIAL YANG MATERIAL TRANSACTIONS INVOLVING
MENGANDUNG BENTURAN KEPENTINGAN CONFLICTS OF INTEREST
Perseroan tidak melakukan transaksi yang mengandung The Company did not engage in any transactions involving
benturan kepentingan selama tahun pelaporan yang conflicts of interest during the reporting year ended
berakhir pada tanggal 31 Desember 2025. December 31, 2025.
KEBIJAKAN TENTANG PIHAK POLICY ON AFFILIATED/RELATED PARTIES
AFILIASI/BERELASI
Perseroan menetapkan bahwa setiap transaksi material The Company stipulates that all material transactions are
selalu dilaksanakan melalui prosedur yang memadai serta carried out through adequate procedures and ensures
memastikan transaksi afiliasi/berelasi dilakukan sesuai that affiliated/related party transactions are conducted in
praktik bisnis yang berlaku umum, termasuk memenuhi accordance with generally accepted business practices,
prinsip kewajaran transaksi (arm’s length principle). including compliance with the arm’s length principle.
Perseroan juga memiliki transaksi dengan pihak berelasi The Company also engages in transactions with related
sebagaimana didefinisikan dalam PSAK 224 dan sebagai parties as defined under PSAK 224 and, as part of a
bagian dari suatu kelompok usaha, dalam menjalankan business group, conducts its operations in coordination
operasinya berhubungan serta melakukan transaksi with and through transactions involving related parties.
dengan pihak-pihak berelasi.
NAMA PIHAK BERTRANSAKSI DAN NAME OF TRANSACTING PARTY AND
SIFAT HUBUNGAN AFILIASI NATURE OF AFFILIATED RELATIONSHIP
Pihak Berelasi Sifat Hubungan Jenis Transaksi
Related parties Nature of Relationship Type of Transaction
Pharmaniaga International Pemegang Saham Pinjaman dengan bunga
Corporation Sdn. Bhd Shareholders Interest bearing loan
Pemegang Saham Pembelian Persediaan
PT Danpac Pharma
Shareholders Inventory Purchases
Entitas Sepengendali Pembelian persediaan dan pinjaman dengan bunga
Pharmaniaga Logistics Sdn. Bhd.
Entity under comon control Purchase of inventories and interest bearing loan
Pembelian persediaan, piutang common control lain-lain atas
barang yang diretur, penyertaan dalam bentuk saham dan
Entitas Sepengendali tanggung renteng atas saldo utang dari PT Bank UOB Indonesia
PT Errita Pharma
Entity under comon control Purchase of inventories, other receivables from returned of
merchandise inventories, investment in shares of stock and
joint liability for the loan obtained from PT Bank UOB Indonesia
Dewan Komisaris dan Direksi
Manajemen Kunci Imbalan kerja Jangka pendek
Board of Commissioners and
Key Management Short-term employee benefits
Board of Directors
Entitas Sepengendali
Pembelian persediaan dan pinjaman dengan bunga
Pharmaniaga Berhad Sdn. Bhd. Entity under common
Purchase of inventories and interest bearing loan
control
Entitas Sepengendali
Pembelian persediaan dan pinjaman dengan bunga
PT Mega Pharmaniaga Entity under common
Purchase of inventories and interest bearing loan
control
Entitas Sepengendali
Pembelian persediaan dan pinjaman dengan bunga
Pristine Pharma Sdn. Bhd. Entity under common
Purchase of inventories and interest bearing loan
control
118 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 119
Positioned for
Profitable Growth
Pihak Berelasi Sifat Hubungan Jenis Transaksi
Related parties Nature of Relationship Type of Transaction
Entitas Sepengendali
Pembelian persediaan dan pinjaman dengan bunga
Pharmaniaga Marketing Sdn. Bhd Entity under common
Purchase of inventories and interest bearing loan
control
REALISASI TRANSAKSI PIHAK BERELASI REALIZATION OF RELATED
PARTY TRANSACTIONS
Realisasi saldo dan transaksi Pihak-pihak Berelasi The realization of balances and transactions with Related
terhadap kinerja keuangan Perseroan dapat disampaikan Parties in relation to the Company’s financial performance
sebagai berikut. is presented as follows.
Uraian
2025 2024
Description
Pembelian Persediaan
44.324 55.870
Purchases of Inventories
Persentase dari jumlah pembelian
0.95% 1,68%
Percentage to total purchase
Biaya Keuangan
0 0
Finance Costs
Persentase dari jumlah biaya keuangan
0 0,00%
Percentage to total Finance Costs
Piutang lain-lain
16.381 19.249
Other Receivables
Persentase dari jumlah aset
0,84% 1,09%
Percentage to total assets
Utang Usaha
5.860 9.211
Trade Payables
Persentase dari jumlah liabilitas
0,36% 0,62%
Percentage to total liabilities
Utang lain-lain
76.099 55.960
Other Payable
Persentase dari jumlah liabilitas
4,63% 3,76%
Percentage to total liabilities
KEBIJAKAN MEKANISME REVIEW ATAS POLICY ON THE REVIEW
TRANSAKSI AFILIASI/BERELASI MECHANISM FOR AFFILIATED/
RELATED PARTY TRANSACTIONS
Direksi dan Dewan Komisaris menyatakan bahwa seluruh The Board of Directors and the Board of Commissioners
transaksi afiliasi/berelasi telah melalui prosedur yang affirm that all affiliated/related party transactions have
memadai untuk memastikan pelaksanaan transaksi undergone adequate procedures to ensure that such
sesuai praktik bisnis yang berlaku umum dan memenuhi transactions are conducted in accordance with generally
prinsip kewajaran (arm’s length). accepted business practices and comply with the arm’s
length principle.
Transaksi pihak berelasi yang material atau signifikan Material or significant related party transactions are
terlebih dahulu direview Komite Audit dan memperoleh subject to prior review by the Audit Committee and
persetujuan Dewan Komisaris, serta dilakukan mekanisme require approval from the Board of Commissioners. A
review sesuai jenis transaksi dan analisis kelayakan review mechanism is implemented in accordance with the
transaksi. type of transaction and the relevant transaction feasibility
analysis.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 119
Page 120
Analisis & Pembahasan Manajemen Positioned for
Management Discussion & Analysis Profitable Growth
Perpajakan
Taxation
Perseroan senantiasa memastikan penerapan kepatuhan The Company consistently ensures compliance with
terhadap ketentuan perpajakan sebagai bentuk kontribusi prevailing tax regulations as a form of its contribution to
Perseroan terhadap pembangunan ekonomi Indonesia. Indonesia’s economic development. In 2025, the Company
Pada 2025 Perseroan telah membayar pajak secara tepat fulfilled its tax obligations in a timely manner, amounting
waktu sesuai kewajibannya, yakni sebesar Rp8.231.295.699. to Rp8,231,295,699.
Perubahan Peraturan Perundang-undangan yang
Berdampak Signifikan Terhadap Perseroan
Changes in Laws and Regulations with a Significant
Impact on the Company
Tidak terdapat perubahan peraturan penrundang- There have been no changes in laws and regulations that
undangan yang berdampak pada operasional Perseroan have an impact on the operations of the Company and
beserta entitas anak. its subsidiaries.
Perubahan Kebijakan Akuntansi dan Dampaknya
Terhadap Perseroan
Changes in Accounting Policies and The Impact on the Company
Laporan keuangan untuk tahun yang berakhir pada The financial statements for the year ending December
tanggal 31 Desember 2025 telah disusun sesuai dengan 31, 2025, have been prepared in accordance with the
Standar Akuntansi Keuangan di Indonesia (“SAK”) yang Indonesian Financial Accounting Standards (“SAK”),
mencakup Pernyataan Standar Akuntansi Keuangan which include the Financial Accounting Standards
(“PSAK”) dan Interpretasi Standar Akuntansi Keuangan Statements (“PSAK”) and the Interpretations of Financial
(“ISAK”) yang diterbitkan oleh Dewan Standar Akuntansi Accounting Standards (“ISAK”) issued by the Financial
Keuangan Ikatan Akuntan Indonesia. Pada tahun 2025 Accounting Standards Board of the Indonesian Institute
tidak ada perubahan atas penerapan kebijakan akuntansi of Accountants. In 2025, there were no changes in the
pada laporan keuangan Perseroan. application of accounting policies in the Company’s
financial statements.
120 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 121
Positioned for
Profitable Growth
Aspek Pemasaran
Marketing Aspects
Perseroan senantiasa berkomitmen untuk memberikan The company is always committed to providing the
kualitas produk dan layanan terbaik kepada pelanggan. best product and service quality to its customers. The
Strategi pemasaran yang dijalankan merupakan marketing strategy implemented is a combination
kombinasi antara penyediaan produk berkualitas unggul of providing superior quality products and excellent
dan layanan prima yang berorientasi pada kebutuhan service oriented toward customer needs. All branch
pelanggan. Seluruh pimpinan cabang bekerja sama managers collaborate with the principals in formulating
dengan prinsipal dalam menyusun strategi pemasaran marketing strategies to achieve the set sales targets,
guna mencapai target penjualan yang telah ditetapkan, thru regularly scheduled coordination meetings.
melalui rapat koordinasi rutin yang terjadwal secara
berkala.
Saat ini, Perseroan berfokus pada sejumlah strategi utama Currently, the Company is focusing on several key
untuk meningkatkan kinerja dan memperluas jangkauan strategies to improve performance and expand business
bisnis. Salah satu prioritas adalah penguatan infrastruktur reach. One of the priorities is strengthening digital
digital melalui implementasi sistem barcode dalam infrastructure thru the implementation of a barcode system
manajemen pergudangan, baik di gudang pusat maupun in warehouse management, both in the central warehouse
seluruh kantor cabang, guna meningkatkan efisiensi and all branch offices, to enhance operational efficiency
dan efektivitas operasional. Selain itu, pengelolaan data and effectiveness. In addition, data management has
menjadi perhatian utama dengan tetap berpedoman become a primary focus while adhering to the applicable
pada peraturan perlindungan data pribadi yang berlaku. personal data protection regulations. The company
Perseroan terus memperkuat integrasi serta tata kelola continues to strengthen data integration and governance
data agar mampu menghasilkan wawasan yang to generate comprehensive insights that support
komprehensif dalam mendukung pengambilan keputusan decision-making and sustainable business planning.
dan perencanaan bisnis yang berkelanjutan.
Perseroan juga memperluas jangkauan distribusi melalui The Company is also expanding its distribution reach
pembukaan cabang di Kota Palu, serta peningkatan by opening a branch in Palu City, as well as increasing
kapasitas gudang pada kantor cabang Denpasar dan warehouse capacity at the Denpasar and Bekasi branch
Bekasi. Langkah ini diharapkan dapat memperkuat offices. This step is expected to strengthen the Company’s
kehadiran Perseroan di pasar serta memperluas cakupan presence in the market and expand the scope of services
layanan kepada pelanggan secara lebih optimal. to customers more optimally.
Di samping itu, pengembangan sumber daya manusia In addition, the development of human resources is
dilaksanakan secara berkelanjutan melalui berbagai carried out continuously thru various training programs
program pelatihan guna mendukung implementasi to support the ongoing implementation of digitalization
digitalisasi dan otomatisasi yang tengah berlangsung, and automation, so that operational transformation can
sehingga transformasi operasional dapat berjalan secara proceed effectively and sustainably.
efektif dan berkelanjutan.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 121
Page 122
Analisis & Pembahasan Manajemen Positioned for
Management Discussion & Analysis Profitable Growth
Prospek Usaha
Business Prospects
Memasuki 2026, prospek usaha tetap terbuka dengan Entering 2026, business prospects remain favorable while
tetap mempertimbangkan dinamika risiko global. Pada taking into account the dynamics of global risks. At the
level global, IMF memproyeksikan pertumbuhan ekonomi global level, the International Monetary Fund (IMF) projects
dunia berada pada kisaran moderat, tetapi resilien world economic growth to remain at a moderate yet
dengan proyeksi 3,3% pada 2026. resilient level, with a forecast of 3.3% in 2026.
Sejalan dengan itu, World Bank dalam Global Economic In line with this, the World Bank, in its Global Economic
Prospects juga menggambarkan pemulihan yang berjalan Prospects describes a gradual recovery accompanied by
bertahap disertai risiko ketidakpastian kebijakan dan risks stemming from policy uncertainty and geopolitical
ketegangan geopolitik yang berpotensi memengaruhi tensions that may affect trade and commodity prices.
perdagangan serta harga komoditas. Dalam konteks In the Indonesian context, Bank Indonesia projects that
Indonesia, Bank Indonesia memprakirakan pertumbuhan economic growth in 2026 will strengthen within the range
ekonomi 2026 akan menguat pada kisaran 4,9%–5,7% of 4.9%–5.7% (yoy), supported by domestic demand and
(yoy), ditopang permintaan domestik dan bauran a pro-growth policy mix. From a fiscal policy perspective,
kebijakan pro-pertumbuhan. Dari sisi kebijakan fiskal, the Government, through the 2026 KEM-PPKF, assumes
pemerintah melalui KEM-PPKF 2026 mengajukan asumsi economic growth in the range of 5.2%–5.8%, reflecting its
pertumbuhan ekonomi 2026 pada kisaran 5,2%–5,8%, agenda to stimulate consumption and investment while
yang mencerminkan agenda mendorong konsumsi dan strengthening economic resilience.
investasi serta memperkuat ketahanan ekonomi.
Bagi industri kesehatan dan rantai pasok farmasi, faktor For the healthcare industry and pharmaceutical supply
struktural, mulai dari peningkatan kebutuhan layanan chain, structural factors—ranging from increasing demand
kesehatan, penguatan program preventif, hingga for healthcare services, the strengthening of preventive
perluasan cakupan layanan, berpotensi menjaga programs, to the expansion of service coverage—are
permintaan obat dan alat kesehatan. Pada 2026, expected to sustain demand for pharmaceuticals and
Kementerian Kesehatan menegaskan fokus lanjutan medical devices. In 2026, the Ministry of Health reaffirmed
Program Cek Kesehatan Gratis (CKG) pada penanganan the continued focus of the Free Health Check Program on
hasil pemeriksaan (tindak lanjut), dengan mekanisme the follow-up of examination results, with continuation
kelanjutan melalui JKN bagi peserta aktif; arah kebijakan ini mechanisms through the National Health Insurance
secara implisit memperluas kebutuhan layanan kesehatan (JKN) scheme for active participants. This policy direction
lanjutan yang berpotensi mendorong permintaan produk implicitly expands the need for follow-up healthcare
kesehatan di sepanjang rantai layanan. services, which may drive demand for healthcare products
throughout the service value chain.
Dari sisi industri, Kementerian Perindustrian juga From an industry perspective, the Ministry of Industry
memandang sektor industri kimia, farmasi, dan tekstil also views the chemical, pharmaceutical, and textile
(IKFT) memiliki peran strategis dalam mendorong (IKFT) sectors as strategic drivers of growth in 2026. This
pertumbuhan 2026, yang menjadi konteks relevan provides a relevant context for pharmaceutical distributors
bagi pelaku distribusi farmasi untuk terus memperkuat to further strengthen service capabilities, distribution
kapabilitas layanan, ketepatan distribusi, dan ketahanan accuracy, and supply chain resilience.
rantai pasok.
Dengan mempertimbangkan lanskap tersebut, prospek Taking this landscape into account, the Company’s
Perseroan pada 2026 dapat diarahkan pada tiga prospects in 2026 will be directed toward three main
pengungkit utama: (i) penguatan efektivitas jaringan levers: (i) strengthening the effectiveness of its distribution
distribusi untuk menjaga ketersediaan dan ketepatan network to maintain product availability and service
layanan lintas wilayah, (ii) penajaman portofolio dan accuracy across regions; (ii) refining its portfolio and
bauran produk agar selaras dengan kebutuhan pasar, product mix to align with market needs; and (iii)
serta (iii) akselerasi kapabilitas data dan digital untuk accelerating data and digital capabilities to enhance
meningkatkan kualitas eksekusi komersial dan layanan, the quality of commercial execution and services, while
122 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 123
Positioned for
Profitable Growth
seraya tetap pruden terhadap risiko nilai tukar, biaya remaining prudent with respect to foreign exchange risk,
pendanaan, serta volatilitas eksternal yang dapat financing costs, and external volatility that may affect
memengaruhi biaya dan permintaan. costs and demand.
Sumber Rujukan References
1. IMF, World Economic Outlook Update – January 2026 1. IMF, World Economic Outlook Update – January 2026
(proyeksi pertumbuhan global 2026). (global growth projection for 2026).
2. World Bank, Global Economic Prospects – January 2. World Bank, Global Economic Prospects – January
2026 (outlook global dan risiko utama). 2026 (global outlook and key risks).
3. Bank Indonesia, Ruang Media – News Release (proyeksi 3. Bank Indonesia, Media Release (Indonesia’s 2026
pertumbuhan ekonomi Indonesia 2026: 4,9%–5,7%). economic growth projection: 4.9%–5.7%).
4. Kementerian Keuangan RI, Berita Utama KEM-PPKF 4. Ministry of Finance of the Republic of Indonesia, KEM-
2026 (asumsi pertumbuhan 2026: 5,2%–5,8%). PPKF 2026 Main Report (2026 growth assumption:
5.2%–5.8%).
5. Kementerian Kesehatan RI, Tahun 2026, Kemenkes 5. Ministry of Health of the Republic of Indonesia, “In 2026,
Fokuskan CKG pada Penanganan Hasil Pemeriksaan the Ministry of Health Focuses the CKG Program on
(arah kebijakan CKG 2026). Follow-Up of Examination Results” (2026 CKG policy
direction).
6. Kementerian Perindustrian RI (unit terkait), publikasi 6. Ministry of Industry of the Republic of Indonesia
sektor IKFT dan konteks pertumbuhan industri menuju (relevant unit), publications on the IKFT sector and
2026. industry growth outlook toward 2026.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 123
Page 124
Analisis & Pembahasan Manajemen Positioned for
Management Discussion & Analysis Profitable Growth
Informasi Kelangsungan Usaha
Information on Going Concern
Perseroan menempatkan kelangsungan usaha sebagai The Company places business continuity as a
prioritas manajemen melalui penerapan langkah-langkah management priority through the implementation of
strategis yang terukur untuk menjaga keberlanjutan bisnis measurable strategic initiatives to safeguard long-
dalam jangka panjang. Keyakinan atas kelangsungan term sustainability. Confidence in its going concern is
usaha tersebut ditopang oleh prospek sektor kesehatan supported by the continued growth prospects of the
yang masih bertumbuh, penguatan kapabilitas internal healthcare sector, the strengthening of the Company’s
Perseroan dalam memperluas jangkauan layanan, internal capabilities in expanding service coverage, and
serta peningkatan kemampuan eksekusi melalui inisiatif enhanced execution capacity through the digitalization
digitalisasi proses komersial dan layanan. of commercial and service processes.
Dalam menjaga resiliensi, Perseroan tetap mengedepankan In maintaining resilience, the Company continues to
prinsip kehati-hatian dengan mempertimbangkan potensi uphold the principle of prudence by taking into account
dampak ketidakpastian global terhadap perekonomian the potential impact of global uncertainties on the
domestik. Penguatan pengelolaan data juga menjadi domestic economy. Strengthening data management is
fokus untuk memastikan kualitas pengambilan keputusan also a key focus to ensure the quality of decision-making
dan kesiapan operasional, dengan tetap mengacu pada and operational readiness, while remaining compliant
ketentuan perlindungan data pribadi yang berlaku. Selain with applicable personal data protection regulations. In
itu, pengembangan kompetensi SDM dilaksanakan secara addition, the development of human capital competencies
berkelanjutan agar implementasi digitalisasi dan otomasi is carried out on an ongoing basis to ensure consistent
berjalan konsisten di seluruh organisasi. implementation of digitalization and automation across
the organization.
Dengan kombinasi prospek pasar, penguatan strategi With a combination of favorable market prospects,
operasional, disiplin tata kelola, serta kesiapan organisasi, strengthened operational strategies, disciplined
Perseroan menilai kelangsungan usahanya dapat governance, and organizational readiness, the Company
dipelihara secara pruden dan adaptif terhadap dinamika believes that its going concern can be maintained
eksternal. prudently and adaptively in response to external dynamics.
124 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 125
Positioned for
Profitable Growth
Halaman ini sengaja dikosongkan
This page is intentionally left blank
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 125
Page 126
Laporan Manajemen Positioned for
Management Report Profitable Growth
05
Tata Kelola
Perusahaan
Good Corporate
Governance
126 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 127
Positioned for Profitable Growth PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 127
Page 128
Tata Kelola Perusahaan Positioned for
Good Corporate Governance Profitable Growth
Komitmen dan Kebijakan Penerapan Tata Kelola
Commitment and Policy on Governance Implementation
Perseroan berkomitmen untuk menerapkan dan The Company is committed to consistently implementing
mengembangkan praktik terbaik Tata Kelola Perusahaan and developing best practices in Good Corporate
yang Baik (Good Corporate Governance/GCG) secara Governance (GCG) across all lines of the organization.
konsisten di seluruh lini organisasi. Penerapan GCG bukan The implementation of GCG is no longer merely a matter
lagi sekadar pemenuhan regulasi, melainkan landasan of regulatory compliance, but rather a foundation for
dalam menjaga kepercayaan pasar pada peran Perseroan maintaining market confidence in the Company’s role as
sebagai mitra distribusi produk kesehatan. Dalam bisnis a distributor of healthcare products. In the pharmaceutical
distribusi farmasi, kualitas layanan bukan hanya soal distribution business, service quality is not only a matter
ketepatan waktu, tetapi juga ketertelusuran, ketepatan of timeliness, but also traceability, accuracy of handling,
penanganan, dan kepatuhan dari hulu ke hilir, yakni mulai and compliance from upstream to downstream, namely
dari penerimaan barang, penyimpanan, pengelolaan from goods receipt, storage, inventory management, to
persediaan, hingga pengiriman kepada pelanggan. delivery to customers.
Oleh karena itu, Perseroan menempatkan GCG sebagai Therefore, the Company places GCG as a guide for
pengarah perilaku organisasi agar setiap keputusan organizational behavior so that every operational
operasional berada dalam koridor integritas dan kehati- decision is made with integrity and prudence. The
hatian. Penerapan GCG didukung oleh pengendalian implementation of GCG is supported by internal controls,
internal, manajemen risiko, serta mekanisme check and risk management, and check and balance mechanisms
balance untuk memitigasi risiko kepatuhan, integritas to mitigate compliance risks, supply chain integrity, fraud,
rantai pasok, fraud, dan benturan kepentingan. Komitmen and conflicts of interest. This commitment is reinforced
tersebut diperkuat melalui penegakan kode etik, kebijakan through the enforcement of a code of ethics, anti-
anti-korupsi/anti-penyuapan, serta mekanisme pelaporan corruption/anti-bribery policies, and a mechanism for
pelanggaran, sehingga pertumbuhan usaha tetap reporting violations, so that business growth remains in
selaras dengan perlindungan kepentingan pemangku line with the protection of stakeholder interests and long-
kepentingan dan keberlanjutan bisnis jangka panjang. term business sustainability.
PENERAPAN PRINSIP TATA IMPLEMENTATION OF CORPORATE
KELOLA PERUSAHAAN GOVERNANCE PRINCIPLES
Perseroan secara konsisten menerapkan 5 (lima) The Company consistently applies the 5 (five) fundamental
prinsip dasar GCG, yaitu Transparency, Accountability, principles of Good Corporate Governance (GCG), namely
Responsibility, Independence, dan Fairness (TARIF) dengan Transparency, Accountability, Responsibility, Independence,
implementasi sebagai berikut: and Fairness (TARIF), implemented as follows:
1. Transparansi (Transparency) 1. Transparency
Perseroan menjamin keterbukaan informasi material The Company ensures the timely and accurate
yang tepat waktu dan akurat kepada publik dan disclosure of material information to the public and
otoritas bursa. Hal ini tercermin dari pelaksanaan Public capital market authorities. This is reflected in the
Expose pada Desember 2025 serta penyajian Laporan conduct of the Public Expose in December 2025, as
Keuangan Interim dan Tahunan yang sesuai dengan well as the presentation of Interim and Annual Financial
Standar Akuntansi Keuangan (SAK) yang berlaku. Statements prepared in accordance with the applicable
Indonesian Financial Accounting Standards (SAK).
2. Akuntabilitas (Accountability) 2. Accountability
Kejelasan fungsi, tugas, dan pertanggungjawaban The clarity of functions, duties, and accountability
organ Perseroan (RUPS, Dewan Komisaris, dan Direksi) of the Company’s organs (the General Meeting of
diatur secara tegas dalam Anggaran Dasar Perseroan. Shareholders, the Board of Commissioners, and
Pada tahun 2025, Perseroan memperkuat akuntabilitas the Board of Directors) is clearly stipulated in the
operasional melalui pengawasan ketat terhadap Company’s Articles of Association. In 2025, the
kinerja 37 kantor cabang, termasuk cabang baru di Company strengthened operational accountability
Palu. through close supervision of the performance of 37
branch offices, including the newly established branch
in Palu.
128 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 129
Positioned for
Profitable Growth
3. Tanggung Jawab (Responsibility) 3. Responsibility
Sebagai distributor farmasi, kepatuhan adalah prioritas As a pharmaceutical distributor, compliance is an
mutlak. Perseroan mematuhi seluruh peraturan absolute priority. The Company complies with all
perundang-undangan, termasuk standar Cara prevailing laws and regulations, including the Good
Distribusi Obat yang Baik (CDOB) yang disertifikasi Distribution Practice for Drugs (Cara Distribusi Obat
oleh BPOM. Pemenuhan sertifikasi CDOB untuk cabang yang Baik/CDOB) standards certified by BPOM. The
Kediri pada November 2025 menjadi wujud komitmen fulfillment of CDOB certification for the Kediri branch
Perseroan terhadap kualitas dan keamanan produk in November 2025 demonstrates the Company’s
farmasi. commitment to maintaining the quality and safety
of pharmaceutical products.
4. Independensi (Independence) 4. Independence
Perseroan dikelola secara profesional tanpa benturan The Company is managed professionally, free from
kepentingan dan pengaruh/tekanan dari pihak mana conflicts of interest and from any influence or pressure
pun yang tidak sesuai dengan peraturan perundang- that is inconsistent with prevailing laws and regulations.
undangan. Pengambilan keputusan strategis, seperti Strategic decisions, such as branch office expansion,
ekspansi kantor cabang, didasarkan pada analisis are made based on objective business analysis and
bisnis yang objektif demi kepentingan terbaik in the best interests of the Company.
perusahaan.
5. Kewajaran dan Kesetaraan (Fairness) 5. Fairness
Perseroan menjamin perlindungan hak-hak The Company ensures the fair and equitable protection
pemegang saham, baik mayoritas maupun minoritas, of the rights of all shareholders, both majority and
serta pemangku kepentingan lainnya secara adil dan minority, as well as other stakeholders, including the
setara, termasuk hak untuk mengakses informasi dan right to access information and to exercise voting rights
memberikan suara dalam RUPS. at the General Meeting of Shareholders.
LANDASAN KEPATUHAN COMPLIANCE FRAMEWORK
Seluruh kebijakan tata kelola Perseroan disusun All of the Company’s governance policies are formulated
berdasarkan pada: based on the following:
1. Undang-Undang No. 40 Tahun 2007 tentang Perseroan 1. Law No. 40 of 2007 on Limited Liability Companies.
Terbatas.
2. Peraturan Otoritas Jasa Keuangan (POJK) terkait Tata 2. Regulation of the Financial Services Authority (OJK)
Kelola Emiten. concerning the governance of public companies.
3. Anggaran Dasar Perusahaan dan Pedoman Etika Bisnis 3. The Company’s Articles of Association and Code of
(Code of Conduct). Conduct.
FOKUS TATA KELOLA TAHUN 2025: 2025 GOVERNANCE FOCUS:
PENGUATAN PENGENDALIAN STRENGTHENING INTERNAL
INTERNAL DAN KEPATUHAN CONTROL AND COMPLIANCE
Sejalan dengan strategi ekspansi fisik yang agresif pada In line with the Company’s aggressive physical expansion
tahun 2025, yang ditandai dengan peresmian gedung strategy in 2025, marked by the inauguration of a new
baru di Bekasi dan pembukaan cabang ke-37 di Palu, building in Bekasi and the opening of the 37 branch in
Perseroan menyadari adanya peningkatan eksposur Palu, the Company recognized an increase in exposure
risiko operasional dan logistik. to operational and logistics risks.
Oleh karena itu, kebijakan tata kelola tahun 2025 Accordingly, the Company’s governance policies in 2025
difokuskan pada: were focused on the following:
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 129
Page 130
Tata Kelola Perusahaan Positioned for
Good Corporate Governance Profitable Growth
1. Penguatan Sistem Pengendalian Internal (SPI) 1. Strengthening the Internal Control System
Memastikan integrasi sistem pelaporan dari cabang Ensuring real-time integration of the reporting system
baru ke kantor pusat berjalan real-time untuk from new branches to the head office to minimize the
meminimalisir risiko kebocoran pendapatan dan risk of revenue leakage and stock inefficiencies.
inefisiensi stok.
2. Kepatuhan Regulasi Distribusi 2. Compliance with Distribution Regulations
Memastikan seluruh infrastruktur baru memenuhi Ensuring that all new infrastructure complies with Good
standar CDOB guna menjaga integritas produk farmasi Distribution Practice for Drugs (Cara Distribusi Obat
sepanjang rantai pasok. yang Baik/CDOB) standards in order to safeguard
the integrity of pharmaceutical products throughout
the supply chain.
3. Manajemen Risiko Terintegrasi 3. Integrated Risk Management
Melakukan pemetaan ulang profil risiko pasca- Re-mapping the post-expansion risk profile to maintain
ekspansi untuk menjaga stabilitas margin dan margin stability and profitability, which began to
profitabilitas yang mulai pulih sejak Kuartal I-2025. recover in the First Quarter of 2025.
STRUKTUR TATA KELOLA GOOD CORPORATE
PERUSAHAAN YANG BAIK [2-9] GOVERNANCE STRUCTURE
Rapat Umum Pemegang Saham (RUPS)
General Meeting of Shareholders (GMS)
Dewan Komisaris Direksi
Board of Commissioners Board of Directors
Komite Audit Sekretaris Perusahaan
Audit Committee Corporate Secretary
Komite Nominasi Satuan Audit Internal
Nomination Committee Internal Audit Unit
Struktur tata kelola Perseroan dikembangkan berlandaskan The Company’s governance structure is developed based
Undang-Undang Republik Indonesia Nomor 40 Tahun on Law of the Republic of Indonesia No. 40 of 2007 on
2007 tentang Perseroan Terbatas, yang menganut sistem Limited Liability Companies, which adopts a two-tier board
dua badan atau two-tier board system. Dalam kerangka system. Within this framework, the Company establishes
ini, Perseroan menetapkan pemisahan yang jelas dan a clear and firm separation between the supervisory
tegas antara fungsi pengawasan (non-executive) yang (non-executive) function carried out by the Board of
dijalankan oleh Dewan Komisaris dan fungsi pengurusan Commissioners and the management (executive) function
(executive) yang dipegang oleh Direksi, di mana keduanya exercised by the Board of Directors. Both organs hold equal
memiliki kedudukan sejajar, tetapi dengan tanggung standing with distinct responsibilities and ultimately report
jawab berbeda dan bermuara kepada Rapat Umum to the General Meeting of Shareholders (GMS) as the
Pemegang Saham (RUPS) sebagai organ pemegang highest governing body of the Company.
kekuasaan tertinggi.
130 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 131
Positioned for
Profitable Growth
Mekanisme ini dirancang untuk menciptakan sistem This mechanism is designed to create an effective system
checks and balances yang efektif. Direksi dipimpin oleh of checks and balances. Led by the President Director, the
Direktur Utama memiliki otoritas penuh dan independen Board of Directors has full and independent authority to
dalam memimpin operasional serta eksekusi strategi manage operations and execute the Company’s day-
bisnis sehari-hari tanpa campur tangan teknis dari Dewan to-day business strategies without technical intervention
Komisaris. Sementara Dewan Komisaris berfokus pada from the Board of Commissioners. Meanwhile, the Board
fungsi pengawasan komprehensif dan pemberian nasihat of Commissioners focuses on comprehensive oversight
strategis guna memastikan pengelolaan perusahaan and the provision of strategic advice to ensure that the
berjalan sesuai prinsip GCG. Company’s management is conducted in accordance
with Good Corporate Governance (GCG) principles.
Untuk mengoptimalkan fungsinya, Dewan Komisaris To optimize the performance of its duties, the Board of
dibantu oleh Komite Audit serta Komite Nominasi dan Commissioners is assisted by the Audit Committee as
Remunerasi, sementara Direksi didukung oleh Sekretaris well as the Nomination and Remuneration Committee,
Perusahaan dan Unit Audit Internal dalam menjaga while the Board of Directors is supported by the Corporate
akuntabilitas serta kepatuhan perusahaan. Secretary and the Internal Audit Unit in maintaining the
Company’s accountability and compliance.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 131
Page 132
Tata Kelola Perusahaan Positioned for
Good Corporate Governance Profitable Growth
Rapat Umum Pemegang Saham
General Meeting of Shareholders
Rapat Umum Pemegang Saham, yang selanjutnya disebut The General Meeting of Shareholders, hereinafter
“RUPS”, merupakan organ Perseroan yang mempunyai referred to as “GMS”, is an organ of the Company that
wewenang yang tidak diberikan kepada Direksi atau has authority not granted to the Board of Directors or
Dewan Komisaris dalam batas yang ditentukan dalam Board of Commissioners within the limits specified in Law
Undang-Undang No. 40 Tahun 2007 tentang Perseroan No. 40 of 2007 concerning Limited Liability Companies,
Terbatas, Anggaran Dasar Perseroan, serta POJK No. 15/ the Company’s Articles of Association, and POJK No. 15/
POJK.04/2020 tentang Rencana dan Penyelenggaraan POJK.04/2020 concerning the Plan and Implementation
Rapat Umum Pemegang Saham Perusahaan Terbuka of General Meetings of Shareholders of Public Companies
(POJK 15/2020). Dalam hal ini, RUPS merupakan forum (POJK 15/2020). In this case, the GMS is the forum that
yang memiliki kewenangan tertinggi dalam pengambilan has the highest authority in decision-making within the
keputusan di organisasi Perseroan. Company.
JENIS RUPS TYPES OF GMS
RUPS yang dilaksanakan di Perseroan terdiri dari RUPS The GMS convened by the Company consist of the Annual
Tahunan (“RUPST”) yang dilakukan paling lambat 6 General Meeting of Shareholders (“AGMS”), which is held no
(enam) bulan setelah berakhirnya tahun buku dan RUPS later than 6 (six) months after the end of the financial year,
Luar Biasa (“RUPSLB”) yang dilaksanakan di luar waktu and the Extraordinary General Meeting of Shareholders
penyelenggaraan RUPS Tahunan atas permintaan Direksi (“EGMS”), which is convened outside the schedule of
atau pemegang saham yang mewakili minimum 10% dari the AGMS at the request of the Board of Directors or
total saham ditempatkan dan disetor penuh. shareholders representing at least 10% (ten percent) of
the total issued and fully paid shares.
PEMEGANG SAHAM SHAREHOLDERS
Pemegang Saham adalah pihak yang memiliki saham Shareholders are parties, whether individuals or institutions,
Perseroan, baik perorangan maupun institusi, dan that own shares in the Company and, accordingly, are
karenanya memperoleh hak serta perlindungan sesuai entitled to rights and protections as stipulated under
Undang-Undang Perseroan Terbatas dan Anggaran the Limited Liability Companies Law and the Company’s
Dasar Perseroan. Hak-hak Pemegang Saham terutama Articles of Association. Shareholders’ rights are primarily
dijalankan melalui Rapat Umum Pemegang Saham (RUPS) exercised through the General Meeting of Shareholders
sebagai organ tertinggi Perseroan, dengan kewenangan (GMS) as the Company’s highest governing organ, with
tertentu yang tidak diberikan kepada Direksi maupun specific authorities not delegated to the Board of Directors
Dewan Komisaris. or the Board of Commissioners.
Selaras dengan prinsip kesetaraan, Perseroan menerapkan In line with the principle of equality, the Company
prinsip one share one vote, sehingga setiap saham applies the one share, one vote principle, whereby each
memberikan hak suara yang setara sesuai ketentuan shvare carries equal voting rights in accordance with
yang berlaku. Melalui RUPS, Pemegang Saham antara prevailing regulations. Through the GMS, Shareholders,
lain menetapkan keputusan strategis, mengangkat dan among others, determine strategic decisions, appoint
memberhentikan anggota Direksi dan Dewan Komisaris, and dismiss members of the Board of Directors and the
serta menyetujui penggunaan laba bersih termasuk Board of Commissioners, and approve the appropriation
pembagian dividen. Perseroan juga mengungkapkan of net profit, including dividend distributions. The Company
struktur kepemilikan saham secara transparan, termasuk also discloses its share ownership structure transparently,
pemegang saham utama dan/atau pengendali (apabila including major and/or controlling shareholders (if
ada) serta kepemilikan langsung maupun tidak langsung any), as well as direct and indirect ownership up to the
hingga pemilik akhir, sesuai ketentuan yang berlaku. ultimate beneficial owner, in compliance with applicable
regulations.
132 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 133
Positioned for
Profitable Growth
31 Desember 2025
December 31, 2025
Pemegang Saham Persentase Kepemilikan Saham
No.
Shareholders Jumlah Lembar Saham (%)
Number of Shares Percentage of Share Ownership
(%)
Pharmaniaga International Corp.
1 935.541.534 73,43
Sdn. Bhd., Malaysia
2 PT Danpac Pharma 123.844.020 9,72
3 PT Indolife Pensiontama 42.762.830 3,36
4 PT Ngrumat Bondo Utomo 23.731.000 1,86
Masyarakat
5 148.120.616 11,63
Public
Jumlah
1.274.000.000 100,00
Total
PENYELENGGARAAN RUPS TAHUN 2025 IMPLEMENTATION OF GMS IN 2025
Sepanjang tahun 2025, Perseroan menyelenggarakan 1 Throughout 2025, the Company held one GMS, namely
(satu) kali RUPS, yaitu RUPS Tahunan yang diselenggarakan the Annual General Meeting of Shareholders held on
pada Rabu, 28 Mei 2025, secara fisik dan elektronik dengan Wednesday, May 28, 2025, physically and electronically
menggunakan Aplikasi Electronic General Meeting System using the Electronic General Meeting System Application
PT Kustodian Sentral Efek Indonesia (“Aplikasi eASY.KSEI”) of PT Kustodian Sentral Efek Indonesia (“eASY Application.
dengan memperhatikan POJK No. 16/POJK.04/2020 tentang KSEI“) in accordance with POJK No. 16/POJK.04/2020
Pelaksanaan Rapat Umum Pemegang Saham Perusahaan concerning the Implementation of Electronic General
Terbuka Secara Elektronik (“POJK No.16/POJK.04/2020”) Meetings of Shareholders of Public Companies (”POJK No.
serta ketentuan Anggaran Dasar Perseroan. 16/POJK.04/2020”) and the provisions of the Company’s
Articles of Association.
Berikut disampaikan kronologis pengumuman rencana The following is a chronology of the announcement of the
pelaksanaan hingga pengumuman hasil risalah RUPS implementation plan to the announcement of the results
Tahunan yang dilakukan pada tahun 2025. of the Annual GMS minutes conducted in 2025.
Tahapan Pelaksanaan RUPS Tahunan Tahun Buku 2025
Stages of Implementation of the Annual GMS for Fiscal Year 2025
Kegiatan Tanggal Keterangan
Activity Date Description
Memberitahukan rencana akan Penyelenggaraan RUPS Tahunan Tahun Buku
2024 beserta Agenda Rapat kepada Otoritas Jasa Keuangan (“OJK”), sesuai
Pemberitahuan Agenda RUPS dengan peraturan POJK No. 15/POJK.04/2020 pasal 13 ayat 1. Pemberitahuan
Tahunan kepada OJK 10 April 2025 disampaikan 5 hari kerja sebelum pengumuman RUPS Tahunan.
Notification of the Annual GMS April 10, 2025 Notify the Financial Services Authority (“OJK”) of the plan to hold the Annual
Agenda to the OJK GMS for the Fiscal Year 2024 along with the Meeting Agenda, in accordance
with POJK Regulation No. 15/POJK.04/2020 Article 13 paragraph 1. The notification
is submitted 5 working days before the announcement of the Annual GMS.
Pengumuman RUPS Tahunan disampaikan kepada Pemegang Saham melalui:
• Situs web Bursa Efek Indonesia ([www.idx.co.id](http://www.idx.co.id)).
Pengumuman RUPS Tahunan • Situs web Perseroan dalam bahasa Indonesia dan bahasa Inggris.
kepada Pemegang Saham 21 April 2025 • Sistem PT Kustodian Sentral Efek Indonesia (eASY.KSEI).
Announcement of the Annual April 21, 2025 The Annual GMS announcement is delivered to Shareholders through:
GMS to Shareholders • The Indonesia Stock Exchange website ([www.idx.co.id](http://www.idx.co.id)).
• The Company's website in Indonesian and English.
• The Indonesian Central Securities Depository (eASY.KSEI) system.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 133
Page 134
Tata Kelola Perusahaan Positioned for
Good Corporate Governance Profitable Growth
Tahapan Pelaksanaan RUPS Tahunan Tahun Buku 2025
Stages of Implementation of the Annual GMS for Fiscal Year 2025
Kegiatan Tanggal Keterangan
Activity Date Description
• Pemanggilan kepada Pemegang Saham dilakukan 21 hari kerja sebelum
pelaksanaan RUPS Tahunan.
Pemanggilan dan Informasi
• Pemanggilan kepada Pemegang Saham dilakukan melalui:
Penjelasan Mata Acara RUPS
a. Situs web Bursa Efek Indonesia ([www.idx.co.id](http://www.idx.co.id).
Tahunan kepada Pemegang
b. Situs web Perseroan dalam bahasa Indonesia dan bahasa Inggris.
Saham. 06 Mei 2025
c. Sistem PT Kustodian Sentral Efek Indonesia (eASY.KSEI).
Notice and Information May 6, 2025
Regarding the Annual GMS • Shareholders are notified 21 business days prior to the Annual GMS.
Agenda to Shareholders. • Shareholders are notified through:
a. The Indonesia Stock Exchange website ([www.idx.co.id](http://www.idx.co.id).
b. The Company's website in Indonesian and English.
c. The Indonesian Central Securities Depository (eASY.KSEI) system.
Rapat diselenggarakan pada hari Rabu, 28 Mei 2025, pukul 14.20-14.59 WIB
Pelaksanaan RUPS
secara offline dan online, bertempat di Ruang Yudhisthira, Hotel Artotel
Tahunan.
28 Mei 2025 Senayan, Jl. Pintu Satu Senayan, Jakarta.
Implementation of the Annual
May 28, 2025 The meeting was held on Wednesday, May 28, 2025, from 14:20 to 14:59 Western
GMS.
Indonesia Time (WIB), in both offline and online formats, and took place at
the Yudhisthira Room, Artotel Senayan Hotel, Jl. Pintu Satu Senayan, Jakarta.
• Dilakukan paling lambat 2 (dua) hari kerja setelah pelaksanaan RUPST dan
RUPSLB.
• Publikasi Resume RUPST dan RUPSLB (notaril) dan Ringkasan Risalah RUPST
dan RUPSLB, termasuk hasil pemungutan suara setiap agenda, diunggah
dalam Bahasa Indonesia dan Bahasa Inggris di situs web Perseroan, situs
Ringkasan Risalah RUPS
web BEI, dan situs web KSEI.
Tahunan 02 Juni 2025
• Conducted no later than 2 (two) business days after the convening of the
Summary of Minutes of the June 02, 2025
Annual GMS AGMS and EGMS.
• The publication of the notarized Summary of the AGMS and EGMS and the
Summary of the Minutes of the AGMS and EGMS, including the voting results
for each agenda item, is uploaded in both Indonesian and English on the
Company’s website, the Indonesia Stock Exchange (IDX) website, and the
KSEI website.
INFORMASI PELAKSANAAN RUPS IMPLEMENTATION OF THE ANNUAL
TAHUNAN 28 MEI 2025 GMS ON MAY 28, 2025
Hari, Tanggal, dan Waktu
Rabu, 28 Mei 2025, pukul 14.20-14.59 WIB
Day, Date, and Time
Wednesday, May 28, 2025, 2:20 PM - 2:59 PM WIB
Tempat Ruang Yudhisthira, Hotel Artotel Senayan
Venue Jl. Pintu Satu Senayan, Jakarta
Rapat dihadiri oleh Para Pemegang Saham dan/atau Kuasa/Wakil Pemegang Saham yang
seluruhnya mewakili 983.031.815 (sembilan ratus delapan puluh tiga juta tiga puluh satu ribu
delapan ratus lima belas) saham atau 77,1611 % (tujuh puluh tujuh koma satu enam satu
satu persen) dari 1.274.000.000 (satu miliar dua ratus tujuh puluh empat juta) saham yang
Kuorum merupakan seluruh saham dengan hak suara yang sah yang telah dikeluarkan oleh Perseroan.
Quorum The meeting was attended by Shareholders and/or their duly authorized proxies, representing
a total of 983,031,815 (nine hundred eighty-three million thirty-one thousand eight hundred
fifteen) shares, or 77.1611% (seventy-seven point one six one one percent) of the 1,274,000,000
(one billion two hundred seventy-four million) shares constituting all issued shares with valid
voting rights of the Company.
Pimpinan RUPST
Joefly Joesoef Bahroeny
Chairperson of the GMS
Joefly Joesoef Bahroeny, Komisaris Utama merangkap Komisaris Independen
Joefly Joesoef Bahroeny, President Commissioner and Independent Commissioner
Sarah Azreen binti Abdul Samat, Komisaris Independen
Kehadiran anggota Dewan Sarah Azreen binti Abdul Samat, Independent Commissioner
Komisaris
Aman Bhakti Pulungan, Komisaris Independen
Attendance of the Board of
Aman Bhakti Pulungan, Independent Commissioner
Commissioners members
Dr. Imam Fathorrahman, M.M., Komisaris Independen
Dr. Imam Fathorrahman, M.M., Independent Commissioner
Dato’ Zulkifli Bin Jafar, Komisaris
Dato’ Zulkifli Bin Jafar, Commissioner
134 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 135
Positioned for
Profitable Growth
Kehadiran anggota Direksi Ahmad bin Abu Bakar, Direktur Utama
Attendance of the Board of Ahmad bin Abu Bakar, President Director
Directors members Mohamad Fazly bin Hassan, Direktur
Mohamad Fazly bin Hassan, Director
Notaris, Dini Lastari Siburian, S.H.
Notary, Dini Lastari Siburian, S.H.
Kehadiran Pihak Independen
Biro Administrasi Efek, PT Raya Saham Registra
Attendance of Independent
Securities Administration Bureau, PT Raya Saham Registra
Parties
Kantor Akuntan Publik, Tanubrata Sutanto Fahmi Bambang & Rekan
Public Accounting Firm, Tanubrata Sutanto Fahmi Bambang & Partners
Sepanjang rapat berlangsung, tidak ada pertanyaan dan/ Throughout the meeting, there were no questions and/
atau pendapat dari pemegang saham ataupun kuasa or opinions raised by the shareholders or their proxies.
pemegang saham. Seluruh keputusan disetujui secara All resolutions were approved through deliberation to
musyawarah untuk mufakat dan setiap agenda rapat reach consensus, and each agenda item was adopted
menghasilkan suara bulat atau 100% setuju. Keputusan unanimously, representing 100% approval. The resolutions
RUPST telah direalisasikan dan disahkan ke dalam Akta of the AGMS have been implemented and formalized
Pernyataan Keputusan Rapat No. 75 tanggal 28 Mei 2025. in the Deed of Statement of Meeting Resolutions No. 75
dated May 28, 2025. .
Agenda dan Realisasi Keputusan RUPS Tahunan Tahun Buku 2024
Agenda and Implementation of the Annual GMS for the Fiscal Year 2024 Resolutions
Agenda Keputusan Keterangan
No
Agenda Resolutions Description
Persetujuan dan Menyetujui dan mengesahkan Laporan Tahunan Perseroan Telah direalisasikan
pengesahan Laporan untuk tahun buku yang berakhir pada tanggal 31 Desember 2024, pada tahun buku
Tahunan Perseroan tahun termasuk di dalamnya Laporan Kegiatan Perseroan, Laporan Tugas Implemented in the
buku 2024 termasuk Pengawasan Dewan Komisaris Perseroan, dan Laporan Keuangan fiscal year
di dalamnya Laporan Perseroan untuk tahun buku yang berakhir pada tanggal 31 Desember
Kegiatan Perseroan, 2024 yang meliputi Neraca dan Perhitungan Laba Rugi Perseroan,
Laporan Pengawasan serta memberikan pelunasan dan pembebasan tanggung jawab
Dewan Komisaris dan sepenuhnya (acquit et de charge) kepada anggota Direksi dan Dewan
Laporan Keuangan Komisaris Perseroan atas tindakan pengurusan dan pengawasan
tahun buku 2024, serta yang dilakukan, sepanjang tindakan-tindakan tersebut tercermin
pemberian pelunasan dan dalam Laporan Tahunan tersebut.
pembebasan tanggung Approved and ratified the Company’s Annual Report for the fiscal
jawab sepenuhnya (acquit year ended December 31, 2024, including the Company’s Activity
et de charge ) kepada Report, the Board of Commissioners' Supervisory Report, and the
Direksi dan Dewan Komisaris Company’s Financial Statements for the fiscal year ended December
1 Perseroan; 31, 2024, comprising the Balance Sheet and the Statement of Profit
Approval and ratification and Loss, and granted full release and discharge of responsibility
of the Company's Annual (acquit et de charge) to the members of the Board of Directors and
Report for the fiscal the Board of Commissioners of the Company for their management
year 2024, including the and supervisory actions, insofar as such actions were reflected in
Company's Activity Report, the said Annual Report.
the Board of Commissioners'
Supervisory Report, and
the Financial Statements
for the fiscal year 2024,
as well as the granting of
full discharge and release
of liability (acquit et de
charge) to the Company's
Board of Directors and
Board of Commissioners;
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 135
Page 136
Tata Kelola Perusahaan Positioned for
Good Corporate Governance Profitable Growth
Agenda dan Realisasi Keputusan RUPS Tahunan Tahun Buku 2024
Agenda and Implementation of the Annual GMS for the Fiscal Year 2024 Resolutions
Agenda Keputusan Keterangan
No
Agenda Resolutions Description
1. Menyetujui penggunaan laba bersih Perseroan tahun buku yang berakhir
pada tanggal 31 Desember 2024, sebagai berikut :
a. sebesar Rp2.548.000.000,00 (dua miliar lima ratus empat puluh
delapan juta rupiah) atau sebesar 15% (lima belas persen) dari
laba bersih Perseroan tahun buku yang berakhir pada tanggal
31 Desember 2024, dibagikan sebagai dividen tunai kepada
para pemegang saham Perseroan sehingga setiap saham
akan memperoleh dividen tunai sebesar Rp 2,00 (dua rupiah)
dengan memperhatikan peraturan perpajakan yang berlaku;
b. sebesar Rp 2.548.000.000,00 (dua miliar lima ratus empat puluh
delapan juta rupiah) dialokasikan dan dibukukan sebagai
dana cadangan;
c. sisanya dibukukan sebagai laba ditahan, untuk menambah
modal kerja Perseroan;
Penetapan penggunaan
2. Memberikan kuasa dan wewenang kepada Direksi Perseroan untuk
laba bersih Perseroan tahun Telah direalisasikan
melakukan setiap dan semua tindakan yang diperlukan sehubungan
buku 2024; pada tahun buku
dengan keputusan tersebut di atas, sesuai dengan peraturan perundang-
2 Determination of the use of Implemented in the
undangan yang berlaku.
the Company's net profit for fiscal year
1. Approved the appropriation of the Company’s net profit for the fiscal
the fiscal year 2024;
year ended December 31, 2024, as follows:
a. an amount of Rp2,548,000,000.00 (two billion five hundred forty-
eight million rupiah), or 15% (fifteen percent) of the Company’s net
profit for the fiscal year ended December 31, 2024, was distributed
as cash dividends to the Company’s shareholders, so that each
share received a cash dividend of Rp2.00 (two rupiah), subject to
the applicable tax regulations;
b. an amount of Rp2,548,000,000.00 (two billion five hundred forty-
eight million rupiah) was allocated and recorded as a statutory
reserve;
c. the remaining balance was recorded as retained earnings to
strengthen the Company’s working capital.
2. b. Granted power and authority to the Company’s Board of Directors to
carry out any and all actions necessary in connection with the above
resolutions, in accordance with the prevailing laws and regulations.
Memberikan wewenang dan kuasa kepada Dewan Komisaris
Perseroan untuk menunjuk Akuntan Publik dan/atau Kantor Akuntan
Publik, dengan kriteria Independen dan terdaftar di Otoritas Jasa
Penunjukan Akuntan Keuangan, yang akan mengaudit laporan keuangan Perseroan untuk
Publik dan/atau Kantor tahun buku yang berakhir pada tanggal 31 Desember 2025, serta
Akuntan Publik yang menetapkan honorarium Akuntan Publik dan/atau Kantor Akuntan
akan mengaudit laporan Publik tersebut berikut syarat-syarat penunjukannya termasuk
keuangan Perseroan untuk pemberhentiannya, dan untuk menunjuk Akuntan Publik dan/atau
tahun buku 2026, dan Kantor Akuntan Publik pengganti maupun memberhentikan Akuntan
pemberian wewenang Publik dan/atau Kantor Akuntan Publik yang telah ditunjuk, bilamana
untuk menetapkan karena sebab apa pun juga berdasarkan ketentuan Pasar Modal di
Telah direalisasikan
honorarium Akuntan Publik Indonesia, Akuntan Publik dan/atau Kantor Akuntan Publik yang telah
pada tahun buku
serta persyaratan lainnya. ditunjuk tersebut tidak dapat melakukan/menyelesaikan tugasnya.
3 Implemented in the
Appointment of a Public Granted authority and power to the Company’s Board of
fiscal year
Accountant and/or Public Commissioners to appoint an independent Public Accountant and/or
Accounting Firm to audit Public Accounting Firm registered with the Financial Services Authority
the Company's financial to audit the Company’s financial statements for the fiscal year
statements for the fiscal ended December 31, 2025, and to determine the fees of such Public
year 2026, and granting Accountant and/or Public Accounting Firm, including the terms and
of authority to determine conditions of their appointment and dismissal, as well as to appoint
the Public Accountant's a replacement Public Accountant and/or Public Accounting Firm or
remuneration and other dismiss the appointed Public Accountant and/or Public Accounting
requirements. Firm, should, for any reason and in accordance with the provisions
of the Indonesian capital market regulations, the appointed Public
Accountant and/or Public Accounting Firm be unable to perform
and/or complete its duties.
136 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 137
Positioned for
Profitable Growth
Agenda dan Realisasi Keputusan RUPS Tahunan Tahun Buku 2024
Agenda and Implementation of the Annual GMS for the Fiscal Year 2024 Resolutions
Agenda Keputusan Keterangan
No
Agenda Resolutions Description
1. Memberikan wewenang dan kuasa kepada PHARMANIAGA INTERNATIONAL
SDN.BHD., selaku pemegang saham mayoritas Perseroan untuk
menetapkan gaji dan/atau tunjangan lainnya bagi anggota Dewan
Komisaris Perseroan, dengan memperhatikan rekomendasi dari Komite
Nominasi dan Remunerasi.
Penentuan gaji, honorarium
2. Memberikan wewenang kepada Dewan Komisaris Perseroan untuk
dan tunjangan lainnya bagi
menetapkan gaji dan/atau tunjangan lainnya bagi anggota Direksi
anggota Dewan Komisaris Telah direalisasikan
Perseroan, dengan memperhatikan rekomendasi dari Komite Nominasi
dan Direksi. pada tahun buku
dan Remunerasi.
4 Determination of salaries, Implemented in the
1. Granted authority and power to PHARMANIAGA INTERNATIONAL SDN.
honorariums and other fiscal year
BHD., as the Company’s majority shareholder, to determine the salaries
allowances for members of
and/or other benefits of the members of the Company’s Board of
the Board of Commissioners
Commissioners, taking into account the recommendations of the
and Directors.
Nomination and Remuneration Committee.
2. Granted authority to the Company’s Board of Commissioners
to determine the salaries and/or other benefits of the members
of the Company’s Board of Directors, taking into account the
recommendations of the Nomination and Remuneration Committee.
PELAKSANAAN RUPS TAHUN 2024 IMPLEMENTATION OF GMS IN 2024
Pada tahun 2024, Perseroan melakukan satu kali RUPS, In 2024, the Company held one GMS, namely:
yaitu:
RUPS Hari/Tanggal Tempat Jumlah Keputusan Realisasi
GMS Day/Date Venue Number of Resolutions Implementation
Seluruh keputusan yang diambil telah
4 (empat) mata agenda dengan
direalisasikan pada tahun 2024.
Tahunan 31 Mei 2024 6 (enam) keputusan
Veranda Hotel All resolutions were implemented in
Annual May 31, 2024 4 (Four) agenda items with 6
2024.
(six) resolutions
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 137
Page 138
Tata Kelola Perusahaan Positioned for
Good Corporate Governance Profitable Growth
Dewan Komisaris
Board of Commissioners
Berdasarkan Undang-Undang No. 40 tahun 2007, Pursuant to Law No. 40 of 2007, the Board of
Dewan Komisaris merupakan organ utama tata kelola Commissioners is a principal organ of the Company’s
Perusahaan yang bertugas melakukan pengawasan corporate governance structure, tasked with supervising
atas kebijakan pengurusan, jalannya pengurusan pada management policies and the overall conduct of
umumnya, baik mengenai Perseroan maupun usaha management, both in relation to the Company and its
Perseroan, dan memberi nasihat kepada Anggota Direksi. business activities, as well as providing advice to the
Kemudian, berdasarkan POJK No. 33/POJK.04/2014 tentang members of the Board of Directors. Furthermore, pursuant
Direksi dan Dewan Komisaris Emiten atau Perusahaan to POJK No. 33/POJK.04/2014 concerning the Board of
Publik, Dewan Komisaris melakukan pengawasan secara Directors and Board of Commissioners of Issuers or
umum atau khusus sesuai dengan Anggaran Dasar Public Companies, the Board of Commissioners conducts
Perseroan dan bertanggung jawab untuk mengawasi general and/or specific supervision in accordance with
setiap tindakan Direksi. the Company’s Articles of Association and is responsible
for overseeing all actions of the Board of Directors.
PIAGAM DEWAN KOMISARIS BOARD OF COMMISSIONERS CHARTER
Dewan Komisaris telah memiliki Piagam Dewan Komisaris The Board of Commissioners has established a Board of
sebagai acuan dalam menjalankan tugas dan fungsinya Commissioners Charter as a reference in carrying out
yang disusun berdasarkan Anggaran Dasar Perseroan its duties and functions, which was formulated based
serta POJK No. 33/POJK.04/2014 tentang Direksi dan Dewan on the Company’s Articles of Association and POJK No.
Komisaris Emiten atau Perusahaan Publik. Piagam Dewan 33/POJK.04/2014 concerning the Board of Directors and
Komisaris juga dapat diakses oleh masyarakat dan Board of Commissioners of Issuers or Public Companies.
para pemangku kepentingan lainnya melalui Website The Board of Commissioners Charter is also accessible to
Perseroan. the public and other stakeholders through the Company’s
website.
KRITERIA ANGGOTA DEWAN KOMISARIS CRITERIA FOR MEMBERS OF THE
BOARD OF COMMISSIONERS
Kriteria Dewan Komisaris Perseroan di antaranya meliputi The criteria for the Company’s Board of Commissioners
hal-hal sebagai berikut: include, among others, the following:
1. Cakap melakukan perbuatan hukum; 1. Capable of performing legal acts;
2. Dalam jangka waktu 5 (lima) tahun sebelum 2. Within a period of 5 (five) years prior to the appointment,
pengangkatannya tidak pernah: has never:
a. Dinyatakan pailit; a. Been declared bankrupt;
b. Menjadi anggota Direksi atau anggota Dewan b. Served as a member of the Board of Directors or
Komisaris yang dinyatakan bersalah menyebabkan the Board of Commissioners who was found guilty
suatu Perseroan dinyatakan pailit; of causing a company to be declared bankrupt;
c. Dihukum karena melakukan tindak pidana yang c. Been convicted of a criminal offense that caused
merugikan keuangan negara dan/atau berkaitan losses to state finances and/or related to the
dengan sektor keuangan. financial sector.
3. Mempunyai akhlak, moral, dan integritas yang baik; 3. Possessing good character, morals, and integrity;
4. Memiliki komitmen untuk mematuhi perundang- 4. Having a commitment to comply with prevailing laws
undangan; and regulations;
5. Memiliki pengetahuan dan/atau keahlian di bidang 5. Possessing knowledge and/or expertise in fields
yang dibutuhkan oleh Perseroan terbuka yang required by the public company appointing him/her;
mengangkatnya; dan and
6. Dalam jangka waktu 5 (lima) tahun sebelum 6. Within a period of 5 (five) years prior to the appointment,
pengangkatannya tidak pernah menjadi anggota has never served as a member of the Board of Directors
Direksi dan/atau Dewan Komisaris yang selama and/or the Board of Commissioners who, during his/
menjabat: her term of office:
138 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 139
Positioned for
Profitable Growth
a. Pernah tidak menyelenggarakan RUPS Tahunan; a. Failed to convene an Annual GMS;
b. Pertanggungjawabannya sebagai anggota Direksi b. Had his/her accountability as a member of
dan/atau anggota Dewan Komisaris pernah tidak the Board of Directors and/or the Board of
diterima oleh RUPS atau pernah tidak memberikan Commissioners not accepted by the GMS, or failed
pertanggungjawaban sebagai anggota Direksi to submit accountability as a member of the Board
dan/atau anggota Dewan Komisaris kepada RUPS; of Directors and/or the Board of Commissioners
to the GMS;
c. Pernah menyebabkan Perseroan yang memperoleh c. Caused a company that obtained a license,
izin, persetujuan, atau pendaftaran dari OJK tidak approval, or registration from the Financial Services
memenuhi kewajiban menyampaikan laporan Authority (OJK) to fail to fulfill its obligation to submit
tahunan dan/atau laporan keuangan kepada OJK; annual reports and/or financial statements to the
d. Dihukum karena melakukan tindak pidana yang OJK;
merugikan keuangan negara dan/atau berkaitan d. Been convicted of a criminal offense that caused
dengan sektor keuangan. losses to state finances and/or related to the
financial sector.
MASA JABATAN DEWAN KOMISARIS TERM OF OFFICE OF THE BOARD
OF COMMISSIONERS
1. Masa Jabatan Dewan Komisaris adalah 5 (lima) tahun 1. The term of office of the Board of Commissioners is
tahun dengan tidak mengurangi hak Rapat Umum 5 (five) years, without prejudice to the right of the
Pemegang Saham untuk memberhentikan para General Meeting of Shareholders to dismiss members
anggota Dewan Komisaris sewaktu-waktu. Setelah of the Board of Commissioners at any time. Upon the
masa jabatan berakhir, anggota Dewan Komisaris expiration of their term of office, members of the Board
dapat diangkat kembali oleh Rapat Umum Pemegang of Commissioners may be reappointed by the General
Saham; Meeting of Shareholders.
2. Masa jabatan anggota Dewan Komisaris berakhir 2. The term of office of a member of the Board of
apabila: Commissioners shall end if he/she:
a. Meninggal Dunia; a. Passes away;
b. Masa jabatannya berakhir; b. Reaches the end of his/her term of office;
c. Diberhentikan berdasarkan Rapat Umum c. Is dismissed pursuant to a resolution of the General
Pemegang Saham; Meeting of Shareholders;
d. Mengundurkan diri; d. Resigns;
e. Dinyatakan pailit atau ditaruh di bawah e. Is declared bankrupt or placed under guardianship
pengampuan berdasarkan suatu keputusan based on a court decision;
Pengadilan; f. No longer meets the requirements to serve as
f. Tidak lagi memenuhi persyaratan sebagai anggota a member of the Board of Commissioners in
Dewan Komisaris berdasarkan Anggaran Dasar accordance with the Company’s Articles of
Perseroan dan peraturan Perundang-undangan Association and prevailing laws and regulations.
lainnya.
SUSUNAN DAN KOMPOSISI COMPOSITION OF THE BOARD
DEWAN KOMISARIS OF COMMISSIONERS
Hingga berakhirnya tahun 2025, jumlah dan komposisi As of the end of 2025, the Company’s Board of
Dewan Komisaris Perseroan sebanyak 5 (lima) orang, yang Commissioners consisted of 5 (five) members, comprising
terdiri dari 1 (satu) orang Komisaris Utama merangkap 1 (one) President Commissioner who also serves as an
Komisaris Independen, dengan 3 (tiga) orang Komisaris Independent Commissioner, 3 (three) Independent
Independen, dan 1 (satu) orang Komisaris. Komposisi Commissioners, and 1 (one) Commissioner. The
Dewan Komisaris juga memperhatikan keberagaman, composition of the Board of Commissioners also takes
keahlian, pengetahuan dan pengalaman yang sesuai into account diversity, as well as expertise, knowledge, and
dengan kebutuhan Perseroan. Berikut susunan dan experience in line with the Company’s needs. The following
komposisi keanggotaan Dewan Komisaris Perseroan: is the structure and composition of the Company’s Board
of Commissioners:
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 139
Page 140
Tata Kelola Perusahaan Positioned for
Good Corporate Governance Profitable Growth
Nama Jabatan Dasar Hukum Pengangkatan Masa Jabatan
Name Position Legal Basis of Appointment Term of Office
Akta Pernyataan Keputusan Rapat No. 30
tanggal 29 April 2021
Deed of Statement of Meeting Resolutions No.
Komisaris Utama merangkap 30 dated April 29, 2021 Ditutupnya RUPST
Joefly Joesoef Komisaris Independen Perseroan tahun 2027
Bahroeny President Commissioner and Diangkat kembali, sesuai Akta Pernyataan Closing of the Company's
Independent Commissioner Keputusan Rapat No. 71 tanggal 28 April 2022. 2027 AGMS
Reappointed, in accordance with the Deed of
Statement of Meeting Resolution No. 71 dated
April 28, 2022.
Akta Pernyataan Keputusan Rapat No. 2 tanggal
1 November 2021
Deed of Statement of Meeting Resolutions No. 2
dated November 1, 2021 Ditutupnya RUPST
Sarah Azreen binti Komisaris Independen Perseroan tahun 2027
Abdul Samat Independent Commissioner Diangkat kembali, sesuai Akta Pernyataan Closing of the Company's
Keputusan Rapat No. 71 tanggal 28 April 2022. 2027 AGMS
Reappointed, in accordance with the Deed of
Statement of Meeting Resolution No. 71 dated
April 28, 2022.
Prof. Aman Bhakti Akta Pernyataan Keputusan Rapat No. 26 Ditutupnya RUPST
Pulungan, MD, Paed Komisaris Independen tanggal 21 November 2022. Perseroan tahun 2027
Consultant, PhD, FAAP, Independent Commissioner Deed of Statement of Meeting Resolutions No. Closing of the Company's
FRCPI (Hon.) 26 dated November 21, 2022. 2027 AGMS
Akta Pernyataan Keputusan Rapat No. 26 Ditutupnya RUPST
Dr. Imam Komisaris Independen tanggal 21 November 2022. Perseroan tahun 2027
Fathorrahman, M.M Independent Commissioner Deed of Statement of Meeting Resolutions No. Closing of the Company's
26 dated November 21, 2022. 2027 AGMS
Akta Pernyataan Keputusan Rapat No. 49 Ditutupnya RUPST
Komisaris tanggal 25 Mei 2023 Perseroan tahun 2027
Dato’ Zulkifli Bin Jafar
Commissioner Deed of Statement of Meeting Resolutions No. Closing of the Company's
49 dated May 25, 2023 2027 AGMS
Profil Dewan Komisaris Perseroan disampaikan terperinci The profiles of the Company’s Board of Commissioners
pada Bab Profil Perusahaan, Laporan Tahunan ini. are presented in detail in the Company Profile Chapter
of this Annual Report.
TUGAS DAN TANGGUNG JAWAB DUTIES AND RESPONSIBILITIES OF
DEWAN KOMISARIS THE BOARD OF COMMISSIONERS
Dewan Komisaris Perseroan bertanggung jawab untuk: The Company’s Board of Commissioners is responsible
1. Dewan Komisaris bertugas melakukan pengawasan for the following:
dan bertanggung jawab atas pengawasan terhadap 1. The Board of Commissioners is tasked with supervising
kebijakan pengurusan, jalannya pengurusan pada and is responsible for oversight of management
umumnya, baik mengenai Emiten atau Perusahaan policies and the overall conduct of management,
Publik maupun usaha Emiten atau Perusahaan Publik, both in relation to the Issuer or Public Company and
dan memberi nasihat kepada Direksi. its business activities, and for providing advice to the
2. Dalam kondisi tertentu, Dewan Komisaris wajib Board of Directors.
menyelenggarakan RUPS tahunan dan RUPS lainnya 2. Under certain conditions, the Board of Commissioners
sesuai dengan kewenangannya sebagaimana is required to convene the Annual GMS and other GMS
diatur dalam peraturan perundang-undangan dan within its authority, as stipulated in the prevailing laws
anggaran dasar. and regulations and the Articles of Association.
3. Anggota Dewan Komisaris wajib melaksanakan tugas 3. Members of the Board of Commissioners are required
dan tanggung jawab sebagaimana dimaksud pada to perform their duties and responsibilities as referred
ayat (1) dengan itikad baik, penuh tanggung jawab, to in point (1) in good faith, with full responsibility, and
dan kehati-hatian. with due care.
4. Dalam rangka mendukung efektivitas pelaksanaan 4. In order to support the effective performance of its
tugas dan tanggung jawabnya sebagaimana duties and responsibilities as referred to in point (1),
dimaksud pada ayat (1) Dewan Komisaris wajib the Board of Commissioners is required to establish an
membentuk Komite Audit dan dapat membentuk Audit Committee and may establish other committees.
komite lainnya.
140 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 141
Positioned for
Profitable Growth
5. Dewan Komisaris wajib melakukan evaluasi terhadap 5. The Board of Commissioners is required to conduct
kinerja komite yang membantu pelaksanaan tugas an evaluation of the performance of the committees
dan tanggung jawabnya sebagaimana dimaksud assisting in the performance of its duties and
pada ayat (4) setiap akhir tahun buku. responsibilities as referred to in point (4) at the end
of each fiscal year.
RAPAT DEWAN KOMISARIS BOARD OF COMMISSIONERS
DAN RAPAT GABUNGAN MEETINGS AND JOINT MEETINGS
Dewan Komisaris memiliki kewajiban untuk mengadakan The Board of Commissioners is required to hold internal
Rapat internal minimal 3 (tiga) bulan sekali demikian juga meetings at least once every 3 (three) months, and joint
rapat gabungan dengan Direksi yang wajib diadakan meetings with the Board of Directors are also required to
minimal setiap 3 (tiga) bulan sekali. be held at least once every 3 (three) months.
Sepanjang tahun 2025, Dewan Komisaris telah Throughout 2025, the Board of Commissioners held 7
mengadakan Rapat sebanyak 7 (tujuh) kali dan Rapat (seven) meetings, and 8 (eight) joint meetings of the
Gabungan Dewan Komisaris dan Direksi sebanyak 8 Board of Commissioners and the Board of Directors, with
(delapan) kali dengan tingkat kehadiran Dewan Komisaris the attendance level of the Board of Commissioners as
sebagai berikut: follows:
Rapat Dewan Komisaris Rapat Gabungan termasuk RUPS
Board of Commissioners Meeting Joint Meetings including GMS
Nama Jabatan Jumlah Jumlah
Name Position Rapat Kehadiran Rapat Kehadiran
% %
Number of Attendance Number of Attendance
Meetings Meetings
Komisaris
Joefly Joesoef Utama
7 7 100 % 8 8 100%
Bahroeny President
Commissioner
Komisaris
Sarah Azreen binti Abdul Independen
7 7 100 % 8 8 100%
Samat Independent
Commissioner
Prof. Aman Bhakti Komisaris
Pulungan, MD, Paed Independen
7 7 100 % 8 8 100%
Consultant, PhD, FAAP, Independent
FRCPI (Hon.) Commissioner
Komisaris
Dr. Imam Fathorrahman, Independen
7 7 100 % 8 8 100%
M.M Independent
Commissioner
Komisaris
Dato’ Zulkifli bin Jafar 7 7 100 % 8 8 100%
Commissioner
PELAKSANAAN TUGAS DAN TANGGUNG IMPLEMENTATION OF THE DUTIES
JAWAB DEWAN KOMISARIS TAHUN 2025 AND RESPONSIBILITIES OF THE BOARD
OF COMMISSIONERS IN 2025
Selama 2025, Dewan Komisaris Perseroan telah melakukan Throughout 2025, the Company’s Board of Commissioners
tugas sebagai berikut: carried out the following duties:
1. Mengawasi dan bertanggung jawab terhadap 1. Supervising and being responsible for the Company’s
kebijakan serta pelaksanaan pengelolaan perusahaan, management policies and their implementation, both
baik yang berkaitan dengan Perseroan maupun in relation to the Company and its business activities,
kegiatan usaha Perseroan, serta memberikan saran and providing advice to the Board of Directors,
kepada Direksi. Juga memberikan persetujuan including granting approval of the Company’s annual
terhadap rencana kerja tahunan dan jangka panjang and long-term work plans prior to the commencement
perusahaan sebelum dimulainya tahun buku yang of the new fiscal year;
baru;
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 141
Page 142
Tata Kelola Perusahaan Positioned for
Good Corporate Governance Profitable Growth
2. Melakukan tugas yang secara khusus diberikan 2. Performing duties specifically assigned to it in
kepadanya menurut Anggaran Dasar, peraturan accordance with the Company’s Articles of Association,
perundang-undangan yang berlaku, dan/atau prevailing laws and regulations, and/or resolutions of
berdasarkan keputusan Rapat Umum Pemegang the General Meeting of Shareholders;
Saham;
3. Melakukan tugas, wewenang, dan tanggung jawab 3. Exercising its duties, authorities, and responsibilities
sesuai dengan ketentuan Anggaran Dasar Perseroan in accordance with the provisions of the Company’s
dan keputusan Rapat Umum Pemegang Saham; Articles of Association and resolutions of the General
Meeting of Shareholders;
4. Menganalisis dan memeriksa laporan tahunan yang 4. Analyzing and reviewing the annual report prepared
disusun oleh Direksi serta menandatangani laporan by the Board of Directors and signing such report.
tersebut. Selanjutnya, mematuhi Anggaran Dasar dan Furthermore, complying with the Articles of Association
peraturan yang berlaku serta menerapkan prinsip and applicable regulations and applying the
profesionalisme, efisiensi, transparansi, kemandirian, principles of professionalism, efficiency, transparency,
akuntabilitas, tanggung jawab, dan kewajaran; independence, accountability, responsibility, and
fairness;
5. Menentukan kebijakan dan kriteria terkait proses 5. Determining policies and criteria related to the
nominasi, remunerasi, evaluasi kinerja, penilaian diri nomination process, remuneration, performance
(self-assessment) bagi anggota Direksi dan/atau evaluation, self-assessment of members of the Board
Dewan Komisaris, serta kebijakan dan kriteria suksesi of Directors and/or the Board of Commissioners, as well
atau regenerasi dalam pemilihan calon anggota as succession or regeneration policies and criteria in
Direksi dan/atau Dewan Komisaris; the selection of candidates for members of the Board
of Directors and/or the Board of Commissioners;
6. Menetapkan kebijakan serta kriteria untuk evaluasi 6. Establishing policies and criteria for the evaluation and
dan penilaian terhadap aspek keuangan yang sehat, assessment of sound, stable, growing, and sustainable
stabil, berkembang, dan berkelanjutan; financial conditions;
7. Menetapkan kriteria pemantauan penerapan prinsip 7. Establishing criteria for monitoring the implementation
tata kelola perusahaan yang baik. of good corporate governance principles.
PROGRAM ORIENTASI DEWAN KOMISARIS ORIENTATION PROGRAM FOR THE
BOARD OF COMMISSIONERS
Perseroan menyelenggarakan program orientasi bagi The Company organizes an orientation program for newly
anggota Dewan Komisaris yang baru untuk memastikan appointed members of the Board of Commissioners to
yang bersangkutan memperoleh pemahaman yang ensure that they obtain a comprehensive understanding
komprehensif baik tentang bisnis, profil risiko, serta of the Company’s business, risk profile, and strategic
isu strategis Perseroan, sehingga diharapkan Dewan issues. This program is intended to enable the Board
Komisaris dapat menjalankan fungsi pengawasan dan of Commissioners to effectively perform its supervisory
pemberian nasihat secara efektif dan berkontribusi and advisory functions and to contribute optimally to the
terhadap pertumbuhan Perseroan secara optimal. Company’s growth.
Sekretaris Perusahaan dan/atau Sekretaris Dewan The Corporate Secretary and/or the Board of
Komisaris bertanggung jawab untuk mengembangkan Commissioners Secretary is responsible for developing
dan mengoordinasikan program orientasi ini. Pada tahun and coordinating this orientation program. In 2025, the
2025, Perseroan tidak melaksanakan program orientasi Company did not conduct an orientation program,
karena tidak mengangkat Komisaris baru. as there were no new appointments to the Board of
Commissioners.
PELATIHAN DAN/ATAU TRAINING AND/OR COMPETENCY
PENGEMBANGAN KOMPETENSI DEVELOPMENT OF MEMBERS OF THE
ANGGOTA DEWAN KOMISARIS BOARD OF COMMISSIONERS
Perseroan memberikan kesempatan kepada Dewan The Company provides opportunities for members of the
Komisaris untuk meningkatkan kompetensi diri. Pendidikan Board of Commissioners to enhance their competencies.
dan pelatihan Dewan Komisaris sepanjang tahun 2025 The education and training undertaken by the Board of
sebagai berikut: Commissioners throughout 2025 were as follows:
142 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 143
Positioned for
Profitable Growth
Nama Pelatihan/
Workshop/
Lembaga Waktu dan
Nama/Jabatan Konferensi/Seminar
Penyelenggara Tempat
Name/Position Name of Training/
Organizer Time and Venue
Workshop/
Conference/Seminar
ICOPE 2025
Conference Programme 12-14 Februari 2025.
Oil Palm Agro-ecological February 12-14, 2025.
ICOPE
transformation: Towards Bali
Climate-and nature-positive
agriclture
Joefly Joesoef Bahroeny 13-14 November 2025.
IPOC 2025
(Komisaris Utama merangkap Komisaris November 13-14, 2025.
21th Indonesia Palm Oil
Independen) GAPKI Megapura Hall, BICC,
Conference and 2026 Price
(President Commissioner and Independent The Westin Resort Nusa
Outlook (IPOC 2025)
Commissioner) Dua, Bali.
KADIN Tahun 2025
30 November – 02
Rapat Pimpinan Nasional Kadin
Desember 2025.
Indonesia
KADIN November 30 -
National Leadership Meeting
December 2, 2025.
of the Indonesian Chamber of
Park Hyatt Jakarta.
Commerce
PENILAIAN KINERJA KOMITE PERFORMANCE ASSESSMENT OF
PENDUKUNG DEWAN KOMISARIS THE COMMITTEES SUPPORTING THE
BOARD OF COMMISSIONERS
Penilaian Dewan Komisaris terhadap kinerja kinerja Komite The Board of Commissioners conducts an annual
Audit serta Komite Nominasi dan Remunerasi dilakukan evaluation of the performance of the Audit Committee
setiap 1 (satu) tahun sekali berdasarkan realisasi dan and the Nomination and Remuneration Committee based
penyelesaian program kerja yang telah tersusun dalam on the realization and completion of work programs as
rencana kerja dan anggaran tahunan, kompetensi dan set out in the annual work plan and budget, as well as
tingkat kehadiran dalam rapat dari masing-masing the competencies and meeting attendance levels of
komite. Untuk tahun 2025, Dewan Komisaris menilai bahwa each committee. For 2025, the Board of Commissioners
kinerja Komite Audit, Komite Manajemen Risiko, dan Komite assessed that the performance of the Audit Committee,
Nominasi dan Remunerasi cukup baik dan sesuai dengan the Risk Management Committee, and the Nomination
program kerja yang telah direncanakan. and Remuneration Committee was satisfactory and in
line with the approved work programs.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 143
Page 144
Tata Kelola Perusahaan Positioned for
Good Corporate Governance Profitable Growth
Komisaris Independen
Independent Commissioner
Jumlah Komisaris Independen Perseroan telah memenuhi The number of Independent Commissioners of the
ketentuan POJK No. 33/POJK.04/2014, yaitu paling sedikit Company has complied with the provisions of POJK No.
30% dari total anggota Dewan Komisaris. Pada tahun 33/POJK.04/2014, which require at least 30% of the total
pelaporan, Perseroan memiliki 5 (lima) anggota Dewan members of the Board of Commissioners. In the reporting
Komisaris, terdiri dari 4 (empat) Komisaris Independen year, the Company had 5 (five) members of the Board
dan 1 (satu) Komisaris, sehingga proporsi Komisaris of Commissioners, consisting of 4 (four) Independent
Independen mencapai 80% dan melampaui ketentuan Commissioners and 1 (one) Commissioner; accordingly,
minimum tersebut. the proportion of Independent Commissioners reached
80%, exceeding the minimum requirement.
KRITERIA KOMISARIS INDEPENDEN CRITERIA FOR INDEPENDENT
COMMISSIONERS
Kriteria Komisaris Independen yang tercantum dalam The criteria for Independent Commissioners as stipulated
undang-undang tersebut adalah sebagai berikut: in the relevant law are as follows:
1. Bukan merupakan orang yang bekerja atau 1. Is not a person who has worked for or had the authority
mempunyai wewenang dan tanggung jawab untuk and responsibility to plan, lead, control, or supervise the
merencanakan, memimpin, mengendalikan, atau activities of the Issuer or Public Company within the last
mengawasi kegiatan emiten atau Perseroan Publik 6 (six) months, for the purpose of reappointment as
tersebut dalam waktu 6 (enam) bulan terakhir, untuk an Independent Commissioner of the Issuer or Public
pengangkatan kembali sebagai Komisaris Independen Company for the subsequent term;
Emiten atau Perseroan Publik pada periode berikutnya;
2. Tidak mempunyai saham baik langsung maupun tidak 2. Does not own shares, either directly or indirectly, in the
langsung pada Emiten atau Perseroan Publik tersebut; Issuer or Public Company;
3. Tidak mempunyai hubungan Afiliasi dengan emiten 3. Does not have any affiliation with the Issuer or Public
atau Perseroan Publik, anggota Dewan Komisaris, Company, members of the Board of Commissioners,
anggota Direksi, atau pemegang saham utama Emiten members of the Board of Directors, or the major
atau Perseroan Publik tersebut; dan shareholders of the Issuer or Public Company; and
4. Tidak mempunyai hubungan usaha baik langsung 4. Does not have any business relationship, either directly
maupun tidak langsung yang berkaitan dengan or indirectly, related to the business activities of the
kegiatan usaha Emiten atau Perseroan Publik tersebut. Issuer or Public Company.
PERNYATAAN INDEPENDENSI STATEMENT OF INDEPENDENCE OF
KOMISARIS INDEPENDEN INDEPENDENT COMMISSIONERS
Independensi Dewan Komisaris dibutuhkan dalam The independence of the Board of Commissioners is
menjalankan tugas pengawasan, melakukan penilaian essential in carrying out its supervisory duties, evaluating
terhadap kinerja Direksi, dan terutama dalam fungsi the performance of the Board of Directors, and, in particular,
pengambilan keputusan. Seorang Dewan Komisaris harus in the decision-making process. Members of the Board
terbebas dari benturan kepentingan dan latar belakang of Commissioners must be free from conflicts of interest
lainnya dalam melaksanakan fungsi tersebut. and other influences while performing these functions.
144 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 145
Positioned for
Profitable Growth
Tabel Pernyataan Independensi Komisaris Independen
Table of Independent Commissioners’ Independence Statements
Joefly Sarah Azreen Prof. Aman Dr. Imam
Pernyataan Independensi
Joesoef binti Abdul Bhakti Fathorrahman,
Independence Statements
Bahroeny Samat Pulungan M.M
Bukan merupakan orang yang bekerja atau
mempunyai wewenang dan tanggung
jawab untuk merencanakan, memimpin,
mengendalikan, atau mengawasi kegiatan
Emiten atau Perseroan Publik tersebut dalam
waktu 6 (enam) bulan terakhir, kecuali untuk
pengangkatan kembali sebagai Komisaris
Independen Perseroan pada periode
√ √ √ √
berikutnya.
Is not a person who has worked for or had
the authority and responsibility to plan, lead,
control, or supervise the activities of the Issuer or
Public Company within the last 6 (six) months,
except for the purpose of reappointment as an
Independent Commissioner of the Company
for the subsequent term.
Tidak mempunyai saham baik langsung
maupun tidak langsung pada Perseroan.
√ √ √ √
Does not own any shares, either directly or
indirectly, in the Company.
Tidak mempunyai hubungan afiliasi dengan
Perseroan, anggota Dewan Komisaris, anggota
Direksi, atau pemegang saham utama
Perseroan.
√ √ √ √
Does not have any affiliation with the Company,
members of the Board of Commissioners,
members of the Board of Directors, or the major
shareholders of the Company.
Tidak mempunyai hubungan usaha baik
langsung maupun tidak langsung yang
berkaitan dengan kegiatan usaha Perseroan.
√ √ √ √
Does not have any business relationship, either
directly or indirectly, related to the Company’s
business activities.
Memenuhi kriteria independensi sebagaimana
telah diatur dalam ketentuan yang berlaku.
√ √ √ √
Meets the independence criteria as stipulated
in the prevailing regulations.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 145
Page 146
Tata Kelola Perusahaan Positioned for
Good Corporate Governance Profitable Growth
Direksi
Board of Directors
Direksi merupakan organ perusahaan yang berwenang The Board of Directors is a corporate organ authorized
dan bertanggung jawab penuh atas pengurusan and fully responsible for managing the Company in
perusahaan untuk kepentingan perusahaan, sesuai the Company’s best interests, in accordance with the
dengan maksud dan tujuan perusahaan serta mewakili Company’s objectives, and represents the Company both
perusahaan, baik di dalam maupun di luar pengadilan in and out of court, in accordance with the provisions of
sesuai ketentuan anggaran Dasar perusahaan. the Company’s Articles of Association.
PIAGAM DIREKSI BOARD OF DIRECTORS CHARTER
Direksi melaksanakan tugas, wewenang, dan tanggung The Board of Directors carries out its duties, authorities,
jawabnya dengan mengacu pada Pedoman dan Tata and responsibilities by referring to the Board of Directors’
Kerja Direksi yang disusun berdasarkan Anggaran Dasar Guidelines and Work Procedures, which are compiled
Perseroan, Peraturan Otoritas Jasa Keuangan (POJK) No. based on the Company’s Articles of Association,
33/POJK.04/2014 tentang Direksi dan Dewan Komisaris Financial Services Authority Regulation (POJK) No. 33/
Emiten atau Perseroan Publik, serta ketentuan peraturan POJK.04/2014 concerning the Board of Directors and Board
perundang-undangan yang berlaku lainnya. Pedoman of Commissioners of Issuers or Public Companies, as well
dan Tata Kerja Direksi dapat diakses melalui website resmi as other applicable laws and regulations. The Board of
Perseroan. Directors’ Guidelines and Procedures can be accessed
through the Company’s official website.
KRITERIA ANGGOTA DIREKSI CRITERIA FOR MEMBERS OF THE BOARD
OF DIRECTORS
Sesuai dengan POJK No. 21/POJK.04/2015 tentang In accordance with POJK No. 21/POJK.04/2015 concerning
Penerapan Pedoman Tata Kelola Perseroan Terbuka, the Implementation of Good Corporate Governance
kriteria Anggota Direksi Perseroan, sebagai berikut: Guidelines for Public Companies, the criteria for members
of the Company’s Board of Directors are as follows:
1. Cakap melakukan perbuatan hukum; 1. Capable of performing legal acts;
2. Dalam jangka waktu 5 (lima) tahun sebelum 2. Within 5 (five) years prior to their appointment, have
pengangkatannya tidak pernah: never:
a. dinyatakan pailit; a. Been declared bankrupt;
b. menjadi anggota Direksi atau anggota Dewan b. Served as a member of the Board of Directors or
Komisaris yang dinyatakan bersalah menyebabkan the Board of Commissioners who was found guilty
suatu Perseroan dinyatakan pailit; of causing a company to be declared bankrupt;
c. dihukum karena melakukan tindak pidana yang c. Been convicted of a criminal offense causing losses
merugikan keuangan negara dan/atau berkaitan to state finances and/or related to the financial
dengan sektor keuangan; sector;
3. Mempunyai akhlak, moral, dan integritas yang baik; 3. Possessing good character, morals, and integrity;
4. Memiliki komitmen untuk mematuhi peraturan 4. Having a commitment to comply with prevailing laws
perundang-undangan; and regulations;
5. Memiliki pengetahuan dan/atau keahlian di bidang 5. Possessing knowledge and/or expertise in fields
yang dibutuhkan oleh Perseroan; dan required by the Company; and
6. Dalam jangka waktu 5 (lima) tahun sebelum 6. Within 5 (five) years prior to their appointment, have
pengangkatannya tidak pernah menjadi anggota never served as a member of the Board of Directors
Direksi dan/atau Dewan Komisaris yang selama and/or Board of Commissioners who, during their
menjabat: tenure:
a. pernah tidak menyelenggarakan RUPS tahunan; a. Failed to convene an Annual GMS;
b. pertanggungjawabannya sebagai anggota Direksi b. Had their accountability as a member of the Board of
dan/atau anggota Dewan Komisaris pernah tidak Directors and/or Board of Commissioners rejected
diterima oleh RUPS atau pernah tidak memberikan by the GMS, or failed to submit accountability to
pertanggungjawaban sebagai anggota Direksi the AGMS;
dan/atau anggota Dewan Komisaris kepada RUPS;
146 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 147
Positioned for
Profitable Growth
c. pernah menyebabkan Perseroan yang memperoleh c. Caused a company that obtained a license,
izin, persetujuan, atau pendaftaran dari OJK tidak approval, or registration from the Financial Services
memenuhi kewajiban menyampaikan laporan Authority (OJK) to fail to fulfill its obligation to submit
tahunan dan/atau laporan keuangan kepada OJK; annual reports and/or financial statements to the
d. menjadi anggota Direksi atau anggota Dewan OJK;
Komisaris yang dinyatakan bersalah menyebabkan d. Served as a member of the Board of Directors or
suatu Perseroan dinyatakan pailit; Board of Commissioners who was found guilty of
e. dihukum karena melakukan tindak pidana yang causing a company to be declared bankrupt;
merugikan keuangan negara dan/atau berkaitan e. Been convicted of a criminal offense causing losses
dengan sektor keuangan. to state finances and/or related to the financial
sector.
SUSUNAN DAN KOMPOSISI DIREKSI COMPOSITION OF THE
BOARD OF DIRECTORS
Jumlah dan komposisi Direksi Perseroan telah sesuai The number and composition of the Company’s Board of
dengan POJK No. 33/POJK.04/2014 tentang Direksi dan Directors comply with POJK No. 33/POJK.04/2014 concerning
Dewan Komisaris Emiten atau Perusahaan Publik, yaitu the Board of Directors and Board of Commissioners of
jumlah anggota Direksi paling sedikit 2 (dua) orang serta Issuers or Public Companies, which requires that the Board
kecukupan pengetahuan dan pengalaman pengelolaan of Directors consist of at least 2 (two) members and that
risiko yang relevan pada paling sedikit separuh anggota at least half of the members possess sufficient knowledge
Direksi. and experience in relevant risk management.
Susunan Direksi Perseroan per 31 Desember 2025 disajikan The composition of the Company’s Board of Directors as
pada tabel berikut: of December 31, 2025, is presented in the following table:
Tanggal
Dasar Akhir Masa
Pengangkatan
Nama Jabatan Pengangkatan Jabatan
No. Kembali
Name Position Basis of End of Term of
Date of
Appointment Office
Reappointment
Akta Pernyataan
Keputusan Rapat Ditutupnya RUPST
No. 161 tanggal 16 Perseroan tahun
Direktur Utama Juli 2020 28 April 2022 2027
1 Ahmad bin Abu Bakar
President Director Deed of Statement of April 28, 2022 Closing of the
Meeting Resolutions Company's 2027
No. 161 dated July 16, AGMS
2020
Akta Pernyataan
Keputusan Rapat Ditutupnya RUPST
No. 161 tanggal 16 Perseroan tahun
Direktur Juli 2020 28 April 2022 2027
2 Mohamad Fazly bin Hassan
Director Deed of Statement of April 28, 2022 Closing of the
Meeting Resolutions Company's 2027
No. 161 dated July 16, AGMS
2020
Profil Direksi Perseroan disampaikan terperinci pada Bab The profiles of the Company’s Board of Directors are
Profil Perusahaan, Laporan Tahunan ini. presented in detail in the Company Profile Chapter of
this Annual Report.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 147
Page 148
Tata Kelola Perusahaan Positioned for
Good Corporate Governance Profitable Growth
RUANG LINGKUP TUGAS, TANGGUNG SCOPE OF DUTIES, RESPONSIBILITIES,
JAWAB, DAN WEWENANG DIREKSI AND AUTHORITIES OF THE
BOARD OF DIRECTORS
Ruang lingkup tugas, tanggung jawab, dan Wewenang The scope of duties, responsibilities, and authorities of the
Direksi, sebagai berikut: Board of Directors is as follows:
1. Direksi bertugas menjalankan dan bertanggung jawab 1. The Board of Directors is tasked with managing and
atas pengurusan Emiten atau Perusahaan Publik untuk is responsible for the management of the Issuer or
kepentingan Emiten atau Perusahaan Publik sesuai Public Company in the best interests of the Issuer or
dengan maksud dan tujuan Emiten atau Perusahaan Public Company, in accordance with the objectives
Publik yang ditetapkan dalam anggaran dasar. and purposes of the Issuer or Public Company as set
forth in the Articles of Association.
2. Dalam menjalankan tugas dan tanggung jawab atas 2. In carrying out the management duties and
pengurusan sebagaimana dimaksud pada ayat (1), responsibilities as referred to in point (1), the Board of
Direksi wajib menyelenggarakan RUPS tahunan dan Directors is required to convene the Annual GMs and
RUPS lainnya sebagaimana diatur dalam peraturan other GMS as stipulated in the prevailing laws and
perundang-undangan dan anggaran dasar. regulations and the Articles of Association.
3. Setiap anggota Direksi wajib melaksanakan tugas 3. Each member of the Board of Directors is required to
dan tanggung jawab sebagaimana dimaksud pada perform the duties and responsibilities referred to in
ayat (1) dengan itikad baik, penuh tanggung jawab, point (1) in good faith, with full responsibility, and with
dan kehati-hatian. due care.
4. Dalam rangka mendukung efektivitas pelaksanaan 4. To support the effective performance of the duties
tugas dan tanggung jawab sebagaimana dimaksud and responsibilities referred to in point (1), the Board
pada ayat (1), Direksi dapat membentuk komite. of Directors may establish committees.
5. Dalam hal dibentuk komite sebagaimana dimaksud 5. In the event that committees are established as
pada ayat (4), Direksi wajib melakukan evaluasi referred to in point (4), the Board of Directors is required
terhadap kinerja komite setiap akhir tahun buku. to evaluate the performance of such committees at
the end of each fiscal year.
Pembagian Tugas Masing-masing Direksi
Division of Duties Among Members of the Board of Directors
Nama/Jabatan Tugas dan Tanggung Jawab
Name/Position Duties and responsibilities
1. Mengarahkan perumusan penetapan kebijakan Perseroan berikut kewajiban lainnya sesuai dengan
kebijakan dalam pencapaian sasaran Perseroan;
2. Mengarahkan penetapan visi, misi, dan tata nilai Perseroan;
3. Penetapan RJPP, RKAP, Laporan Manajemen Perseroan, Laporan Tahunan Perseroan dan Laporan Keuangan
Konsolidasian;
4. Menetapkan kebijakan strategis bidang manajemen risiko dan memimpin pengendalian Risiko Perseroan;
5. Mengarahkan pengusahaan serta pengembangan bisnis distribusi dan usaha lain;
6. Mengarahkan penyiapan rencana dan anggaran serta penyampaian laporan pertanggungjawaban
dan perhitungan hasil usaha Perusahaan menurut cara dan waktu yang telah ditetapkan oleh Rapat
Umum Pemegang Saham;
7. Mengarahkan penyelenggaraan aktivitas Perseroan sesuai dengan peraturan perundangan dan Peraturan
Perusahaan yang berlaku (zero non-compliance);
Ahmad bin Abu Bakar
8. Mengarahkan pelaksanaan kegiatan audit internal dan audit eksternal serta audit khusus Perseroan;
Direktur Utama
9. Mengendalikan tugas pengawasan intern dan para kepala unit pelaksana lainnya;
President Director
10. Mengkoordinasikan tugas-tugas lain atas nama Direksi yang telah ditetapkan dalam Anggaran Dasar
Perseroan.
1. Directing the formulation and determination of the Company’s policies, including other obligations in
line with the Company’s target achievement;
2. Directing the establishment of the Company’s vision, mission, and core values;
3. Approving the Long-Term Corporate Plan (RJPP), Annual Work Plan and Budget (RKAP), the Company’s
Management Report, Annual Report, and Consolidated Financial Statements;
4. Establishing strategic policies in the area of risk management and leading the Company’s risk control;
5. Directing the management and development of distribution and other business activities;
6. Directing the preparation of plans and budgets, as well as the submission of accountability reports
and the calculation of the Company’s operating results according to the methods and timeline set
by the General Meeting of Shareholders;
7. Directing the implementation of the Company’s activities in compliance with applicable laws, regulations,
and Company Rules (zero non-compliance);
8. Directing the conduct of internal audits, external audits, and special audits of the Company;
9. Controlling internal supervision tasks and the heads of other implementing units;
10. Coordinating other tasks on behalf of the Board of Directors as stipulated in the Company’s Articles
of Association.
148 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 149
Positioned for
Profitable Growth
Pembagian Tugas Masing-masing Direksi
Division of Duties Among Members of the Board of Directors
Nama/Jabatan Tugas dan Tanggung Jawab
Name/Position Duties and responsibilities
1. Memimpin dan memastikan penyusunan Rencana Jangka Panjang Perusahaan sesuai dengan rencana
strategis Perseroan;
2. Memimpin pemantauan dan evaluasi pelaksanaan program kerja Perseroan dan Anak Perusahaan
agar terintegrasi dan selaras dengan Rencana Strategis Perseroan;
3. Memimpin dan memastikan kegiatan penyusunan dan pengendalian portofolio investasi keuangan
Perseroan;
4. Memimpin kebijakan dan strategi pengelolaan keuangan serta pendanaan Perseroan dan optimalisasi
aset, investasi, kredit serta terkait pasar modal untuk mendukung pertumbuhan dan perkembangan
Perseroan;
5. Memimpin kebijakan dan strategi yang berkaitan dengan kewajiban perpajakan untuk memastikan
efisiensi dan efektivitas pemenuhan kewajiban perpajakan sesuai peraturan dan perundang-undangan
yang berlaku;
6. Memimpin kegiatan pengelolaan keuangan Perseroan terlaksana sesuai dengan standar yang berlaku;
Mohamad Fazly bin Hassan 7. Memastikan pengendalian keuangan dan kepatuhan Anak Perusahaan sesuai dengan ketentuan dan
Direktur mekanisme yang berlaku dalam pola hubungan Induk dan Anak Perusahaan.
Director 1. Leading and ensuring the preparation of the Company’s Long-Term Plan in accordance with the
Company’s strategic plan;
2. Leading the monitoring and evaluation of the implementation of the Company’s and Subsidiaries’
work programs to ensure integration and alignment with the Company’s Strategic Plan;
3. Leading and ensuring the preparation and control of the Company’s financial investment portfolio;
4. Leading policies and strategies related to the Company’s financial management and funding, as well
as the optimization of assets, investments, credit, and matters related to the capital market, to support
the Company’s growth and development;
5. Leading policies and strategies related to tax obligations to ensure efficiency and effectiveness in
fulfilling tax obligations in accordance with applicable laws and regulations;
6. Leading the Company’s financial management activities to ensure compliance with applicable
standards;
7. Ensuring financial control and compliance of the Subsidiaries in accordance with the provisions and
mechanisms applicable under the Parent-Subsidiary relationship framework.
RAPAT DIREKSI BOARD OF DIRECTORS MEETINGS
Berdasarkan POJK No. 33/POJK.04/2014 pasal 16, Direksi Pursuant to POJK No. 33/POJK.04/2014, Article 16, the Board
wajib menyelenggarakan rapat Direksi secara berkala of Directors is required to hold regular meetings at least
paling kurang 1 (satu) kali dalam setiap bulan serta once every month and to hold joint meetings with the
menyelenggarakan rapat Direksi bersama Dewan Board of Commissioners at least once every 3 (three)
Komisaris secara berkala paling kurang 1 (satu) kali dalam months. A Board of Directors meeting is valid and entitled
3 (tiga) bulan. Rapat Direksi sah dan berhak mengambil to make binding decisions based on consensus only if
keputusan berdasarkan musyawarah untuk mufakat attended by at least ½ (half) of the total members of the
yang bersifat mengikat hanya jika dihadiri sekurang- Board of Directors or their duly authorized representatives.
kurangnya ½ (setengah) dari jumlah anggota Direksi atau
yang mewakili secara sah dalam rapat tersebut.
Sepanjang tahun 2025, Direksi telah mengadakan Rapat Throughout 2025, the Board of Directors held 12 (twelve)
sebanyak 12 (dua belas) kali dan Rapat Gabungan dengan meetings, and 8 (eight) joint meetings with the Board
Dewan Komisaris sebanyak 8 (delapan) kali dengan of Commissioners, with the attendance of the Board of
tingkat kehadiran Direksi sebagai berikut: Directors as follows:
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 149
Page 150
Tata Kelola Perusahaan Positioned for
Good Corporate Governance Profitable Growth
Rapat Direksi Rapat Gabungan termasuk RUPS
Board of Directors Meeting Joint Meetings including GMS
Nama Jabatan Jumlah Jumlah
Name Position Rapat Kehadiran Rapat Kehadiran
% %
Number of Attendance Number of Attendance
Meetings Meetings
Direktur
Ahmad bin Utama
12 12 100% 8 8 100%
Abu Bakar President
Director
Mohamad
Direktur
Fazly bin 12 12 100% 8 7 84%
Director
Hassan
PROGRAM ORIENTASI DIREKSI ORIENTATION PROGRAM FOR
THE BOARD OF DIRECTORS
Program orientasi atau pengenalan perusahaan untuk The orientation program for newly appointed members
anggota Direksi baru bertujuan untuk membantu of the Board of Directors is designed to assist them in
Direksi dalam hal penerapan GCG, peningkatan kinerja, the implementation of Good Corporate Governance
pemahaman visi, misi, dan strategi usaha Perseroan. (GCG), performance improvement, and understanding
Tanggung jawab terhadap program pengenalan ini of the Company’s vision, mission, and business strategy.
berada pada Direktur Utama atau jika Direktur Utama Responsibility for this orientation program rests with the
berhalangan dapat dilakukan oleh anggota Direksi President Director, or in the event the President Director
lainnya. Implementasi program tersebut dilaksanakan is unavailable, it may be carried out by other members
melalui presentasi, pertemuan, dan kunjungan kerja ke of the Board of Directors. The program is implemented
fasilitas Perseroan. through presentations, meetings, and site visits to the
Company’s facilities.
Selain pemaparan atas Perseroan, dalam program In addition to an overview of the Company, the orientation
orientasi juga disampaikan dokumen-dokumen program provides supporting documents, including the
penunjang, antara lain Laporan Tahunan, Rencana Kerja Annual Report, Annual Work Plan and Budget (RKAP),
dan Anggaran Perseroan (RKAP), Rencana Jangka Panjang Long-Term Corporate Plan (RJPP), Articles of Association,
Perseroan (RJPP), Anggaran Dasar Perseroan, Kebijakan Corporate Governance Policies, Code of Conduct, Board
Tata Kelola Perseroan, Kode Etik, Program Kerja Direksi, of Directors Work Program, Board of Directors’ Work
Pedoman Kerja Direksi, serta peraturan-peraturan yang Guidelines, and regulations related to the execution of the
terkait dengan pelaksanaan tugas Direksi. Selain itu, guna Board of Directors’ duties. To gain a direct understanding
memahami secara langsung proses bisnis Perseroan, of the Company’s business processes, the program also
program orientasi juga meliputi kunjungan langsung ke includes on-site visits.
lapangan.
Pada tahun 2025, Perseroan tidak melakukan perubahan In 2025, the Company did not make any changes to the
susunan maupun komposisi keanggotaan Direksi, composition or membership of the Board of Directors;
sehingga program tersebut tidak dilaksanakan. therefore, the orientation program was not conducted.
LAPORAN PELAKSANAAN TUGAS REPORT ON THE IMPLEMENTATION OF THE
DIREKSI TAHUN 2025 BOARD OF DIRECTORS’ DUTIES IN 2025
Terkait pelaksanaan tugas di tahun 2025, Direksi In 2025, the Board of Directors carried out the following
melakukan kegiatan sebagai berikut: activities:
1. Talent Management. 1. Talent Management
2. Pembagian Tugas dan Kewenangan Direksi. 2. Division of Duties and Authorities of the Board of
Directors
3. Organisasi dan Uraian Jabatan. 3. Organization and Job Descriptions
4. Kelompok dan Stratifikasi Jabatan. 4. Job Grouping and Stratification
5. Tunjangan Hari Raya Keagamaan Tahun 2025. 5. Religious Holiday Allowances for 2025
6. Pakaian Dinas Karyawan. 6. Employee Uniforms
7. Talent Acquisition. 7. Talent Acquisition
150 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 151
Positioned for
Profitable Growth
8. Jaminan Pemeliharaan Kesehatan Karyawan dan 8. Employee and Family Health Maintenance Coverage
Keluarga Karyawan.
9. Penghargaan Pengabdian Karyawan dan 9. Employee Service Awards and Retirement Awards
Penghargaan Pensiunan.
10. Rekreasi Karyawan. 10. Employee Recreation
11. Standar Prosedur Transaksi Keuangan. 11. Financial Transaction Standard Operating Procedures
12. Kebijakan Tata Kelola Teknologi Informasi dan Data. 12. Information Technology and Data Governance Policies
13. Motivational Reward Tahunan Karyawan. 13. Annual Employee Motivational Rewards
14. Program Pensiun Karyawan. 14. Employee Pension Program
15. Peningkatan Penggunaan Produk Dalam Negeri. 15. Enhancement of Domestic Product Usage
16. Struktur Organisasi. 16. Organizational Structure
17. Rencana Kerja dan Anggaran Konsolidasi. 17. Consolidated Work Plan and Budget
18. Kendaraan Dinas Perusahaan. 18. Company Official Vehicles
19. Kegiatan Olah Raga dan Kesenian. 19. Sports and Arts Activities
20. Audit Internal Implementasi Sistem Manajemen SNI. 20. Internal Audit of SNI Management System
Implementation
21. Whistleblowing System. 21. Whistleblowing System
22. Komite Manajemen Risiko. 22. Risk Management Committee
23. Pedoman Gratifikasi. 23. Gratuities Guidelines
24. Audit Internal Penerapan Sistem Manajemen Anti 24. Internal Audit of Anti-Bribery Management System
Penyuapan (SMAP). (SMAP) Implementation
25. Audit Umum Laporan Keuangan 2025. 25. General Audit of 2025 Financial Statements
26. Kelompok Jabatan Keahlian (Expertise). 26. Job Expertise Grouping
27. Pedoman Perjalanan Dinas. 27. Official Travel Guidelines
28. Kebijakan Anti Penyuapan. 28. Anti-Bribery Policy
29. Manual Sistem Manajemen Anti Penyuapan (SMAP). 29. Anti-Bribery Management System (SMAP) Manual
30. Pedoman Penulisan dan Pemutakhiran Database 30. Guidelines for Employee Database Writing and
Karyawan. Updating
PELATIHAN DAN/ATAU PENGEMBANGAN TRAINING AND/OR COMPETENCY
KOMPETENSI DIREKSI DEVELOPMENT OF THE
BOARD OF DIRECTORS
Perseroan memberikan kesempatan kepada anggota The Company provides its Board of Directors with
Direksi untuk meningkatkan kompetensi dengan mengikuti opportunities to enhance their competencies through
pendidikan, pelatihan, atau seminar terkait tugas dan participation in relevant education programs, training
tanggung jawabnya. Pendidikan dan pelatihan yang diikuti sessions, and seminars aligned with their roles and
oleh Direksi pada tahun 2025 adalah sebagai berikut: responsibilities. The training and development activities
undertaken by the Board of Directors in 2025 included
the following:
Nama Pelatihan/Workshop/
Lembaga Waktu dan
Nama Jabatan Konferensi/Seminar
Penyelenggara Tempat
Name Position Name of Training/Workshop/
Organizer Time and Venue
Conference/Seminar
Badan Pengawas Obat
& Makanan (BPOM)
Sosialisasi Kebijakan sertifikasi CDOB Republik Indonesia
Ahmad bin Abu Presiden Direktur 24 November 2025
Socialization of CDOB certification Food and Drug
Bakar President Director November 24, 2025
policy Supervisory Agency
(BPOM) of the Republic
of Indonesia
Strategic Workforce Planning : 16 May 2025
PT Anaplan Indonesia
Navigating the Future of Work May 16, 2025
Mohamad Fazly Direktur Etik Business Dan Kepatuhan Hukum 12 Juli 2025
Kantor Hukum DRS
bin Hassan Director Business Ethics and Legal Compliance July 12, 2025
12 Agusutus 2025
Market Insight And Potential Market PT Inspiry
August 12, 2025
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 151
Page 152
Tata Kelola Perusahaan Positioned for
Good Corporate Governance Profitable Growth
Nama Pelatihan/Workshop/
Lembaga Waktu dan
Nama Jabatan Konferensi/Seminar
Penyelenggara Tempat
Name Position Name of Training/Workshop/
Organizer Time and Venue
Conference/Seminar
Future Proofing Economics: The
Strategic Role of Accountants n 23 Mei 2025
IAI
Turbulent Times May 23, 2025
Dengar Pendapat Publik: DE
Amendmen PSAK119 14 Oktober 2025
IAI
Public Hearing: DE Amendment October 14, 2025
PSAK119
PENILAIAN ATAS KINERJA PERFORMANCE ASSESSMENT
KOMITE PENUNJANG DIREKSI OF COMMITTEES SUPPORTING
THE BOARD OF DIRECTORS
Hingga akhir tahun pelaporan, Perseroan tidak membentuk As of the end of the reporting year, the Company had
Komite di bawah Direksi. Pelaksanaan tugas dan tanggung not established any committees under the Board of
jawab Direksi didukung oleh satuan kerja yang dipimpin Directors. The execution of the Board of Directors’ duties
oleh Sekretaris Perseroan dan Manajer Divisi. and responsibilities was supported by work units led by
the Corporate Secretary and Division Managers.
152 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 153
Positioned for
Profitable Growth
Transparansi Informasi
Dewan Komisaris dan Direksi
Transparency of Information of the
Board of Commissioners and Directors
KEBIJAKAN REMUNERASI DEWAN REMUNERATION POLICY FOR THE BOARD
KOMISARIS DAN DIREKSI OF COMMISSIONERS AND DIRECTORS
Prosedur Penetapan Remunerasi Remuneration Determination Procedure
Proses penetapan remunerasi bagi Dewan Komisaris The process for determining remuneration for the Board
dan Direksi dilakukan dan disetujui dalam Rapat Umum of Commissioners and the Board of Directors is carried
Pemegang Saham (RUPS). Pada tahun 2025, remunerasi out and approved in the General Meeting of Shareholders
yang diterima Dewan Komisaris dan Direksi ditetapkan (GMS). In 2025, the remuneration received by the Board of
melalui Akta No. 75 tanggal 28 Mei 2025 Jumlah remunerasi Commissioners and the Board of Directors was established
yang diterima oleh Dewan Komisaris dan Direksi secara through Deed No. 75 dated 28 Mei 2025. The total
total adalah sebesar Rp4.997.622.037. remuneration received by the Board of Commissioners
and the Board of Directors amounted to Rp4,997,622,037.
Penetapan dan besarnya remunerasi Dewan Komisaris The determination and amount of remuneration for the
dan Direksi diatur dalam Anggaran Dasar Perseroan yang Board of Commissioners and the Board of Directors are
menjelaskan bahwa remunerasi Dewan Komisaris terdiri governed by the Company’s Articles of Association, which
dari gaji pokok, fasilitas, serta tunjangan lain, termasuk stipulate that the Board of Commissioners’ remuneration
dana purnajabatan yang jumlahnya ditentukan oleh consists of a basic salary, benefits, and other allowances,
RUPS Tahunan. Pemegang saham memiliki wewenang including post-employment funds, with the amounts
untuk menetapkan besaran remunerasi Dewan Komisaris determined by the Annual GMS. Shareholders have
dengan mengacu pada Pasal 96 ayat (1) Undang-undang the authority to set the remuneration of the Board of
Perseroan Terbatas No. 40 Tahun 2007. Commissioners with reference to Article 96 paragraph
(1) of Law No. 40 of 2007 concerning Limited Liability
Companies.
Pada tahun 2025, remunerasi ditetapkan oleh Wakil In 2025, the remuneration was determined by the
Pemegang Saham Utama Perseroan dalam Rapat Umum Company’s Major Shareholder Representative during
Pemegang Saham Tahunan. the Annual General Meeting of Shareholders.
Struktur Remunerasi Remuneration Structure
RUPS menetapkan komponen remunerasi Dewan The GMS determines the components of remuneration
Komisaris per bulan dan per tahun yang terdiri dari for the Board of Commissioners on a monthly and annual
gaji/honorarium, tunjangan, dan fasilitas. Pada tahun basis, consisting of salary/honorarium, allowances, and
2025, jumlah remunerasi yang diberikan kepada Dewan facilities. In 2025, the total remuneration granted to the
Komisaris dan Direksi masing-masing sebesar Rp2.248 Board of Commissioners and the Board of Directors
juta dan 5.087 juta. amounted to Rp2,248 million and Rp5,087 million,
respectively.
Direksi Dewan Komisaris
Jenis Remunerasi/Fasilitas (Rp Juta) (Rp Juta)
Type of Remuneration/Facilities Board of Directors Board of Commissioners
(Rp Million) (Rp Million)
Gaji/Honorarium
Salary/Honorarium
Tunjangan
5.087 2.248
Allowance
Fasilitas
Facility
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 153
Page 154
Tata Kelola Perusahaan Positioned for
Good Corporate Governance Profitable Growth
PENILAIAN ATAS KINERJA DEWAN PERFORMANCE ASSESSMENT OF
KOMISARIS DAN DIREKSI THE BOARD OF COMMISSIONERS
AND THE BOARD OF DIRECTORS
Perseroan melaksanakan penilaian kinerja Dewan The Company conducts an annual performance
Komisaris dan Direksi setiap tahun melalui mekanisme assessment of the Board of Commissioners and the
yang terstruktur. Proses penilaian diawali dengan Board of Directors through a structured mechanism.
penilaian mandiri (self-assessment) oleh masing- The assessment process begins with a self-assessment
masing organ dan anggota, yang kemudian ditelaah oleh by each governing body and its respective members,
Komite Nominasi dan Remunerasi untuk menghasilkan which is subsequently reviewed by the Nomination and
rekomendasi. Rekomendasi tersebut menjadi dasar Remuneration Committee to formulate recommendations.
bagi Pemegang Saham dalam melakukan penilaian These recommendations serve as the basis for the
dan mengambil keputusan dalam RUPS, termasuk Shareholders in conducting evaluations and making
terkait evaluasi kinerja, penetapan remunerasi, serta decisions at the GMS, including matters relating to
pertimbangan pengangkatan kembali anggota Dewan performance evaluation, determination of remuneration,
Komisaris dan Direksi. and considerations for the reappointment of members of
the Board of Commissioners and the Board of Directors.
Penilaian Kinerja Dewan Komisaris Performance Assessment of the
Board of Commissioners
Prosedur Pelaksanaan Implementation Procedure
Evaluasi kinerja Dewan Komisaris dilakukan setiap The performance evaluation of the Board of Commissioners
tahun melalui self-assessment dengan mengacu pada is conducted annually through a self-assessment
pelaksanaan tugas dan tanggung jawab Dewan Komisaris process, with reference to the performance of the duties
sesuai Anggaran Dasar dan ketentuan peraturan and responsibilities of the Board of Commissioners in
perundang-undangan. Hasil self-assessment ditelaah accordance with the Company’s Articles of Association
oleh Komite Nominasi dan Remunerasi, kemudian and prevailing laws and regulations. The results of the
dilaporkan kepada Pemegang Saham melalui RUPS dan self-assessment are reviewed by the Nomination and
diungkapkan dalam Laporan Tahunan. Remuneration Committee and subsequently reported
to the Shareholders through the GMS and disclosed in
the Annual Report.
Kriteria Penilaian Assessment Criteria
Penilaian dilakukan secara kolegial dan individual. Secara The assessment is carried out on both a collegial and
kolegial, penilaian antara lain mencakup pencapaian individual basis. On a collegial basis, the assessment
kinerja Perseroan terhadap target yang ditetapkan, includes, among others, the Company’s performance
efektivitas pengawasan dan pemberian nasihat kepada against the established targets, the effectiveness of
Direksi, kepatuhan terhadap ketentuan yang berlaku dan supervision and advisory functions provided to the Board
kebijakan Perseroan, serta penerapan tata kelola. Secara of Directors, compliance with applicable regulations
individual, penilaian antara lain mempertimbangkan and Company policies, and the implementation of
kompetensi dan kontribusi dalam proses pengawasan, good corporate governance. On an individual basis,
serta tingkat kehadiran dan partisipasi dalam rapat the assessment considers, among others, competence
Dewan Komisaris, rapat gabungan dengan Direksi, dan and contribution to the supervisory process, as well as
rapat dengan komite pendukung. attendance levels and participation in meetings of the
Board of Commissioners, joint meetings with the Board
of Directors, and meetings with supporting committees.
Pihak yang Melakukan Penilaian Assessing Party
Pemegang Saham melakukan penilaian dalam RUPS The Shareholders conduct the assessment at the GMS,
dengan mempertimbangkan hasil self-assessment dan taking into account the results of the self-assessment
rekomendasi Komite Nominasi dan Remunerasi. and the recommendations of the Nomination and
Remuneration Committee.
Berdasarkan evaluasi untuk tahun buku 2025, Dewan Based on the evaluation for the fiscal year 2025, the Board
Komisaris dinilai telah menjalankan fungsi pengawasan of Commissioners was assessed to have effectively carried
dan pemberian nasihat secara efektif serta memenuhi out its supervisory and advisory functions and to have
kriteria yang ditetapkan. met the established criteria.
154 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 155
Positioned for
Profitable Growth
Penilaian Kinerja Direksi Performance Assessment of
the Board of Directors
Prosedur Pelaksanaan Implementation Procedure
Penilaian kinerja Direksi dilakukan secara terukur melalui The performance assessment of the Board of Directors
self-assessment yang mengacu pada pencapaian RKAP is conducted in a measurable manner through a self-
serta KPI yang disepakati. Hasil penilaian ditelaah oleh assessment process that refers to the achievement of the
Komite Nominasi dan Remunerasi untuk menghasilkan Company’s Work Plan and Budget (RKAP) as well as the
rekomendasi kepada Dewan Komisaris dan selanjutnya agreed Key Performance Indicators (KPIs). The assessment
menjadi bahan penilaian Pemegang Saham dalam RUPS, results are reviewed by the Nomination and Remuneration
termasuk untuk penetapan remunerasi dan pertimbangan Committee to formulate recommendations to the Board
pengangkatan kembali anggota Direksi. of Commissioners and subsequently serve as a basis for
Shareholders’ assessment at the GMS, including for the
determination of remuneration and consideration of the
reappointment of members of the Board of Directors.
Kriteria Penilaian Assessment Criteria
Penilaian dilakukan secara kolegial dan individual. Secara The assessment is carried out on both a collegial and
kolegial, penilaian mencakup pencapaian target kinerja individual basis. On a collegial basis, the assessment
Perseroan (termasuk kinerja keuangan dan operasional), covers the achievement of the Company’s performance
efektivitas pelaksanaan strategi, tata kelola dan targets, including financial and operational performance,
pengendalian internal, serta pengelolaan risiko sesuai the effectiveness of strategy implementation, the
kebutuhan usaha. Secara individual, penilaian mencakup application of governance and internal control, as
pencapaian target kinerja sesuai tugas dan tanggung well as risk management in accordance with business
jawab masing-masing anggota Direksi, kompetensi dan needs. On an individual basis, the assessment includes
kepemimpinan dalam pelaksanaan mandat, serta tingkat the achievement of performance targets in line with the
kehadiran dan partisipasi aktif dalam rapat Direksi, rapat respective duties and responsibilities of each member
gabungan dengan Dewan Komisaris, dan RUPS. of the Board of Directors, competence and leadership in
carrying out the mandate, as well as attendance levels
and active participation in meetings of the Board of
Directors, joint meetings with the Board of Commissioners,
and General Meetings of Shareholders.
Pihak yang Melakukan Penilaian Assessing Party
Pemegang Saham melakukan penilaian dalam RUPS The Shareholders conduct the assessment at the GMS,
dengan mempertimbangkan hasil self-assessment dan taking into account the results of the self-assessment
rekomendasi Komite Nominasi dan Remunerasi. and the recommendations of the Nomination and
Remuneration Committee.
Berdasarkan hasil penilaian kinerja tahun buku 2025, Based on the results of the performance assessment
kinerja Direksi secara kolektif maupun individual dinilai for the fiscal year 2025, the performance of the Board of
sangat baik dan menjadi dasar pertimbangan dalam Directors, both collectively and individually, was assessed
penetapan tindak lanjut yang relevan, termasuk kebijakan as very good and served as a basis for determining
remunerasi. relevant follow-up actions, including remuneration policies.
PENGUNGKAPAN HUBUNGAN DISCLOSURE OF AFFILIATIONS AMONG
AFILIASI ANTARA DIREKSI, DEWAN THE BOARD OF DIRECTORS, THE BOARD
KOMISARIS, DAN PEMEGANG OF COMMISSIONERS, AND THE MAJOR/
SAHAM UTAMA/PENGENDALI CONTROLLING SHAREHOLDERS
Berikut merupakan informasi terkait hubungan afiliasi The following information presents the affiliations among
antara anggota Direksi dan anggota Direksi lainnya, members of the Board of Directors and other members of
anggota Direksi dan pemegang saham utama dan/ the Board of Directors, between members of the Board of
atau pengendali, anggota Dewan Komisaris dan anggota Directors and the major and/or controlling shareholders,
Dewan Komisaris lainnya, serta anggota Dewan Komisaris among members of the Board of Commissioners and
dengan pemegang saham utama dan/atau pengendali. other members of the Board of Commissioners, as well
as between members of the Board of Commissioners and
the major and/or controlling shareholders.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 155
Page 156
Tata Kelola Perusahaan Positioned for
Good Corporate Governance Profitable Growth
Hubungan Afiliasi dengan Organ Perseroan
Affiliation with Company Organs
Nama Pemegang Saham Utama/
Name Dewan Komisaris Direksi Pengendali Perseroan
Board of Commissioners Board of Directors Major Shareholder/Controlling
Shareholder of the Company
Dewan Komisaris
Board of Commissioners
Joefly Joesoef Bahroeny - - -
Sarah Azreen binti Abdul
- - -
Samat
Prof. Aman Bhakti Pulungan,
MD, Paed Consultant, PhD, - - -
FAAP, FRCPI (Hon.)
Dr. Imam Fathorrahman, M.M - - -
Dato’ Zulkifli Bin Jafar - - √
Direksi
Board of Directors
Ahmad bin Abu Bakar - - √
Mohamad Fazly bin Hassan - - √
Kepengurusan pada Perseroan Lain Oleh Dewan Komisaris dan Direksi
Concurrent Positions in Other Companies Held by the Board of Commissioners and the Board of Directors
Kepengurusan pada Perseroan/Institusi Lain
Nama Concurrent Positions in Other Companies/Institutions
Name Sebagai Dewan Komisaris Sebagai Direksi Jabatan Lainnya
As Board of Commissioners As Board of Directors Other Positions
Dewan Komisaris
Board of Commissioners
Joefly Joesoef Bahroeny √ √ -
Sarah Azreen binti Abdul
√ - -
Samat
Prof. Aman Bhakti Pulungan,
MD, Paed Consultant, PhD, - - -
FAAP, FRCPI (Hon.)
Dr. Imam Fathorrahman, M.M √ - -
Dato’ Zulkifli Bin Jafar - √ -
Direksi
Board of Directors
Ahmad bin Abu Bakar √ - -
Mohamad Fazly bin Hassan - √ -
RANGKAP JABATAN DEWAN CONCURRENT POSITIONS OF THE
KOMISARIS DAN DIREKSI BOARD OF COMMISSIONERS AND
THE BOARD OF DIRECTORS
Rangkap jabatan Dewan Komisaris dan Direksi hanya Members of the Board of Commissioners and the Board
dapat dilakukan sepanjang tidak bertentangan dengan of Directors may hold concurrent positions, provided that
peraturan perundang-undangan yang berlaku dan/atau such positions do not conflict with the prevailing laws and
peraturan Perusahaan. regulations and/or the Company’s internal regulations.
156 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 157
Positioned for
Profitable Growth
Dalam Lingkup Grup Luar Lingkup Grup
Nama Jabatan di Perseroan Usaha Usaha
Name Position in the Company Within the Business Outside the Business
Group Group
Dewan Komisaris
Board of Commissioners
Komisaris Utama
Joefly Joesoef Bahroeny √ √
President Commissioner
Sarah Azreen binti Abdul Komisaris Independen
√ √
Samat Independent Commissioner
Prof. Aman Bhakti Pulungan,
Komisaris Independen
MD, Paed Consultant, PhD, √ -
Independent Commissioner
FAAP, FRCPI (Hon.)
Komisaris Independen
Dr. Imam Fathorrahman, M.M √ -
Independent Commissioner
Komisaris
Dato’ Zulkifli Bin Jafar √ √
Commissioner
Direksi
Board of Directors
Direktur Utama
Ahmad bin Abu Bakar √ -
President Director
Direktur
Mohamad Fazly bin Hassan √ -
Director
Informasi terperinci terkait kepengurusan dan rangkap Detailed information regarding the management positions
jabatan Dewan Komisaris dan Direksi pada perusahaan and concurrent positions held by members of the Board
lain, disampaikan pada Bab Profil Perusahaan, Laporan of Commissioners and the Board of Directors in other
Tahunan ini. companies is disclosed in the Company Profile Chapter
of this Annual Report.
KEBERAGAMAN KOMPOSISI DEWAN DIVERSITY IN THE COMPOSITION OF
KOMISARIS DAN DIREKSI THE BOARD OF COMMISSIONERS
AND THE BOARD OF DIRECTORS
Perseroan senantiasa berupaya menjaga keberagaman The Company consistently strives to maintain diversity in
komposisi keahlian, gender, kebangsaan, dan pengalaman the composition of the Board of Commissioners and the
anggota Dewan Komisaris dan Direksi yang mencakup Board of Directors in terms of expertise, gender, nationality,
keuangan, akuntansi, manajemen risiko, operasional, and experience, encompassing finance, accounting, risk
tata kelola, dan bidang lainnya. Keberagaman komposisi management, operations, corporate governance, and
anggota Dewan Komisaris dan Direksi dapat dilihat pada other relevant fields. The diversity of the composition of
tabel berikut: the Board of Commissioners and the Board of Directors
is presented in the table below:
Tabel Keberagaman Komposisi Dewan Komisaris dan Direksi
Table of Diversity in the Composition of the Board of Commissioners and Board of Directors.
Usia
Nama Jabatan Pendidikan Gender
(tahun)
Name Position Education Gender
Age
Komisaris Utama
Joefly Joesoef Master of Managament Laki-laki
President 69
Bahroeny Master of Managament Male
Commissioner
• Bachelor of Commerce (Accounting)
• Certified Practising Accountant (CPA)
Komisaris • Capital Markets Services Representative’s License
Sarah Azreen binti Independen (CMSRL) Perempuan
50
Abdul Samat Independent • Bachelor of Commerce (Accounting) Female
Commissioner • Certified Practising Accountant (CPA)
• Capital Markets Services Representative’s License
(CMSRL)
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 157
Page 158
Tata Kelola Perusahaan Positioned for
Good Corporate Governance Profitable Growth
Tabel Keberagaman Komposisi Dewan Komisaris dan Direksi
Table of Diversity in the Composition of the Board of Commissioners and Board of Directors.
Usia
Nama Jabatan Pendidikan Gender
(tahun)
Name Position Education Gender
Age
• Apoteker
Komisaris • Master of Strategic Management
Dr. Imam Independen • Doktor Farmasi (Dr.pharm) Laki-laki
61
Fathorrahman, M.M Independent • Pharmacist Male
Commissioner • Master of Strategic Management
• Doctor of Pharmacy (Dr.pharm)
• Dokter Spesialis Anak (Sp.A)
• Fellow of the American Academy of Paediatrics
(FAAP)
Komisaris • Honorary Fellow Royal College of Physicians of
Independen Ireland (RCPI.hon) Laki-laki
Aman B. Pulungan 68
Independent • Pediatrician (Sp.A) Male
Commissioner • Fellow of the American Academy of Pediatrics
(FAAP)
• Honorary Fellow of the Royal College of Physicians
of Ireland (RCPI.hon)
• Ekonomi Sirkular dan Strategi Keberlanjutan,
Cambridge Judge Business School, University of
Cambridge, 2002
• Certified Patent Agent, 2002
• Admission to Malaysian Bar, 1997
• Advocate and Solicitor of the High Court of Malaysia,
1997
• Sarjana Hukum, International Islamic University
Komisaris Malaysia, 1996 Laki-laki
Dato’ Zulkifli Bin Jafar 53
Commissioner • Circular Economy and Sustainability Strategy, Male
Cambridge Judge Business School, University of
Cambridge, 2002
• Certified Patent Agent, 2002
• Admission to the Malaysian Bar, 1997
• Advocate and Solicitor of the High Court of Malaysia,
1997
• Bachelor of Laws, International Islamic University
Malaysia, 1996
• Bachelor of Pharmacy
Direktur Utama • Registered Pharmacist Laki-laki
Ahmad bin Abu Bakar 56
President Director • Bachelor of Pharmacy Male
• Registered Pharmacist
• Bachelor of Accountancy from University
Technology of MARA
• Certified Accountant from Malaysia Institute of
Accountant
Mohamad Fazly bin Direktur • Certified Risk Management Officer (CRMO) Laki-laki
51
Hassan Director • Bachelor of Accountancy from University Male
Technology of MARA
• Certified Accountant from Malaysia Institute of
Accountant
• Certified Risk Management Officer (CRMO)
158 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 159
Positioned for
Profitable Growth
Komite Audit
Audit Committee
Dewan Komisaris memiliki Komite Audit sebagai organ The Board of Commissioners is supported by an Audit
perusahaan yang membantu Dewan Komisaris dalam Committee as a corporate organ that assists in carrying
menjalankan tugas dan tanggung jawab pengawasan. out its supervisory duties and responsibilities. The Company
Perseroan telah membentuk Komite Audit sesuai dengan has established an Audit Committee in accordance
POJK No. 55/POJK.04/2015 tanggal 23 Desember 2015 with POJK No. 55/POJK.04/2015 dated December 23, 2015
tentang Pembentukan dan Pedoman Pelaksanaan Kerja concerning the Establishment and Guidelines for the
Komite Audit. Komite Audit merupakan alat kelengkapan Implementation of Audit Committee Duties. The Audit
Dewan Komisaris yang berfungsi untuk melakukan Committee serves as a supporting body of the Board
pengawasan atas efektivitas sistem pengendalian intern, of Commissioners, with the function of overseeing the
internal audit, proses, pelaporan keuangan, sehingga effectiveness of the internal control system, internal audit
Perseroan dapat dikelola berdasarkan GCG secara tepat. function, processes, and financial reporting, thereby
ensuring that the Company is managed in accordance
with the principles of Good Corporate Governance.
PIAGAM KOMITE AUDIT AUDIT COMMITTEE CHARTER
Komite Audit memiliki Piagam Komite Audit yang The Audit Committee has an Audit Committee Charter,
digunakan sebagai acuan dalam menjalankan tugas dan which serves as a reference in carrying out its duties and
tanggung jawabnya secara profesional dan independen. responsibilities in a professional and independent manner.
Piagam ini senantiasa ditinjau kelayakannya secara The Charter is reviewed periodically to ensure its suitability
periodik dan mencakup antara lain: and covers among others:
1. Komposisi, Kriteria, dan Masa Jabatan. 1. Composition, criteria, and term of office.
2. Tugas dan tanggung jawab. 2. Duties and responsibilities.
3. Kewenangan. 3. Authority.
4. Etika. 4. Ethics.
5. Rapat dan Tata Kerja. 5. Meetings and working procedures.
6. Tanggung jawab pelaporan. 6. Reporting responsibilities.
TUGAS DAN TANGGUNG DUTIES AND RESPONSIBILITIES
JAWAB KOMITE AUDIT OF THE AUDIT COMMITTEE
Komite Audit membantu Dewan Komisaris dalam The Audit Committee assists the Board of Commissioners
mengidentifikasi hal-hal yang memerlukan perhatian, in identifying matters requiring attention and in providing
serta memberikan pendapat kepada Dewan Komisaris opinions to the Board of Commissioners on financial
terhadap laporan keuangan atau hal-hal yang statements or other matters submitted by the Board
disampaikan oleh Direksi kepada Dewan Komisaris. Komite of Directors to the Board of Commissioners. The Audit
ini juga melaksanakan tugas-tugas lain yang berkaitan Committee also performs other duties related to the
dengan tugas Dewan Komisaris, meliputi: responsibilities of the Board of Commissioners, which
include:
1. Melakukan penelaahan atas informasi keuangan yang 1. Reviewing financial information to be issued by the
akan dikeluarkan Perseroan, seperti laporan keuangan, Company, such as financial statements, projections,
proyeksi, dan informasi keuangan lainnya. and other financial information.
2. Melakukan penelaahan atas ketaatan Perseroan 2. Reviewing the Company’s compliance with capital
terhadap peraturan perundang-undangan di bidang market laws and regulations and other prevailing laws
pasar modal dan peraturan perundang-undangan and regulations related to the Company’s activities.
lainnya yang berhubungan dengan kegiatan
Perseroan.
3. Melakukan penelaahan atas pelaksanaan 3. Reviewing the implementation of audits conducted
pemeriksaan oleh auditor internal. by the internal auditor.
4. Melaporkan kepada Komisaris berbagai risiko yang 4. Reporting to the Board of Commissioners on various
dihadapi Perseroan dan pelaksanaan manajemen risks faced by the Company and the implementation
risiko oleh Direksi. of risk management by the Board of Directors.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 159
Page 160
Tata Kelola Perusahaan Positioned for
Good Corporate Governance Profitable Growth
5. Melakukan penelaahan dan melaporkan kepada 5. Reviewing and reporting to the Board of Commissioners
Dewan Komisaris atas pengaduan yang berkaitan on complaints related to the Issuer and the Public
dengan Emiten dan Perseroan Publik. Company.
6. Menjaga kerahasiaan dokumen, data, dan informasi 6. Maintaining the confidentiality of the Company’s
Perseroan. documents, data, and information.
Sedangkan wewenang Komite Audit adalah sebagai The Audit Committee holds the following authority:
berikut: 1. Access to the Company’s and Public Company’s
1. Mengakses dokumen, data, dan informasi Perseroan documents, data, and information concerning
dan Perseroan Publik tentang karyawan, dana, aset, employees, funds, assets, and data sources as needed;
dan sumber data Perseroan yang diperlukan.
2. Berkomunikasi langsung dengan karyawan, termasuk 2. Direct communication with employees, including the
Direksi dan pihak yang menjalankan fungsi audit Board of Directors and parties responsible for internal
internal, manajemen risiko, dan akuntan terkait tugas audit functions, risk management, and accountants
dan tanggung jawab Komite Audit. regarding the committee’s duties and responsibilities;
3. Melibatkan pihak independen di luar Komite Audit yang 3. Involving independent third parties outside the Audit
diperlukan untuk membantu pelaksanaan tugasnya Committee, if necessary, to assist in carrying out its
(jika diperlukan). duties; and
4. Melakukan kewenangan lain yang diberikan oleh 4. Exercising other authorities granted by the Board of
Dewan Komisaris. Commissioners.
Jabatan Tugas
Position Duties
Membantu Dewan Komisaris dalam memberikan pendapat profesional dan independen guna
memastikan diterapkannya proses pengawasan dan pengendalian intern dalam menilai
Ketua Komite Audit
pelaksanaan kegiatan Perseroan.
Chairperson of the Audit
Assisting the Board of Commissioners in providing professional and independent opinions to
Committee
ensure the effective implementation of oversight and internal control processes in assessing
the Company’s operations.
Membantu Ketua Komite Audit dalam memberikan rekomendasi mengenai sistem pengendalian
manajemen serta pelaksanaannya, memastikan prosedur evaluasi terhadap segala evaluasi
yang dikeluarkan oleh Perseroan, serta melakukan identifikasi hal-hal yang memerlukan
Anggota Komite Audit
perhatian Dewan Komisaris.
Member of the Audit
Assisting the Chairperson of the Audit Committee in providing recommendations on the
Committee
management control system and its implementation, ensuring the evaluation procedures for
all assessments issued by the Company, and identifying matters that require the attention of
the Board of Commissioners.
SUSUNAN DAN KOMPOSISI COMPOSITION AND MEMBERSHIP
KEANGGOTAAN KOMITE AUDIT OF THE AUDIT COMMITTEE
Komposisi Komite Audit
Audit Committee Composition
Jabatan Nama Dasar Pengangkatan Akhir Masa Jabatan
Position Name Basis of Appointment End of Term of Office
Sesuai ketentuan yang berlaku,
masa jabatan tidak melebihi
No. 01/SK-DK/MPI/2023 tanggal masa jabatan Dewan Komisaris.
Ketua Komite Audit
25 Mei 2023 In accordance with the
Chairperson of Audit Sarah Azreen binti Abdul Samat
No. 01/SK-DK/MPI/2023 dated applicable regulations, the term
Committee
May 25, 2023 of office does not exceed the
term of office of the Board of
Commissioners.
Sesuai ketentuan yang berlaku,
masa jabatan tidak melebihi
No. 01/SK-DK/MPI/2023 tanggal masa jabatan Dewan Komisaris.
Anggota Komite Audit
25 Mei 2023 In accordance with the
Member of Audit Ary Gunawan
No. 01/SK-DK/MPI/2023 dated applicable regulations, the term
Committee
May 25, 2023 of office does not exceed the
term of office of the Board of
Commissioners.
160 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 161
Positioned for
Profitable Growth
Komposisi Komite Audit
Audit Committee Composition
Jabatan Nama Dasar Pengangkatan Akhir Masa Jabatan
Position Name Basis of Appointment End of Term of Office
Sesuai ketentuan yang berlaku,
masa jabatan tidak melebihi
No. 01/SK-DK/MPI/2023 tanggal masa jabatan Dewan Komisaris.
Anggota Komite Audit
25 Mei 2023 In accordance with the
Member of Audit Dr. Imam Fathorrahman, M.M
No. 01/SK-DK/MPI/2023 dated applicable regulations, the term
Committee
May 25, 2023 of office does not exceed the
term of office of the Board of
Commissioners.
Sesuai ketentuan yang berlaku,
masa jabatan tidak melebihi
No. 01/SK-DK/MPI/2023 tanggal masa jabatan Dewan Komisaris.
Anggota Komite Audit
25 Mei 2023 In accordance with the
Member of Audit Dato’ Zulkifli Bin Jafar
No. 01/SK-DK/MPI/2023 dated applicable regulations, the term
Committee
May 25, 2023 of office does not exceed the
term of office of the Board of
Commissioners.
PROFIL KOMITE AUDIT AUDIT COMMITTEE PROFILE
SARAH AZREEN BINTI ABDUL SAMAT
Ketua Komite Audit
Chairperson of Audit Committee
Usia 50 tahun
Age 50 years old
Kewarganegaraan Malaysia
Nationality Malaysian
• Capital Markets Services Representative’s License (CMSRL)
Pendidikan • Certified Practising Accountant (CPA) Australia
Education • Sarjana Akuntansi, University of Canberra, Australia
• Bachelor of Accounting, University of Canberra, Australia
Dasar Pengangkatan No 01/SK-DK/MPI/2023 tanggal 25 Mei 2023
Basis of Appointment No. 01/SK-DK/MPI/2023 dated May 25, 2023
• Independent Non-Executive Director Pharmaniaga Berhad, 2021 - present
• Executive Director of Reneuco Berhad, present;
• Executive Director, 3p Capital Advisers Sdn Bhd (an advisory firm licensed by the SC), 2018 – present;
• Director Corporate Finance Department, RHB Investment Bank Berhad, 2009 – 2018;
Pengalaman Kerja
• Assistant Vice President Corporate Finance Department, Maybank Investment Bank Berhad, 2006 – 2009;
Work Experience
• Manager Corporate Finance Department, AmMerchant Bank Berhad, 2005 – 2006;
• Managing Consultant Corporate Finance Department, KPMG Corporate Services Sdn Bhd, 2004;
• Assistant Manager Corporate Finance Department, Malaysian International Merchant Bankers Berhad, 2001 – 2004;
• Senior Associate – Audit, Business, and Advisory Services, Price Waterhouse Coopers (PWC), 1997 – 2000.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 161
Page 162
Tata Kelola Perusahaan Positioned for
Good Corporate Governance Profitable Growth
ARY GUNAWAN
Anggota Komite Audit
Member of Audit Committee
Usia 66 tahun
Age 66 years old
Kewarganegaraan
Indonesia
Nationality
• Akademi Meteorologi & Geofisika di Jakarta
• STIE Bisnis Indonesia di Jakarta
Pendidikan • Magister Administrasi Bisnis di IPWI Jakarta
Education • Academy of Meteorology and Geophysics, Jakarta
• STIE Bisnis Indonesia, Jakarta
• Master of Business Administration, IPWI Jakarta
Dasar Pengangkatan No 01/SK-DK/MPI/2023 tanggal 25 Mei 2023
Basis of Appointment No. 01/SK-DK/MPI/2023 dated May 25, 2023
• Managing Director, PT Wooribio Antamax Indonesia, 2022 – sekarang
• Komisaris Utama, PT Woori Bio Corpora, 2018 – sekarang
• Pendiri & pemilik www.rajaalkes.com 2014 – sekarang
• Direktur Utama, PT Bioaxi Medika Healthindo, 2018 – 2021
Pengalaman Kerja • Komisaris Utama, PT Bio Axion Healthindo, 2015 – 2021
Work Experience • Managing Director, PT Wooribio Antamax Indonesia, 2022 – present
• President Commissioner, PT Woori Bio Corpora, 2018 – present
• Founder and Owner, www.rajaalkes.com , 2014 – present
• President Director, PT Bioaxi Medika Healthindo, 2018 – 2021
• President Commissioner, PT Bio Axion Healthindo, 2015 – 2021
DR. IMAM FATHORRAHMAN, M.M
Anggota Komite Audit
Member of Audit Committee
Usia 61 tahun
Age 61 years old
Kewarganegaraan
Indonesia
Nationality
• Profesi Apoteker, Universitas Airlangga, 1989
• Magister Strategic Management, Sekolah Tinggi Manajemen PPM, 2003
Pendidikan • Kandidat Doktor, Universitas Airlangga, sekarang
Education • Pharmacist (Professional Degree), Universitas Airlangga, 1989
• Master’s Degree in Strategic Management, PPM School of Management, 2003
• Doctoral Candidate, Universitas Airlangga, present
Dasar Pengangkatan No 01/SK-DK/MPI/2023 tanggal 25 Mei 2023
Basis of Appointment No. 01/SK-DK/MPI/2023 dated May 25, 2023
• Direktur Utama Kimia Farma Apotek, 2011 – 2019
• Direktur Pengembangan Bisnis PT Kimia Farma Tbk, 2019 – 2021
Pengalaman Kerja • Direktur Pemasaran & Komersial PT Kimia Farma Tbk, 2021 – 2022
Work Experience • President Director, Kimia Farma Apotek, 2011–2019
• Director of Business Development, PT Kimia Farma Tbk, 2019–2021
• Director of Marketing & Commercial, PT Kimia Farma Tbk, 2021–2022
162 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 163
Positioned for
Profitable Growth
DATO‘ ZULKIFLI BIN JAFAR
Anggota Komite Audit
Member of Audit Committee
Usia 53 tahun
Age 53 years old
Kewarganegaraan
Malaysia
Nationality
• Ekonomi Sirkular dan Strategi Keberlanjutan, Cambridge Judge Business School, University of Cambridge, 2002
• Certified Patent Agent, 2002
• Admission to Malaysian Bar, 1997
• Advocate and Solicitor of the High Court of Malaysia, 1997
Pendidikan • Sarjana Hukum, International Islamic University Malaysia, 1996
Education • Circular Economy and Sustainability Strategy, Cambridge Judge Business School, University of Cambridge, 2002
• Certified Patent Agent, 2002
• Admission to the Malaysian Bar, 1997
• Advocate and Solicitor of the High Court of Malaysia, 1997
• Bachelor of Laws, International Islamic University Malaysia, 1996
Dasar Pengangkatan No 01/SK-DK/MPI/2023 tanggal 25 Mei 2023
Basis of Appointment No. 01/SK-DK/MPI/2023 dated May 25, 2023
• Deputy Chief Executive Officer Pharmaniaga Berhad, 2023
• Direktur Eksekutif Pharmaniaga Berhad, 2022
• Anggota Komite (Komite Nominasi dan Remunerasi, Komite Audit, Komite Dewan Manajemen Risiko) Pharmaniaga
Berhad, 2020 – 2022
• Kepala Komite Tender Pharmaniaga Berhad, 2020 – 2022
• Direktur dan Anggota Manajemen Chatridge Conference Centre (UK) Limited, 2015 – 2021
• Chairman Idaman PharmaManufacturing Sdn Bhd, 2021 – 2022
• Chairman dan Direktur Era Universe Development Sdn Bhd, 2014 – Present
• Penasehat Hukum Johor State GLC, 2016 – 2019
• Direktur Aladdin Group Sdn Bhd, 2016 – 2019
• Dewan Kepercayaan Foundation of Research and Transformation (Kantor Perdana Menteri), 2015 – 2021
• Direktur Songa Offshore Malaysia Sdn Bhd, 2012 – 2015
• Direktur Cooperative Commission of Malaysia, 2008 – 2010
• Pemegang Saham Mayoritas dan Direktur MMA Resource Sdn Bhd, 2007 – Present
• Partner Messr Rashid Zulkifli, 2002 – 2020
• Asisten Hukum Senior Messrs Raslan Loong, 1997 – 2002
Pengalaman Kerja • Penasehat Hukum Panglima Aces Sdn Bhd, 1997
Work Experience • Deputy Chief Executive Officer, Pharmaniaga Berhad, 2023
• Executive Director, Pharmaniaga Berhad, 2022
• Committee Member (Nomination and Remuneration Committee, Audit Committee, Risk Management Committee),
Pharmaniaga Berhad, 2020–2022
• Head of Tender Committee, Pharmaniaga Berhad, 2020–2022
• Director and Management Member, Chatridge Conference Centre (UK) Limited, 2015–2021
• Chairman, Idaman PharmaManufacturing Sdn. Bhd., 2021–2022
• Chairman and Director, Era Universe Development Sdn. Bhd., 2014–present
• Legal Advisor, Johor State GLCs, 2016–2019
• Director, Aladdin Group Sdn. Bhd., 2016–2019
• Board of Trustees, Foundation of Research and Transformation (Prime Minister’s Office), 2015–2021
• Director, Songa Offshore Malaysia Sdn. Bhd., 2012–2015
• Director, Cooperative Commission of Malaysia, 2008–2010
• Majority Shareholder and Director, MMA Resource Sdn. Bhd., 2007–present
• Partner, Messrs Rashid Zulkifli, 2002–2020
• Senior Legal Assistant, Messrs Raslan Loong, 1997–2002
• Legal Advisor, Panglima Aces Sdn. Bhd., 1997
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 163
Page 164
Tata Kelola Perusahaan Positioned for
Good Corporate Governance Profitable Growth
Independensi Komite Audit
Independence of the Audit Committee
Aspek Independensi Sarah Azreen Binti Dr. Imam Dato’ Zulkifli Bin
Ary Gunawan
Independence Aspect Abdul Samat Fathorrahman, M.M Jafar
Memiliki hubungan keuangan
dengan Dewan Komisaris dan
Direksi.
Having financial relationships X X X X
with members of the Board of
Commissioners and the Board of
Directors.
Memiliki hubungan kepengurusan di
Perseroan, anak Perseroan, maupun
Perseroan afiliasi.
X X X X
Having management relationships
within the Company, its subsidiaries,
and affiliated companies.
Memiliki hubungan kepemilikan
saham Perseroan.
X X X X
Having share ownership in the
Company.
Memiliki hubungan keluarga
dengan Dewan Komisaris, Direksi,
dan/atau sesama anggota Komite
Audit.
Having family relationships X X X X
with members of the Board of
Commissioners, the Board of
Directors, and/or fellow members of
the Audit Committee.
Menjabat sebagai pengurus partai
politik, pejabat pemerintah daerah.
Holding positions as a political X X X X
party official and/or a regional
government official.
RAPAT KOMITE AUDIT AUDIT COMMITTEE MEETINGS
Komite Audit melakukan rapat secara berkala yang The Audit Committee holds meetings on a regular basis, at
dilakukan sekurang-kurangnya 1 (satu) kali dalam 3 (tiga) least 1 (one) time every 3 (three) months. Audit Committee
bulan. Rapat Komite Audit hanya dapat dilaksanakan meetings may only be convened if attended by more
apabila dihadiri oleh lebih dari ½ (satu per dua) jumlah than ½ (half) of the total number of members. Throughout
anggota. Sepanjang tahun 2025, Komite Audit melakukan 2025, the Audit Committee held 4 (four) meetings, with
rapat sebanyak 4 (empat) kali, dengan tingkat kehadiran the following attendance level:
sebagai berikut:
Persentase Kehadiran
Nama Jabatan Jumlah Rapat Jumlah Kehadiran
Percentage of
Name Position Number of Meetings Number of Attendance
Attendance
Sarah Azreen binti Ketua
4 4 100%
Abdul Samat Chairperson
Anggota
Ary Gunawan 4 4 100%
Member
Dr. Imam Anggota
4 4 100%
Fathorrahman, M.M Member
Anggota
Dato’ Zulkifli Bin Jafar 4 4 100%
Member
164 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 165
Positioned for
Profitable Growth
PERIODE DAN MASA JABATAN PERIOD AND TERM OF OFFICE OF
ANGGOTA KOMITE AUDIT AUDIT COMMITTEE MEMBERS
Berdasarkan Keputusan Dewan Komisaris 001/SKDK/ Based on the Board of Commissioners’ Decision No. 001/
MPI/2020 tertanggal 12 Agustus 2020 serta perubahannya SKDK/MPI/2020 dated August 12, 2020, as amended by
No.: 007/SK/DK/MPI/2022 tanggal 16 Desember 2022, masa Decision No. 007/SK/DK/MPI/2022 dated December 16,
jabatan Komite Audit terhitung sejak ditetapkannya Surat 2022, the term of office of the Audit Committee shall
Keputusan sampai dengan diberhentikannya sesuai commence from the date of issuance of the Decision Letter
dengan Surat Keputusan dan peraturan yang berlaku. and shall continue until termination in accordance with
the relevant Decision Letter and applicable regulations.
LAPORAN PELAKSANAAN TUGAS REPORT ON THE IMPLEMENTATION OF
KOMITE AUDIT TAHUN 2025 THE AUDIT COMMITTEE’S DUTIES IN 2025
Selama tahun 2025, Komite Audit telah melaksanakan Throughout 2025, the Audit Committee carried out its
tugasnya, sebagai berikut: duties as follows:
1. Melakukan meeting dan koordinasi dengan Direksi dan 1. Conducted regular meetings and coordination with the
Dewan Komisaris secara berkala termasuk menyusun Board of Directors and the Board of Commissioners,
rencana kerja Komite Audit. including the preparation of the Audit Committee’s
work plan.
2. Melakukan meeting dengan Internal Audit dalam 2. Held meetings with Internal Audit in relation to the
rangka penyusunan rencana audit tahunan. preparation of the annual audit plan.
3. Melakukan meeting dengan eksternal auditor. 3. Held meetings with the external auditor.
4. Melakukan tinjauan hasil kerja Audit Internal. 4. Reviewed the work results of Internal Audit.
5. Memberikan rekomendasi penunjukan Auditor 5. Provided recommendations on the appointment of the
Eksternal sesuai dengan peraturan OJK. External Auditor in accordance with OJK regulations.
6. Melakukan tinjauan atas laporan keuangan kuartalan. 6. Reviewed the quarterly financial statements.
7. Melakukan tinjauan hasil kinerja external audit. 7. Reviewed the results of the external audit performance.
PENINGKATAN KOMPETENSI COMPETENCY DEVELOPMENT
Pada tahun 2025, Perseroan tidak menyelenggarakan In 2025, the Company did not organize or involve the Audit
dan juga tidak mengikutsertakan Komite Audit ke dalam Committee in training/education.
pelatihan/Pendidikan.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 165
Page 166
Tata Kelola Perusahaan Positioned for
Good Corporate Governance Profitable Growth
Komite Nominasi dan Remunerasi
Nomination and Remuneration Committee
Pembentukan Komite Nominasi dan Remunerasi dilakukan The establishment of the Nomination and Remuneration
sebagai bagian dari upaya Perseroan untuk mematuhi Committee is part of the Company’s efforts to comply
POJK No. 34/POJK.04/2014 tentang Komite Nominasi with POJK No. 34/POJK.04/2014 on the Nomination
dan Remunerasi Emiten atau Perusahaan Publik. Komite and Remuneration Committee of Issuers or Public
Remunerasi dan Nominasi dibentuk oleh dan bertanggung Companies. The Nomination and Remuneration
jawab kepada Dewan Komisaris. Komite Nominasi dan Committee is established by and accountable to the
Remunerasi akan membantu dalam pelaksanaan Board of Commissioners. The Committee assists the
tanggung jawab pengawasan implementasi terhadap Board of Commissioners in carrying out its supervisory
kebijakan nominasi dan remunerasi anggota Direksi dan responsibilities over the implementation of nomination
anggota Dewan Komisaris. and remuneration policies for members of the Board of
Directors and the Board of Commissioners.
PIAGAM KOMITE NOMINASI NOMINATION AND REMUNERATION
DAN REMUNERASI COMMITTEE CHARTER
Komite Nominasi dan Remunerasi memiliki pedoman The Nomination and Remuneration Committee has a
Komite Nominasi dan Remunerasi yang mengacu pada Charter that serves as its guiding framework, referring
POJK No. 34/POJK.04/2014 tentang Komite Nominasi dan to POJK No. 34/POJK.04/2014 on the Nomination and
Remunerasi Emiten atau Perseroan Publik. Remuneration Committee of Issuers or Public Companies.
TUGAS DAN TANGGUNG JAWAB DUTIES AND RESPONSIBILITIES
KOMITE NOMINASI DAN REMUNERASI OF THE NOMINATION AND
REMUNERATION COMMITTEE
Tugas dan tanggung jawab Komite Nominasi dan The duties and responsibilities of the Nomination and
Remunerasi adalah: Remuneration Committee are as follows:
1. Menyusun kebijakan, kriteria, dan seleksi yang 1. Formulating policies, criteria, and selection processes
dibutuhkan untuk jabatan-jabatan strategis di required for strategic positions within the Company,
lingkungan Perseroan, yaitu jabatan satu tingkat namely positions one level below the Board of Directors
di bawah Direktur dan pengurus (anggota Dewan and management positions (members of the Board of
Direksi dan anggota Dewan Komisaris) anak Perseroan Directors and members of the Board of Commissioners)
konsolidasi dengan kepatuhan pada prinsip-prinsip of consolidated subsidiaries, in compliance with the
Tata Kelola Perseroan yang baik. principles of Good Corporate Governance.
2. Evaluasi dalam implementasi tentang Tata Kelola 2. Evaluating the implementation of Good Corporate
Perseroan, terkait kebijakan sumber daya manusia. Governance, related to human resources policies.
3. Membantu Dewan Komisaris atau berkonsultasi 3. Assisting the Board of Commissioners or consulting
dengan Dewan Direksi dalam menyeleksi kandidat with the Board of Directors in selecting candidates
untuk jabatan-jabatan strategis di lingkungan for strategic positions within the Company, namely
Perseroan, yaitu jabatan satu tingkat di bawah Direktur positions one level below the Board of Directors and
dan pengurus (anggota Dewan Direksi dan anggota management positions (members of the Board of
Dewan Komisaris) anak Perseroan konsolidasi. Directors and members of the Board of Commissioners)
of consolidated subsidiaries.
4. Memberikan rekomendasi kepada Dewan Komisaris 4. Providing recommendations to the Board of
mengenai: Commissioners regarding:
a. Komposisi jabatan anggota Dewan Direksi. a. The composition of the Board of Directors.
b. Perencanaan suksesi anggota Dewan Direksi. b. Succession planning for members of the Board
c. Penilaian berdasarkan tolak ukur yang telah of Directors.
disusun sebagai bahan evaluasi untuk tujuan c. Performance assessments based on established
pengembangan kemampuan anggota Dewan benchmarks, to be used as evaluation materials
Direksi. for the development of the capabilities of members
of the Board of Directors.
166 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 167
Positioned for
Profitable Growth
SUSUNAN DAN KOMPOSISI COMPOSITION AND MEMBERSHIP
KEANGGOTAAN KOMITE OF THE NOMINATION AND
NOMINASI DAN REMUNERASI REMUNERATION COMMITTEE
Komposisi Komite Nominasi dan Remuneras
Composition of the Nomination and Remuneration Committee
Jabatan Nama Dasar Pengangkatan Akhir Masa Jabatan
Position Name Basis of Appointment End of Term of Office
Sesuai ketentuan yang berlaku, masa jabatan tidak
Ketua Komite Nominasi dan No. 01/SK-DK/MPI/2023
melebihi masa jabatan Dewan Komisaris.
Remunerasi Joefly Joesoef tanggal 25 Mei 2023
In accordance with the applicable regulations, the
Chairman of the Nomination Bahroeny No. 01/SK-DK/MPI/2023
term of office does not exceed the term of office
and Remuneration Committee dated May 25, 2023
of the Board of Commissioners.
Sesuai ketentuan yang berlaku, masa jabatan tidak
Anggota Komite Nominasi dan No. 01/SK-DK/MPI/2023
melebihi masa jabatan Dewan Komisaris.
Remunerasi Aman Bhakti tanggal 25 Mei 2023
In accordance with the applicable regulations, the
Member of the Nomination and Pulungan No. 01/SK-DK/MPI/2023
term of office does not exceed the term of office
Remuneration Committee dated May 25, 2023
of the Board of Commissioners.
Sesuai ketentuan yang berlaku, masa jabatan tidak
Anggota Komite Nominasi dan No. 01/SK-DK/MPI/2023
Dr. Imam melebihi masa jabatan Dewan Komisaris.
Remunerasi tanggal 25 Mei 2023
Fathorrahman, In accordance with the applicable regulations, the
Member of the Nomination and No. 01/SK-DK/MPI/2023
M.M term of office does not exceed the term of office
Remuneration Committee dated May 25, 2023
of the Board of Commissioners.
PROFIL KOMITE NOMINASI NOMINATION AND REMUNERATION
DAN REMUNERASI COMMITTEE PROFILE
JOEFLY JOESOEF BAHROENY
Ketua Komite Nominasi dan Remunerasi
Chairman of the Nomination and Remuneration Committee
Usia 69 tahun
Age 69 years old
Kewarganegaraan
Indonesia
Nationality
Profil Beliau dapat dilihat pada pembahasan Profil Dewan Komisaris di bab Profil Perusahaan dalam Laporan Tahunan ini.
His profile is presented in the Board of Commissioners’ Profile section in the Company Profile chapter of this Annual Report.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 167
Page 168
Tata Kelola Perusahaan Positioned for
Good Corporate Governance Profitable Growth
DR. IMAM FATHORRAHMAN, M.M
Anggota Komite Nominasi dan Remunerasi
Member of the Nomination and Remuneration Committee
Usia 61 tahun
Age 61 years old
Kewarganegaraan
Indonesia
Nationality
Profil Beliau dapat dilihat pada pembahasan Profil Dewan Komisaris di bab Profil Perusahaan dalam Laporan Tahunan ini.
His profile is presented in the Board of Commissioners’ Profile section in the Company Profile chapter of this Annual Report.
PROF. AMAN BHAKTI PULUNGAN
Anggota Komite Nominasi dan Remunerasi
Member of the Nomination and Remuneration Committee
Usia 68 tahun
Age 68 years old
Kewarganegaraan
Indonesia
Nationality
Profil Beliau dapat dilihat pada pembahasan Profil Dewan Komisaris di bab Profil Perusahaan dalam Laporan Tahunan ini.
His profile is presented in the Board of Commissioners’ Profile section in the Company Profile chapter of this Annual Report.
Independensi Komite Nominasi dan Remunerasi
Independence of the Nomination and Remuneration Committee
Aspek Independensi Dr. Imam Prof. Aman Bhakti
Joefly Joesoef Bahroeny
Independence Aspect Fathorrahman, M.M Pulungan
Memiliki hubungan keuangan dengan
Dewan Komisaris dan Direksi.
Having financial relationships
X X X
with members of the Board of
Commissioners and the Board of
Directors.
Memiliki hubungan kepengurusan di
Perseroan, anak Perseroan, maupun
Perseroan afiliasi.
X X X
Having management relationships
within the Company, its subsidiaries,
and affiliated companies.
Memiliki hubungan kepemilikan
saham Perseroan.
X X X
Having shared ownership in the
Company.
168 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 169
Positioned for
Profitable Growth
Independensi Komite Nominasi dan Remunerasi
Independence of the Nomination and Remuneration Committee
Aspek Independensi Dr. Imam Prof. Aman Bhakti
Joefly Joesoef Bahroeny
Independence Aspect Fathorrahman, M.M Pulungan
Memiliki hubungan keluarga dengan
Dewan Komisaris, Direksi, dan/atau
sesama anggota Komite Nominasi
dan Remunerasi.
Having family relationships
X X X
with members of the Board of
Commissioners, the Board of
Directors, and/or fellow members of
the Nomination and Remuneration
Committee.
Menjabat sebagai pengurus partai
politik, pejabat pemerintah daerah.
Holding positions as a political party X X X
official and/or a regional government
official.
RAPAT KOMITE NOMINASI NOMINATION AND REMUNERATION
DAN REMUNERASI COMMITTEE MEETINGS
Sepanjang tahun 2025, Komite Nominasi dan Remunerasi Throughout 2025, the Nomination and Remuneration
melakukan rapat sebanyak 3 (tiga) kali dengan tingkat Committee held 3 (three) meetings, with the following
kehadiran sebagai berikut: attendance level:
Persentase Kehadiran
Nama Jabatan Jumlah Rapat Jumlah Kehadiran
Percentage of
Name Position Number of Meetings Number of Attendance
Attendance
Joefly Joesoef Ketua
3 3 100%
Bahroeny Chairman
Dr. Imam Anggota
3 3 100%
Fathorrahman, M.M Member
Aman Bhakti Anggota
3 2 66%
Pulungan Member
LAPORAN PELAKSANAAN TUGAS REPORT ON THE IMPLEMENTATION
KOMITE NOMINASI DAN REMUNERASI OF THE NOMINATION AND
REMUNERATION COMMITTEE’S DUTIES
Kegiatan Komite Nominasi dan Remunerasi selama tahun The activities of the Nomination and Remuneration
buku adalah mengadakan rapat sebanyak 3 (tiga) kali Committee during the financial year are to hold 3 (three)
pada tahun 2025 yang dihadiri anggota komite untuk meetings in 2025 which are attended by committee
memberikan persetujuan terhadap nominasi dan members to give approval to the nomination and
remunerasi yang akan ditetapkan oleh Perseroan. remuneration to be determined by the Company.
PENINGKATAN KOMPETENSI COMPETENCY DEVELOPMENT
Pada tahun 2025, Perseroan tidak menyelenggarakan In 2025, the Company did not organize or involve the
dan juga tidak mengikutsertakan Komite Nominasi dan Nomination and Remuneration Committee in training/
Remunerasi ke dalam pelatihan/Pendidikan. education.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 169
Page 170
Tata Kelola Perusahaan Positioned for
Good Corporate Governance Profitable Growth
Komite Manajemen Risiko
Risk Management Committee
Komite Manajemen Risiko berjumlah 5 (lima) orang, terdiri The Risk Management Committee consists of 5 (five)
atas 3 (tiga) orang anggota Dewan Komisaris dan 2 (dua) people, consisting of 3 (three) members of the Board of
orang anggota Dewan Direksi. Commissioners and 2 (two) members of the Board of
Directors.
Profile pejabat yang membidangi fungsi manajemen The profiles of the officials responsible for risk management
risiko ini dapat dilihat pada bagian Dewan Komisaris dan can be found in the Board of Commissioners and Board
Dewan Direksi. of Directors profiles.
Komite tersebut secara langsung dibantu oleh Kelompok Every 3 (three) months, the Risk Management Committee
Kerja Manajemen Risiko yang secara memadai has a meeting. In this meeting, the Joint Working Group
mengidentifikasi risiko-risiko yang mungkin dialami oleh Committee does a thorough analysis of all risks by
Perseroan. Komite Manajemen Risiko mengadakan rapat examining numerous internal and external elements
setiap 3 (tiga) bulan sekali. Dalam rapat tersebut Komite in depth. The Joint Committee of the Working Group
bersama Kelompok Kerja secara saksama menganalisis formulates measures to address the identified hazards
semua risiko dengan mempelajari secara rinci berbagai in order to decrease or eliminate the final danger.
faktor internal dan eksternal. Komite bersama Kelompok
Kerja merumuskan langkah-langkah untuk mengatasi
risiko-risiko yang teridentifikasi tersebut untuk memastikan
bahwa risiko akhir dapat dikurangi atau dihilangkan.
170 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 171
Positioned for
Profitable Growth
Organ Pendukung Direksi
Supporting Organs of The Board of Directors
SEKRETARIS PERUSAHAAN CORPORATE SECRETARY
Sekretaris Perseroan membantu dalam pengelolaan The Corporate Secretary assists in the management of
perusahaan karena selain bertugas memastikan bahwa the Company by not only ensuring that the Company’s
informasi yang dimiliki perusahaan telah disampaikan information is communicated effectively but also serving
secara efektif, Sekretaris Perseroan juga menjadi as a liaison officer between the Board of Directors, the Board
penghubung (liaison officer) antara Direksi, Dewan of Commissioners, shareholders, and other stakeholders.
Komisaris, serta Pemegang Saham maupun pemangku The establishment of the Corporate Secretary is governed
kepentingan lainnya. Pembentukan Sekretaris Perseroan by POJK No. 35/POJK.04/2014 on the Corporate Secretary
diatur dalam POJK No. 35/POJK.04/2014 tentang Sekretaris of Issuers or Public Companies.
Perseroan Emiten atau Perseroan Publik.
Sekretaris Perseroan bertanggung jawab memastikan The Corporate Secretary is responsible for ensuring that
bahwa Perseroan telah menerapkan prinsip tata kelola the Company implements the principles of good corporate
Perseroan yang baik, memelihara citra positif dan governance, maintaining the Company’s positive image
kepentingan Perseroan, membangun hubungan yang and interests, fostering good relationships with all
baik dengan seluruh pemangku kepentingan, mendukung stakeholders, supporting the management in conducting
penyelenggaraan usaha Perseroan oleh manajemen, the Company’s business, performing secretarial duties,
menjalankan tugas kesekretariatan, serta memastikan and ensuring the Company’s compliance with all
kepatuhan Perseroan terhadap seluruh regulasi yang applicable regulations.
berlaku.
Masa jabatan Sekretaris Perseroan terhitung sejak tanggal The term of office of the Corporate Secretary is effective
pengangkatan hingga penunjukkan Sekretaris Perseroan from the date of appointment until a new Corporate
yang baru oleh Direksi Perseroan. Secretary is appointed by the Company’s Board of
Directors.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 171
Page 172
Tata Kelola Perusahaan Positioned for
Good Corporate Governance Profitable Growth
Profil Sekretaris Perusahaan Corporate Secretary Profile
OLGA INDRIA BOLANG
Sekretaris Perusahaan
Corporate Secretary
Domisili
Jakarta
Domicile
Usia 50 tahun
Age 50 years old
Kewarganegaraan
Indonesia
Nationality
Universitas Prof. Dr. Moestopo (Beragama) Jakarta, Sarjana Ekonomi (2009)
Pendidikan
Universitas Prof. Dr. Moestopo (Beragama) Jakarta, Bachelor of Economics
Education
(2009)
Dasar Pengangkatan Surat Penunjukkan 234/ MPI/DIR/X/2019 tanggal 7 Oktober 2019
Basis of Appointment Appointment Letter 234/ MPI/DIR/X/2019 dated October 7, 2019
Beliau bergabung dengan Perseroan pada tahun 2017 sebagai Manajer Operasi Keuangan sebelum mengemban
tugas sebagai Sekretaris Perseroan pada tahun 2019. Sebelum bergabung dengan Perseroan, beliau pernah
menjabat sebagai Manajer Administrasi & Keuangan PT Mega Pharmaniaga pada tahun 2013, Manajer Keuangan
di PT Harindo Mitragas Utama pada tahun 2008, dan bekerja sebagai sekretaris di PT Indobel Qualita Usaha
pada tahun 2002 hingga 2007. Beliau sebelumnya bekerja sebagai staf administrasi di PT Sampurna Kartika
Cakra Dwika, 1998 hingga 2002. Pada tahun 1997, beliau bekerja sebagai staf processing di Citibank. Awal karir
Pengalaman Kerja
beliau dimulai pada tahun 1996 sebagai staf administrasi di Securicor Indonesia.
Work Experience
She joined the Company in 2017 as Finance Operations Manager before assuming the role of Corporate
Secretary in 2019. Prior to joining the Company, she served as Administration & Finance Manager at PT Mega
Pharmaniaga in 2013, Finance Manager at PT Harindo Mitragas Utama in 2008, and as a secretary at PT Indobel
Qualita Usaha from 2002 to 2007. She previously worked as an administrative staff member at PT Sampurna
Kartika Cakra Dwika from 1998 to 2002. In 1997, she worked as a processing staff at Citibank. Her career began
in 1996 as an administrative staff member at Securicor Indonesia.
Rangkap Jabatan Tidak memiliki rangkap jabatan di luar maupun di Perseroan
Concurrent Position Does not hold concurrent positions either outside the Company or within the Company.
Tidak memiliki hubungan afiliasi, baik dengan anggota Dewan Komisaris lainnya, Direksi, maupun dengan
Hubungan Afiliasi pemegang saham utama dan pengendali.
Affiliation Does not have any affiliation with members of the Board of Commissioners, the Board of Directors, or with the
major and controlling shareholders.
Tugas dan Tanggung Jawab Duties and Responsibilities of
Sekretaris Perusahaan the Corporate Secretary
Pelaksanaan tugas dan tanggung jawab Sekretaris The implementation of the duties and responsibilities
Perusahaan mengacu pada Peraturan Otoritas Jasa of the Corporate Secretary refers to the Financial
Keuangan No. 35/POJK.04/2014 serta ketentuan internal Services Authority Regulation No. 35/POJK.04/2014 as
Perseroan. Secara umum, Sekretaris Perusahaan well as the Company’s internal regulations. In general,
bertanggung jawab untuk memastikan kelancaran the Corporate Secretary is responsible for ensuring the
administrasi organ perusahaan, kepatuhan terhadap smooth administration of the company’s governing
peraturan pasar modal, serta pengelolaan komunikasi bodies, compliance with capital market regulations, and
dengan pemangku kepentingan. the management of communication with stakeholders.
Fungsi Kepatuhan dan Penasihat Compliance and Advisory Function
Sekretaris Perusahaan bertugas memantau The Corporate Secretary is responsible for monitoring
perkembangan peraturan perundang-undangan developments in capital market regulations and ensuring
di bidang Pasar Modal dan memastikan Perseroan the Company’s compliance with applicable provisions.
mematuhi ketentuan yang berlaku. Dalam fungsi ini, In this role, the Corporate Secretary provides input
Sekretaris Perusahaan memberikan masukan dan saran and advice to the Board of Directors and the Board of
172 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 173
Positioned for
Profitable Growth
kepada Direksi dan Dewan Komisaris terkait kepatuhan Commissioners regarding compliance with laws, and
terhadap undang-undang, serta memastikan seluruh ensures that all corporate decisions are aligned with the
keputusan korporasi selaras dengan prinsip Tata Kelola principles of Good Corporate Governance.
Perusahaan yang Baik.
Administrasi dan Tata Kelola Administration and Governance
Dalam aspek administratif, Sekretaris Perusahaan In the administrative aspect, the Corporate Secretary is
bertanggung jawab atas penyelenggaraan dan responsible for organizing and documenting the General
dokumentasi Rapat Umum Pemegang Saham (RUPS), Meeting of Shareholders (GMS), Board of Directors
Rapat Direksi, serta Rapat Dewan Komisaris. Tugas ini meetings, and Board of Commissioners meetings. This
mencakup persiapan bahan rapat, pembuatan risalah duty includes preparing meeting materials, drafting
rapat yang akurat, serta pemantauan realisasi keputusan accurate minutes of meetings, and monitoring the
rapat. Selain itu, Sekretaris Perusahaan bertugas implementation of meeting decisions. In addition, the
mengadministrasikan Daftar Pemegang Saham dan Corporate Secretary manages the Shareholders Register
Daftar Khusus, serta memfasilitasi pelaksanaan program and the Special Register, and facilitates the orientation
orientasi bagi anggota Direksi dan Dewan Komisaris yang programs for newly appointed members of the Board of
baru menjabat. Directors and the Board of Commissioners.
Keterbukaan Informasi dan Hubungan Eksternal Information Disclosure and External Relations
Sekretaris Perusahaan bertindak sebagai penghubung The Corporate Secretary serves as the official liaison
resmi antara Perseroan dengan pemegang saham, between the Company, its shareholders, the Financial
Otoritas Jasa Keuangan (OJK), dan pemangku Services Authority (OJK), and other stakeholders. This
kepentingan lainnya. Tanggung jawab ini meliputi responsibility includes fulfilling obligations for public
pelaksanaan kewajiban keterbukaan informasi kepada information disclosure, providing up-to-date information
masyarakat, penyediaan informasi terkini pada situs web on the Company’s website, and submitting periodic
Perseroan, serta penyampaian laporan berkala kepada reports to the OJK in a timely manner in accordance with
OJK secara tepat waktu sesuai dengan regulasi yang applicable regulations.
berlaku.
Pelaksanaan Tugas Sekretaris Implementation of the Corporate
Perseroan pada Tahun 2025 Secretary’s Duties in 2025
Selama tahun 2025, Sekretaris Perusahaan telah Throughout 2025, the Corporate Secretary carried out her
melaksanakan tugasnya antara lain sebagai berikut: duties, including the following:
• Laporan kepada OJK dan melalui SPE OJK • Report to OJK and through the OJK SPE
• Laporan kepada BEI melalui IDXnet • Report to IDX via IDXnet
• Penyelenggaraan RUPST dan RUPSLB • Implementation of AGMS and EGMS
• Penyusunan Laporan Tahunan dan Laporan • Preparation of Annual Reports and
Keberlanjutan • Sustainability Reports
• Penyampaian Laporan Keuangan • Submission of Financial Statements
• Pelaksanaan Paparan Publik • Implementation of Public Exposure
• Pembagian Dividen • Dividend Distribution
• Kunjungan Perusahaan • Company Visit
Pelatihan dan/atau Pengembangan Training and/or Competency Development
Kompetensi Sekretaris Perusahaan of the Corporate Secretary
Dalam rangka mendukung pelaksanaan tugasnya, To support the performance of her duties, the Corporate
Sekretaris Perusahaan telah mengikuti sejumlah program Secretary participated in several training and competency
pelatihan dan pengembangan kompetensi berupa development programs, including seminars and
seminar dan workshop sepanjang tahun 2025. workshops, throughout 2025.
Lembaga Waktu dan
Nama Pelatihan/Workshop/Konferensi/Seminar
Penyelenggara Tempat
Name of Training/Workshop/Conference/Seminar
Organizer Time and Venue
Pendalaman POJK No. 29/POJK.04/2016 tentang Laporan Tahunan Emiten atau Perusahaan
Publik & POJK No. 51/POJK.03/2017 tentang Penerapan Keuangan Berkelanjutan bagi
Online by Zoom
Lembaga Jasa Keuangan, Emiten, dan Perusahaan Publik
ICSA 22 Januari 2025
Deepening of POJK No. 29/POJK.04/2016 concerning Annual Report of Issuers or Public
January 22, 2025
Companies & POJK No. 51/POJK.03/2017 concerning the Implementation of Sustainable
Finance for Financial Services Institutions, Issuers, and Public Companies
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 173
Page 174
Tata Kelola Perusahaan Positioned for
Good Corporate Governance Profitable Growth
Lembaga Waktu dan
Nama Pelatihan/Workshop/Konferensi/Seminar
Penyelenggara Tempat
Name of Training/Workshop/Conference/Seminar
Organizer Time and Venue
Pendalaman POJK Nomor 14 Tahun 2022 tentang Penyampaian Laporan Keuangan
Online by Zoom
Berkala Emiten atau Perusahaan Publik
ICSA 18 Februari 2025
Deepening of POJK Number 14 of 2022 concerning the Submission of Periodic Financial
February 18, 2025
Statements of Issuers or Public Companies
Online by Zoom
Corporate Reputation in the Digital Era: Strategies to Build Investor Trust" ICSA 26 Februari 2025
February 26, 2025
Peran Perusahaan Publik dalam Keuangan Berkelanjutan : Memahami Taksonomi
Online by Zoom
Keuangan Berkelanjutan Indonesia Versi 2
ICSA 13 Maret 2025
The Role of Public Companies in Sustainable Finance: Understanding Indonesia’s
March 13, 2025
Sustainable Finance Taxonomy Version 2
Online by Zoom
Menavigasi Tantangan ESG melalui kebijakan GCG
ICSA 18 Maret 2025
Navigating ESG Challenges through GCG policies
March 18, 2025
Pendalaman POJK Nomor 9 Tahun 2023 tentang Penggunaan Jasa Akuntan Publik dan
Kantor Akuntan Publik dalam Kegiatan Jasa Keuangan & SE OJK Nomor 18/SEOJK.03/2023
tentang Tata Cara Penggunaan Jasa Akuntan Publik dan Kantor Akuntan Publik dalam
Online by Zoom
Kegiatan Jasa Keuangan
ICSA 19 Maret 2025
Deepening of POJK Number 9 of 2023 concerning the Use of Public Accountant Services and
March 19, 2025
Public Accounting Firms in Financial Services Activities & OJK SE Number 18/SEOJK.03/2023
concerning Procedures for the Use of Public Accountant Services and Public Accounting
Firms in Financial Services Activities
Peran Corporate Secretary dalam Mendorong Governansi, Manajemen Risiko dan
Online by Zoom
Kepatuhan (GRK) yang baik
ICSA 17 April 2025
The Role of Corporate Secretaries in Encouraging Good Governance, Risk Management
April 17, 2025
and Compliance (GRK)
Pendalaman Peraturan Otoritas Jasa Keuangan Nomor 29 Tahun 2023 tentang Pembelian
Online by Zoom
Kembali Saham yang Dikeluarkan oleh Perusahaan Terbuka.
ICSA 15 Mei 2025
Deepening of Financial Services Authority Regulation Number 29 of 2023 concerning the
May 15, 2025
Repurchase of Shares Issued by Public Companies.
Kesiapan Perusahaan dalam Menghadapi Volatilitas Pasar Global: Perspektif Investor
Online by Zoom
Relations dan Corporate Secretary
ICSA 20 Mei 2025
Corporate Readiness to Face Global Market Volatility: An Investor Relations and Corporate
May 20, 2025
Secretary Perspective
Online by Zoom
Embracing Diversity, Equality and Inclusion (DEI) in the Workplace. ICSA 22 Juli 2025
July 22, 2025
Pendalaman Peraturan Otoritas Jasa Keuangan Nomor 4 Tahun 2024 tentang Laporan
Kepemilikan atau Setiap Perubahan Kepemilikan Saham Perusahaan Terbuka dan
Online by Zoom
Laporan Aktivitas Menjaminkan Saham Perusahaan Terbuka
ICSA 29 Juli 2025
Deepening of Financial Services Authority Regulation Number 4 of 2024 concerning
July 29, 2025
Ownership Reports or Any Change in Share Ownership of Public Companies and Reports
on Activities to Guarantee Public Company Shares
Online by Zoom
Finance for non-Finance "Memahami angka untuk komunikasi yang efektif
ICSA 5 Agustus 2025
Finance for non-Finance “Understanding the numbers for effective communication
August 5, 2025
Sosialisasi POJK Nomor 14 Tahun 2025 Tentang Pelaksanaan Rapat Umum Pemegang
Saham, Rapat Umum Pemegang Obligasi, dan Rapat Umum Pemegang Sukuk Secara
Online by Zoom
Elektronik
AEI 26 Agustus 2025
Socialization of POJK Number 14 of 2025 concerning the Implementation of the General
August 26, 2025
Meeting of Shareholders, General Meeting of Bondholders, and General Meeting of Sukuk
Holders Electronically
Pendalaman Peraturan Otoritas Jasa Keuangan Nomor 17 Tahun 2020 tentang Transaksi
Online by Zoom
Material dan Perubahan Kegiatan Usaha.
ICSA 1 September 2025
Deepening Financial Services Authority Regulation Number 17 of 2020 concerning Material
September 1, 2025
Transactions and Changes in Business Activities.
Webinar Tax for Non Tax: Peran Corporate Secretary dalam Kewajiban Pajak Emiten,
Online by Zoom
M&A, dan Transaksi Saham
ICSA 19 September 2025
Tax for Non Tax Webinar: The Role of Corporate Secretary in Issuer Tax Liabilities, M&A,
September 19, 2025
and Stock Transactions
Online by Zoom
IDX–UN SSE: “Workshop on IFRS Sustainability Standards BEI 23 September 2025
September 23, 2025
Online by Zoom
IFRS 1 & 2 Update and Practical Insights for Public Companies" ICSA 13 November 2025
November 13, 2025
174 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 175
Positioned for
Profitable Growth
Lembaga Waktu dan
Nama Pelatihan/Workshop/Konferensi/Seminar
Penyelenggara Tempat
Name of Training/Workshop/Conference/Seminar
Organizer Time and Venue
Online by Zoom
Media Handling 4.0: Peran Corporate Secretary dalam Era AI dan Reputasi Digital
ICSA 20 November 2025
Media Handling 4.0: The Role of Corporate Secretaries in the Era of AI and Digital Reputation
November 20, 2025
UNIT AUDIT INTERNAL INTERNAL AUDIT UNIT
Perseroan membentuk Unit Audit Internal untuk The Company has established an Internal Audit Unit
memberikan assurance serta masukan secara to provide independent and objective assurance and
independen dan objektif terkait pengendalian internal recommendations regarding the Company’s internal
Perseroan dan meningkatkan pengawasan terhadap controls, as well as to enhance oversight of the
implementasi sistem pengendalian internal serta implementation of internal control systems and risk
manajemen risiko di berbagai unit atau departemen management across various units or departments.
di Perseroan. Unit Audit Internal diharapkan dapat The Internal Audit Unit is expected to make a positive
memberikan kontribusi positif dalam memperkuat tata contribution to strengthening overall corporate
kelola perusahaan secara menyeluruh. Unit Audit Internal governance. The Internal Audit Unit was established
dibentuk berdasarkan: based on:
1. POJK No. 56/POJK.04/2015 tentang Pembentukan dan 1. POJK No. 56/POJK.04/2015 on the Establishment and
Penyusunan Piagam Unit Audit Internal. Charter of the Internal Audit Unit.
2. Surat Keputusan Dewan Direksi No.03/MPI/CSU-DIR/ 2. Board of Directors’ Decree No. 03/MPI/CSU-DIR/VI/17
VI/17 tanggal 30 Juni 2017. dated June 30, 2017.
Piagam Audit Internal Internal Audit Charter
Dalam melaksanakan tugas dan tanggung jawabnya, Unit In carrying out its duties and responsibilities, the Internal
Audit Internal berpedoman pada Piagam Audit Internal Audit Unit refers to the Internal Audit Charter. This Charter
(Internal Audit Charter). Piagam ini berfungsi sebagai serves as the formal working framework, established
landasan kerja formal yang ditetapkan berdasarkan Surat based on the Board of Directors’ Decree Number PAI-00/
Keputusan Direksi Nomor PAI-00/POL/MPI/2023 tanggal 01 POL/MPI/2023 dated 01 September 2023 and has been
September 2023 serta telah mendapatkan persetujuan approved by the Company’s Board of Commissioners.
dari Dewan Komisaris Perseroan.
Tugas dan Tanggung Jawab Audit Internal Duties and Responsibilities of Internal Audit
Unit Audit Internal memiliki peran penting dalam The Internal Audit Unit plays a critical role in assessing
melakukan penilaian terhadap kecukupan pengendalian the adequacy of internal controls and compliance with
internal, kepatuhan terhadap peraturan, dengan demikian regulations, ensuring that internal control is integrated into
pengendalian internal menjadi bagian yang terintegrasi the systems and procedures of every operational unit. This
dalam sistem dan prosedur pada setiap kegiatan di unit enables early detection of any deviations, allowing the
kerja sehingga setiap penyimpangan dapat diketahui respective units to take corrective actions promptly. The
secara dini sehingga dapat dilakukan langkah perbaikan Internal Audit Unit consistently conducts internal oversight
oleh unit kerja yang bersangkutan. Unit Audit Internal using a systematic approach to ensure that the principles
senantiasa melakukan pengawasan internal dengan of good Corporate Governance are implemented correctly
melakukan pendekatan sistematis agar penerapan and effectively.
prinsip-prinsip Governansi Korporat yang baik dapat
berjalan secara baik dan benar.
Adapun tugas dan tanggung jawab serta wewenang Unit The duties, responsibilities, and authorities of the Internal
Audit Internal sebagaimana tertera di Piagam Internal Audit Unit, as set out in the Internal Audit Charter issued
Audit yang diterbitkan oleh Perseroan pada tanggal 28 by the Company on June 28, 2022, are as follows:
Juni 2022 adalah sebagai berikut:
1. Menyusun dan melaksanakan rencana audit tahunan 1. Developing and implementing an annual risk-based
berbasis risiko; audit plan;
2. Menguji dan mengevaluasi pelaksanaan pengendalian 2. Testing and evaluating the implementation of internal
internal dan sistem manajemen risiko sesuai dengan controls and risk management systems in accordance
kebijakan perusahaan; with company policies;
3. Melakukan pemeriksaan dan penilaian atas efisiensi 3. Conducting examinations and assessments of
dan efektivitas di bidang keuangan, akuntansi, efficiency and effectiveness in finance, accounting,
operasional, sumber daya manusia, pemasaran, operations, human resources, marketing, information
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 175
Page 176
Tata Kelola Perusahaan Positioned for
Good Corporate Governance Profitable Growth
teknologi informasi dan kegiatan lainnya; technology, and other activities;
4. Memberikan saran perbaikan dan informasi yang 4. Providing recommendations for improvement and
objektif tentang kegiatan yang diperiksa kepada objective information regarding the activities under
seluruh tingkat manajemen; review to all levels of management;
5. Membuat laporan hasil pemeriksaan dan 5. Preparing audit reports and submitting them to the
menyampaikan laporan tersebut kepada Direktur President Director, Board of Commissioners, and Audit
Utama, Dewan Komisaris dan Komite Audit; Committee;
6. Memantau, menganalisis dan melaporkan 6. Monitoring, analyzing, and reporting on the
pelaksanaan tindak lanjut perbaikan yang telah implementation of agreed corrective actions;
disarankan dan disepakati;
7. Bekerja sama dengan Komite Audit; 7. Collaborating with the Audit Committee;
8. Menyusun program untuk mengevaluasi mutu 8. Developing programs to evaluate the quality of Internal
kegiatan Audit Internal yang dilakukan; Audit activities;
9. Bersama-sama dengan Direktur Utama membahas 9. Discussing Internal Audit targets and Key Performance
target dan KPI (Key Performance Indicator) Audit Indicators (KPIs) with the President Director;
Internal;
10. Melakukan pemeriksaan khusus jika diperlukan; dan 10. Conducting special audits when necessary; and
11. Jika diperlukan oleh manajemen, Kepala Audit Internal 11. If required by management, the Head of Internal Audit
dapat melaksanakan tugas dan tanggung jawab may carry out tasks and responsibilities outside of
di luar kegiatan Audit Internal. Untuk keperluan ini, Internal Audit activities. For such purposes, boundaries
perlu dibuatkan batasan dan pengawasan oleh and oversight must be established by the Audit
Komite Audit untuk dapat menjamin independensi Committee to ensure independence and objectivity.
dan objektivitas.
Struktur dan Kedudukan Unit Audit Internal Structure and Position of the
Internal Audit Unit
Dalam menjalankan fungsinya dalam bidang In carrying out its supervisory functions within the
pengawasan Perseroan, Unit Audit Internal dibantu oleh Company, the Internal Audit Unit (IAU) is assisted by the
Kepala pemeriksa. Kepala Pemeriksa merupakan jabatan Chief Auditor. The Chief Auditor holds a structural position
struktural yang diangkat dan diberhentikan oleh Direksi appointed and dismissed by the Board of Directors and
dan bertanggung jawab langsung kepada Kepala UAI. reports directly to the Head of the IAU. Auditors hold
Pemeriksa merupakan jabatan keahlian yang diangkat a professional position appointed and dismissed by
dan diberhentikan oleh Direksi dan atau pejabat yang the Board of Directors or other authorized officials. In
berwenang. Dalam melaksanakan tugas audit, Pemeriksa performing audit tasks, Auditors report to the Chief Auditor,
bertanggung jawab kepada Kepala Pemeriksa selaku who serves as the Team Leader.
Ketua Tim.
Kedudukan UAI sebagai organ yang membantu Direktur The position of the IAU as a body assisting the President
Utama senantiasa ditempatkan dalam struktur organisasi Director is always placed within the organizational
yang setara dengan peran dan tanggung jawabnya, structure in a manner commensurate with its roles and
dalam pengungkapan pandangan dan pemikiran yang responsibilities, ensuring that its opinions and findings
tidak dapat dipengaruhi ataupun ditekan dari manajemen are disclosed independently and cannot be influenced
dan pihak lain. or pressured by management or other parties.
Penjelasan kedudukan UAI dalam organisasi Perseroan: Explanation of the IAU’s position within the Company’s
organization:
1. Unit Audit Internal secara struktural dikepalai oleh 1. The Internal Audit Unit is structurally headed by the
Kepala Unit Audit Internal. Head of the Internal Audit Unit.
2. Kepala Unit Audit Internal ditunjuk dan diberhentikan 2. The Head of the Internal Audit Unit is appointed and
secara langsung oleh Presiden Direktur setelah dismissed directly by the President Director, with the
disetujui oleh Dewan Komisaris. approval of the Board of Commissioners.
3. Presiden Direktur dapat memberhentikan Kepala 3. The President Director may dismiss the Head of the
Unit Audit Internal, setelah mendapat persetujuan Internal Audit Unit, with the approval of the Board of
Dewan Komisaris, jika Kepala Unit Audit Internal tidak Commissioners, if the Head of the Internal Audit Unit
memenuhi persyaratan sebagai Auditor Internal fails to meet the requirements as an Internal Auditor as
sebagaimana diatur dalam Peraturan Otoritas Jasa stipulated in the Financial Services Authority Regulation
Keuangan No. 56/POJK.04/2015 dan atau gagal atau No. 56/POJK.04/2015, or is unable or incompetent to
tidak cakap menjalankan tugas. perform the duties.
176 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 177
Positioned for
Profitable Growth
4. Kepala Unit Audit Internal bertanggung jawab secara 4. The Head of the Internal Audit Unit reports fully and
penuh dan langsung kepada Presiden Direktur. directly to the President Director.
5. Anggota Unit Audit Internal bertanggung jawab secara 5. Members of the Internal Audit Unit report directly to
langsung kepada Kepala Unit Audit Internal. the Head of the Internal Audit Unit.
Pihak yang Mengangkat dan Appointing and Dismissing Authority
Memberhentikan Kepala Audit Internal of the Head of Internal Audit
Secara struktural UAI dipimpin oleh Kepala Audit Internal Structurally, the IAU is led by the Head of Internal Audit,
yang diangkat dan diberhentikan oleh Direktur Utama who is appointed and dismissed by the President Director
setelah mendapat persetujuan dari Dewan Komisaris dan with the approval of the Board of Commissioners. Every
setiap pengangkatan, penggantian dan pemberhentian appointment, replacement, and dismissal of the Head of
Kepala Audit Internal diberitahukan kepada Otoritas Jasa Internal Audit is notified to the Financial Services Authority
Keuangan (OJK). (OJK).
ARIS SULISTYANTO
Kepala Audit Internal
Head of Internal Audit
Domisili
Jakarta
Domicile
Usia 38 tahun
Age 38 years old
Kewarganegaraan
Indonesia
Nationality
Pendidikan
Bachelor of Accounting, Perbanas Institute (2004 – 2009)
Education
Dasar Pengangkatan Surat Keputusan Dewan Direksi No.317/SK-HRD/DIR/XII/21 tanggal 1 Desember 2021
Basis of Appointment Board of Directors Decree No. 317/SK-HRD/DIR/XII/21 dated December 1, 2021
• Manager Internal Audit, PT Millennium Pharmacon International Tbk (2020 – sekarang).
• Deputy Manager Internal Audit, PT Millennium Pharmacon International Tbk (2019 – 2020);
• Assistant Manager Internal Audit, PT Millennium Pharmacon International Tbk (2016 – 2019);
• Supervisor Internal Audit, PT Millennium Pharmacon International Tbk (2013 – 2016);
Pengalaman Kerja • Staff Internal Audit, PT Millennium Pharmacon International Tbk (2011 – 2013);
Work Experience • Internal Audit Manager, PT Millennium Pharmacon International Tbk (2020 – present).
• Deputy Manager of Internal Audit, PT Millennium Pharmacon International Tbk (2019 – 2020);
• Assistant Manager of Internal Audit, PT Millennium Pharmacon International Tbk (2016 – 2019);
• Internal Audit Supervisor, PT Millennium Pharmacon International Tbk (2013 – 2016);
• Internal Audit Staff, PT Millennium Pharmacon International Tbk (2011 – 2013);
Rangkap Jabatan Tidak memiliki rangkap jabatan di luar maupun di Perseroan
Concurrent Position Does not hold concurrent positions either outside the Company or within the Company.
Tidak memiliki hubungan afiliasi, baik dengan anggota Dewan Komisaris lainnya, Direksi, maupun dengan
Hubungan Afiliasi pemegang saham utama dan pengendali.
Affiliation Does not have any affiliation with members of the Board of Commissioners, the Board of Directors, or with the
major and controlling shareholders.
Kualifikasi/Sertifikasi sebagai Qualification/Certification as an
Profesi Audit Internal Internal Audit Professional
Seluruh anggota Unit Audit Internal memiliki sertifikasi All member of Internal Audit Unit holds certifications to
untuk memastikan integritas dan profesionalisme dalam ensure integrity and professionalism in carrying out its
menjalankan tugas mereka. duties.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 177
Page 178
Tata Kelola Perusahaan Positioned for
Good Corporate Governance Profitable Growth
Pelaksanaan Tugas Unit Audit Implementation of Internal
Internal Tahun 2025 Audit Unit Duties in 2025
Pelaksanaan tugas dan fungsi UAI direalisasikan dalam The implementation of UAI’s duties and functions is realized
Program Kerja Audit Tahunan (PKAT) secara terpadu in the Annual Audit Work Program (PKAT) in an integrated
dalam bentuk memberikan pendapat, masukan dan manner in the form of providing opinions, inputs and
pertimbangan maupun jasa konsultasi yang objektif considerations as well as objective consulting services
kepada Manajemen dan Unit Kerja lainnya berkaitan to the Management and other Work Units related to the
dengan fungsi pengawasan yang bersifat independen independent and objective supervisory function.
dan objektif.
Audit Internal memberikan laporan setelah audit The Internal Audit provides a report after the audit is
dilaksanakan dan melaporkan temuan temuannya carried out and reports its findings to the Board of Directors.
kepada Dewan Direksi. Audit Internal juga memberi The Internal Audit also provides a report to the Audit
laporan kepada Komite Audit setiap tiga bulan sekali Committee every three months which is submitted at the
yang dikemukakan pada Rapat Komite Audit dan Rapat- Audit Committee Meeting and subsequent commissioner
rapat komisaris berikutnya. meetings.
Rapat Unit Audit Internal Internal Audit Unit Meetings
Unit Audit Internal wajib menyelenggarakan rapat minimal The Internal Audit Unit is required to hold meetings at
4 (empat) kali dalam setahun. Sepanjang tahun 2025, least 4 (four) times a year. Throughout 2025, the IAU held
UAI melaksanakan 4 (empat) kali rapat bersama Direksi, 4 (four) meetings with the Board of Directors, Board of
Dewan Komisaris, dan Komite Audit. Commissioners, and Audit Committee.
Pelatihan dan/atau Pengembangan Training and/or Development
Unit Audit Internal of the Internal Audit Unit
Perseroan memberikan kesempatan seluas-luasnya The Company provides extensive opportunities for
bagi anggota Unit Audit Internal untuk mengembangkan members of the Internal Audit Unit to develop their
kompetensi dan wawasannya. Para anggota dapat competencies and knowledge. Members may participate
mengikuti berbagai pelatihan, seminar, workshop untuk in various training, seminars, and workshops to enhance
meningkatkan kompetensi, mendapatkan sertifikasi, their skills, obtain certifications, stay updated on the latest
mengetahui perkembangan regulasi terkini, dan regulations, and strengthen the quality of the Company’s
memperkuat kualitas audit Perseroan. audits.
Pelatihan Divisi Audit Internal
Internal Audit Division Training
Nama dan Jabatan Tanggal Program Pelatihan Penyelenggara
Name and Position Date Training Program Organizer
Andre Surya Ragana, Internal 26 Agustus 2025 Excel Untuk Analisis dan Pengelolaan Data
Internal (HR-MPI)
Audit Supervisor August 26, 2025 Excel For Data Analytics and Management
Ro'in Riyadhi Syifak, Internal 26 Agustus 2025 Excel Untuk Analisis dan Pengelolaan Data
Internal (HR-MPI)
Audit Staff August 26, 2025 Excel For Data Analytics and Management
Kafi Kurnia Sujana, Internal 26 Agustus 2025 Excel Untuk Analisis dan Pengelolaan Data
Internal (HR-MPI)
Audit Staff August 26, 2025 Excel For Data Analytics and Management
26 Agustus 2025 Excel Untuk Analisis dan Pengelolaan Data
Satrio, Internal Audit Staff Internal (HR-MPI)
August 26, 2025 Excel For Data Analytics and Management
Amru Suhaimi Sagala, Internal 26 Agustus 2025 Excel Untuk Analisis dan Pengelolaan Data
Internal (HR-MPI)
Audit Staff August 26, 2025 Excel For Data Analytics and Management
M. Agung Dwiadityo, Internal 26 Agustus 2025 Excel Untuk Analisis dan Pengelolaan Data
Internal (HR-MPI)
Audit Staff August 26, 2025 Excel For Data Analytics and Management
Setya Adhi K, Internal Audit 26 Agustus 2025 Excel Untuk Analisis dan Pengelolaan Data
Internal (HR-MPI)
Staff August 26, 2025 Excel For Data Analytics and Management
178 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 179
Positioned for
Profitable Growth
Akuntan Publik
Public Accountant
Perseroan menunjuk Akuntan Publik (AP) dan Kantor The Company appoints independent Public Accountants
Akuntan Publik (KAP) independen untuk melakukan and Public Accounting Firms to audit the Annual Financial
audit atas Laporan Keuangan Tahunan. Penunjukan Statements. This appointment refers to Law No. 5 of 2011
ini mengacu pada Undang-Undang No. 5 Tahun 2011 concerning Public Accountants and the latest regulation,
tentang Akuntan Publik serta regulasi terbaru Peraturan Financial Services Authority Regulation (POJK) No. 9 of 2023
Otoritas Jasa Keuangan (POJK) No. 9 Tahun 2023 tentang on the Use of Public Accountants and Public Accounting
Penggunaan Jasa Akuntan Publik dan Kantor Akuntan Firms in Financial Services Activities. As independent
Publik dalam Kegiatan Jasa Keuangan. Sebagai pihak external parties, Public Accountants are tasked with
eksternal yang independen, Akuntan Publik bertugas providing an objective opinion on the fairness of the
memberikan opini objektif mengenai kewajaran penyajian financial statement presentation and its compliance
laporan keuangan serta kepatuhannya terhadap Standar with the Financial Accounting Standards applicable in
Akuntansi Keuangan (SAK) yang berlaku di Indonesia. Indonesia.
MEKANISME PENUNJUKAN APPOINTMENT MECHANISM
DAN BIAYA AUDIT AND AUDIT FEES
Mekanisme penunjukan Akuntan Publik ditetapkan melalui The appointment of Public Accountants is determined
Rapat Umum Pemegang Saham (RUPS) Tahunan, dengan through the Annual General Meeting of Shareholders
mempertimbangkan rekomendasi dari Dewan Komisaris (AGMS), taking into account recommendations from the
dan Komite Audit. Rekomendasi tersebut didasarkan pada Board of Commissioners and the Audit Committee. These
evaluasi kinerja, independensi, serta kompetensi auditor recommendations are based on an evaluation of the
pada periode sebelumnya. auditor’s performance, independence, and competence
in the previous period.
Berdasarkan keputusan RUPS Tahunan yang Based on the decision of the Annual GMS held on 25 Mei
diselenggarakan pada tanggal 28 Mei 2025, Perseroan 2025, the Company appointed the Public Accounting Firm
menetapkan Kantor Akuntan Publik Tanubrata Sutanto Tanubrata Sutanto Fahmi Bambang & Rekan to audit the
Fahmi Bambang & Rekan untuk mengaudit Laporan Company’s Financial Statements for the fiscal year ending
Keuangan Perseroan untuk tahun buku yang berakhir pada December 31, 2025. The agreed audit fee (professional
31 Desember 2025. Adapun biaya jasa audit (professional fee) is Rp370,000,000., excluding VAT in accordance with
fee) yang disepakati adalah sebesar Rp370.000.000, applicable regulations and operational costs (out-of-
belum termasuk PPN sesuai ketentuan yang berlaku dan pocket expenses).
biaya operasional (out of pocket expenses).
PERIODE AUDIT AUDIT PERIOD
Perseroan mematuhi ketentuan rotasi audit sebagaimana The Company complies with the audit rotation
diatur dalam Pasal 7 POJK No. 9 Tahun 2023, yang requirements as stipulated in Article 7 of POJK No. 9 of
membatasi penggunaan jasa audit atas informasi 2023, which limits the engagement of the same Public
keuangan historis tahunan dari Akuntan Publik (AP) yang Accountant (PA) for auditing annual historical financial
sama paling lama untuk 7 (tujuh) tahun buku secara information to a maximum of 7 (seven) consecutive fiscal
berturut-turut. years.
Hingga tahun buku 2025, Akuntan Publik yang ditunjuk As of the fiscal year 2025, the appointed Public
belum melampaui batas waktu tersebut. Kebijakan ini Accountant has not exceeded this period. This policy is
diterapkan secara disiplin oleh Perseroan guna menjaga strictly implemented by the Company to maintain audit
independensi dan kualitas audit, serta menghindari independence and quality, and to avoid familiarity threats
ancaman keakraban ( familiarity threat ) antara between management and the external auditor.
manajemen dan auditor eksternal.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 179
Page 180
Tata Kelola Perusahaan Positioned for
Good Corporate Governance Profitable Growth
Berikut dibawah ini penjelasan Perusahaan mengenai The following table provides details of the Public
Kantor Akuntan Publik, Nama Akuntan Publik, Fee, dan Accounting Firm, Public Accountant, the audit fees, and
Izin KAP yang mengaudit Laporan Keuangan selama 6 the firm’s license for conducting the Financial Statement
(enam) tahun. audits over the past 6 (six) years.
KAP Ruang Lingku
Tahun Auditor Nilai Jasa Opini
Public Accounting Jasa
Year Auditor Fee Opinion
Firm Scope of Services
Melaksanakan audit laporan
Nanda Tanubrata Sutanto keuangan.
Rp370.000.000 Wajar tanpa pengecualian
2025 Priyatna Fahmi Bambang & Conducting financial statement
audits. Unqualified opinion
Harahap Rekan
Rp370.000.000 Jasa Non-Audit
Melaksanakan audit laporan
Nanda Tanubrata Sutanto
keuangan. Wajar tanpa pengecualian
2024 Priyatna Fahmi Bambang & Rp345.000.000
Conducting financial statement Unqualified opinion
Harahap Rekan
audits.
Melaksanakan audit laporan
Nanda Tanubrata Sutanto
keuangan. Wajar tanpa pengecualian
2023 Priyatna Fahmi Bambang & Rp334.000.000
Conducting financial statement Unqualified opinion
Harahap Rekan
audits.
Melaksanakan audit laporan
Nanda Tanubrata Sutanto
keuangan. Wajar tanpa pengecualian
2022 Priyatna Fahmi Bambang & Rp280.000.000
Conducting financial statement Unqualified opinion
Harahap Rekan
audits.
Melaksanakan audit laporan
Nanda Tanubrata Sutanto
keuangan. Wajar tanpa pengecualian
2021 Priyatna Fahmi Bambang & Rp250.000.000
Conducting financial statement Unqualified opinion
Harahap Rekan
audits.
Melaksanakan audit laporan
Junarto keuangan. Wajar tanpa pengecualian
2020 Tjahjadi & Tamara Rp217.000.000
Tjahjadi Conducting financial statement Unqualified opinion
audits.
Melaksanakan audit laporan
keuangan. Wajar tanpa pengecualian
2019 Riani Tjahjadi & Tamara Rp220.000.000
Conducting financial statement Unqualified opinion
audits.
JASA LAIN YANG DIBERIKAN OTHER SERVICES PROVIDED BY
AKUNTAN PUBLIK THE PUBLIC ACCOUNTANT
Selain jasa audit keuangan, KAP Tanubrata Sutanto Fahmi Apart from financial audit services, Tanubrata Sutanto
Bambang & Rekan juga memberikan jada Non-Audit Fahmi Bambang & Partners also provided a Non-Audit
kepada Perseroan. Guarantee to the Company.
180 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 181
Positioned for
Profitable Growth
Sistem Pengendalian Internal
Internal Control System
Sistem Pengendalian Internal (Internal Control System) The Internal Control System is implemented in an
diterapkan secara terintegrasi di seluruh lini operasional integrated manner across all operational lines of the
Perseroan. Sistem ini dirancang secara komprehensif Company. It is comprehensively designed to provide
untuk memberikan keyakinan yang memadai dalam reasonable assurance in achieving objectives related
mencapai tujuan efektivitas dan efisiensi operasional, to operational efficiency and effectiveness, reliability of
keandalan pelaporan keuangan, serta kepatuhan financial reporting, and compliance with applicable laws
terhadap peraturan perundang-undangan yang berlaku. and regulations. In addition, these controls serve a vital
Selain itu, pengendalian ini berfungsi vital sebagai function as a risk mitigation mechanism to safeguard the
mekanisme mitigasi risiko untuk mengamankan aset Company’s assets and to prevent and detect potential
perusahaan serta mencegah dan mendeteksi potensi fraud at an early stage.
kecurangan (fraud) sejak dini.
TUJUAN PENGENDALIAN OBJECTIVES OF INTERNAL CONTROL
Sistem Pengendalian Internal dibuat untuk mengamankan The Internal Control System is established to safeguard
investasi dan aset yang dimiliki Perseroan. Keberhasilan the Company’s investments and assets. The effectiveness
dari terwujudnya Sistem Pengendalian Internal berada of the Internal Control System is overseen by the Board
di bawah pengawasan Direksi, Dewan Komisaris, dan of Directors, Board of Commissioners, and managers in
Manajer yang menjabat di setiap bidang. charge of each respective area.
MEKANISME TINJAUAN DAN EVALUASI REVIEW AND EVALUATION MECHANISM
Untuk memastikan efektivitasnya, Perseroan menjalankan To ensure its effectiveness, the Company implements a
mekanisme pemantauan berlapis terhadap aspek layered monitoring mechanism covering both financial
keuangan maupun operasional. Evaluasi kinerja dilakukan and operational aspects. Performance evaluations are
melalui Rapat Manajemen bulanan yang membahas conducted through monthly Management Meetings
pencapaian target jangka pendek. Selanjutnya, that review the achievement of short-term targets.
pemantauan strategis dilaksanakan melalui evaluasi Strategic monitoring is further carried out through
triwulanan yang hasilnya dilaporkan kepada Dewan quarterly evaluations, the results of which are reported
Komisaris guna mendapatkan arahan dan rekomendasi to the Board of Commissioners to obtain guidance and
perbaikan. recommendations for improvement.
Unit Audit Internal memegang peran kunci dalam The Internal Audit Unit plays a key role in periodically
menelaah kecukupan implementasi sistem ini secara reviewing the adequacy of this system’s implementation.
berkala. Sepanjang tahun 2025, Unit Audit Internal telah Throughout 2025, the Internal Audit Unit conducted
melakukan evaluasi menyeluruh untuk memastikan bahwa comprehensive evaluations to ensure that the policies and
kebijakan dan prosedur yang dijalankan manajemen procedures implemented by management were effective
efektif dalam memitigasi risiko bisnis. Hasil evaluasi in mitigating business risks. The evaluation results indicate
menunjukkan bahwa Laporan Keuangan Perseroan that the Company’s Financial Statements have been
telah disusun didukung oleh sistem informasi yang andal, prepared using a reliable information system, producing
sehingga menghasilkan informasi yang akuntabel dan accountable and auditable information.
dapat dipertanggungjawabkan (auditable).
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 181
Page 182
Tata Kelola Perusahaan Positioned for
Good Corporate Governance Profitable Growth
PERNYATAAN DIREKSI DAN/ATAU STATEMENT OF THE BOARD OF
DEWAN KOMISARIS ATAS KECUKUPAN DIRECTORS AND/OR BOARD OF
SISTEM PENGENDALIAN INTERNAL COMMISSIONERS ON THE ADEQUACY
OF THE INTERNAL CONTROL SYSTEM
Berdasarkan tinjauan dan evaluasi yang telah Based on the reviews and evaluations conducted
dilaksanakan sepanjang tahun buku 2025, Dewan throughout the fiscal year 2025, the Board of
Komisaris dan Direksi berkeyakinan bahwa Sistem Commissioners and the Board of Directors are confident
Pengendalian Internal Perseroan telah berjalan secara that the Company’s Internal Control System has been
efektif dan memadai. Perseroan berkomitmen untuk terus operating effectively and adequately. The Company is
memutakhirkan sistem pengendalian ini seiring dengan committed to continuously updating this control system
perkembangan skala bisnis dan kompleksitas risiko, guna in line with the growth of its business scale and the
menjaga keberlangsungan usaha dan kepercayaan complexity of risks, in order to ensure business continuity
pemangku kepentingan. and maintain stakeholder trust.
182 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 183
Positioned for
Profitable Growth
Manajemen Risiko
Risk Management
DASAR PELAKSANAAN DAN BASIS OF IMPLEMENTATION
KERANGKA KERJA AND FRAMEWORK
Perseroan menyadari bahwa setiap aktivitas bisnis The Company recognizes that every business activity
mengandung risiko inheren yang dapat memengaruhi carries inherent risks that may affect the achievement
pencapaian tujuan strategis jangka pendek maupun of both short-term and long-term strategic objectives.
jangka panjang. Oleh karena itu, Perseroan menerapkan Therefore, the Company implements an integrated
Sistem Manajemen Risiko yang terintegrasi sebagai Risk Management System as an inseparable part of
bagian tak terpisahkan dari strategi korporasi. Melalui its corporate strategy. With the support of the Risk
dukungan Unit Kerja Manajemen Risiko, Perseroan secara Management Unit, the Company proactively identifies,
proaktif mengidentifikasi, menganalisis, dan memitigasi analyzes, and mitigates key risks to ensure they remain
risiko-risiko kunci agar tetap berada dalam batas toleransi within the established risk appetite.
risiko (risk appetite) yang ditetapkan.
Secara periodik, Perseroan menyusun profil risiko dengan Periodically, the Company prepares a risk profile by
menganalisis faktor internal dan eksternal, termasuk analyzing internal and external factors, including emerging
potensi risiko baru (emerging risks) serta efektivitas risks, as well as the effectiveness of the mitigation
langkah mitigasi yang telah dijalankan, guna menjamin measures implemented, to ensure the sustainability of
kelangsungan usaha yang berkelanjutan. its business operations.
PROFIL RISIKO DAN MITIGASI RISK PROFILE AND MITIGATION
Berdasarkan pemetaan strategi dan kondisi eksternal, Based on strategic mapping and external conditions,
jenis risiko yang dihadapi Perseroan dikelompokkan the types of risks faced by the Company are classified
sebagai berikut: as follows:
Profil dan Upaya Mitigasi Risiko
Risk Profile and Mitigation Efforts
Jenis Risiko Uraian Upaya Mitigasi
Risk Types Description Mitigation Efforts
Risiko Usaha
Business Risk
Sebagai distributor, hubungan
dengan prinsipal adalah aset
Perseroan secara berkesinambungan meninjau ulang perjanjian kerja
vital. Kegagalan dalam menjaga
sama, menjaga kepercayaan melalui pencapaian target penjualan,
Risiko Ketergantungan hubungan ini dapat berdampak
serta menyempurnakan kualitas layanan logistik dan distribusi untuk
pada Prinsipal langsung pada pendapatan.
menjadi mitra pilihan utama bagi prinsipal.
Risk of Dependence on As a distributor, relationships
The Company continuously reviews cooperation agreements, maintains
Principals with principals are a vital
trust by achieving sales targets, and enhances the quality of logistics
asset. Failure to maintain these
and distribution services to remain the preferred partner for principals.
relationships can have a direct
impact on revenue.
Perseroan menerapkan standar Good Distribution Practice (GDP) yang
Risiko kerusakan produk dalam
ketat untuk mencegah kerusakan produk. Terkait obat palsu, Perseroan
distribusi serta maraknya obat
menjamin integritas rantai pasok agar hanya mendistribusikan
palsu dapat menurunkan
Risiko Produk Rusak dan produk asli yang memenuhi syarat Badan POM, sehingga kualitas dan
kepercayaan konsumen dan
Peredaran Obat Palsu keamanan produk terjamin hingga ke tangan pelanggan.
reputasi prinsipal.
Risk of Damaged The Company implements strict Good Distribution Practice (GDP)
The risk of product damage
Products and Circulation standards to prevent product damage. Regarding counterfeit medicines,
during distribution and the
of Counterfeit Medicines the Company ensures the integrity of the supply chain by distributing
prevalence of counterfeit
only genuine products that meet the requirements of the National
medicines can undermine
Agency of Drug and Food Control (BPOM), thereby guaranteeing product
consumer trust and the
quality and safety up to the customer.
reputation of principals.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 183
Page 184
Tata Kelola Perusahaan Positioned for
Good Corporate Governance Profitable Growth
Profil dan Upaya Mitigasi Risiko
Risk Profile and Mitigation Efforts
Jenis Risiko Uraian Upaya Mitigasi
Risk Types Description Mitigation Efforts
Perseroan memonitor tingkat persediaan (inventory level) secara
Kinerja Perseroan dipengaruhi
real-time dan melakukan analisis tren pasar secara cermat untuk
oleh volatilitas harga produk di
Risiko Fluktuasi Harga mengambil keputusan pengadaan yang tepat, guna meminimalisir
pasar.
Risk of Price Fluctuation dampak fluktuasi harga.
The Company’s performance
The Company monitors inventory levels in real time and conducts
is affected by product price
careful market trend analysis to make precise procurement decisions,
volatility in the market.
aiming to minimize the impact of price fluctuations.
Industri distribusi farmasi sangat
kompetitif dengan banyaknya Perseroan memperkuat keunggulan kompetitif melalui sinergi strategis
pemain yang menawarkan dengan produsen, perluasan jaringan distribusi, serta peningkatan
kedalaman produk dan kualitas layanan pelanggan (service level) untuk mempertahankan
Risiko Persaingan Usaha
jangkauan layanan beragam. dan meningkatkan pangsa pasar.
Risk of Business
The pharmaceutical distribution The Company strengthens its competitive advantage through strategic
Competition
industry is highly competitive, synergies with manufacturers, expansion of its distribution network,
with numerous players offering and enhancement of customer service quality to maintain and grow
a wide range of products and market share.
service coverage.
Perseroan secara berkelanjutan berinvestasi pada pembaruan
Keterlambatan dalam
infrastruktur TI dan digitalisasi proses bisnis. Hal ini dilakukan untuk
Risiko Perubahan mengadopsi teknologi dapat
memastikan layanan yang responsif, akurat, dan mampu beradaptasi
Teknologi menghambat efisiensi
dengan dinamika industri farmasi modern.
Risk of Technology operasional.
The Company continuously invests in IT infrastructure upgrades and
Change Delays in adopting technology
business process digitalization. This is done to ensure responsive and
can hinder operational
accurate services that can adapt to the dynamics of the modern
efficiency.
pharmaceutical industry.
Ketergantungan pada SDM Perseroan memandang SDM sebagai aset paling berharga. Strategi
Risiko Kelangkaan yang kompeten merupakan retensi dilakukan melalui pengembangan karir yang jelas, pelatihan
Sumber Daya Manusia tantangan utama dalam berkelanjutan, serta kebijakan remunerasi yang kompetitif berdasarkan
(SDM) menjaga kualitas operasional. analisis pasar.
Risk of Human Resource Dependence on competent The Company views human resources as its most valuable asset.
Shortages human resources is a major Retention strategies are implemented through clear career development,
challenge in maintaining continuous training, and competitive compensation policies based on
operational quality. market analysis.
Risiko Umum
General Risks
Ketidakstabilan ekonomi, inflasi,
dan penurunan daya beli Perseroan secara rutin memantau indikator makroekonomi nasional
Risiko Kondisi masyarakat dapat menekan untuk melakukan penyesuaian strategi penjualan dan efisiensi biaya
Makroekonomi permintaan produk farmasi. operasional guna mempertahankan margin profitabilitas.
Risk of Macroeconomic Economic instability, inflation, The Company routinely monitors national macroeconomic indicators
Conditions and declining consumer to adjust sales strategies and operational cost efficiency in order to
purchasing power can suppress maintain profitability margins.
demand for pharmaceutical
products.
Industri farmasi adalah sektor
yang sarat regulasi (seperti
penetapan HET obat, UU Divisi Legal dan Kepatuhan Perseroan aktif memantau perubahan
Perlindungan Konsumen, dan regulasi dan memastikan seluruh kegiatan usaha selaras dengan
Risiko Regulasi
lain-lain). peraturan perundang-undangan yang berlaku untuk menghindari
Pemerintah
The pharmaceutical industry sanksi administratif maupun hukum.
Risk of Government
is a highly regulated sector, The Company’s Legal and Compliance Division actively monitors
Regulation
including regulations such as regulatory changes and ensures that all business activities comply
the determination of maximum with applicable laws and regulations to avoid administrative or legal
retail prices (HET) for medicines, sanctions.
the Consumer Protection Law,
and others.
Sengketa hukum terkait produk
atau perjanjian kerja sama Perseroan mengedepankan prinsip kehati-hatian dalam setiap
dapat berdampak material perikatan kontrak. Saat ini, Perseroan tidak terlibat dalam sengketa
terhadap reputasi dan hukum material. Namun, Perseroan tetap menyiagakan tim hukum
Risiko Hukum (Litigasi)
keuangan. yang kompeten untuk menangani potensi sengketa di masa depan.
Legal Risk (Litigation)
Legal disputes related to The Company upholds the principle of prudence in all contractual
products or partnership engagements. Currently, the Company is not involved in any material
agreements can have a material legal disputes. However, it maintains a competent legal team ready to
impact on both reputation and address potential disputes in the future.
finances.
184 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 185
Positioned for
Profitable Growth
Profil dan Upaya Mitigasi Risiko
Risk Profile and Mitigation Efforts
Jenis Risiko Uraian Upaya Mitigasi
Risk Types Description Mitigation Efforts
Risiko Keuangan
Financial Risk
Perseroan menerapkan kebijakan Know Your Customer (KYC) dan
Risiko gagal bayar dari analisis kredit yang ketat sebelum memberikan termin pembayaran,
pelanggan (piutang usaha) serta melakukan penagihan secara disiplin dan pemantauan umur
Risiko Kredit dapat mengganggu arus kas. piutang secara berkala.
Credit Risk Risk of customer default The Company implements strict Know Your Customer (KYC) and
(accounts receivable) can credit analysis policies before granting payment terms, and conducts
disrupt cash flow. disciplined collections along with regular monitoring of accounts
receivable aging.
Bagian Keuangan melakukan proyeksi arus kas (cash flow projection)
Kegagalan memenuhi
secara harian dan bulanan untuk memastikan ketersediaan dana
kewajiban jangka pendek dapat
operasional, serta menjaga fasilitas kredit perbankan yang memadai
Risiko Likuiditas mengganggu operasional.
sebagai penyangga likuiditas.
Liquidity Risk Failure to meet short-term
The Finance Division prepares daily and monthly cash flow projections to
obligations can disrupt
ensure the availability of operational funds, while maintaining adequate
operations.
banking credit facilities as a liquidity buffer.
Eksposur terhadap pinjaman
Perseroan berupaya memperoleh tingkat suku bunga yang kompetitif
dengan bunga mengambang
dari kreditur dan mengelola bauran utang secara bijak sesuai dengan
(floating rate) dapat
Risiko Suku Bunga kapasitas arus kas perusahaan.
memengaruhi beban keuangan.
Interest Rate Risk The Company strives to secure competitive interest rates from lenders
Exposure to loans with floating
and manages its debt mix prudently in accordance with the Company’s
interest rates can affect financial
cash flow capacity.
expenses.
EVALUASI DAN PERNYATAAN EVALUATION AND THE BOARD
DIREKSI ATAS KECUKUPAN OF DIRECTORS’ STATEMENT ON
SISTEM MANAJEMEN RISIKO THE ADEQUACY OF THE RISK
MANAGEMENT SYSTEM
Perseroan telah melaksanakan evaluasi menyeluruh The Company has conducted a comprehensive evaluation
terhadap efektivitas penerapan Sistem Manajemen Risiko of the effectiveness of the Risk Management System
sepanjang tahun 2025. Evaluasi ini mencakup tinjauan throughout 2025. This evaluation covered the review of risk
atas identifikasi risiko, ketepatan langkah mitigasi, serta identification, the appropriateness of mitigation measures,
efisiensi prosedur pengelolaan risiko. and the efficiency of risk management procedures.
Berdasarkan hasil evaluasi tersebut, Direksi menyatakan Based on the results of this evaluation, the Board of
bahwa Sistem Manajemen Risiko yang diterapkan Directors affirms that the Risk Management System
Perseroan sepanjang tahun buku 2025 telah berjalan implemented by the Company during the fiscal year 2025
secara memadai dan efektif. Perseroan berkomitmen has operated adequately and effectively. The Company
untuk terus menyempurnakan sistem ini guna is committed to continuously improving this system to
menghadapi tantangan bisnis yang dinamis di masa address the dynamic business challenges of the future.
mendatang.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 185
Page 186
Tata Kelola Perusahaan Positioned for
Good Corporate Governance Profitable Growth
Perkara Hukum
Legal Matters
Dampak terhadap
Para Pihak Pokok Perkara Status Penyelesaian
No Perusahaan
Parties Subject Matter Settlement Status
Impact on the Company
Perdata
Civil
Penggugat: Yuni Arriyani
(Karyawan MPI) Tidak berdampak signifikan
Perkara Hubungan Dalam proses penyelesaian di PN
Plaintiff: Yuni Arriyani (MPI terhadap bisnis Perseroan.
Industrial Jakarta Pusat.
1 Employee) It does not have a significant
Industrial Relations In the process of settlement at the
impact on the Company’s
Dispute Central Jakarta District Court.
Tergugat: MPI business.
Defendant: MPI
Penggugat: WRP Law Office Tidak berdampak signifikan
Dalam proses penyelesaian di PN
Plaintiff: WRP Law Office Gugatan wanprestasi terhadap bisnis Perseroan.
Jakarta Pusat.
2 Breach of Contract It does not have a significant
In the process of settlement at the
Tergugat: MPI Lawsuit impact on the Company’s
Central Jakarta District Court.
Defendant: MPI business.
Dampak terhadap
Para Pihak Pokok Perkara Status Penyelesaian
No Perusahaan
Parties Subject Matter Settlement Status
Impact on the Company
Pidana
Criminal
Pelapor: MPI
Penyalahgunaan
Complainant: MPI
fasilitas dan dana Tidak berdampak signifikan
Dalam proses sesuai mekanisme
Perseroan terhadap bisnis Perseroan.
Terlapor: Yuni Arriyani yang berlaku.
1 Misuse of the It does not have a significant
(Karyawan MPI) In the process according to the
Company’s impact on the Company’s
Reported Party: Yuni Arriyani applicable mechanism.
facilities and business.
(MPI Employee)
funds
Laporan palsu
Pelapor: Yuni Arriyani
kepada otoritas
(Karyawan MPI)
pada sidang
Complainant: Yuni Arriyani
tripartit Disnaker
(MPI Employee) Tidak berdampak signifikan
Jakarta Selatan Dalam proses sesuai mekanisme
terhadap bisnis Perseroan.
False report to yang berlaku.
2 Terlapor: MPI Tbk dan Bapak It does not have a significant
the authorities In the process according to the
Ahmad bin Abu Bakar (Direksi impact on the Company’s
at the tripartite applicable mechanism.
MPI) business.
session of the
Reported Party: MPI Tbk and Mr.
South Jakarta
Ahmad bin Abu Bakar (Board of
Department of
Directors of MPI)
Manpower.
Informasi Sanksi Administrasi
Administrative Sanctions
Hingga akhir tahun 2025, Perseroan tidak menerima sanksi As of the end of 2025, the Company did not receive any
administratif dari otoritas terkait, seperti OJK atau otoritas/ administrative sanctions from relevant authorities, such as
regulator lainnya. the Financial Services Authority (OJK) or other regulatory
bodies.
186 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 187
Positioned for
Profitable Growth
Akses Informasi dan Data Perseroan
Access to Company Information and Data
Undang-Undang Nomor 8 Tahun 1995 tentang Law No. 8 of 1995 concerning the Capital Market (Capital
Pasar Modal (UU Pasar Modal) mengatur mengenai Market Law) regulates information disclosure and
keterbukaan informasi dan kewajiban pelaporan reporting obligations for Issuers and Public Companies.
bagi Emiten dan Perusahaan Publik. Undang-undang The law defines the Principle of Transparency as a general
tersebut mendefinisikan Prinsip Keterbukaan sebagai guideline requiring Issuers, Public Companies, or other
suatu pedoman umum yang mewajibkan Emiten dan relevant parties to disclose all Material Information
Perusahaan Publik atau pihak lain yang disebutkan agar regarding their business or securities that may influence
mengungkapkan seluruh Informasi Material mengenai investors’ decisions.
usaha atau Efeknya yang dapat berpengaruh pada
keputusan pemodal atau investor.
Website Perseroan beralamat di www.mpi-indonesia. The Company’s website, accessible at www.mpiindonesia.
co.id, yang tersaji dalam dua bahasa, yaitu bahasa co.id, is available in both English and Indonesian and
Inggris dan bahasa Indonesia, disertai sistem navigasi features a navigation system to facilitate stakeholders in
untuk memudahkan para pemangku kepentingan dalam accessing information. The website is regularly updated
mencari informasi. Website senantiasa diperbaharui as part of the Company’s commitment to information
secara periodik sebagai bentuk keterbukaan informasi transparency and in compliance with POJK No. 8/
di Perusahaan dan pemenuhan POJK No. 8/POJK.04/2015 POJK.04/2015 concerning Websites of Public Companies
tentang Situs Web Perusahaan Publik dan Emiten. and Issuers.
Dengan tersedianya website Perusahaan sebagai sarana By providing the Company’s website for information
keterbukaan informasi tentang Perusahaan, diharapkan disclosure, the Company aims to strengthen transparency
akan meningkatkan kepercayaan masyarakat luas serta and foster trust among the public and its Shareholders.
tentunya Pemegang Saham. Melalui situs web tersebut, Through this website, all stakeholders can access
seluruh pemangku kepentingan dapat memperoleh information regarding:
informasi mengenai:
Informasi Link Situs Web MPI
Information Website Link
Sejarah Perusahaan https://www.mpi-indonesia.co.id/index.php/
Company History about
Tata Kelola Perusahaan https://www.mpi-indonesia.co.id/index.php/
Corporate Governance about
Informasi Rapat Umum Pemegang Saham
(RUPS) https://www.mpi-indonesia.co.id/index.php/
Information on the General Meeting of room/rups
Shareholders (GMS)
Laporan Keuangan https://www.mpi-indonesia.co.id/index.php/
Financial Report room/pelaporan
Laporan Tahunan dan Keberlanjutan https://www.mpi-indonesia.co.id/index.php/
Annual and Sustainability Report room/pelaporan
Profil Dewan Komisaris dan Direksi
https://www.mpi-indonesia.co.id/index.php/
Profile of Board of Commissioners and Board
room/room-list
of Directors
Piagam Dewan Komisaris, Direksi, Komite dan
Unit Audit Internal.
https://www.mpi-indonesia.co.id/index.php/
Charter of the Board of Commissioners, Board
room/room-details
of Directors, Committees, and Internal Audit
Unit.
Tanggung Jawab Sosial Perusahaan https://www.mpi-indonesia.co.id/index.
Corporate Social Responsibility (CSR) php/berita
Berita dan Acara https://www.mpi-indonesia.co.id/index.
News and Events php/berita
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 187
Page 188
Tata Kelola Perusahaan Positioned for
Good Corporate Governance Profitable Growth
Untuk mendapatkan informasi lebih lanjut, pemegang For further information, stakeholders may contact the
kepentingan dapat menghubungi Corporate Secretary/ Company’s Corporate Secretary/Investor Relations by
Investor Relations Perseroan dengan mengirim email ke: sending an email to:
investor.relation@mpi-pharmaniaga.co.id atau telepon investor.relation@mpi-pharmaniaga.co.id or by calling
ke (62-21) 2708-5961, 64, 65, 66. (62-21) 2708-5961, 64, 65, 66.
Kode Etik
Code of Conduct
Perseroan telah menetapkan Kode Etik (Code of Conduct) The Company has established a Code of Conduct,
yang menjadi salah satu pilar utama penegakan tata which serves as a key pillar in upholding good corporate
kelola perusahaan yang baik. Kode etik mengikat seluruh governance. The code applies to all levels of the
level organisasi dan berfungsi sebagai kompas moral organization and functions as a moral compass guiding
yang membimbing standar perilaku profesional. professional behavior standards.
POKOK-POKOK KODE ETIK KEY POINTS OF THE CODE OF CONDUCT
Pokok-pokok Kode Etik mencakup dua dimensi utama: The Code of Conduct encompasses two primary
dimensions:
1. Etika Bisnis: Mengatur interaksi Perseroan dengan 1. Business Ethics: Governing the Company’s interactions
pemangku kepentingan eksternal secara adil dan with external stakeholders in a fair and transparent
transparan. manner.
2. Etika Kerja: Mengatur norma perilaku internal antar- 2. Work Ethics: Regulating internal behavioral norms
individu di lingkungan kerja untuk menciptakan among individuals in the workplace to foster a culture
budaya yang saling menghormati dan produktif. of mutual respect and productivity.
PERNYATAAN PEMBERLAKUAN STATEMENT OF IMPLEMENTATION
DAN SOSIALISASI AND DISSEMINATION
Kepatuhan terhadap Kode Etik bersifat mutlak bagi seluruh Compliance with the Code of Conduct is mandatory
insan Perseroan, mulai dari Dewan Komisaris, Direksi, for all members of the Company, from the Board of
hingga seluruh karyawan tetap maupun tidak tetap Commissioners and Board of Directors to all permanent
agar nilai-nilai tersebut dipahami sepenuhnya. Perseroan and non-permanent employees, to ensure these values
melakukan sosialisasi secara berkala melalui saluran are fully understood. The Company conducts regular
komunikasi internal (email dan portal perusahaan) serta awareness programs through internal communication
menjadikannya materi wajib dalam program orientasi channels (email and company portal) and includes the
bagi setiap pegawai baru. Code as a mandatory component of the orientation
program for all new employees.
188 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 189
Positioned for Profitable Growth UPAYA PENEGAKAN DAN ENFORCEMENT EFFORTS PAKTA INTEGRITAS AND INTEGRITY PACT Sebagai upaya nyata penegakan kode etik, Perseroan As a concrete measure to enforce the Code of Conduct, mewajibkan seluruh jajaran manajemen dan karyawan the Company requires all management and employees untuk menandatangani Pakta Integritas sebagai wujud to sign an Integrity Pact as a formal demonstration of their komitmen formal. Secara spesifik, Direksi dan Dewan commitment. Specifically, the Board of Directors and Board Komisaris juga menandatangani Kontrak Manajemen of Commissioners also sign a Management Contract at di awal tahun yang memuat komitmen terhadap praktik the beginning of each year, which includes a commitment bisnis bersih. Perseroan menerapkan sanksi tegas to clean business practices. The Company imposes strict terhadap setiap ketidakpatuhan sesuai dengan peraturan sanctions for any non-compliance in accordance with perusahaan yang berlaku. applicable company regulations. JUMLAH PELANGGARAN NUMBER OF CODE OF CONDUCT KODE ETIK DAN SANKSI YANG VIOLATIONS AND SANCTIONS IN 2025 DIBERIKAN PADA TAHUN 2025 Perseroan menerapkan kebijakan toleransi nol The Company implements a zero-tolerance policy toward (zero tolerance policy) terhadap pelanggaran etika. ethical violations. Based on monitoring conducted by the Berdasarkan pemantauan yang dilakukan oleh Unit Compliance and Internal Audit Units throughout the fiscal Kepatuhan dan Audit Internal sepanjang tahun buku year 2025, no reports or incidents of Code of Conduct 2025, tidak ditemukan adanya laporan maupun insiden violations were identified within the Company. pelanggaran terhadap Kode Etik di lingkungan Perseroan. PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 189
Page 190
Tata Kelola Perusahaan Positioned for
Good Corporate Governance Profitable Growth
Kebijakan Pengungkapan Informasi
Kepemilikan Saham Anggota Direksi dan Anggota
Dewan Komisaris
Policy on Disclosure of Information on Share Ownership of
Members of the Board of Directors and Members
of the Board of Commissioners
Perseroan menerapkan kebijakan transparansi terkait The Company implements a transparency policy
kepemilikan saham oleh Manajemen, dengan mengacu regarding share ownership by Management, referring to
pada POJK No. 4 Tahun 2024 tentang Laporan Kepemilikan POJK No. 4 of 2024 on Reports of Share Ownership or Any
atau Setiap Perubahan Kepemilikan Saham Perusahaan Changes in Share Ownership of Public Companies and
Terbuka dan Laporan Aktivitas Menjaminkan Saham Reports on Pledging Activities of Public Company Shares.
Perusahaan Terbuka.
Sesuai dengan ketentuan tersebut, Perseroan In accordance with these provisions, the Company
mewajibkan setiap anggota Direksi dan Dewan Komisaris requires each member of the Board of Directors and Board
untuk melaporkan kepemilikan saham serta setiap of Commissioners to report their share ownership and any
perubahannya kepada Otoritas Jasa Keuangan (OJK) changes therein to the Financial Services Authority (OJK)
paling lambat 5 (lima) hari kerja setelah terjadinya no later than 5 (five) Business Days after the transaction,
transaksi atau 3 (tiga) hari kerja apabila laporan or within 3 (three) business days if the report is submitted
disampaikan melalui sistem pelaporan elektronik OJK. through OJK’s electronic reporting system. To ensure
Guna memastikan kepatuhan pelaporan yang tepat timely and accurate reporting compliance, the Corporate
waktu dan akurat, Sekretaris Perusahaan bertugas Secretary is responsible for facilitating the administration
memfasilitasi administrasi pelaporan tersebut. of these reports.
Berdasarkan data pemegang saham per 31 Desember Based on shareholder data as of December 31, 2025,
2025, tercatat bahwa tidak ada anggota Direksi maupun no members of the Board of Directors or Board of
anggota Dewan Komisaris yang memiliki saham Commissioners hold shares in the Company, either directly
Perseroan, baik secara langsung maupun tidak langsung. or indirectly.
190 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 191
Positioned for
Profitable Growth
Kebijakan Pemberian Kompensasi Jangka Panjang
Berbasis Kinerja kepada Manajemen dan/atau
Karyawan
Policy on Performance-Based Long-Term Compensation for
Management and/or Employees
Hingga akhir tahun 2025, Perseroan tidak memiliki As of the end of 2025, the Company does not have a policy
kebijakan terkait kompensasi jangka panjang berbasis regarding performance-based long-term compensation.
kinerja. Perusahaan juga tidak melaksanakan Program The Company also does not implement any Stock Option
Opsi Kepemilikan Saham baik oleh Manajemen atau Programs, either for Management (Management Stock
Management Stock Option Program (MSOP) maupun Option Program/MSOP) or for Employees (Employee Stock
oleh Karyawan atau Employee Stock Option Program Option Program/ESOP), as a form of performance-based
(ESOP) untuk pemberian kompensasi jangka panjang long-term compensation.
berbasis kinerja.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 191
Page 192
Tata Kelola Perusahaan Positioned for
Good Corporate Governance Profitable Growth
Sistem Pelaporan Pelanggaran [2-25]
Whistleblowing System
Perseroan telah menerapkan Sistem Pelaporan The Company has implemented a Whistleblowing System
Pelanggaran (Whistleblowing System/WBS) sebagai (WBS) as a channel for employees and/or stakeholders to
sarana bagi insan Perseroan dan/atau pemangku report suspected violations occurring within the Company.
kepentingan untuk menyampaikan laporan atas dugaan The WBS serves as an early warning mechanism to detect
pelanggaran yang terjadi di lingkungan Perseroan. WBS indications of irregularities at an early stage, supports the
berfungsi sebagai mekanisme early warning untuk enforcement of the Code of Conduct and compliance,
mendeteksi indikasi penyimpangan sejak dini, mendukung and reinforces the implementation of good corporate
penegakan kode etika dan kepatuhan, serta memperkuat governance.
penerapan tata kelola perusahaan yang baik.
RUANG LINGKUP PELAPORAN SCOPE OF REPORTING
WBS mencakup pelaporan atas dugaan pelanggaran, The WBS covers reports of suspected violations,
termasuk namun tidak terbatas pada pelanggaran Kode including but not limited to breaches of the Code of
Etik (Etika Bisnis dan Etika Kerja), ketentuan Anggaran Conduct (Business Ethics and Work Ethics), the Articles
Dasar, benturan kepentingan, penyalahgunaan of Association, conflicts of interest, abuse of authority,
wewenang, kecurangan (fraud), pelanggaran terhadap fraud, violations of agreements/contracts with external
perjanjian/kontrak dengan pihak eksternal, pelanggaran parties, breaches of information confidentiality, and non-
kerahasiaan informasi, serta ketidakpatuhan terhadap compliance with applicable laws and regulations.
peraturan perundang-undangan yang berlaku.
MEKANISME PELAPORAN PELANGGARAN WHISTLEBLOWING REPORTING
MECHANISM
Perseroan menyediakan kanal pelaporan untuk The Company provides reporting channels to facilitate
memudahkan penyampaian pengaduan, antara lain the submission of complaints, including:
melalui:
1. Pengisian formulir pelaporan online yang dapat 1. Completing an online reporting form accessible by
diakses melalui pemindaian kode QR pada situs web scanning the QR code on the Company’s website.
Perseroan.
Agar laporan dapat ditindaklanjuti secara memadai, To ensure that reports can be adequately addressed,
pelapor diharapkan menyampaikan informasi sekurang- whistleblowers are expected to provide information that
kurangnya memuat: includes at a minimum:
1. Fakta pelanggaran 1. Facts of the violation
2. Nama terlapor 2. Name of the reported individual
3. Cara melakukan pelanggaran 3. Method by which the violation occurred
4. Waktu dan tempat terjadinya pelanggaran 4. Time and place of the violation
Kelengkapan informasi adalah untuk memastikan Providing complete information ensures that reports are
bahwa laporan dilakukan dengan itikad baik dan dapat made in good faith and can be properly verified.
dipertanggungjawabkan.
192 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 193
Positioned for
Profitable Growth
PERLINDUNGAN BAGI PELAPOR PROTECTION FOR WHISTLEBLOWERS
Perseroan memberikan perlindungan kepada pelapor The Company provides protection for whistleblowers
yang beritikad baik, termasuk perlindungan dari tindakan acting in good faith, including protection from retaliation,
pembalasan, ancaman, intimidasi, maupun perlakuan threats, intimidation, or any adverse treatment. The
yang merugikan. Perseroan menjaga kerahasiaan Company ensures the confidentiality of the whistleblower’s
identitas pelapor dan isi laporan, serta memberikan identity and the content of the report, and provides
perlindungan yang layak kepada pelapor dan/atau appropriate protection to the whistleblower and/or any
pihak yang menjadi saksi. Perlindungan juga berlaku witnesses. Protection also extends to WBS administrators,
bagi pengelola WBS, pihak yang melakukan investigasi, investigators, and parties providing information during the
serta pihak yang memberikan informasi dalam proses complaint handling process. If necessary, the Company
penanganan pengaduan. Apabila diperlukan, Perseroan will seek legal protection in accordance with applicable
mengupayakan perlindungan hukum sesuai ketentuan laws and regulations.
peraturan perundang-undangan.
Perlindungan yang diberikan bagi pelapor meliputi: Protections provided to whistleblowers include:
1. Jaminan atas kerahasiaan identitas pelapor 1. Assurance of the confidentiality of the whistleblower’s
(whistleblower). identity.
2. Jaminan kerahasiaan atas isi laporan. 2. Assurance of the confidentiality of the report content.
3. Jaminan atas perlindungan kemungkinan adanya 3. Assurance of protection against potential threats,
tindakan ancaman, intimidasi, hukuman, ataupun intimidation, punishment, or any other unpleasant
tindakan tidak menyenangkan lainnya. actions.
4. Apabila diperlukan Perseroan juga mengupayakan 4. If necessary, the Company will also seek legal
perlindungan hukum kepada pelapor yang beritikad protection for whistleblowers acting in good faith, in
baik sebagaimana ketentuan yang diatur peraturan accordance with applicable laws and regulations.
perundang-undangan.
PIHAK PENGELOLA DAN COMPLAINT MANAGEMENT
PENANGANAN PENGADUAN AND HANDLING PARTIES
Pengaduan yang memenuhi persyaratan ditindaklanjuti Complaints that meet the required criteria are followed
oleh Komite Audit dan dipantau secara berkala. Perseroan up by the Audit Committee and monitored regularly. The
melakukan penelaahan awal atas setiap laporan yang Company conducts an initial review of each incoming
masuk dan, apabila diperlukan, membentuk tim investigasi report and, if necessary, establishes a neutral investigation
yang netral sesuai jenis pelanggaran. Hasil investigasi team appropriate to the type of violation. The results of
beserta bukti pendukung disampaikan kepada Direksi the investigation, along with supporting evidence, are
untuk penetapan tindakan perbaikan dan/atau sanksi submitted to the Board of Directors for determination of
sesuai ketentuan internal yang berlaku. corrective actions and/or sanctions in accordance with
applicable internal regulations.
HASIL PENANGANAN PENGADUAN COMPLAINT HANDLING RESULTS
Selama periode tahun 2025, tidak terdapat pelaporan Throughout 2025, the Company did not receive any reports
kasus pelanggaran yang terjadi di dalam Perseroan. of internal violations.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 193
Page 194
Tata Kelola Perusahaan Positioned for
Good Corporate Governance Profitable Growth
Kebijakan Anti Korupsi dan Anti Gratifikasi [205-2]
Anti-Corruption and Anti-Gratification Policy
Perseroan menegakkan prinsip tata kelola perusahaan The Company upholds the principles of good corporate
yang baik serta persaingan usaha yang sehat dengan governance and fair business competition by maintaining
menjunjung integritas, profesionalisme, dan keadilan. integrity, professionalism, and fairness. This commitment
Komitmen tersebut diwujudkan melalui penegakan is realized through the enforcement of anti-corruption
kebijakan anti korupsi dan anti gratifikasi untuk mencegah and anti-gratification policies to prevent practices of
praktik Korupsi, Kolusi, dan Nepotisme (KKN), memitigasi Corruption, Collusion, and Nepotism (KKN), mitigate
benturan kepentingan, serta menjaga lingkungan kerja conflicts of interest, and maintain an ethical work
dan hubungan usaha yang beretika. environment and business relationships.
Kebijakan anti korupsi Perseroan mengacu pada The Company’s anti-corruption policy refers to applicable
ketentuan peraturan perundang-undangan yang berlaku, laws and regulations, including Law No. 20 of 2001
termasuk Undang-Undang No. 20 Tahun 2001 tentang concerning Amendments to Law No. 31 of 1999 on the
Perubahan atas Undang-Undang No. 31 Tahun 1999 Eradication of Corruption Crimes, and incorporates best
tentang Pemberantasan Tindak Pidana Korupsi, serta practices, including the principles outlined in ISO 37001:2016
mempertimbangkan praktik terbaik, termasuk prinsip- on Anti-Bribery Management Systems.
prinsip dalam ISO 37001:2016 tentang Sistem Manajemen
Anti Penyuapan.
SOSIALISASI KEBIJAKAN ANTI ANTI-CORRUPTION AND
KORUPSI DAN GRATIFIKASI GRATIFICATION POLICY AWARENESS
Untuk memastikan kebijakan ini dipahami dan dijalankan To ensure that this policy is understood and implemented
di seluruh jenjang organisasi, Perseroan melakukan across all levels of the organization, the Company actively
sosialisasi dan komunikasi secara aktif dan berkala. and regularly conducts awareness and communication
Saluran komunikasi yang digunakan meliputi situs web programs. Communication channels include the internal
internal, pemasangan banner edukasi di area kerja, serta website, educational banners in the workplace, and
penyebaran informasi melalui email blast. information dissemination via email blasts.
Sepanjang tahun buku 2025, sosialisasi mengenai Throughout the fiscal year 2025, awareness programs
Kebijakan Anti Korupsi dan Anti Gratifikasi telah on the Anti-Corruption and Anti-Gratification Policy
dilaksanakan secara menyeluruh kepada seluruh insan were comprehensively conducted for all members of
Perseroan, mencakup Dewan Komisaris, Direksi, hingga the Company, including the Board of Commissioners,
seluruh karyawan, guna menanamkan budaya integritas Board of Directors, and all employees, to instill a culture
dalam setiap aktivitas bisnis. of integrity in every business activity.
Pemenuhan Rekomendasi Pedoman Tata Kelola Perusahaan Terbuka
Fulfillment of Recommendations for Public Company Governance Guidelines
Aspek Prinsip Rekomendasi Pelaksanaan
Aspect Principles Recommendation Implementation
Perusahaan Terbuka memiliki cara
Hubungan Perusahaan atau prosedur teknis pengumpulan
Terbuka dengan Pemegang Prinsip 1: suara (voting) baik secara
Saham Dalam Menjamin Meningkatkan Nilai terbuka maupun tertutup yang
Hak-Hak Pemegang Saham Penyelenggaraan RUPS mengedepankan independensi, dan
1.1 Terpenuhi (comply).
Relationship of Public Principle 1: kepentingan pemegang saham.
Company with the Improving the Value of GMS Public Company has technical
Shareholders in Ensuring Convention procedures for opened or closed
the Shareholders’ Rights voting that promote independency
nd shareholders’ interest.
194 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 195
Positioned for
Profitable Growth
Pemenuhan Rekomendasi Pedoman Tata Kelola Perusahaan Terbuka
Fulfillment of Recommendations for Public Company Governance Guidelines
Aspek Prinsip Rekomendasi Pelaksanaan
Aspect Principles Recommendation Implementation
Seluruh anggota Direksi dan anggota
Dewan Komisaris Perusahaan Terbuka
hadir dalam RUPST.
1.2 Terpenuhi (comply).
All members of the Board of Directors
and Board of Commissioners are
present at AGMS.
Ringkasan risalah RUPS tersedia
dalam situs web Perusahaan Terbuka
paling sedikit selama 1 (satu) tahun.
1.3 Terpenuhi (comply).
Summary of GMS minutes is available
on Public Company’s website by no
less than 1 (one) year.
Perusahaan Terbuka memiliki suatu
Prinsip 2: kebijakan komunikasi dengan
Meningkatkan Kualitas 2.1 pemegang saham atau investor. Terpenuhi (comply).
komunikasi Perusahaan Public company has a communication
Terbuka dengan policy with shareholders or investors.
Pemegang Saham atau
Investor Perusahaan Terbuka mengungkapkan
Principle 2: kebijakan komunikasi Perusahaan
Improving Communication Terbuka dengan pemegang saham
Quality of Public Company 2.2 atau investor dalam Situs Web. Terpenuhi (comply).
with Shareholders or Public Company discloses its
Investors. communication policy with
shareholders or investors in Website.
Penentuan jumlah anggota Dewan
Komisaris mempertimbangkan
kondisi Perusahaan Terbuka.
3.1 Determination of number of Board Terpenuhi (comply).
Prinsip 3: Memperkuat of Commissioners member shall
Keanggotaan dan consider the condition of Public
Komposisi Dewan Company.
Komisaris
Principle 3: Penentuan komposisi anggota
Strengthening the Dewan Komisaris memperhatikan
Membership and keberagaman keahlian,
Composition of Board of pengetahuan dan pengalaman yang
Fungsi dan Peran Dewan Commissioners 3.2 dibutuhkan. Terpenuhi (comply).
Komisaris Determination of Composition of
Board of Commissioners Board of Commissioners member
Function and Role considers the variety of expertise,
knowledge, and experiences required.
Prinsip 4:
Meningkatkan Kualitas Dewan Komisaris mempunyai
Pelaksanaan Tugas kebijakan Penilaian sendiri ( self
dan Tanggung Jawab assessment) untuk menilai kinerja
Dewan Komisaris Dewan Komisaris.
4.1 Terpenuhi (comply).
Principle 4: The Board of Commissioners has
Improving the Quality of self assessment policy to assess
Job and Responsibility the performance of the Board of
Performance of Board of Commissioners .
Commissioners
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 195
Page 196
Tata Kelola Perusahaan Positioned for
Good Corporate Governance Profitable Growth
Pemenuhan Rekomendasi Pedoman Tata Kelola Perusahaan Terbuka
Fulfillment of Recommendations for Public Company Governance Guidelines
Aspek Prinsip Rekomendasi Pelaksanaan
Aspect Principles Recommendation Implementation
Kebijakan Penilaian sendiri ( self-
assessment) untuk menilai kinerja
Dewan Komisaris, diungkapkan
melalui Laporan Tahunan Perusahaan
Terpenuhi (comply).
4.2 Terbuka.
Self-assessment policy to assess
the performance of the Board of
Commissioners is disclosed in Annual
Report of the Public Company.
Dewan Komisaris mempunyai
kebijakan terkait pengunduran diri
anggota Dewan Komisaris apabila
terlibat dalam kejahatan keuangan. Terpenuhi (comply).
4.3
The Board of Commissioners has a
policy with respect to the resignation
of the member of the BoC if such
member is involved in financial crime.
Dewan Komisaris atau Komite yang
menjalankan fungsi Nominasi dan
Remunerasi menyusun kebijakan
suksesi dalam proses Nominasi
Terpenuhi (comply).
anggota Direksi.
4.4 .
The Board of Commissioners or
Committee that conduct Nomination
and Remuneration function arrange
succession policy in Nomination
process of Directors member.
Penentuan jumlah anggota Direksi
mempertimbangkan kondisi
Perusahaan Terbuka serta efektivitas
dalam pengambilan keputusan. Terpenuhi (comply).
5.1
Determination of Number of Board
of Directors members considers the
condition of a Public Company and
the effectiveness of decision-making.
Penentuan komposisi anggota Direksi
Prinsip 5: Memperkuat
memperhatikan,
Keanggotaan dan
keberagaman, keahlian,
Komposisi Direksi
Fungsi dan Peran Direksi pengetahuan, dan pengalaman
Principle 5: Terpenuhi (comply).
Board of Directors Function 5.2 yang dibutuhkan.
Strengthening the
and Role Determination of composition of
Membership and
Board of Directors members considers
Composition of the Board
the variety of expertise, knowledge,
of Directors
and experiences required.
Anggota Direksi yang membawahi
bidang akuntansi atau keuangan
memiliki keahlian dan/atau
pengetahuan di bidang akuntansi. Terpenuhi (comply).
5.3
Members of the Board of Directors
who are liable for accounting or
finance have accounting expertise
and/or knowledge.
196 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 197
Positioned for
Profitable Growth
Pemenuhan Rekomendasi Pedoman Tata Kelola Perusahaan Terbuka
Fulfillment of Recommendations for Public Company Governance Guidelines
Aspek Prinsip Rekomendasi Pelaksanaan
Aspect Principles Recommendation Implementation
Direksi mempunyai kebijakan
penilaian sendiri (self assessment)
untuk menilai kinerja Direksi. Terpenuhi (comply).
6.1
The Board of Directors has a self-
assessment policy to assess
performance of Directors.
Kebijakan penilaian sendiri ( self
Prinsip 6:
assessment) untuk menilai kinerja
Meningkatkan Kualitas
Direksi diungkapkan melalui laporan
Pelaksanaan Tugas dan
6.2 tahunan Perusahaan Terbuka. Terpenuhi (comply).
Tanggung Jawab Direksi
Self-assessment policy to assess the
Principle 6:
performance of BoD is disclosed in
Improving the Quality of
Annual Report of Public Company.
Job and Responsibility
Performance of BoD Direksi mempunyai kebijakan terkait
pengunduran diri anggota Direksi
apabila terlibat dalam kejahatan
keuangan. Terpenuhi (comply).
6.3
Board of Directors have a policy
related to resignation of Board of
Directors member if involved in
financial crimes.
Perusahaan Terbuka memiliki
kebijakan untuk mencegah terjadinya
Terpenuhi (comply).
7.1 insider trading.
Public Company has a policy to
prevent insider trading.
Perusahaan Terbuka memiliki
kebijakan anti korupsi dan anti fraud. Terpenuhi (comply).
7.2
Public Company has anti corruption
and anti fraud policy.
Perusahaan Terbuka memiliki
kebijakan tentang seleksi dan
peningkatan kemampuan pemasok
Prinsip 7: atau vendor. Terpenuhi (comply).
Meningkatkan 7.3
Public Company has policies
Aspek Tata Kelola concerning selection and capability
Partisipasi Pemangku
Perusahaan melalui improvement of suppliers and
Kepentingan
Partisipasi Pemangku vendors.
Participation of the
Kepentingan
Stakeholders Perusahaan Terbuka memiliki
Principle 7:
Improving Corporate kebijakan untuk pemenuhan hak-hak
Governance Aspect kreditur.
7.4 Terpenuhi (comply).
through Participation of Public Company has a policy
Stakeholders concerning the fulfillment of creditor’s
rights.
Perusahaan Terbuka memiliki
kebijakan sistem whistleblowing Terpenuhi (comply).
7.5
Public Company has a policy of
whistleblowing system.
Perusahaan Terbuka memiliki
kebijakan pemberian insentif
jangka panjang kepada Direksi dan
Terpenuhi (comply).
7.6 karyawan.
Public Company has long-term
incentive policy for Directors and
employees.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 197
Page 198
Tata Kelola Perusahaan Positioned for
Good Corporate Governance Profitable Growth
Pemenuhan Rekomendasi Pedoman Tata Kelola Perusahaan Terbuka
Fulfillment of Recommendations for Public Company Governance Guidelines
Aspek Prinsip Rekomendasi Pelaksanaan
Aspect Principles Recommendation Implementation
Perusahaan Terbuka memanfaatkan
penggunaan teknologi informasi
secara lebih luas selain Situs
Web sebagai media keterbukaan
informasi. Terpenuhi (comply).
8.1
Public Company takes benefit
from the application of a broader
information technology other than
Website as information disclosure
media.
Prinsip 8:
Meningkatkan Laporan Tahunan Perusahaan
Pelaksanaan Terbuka mengungkapkan pemilik
Keterbukaan Informasi Keterbukaan Informasi manfaat akhir dalam kepemilikan
Information Disclosure Principle 8: saham Perusahaan Terbuka paling
Improving the sedikit 5% (lima persen), selain
Implementation of pengungkapan pemilik manfaat
Information Disclosure akhir dalam kepemilikan saham
Perusahaan Terbuka melalui
Terpenuhi (comply).
8.2 pemegang saham utama dan
pengendali.
Annual Report of Public Company
discloses beneficial owner in share
ownership of Public Company of at
least 5% (five percent), other than
disclosure of beneficial owner in share
ownership of Public Company through
major and controlling shareholders.
198 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 199
Positioned for
Profitable Growth
Halaman ini sengaja dikosongkan
This page is intentionally left blank
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 199
Page 200
Positioned for
Profitable Growth
06
Laporan
Keberlanjutan
Sustainability Report
200 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 201
Positioned for Profitable Growth PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 201
Page 202
Laporan Keberlanjutan Positioned for
Sustainability Report Profitable Growth
Standar Pelaporan
Reporting Standards
Laporan Keberlanjutan PT Millennium Pharmacon The 2025 Sustainability Report of PT Millennium Pharmacon
International Tbk (“MPI” atau “Perseroan”) Tahun 2025 International Tbk (“MPI” or the “Company”) has been
disusun dengan mengacu pada Peraturan Otoritas prepared with reference to Financial Services Authority
Jasa Keuangan (POJK) Nomor 51/POJK.03/2017 tentang Regulation (POJK) Number 51/POJK.03/2017 concerning
Penerapan Keuangan Berkelanjutan Bagi Lembaga Jasa the Implementation of Sustainable Finance for Financial
Keuangan, Emiten, dan Perusahaan Publik, Consolidated Services Institutions, Issuers, and Public Companies, the
GRI Standards 2021, dan GRI Standards Topic dengan opsi Consolidated GRI Standards 2021, and the GRI Topic
“with reference”. Standards with the “with reference” option.
Guna memudahkan pembaca menemukan informasi To facilitate readers in locating information in accordance
yang sesuai dengan rujukan, Perseroan menyertakan with the applicable references, the Company provides
penanda khusus berupa angka dan huruf sesuai Isi specific markers in the form of numbers and letters
Laporan Keberlanjutan sebagaimana diatur dalam corresponding to the Sustainability Report content as
Lampiran POJK No.51/2017, SEOJK Nomor 16/SEOJK.04/2021, stipulated in Appendix to POJK No. 51/2017, SEOJK Number
atau pencantuman angka pengungkapan Standar GRI di 16/SEOJK.04/2021, or by indicating the relevant GRI
belakang kalimat atau alinea yang relevan. Data lengkap Standard disclosure number at the end of the relevant
mengenai kesesuaian isi laporan dengan kedua referensi sentence or paragraph. Full data on the suitability of the
tersebut disajikan dalam bagian lampiran Laporan content of the report with the two references is presented
Keberlanjutan ini. in the appendix to this Sustainability Report.
Laporan ini disusun sebagai rujukan dalam mengambil This report is prepared as a reference for decision-
keputusan bagi seluruh pembaca dan pemangku making by all readers and stakeholders, providing a
kepentingan, guna memberikan gambaran menyeluruh comprehensive overview of the sustainability performance
mengenai pencapaian kinerja keberlanjutan PT Millennium achievements of PT Millennium Pharmacon International
Pharmacon International Tbk sepanjang tahun 2025. Tbk throughout 2025. The Company expects this report to
Perseroan berharap laporan ini dapat menjadi sumber serve as a reliable source of information and an important
informasi yang andal dan menjadi referensi penting dalam reference in future strategic decision-making.
pengambilan keputusan strategis di masa mendatang.
Penyusunan laporan ini merupakan tanggung jawab The preparation of this report is the full responsibility of the
penuh Direktur Utama. Perseroan menerbitkan laporan ini President Director. The Company publishes this report in
dalam dua bahasa, yakni Bahasa Indonesia dan Bahasa two languages, namely Indonesian and English. The report
Inggris. Laporan bisa didapatkan, dibaca dan/atau can be obtained, read, and/or downloaded through the
diunduh melalui situs resmi Perseroan dengan alamat Company’s official website at https://mpi-indonesia.co.id/
https://mpi-indonesia.co.id/
202 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 203
Positioned for
Profitable Growth
Prinsip Pelaporan
Reporting Principles
Laporan Keberlanjutan PT Millennium Pharmacon The Sustainability Report of PT Millennium Pharmacon
International Tbk disusun dengan mengacu pada prinsip International Tbk has been prepared with reference to the
pelaporan GRI, yang meliputi akurasi, keseimbangan, GRI reporting principles, which include accuracy, balance,
kejelasan, keterbandingan, kelengkapan, konteks clarity, comparability, completeness, sustainability context,
keberlanjutan, ketepatan waktu, dan keterverifikasian. timeliness, and verifiability. In applying the principle of
Dalam penerapan prinsip materialitas, Perusahaan materiality, the Company adopts a double materiality
menggunakan pendekatan double materiality, dengan approach, taking into account the Company’s significant
mempertimbangkan dampak signifikan Perusahaan impacts on the economy, environment, and society, as
terhadap ekonomi, lingkungan, dan sosial, serta risiko dan well as sustainability-related risks and opportunities that
peluang keberlanjutan yang berpotensi memengaruhi may affect the Company’s performance and business
kinerja dan keberlangsungan usaha Perusahaan. Prinsip- continuity. These principles serve as the foundation to
prinsip tersebut menjadi dasar untuk memastikan ensure that the sustainability information presented
informasi keberlanjutan yang disajikan relevan, objektif, is relevant, objective, comparable across periods,
dapat dibandingkan antar periode, disajikan tepat waktu, delivered in a timely manner, and supported by data
serta didukung data dan dokumentasi yang dapat and documentation that can be traced for verification
ditelusuri untuk keperluan verifikasi. purposes.
Entitas yang dimasukan dalam Laporan [GRI 2-2]
Entities Included in the Report [GRI 2-2]
Cakupan pelaporan Laporan Keberlanjutan ini meliputi PT The scope of reporting in this Sustainability Report
Millennium Pharmacon International Tbk sebagai entitas covers PT Millennium Pharmacon International Tbk as
induk serta entitas anak yang dikonsolidasikan dalam the parent entity as well as its subsidiaries consolidated
Laporan Keuangan Perusahaan yang telah diaudit oleh in the Company’s Financial Statements, which have been
Kantor Akuntan Publik Tanubrata Sutanto Fahmi Bambang audited by Public Accounting Firm Tanubrata Sutanto
& Rekan. Fahmi Bambang & Partners.
Penetapan cakupan pelaporan keberlanjutan selaras The determination of the sustainability reporting scope
dengan ruang lingkup laporan keuangan konsolidasian, is aligned with the scope of the consolidated financial
sehingga informasi keberlanjutan yang disajikan statements, ensuring that the sustainability information
mencerminkan dampak dan kinerja Perusahaan secara presented reflects the Company’s overall impacts and
menyeluruh. Apabila terdapat keterbatasan cakupan performance. If there are any limitations in scope for
pada topik tertentu, Perusahaan mengungkapkannya certain topics, the Company clearly discloses them in
secara jelas dalam laporan ini. this report.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 203
Page 204
Laporan Keberlanjutan Positioned for
Sustainability Report Profitable Growth
Periode Pelaporan, Frekuensi, dan
Titik Kontak Pelaporan [GRI 2-3]
Reporting Period, Frequency, and Contact Point [GRI 2-3]
Perseroan menerbitkan Laporan Keberlanjutan bersamaan The Company publishes its Sustainability Report
dengan Laporan Tahunan yang diterbitkan secara berkala simultaneously with the Annual Report, which is issued on a
setiap tahunnya. Laporan Keberlanjutan ini disusun periodic annual basis. This Sustainability Report covers the
untuk periode 1 Januari sampai dengan 31 Desember period from January 1 to December 31, 2025, in line with the
2025, sesuai dengan periode pada Laporan Keuangan reporting period of the Company’s Financial Statements.
Perseroan. Laporan keberlanjutan ini dipublikasikan pada This Sustainability Report was published on April 24, 2026.
24 April 2026.
Para pemangku kepentingan dapat menyampaikan Stakeholders may submit any questions regarding this
mengenai pertanyaan tentang laporan atau informasi report or the information disclosed herein through the
yang dilaporkan dalam laporan ini melalui narahubung Company’s contact person as follows:
Perseroan, yaitu:
Sekretaris Perusahaan Corporate Secretary
PT Millennium Pharmacon International Tbk PT Millennium Pharmacon International Tbk
Email: investor.relation@mpi-pharmaniaga.co.id Email: investor.relation@mpi-pharmaniaga.co.id
No Telp: +6221-27085961 No Telp: +6221-27085961
Penyajian Kembali (Restatement) Informasi [GRI 2-4]
Restatement of Information [GRI 2-4]
Dalam Laporan Keberlanjutan tahun 2025 tidak terdapat In the 2025 Sustainability Report, there are no data and
data dan informasi yang disajikan kembali (restated). information that have been restated.
204 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 205
Positioned for
Profitable Growth
Proses Penentuan Topik Material [GRI 3-1]
Process to Determine Material Topics [GRI 3-1]
Topik material merupakan topik yang mencerminkan Material topics are those that reflect the most significant
dampak paling signifikan dari kegiatan Perseroan impacts of the Company’s activities on economic,
terhadap aspek ekonomi, lingkungan, dan sosial, serta environmental, and social aspects, and that may influence
berpotensi memengaruhi penilaian dan pengambilan stakeholders’ assessments and decision-making. The
keputusan pemangku kepentingan. Penetapan topik determination of material topics in this Sustainability
material dalam Laporan Keberlanjutan ini dilakukan Report is conducted using an impact-based materiality
dengan pendekatan impact-based materiality yang approach, strengthened by a double materiality
diperkuat melalui perspektif double materiality, dengan perspective, by considering both the impacts of the
mempertimbangkan baik dampak aktivitas Perseroan Company’s activities (inside-out) and the significance
(inside-out) maupun tingkat kepentingan isu bagi of issues to stakeholders (outside-in).
pemangku kepentingan (outside-in).
Untuk memastikan Laporan Keberlanjutan 2025 To ensure that the 2025 Sustainability Report presents
menyajikan informasi yang relevan dan esensial bagi information that is relevant and essential to stakeholders,
pemangku kepentingan, Perseroan menerapkan proses the Company implements a systematic and continuous
penentuan topik material yang dilakukan secara material topic determination process. This process aims
sistematis dan berkesinambungan. Proses ini bertujuan to identify and assess actual and potential impacts, both
untuk mengidentifikasi dan menilai dampak aktual dan positive and negative, on economic, environmental, and
potensial, baik positif maupun negatif, terhadap aspek social aspects, including human rights, arising from
ekonomi, lingkungan, dan sosial, termasuk hak asasi the Company’s operational activities and business
manusia, yang timbul dari aktivitas operasional dan relationships.
hubungan bisnis Perseroan.
Proses penentuan topik material dilakukan melalui The material topic determination process is carried out
tahapan berikut: through the following stages:
Proses Penentuan Topik Material
Process to determine material topics
Mengidentifikasi dan menilai dampak
secara berkesinambungan Menentukan topik material untuk pelaporan
Identify and assess impacts on an ongoing basis Determine material topics for reporting
Menguji topik material dengan
Melibatkan berbagai pemangku
pakar dan pengguna informasi
kepentingan dan pakar yang relevan
Test the material topics with
Engage with relevant stakeholders
experts and information users
and experts
1 2 3 4
Topik Material
Material topics
Memprioritaskan
Mengidentifikasi Menilai signifikansi dampak paling
Memahami dampak aktual dan dampak signifikansi untuk
konteks organisasi potensial Assess the pelaporan
Understand the Identify actual and significance of the Prioritize the most
organization’s context potential impacts impacts significant impacts for
reporting
Menggunakan Standar Mempertimbangkan Menguji topik material
Sektor untuk memahami topik dan dampak yang terhadap topik dalam
konteks sektor dideskripsikan dalam Standar Sektor
Use the Sector Standards Standar Sektor Test the material topics
to understand the sectors’ Consider the topics and against the topics in the
context impacts described in the Sector Standards
Sector Standards
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 205
Page 206
Laporan Keberlanjutan Positioned for
Sustainability Report Profitable Growth
Tahap 1: Pemahaman Konteks Organisasi Step 1: Understand the Organization’s Context
Perseroan memulai proses dengan memahami konteks The Company begins the process by understanding the
organisasi dan sektor usaha yang dijalankan sebagai organizational and industry context in which it operates
distributor farmasi nasional. Pada tahap ini, Perseroan as a national pharmaceutical distributor. At this stage,
menelaah karakteristik kegiatan usaha, rantai nilai, model the Company reviews the characteristics of its business
bisnis, serta lingkungan operasional yang mencakup activities, value chain, business model, and operational
penerimaan produk dari prinsipal, pengelolaan di fasilitas environment, which includes the receipt of products from
pergudangan, hingga distribusi kepada pelanggan, principals, management within warehouse facilities,
seperti apotek dan rumah sakit. and distribution to customers such as pharmacies and
hospitals.
Pemahaman konteks ini juga mempertimbangkan This contextual understanding also takes into account
dinamika industri farmasi, kewajiban kepatuhan regulasi, the dynamics of the pharmaceutical industry, regulatory
serta ekspektasi pemangku kepentingan utama. Tahap compliance obligations, and the expectations of key
ini menjadi dasar untuk memastikan bahwa identifikasi stakeholders. This stage serves as the foundation to ensure
dampak dilakukan secara relevan dengan konteks sektor that the identification of impacts is conducted in a manner
dan organisasi. relevant to the sectoral and organizational context.
Tahap 2: Mengidentifikasi Dampak Aktual dan Step 2: Identify Actual and Potential Impacts
Potensial
Perseroan mengidentifikasi dampak aktual dan potensial The Company identifies actual and potential impacts
yang timbul dari aktivitas operasional dan hubungan arising from its operational activities and business
bisnis Perseroan. Identifikasi dilakukan terhadap dampak relationships. The identification covers both positive and
positif maupun negatif pada aspek ekonomi, lingkungan, negative impacts on economic, environmental, and social
dan sosial, termasuk dampak terhadap hak asasi manusia. aspects, including impacts on human rights.
Pada tahap ini, Perseroan mempertimbangkan At this stage, the Company considers various relevant
berbagai topik dan dampak yang relevan sebagaimana topics and impacts as described in the GRI Standards, as
dideskripsikan dalam Standar GRI, serta isu-isu yang well as issues emerging within the Company’s value chain,
muncul dalam rantai nilai Perseroan, antara lain terkait including product quality and safety, occupational health
mutu dan keamanan produk, keselamatan kerja, integritas and safety, business integrity, digital transformation, and
bisnis, transformasi digital, dan pengelolaan sumber daya human resource management.
manusia.
Tahap 3: Menilai Signifikansi Dampak Step 3: Assess the Significance of the Impacts
Perseroan menilai tingkat signifikansi dari setiap dampak The Company assesses the level of significance of each
yang telah diidentifikasi. Penilaian ini dilakukan melalui identified impact. This assessment is conducted through
pelibatan pemangku kepentingan internal dan eksternal the engagement of internal and external stakeholders to
untuk memperoleh perspektif yang komprehensif. obtain comprehensive perspectives.
Penilaian internal melibatkan 63 (enam puluh tiga) The internal assessment involved 63 (sixty-three)
partisipan, yang terdiri dari Kepala Divisi, Kepala participants, consisting of Division Heads, Department
Departemen, dan Kepala Cabang, untuk menilai Heads, and Branch Heads, to evaluate the significance
signifikansi dampak terhadap keberlangsungan bisnis of impacts on the Company’s business continuity and
dan operasional Perseroan. Sementara itu, penilaian operations. Meanwhile, the external assessment involved
eksternal melibatkan 9 (sembilan) partisipan yang 9 (nine) participants representing Principals, Customers,
mewakili Prinsipal, Pelanggan, Mitra Logistik, dan Vendor, Logistics Partners, and Vendors, to assess the level of
untuk menilai tingkat kepentingan isu keberlanjutan bagi importance of sustainability issues to stakeholders.
pemangku kepentingan.
206 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 207
Positioned for
Profitable Growth
Penilaian dilakukan melalui kuesioner dengan The assessment was conducted through a questionnaire
skala penilaian yang seragam untuk memastikan using a uniform rating scale to ensure comparability of
keterbandingan hasil antar responden. results among respondents.
Tahap 4: Memprioritaskan Dampak Paling Step 4: Prioritize the Most Significant Impacts for
Signifikan untuk Pelaporan Reporting
Hasil penilaian signifikansi dampak selanjutnya dianalisis The results of the impact significance assessment were
dan dipetakan ke dalam Matriks Materialitas. Pada tahap subsequently analyzed and mapped into a Materiality
ini, Perseroan memprioritaskan dampak yang paling Matrix. At this stage, the Company prioritizes the most
signifikan untuk ditetapkan sebagai topik material, significant impacts to be determined as material topics,
berdasarkan tingkat signifikansi dampak terhadap based on the level of impact significance to the Company
Perseroan dan tingkat kepentingannya bagi pemangku and the level of importance to stakeholders.
kepentingan.
Topik yang memenuhi ambang batas materialitas, Topics that meet the materiality threshold, namely
yaitu memiliki signifikansi tinggi pada salah satu atau those with high significance in one or both assessment
kedua dimensi penilaian (internal dan/atau eksternal), dimensions (internal and/or external), are determined as
ditetapkan sebagai topik material untuk pelaporan. material topics for reporting. The resulting list of material
Daftar topik material yang dihasilkan kemudian diuji topics is then tested against the topics in the GRI Standards
kesesuaiannya terhadap topik-topik dalam Standar to ensure completeness and consistency of reporting.
GRI guna memastikan kelengkapan dan konsistensi
pelaporan.
Validasi dan Peran Badan Tata Kelola Tertinggi Validation and the Role of the Highest
Daftar topik material dan matriks materialitas yang Governance Body
dihasilkan telah ditinjau dan divalidasi oleh Direksi. Peran The list of material topics and the resulting materiality
Badan Tata Kelola Tertinggi ini memastikan bahwa topik matrix have been reviewed and validated by the Board of
material yang ditetapkan selaras dengan strategi bisnis, Directors. The role of the Highest Governance Body ensures
manajemen risiko, serta arah jangka panjang Perseroan, that the determined material topics are aligned with the
dan menjadi dasar bagi penyusunan pengungkapan Company’s business strategy, risk management, and
keberlanjutan dalam Laporan Keberlanjutan 2025. long-term direction, and serve as the basis for preparing
[GRI 2-14] sustainability disclosures in the 2025 Sustainability Report.
[GRI 2-14]
Badan tata kelola tertinggi Perusahaan berperan dalam The Company’s Highest Governance Body plays a role in
mengawasi dan memberikan arahan atas penyusunan overseeing and providing direction for the preparation of
Laporan Keberlanjutan, termasuk dalam penetapan topik the Sustainability Report, including the determination of
material dan pengungkapan informasi utama. Peran material topics and the disclosure of key information. This
tersebut memastikan bahwa pelaporan keberlanjutan role ensures that sustainability reporting is aligned with
selaras dengan strategi, manajemen risiko, dan arah the Company’s strategy, risk management, and long-term
jangka panjang Perusahaan. [GRI 2-14] direction. [GRI 2-14]
Tabel Hasil Identifikasi Dampak Aktual dan Potensial
Table of Actual and Potential Impact Identification Results
Topik Material
No
Material Topic
Integritas Bisnis & Anti-Fraud
1
Business Integrity & Anti-Fraud
Kepatuhan terhadap Kebijakan Lingkungan
2
Compliance with Environmental Policies
Kepatuhan terhadap Regulasi - BPOM, Kemenkes, OJK, BEI
3
Regulatory Compliance – BPOM, Ministry of Health, OJK, IDX
Perlindungan Data & Keamanan Siber
4
Data Protection & Cybersecurity
Kesehatan & Keselamatan Kerja (K3)
5
Occupational Health & Safety (OHS)
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 207
Page 208
Laporan Keberlanjutan Positioned for
Sustainability Report Profitable Growth
Tabel Hasil Identifikasi Dampak Aktual dan Potensial
Table of Actual and Potential Impact Identification Results
Topik Material
No
Material Topic
Keandalan Sistem IT & Keamanan Data
6
IT System Reliability & Data Security
Ketahanan & Ketersediaan Pasokan Obat
7
Drug Supply Resilience & Availability
Arus Kas Perusahaan
8
Company Cash Flow
Kesetaraan & Keberagaman
9
Equality & Diversity
Kepuasan Pelanggan dan Principal
10
Customer and Principal Satisfaction
Manajemen Risiko Perusahaan
11
Enterprise Risk Management
Kesejahteraan & Keterlibatan Karyawan
12
Employee Welfare & Engagement
Reputasi & Kepercayaan Mitra Bisnis
13
Reputation & Trust of Business Partners
Efisiensi & Ketepatan Waktu Distribusi
14
Distribution Efficiency & Timeliness
Pengelolaan Pemasok & Pengadaan Bertanggung Jawab
15
Supplier Management & Responsible Procurement
Mutu & Keamanan Produk
16
Product Quality & Safety
Ketertelusuran & Sistem Monitoring Produk
17
Product Traceability & Monitoring Systems
Etika Bisnis & Perilaku Karyawan
18
Business Ethics & Employee Conduct
Bencana Alam
19
Natural Disasters
K3 & Potensi Kecelakaan Kerja
20
OHS & Potential Workplace Accidents
Transformasi Digital & Inovasi Operasional
21
Digital Transformation & Operational Innovation
Pengelolaan Produk Rusak & Proses Retur
22
Damaged Product Management & Return Process
Emisi Energi Gudang & Cold Chain
23
Warehouse Energy Emissions & Cold Chain
Pembayaran & Piutang dari Pelanggan
24
Payments & Receivables from Customers
Efisiensi Armada & Biaya Distribusi
25
Fleet Efficiency & Distribution Costs
Transparansi Informasi & Keterlibatan Publik
26
Information Transparency & Public Engagement
Pelatihan & Pengembangan Kompetensi
27
Training & Competency Development
208 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 209
Positioned for
Profitable Growth
Tabel Hasil Identifikasi Dampak Aktual dan Potensial
Table of Actual and Potential Impact Identification Results
Topik Material
No
Material Topic
Kepatuhan terhadap Regulasi
28
Regulatory Compliance
Pengelolaan Limbah & Kemasan Produk
29
Waste Management & Product Packaging
Pinjaman Bank
30
Bank Loans
Emisi Armada Transportasi & Logistik
31
Transportation & Logistics Fleet Emissions
Ketersediaan Pasokan Obat
32
Drug Supply Availability
Transformasi Digital & Peluang Layanan Baru
33
Digital Transformation & New Service Opportunities
Prioritisasi Topik Material Material Topic Prioritization
Hasil penilaian materialitas dipetakan ke dalam matriks The results of the materiality assessment are mapped into
yang terbagi menjadi 3 (tiga) zona warna, yaitu: a matrix divided into 3 (three) color-coded zones, as follows:
• Zona Prioritas Utama (hijau) • Primary Priority Zone (green)
Zona ini menunjukkan topik-topik dengan tingkat This zone represents topics with a high level of impact
signifikansi dampak yang tinggi bagi Perseroan significance to the Company and a high level of
sekaligus tingkat kepentingan yang tinggi bagi importance to external stakeholders. Topics within
pemangku kepentingan eksternal. Topik yang berada this zone become the main focus of management
pada zona ini menjadi fokus utama pengelolaan and disclosure in the Sustainability Report, as they
dan pengungkapan dalam Laporan Keberlanjutan, have the most significant potential impact on business
karena memiliki potensi dampak paling signifikan sustainability and stakeholder relationships.
terhadap keberlanjutan usaha dan hubungan dengan
pemangku kepentingan.
• Zona Prioritas Menengah / Fokus Strategis (kuning) • Medium Priority / Strategic Focus Zone (yellow)
Zona ini mencakup topik-topik yang memiliki signifikansi This zone includes topics that have high impact
dampak tinggi namun tingkat kepentingannya relatif significance but relatively lower importance compared
lebih rendah dibandingkan zona prioritas utama, atau to the primary priority zone, or vice versa. Topics
sebaliknya. Topik dalam zona ini tetap dikategorikan within this zone are still categorized as material and
material dan dikelola secara strategis sesuai dengan are managed strategically in accordance with the
konteks bisnis dan kebutuhan pemangku kepentingan. business context and stakeholder needs.
• Zona Pendukung (netral) • Supporting Zone (neutral)
Zona ini menunjukkan topik-topik yang memiliki tingkat This zone represents topics with relatively lower levels
signifikansi dan kepentingan relatif lebih rendah of significance and importance compared to other
dibandingkan topik lainnya. Meskipun demikian, topik topics. Nevertheless, topics within this zone continue to
dalam zona ini tetap dipantau dan dikelola sebagai be monitored and managed as part of the Company’s
bagian dari praktik keberlanjutan Perseroan. sustainability practices.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 209
Page 210
Laporan Keberlanjutan Positioned for
Sustainability Report Profitable Growth
Garis putus-putus pada matriks merepresentasikan The dotted line in the matrix represents the materiality
ambang batas (threshold) materialitas yang digunakan threshold used by the Company to distinguish the priority
Perseroan untuk membedakan tingkat prioritas masing- level of each topic.
masing topik.
4,6
Fokus Strategis (Dorongan Pasangan) Prioritas Utama (Area Wajib)
Strategic Focus (Couple Encouragement) Top Priority (Required Areas)
Pengaruh pada Keputusan Pemangku Kepentingan (Eksternal)
4,5
Influence on Stakeholder Decisions (External)
A
4,4
F
4,3
D C B
4,2
E
4,1
Pendukung (Fondasi)
Supporters (Foundation)
4,0
4,4 4,5 4,6 4,7 4,8 4,9 5,0
Signifikan Dampak Ekonomi, Lingkungan & Sosial (Internal)
Significant Economic, Environmental & Social Impact (Internal)
Keterangan Kode | Code Description:
A
Kepatuhan Regulasi & Integritas Bisnis D
Kesehatan & Keselamatan Kerja (K3)
Regulatory Compliance & Business Integrity Occupational Health & Safety (OHS)
B
Mutu & Keamanan Produk E
Pengembangan SDM
Product Quality & Safety Human Capital Development
C
Kepuasan Pelanggan F
Transformasi Digital
Customer SatisfactionSafety Digital Transformation
Pergeseran materialitas pada tahun 2025 menunjukkan The shift in materiality in 2025 indicates that MPI is
bahwa MPI sedang berada dalam fase “Penguatan currently in a phase of “Fundamental Strengthening and
Fundamental dan Akselerasi Digital”. Fokus perusahaan Digital Acceleration.” The Company’s focus is no longer
tidak lagi hanya pada kinerja finansial semata, melainkan solely on financial performance, but has shifted toward
bergeser pada penguatan tata kelola (Governance), strengthening governance, enhancing the quality of
kualitas layanan fisik, serta modernisasi layanan digital physical services, and modernizing digital services to
untuk menjawab tuntutan zaman. respond to evolving demands.
210 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 211
Positioned for
Profitable Growth
Halaman ini sengaja dikosongkan
This page is intentionally left blank
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 211
Page 212
Laporan Keberlanjutan Positioned for
Sustainability Report Profitable Growth
Daftar Topik Material [GRI 3-2]
List of Material Topics[GRI 3-2]
Topik Material MPI Deskripsi Dampak Signifikan Standar GRI Terkait (Topic Standard)
No
MPI Material Topics Description of Significant Impacts Relevant GRI Topic Standards
Risiko hukum, sanksi, dan reputasi akibat
ketidakpatuhan terhadap regulasi distribusi
farmasi (termasuk CDOB), serta risiko praktik
Kepatuhan Regulasi
fraud atau suap yang dapat mengganggu
& Tata Kelola Bisnis
integritas rantai nilai dan keberlanjutan usaha. GRI 419: Socioeconomic Compliance (2016);
Regulatory
1 Legal, sanction, and reputational risks arising from GRI 205: Anti-corruption (2016)
Compliance
non-compliance with pharmaceutical distribution
& Business
regulations (including Good Distribution Practice/
Governance
CDOB), as well as risks of fraud or bribery practices
that may disrupt the integrity of the value chain
and business sustainability.
Dampak langsung terhadap keselamatan pasien/
konsumen akhir apabila terjadi kegagalan dalam
menjaga mutu produk, termasuk pengendalian
suhu penyimpanan, masa kedaluwarsa,
integritas kemasan, penanganan distribusi, serta
memastikan tidak adanya produk palsu di pasar
Mutu & Keamanan
melalui sistem pelacakan berbasis kode batang.
Produk GRI 416: Customer Health and Safety (2016)
2 Direct impacts on patient/end-consumer safety
Product Quality &
in the event of failure to maintain product quality,
Safety
including temperature control during storage,
expiry date management, packaging integrity,
and proper distribution handling, as well as
ensuring the absence of counterfeit products in
the market through a barcode-based tracking
system.
Risiko kecelakaan kerja pada aktivitas
Kesehatan & pergudangan, pengelolaan cold chain, dan
Keselamatan Kerja distribusi/logistik, termasuk risiko lalu lintas
(K3) armada dan pekerjaan berisiko fisik.
3 GRI 403: Occupational Health and Safety (2018)
Occupational Risk of workplace accidents in warehouse
Health & Safety operations, cold chain management, and
(OHS) distribution/logistics activities, including fleet
traffic risks and physically hazardous work.
Dampak terhadap keandalan layanan distribusi
farmasi, termasuk ketepatan waktu pengiriman,
GRI 416: Customer Health and Safety (2016);
Kepuasan keakuratan pemenuhan pesanan, serta efektivitas
GRI 417: Marketing and Labeling (2016) (untuk
Pelanggan & penanganan keluhan yang memengaruhi
aspek informasi/komunikasi layanan)
Kualitas Layanan kepercayaan pelanggan dan principal.
4 GRI 416: Customer Health and Safety (2016);
Customer Impacts on the reliability of pharmaceutical
GRI 417: Marketing and Labeling (2016) (for
Satisfaction & distribution services, including on-time delivery,
service information/ communication aspects)
Service Quality order fulfillment accuracy, and the effectiveness
of complaint handling, which influence customer
and principal trust.
Risiko kebocoran atau penyalahgunaan data
pelanggan/mitra seiring digitalisasi sistem
Transformasi Digital pemesanan dan distribusi, serta dampak
& Privasi Data operasional akibat gangguan sistem informasi.
5 Digital Risks of data breaches or misuse of customer/ GRI 418: Customer Privacy (2016)
Transformation & partner data in line with the digitalization of
Data Privacy ordering and distribution systems, as well as
operational impacts resulting from information
system disruptions.
Dampak terhadap kesiapan kompetensi,
Pengembangan produktivitas, dan retensi karyawan, termasuk
SDM & kemampuan beradaptasi terhadap perubahan
Kesejahteraan proses bisnis dan teknologi.
GRI 401: Employment (2016);
6 Karyawan Impacts on employee competency readiness,
GRI 404: Training and Education (2016)
Human Capital productivity, and retention, including the ability
Development & to adapt to changes in business processes and
Employee Welfare technology.
212 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 213
Positioned for
Profitable Growth
Indikator Pengungkapan Utama (Disclosure) Batasan Dampak (Impact Boundary)
Key Disclosure Indicators Impact Boundaries
Internal
419-1 Ketidakpatuhan terhadap hukum dan peraturan sosial (kantor pusat, cabang, gudang/cold chain, proses operasional
ekonomi (termasuk pernyataan nihil jika tidak ada); & kepatuhan);
205-2 Komunikasi dan pelatihan kebijakan/prosedur anti- Upstream
korupsi; (vendor/mitra bisnis terkait kepatuhan & etika);
205-3 Insiden korupsi yang terbukti (jika ada/nihil) Downstream (pelanggan/principal dalam hubungan bisnis)
419-1 Non-compliance with laws and regulations in the social Internal
and economic area (including a nil statement if none); (head office, branches, warehouses/cold chain, operational
205-2 Communication and training on anti-corruption policies and compliance processes);
and procedures; Upstream
205-3 Confirmed incidents of corruption (if any/nil) (vendors/business partners related to compliance and ethics);
Downstream
(customers/principals within business relationships)
416-1 Penilaian dampak kesehatan dan keselamatan untuk
Internal (gudang, cold chain, proses distribusi & penanganan
kategori produk/jasa;
produk);
416-2 Insiden ketidakpatuhan terkait dampak kesehatan dan
Downstream (pelanggan dan dampak lanjutan ke pasien/
keselamatan produk/jasa (jika ada/nihil)
konsumen)
416-1 Assessment of the health and safety impacts of product
Internal (warehouses, cold chain, distribution processes, and
and service categories;
product handling);
416-2 Incidents of non-compliance concerning the health and
Downstream (customers and subsequent impacts on
safety impacts of products and services (if any/nil)
patients/end-consumers)
403-1 Sistem manajemen K3;
Internal (karyawan gudang, logistik, kantor);
403-2 Identifikasi bahaya dan penilaian risiko;
Upstream
403-5 Pelatihan K3;
(tenaga alih daya/kontraktor yang bekerja dalam aktivitas
403-9 Cedera kerja (jika data tersedia)
distribusi)
403-1 Occupational health and safety management system;
Internal (warehouse, logistics, and office employees);
403-2 Hazard identification and risk assessment;
Upstream
403-5 OHS training;
(outsourced workers/contractors involved in distribution
403-9 Work-related injuries (if data is available)
activities)
416-2 Ketidakpatuhan terkait dampak kesehatan dan
keselamatan (jika ada/nihil);
417-1 Persyaratan informasi terkait produk/jasa (dalam
konteks informasi layanan); Downstream (pelanggan/principal);
Indikator manajemen internal: CSI, SLA pengiriman, tingkat Internal (perencanaan distribusi, customer service, sistem
penyelesaian keluhan pemantauan layanan)
416-2 Incidents of non-compliance concerning health and Downstream (customers/principals);
safety impacts (if any/nil); Internal (distribution planning, customer service, service
417-1 Requirements for product and service information (in the monitoring systems)
context of service information);
Internal management
indicators: Customer Satisfaction Index (CSI), delivery Service
Level Agreement (SLA), complaint resolution rate
Internal
(sistem TI, proses bisnis, keamanan informasi);
418-1 Pengaduan yang beralasan mengenai pelanggaran
Downstream/External (data pelanggan dan mitra yang
privasi pelanggan dan hilangnya data pelanggan (jika ada/
dikelola Perseroan)
nihil)
Internal
418-1 Substantiated complaints concerning breaches of
(IT systems, business processes, information security);
customer privacy and losses of customer data (if any/nil)
Downstream/External (customer and partner data managed
by the Company)
401-1 Perekrutan dan pergantian karyawan;
401-2 Tunjangan/benefit karyawan (jika diungkap);
404-1 Rata-rata jam pelatihan per karyawan;
404-2 Program peningkatan kompetensi Internal (seluruh karyawan di seluruh unit dan cabang)
401-1 New employee hires and employee turnover; Internal (all employees across all units and branches)
401-2 Employee benefits (if disclosed);
404-1 Average hours of training per employee;
404-2 Programs for upgrading employee skills
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 213
Page 214
Laporan Keberlanjutan Positioned for
Sustainability Report Profitable Growth
Inisiatif Strategis Keberlanjutan
Strategic Sustainability Initiatives
KOMITMEN KEBERLANJUTAN DAN SUSTAINABILITY COMMITMENT AND NET
KOMITMEN NET ZERO EMISSION [IDX E-06] ZERO EMISSION COMMITMENT [IDX E-06]
Perseroan berkomitmen untuk menjalankan kegiatan usaha The Company is committed to conducting its business
secara bertanggung jawab dengan mengintegrasikan activities responsibly by integrating sustainability
prinsip keberlanjutan dalam pengelolaan operasional, principles into its operational management, governance
tata kelola, serta hubungan dengan pemangku practices, and stakeholder relationships. This sustainability
kepentingan. Komitmen keberlanjutan ini didasarkan commitment is based on the understanding that the
pada pemahaman bahwa keberlangsungan usaha Company’s long-term business continuity is determined
Perseroan tidak hanya ditentukan oleh kinerja ekonomi, not only by economic performance, but also by its ability
tetapi juga oleh kemampuan Perseroan dalam mengelola to manage social and environmental impacts in a
dampak sosial dan lingkungan secara terukur, konsisten, measurable, consistent, and sustainable manner.
dan berkelanjutan.
Sejalan dengan komitmen tersebut, Perseroan menyatakan In line with this commitment, the Company declares
dukungan terhadap agenda Net Zero Emission melalui its support for the Net Zero Emission agenda through
penerapan langkah-langkah dekarbonisasi operasional the gradual and data-driven implementation of
yang dilaksanakan secara bertahap dan berbasis data. operational decarbonization measures. The Company
Perseroan telah melakukan perhitungan emisi gas has conducted greenhouse gas emissions calculations
rumah kaca yang mencakup Cakupan Scope 1, Scope covering Scope 1, Scope 2, and Scope 3, and has identified
2, dan Scope 3, serta mengidentifikasi sumber emisi key emission sources relevant to the characteristics of
utama yang relevan dengan karakteristik kegiatan its pharmaceutical distribution activities. The results of
usaha distribusi farmasi. Hasil perhitungan tersebut these calculations serve as the basis for formulating
menjadi dasar bagi Perseroan dalam merumuskan dan and implementing various emission reduction initiatives,
melaksanakan berbagai upaya pengurangan emisi, including improving energy efficiency, optimizing
termasuk peningkatan efisiensi energi, optimalisasi operational and logistics activities, and adopting more
aktivitas operasional dan logistik, serta penerapan praktik environmentally friendly work practices.
kerja yang lebih ramah lingkungan.
Meskipun Perseroan belum menetapkan target tahun Although the Company has not yet set a target year
pencapaian Net Zero Emission, Perseroan telah memulai for achieving Net Zero Emissions, it has commenced
pemantauan dan pelaporan emisi gas rumah kaca (GRK) the monitoring and reporting of greenhouse gas (GHG)
sesuai dengan persyaratan Grup. Ke depan, Perseroan emissions in accordance with Group requirements.
berkomitmen untuk terus memperkuat tata kelola emisi, Going forward, the Company remains committed to
meningkatkan kualitas pengukuran dan pelaporan, strengthening emissions governance, improving the
serta mengevaluasi peluang penurunan emisi secara quality of measurement and reporting, and continuously
berkelanjutan dengan mempertimbangkan kapasitas evaluating opportunities for emissions reduction by
internal, kesiapan operasional, dan perkembangan taking into account internal capacity, operational
regulasi yang berlaku. Komitmen ini mencerminkan readiness, and applicable regulatory developments. This
pendekatan yang terukur dalam mendukung transisi commitment reflects the Company’s measured approach
menuju ekonomi rendah karbon sekaligus menjaga in supporting the transition toward a low-carbon economy
ketahanan dan keberlanjutan usaha dalam jangka while maintaining long-term business resilience and
panjang. sustainability.
PENJELASAN STRATEGI EXPLANATION OF SUSTAINABILITY
KEBERLANJUTAN [OJK A.1] [GRI 2-22] STRATEGY [OJK A.1] [GRI 2-22]
Dalam rangka memperkuat keberlanjutan usaha secara In order to strengthen business sustainability in a
komprehensif dan berkesinambungan, Perseroan comprehensive and continuous manner, the Company
merumuskan strategi keberlanjutan yang selaras dengan has formulated a sustainability strategy aligned
visi dan misi Perusahaan serta prinsip pengelolaan usaha with its vision and mission, as well as the principles of
yang bertanggung jawab. Strategi ini menjadi kerangka responsible business management. This strategy serves
214 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 215
Positioned for Profitable Growth bagi Perseroan dalam mengintegrasikan pertimbangan as a framework for integrating economic, social, and ekonomi, sosial, dan lingkungan ke dalam proses environmental considerations into planning processes, perencanaan, pengambilan keputusan, dan pelaksanaan decision-making, and operational implementation, in operasional, sejalan dengan ekspektasi pemangku line with stakeholder expectations and the dynamics of kepentingan serta dinamika industri distribusi farmasi. the pharmaceutical distribution industry. Perseroan meyakini bahwa pencapaian kinerja tidak The Company believes that performance achievement hanya ditentukan oleh pertumbuhan ekonomi, tetapi is determined not only by economic growth, but also by juga oleh kemampuan Perusahaan dalam mengelola its ability to manage social and environmental impacts dampak sosial dan lingkungan secara terukur. Oleh in a measurable manner. Therefore, the sustainability karena itu, strategi keberlanjutan diarahkan untuk strategy is directed toward strengthening the Company’s memperkuat kontribusi Perseroan pada pelestarian contribution to environmental preservation, improving lingkungan, peningkatan kesejahteraan masyarakat the welfare of surrounding communities, and enhancing sekitar, serta penguatan keterlibatan karyawan dan employee engagement and customer satisfaction as kepuasan pelanggan sebagai fondasi hubungan the foundation of long-term relationships. This strategy jangka panjang. Strategi ini juga memastikan bahwa also ensures that sustainability considerations form part pertimbangan keberlanjutan menjadi bagian dari of investment decisions and human capital capability keputusan investasi dan penguatan kapabilitas sumber development, including workforce readiness to address daya manusia, termasuk kesiapan tenaga kerja untuk technological changes, compliance demands, and menghadapi perubahan teknologi, tuntutan kepatuhan, evolving service needs. serta kebutuhan layanan yang semakin berkembang. Dengan mengintegrasikan strategi bisnis, tanggung jawab By integrating business strategy, social responsibility, sosial, dan pengelolaan lingkungan ke dalam setiap aspek and environmental management into every aspect of its operasional, Perseroan berupaya meningkatkan nilai operations, the Company seeks to enhance added value tambah bagi seluruh pemangku kepentingan. Komitmen for all stakeholders. This commitment is reflected through tersebut tercermin melalui penerapan praktik bisnis yang the implementation of responsible business practices bertanggung jawab di seluruh lini usaha, penguatan across all business lines, strengthened governance, and tata kelola, serta upaya perbaikan berkelanjutan agar continuous improvement efforts to enable the Company Perseroan mampu merespons tantangan keberlanjutan to respond to sustainability challenges in an adaptive and secara adaptif dan konsisten. consistent manner. PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 215
Page 216
Laporan Keberlanjutan Positioned for
Sustainability Report Profitable Growth
KEGIATAN MEMBANGUN BUDAYA BUILDING A SUSTAINABILITY
KEBERLANJUTAN [OJK F.1] CULTURE [OJK F.1]
Perseroan membangun budaya keberlanjutan sebagai The Company builds a sustainability culture as a
fondasi agar prinsip keberlanjutan tidak berhenti pada foundation to ensure that sustainability principles do
kebijakan, tetapi menjadi cara kerja (ways of working) not stop at the policy level, but instead become ways of
yang melekat dalam perilaku, pengambilan keputusan, working embedded in behaviour, decision-making, and
dan pelaksanaan operasional sehari-hari. Budaya daily operational practices. The Company’s sustainability
keberlanjutan Perseroan dikembangkan di atas tiga culture is developed upon three fundamental pillars,
pilar dasar, yaitu Bisnis yang Lebih Baik (Better Business), namely Better Business, Better Society, and Better Planet.
Masyarakat yang Lebih Baik (Better Society), dan Planet These three pillars are implemented in adherence to the
yang Lebih Baik (Better Planet). Ketiga pilar tersebut Company’s core values—Respect, Integrity, Teamwork,
dijalankan dengan berpegang pada nilai inti Perseroan, and Excellence—which serve as ethical guidance and
yaitu Hormat, Integritas, Kerja Tim, dan Keunggulan, behavioural standards for all employees. This culture
sebagai rujukan etika dan standar perilaku bagi seluruh is supported by a structured governance mechanism,
insan perusahaan. Budaya ini didukung oleh mekanisme including clear roles and responsibilities, internal
tata kelola yang terstruktur, termasuk peran dan tanggung policies and procedures, as well as periodic monitoring
jawab yang jelas, kebijakan dan prosedur internal, serta and reporting processes to ensure accountability and
proses pemantauan dan pelaporan berkala untuk continuous improvement in sustainability performance.
memastikan akuntabilitas dan peningkatan berkelanjutan
dalam kinerja keberlanjutan.
Untuk memastikan budaya keberlanjutan terinternalisasi To ensure that the sustainability culture is consistently
secara konsisten, Perseroan melaksanakan berbagai internalized, the Company implements various initiatives
inisiatif yang mencakup aspek tata kelola, penguatan covering governance, capability enhancement, service
kapabilitas, layanan, serta pengelolaan dampak sosial excellence, as well as social and environmental impact
dan lingkungan, antara lain sebagai berikut: management, including the following:
Better Business (Bisnis yang Lebih Baik) Better Business
Perseroan meneguhkan praktik usaha yang bertanggung The Company reinforces responsible business practices
jawab melalui penguatan tata kelola dan integritas di by strengthening governance and integrity across all
seluruh lini bisnis. Upaya ini mencakup penerapan etika business lines. These efforts include the implementation of
bisnis, kepatuhan terhadap ketentuan yang berlaku, serta business ethics, compliance with applicable regulations,
pengambilan keputusan yang mempertimbangkan aspek and decision-making that effectively and efficiently
keberlanjutan secara efektif dan efisien. Perseroan juga integrates sustainability considerations. The Company
menginvestasikan sumber daya untuk memastikan produk also invests resources to ensure that its products and
dan layanan yang diberikan tetap relevan, berkualitas, services remain relevant, high-quality, and responsive to
serta mampu menjawab kebutuhan pelanggan. Dalam customer needs. In supporting the equitable distribution of
mendukung pemerataan manfaat ekonomi, Perseroan economic benefits, the Company prioritizes collaboration
memprioritaskan peluang kolaborasi yang memungkinkan opportunities that enable the involvement of local
keterlibatan bisnis lokal sesuai kebutuhan dan kapasitas businesses in accordance with operational needs and
operasional. capacities.
Better Society (Masyarakat Better Society
yang Lebih Baik)
Perseroan berupaya menciptakan lingkungan kerja The Company strives to create a safe, healthy,
yang aman, sehat, dan kondusif melalui penerapan and conducive working environment through the
standar Keselamatan dan Kesehatan Kerja (K3) serta implementation of Occupational Health and Safety (OHS)
penguatan kesadaran disiplin kerja. Perseroan juga standards and strengthened awareness of work discipline.
menjalankan pengembangan kompetensi sumber daya The Company also carries out human capital development
manusia melalui pembelajaran berkelanjutan, penguatan through continuous learning, skills enhancement, and
keterampilan, dan peningkatan kesiapan tenaga kerja workforce readiness improvement to respond to industry
untuk menghadapi dinamika industri. Sejalan dengan itu, dynamics. In line with this, the Company upholds respect
Perseroan menjunjung tinggi penghormatan terhadap for human rights in conducting its business activities
hak asasi manusia dalam menjalankan kegiatan usaha and fosters fair and respectful working relationships. The
dan membangun hubungan kerja yang adil dan saling corporate culture is continuously nurtured to maintain
menghormati. Budaya perusahaan terus dipelihara untuk employee retention, engagement, and motivation,
menjaga retensi, keterlibatan, dan motivasi karyawan agar enabling consistent high performance.
mampu memberikan kinerja terbaik secara konsisten.
216 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 217
Positioned for Profitable Growth Better Planet (Planet yang Lebih Baik) Better Planet Perseroan berkomitmen untuk meningkatkan perhatian The Company is committed to enhancing environmental terhadap lingkungan hidup melalui penerapan stewardship through the adoption of more environmentally praktik yang lebih ramah lingkungan dan penguatan friendly practices and strengthened awareness of kesadaran pengelolaan dampak lingkungan dari aktivitas environmental impact management arising from operasional. Komitmen tersebut tercermin dalam upaya operational activities. This commitment is reflected in konservasi dan pelestarian lingkungan, efisiensi sumber environmental conservation efforts, resource efficiency daya, serta kepedulian terhadap isu perubahan iklim. initiatives, and attention to climate change issues. The Perseroan secara bertahap mendorong praktik kerja yang Company gradually promotes more environmentally lebih ramah lingkungan sebagai bagian dari perbaikan responsible work practices as part of continuous berkelanjutan dalam operasional. operational improvement. Melalui inisiatif-inisiatif tersebut, Perseroan membangun Through these initiatives, the Company builds a budaya keberlanjutan yang tidak hanya memperkuat sustainability culture that not only strengthens ketahanan dan kualitas bisnis, tetapi juga menciptakan business resilience and quality, but also creates value manfaat bagi pemangku kepentingan. Perseroan terus for stakeholders. The Company continues to foster menjalin hubungan yang konstruktif dan saling memberi constructive and mutually beneficial relationships with nilai (value) dengan pelanggan, karyawan, mitra usaha, customers, employees, business partners, communities, masyarakat, dan pemangku kepentingan lainnya, sebagai and other stakeholders as part of its long-term bagian dari komitmen keberlanjutan jangka panjang. sustainability commitment. PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 217
Page 218
Laporan Keberlanjutan Positioned for
Sustainability Report Profitable Growth
Tata Kelola Keberlanjutan [OJK E.1] [GRI 2-11, 2-12, 2-13, 2-14, 2-16, 2-27]
Sustainability Governance [OJK E.1] [GRI 2-11, 2-12, 2-13, 2-14, 2-16, 2-27]
Perseroan menerapkan tata kelola keberlanjutan sebagai The Company implements sustainability governance
bagian yang tidak terpisahkan dari penerapan Tata Kelola as an integral part of Good Corporate Governance
Perusahaan yang Baik (Good Corporate Governance/ (GCG) practices. Sustainability governance is designed
GCG). Tata kelola keberlanjutan dirancang untuk to ensure that the management of economic, social,
memastikan bahwa pengelolaan aspek ekonomi, sosial, and environmental aspects is conducted in a directed,
dan lingkungan dilakukan secara terarah, terintegrasi, integrated, and accountable manner, in line with the
dan dapat dipertanggungjawabkan, sejalan dengan visi Company’s vision and mission and the principle of
dan misi Perseroan serta prinsip keseimbangan antara balancing people, planet, and profit.
manusia, planet, dan profit.
Struktur tata kelola keberlanjutan Perseroan mengacu The Company’s sustainability governance structure
pada struktur GCG yang berlaku, yaitu Rapat Umum refers to the prevailing GCG structure, consisting of the
Pemegang Saham (RUPS), Dewan Komisaris, dan Direksi, General Meeting of Shareholders (GMS), the Board of
dengan pembagian peran dan tanggung jawab yang Commissioners, and the Board of Directors, with clearly
jelas. RUPS merupakan organ tertinggi yang menetapkan defined roles and responsibilities. The GMS serves as the
arah umum pengelolaan Perusahaan dan memberikan highest governing body that determines the general
legitimasi atas kebijakan strategis yang berdampak direction of the Company’s management and provides
material terhadap keberlanjutan usaha jangka panjang. legitimacy for strategic policies that have a material
Melalui RUPS, Perseroan memastikan adanya akuntabilitas impact on long-term business sustainability. Through
Direksi dan Dewan Komisaris kepada Pemegang Saham, the GMS, the Company ensures the accountability of
termasuk dalam pengelolaan isu-isu keberlanjutan. the Board of Directors and the Board of Commissioners
to the Shareholders, including in the management of
sustainability-related issues.
Dewan Komisaris menjalankan fungsi pengawasan The Board of Commissioners performs an oversight
atas kebijakan, strategi, dan pelaksanaan pengelolaan function over the policies, strategies, and implementation
keberlanjutan yang dilakukan oleh Direksi. Dalam of sustainability management carried out by the Board
pelaksanaan tugasnya, Dewan Komisaris memastikan of Directors. In performing its duties, the Board of
bahwa pertimbangan keberlanjutan telah terintegrasi ke Commissioners ensures that sustainability considerations
dalam arah strategis Perusahaan, manajemen risiko, serta are integrated into the Company’s strategic direction, risk
pengambilan keputusan yang bersifat material. Dewan management, and material decision-making processes.
Komisaris juga memberikan arahan dan rekomendasi The Board of Commissioners also provides direction and
kepada Direksi terkait pengelolaan risiko dan peluang recommendations to the Board of Directors regarding the
keberlanjutan yang dapat memengaruhi kinerja, reputasi, management of sustainability risks and opportunities that
dan keberlangsungan usaha Perseroan. may affect the Company’s performance, reputation, and
business continuity.
Direksi bertanggung jawab atas perumusan dan The Board of Directors is responsible for formulating and
implementasi strategi, kebijakan, serta program implementing the Company’s sustainability strategies,
keberlanjutan Perseroan. Direksi memastikan bahwa policies, and programs. The Board of Directors ensures
aspek ekonomi, sosial, dan lingkungan terintegrasi ke that economic, social, and environmental aspects are
dalam perencanaan bisnis, pelaksanaan operasional, integrated into business planning, operational execution,
serta proses pengendalian dan evaluasi kinerja. Dalam as well as performance control and evaluation processes.
menjalankan tanggung jawab tersebut, Direksi didukung In carrying out these responsibilities, the Board of Directors
oleh manajemen dan unit kerja terkait yang melaksanakan is supported by management and relevant work units that
inisiatif keberlanjutan di tingkat operasional, sekaligus implement sustainability initiatives at the operational level,
melakukan pemantauan dan pelaporan secara berkala. while also conducting regular monitoring and reporting.
Sebagai bagian dari tata kelola keberlanjutan, Perseroan As part of sustainability governance, the Company
menerapkan mekanisme komunikasi, pelaporan, dan implements communication, reporting, and escalation
eskalasi atas isu-isu keberlanjutan yang relevan. mechanisms for relevant sustainability issues. These
Mekanisme ini memungkinkan manajemen untuk mechanisms enable management to identify, manage,
218 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 219
Positioned for
Profitable Growth
mengidentifikasi, mengelola, dan menindaklanjuti isu and respond to material sustainability issues in a timely
keberlanjutan yang bersifat material secara tepat waktu, manner, including issues that may affect compliance,
termasuk isu yang berpotensi memengaruhi kepatuhan, operational risk, and the Company’s reputation. Such
risiko operasional, dan reputasi Perseroan. Isu-isu tersebut issues are subsequently reported to the Board of
selanjutnya dilaporkan kepada Direksi dan, apabila Directors and, where necessary, escalated to the Board
diperlukan, menjadi perhatian Dewan Komisaris. of Commissioners.
Tata kelola keberlanjutan Perseroan juga didukung oleh The Company’s sustainability governance is also
komitmen kebijakan dan etika yang menjadi pedoman supported by policy commitments and ethical standards
perilaku seluruh insan Perusahaan. Perseroan menetapkan that guide the behavior of all employees. The Company
dan menginternalisasikan nilai-nilai integritas, kepatuhan, establishes and internalizes values of integrity, compliance,
dan tanggung jawab melalui Kode Etik serta kebijakan and responsibility through its Code of Conduct and other
internal lainnya, guna memastikan bahwa prinsip internal policies to ensure that sustainability principles are
keberlanjutan tertanam dalam budaya kerja dan praktik embedded in the corporate culture and daily operational
operasional sehari-hari. Selain itu, Perseroan memastikan practices. In addition, the Company ensures compliance
kepatuhan terhadap seluruh peraturan perundang- with all applicable laws and regulations as part of its efforts
undangan yang berlaku sebagai bagian dari upaya to maintain accountability and stakeholder trust.
menjaga akuntabilitas dan kepercayaan pemangku
kepentingan.
Melalui penerapan tata kelola keberlanjutan yang Through the implementation of structured sustainability
terstruktur dan terintegrasi dengan sistem GCG, governance integrated with the GCG system, the Company
Perseroan berupaya memastikan bahwa seluruh inisiatif seeks to ensure that all sustainability initiatives are
keberlanjutan dikelola secara konsisten, selaras dengan managed consistently, aligned with business strategy, and
strategi bisnis, serta mendukung penciptaan nilai jangka supportive of long-term value creation for stakeholders.
panjang bagi pemangku kepentingan.
PENANGGUNG JAWAB PENERAPAN PERSON RESPONSIBLE FOR
KEUANGAN BERKELANJUTAN [OJK E.1] THE IMPLEMENTATION OF
SUSTAINABLE FINANCE [OJK E.1]
Perseroan menetapkan pegawai, pejabat, dan/atau unit The Company appoints employees, officers, and/or work
kerja yang bertanggung jawab dalam penerapan usaha units responsible for the implementation of sustainable
berkelanjutan serta pengelolaan isu-isu keberlanjutan di business practices and the management of sustainability
seluruh jenjang organisasi. Penetapan penanggung jawab issues across all organizational levels. This appointment
ini bertujuan memastikan bahwa prinsip keberlanjutan aims to ensure that sustainability principles are integrated
terintegrasi ke dalam proses pengorganisasian, into organizing, planning, implementation, monitoring,
perencanaan, pelaksanaan, pemantauan, hingga evaluasi performance evaluation processes, as well as the
kinerja, serta pelaporan dampak ekonomi, lingkungan, consistent reporting of economic, environmental, and
dan sosial secara konsisten. social impacts.
Badan tata kelola tertinggi yang bertanggung jawab atas The highest governance body responsible for overseeing
penyelenggaraan manajemen keberlanjutan di Perseroan sustainability management within the Company is the
adalah Presiden Direktur. Presiden Direktur memiliki President Director. The President Director plays a primary
peran utama untuk memastikan bahwa pengelolaan role in ensuring that the management of economic,
dampak ekonomi, lingkungan, dan sosial dari kegiatan environmental, and social impacts arising from the
operasional Perseroan dilakukan secara terarah, termasuk Company’s operational activities is conducted in a
melaksanakan tinjauan dan identifikasi risiko lingkungan structured manner, including conducting periodic reviews
dan sosial secara berkala serta menganalisis peluang and identification of environmental and social risks, as
yang relevan dari pengelolaan dampak tersebut. well as analyzing relevant opportunities arising from the
management of such impacts.
Secara kolektif, Presiden Direktur didampingi oleh Collectively, the President Director, together with the other
Direktur lainya yang bertanggung jawab atas Directors, is responsible for the implementation of the
implementasi tata kelola keberlanjutan Perseroan. Dalam Company’s sustainability governance. At the operational
pelaksanaan operasional, Direktur yang membawahi level, the Director overseeing the human resources function
fungsi sumber daya manusia didukung oleh Kepala is supported by the Head of Sustainability Division, who
Divisi Keberlanjutan, yang bertanggung jawab kepada reports to the Director in charge of human resources,
Direktur yang membawahi sumber daya manusia, untuk to coordinate the implementation of cross-functional
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 219
Page 220
Laporan Keberlanjutan Positioned for
Sustainability Report Profitable Growth
mengoordinasikan pelaksanaan inisiatif keberlanjutan sustainability initiatives. This role includes:
lintas fungsi. Peran ini mencakup, antara lain:
1. mendorong peningkatan nilai Perseroan melalui 1. promoting the enhancement of the Company’s
penerapan prinsip-prinsip tata kelola berkelanjutan; value through the implementation of sustainable
governance principles;
2. memastikan penerapan tata kelola berkelanjutan 2. ensuring the effective implementation of sustainable
berjalan efektif hingga ke seluruh jenjang organisasi; governance across all organizational levels; and
dan
3. memantau perkembangan serta isu terkini terkait 3. monitoring developments and emerging sustainability
keberlanjutan, menyusun laporan, dan menyampaikan issues, preparing reports, and providing follow-up
rekomendasi tindak lanjut kepada manajemen. recommendations to management.
Prinsip-prinsip usaha berkelanjutan dijalankan melalui Sustainable business principles are implemented
siklus manajemen keberlanjutan yang mencakup through a sustainability management cycle that includes
pengorganisasian, perencanaan, pelaksanaan, serta organizing, planning, execution, and evaluation of
evaluasi kinerja keberlanjutan. Dalam penyusunan sustainability performance. In preparing this Sustainability
Laporan Keberlanjutan ini, Direksi melimpahkan koordinasi Report, the Board of Directors delegates the coordination
penyusunan laporan kepada Sekretaris Perseroan untuk of the report preparation to the Corporate Secretary to
memastikan bahwa topik-topik material telah tercakup ensure that material topics are adequately covered. Prior
secara memadai. Sebelum diterbitkan, draf laporan to publication, the draft report is circulated to the Board
disirkulasikan kepada Direksi dan Dewan Komisaris untuk of Directors and the Board of Commissioners to obtain
memperoleh tanggapan, penyelarasan, dan persetujuan. feedback, alignment, and approval.
PENGEMBANGAN KOMPETENSI COMPETENCY DEVELOPMENT RELATED
TERKAIT KEUANGAN TO SUSTAINABLE FINANCE [OJK E.2] [GRI 2-17]
BERKELANJUTAN [OJK E.2] [GRI 2-17]
During the reporting year, competency development was
Selama tahun pelaporan, pengembangan kompetensi carried out through various external and internal forums,
yang dilakukan melalui berbagai forum eksternal dan as follows:
internal, sebagai berikut:
Pengembangan Kompetensi Keuangan Berkelanjutan
Sustainable Finance Competency Development
Nama Jabatan Tema/ Judul Pelatihan Waktu Pelaksanaan
Name Position Training Theme/Title Date
Penanggung Jawab Penerapan Keberlanjutan
Person in Charge of Sustainability Implementation
Peran Perusahaan Publik dalam Keuangan
Berkelanjutan : Memahami Taksonomi Keuangan
Corporate Berkelanjutan Indonesia Versi 2 13 Maret 2025
Olga Indria Bolang
Secretary The Role of Public Companies in Sustainable March 13, 2025
Finance: Understanding Indonesia’s Sustainable
Finance Taxonomy Version 2
Menavigasi Tantangan ESG melalui kebijakan GCG 18 Maret 2025
Navigating ESG Challenges through GCG policies March 18, 2025
23 September 2025
Corporate IDX–UN SSE: “Workshop on IFRS Sustainability
Olga Indria Bolang September 23, 2025
Secretary Standards”
IFRS 1 & 2: “Update and Practical Insights for Public 13 November 2025
Companies” November 13, 2025
PENILAIAN RISIKO ATAS PENERAPAN RISK ASSESSMENT OF SUSTAINABLE
KEUANGAN BERKELANJUTAN [OJK E.3] FINANCE IMPLEMENTATION [OJK E.3]
Perseroan menyadari bahwa dalam menjalankan kegiatan The Company recognizes that in conducting its business
usaha, terdapat berbagai risiko yang dapat memengaruhi activities, various risks may arise that could affect the
pencapaian kinerja dan target yang ditetapkan dalam achievement of performance and targets set out in
rencana kerja dan anggaran perusahaan. Risiko tersebut the Company’s work plan and budget. These risks may
dapat timbul dari faktor internal maupun eksternal, originate from internal or external factors and may
220 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 221
Positioned for Profitable Growth serta berpotensi berdampak pada aspek operasional, potentially impact operational, compliance, reputational, kepatuhan, reputasi, dan keberlangsungan usaha apabila and business continuity aspects if not properly managed. tidak dikelola secara memadai. Untuk mencegah dan meminimalkan dampak risiko yang To prevent and minimize potential risk impacts, the mungkin terjadi, Perseroan menerapkan Manajemen Company implements Risk Management as part of its Risiko sebagai bagian dari sistem pengendalian dan internal control and corporate governance system. Risk tata kelola perusahaan. Penerapan manajemen risiko management is applied systematically through risk dilakukan secara sistematis melalui proses identifikasi, identification, measurement, monitoring, and control pengukuran, pemantauan, dan pengendalian risiko, processes, including the preparation of a risk map termasuk penyusunan peta risiko (risk map) yang that illustrates the likelihood of risk occurrence and the menggambarkan tingkat kemungkinan terjadinya risiko magnitude of its impact. Based on this mapping, the dan besaran dampaknya. Berdasarkan pemetaan Company formulates appropriate and efficient mitigation tersebut, Perseroan merumuskan rencana mitigasi yang plans to reduce risk exposure levels, while ensuring tepat dan efisien untuk menekan tingkat eksposur risiko, effective implementation through periodic monitoring sekaligus memastikan efektivitas pelaksanaannya melalui and evaluation. pemantauan dan evaluasi berkala. Profil risiko Perseroan beserta upaya mitigasi yang The Company’s risk profile and the mitigation measures diterapkan telah diungkapkan lebih lanjut dalam Bab implemented are further disclosed in the Corporate Tata Kelola Perusahaan pada Laporan Tahunan Perseroan. Governance Chapter of the Company’s Annual Report. Dengan pengelolaan risiko yang terstruktur, Perseroan Through structured risk management, the Company seeks berupaya menjaga ketahanan operasional dan to maintain operational resilience and ensure that the memastikan bahwa penerapan usaha berkelanjutan implementation of sustainable business practices aligns berjalan sejalan dengan strategi dan target Perusahaan, with the Company’s strategy and targets, while supporting serta mendukung penciptaan nilai jangka panjang bagi long-term value creation for stakeholders. pemangku kepentingan. KOMITMEN KEBIJAKAN [GRI2-23] POLICY COMMITMENT [GRI 2-23] Perseroan menetapkan komitmen kebijakan sebagai The Company establishes policy commitments as the landasan dalam menjalankan kegiatan usaha yang foundation for conducting business activities in an ethical, beretika, bertanggung jawab, dan berkelanjutan. Komitmen responsible, and sustainable manner. These policy kebijakan tersebut mencerminkan nilai-nilai Perseroan commitments reflect the Company’s values and serve serta menjadi pedoman bagi seluruh insan Perusahaan as guidelines for all employees in decision-making and dalam pengambilan keputusan dan pelaksanaan aktivitas operational activities, while taking into account economic, operasional, dengan memperhatikan dampak ekonomi, social, and environmental impacts. sosial, dan lingkungan. Komitmen kebijakan Perseroan mencakup antara The Company’s policy commitments include, among lain penerapan etika bisnis dan integritas, kepatuhan others, the implementation of business ethics and integrity, terhadap peraturan perundang-undangan yang berlaku, compliance with applicable laws and regulations, respect penghormatan terhadap hak asasi manusia, penerapan for human rights, the implementation of occupational keselamatan dan kesehatan kerja, pengelolaan lingkungan health and safety practices, environmental management, hidup, serta pembangunan hubungan yang adil dan saling and the development of fair and mutually respectful menghormati dengan pemangku kepentingan. Kebijakan- relationships with stakeholders. These policies are kebijakan tersebut dirumuskan untuk memastikan bahwa formulated to ensure that sustainability principles are prinsip keberlanjutan terintegrasi ke dalam tata kelola, integrated into the Company’s governance, strategy, and strategi, dan proses operasional Perseroan. operational processes. MENANAMKAN KOMITMEN EMBEDDING POLICY KEBIJAKAN [GRI 2-24] COMMITMENTS [GRI 2-24] Perseroan menanamkan komitmen kebijakan ke dalam The Company embeds its policy commitments into praktik operasional melalui integrasi kebijakan dan nilai operational practices by integrating corporate policies and perusahaan ke dalam sistem tata kelola, proses bisnis, values into its governance system, business processes, serta budaya kerja. Penanaman komitmen kebijakan and work culture. This embedding process ensures dilakukan agar prinsip etika, kepatuhan, dan tanggung that principles of ethics, compliance, and responsibility PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 221
Page 222
Laporan Keberlanjutan Positioned for
Sustainability Report Profitable Growth
jawab menjadi bagian dari pengambilan keputusan dan become an integral part of decision-making and daily
perilaku kerja sehari-hari di seluruh jenjang organisasi. work behavior at all organizational levels.
Implementasi komitmen kebijakan dilakukan melalui The implementation of policy commitments is carried
sosialisasi kode etik dan kebijakan internal kepada out through the dissemination of the Code of Conduct
karyawan, penguatan peran pimpinan sebagai teladan and internal policies to employees, reinforcement of
(tone from the top), serta pengintegrasian kebijakan leadership roles as role models (tone from the top), and
ke dalam prosedur kerja yang relevan. Perseroan the integration of policies into relevant work procedures.
juga memastikan bahwa kebijakan yang berlaku The Company also ensures that applicable policies are
dikomunikasikan secara memadai kepada pihak terkait, adequately communicated to relevant parties, including
termasuk mitra usaha, melalui ketentuan kerja sama dan business partners, through cooperation agreements and
mekanisme komunikasi yang relevan. appropriate communication mechanisms.
Untuk menjaga efektivitas penerapan, Perseroan To maintain effectiveness, the Company conducts periodic
melakukan pemantauan dan peninjauan kebijakan secara monitoring and review of its policies in line with business
berkala, sejalan dengan perkembangan kegiatan usaha developments and regulatory requirements. Through
dan ketentuan peraturan perundang-undangan. Melalui this approach, the Company seeks to ensure that policy
pendekatan ini, Perseroan berupaya memastikan bahwa commitments are not merely normative in nature, but are
komitmen kebijakan tidak hanya bersifat normatif, tetapi genuinely embedded in its governance and operational
benar-benar tertanam dalam tata kelola dan operasional practices.
Perusahaan.
PROSES UNTUK MENGELOLA PROCESSES FOR MANAGING
DAMPAK NEGATIF [GRI 2-25] NEGATIVE IMPACTS [GRI 2-25]
Perseroan menyadari bahwa dalam menjalankan kegiatan The Company recognizes that in conducting its
usaha, terdapat potensi dampak negatif terhadap aspek business activities, there are potential negative impacts
ekonomi, sosial, dan lingkungan. Untuk mengelola potensi on economic, social, and environmental aspects. To
dampak tersebut, Perseroan menerapkan pendekatan manage these potential impacts, the Company applies
yang terintegrasi melalui sistem tata kelola, manajemen an integrated approach through its governance system,
risiko, dan pengendalian internal, guna memastikan risk management, and internal control mechanisms to
bahwa dampak negatif dapat diidentifikasi, dicegah, ensure that negative impacts are properly identified,
dan diminimalkan secara tepat. prevented, and minimized.
Pengelolaan dampak negatif dilakukan melalui proses The management of negative impacts is carried out
identifikasi dan evaluasi risiko yang relevan, termasuk through the identification and evaluation of relevant
risiko operasional, ketenagakerjaan, keselamatan dan risks, including operational, labor, occupational health
kesehatan kerja, kepatuhan, serta lingkungan. Hasil and safety, compliance, and environmental risks. The
evaluasi tersebut menjadi dasar bagi Perseroan dalam results of this evaluation serve as the basis for determining
menetapkan langkah pengendalian dan mitigasi yang appropriate control and mitigation measures, as well as
sesuai, serta melakukan pemantauan atas efektivitasnya for conducting periodic monitoring of their effectiveness.
secara berkala. Apabila ditemukan potensi atau kejadian If potential or actual negative impacts are identified,
yang berdampak negatif, Perseroan menindaklanjutinya the Company follows up through applicable internal
melalui mekanisme internal yang berlaku sesuai tingkat mechanisms in accordance with their level of materiality
materialitas dan dampaknya. and impact.
Selain itu, Perseroan menyediakan saluran komunikasi In addition, the Company provides communication
dan mekanisme pengaduan internal untuk menerima channels and internal grievance mechanisms to
laporan atas dugaan pelanggaran atau dampak negatif receive reports of alleged violations or negative impacts
yang timbul dari kegiatan usaha. Mekanisme ini dirancang arising from its business activities. These mechanisms
untuk mendorong penyampaian laporan secara are designed to encourage responsible reporting and
bertanggung jawab serta memastikan adanya tindak ensure proportional follow-up actions in accordance
lanjut yang proporsional dan sesuai dengan ketentuan with applicable regulations. Through this process, the
yang berlaku. Melalui proses ini, Perseroan berupaya Company seeks to strengthen accountability, prevent the
memperkuat akuntabilitas, mencegah terulangnya recurrence of negative impacts, and support continuous
dampak negatif, dan mendukung perbaikan berkelanjutan improvement in business management.
dalam pengelolaan usaha.
222 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 223
Positioned for
Profitable Growth
HUBUNGAN DENGAN PEMANGKU STAKEHOLDER ENGAGEMENT
KEPENTINGAN [OJK E.4] [GRI 2-29] [OJK E.4] [GRI 2-29]
Perseroan meyakini bahwa keberlanjutan usaha sangat The Company believes that business sustainability is
dipengaruhi oleh kualitas hubungan dengan pemangku strongly influenced by the quality of its relationships
kepentingan. Oleh karena itu, Perseroan melakukan with stakeholders. Therefore, the Company conducts
identifikasi pemangku kepentingan secara sistematis a systematic stakeholder identification process based
berdasarkan penilaian manajemen, ketentuan regulasi, on management assessment, regulatory requirements,
keputusan korporasi, serta karakteristik kegiatan usaha corporate decisions, and the characteristics of its business
Perseroan sebagai perusahaan publik dan distributor activities as a public company and pharmaceutical
farmasi. Hasil identifikasi ini menjadi dasar dalam distributor. The results of this identification serve as
menetapkan pendekatan keterlibatan dan respons atas the basis for determining appropriate engagement
ekspektasi pemangku kepentingan secara proporsional approaches and responses to stakeholder expectations
dan berkelanjutan. in a proportional and sustainable manner.
Pemangku kepentingan utama Perseroan meliputi The Company’s key stakeholders include shareholders,
pemegang saham, induk perusahaan, regulator, prinsipal, the parent company, regulators, principals, customers,
pelanggan, karyawan, lembaga jasa keuangan, vendor, employees, financial services institutions, vendors, the
media, dan masyarakat sekitar wilayah operasional. media, and communities surrounding its operational areas.
Perseroan melibatkan pemangku kepentingan melalui The Company engages with stakeholders through various
berbagai kanal yang relevan. Tujuan pelibatan adalah relevant channels. The purpose of such engagement is to
untuk memahami ekspektasi dan kebutuhan, memastikan understand expectations and needs, ensure compliance,
kepatuhan, menjaga kelangsungan rantai pasok dan maintain the continuity of the supply chain and distribution
layanan distribusi, serta mendukung penciptaan nilai services, and support long-term value creation.
jangka panjang.
Tabel Hubungan dengan Pemangku Kepentingan
Table of Stakeholder Engagement
Pendekatan /
Dasar Identifikasi
Pemangku Ekspektasi Utama Model Komunikasi
Basis for Respons Perseroan
No Kepentingan Key Expectations Approach /
Identification Company Response
Stakeholder Communication Model
Kinerja usaha,
Peraturan pasar RUPS, laporan tahunan Penyampaian kinerja
transparansi, tata
modal, RUPS dan keberlanjutan, dan informasi material
kelola
Pemegang Saham Capital market keterbukaan informasi secara berkala
Business
1 Shareholders regulations, GMS, annual and Periodic disclosure
performance,
General Meeting of sustainability reports, of performance and
transparency,
Shareholders (GMS) public disclosures material information
governance
Sinergi usaha, Koordinasi manajemen, Penyelarasan strategi
Hubungan
keselarasan pelaporan internal dan koordinasi
Induk Perusahaan kepemilikan
strategi Management operasional
2 Parent Company Ownership
Business synergy, coordination, internal Strategic alignment and
relationship
strategic alignment reporting operational coordination
Ketentuan peraturan Pelaporan berkala, Pemenuhan kewajiban
perundang- Kepatuhan koordinasi dan kepatuhan dan
Regulator undangan terhadap regulasi komunikasi resmi pelaporan
3 Regulators Statutory and Regulatory Periodic reporting, Fulfillment of compliance
regulatory compliance formal coordination and and reporting
requirements communication obligations
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 223
Page 224
Laporan Keberlanjutan Positioned for
Sustainability Report Profitable Growth
Tabel Hubungan dengan Pemangku Kepentingan
Table of Stakeholder Engagement
Pendekatan /
Dasar Identifikasi
Pemangku Ekspektasi Utama Model Komunikasi
Basis for Respons Perseroan
No Kepentingan Key Expectations Approach /
Identification Company Response
Stakeholder Communication Model
Kepatuhan standar Pemenuhan standar
Hubungan kerja distribusi, mutu Koordinasi bisnis, distribusi dan
sama distribusi layanan komunikasi operasional penguatan layanan
Prinsipal
Distribution Compliance Business coordination, Compliance
4 Principals
partnership with distribution operational with distribution
agreements standards, service communication standards and service
quality enhancement
Peningkatan kualitas
Ketersediaan
Komunikasi bisnis, layanan dan keandalan
Hubungan bisnis produk, kualitas
Pelanggan layanan pelanggan distribusi
Business layanan
5 Customers Business communication, Improvement of service
relationships Product availability,
customer service quality and distribution
service quality
reliability
Kesejahteraan, K3,
Program SDM, K3,
pengembangan
dan pengembangan
kompetensi Komunikasi internal,
Hubungan kerja kompetensi
Karyawan Welfare, kebijakan SDM
Employment HR programs,
6 Employees occupational Internal communication,
relationship OHS initiatives,
health and safety HR policies
and competency
(OHS), competency
development
development
Pemenuhan kewajiban
Lembaga Jasa Hubungan Transparansi dan Pelaporan dan dan pengelolaan
Keuangan pendanaan pengelolaan risiko komunikasi keuangan hubungan
7 Financial Services Financing Transparency and Financial reporting and Fulfillment of obligations
Institutions relationships risk management communication and relationship
management
Kepastian kerja Pengelolaan hubungan
Hubungan sama dan Koordinasi operasional kerja sama yang
Vendor pengadaan pembayaran dan kontraktual profesional
8 Vendors Procurement Certainty of Operational and Professional
relationships cooperation and contractual coordination management of
timely payment partnership relationships
Saluran komunikasi Informasi yang Penyampaian informasi
Siaran pers, komunikasi
publik akurat dan tepat perusahaan secara
Media media
Public waktu bertanggung jawab
9 Media Press releases, media
communication Accurate and Responsible disclosure
communication
channel timely information of corporate information
Pelaksanaan kegiatan
Kepedulian sosial
Komunikasi dan kegiatan sosial dan hubungan
dan lingkungan
Masyarakat Dampak operasional sosial kemasyarakatan
Social and
10 Communities Operational impacts Communication and Implementation of
environmental
social initiatives social programs and
responsibility
community relations
224 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 225
Positioned for Profitable Growth PERMASALAHAN TERHADAP PENERAPAN CHALLENGES IN THE IMPLEMENTATION KEUANGAN BERKELANJUTAN [OJK E.5] OF SUSTAINABLE FINANCE [OJK E.5] Dalam penerapan prinsip keberlanjutan, Perseroan In implementing sustainability principles, the Company menghadapi sejumlah tantangan yang bersifat internal faces several internal and operational challenges. One of dan operasional. Salah satu tantangan utama adalah the primary challenges is strengthening understanding penguatan pemahaman dan internalisasi prinsip and ensuring the consistent internalization of sustainability keberlanjutan secara merata di seluruh organisasi, principles across the organization, as sustainability is an mengingat keberlanjutan merupakan pendekatan yang evolving approach that requires shifts in mindset and terus berkembang dan memerlukan perubahan pola pikir work habits. serta kebiasaan kerja. Selain itu, tantangan juga muncul dalam pengelolaan In addition, challenges arise in the management and dan konsistensi data keberlanjutan, khususnya yang consistency of sustainability data, particularly relating to berkaitan dengan aspek lingkungan dan rantai nilai environmental aspects and the operational value chain, operasional, yang membutuhkan koordinasi lintas fungsi which require cross-functional coordination and adequate serta sistem pendukung yang memadai. Dinamika supporting systems. The evolving regulatory landscape regulasi dan ekspektasi pemangku kepentingan yang and increasing stakeholder expectations also require the terus berkembang turut menuntut Perseroan untuk Company to adaptively align its sustainability policies secara adaptif menyelaraskan kebijakan dan praktik and practices. keberlanjutan. Untuk merespons tantangan tersebut, Perseroan secara To address these challenges, the Company is gradually bertahap memperkuat sosialisasi, koordinasi internal, serta strengthening internal socialization, coordination, and integrasi prinsip keberlanjutan ke dalam proses bisnis dan the integration of sustainability principles into business tata kelola, guna memastikan penerapan keberlanjutan processes and governance structures, in order to ensure berjalan lebih efektif dan berkesinambungan. more effective and sustainable implementation. PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 225
Page 226
Laporan Keberlanjutan Positioned for
Sustainability Report Profitable Growth
Kinerja Ekonomi
Economic Performance
PERBANDINGAN TARGET DAN COMPARISON OF TARGETS AND
REALISASI KINERJA [OJK F.2] [GRI 201-1] REALIZATION [OJK F.2] [GRI 201-1]
Pada tahun buku 2025, Perseroan menjaga kesinambungan In fiscal year 2025, the Company maintained the
kinerja ekonomi melalui penguatan jaringan distribusi sustainability of its economic performance by
obat resep, obat non-resep, serta alat kesehatan di strengthening its distribution network for prescription
berbagai wilayah operasional, seraya mengelola biaya drugs, over-the-counter medicines, and medical
secara pruden untuk mendukung profitabilitas. Di tengah devices across various operational areas, while prudently
dinamika kebutuhan layanan kesehatan dan tuntutan managing costs to support profitability. Amid the evolving
ketepatan layanan distribusi, Perseroan mengarahkan dynamics of healthcare service needs and the demand for
pengelolaan kinerja pada pencapaian target yang accuracy in distribution services, the Company focused its
ditetapkan dalam rencana kerja, sekaligus memastikan performance management on achieving the targets set
disiplin eksekusi operasional berjalan konsisten sepanjang out in its work plan, while ensuring consistent operational
periode pelaporan. execution discipline throughout the reporting period.
Kinerja ekonomi Perseroan dipantau melalui perbandingan The Company’s economic performance is monitored
target dan realisasi atas indikator utama, termasuk through a comparison between targets and actual
pendapatan dan laba/rugi. Pemantauan tersebut menjadi realization of key indicators, including revenue and profit/
dasar evaluasi manajemen dalam menjaga ketahanan loss. Such monitoring serves as the basis for management
kinerja, mengelola faktor-faktor yang memengaruhi evaluation in maintaining performance resilience,
profitabilitas, serta menyempurnakan respons strategis managing factors affecting profitability, and refining
terhadap perubahan kondisi usaha. strategic responses to changes in business conditions.
Selain mencerminkan capaian kinerja, Perseroan Beyond reflecting performance achievements, the
menempatkan penciptaan nilai ekonomi dalam kerangka Company places economic value creation within the
distribusi manfaat kepada pemangku kepentingan. Nilai framework of benefit distribution to stakeholders. The
ekonomi yang dihasilkan tercermin dari pendapatan economic value generated is reflected in the Company’s
usaha Perseroan, sedangkan nilai yang didistribusikan operating revenue, while the economic value distributed
tercermin melalui arus pembayaran kepada pemasok is represented through cash outflows to suppliers and
dan tenaga kerja, penyedia modal (antara lain biaya employees, providers of capital (including finance costs
keuangan dan dividen), serta pemerintah melalui pajak and dividends), as well as to the government through taxes
dibayar. Di saat yang sama, Perseroan mempertahankan paid. At the same time, the Company retains a portion of
sebagian nilai ekonomi untuk menjaga kapasitas the economic value to preserve operational capacity and
operasional dan mendukung keberlanjutan usaha pada support business sustainability in subsequent periods.
periode berikutnya.
226 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 227
Positioned for
Profitable Growth
Perbandingan Target dan Realisasi Pendapatan dan Laba Rugi [OJK F.2]
Comparison of Target and Realization of Revenue and Profit and Loss [OJK F2]
Pendapatan Laba (Rugi)
Tahun Revenue Profit (Loss)
Year Target Realisasi Target Realisasi
Target Realization Target Realization
2025 4.329.993 4.109.810 45.168 38.466
2024 3.887.987 3.916.864 40.394 16.914
2023 3.561.845 3.363.518 41.884 33.081
Nilai Ekonomi yang Dihasilkan dan Didistribusikan [GRI 201-1]
Economic Value Generated and Distributed [GRI 201-1]
(dalam jutaan Rupiah)
(in million Rupiah)
Komponen
2025 2024
Component
Nilai Ekonomi yang Dihasilkan
Economic Value Generated
Pendapatan
4.109.810 3.916.864
Revenue
Nilai Ekonomi yang Didistribusikan
Economic Value Distributed
Pembayaran kepada pemasok dan karyawan
3.832.652 3.878.053
Payments to suppliers and employees
Pembayaran biaya keuangan
10.380 65.635
Payment of finance costs
Pembayaran pajak penghasilan
8.586 21.164
Payment of income tax
Pembayaran dividen
2.548 3.185
Dividend payments
Investasi komunitas/CSR
289 43
Community investment/CSR
Nilai Ekonomi yang Ditahan (Dihasilkan – Didistribusikan)
183.494 51.173
Retained Economic Value (Generated – Distributed)
Penciptaan nilai ekonomi Perseroan tidak berhenti The Company’s economic value creation does not end
pada pertumbuhan usaha, melainkan tercermin pada with business growth, but is reflected in the distribution
distribusi manfaat ekonomi yang memperkuat ekosistem of economic benefits that strengthen the business
bisnis. Nilai ekonomi didistribusikan melalui pembayaran ecosystem. Economic value is distributed through
kepada pemasok dan tenaga kerja, penyedia modal, payments to suppliers and employees, providers of capital,
serta pemerintah melalui pajak dibayar, sementara and to the government through taxes paid, while a portion
sebagian nilai ekonomi ditahan untuk menjaga ketahanan of the economic value is retained to maintain operational
operasional dan mendukung agenda penguatan kinerja resilience and support future performance enhancement
ke depan. Penyajian distribusi nilai ekonomi menggunakan initiatives. The presentation of economic value distribution
basis kas sesuai klasifikasi laporan arus kas. is prepared on a cash basis in accordance with the
classification of the statement of cash flows.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 227
Page 228
Laporan Keberlanjutan Positioned for
Sustainability Report Profitable Growth
PERBANDINGAN TARGET DAN COMPARISON OF TARGET AND
KINERJA PORTOFOLIO/PEMBIAYAAN/ PORTFOLIO/FINANCING/INVESTMENT
INVESTASI YANG SEJALAN DENGAN PERFORMANCE ALIGNED WITH
KEUANGAN BERKELANJUTAN [OJK F.3] SUSTAINABLE FINANCE [OJK F.3]
Pada tahun buku 2025, Perseroan melanjutkan penguatan In fiscal year 2025, the Company continued to strengthen
kinerja portofolio distribusi yang selaras dengan prinsip the performance of its distribution portfolio in line with
keuangan berkelanjutan melalui pengelolaan kerja sama sustainable finance principles through the management
dengan prinsipal serta penguatan eksekusi distribusi of partnerships with principals and the reinforcement of
di berbagai wilayah operasional. Pemantauan kinerja distribution execution across various operational areas.
dilakukan melalui perbandingan target dan realisasi atas Performance monitoring is conducted by comparing
kinerja distribusi berkelanjutan pada portofolio tertentu targets and actual realization of sustainable distribution
sebagaimana disajikan dalam tabel. performance within certain portfolios, as presented in
the table below.
Perbandingan Target dan Realisasi pada Distribusi Berkelanjutan
Comparison of Target and Realization in Sustainable Distribution
2025 2024
Uraian
Description Target Realisasi Target Realisasi
Target Realization Target Realization
PT Lapi Laboratories Indonesia 1.210.160 1.395.460 1.154.543 1.296.272
PT Global Dispomedika 552.813 576.021 410.347 547.679
PT Medi Hop 351.552 435.527 369.950 431.766
Program Pembiayaan atau Investasi Sustainable Financing or
Keuangan Berkelanjutan Investment Programs
Perseroan berkomitmen melaksanakan ketentuan POJK The Company is committed to implementing the
Keuangan Berkelanjutan melalui pelaksanaan program provisions of the OJK Regulation on Sustainable Finance
pembiayaan atau investasi pada instrumen maupun through the execution of financing or investment programs
proyek yang sejalan dengan keuangan/kegiatan in instruments and/or projects aligned with sustainable
berkelanjutan. Dalam pelaksanaannya, program finance/sustainable activities. In practice, such financing
pembiayaan atau investasi tersebut diarahkan pada or investment programs are directed toward criteria
kriteria antara lain: (i) mengutamakan efisiensi dan including: (i) prioritizing the efficient and effective use
efektivitas penggunaan sumber daya alam secara of natural resources in a sustainable manner; and/or
berkelanjutan; dan/atau (ii) mencegah, membatasi, (ii) preventing, limiting, reducing, and/or remedying
mengurangi, maupun memperbaiki kerusakan lingkungan, environmental damage, increased pollution, waste,
peningkatan polusi, limbah, kerusakan ekosistem, serta ecosystem degradation, as well as social inequality/
ketidakadilan/kesenjangan sosial. disparities.
228 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 229
Positioned for Profitable Growth Investasi/Proyek yang Sejalan Investments/Projects Aligned dengan Kegiatan Berkelanjutan with Sustainable Activities Sebagai bagian dari penguatan kapasitas usaha dan As part of strengthening business capacity and ensuring keberlanjutan operasional jangka panjang, Perseroan long-term operational sustainability, the Company also juga melaksanakan investasi/proyek yang sejalan undertakes investments/projects aligned with sustainable dengan kegiatan berkelanjutan. Pada tahun sebelumnya, activities. In the previous year, the Company carried out Perseroan melaksanakan investasi tanah/bangunan yang an investment in land/buildings projected to support the diproyeksikan untuk mendukung pembangunan gedung development of a facility in Bintara, Bekasi City, which is di Bintara, Kota Bekasi, yang direncanakan berfungsi planned to function as a central warehouse as well as sebagai gudang pusat sekaligus kantor cabang Bekasi, the Bekasi branch office, with the objective of enhancing dengan tujuan meningkatkan efisiensi distribusi dan distribution efficiency and supporting infrastructure mendukung optimalisasi infrastruktur serta proses bisnis optimization and more environmentally friendly business yang lebih ramah lingkungan. processes. PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 229
Page 230
Laporan Keberlanjutan Positioned for
Sustainability Report Profitable Growth
Kinerja Lingkungan
Environmental Performance
MPI sebagai entitas yang berorientasi terhadap As a sustainability-oriented entity, MPI is committed to
keberlanjutan berkomitmen untuk menerapkan kegiatan- implementing activities that prioritize environmental
kegiatan yang mengedepankan perlindungan lingkungan protection, including monitoring energy consumption,
hidup seperti pemantauan penggunaan energi, emisi, emissions, water usage, and waste management.
air dan pengelolaan limbah. Dengan kegiatan-kegiatan Through these initiatives, the Company seeks to
tersebut, Perseroan dapat menciptakan kegiatan establish environmentally friendly operational activities
operasional yang ramah lingkungan yang secara tidak that indirectly contribute positively to environmental
langsung berkontribusi positif terhadap keberlanjutan sustainability by prioritizing the efficient and effective use
lingkungan hidup dengan mengutamakan efisiensi of resources on an ongoing basis and aligning industrial
dan efektivitas penggunaan sumber daya secara development with the preservation of environmental
berkelanjutan dan menyelaraskan pembangunan industri functions, while also delivering maximum benefits to the
dengan kelestarian fungsi lingkungan hidup, sekaligus community.
memberikan manfaat maksimal bagi masyarakat.
KEBIJAKAN PENGELOLAAN LINGKUNGAN ENVIRONMENTAL MANAGEMENT POLICY
Perseroan percaya bahwa setiap upaya menjaga The Company believes that every effort to preserve
kelestarian lingkungan memiliki dampak positif terhadap environmental sustainability has a positive impact
mewujudkan lingkungan yang berkelanjutan bagi on creating a sustainable environment for humanity,
manusia, terutama untuk generasi mendatang. Sebagai particularly for future generations. As a concrete
bentuk konkret dari komitmen Perseroan terhadap manifestation of the Company’s commitment to
kelestarian lingkungan, setiap kegiatan operasional environmental preservation, all operational and business
dan bisnis Perseroan melibatkan studi lingkungan dan activities involve environmental studies and environmental
pengelolaan lingkungan hidup guna mengurangi potensi management measures aimed at reducing potential
dampak lingkungan yang mungkin timbul. environmental impacts that may arise.
Dasar hukum Perseroan dalam melakukan pengelolaan The Company’s legal basis for carrying out environmental
lingkungan hidup adalah UU No. 32 Tahun 2009 tentang management refers to Law No. 32 of 2009 concerning
Perlindungan dan Pengelolaan Lingkungan Hidup. Environmental Protection and Management. This law
Undang-undang ini menyatakan bahwa perlindungan stipulates that environmental protection and management
dan pengelolaan lingkungan hidup melibatkan usaha involve systematic and integrated efforts, including
sistematis dan terpadu, yang mencakup perencanaan, planning, utilization, control, maintenance, supervision,
pemanfaatan, pengendalian, pemeliharaan, pengawasan, and law enforcement.
dan penegakan hukum.
Keberlanjutan bisnis Perseroan tidak hanya diukur dari The sustainability of the Company’s business is
kinerja finansial, tetapi juga dari kepedulian terhadap measured not only by financial performance, but also
lingkungan dan dampak positif bagi masyarakat by environmental stewardship and its positive impact on
sekitarnya. Untuk mencapai hal tersebut, Perseroan telah surrounding communities. To achieve this, the Company
merumuskan beberapa upaya pelestarian lingkungan has formulated several environmental preservation
hidup yang dilaksanakan oleh Perseroan antara lain: initiatives implemented by the Company, including:
1. Menyediakan produk yang aman dan berkualitas. 1. Providing safe and high-quality products.
2. Memberikan layanan dan informasi tentang 2. Delivering services and information regarding the
penggunaan dan penanganan produk yang dihasilkan. proper use and handling of its products.
3. Menetapkan, menerapkan, dan memelihara sistem 3. Establishing, implementing, and maintaining systems
pencegahan kecelakaan dan penyakit akibat kerja, to prevent occupational accidents and diseases,
pencemaran lingkungan dan dampaknya dalam environmental pollution and its impacts in all
setiap aktivitas operasional Perseroan sesuai dengan operational activities, in compliance with applicable
persyaratan dan peraturan yang berlaku. requirements and regulations.
4. Menetapkan, menerapkan dan memelihara sistem 4. Establishing, implementing, and maintaining risk
pengelolaan risiko dalam setiap aktivitas operasional management systems in all operational activities.
Perseroan.
230 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 231
Positioned for Profitable Growth 5. Menetapkan, menerapkan dan memelihara sistem 5. Establishing, implementing, and maintaining work kerja yang berorientasi pada peningkatan produktivitas, systems oriented toward enhancing productivity, efisiensi dan inovasi dengan mempertimbangkan efficiency, and innovation, while considering quality perbaikan mutu dan konservasi sumber daya alam. improvement and natural resource conservation. 6. Perbaikan berkesinambungan atas proses, 6. Continuously improving processes, infrastructure, infrastruktur, teknologi dan kompetensi SDM sesuai technology, and human resource competencies in tuntutan persyaratan manajemen mutu, lingkungan accordance with quality management, environmental, serta keselamatan dan kesehatan kerja. and occupational health and safety requirements. 7. Meningkatkan kepedulian lingkungan dalam rangka 7. Enhancing environmental awareness as part of the tanggung jawab sosial Perseroan. Company’s social responsibility. 8. Menerapkan Governansi Korporat dalam setiap 8. Implementing Corporate Governance in all operational aktivitas operasional Perseroan. activities. ASPEK UMUM GENERAL ASPECT Biaya Lingkungan Hidup [F.4] Environmental Costs [F.4] Perseroan menjalankan pengelolaan aspek lingkungan The Company manages environmental aspects through melalui penerapan prosedur operasional dan pemenuhan the implementation of operational procedures and ketentuan yang relevan, termasuk pengelolaan limbah compliance with relevant regulations, including the operasional serta pemeliharaan sarana prasarana management of operational waste and the maintenance penunjang. Hingga akhir tahun buku 2025, Perseroan of supporting facilities and infrastructure. As of the end belum melakukan pemisahan pencatatan biaya of fiscal year 2025, the Company has not yet separately lingkungan hidup sebagai pos biaya tersendiri, karena recorded environmental costs as a distinct cost item, biaya terkait pengelolaan lingkungan masih terintegrasi as expenses related to environmental management dalam biaya operasional pada masing-masing unit kerja remain integrated within the operational expenses of (antara lain pemeliharaan fasilitas, kebersihan, dan each respective work unit (including facility maintenance, pengelolaan limbah oleh pihak ketiga berizin apabila cleaning services, and waste management by licensed relevan). Ke depan, Perseroan akan menyempurnakan third parties, where relevant). Going forward, the Company pemetaan dan klasifikasi biaya agar pengungkapan will enhance the mapping and classification of costs so biaya lingkungan hidup dapat disajikan lebih terukur that the disclosure of environmental expenses can be dan konsisten. presented in a more measurable and consistent manner. Jumlah dan Materi Pengaduan Number and Nature of Environmental Lingkungan Hidup yang Diterima Complaints Received and Resolved [OJK F16] dan Diselesaikan [OJK F16] Selama periode pelaporan, tidak pernah tercatat bahwa During the reporting period, there were no recorded Perseroan melakukan pelanggaran terhadap peraturan violations by the Company of laws and regulations in perundang-undangan di bidang lingkungan hidup. the environmental sector. ASPEK MATERIAL MATERIAL ASPECT Penggunaan Material yang Use of Environmentally Ramah Lingkungan [OJK F5] Friendly Materials [OJK F5] Pada tahun buku 2025, Perseroan menerapkan kebijakan In fiscal year 2025, the Company implemented ramah lingkungan melalui program pengelolaan environmentally friendly policies through environmental lingkungan dengan tujuan dan sasaran yang jelas, management programs with clear objectives and yaitu menjaga tingkat kepatuhan yang tinggi dalam targets, namely maintaining a high level of compliance pengelolaan lingkungan, meningkatkan efisiensi in environmental management, improving operational kegiatan operasional, serta memperkuat tanggung efficiency, and strengthening the Company’s jawab Perseroan terhadap lingkungan dan sosial. environmental and social responsibility. Environmental Sasaran pengelolaan lingkungan mencakup pengelolaan management targets encompass comprehensive lingkungan secara komprehensif, termasuk udara, air environmental management, including air, wastewater, limbah, limbah padat, serta limbah Bahan Berbahaya dan solid waste, and Hazardous and Toxic Waste (B3), in Beracun (B3), sesuai standar regulasi yang ditetapkan accordance with regulatory standards established by oleh pemerintah, disertai inovasi program sebagai bentuk the government, accompanied by program innovations perbaikan berkesinambungan. as part of continuous improvement efforts. Komitmen tersebut juga tercermin melalui upaya This commitment is also reflected in material efficiency penghematan material dan penerapan praktik daur ulang, initiatives and the implementation of recycling practices, PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 231
Page 232
Laporan Keberlanjutan Positioned for
Sustainability Report Profitable Growth
antara lain penghematan kertas melalui penggunaan including paper reduction through double-sided printing
kertas dua sisi dan daur ulang sampah kertas, serta and paper waste recycling, as well as collaboration with
pemanfaatan pihak ketiga yang memiliki kompetensi competent third parties in the recycling sector for materials
di bidang daur ulang untuk material yang sudah tidak that can no longer be used but still retain residual value.
dapat digunakan namun masih memiliki nilai manfaat.
Kerangka Kebijakan Ramah Lingkungan Perseroan
The Company’s Environmentally Friendly Policy Framework
Pilar Kebijakan Fokus Penerapan dalam Proses Bisnis
Policy Pillar Focus of Implementation in Business Processes
Integrasi dari hulu ke hilir: mulai seleksi pemasok, pemilihan produk, hingga penanganan
Menjaga Kelestarian Lingkungan
pengiriman kepada pelanggan.
Preserving Environmental
Integrated implementation from upstream to downstream: starting from supplier
Sustainability
selection, product selection, to delivery handling for customers.
Efisiensi Energi Upaya mengurangi kebutuhan energi dalam proses distribusi.
Energy Efficiency Efforts to reduce energy requirements in distribution processes.
Menggunakan Air secara
Penerapan prinsip 4R: reduce, reuse, recycle, dan recovery.
Bertanggung Jawab
Application of the 4R principles: reduce, reuse, recycle, and recovery.
Responsible Water Use
Pemilahan sampah dalam lima kategori untuk memudahkan proses pengolahan di
Pengelolaan Limbah
tempat pembuangan akhir.
Waste Management
Waste segregation into five categories to facilitate processing at the final disposal site.
Internalisasi Budaya Ramah Kampanye budaya/perilaku yang mendukung kelestarian lingkungan di tempat kerja dan
Lingkungan lingkungan keluarga karyawan.
Internalization of an Cultural and behavioral campaigns that promote environmental sustainability in the
Environmentally Friendly Culture workplace and within employees’ family environments.
ASPEK ENERGI ENERGY ASPECT
Pengelolaan energi menjadi salah satu perhatian Energy management is one of the Company’s key priorities
Perseroan dalam mendorong efisiensi operasional in promoting operational efficiency while upholding
sekaligus menjaga tanggung jawab lingkungan. environmental responsibility. Guided by the 3R principles
Berlandaskan prinsip 3R (Reduce, Reuse, dan Recycle), (Reduce, Reuse, and Recycle), the Company directs
Perseroan mengarahkan penggunaan energi secara lebih energy use in a more measurable manner, particularly
terukur, terutama pada aktivitas distribusi yang ditopang in distribution activities supported by operational vehicles.
oleh kendaraan operasional. Sejalan dengan karakteristik In line with its business characteristics as a distributor,
usaha sebagai distributor, konsumsi BBM menjadi fuel consumption constitutes the dominant component
komponen dominan dalam profil energi Perseroan. in the Company’s energy profile. Therefore, the Company
Oleh karena itu, Perseroan melakukan pencatatan dan records and monitors energy usage and strengthens
pemantauan penggunaan energi serta penguatan delivery arrangements to enhance operational efficiency
pengaturan pengiriman agar efisiensi operasional while maintaining controlled energy consumption.
meningkat dan konsumsi energi tetap terkendali.
Penggunaan Energi [OJK F.6] Energy Consumption [OJK F.6]
Perseroan membutuhkan energi untuk mendukung The Company requires energy to support its operational
kegiatan operasional maupun kegiatan pendukung and supporting activities. Energy needs are met from
lainnya. Kebutuhan energi dipenuhi dari sumber energi non-renewable energy sources and/or other energy
tak terbarukan dan/atau sumber energi lain yang sources utilized in operations. Throughout fiscal year 2025,
digunakan dalam operasional. Sepanjang tahun buku the Company conducted periodic monitoring of energy
2025, Perseroan melakukan pemantauan konsumsi energi consumption to ensure that energy use remained efficient
secara berkala untuk memastikan penggunaan energi and well controlled.
tetap efisien dan terkendali.
Konsumsi Energi Listrik Electricity Consumption
Kebutuhan listrik Perseroan terutama dipasok oleh PT The Company’s electricity needs are primarily supplied
PLN (Persero), dengan dukungan genset dalam kondisi by PT PLN (Persero), with generator sets available for
darurat. Perubahan konsumsi listrik pada tahun buku 2025 emergency situations. Changes in electricity consumption
dipengaruhi oleh dinamika aktivitas operasional, termasuk during fiscal year 2025 were influenced by operational
penyesuaian kapasitas dan kebutuhan layanan di kantor dynamics, including adjustments to capacity and service
pusat maupun kantor cabang. requirements at both the head office and branch offices.
232 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 233
Positioned for
Profitable Growth
Konsumsi Energi Listrik
Electrical Energy Consumption
Tahun
kWh Gigajoule (GJ)
Year
2025 2.638.910,14 9.500,08
2024 2.729.272,58 9.825,38
2023 2.529.414,49 9.105,89
Konsumsi BBM (Petrol) Fuel Consumption (Petrol)
Perseroan mengoperasikan kendaraan di kantor pusat The Company operates vehicles at both the head
dan kantor cabang untuk mendukung kegiatan distribusi office and branch offices to support distribution and
dan operasional. Konsumsi BBM pada tahun buku operational activities. Fuel consumption in fiscal year
2025 dipengaruhi oleh kebutuhan layanan distribusi, 2025 was influenced by distribution service requirements,
pengelolaan rute pengiriman, serta skema operasional delivery route management, and the operational schemes
yang diterapkan (termasuk pemanfaatan pihak ketiga implemented (including the engagement of third parties,
apabila relevan). where relevant).
Konsumsi BBM (Petrol)
Fuel Consumption (Petrol)
Tahun
Liter Gigajoule (GJ)
Year
2025 587.770,06 19.268,28
2024 607.155,18 20.764,71
2023 626.418,85 21.423,52
Intensitas Penggunaan Energi
Energy Usage Intensity
Uraian
2025 2024
Description
Energi Listrik (GJ)
9.500,08 9.825,38
Electrical Energy (GJ)
Energi BBM Petrol (GJ)
19.268,28 20.764,71
Petroleum Fuel Energy (GJ)
Total Energi (GJ)
28.768,36 30.590,09
Total Energy (GJ)
Intensitas Energi Total (GJ/Pendapatan)
Total Energy Intensity (GJ/Revenue)
Pendapatan (Juta Rp)
4.109.810 3.916.864
Revenue (Million Rp)
Intensitas Energi Total (GJ/Juta Rp Pendapatan)
6.999,92 7.809,90
Total Energy Intensity (GJ/ Million Rp Revenue)
UPAYA PENGHEMATAN ENERGY EFFICIENCY INITIATIVES (OJK F.7)
PENGGUNAAN ENERGI (OJK F.7)
Sepanjang tahun buku 2025, Perseroan melanjutkan Throughout fiscal year 2025, the Company continued
upaya efisiensi energi untuk menjaga pengendalian its energy efficiency efforts to manage and control the
dampak operasional terhadap lingkungan. Upaya efisiensi environmental impact of its operations. Efficiency measures
dilakukan melalui peningkatan disiplin penggunaan were implemented through improved discipline in energy use,
energi, perbaikan bertahap pada peralatan fasilitas yang gradual upgrades to more energy-efficient equipment and
lebih hemat energi, serta penguatan efisiensi pada sistem facilities, as well as strengthened efficiency in transportation
transportasi dan pengaturan aktivitas operasional. systems and operational activity arrangements.
Perseroan juga mendorong partisipasi karyawan melalui The Company also encouraged employee participation
sosialisasi internal untuk membangun kebiasaan hemat through internal socialization programs aimed at fostering
energi dan memperkuat budaya efisiensi. Evaluasi internal energy-saving habits and reinforcing a culture of efficiency.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 233
Page 234
Laporan Keberlanjutan Positioned for
Sustainability Report Profitable Growth
dilakukan secara berkelanjutan melalui pemantauan Internal evaluations were carried out on an ongoing basis
data konsumsi energi, penetapan peluang perbaikan, through monitoring energy consumption data, identifying
serta penyusunan rencana tindak lanjut efisiensi energi improvement opportunities, and preparing follow-up
sesuai kebutuhan Perseroan. action plans for energy efficiency in accordance with the
Company’s needs.
Aspek Air Water Aspect
Pengelolaan air menjadi bagian dari upaya Perseroan Water management forms part of the Company’s efforts
dalam menjaga efisiensi sumber daya serta memastikan to maintain resource efficiency and ensure that operations
operasional berjalan selaras dengan prinsip keberlanjutan. align with sustainability principles. In the context of the
Dalam konteks kegiatan usaha Perseroan sebagai Company’s business activities as a distributor, water usage
distributor, penggunaan air terutama terkait aktivitas is primarily related to office and domestic operational
perkantoran dan operasional domestik, sehingga fokus activities. Accordingly, water management focuses on
pengelolaan diarahkan pada pemenuhan kebutuhan dasar meeting basic needs in a reasonable manner, controlling
secara wajar, pengendalian konsumsi, serta peningkatan consumption, and enhancing awareness of water-saving
kesadaran perilaku hemat air di lingkungan kerja. behavior within the workplace.
Penggunaan Air (OJK F.8) Water Usage (OJK F.8)
Air yang digunakan oleh karyawan di lingkungan kantor Water used by employees within the office environment
bersumber dari Perusahaan Daerah Air Minum (PDAM) is sourced from the Regional Water Supply Company
dan dimanfaatkan untuk kebutuhan domestik, antara (PDAM) and is utilized for domestic purposes, including
lain cuci tangan, wudhu, serta kebersihan kantor. handwashing, ablution, and office sanitation.
Tabel Konsumsi Air
Water Consumption Table
Tahun Sumber Air Konsumsi Air (liter)
Year Water Source Water Consumption (liters)
2025 PDAM 6.681,78
2024 PDAM 7.284,55
Hingga akhir tahun buku 2025, konsumsi air Perseroan As of the end of fiscal year 2025, the Company’s total water
tercatat sebesar 6.681,78 liter. Sebagai pembanding, pada consumption amounted to 6,681.78 liters. As a comparison,
akhir tahun 2024 konsumsi air Perseroan tercatat 7.284,55 as of the end of 2024, the Company’s water consumption
liter. konsumsi air dicatat berdasarkan penggunaan air was recorded at 7,284.55 liters. Water consumption is
di lingkungan kantor untuk kebutuhan domestik, antara recorded based on office water usage for domestic
lain cuci tangan, wudhu, dan kebersihan kantor. purposes, including handwashing, ablution, and office
sanitation.
Dalam rangka menjaga penggunaan air yang bertanggung To ensure responsible water use, the Company conducts
jawab, Perseroan melakukan pemantauan konsumsi periodic monitoring of water consumption and promotes
air secara berkala dan mendorong praktik efisiensi di efficiency practices within the workplace. These efficiency
lingkungan kerja. Upaya efisiensi tersebut diarahkan untuk efforts are aimed at reducing water wastage while
menekan pemborosan air sekaligus menjaga kualitas maintaining cleanliness standards and the comfort of
kebersihan dan kenyamanan fasilitas kerja. workplace facilities.
Air Digunakan Kembali Water Reuse
Hingga akhir tahun buku 2025, Perseroan belum memiliki As of the end of fiscal year 2025, the Company has not yet
mekanisme daur ulang air. Prioritas pelestarian sumber implemented a water recycling mechanism. The priority
daya air dilakukan melalui efisiensi penggunaan air, for water resource conservation is therefore focused on
termasuk kampanye untuk meningkatkan kesadaran efficient water use, including campaigns to raise employee
karyawan agar menerapkan perilaku hemat air dalam awareness in adopting water-saving behaviors in daily
aktivitas sehari-hari di lingkungan kerja. workplace activities.
Ke depan, Perseroan akan terus memperkuat budaya Going forward, the Company will continue to strengthen
hemat air melalui penguatan komunikasi internal, a water-saving culture through enhanced internal
pemeliharaan sarana sanitasi yang memadai, serta communication, proper maintenance of sanitation
penyempurnaan pencatatan konsumsi air agar efektivitas facilities, and improved recording of water consumption
upaya efisiensi dapat dipantau lebih terukur. so that the effectiveness of efficiency initiatives can be
monitored in a more measurable manner.
234 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 235
Positioned for Profitable Growth ASPEK KEANEKARAGAMAN BIODIVERSITY ASPECT [OJK F.9, F.10] HAYATI [OJK F.9, F.10] Hingga akhir tahun buku 2025, Perseroan belum Until the end of the 2025 financial year, the Company has menjalankan program konservasi keanekaragaman not implemented a specific and structured biodiversity hayati yang bersifat spesifik dan terstruktur, mengingat conservation program, considering that the Company’s kegiatan usaha Perseroan tidak beroperasi pada area business activities do not operate in areas that directly yang secara langsung bersinggungan dengan kawasan intersect with conservation areas or areas with high konservasi atau wilayah dengan nilai keanekaragaman biodiversity values. Nevertheless, the Company continues hayati yang tinggi. Meskipun demikian, Perseroan tetap to show concern for environmental conservation menunjukkan kepedulian terhadap pelestarian lingkungan through various supporting efforts that are relevant to melalui berbagai upaya pendukung yang relevan dengan the characteristics of its business activities, including karakteristik kegiatan usahanya, antara lain penguatan strengthening an environmentally friendly culture in the budaya ramah lingkungan di tempat kerja, pengendalian workplace, waste control, efficiency in the use of energy limbah, efisiensi penggunaan sumber energi, serta sources, and participation in planting 750 mangrove tree partisipasi dalam kegiatan penanaman 750 bibit pohon seedlings which are divided into 2 (two) phases, namely: mangrove yang terbagi menjadi 2 (dua) fase, yaitu: 1. Fase pertama, diselenggarakan pada 26 Juli 2025 di 1. Phase will be held on July 26, 2025 on Pramuka Island Pulau Pramuka dengan menanam 500 bibit pohon by planting 500 mangrove tree seedlings; and mangrove; dan 2. Fase kedua, dilanjutkan pada 9 Agustus 2025 di Hutan 2. Phase will continue on August 9, 2025 in the Muara Lindung Muara Angke dengan penanaman 250 bibit Angke Protected Forest with the planting of 250 pohon mangrove. mangrove tree seedlings. Kegiatan penanaman mangrove tersebut mencerminkan The mangrove planting activity reflects the Company’s kontribusi Perseroan terhadap upaya mitigasi perubahan contribution to climate change mitigation efforts while iklim sekaligus pelestarian ekosistem pesisir, yang sejalan also supporting the preservation of coastal ecosystems, in dengan Tujuan Pembangunan Berkelanjutan, khususnya line with the Sustainable Development Goals, particularly TPB 13 Penanganan Perubahan Iklim, TPB 14 Ekosistem Laut, SDG 13 Climate Action, SDG 14 Life Below Water, and SDG dan TPB 15 Ekosistem Daratan. Dengan demikian, meskipun 15 Life on Land. Accordingly, although the Company has belum memiliki program konservasi biodiversitas yang not yet established a dedicated biodiversity conservation tersusun secara khusus, Perseroan tetap berupaya program, it remains committed to making a positive memberikan kontribusi positif terhadap perlindungan contribution to environmental protection through lingkungan melalui inisiatif yang terukur dan relevan. measured and relevant initiatives. ASPEK EMISI EMISSIONS ASPECT Pengendalian emisi merupakan bagian dari upaya Emission control forms part of the Company’s efforts to pengendalian dampak lingkungan dari kegiatan manage the environmental impact of its operational operasional Perseroan. Pengendalian emisi dilakukan activities. Emission management is carried out in reference mengacu pada ketentuan yang relevan, termasuk to relevant regulations, including Minister of Environment Permen LH Nomor 15 Tahun 2019 tentang Baku Mutu Emisi Regulation (Permen LH) No. 15 of 2019 concerning Emission Pembangkit Thermal (sepanjang relevan dengan sumber Standards for Thermal Power Plants (to the extent emisi Perseroan). Perseroan melakukan inventarisasi applicable to the Company’s emission sources). The emisi yang mencakup emisi absolut dan intensitas emisi Company conducts an emissions inventory covering both untuk Cakupan 1, Cakupan 2, dan Cakupan 3, dengan absolute emissions and emission intensity for Scope 1, ruang lingkup pelaporan perusahaan tunggal dan tanpa Scope 2, and Scope 3. The reporting scope applies to a menerapkan pendekatan pembagian ekuitas, kontrol single-entity company and does not adopt an equity keuangan, maupun pengendalian operasional dalam share approach, financial control approach, or operational perhitungan emisi. control approach in the calculation of emissions. Jumlah dan Intensitas Emisi yang Total and Intensity of Emissions Dihasilkan Berdasarkan Jenisnya [OJK F.11] Generated by Type [OJK F.11] Emisi GRK Langsung (Cakupan 1) Direct GHG Emissions (Scope 1) Sumber emisi gas rumah kaca langsung (Cakupan 1) The Company’s direct greenhouse gas (GHG) emission Perseroan bersumber dari kendaraan operasional, generator sources (Scope 1) originate from operational vehicles, set yang digunakan dalam aktivitas produksi, pembakaran generator sets used in production activities, and fuel bahan bakar untuk membangkitkan energi listrik. combustion to generate electricity. PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 235
Page 236
Laporan Keberlanjutan Positioned for
Sustainability Report Profitable Growth
Penghitungan emisi dari kendaraan operasional dilakukan Emissions from operational vehicles are calculated using
dengan mengacu pada UK Government GHG Conversion the UK Government GHG Conversion Factors for Company
Factors for Company Reporting Version 1.0 Year 2024. Reporting, Version 1.0, Year 2024.
Sementara itu, penghitungan emisi dari penggunaan Meanwhile, the calculation of emissions from generator
genset dilakukan dengan mengacu pada UK Government (genset) usage refers to the UK Government GHG
GHG Conversion Factors for Company Reporting Version Conversion Factors for Company Reporting Version 1.0 Year
1.0 Year 2024 serta US EPA Emission Factors for Greenhouse 2024 as well as the US EPA Emission Factors for Greenhouse
Gas Inventories, 2024. Gas Inventories, 2024.
Selain bersumber dari konsumsi bahan bakar, emisi GRK In addition to fuel consumption, the Company’s direct GHG
langsung Perseroan juga mencakup pelepasan gas SF6. emissions also include the release of SF6 gas. Emissions
Penghitungan emisi dari pelepasan gas tersebut dilakukan from this release are calculated by multiplying the amount
dengan mengalikan jumlah penambahan gas SF6 dengan of SF6 gas added by the Global Warming Potential (GWP)
faktor Global Warming Potential (GWP) yang mengacu factor based on the IPCC Assessment Report 5 (AR5)
pada IPCC Assessment Report 5 (AR5) Tahun 2014. Year 2014.
Emisi Gas Rumah Kaca (Cakupan 1)
Greenhouse Gas Emissions (Scope 1)
Tahun Sumber Emisi Total Emisi (kgCO2e) Total Emisi (tonCO2e)
Year Emission Source Total Emissions (kgCO2e) Total Emissions (tonCO2e)
Mobil
240.291,47 140,29
Cars
Sepeda motor milik sendiri
211.916,57 211,92
Motorcycles (owned)
Generator set
2025 6.935,36 6,94
Generator
Kendaraan niaga ringan
101.791,84 101,79
Light Goods vehicles
Kendaraan niaga berat
2.999,39 3,00
Heavy Goods vehicles
TOTAL 560.112,43 560.11
Mobil
255.356,26 255,36
Cars
Sepeda motor milik sendiri
233.545,71 233,55
Motorcycles (owned)
Generator set
2024 4.011,41 4,01
Generator
Kendaraan niaga ringan
133.544,50 133,54
Light Goods vehicles
Kendaraan niaga berat
13.383,77 13,38
Heavy Goods vehicles
TOTAL 639.841,65 639,84
Mobil
266.973,63 266,97
Cars
Sepeda motor milik sendiri
2023 274.890,78 274,89
Motorcycles (owned)
Generator set
2.938,43 2,94
Generator
Kendaraan niaga ringan
163.792,91 163,79
Light Goods vehicles
Kendaraan niaga berat
2.107,16 2,11
Heavy Goods vehicles
TOTAL 710.161,58 710,70
236 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 237
Positioned for
Profitable Growth
Emisi GRK Tidak Langsung (Cakupan 2) Indirect GHG Emissions (Scope 2)
Sumber emisi gas rumah kaca tidak langsung (Cakupan Indirect greenhouse gas (GHG) emissions (Scope 2)
2) adalah konsumsi listrik dari PLN yang merupakan emisi arise from electricity consumption supplied by PLN.
GRK yang berasal dari kehilangan energi atau susut energi These emissions represent GHG emissions resulting from
atas energi listrik yang dibeli dihitung dengan mengalikan energy losses associated with purchased electricity and
susut energi tersebut dengan Faktor Emisi Sistem are calculated by multiplying the amount of energy loss
Ketenagalistrikan terbaru yang diterbitkan oleh DJK (tahun by the latest Electricity System Emission Factor issued
2019). Beban Emisi CO2 yang dihasilkan oleh aktivitas yang by the Directorate General of Electricity (DJK) (2019). The
menggunakan listrik PLN dihitung berdasarkan faktor CO2 emission load generated from activities using PLN
emisi untuk sistem interkoneksi Jawa-Madura- Bali yang electricity is calculated based on the emission factor for the
diatur dalam Surat Keputusan (SK) Direktorat Jenderal Java–Madura–Bali interconnected system, as stipulated
Ketenagalistrikan tahun 2016 sebesar 0,85 (ton) setara in the 2016 Decree of the Directorate General of Electricity,
karbon dioksida (CO2eq)/Megawatt jam (MWh). amounting to 0.85 tons of carbon dioxide equivalent
(CO2eq) per megawatt hour (MWh).
Emisi Gas Rumah Kaca (Cakupan 2)
Greenhouse Gas Emissions (Scope 2)
Tahun Sumber Emisi Total Emisi (kgCO2e) Total Emisi (tonCO2e)
Year Emission Source Total Emissions (kgCO2e) Total Emissions (tonCO2e)
Listrik
2025 2.155.989,58 2.155,99
Electricity
Listrik
2024 2.183.418,06 2.183,42
Electricity
Listrik
2023 2.023.531,59 2.023,53
Electricity
Emisi GRK Tidak Langsung Other Indirect GHG Emissions (Scope 3)
Lainnya (Cakupan 3)
Emisi GRK tidak langsung lainnya (Cakupan 3) mencakup Other indirect GHG emissions (Scope 3) comprise emission
sumber emisi yang terjadi di luar kendali langsung sources that occur outside the Company’s direct control
Perseroan, namun tetap terkait dengan aktivitas Perseroan, but remain related to its activities, such as business
seperti perjalanan dinas dan aktivitas logistik/distribusi. travel and logistics/distribution activities. Emissions
Perhitungan emisi dilakukan dengan menggunakan are calculated using a reference-based approach by
metode pendekatan referensi, yaitu dengan mengalikan multiplying the emissions load from fuel combustion by
beban emisi dari pembakaran bahan bakar dengan nilai the applicable Global Warming Potential (GWP) value.
Global Warming Potential (GWP). Beban emisi diperoleh dari The emissions load is derived from multiplying fuel
hasil perkalian konsumsi bahan bakar dengan faktor emisi, consumption by the relevant emission factor, while the
sedangkan nilai faktor emisi GRK untuk bahan bakar bensin GHG emission factors for gasoline and diesel refer to the UK
dan solar mengacu pada UK Government Conversion Government Conversion Factors for Company Reporting
Factors for Company Reporting Version 1 Tahun 2024. Version 1 of 2024.
Selain itu, Perseroan juga telah berpartisipasi dalam In addition, the Company has participated in the collection
pengumpulan data emisi Cakupan 3 melalui survei indikator of Scope 3 emissions data through the employee
perjalanan pulang-pergi karyawan yang diselenggarakan commuting indicator survey conducted by Pharmaniaga
oleh Pharmaniaga untuk tahun 2024 dan 2025, sebagai bagian for the 2024 and 2025 reporting years, as part of its ongoing
dari upaya penguatan kualitas data dan pengembangan efforts to strengthen data quality and gradually enhance
pengukuran emisi tidak langsung secara bertahap. the measurement of indirect emissions.
Emisi GRK Tidak Langsung Lainnya (Cakupan 3)
Other Indirect GHG Emissions (Scope 3)
Tahun Total Emisi (kgCO2e) Total Emisi (tonCO2e)
Year Total Emissions (kgCO2e) Total Emissions (tonCO2e)
2025 668.534,55 668,53
2024 768.512,84 768,51
2023 741.701,94 741,70
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 237
Page 238
Laporan Keberlanjutan Positioned for
Sustainability Report Profitable Growth
Intensitas Emisi GRK
GHG Emission Intensity
Uraian
2025 2024
Description
Emisi Cakupan 1 (tonCO2e)
560,11 639,84
Scope 1 Emissions (tons CO2e)
Emisi Cakupan 2 (tonCO2e)
2.155,99 2.183,42
Scope 2 Emissions (tons CO2e)
Emisi Cakupan 3 (tonCO2e)
668,53 768,51
Scope 3 Emissions (tons CO2e)
Total Emisi (tonCO2e)
3,384.64 3,591.77
Total Emissions (tons CO2e)
Intensitas Emisi (tonCO2e/Pendapatan)
Emission Intensity (tons CO2e/Revenue)
Pendapatan (Juta Rp)
4.109.810 3.916.864
Revenue (Million Rp)
Intensitas Emisi (tonCO2e/Juta Rp Pendapatan) 0,00092
0,00082
Emission Intensity (tons CO2e/Million Rp Revenue)
Upaya dan Pencapaian Pengurangan Emission Reduction Efforts and
Emisi yang Dilakukan [OJK F.12] Achievements [OJK F.12]
Sepanjang tahun buku 2025, Perseroan melanjutkan upaya Throughout fiscal year 2025, the Company continued
pengurangan emisi melalui efisiensi energi dan penguatan its emission reduction efforts through energy efficiency
pengelolaan armada operasional. Upaya yang dilakukan initiatives and strengthened management of its operational
mencakup pemeliharaan kendaraan secara berkala, fleet. Measures undertaken included periodic vehicle
termasuk pengujian emisi gas buang, serta peremajaan maintenance, including exhaust emission testing, as well as
kendaraan yang sudah tidak layak pakai. Perseroan juga the replacement of vehicles that were no longer roadworthy.
mendorong penggunaan kendaraan yang lebih hemat The Company also promoted the use of more fuel-efficient
bahan bakar melalui pengelolaan spesifikasi kendaraan vehicles through vehicle specification management and
dan penyesuaian kebutuhan operasional secara bertahap. the gradual adjustment of operational requirements. In
Sejalan dengan upaya tersebut, total emisi Perseroan pada line with these efforts, the Company’s total emissions in
tahun 2025 turun menjadi 3.384,63 tonCO2e dari 3.591,77 2025 decreased to 3,384.63 metric tonsCO2e from 3,591.77
tonCO2e pada tahun 2024, atau menurun 5,77%. metric tonsCO2e in 2024, representing a 5.77% decrease.
ASPEK LIMBAH DAN EFLUEN WASTE AND EFFLUENT ASPECT
Jumlah Limbah dan Efluen yang Total Waste and Effluent
Dihasilkan Berdasarkan Jenis [OJK F.13] Generated by Type [OJK F.13]
Perseroan telah melakukan identifikasi atas potensi The company has identified the potential waste and
timbulan limbah dan efluen yang berasal dari aktivitas effluent generation from office activities, warehouses,
perkantoran, gudang, dan kegiatan distribusi. Namun, and distribution activities. However, until the fiscal year
sampai dengan tahun buku 2025, Perseroan belum 2025, the Company has not specifically recorded the
melakukan pencatatan secara khusus atas jumlah limbah amount of waste and effluent produced based on its type.
dan efluen yang dihasilkan berdasarkan jenisnya.
Mekanisme Pengelolaan Waste and Effluent Management
Limbah dan Efluen [OJK F.14] Mechanism [OJK F.14]
Perseroan memandang bahwa limbah dan efluen perlu The Company recognizes that waste and effluent must
dikelola secara bertanggung jawab untuk mencegah be managed responsibly to prevent pollution and
pencemaran dan menjaga kepatuhan lingkungan. ensure environmental compliance. The management
Mekanisme pengelolaan diarahkan pada pengurangan mechanism is directed toward reducing waste generation
timbulan dari sumbernya, pemilahan, pemanfaatan at the source, segregation, reuse, and final handling in
kembali, serta penanganan akhir sesuai ketentuan. accordance with applicable regulations.
238 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 239
Positioned for
Profitable Growth
Pada tahun buku 2025, mekanisme pengelolaan limbah In fiscal year 2025, the waste and effluent management
dan efluen dilaksanakan melalui langkah-langkah berikut: mechanism was implemented through the following
measures:
1. Pengendalian limbah B3 terbatas 1. Limited hazardous waste (B3) control
Perseroan melakukan penggantian lampu yang The Company gradually replaced mercury-containing
mengandung merkuri menjadi lampu LED secara lamps with LED lamps to reduce the potential generation
bertahap untuk menekan potensi timbulan limbah of hazardous waste (B3). In daily operations, hazardous
B3. Dalam operasional sehari-hari, timbulan limbah B3 waste generation is neither continuous nor significant.
tidak bersifat kontinu dan tidak signifikan.
2. Pengelolaan produk kedaluwarsa melalui retur 2. Management of expired products through returns to
kepada principal the principal
Perseroan menerapkan prosedur pengembalian The Company applies routine procedures for returning
produk kedaluwarsa secara rutin kepada perusahaan expired products to the product owner (principal) in
pemilik (principal) sesuai ketentuan, sehingga produk accordance with applicable provisions. As such, expired
kedaluwarsa tidak dikelola sebagai limbah oleh products are not managed as waste by the Company.
Perseroan.
3. Pengurangan limbah kertas melalui digitalisasi proses 3. Reduction of paper waste through process
Perseroan melanjutkan digitalisasi dokumen digitalization
operasional, termasuk peralihan surat pesanan cetak The Company continued the digitalization of operational
menjadi elektronik (e-SP) dan pemanfaatan sistem documents, including the transition from printed
pendukung proses bisnis. Langkah ini ditujukan untuk purchase orders to electronic sales orders (e-SP) and
menekan penggunaan kertas dan meningkatkan the utilization of business process support systems. This
efisiensi administrasi. initiative aims to reduce paper usage and enhance
administrative efficiency.
4. Pengurangan plastik sekali pakai dan penguatan 4. Reduction of single-use plastics and strengthening
budaya ramah lingkungan of an environmentally friendly culture
Perseroan mendorong perubahan perilaku untuk The Company encourages behavioral changes to
mengurangi penggunaan plastik sekali pakai melalui reduce single-use plastic consumption through the
penggunaan tumbler, peralatan makan yang use of tumblers, reusable dining utensils, and other
dapat digunakan kembali, serta sarana pendukung supporting facilities. Plastic waste is also segregated
lainnya. Perseroan juga melakukan pemilahan dan and collected for further management through
pengumpulan sampah plastik untuk dikelola lebih lanjut established mechanisms.
melalui mekanisme yang ditetapkan.
5. Pengelolaan efluen domestik 5. Domestic effluent management
Efluen yang dihasilkan pada umumnya bersifat The effluent generated is generally domestic in nature
domestik (sanitasi kantor/gudang). Pengelolaan efluen (office/warehouse sanitation). Effluent management is
diarahkan untuk memastikan sistem sanitasi berfungsi focused on ensuring proper functioning of sanitation
baik, pemeliharaan berkala, serta pencegahan systems, conducting periodic maintenance, and
kebocoran/limpasan. preventing leaks or overflow.
Tumpahan yang Terjadi [OJK F.15] Spills Occurred [OJK F.15]
Sepanjang tahun buku 2025, tidak terdapat tumpahan Throughout the 2025 fiscal year, there were no significant
signifikan yang berdampak pada lingkungan. Perseroan spills that impacted the environment. The Company
mempertahankan kepatuhan penuh terhadap peraturan maintained full compliance with applicable environmental
lingkungan yang berlaku, mencatat nol keluhan regulations, recording zero environmental complaints and
lingkungan dan tidak ada denda atau sanksi selama no fines or penalties during the reporting period.
periode pelaporan.
Perseroan mempertahankan kepatuhan penuh terhadap The Company maintained full compliance with applicable
peraturan lingkungan yang berlaku, mencatat nol keluhan environmental regulations, recording zero environmental
lingkungan dan tidak ada denda atau sanksi selama complaints and no fines or penalties during the reporting
periode pelaporan. period.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 239
Page 240
Laporan Keberlanjutan Positioned for
Sustainability Report Profitable Growth
Kinerja Sosial
Social Performance
Pada tahun buku 2025, Perseroan menempatkan kinerja In fiscal year 2025, the Company positioned social
sosial sebagai bagian dari upaya menjaga kualitas performance as an integral part of its efforts to maintain
layanan, memperkuat hubungan dengan pemangku service quality, strengthen relationships with stakeholders,
kepentingan, serta memastikan penerapan praktik usaha and ensure the implementation of responsible business
yang bertanggung jawab di seluruh rantai kegiatan practices throughout its value chain. The focus of social
bisnis. Fokus kinerja sosial diarahkan pada kepuasan performance was directed toward customer satisfaction
dan perlindungan konsumen, penguatan kualitas SDM, and protection, the enhancement of human resource
serta penciptaan lingkungan kerja yang inklusif, aman, quality, and the creation of an inclusive, safe, and equitable
dan berkeadilan. work environment.
ASPEK KETENAGAKERJAAN EMPLOYMENT ASPECT
Perseroan memandang sumber daya manusia sebagai The Company views human capital as a strategic asset
aset strategis yang menentukan kualitas layanan, that determines service quality, operational resilience, and
ketahanan operasional, dan keberlanjutan pertumbuhan. sustainable growth. Accordingly, employment policies
Oleh karena itu, kebijakan ketenagakerjaan diarahkan are directed toward establishing structured recruitment
untuk membangun proses rekrutmen dan pengembangan and competency development processes, promoting
kompetensi yang terstruktur, mendorong praktik kerja inclusive workplace practices, and ensuring the fulfillment
yang inklusif, serta memastikan pemenuhan hak-hak of employees’ fundamental rights.
dasar karyawan.
Kesetaraan dan Keberagaman Equal Opportunity and Diversity
[OJK F18] [GRI 405-1, 406-1] [OJK F18] [GRI 405-1, 406-1]
Perseroan memberikan kesempatan kerja dengan tidak The Company provides equal employment opportunities
membedakan suku, agama, ras, jenis kelamin, maupun without discrimination based on ethnicity, religion,
pilihan politik. Komitmen tersebut direalisasikan melalui race, gender, or political affiliation. This commitment is
pemberian kesempatan kerja yang sama bagi seluruh implemented through equal opportunity in the recruitment
kandidat dalam proses rekrutmen dan hanya berfokus process, focusing solely on qualification requirements and
pada persyaratan kualifikasi serta tingkat kebutuhan. organizational needs.
Tabel demografi karyawan berdasarkan jenis kelamin, The employee demographic table by gender, education
pendidikan, usia, dan level jabatan dapat dilihat pada level, age, and position level is presented in the Company
bab Profil Perusahaan dalam buku Laporan Tahunan Profile chapter of this Annual Report. Throughout 2025,
ini. Tercatat sepanjang tahun 2025 tidak ada insiden there were no reported incidents of discrimination within
diskriminasi yang dilaporkan dalam lingkungan kerja the Company’s work environment. [2-7, 405-1]
Perseroan. [2-7, 405-1]
The majority of the Company’s employees fall within
Mayoritas karyawan Perseroan berada dalam kelompok the productive age group, totaling 917 employees or
usia produktif, yaitu 917 orang atau sekitar 77.19% dari total approximately 77.19% of the total workforce. Meanwhile,
karyawan. Adapun karyawan dengan tingkat pendidikan employees holding undergraduate and postgraduate
sarjana dan pascasarjana sebanyak 534 orang atau degrees amount to 534 employees or approximately 44.5%
sekitar 44.5% dari total karyawan. Data ini mencerminkan of the total workforce. This data reflects the Company’s
komitmen Perseroan untuk menciptakan tim yang commitment to fostering a diverse and inclusive team
beragam dan inklusif di semua tingkatan. across all levels.
Pekerja Lokal Local Workforce
Sebagai wujud dukungan terhadap pemberdayaan As part of its commitment to empowering local
masyarakat lokal, Perseroan menjadikan penerimaan communities, the Company prioritizes the recruitment
tenaga kerja dari kalangan masyarakat setempat of employees from local communities across its entire
sebagai prioritas. Hal ini secara konsisten diterapkan operational network. The hiring of local workers remains a
240 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 241
Positioned for Profitable Growth pada seluruh jaringan operasional. Penerimaan tenaga key focus, and they are given priority once they meet the kerja dari masyarakat setempat menjadi fokus utama, dan competency requirements established by the Company. mereka diberikan prioritas setelah memenuhi persyaratan kompetensi yang telah ditetapkan oleh Perseroan. Disabilitas Persons with Disabilities Perseroan membuka kesempatan kerja secara khusus bagi The Company provides employment opportunities for para penyandang disabilitas (difabel) sebagai bagian persons with disabilities as part of its inclusive workforce dari masyarakat yang dapat memberikan kontribusi policy. Individuals with disabilities are placed in positions pada kemajuan Perseroan. Para difabel ditempatkan where they can contribute optimally in accordance with pada posisi di mana mereka dapat berkontribusi dengan their respective conditions. maksimal sesuai keadaan mereka. Pada tahun 2025, Perseroan belum memiliki karyawan In 2025, the Company did not yet employ any persons penyandang disabilitas. Meskipun demikian, Perseroan with disabilities. Nevertheless, the Company remains tetap membuka kesempatan yang setara bagi committed to providing equal opportunities for persons penyandang disabilitas untuk mengisi posisi-posisi with disabilities to fill certain positions, subject to the tertentu sesuai dengan kebutuhan dan kualifikasi yang Company’s needs and the required qualifications. dipersyaratkan. Rasio Gaji Pokok dan Remunerasi Ratio of Basic Salary and Perempuan Dibandingkan Laki-laki Remuneration of Women to Men Remunerasi karyawan diberikan berdasarkan Employee remuneration is determined based on pengalaman, kompetensi, dan kinerja setiap karyawan. experience, competence, and performance. The Company Pemenuhan remunerasi di lingkup Perseroan senantiasa ensures that remuneration practices comply with all menaati seluruh aturan yang berlaku. Sistem remunerasi applicable regulations. The remuneration system is di Perseroan dirancang berdasarkan jenjang jabatan, structured according to job grade, competency, and kompetensi, dan penilaian kinerja, bukan dipengaruhi performance evaluation, and is not influenced by gender oleh faktor gender. Dengan pendekatan ini, Perseroan factors. Through this approach, the Company ensures memastikan bahwa setiap karyawan, tanpa memandang that every employee, regardless of gender, receives equal jenis kelamin, mendapatkan kompensasi yang setara compensation with a ratio of 1:1 for equivalent positions. dengan rasio 1:1 untuk posisi yang setara. Memenuhi Hak Asasi Manusia Fulfillment of Employees’ Human Rights (HAM) Karyawan Perseroan, sebagai entitas bisnis yang bertanggung As a responsible business entity, the Company is jawab, berkomitmen untuk memastikan bahwa hak dasar committed to ensuring that the fundamental rights of setiap karyawan dihormati dan diperhatikan dengan every employee are respected and upheld. As of the end of sungguh-sungguh. Hingga akhir tahun 2025 Perseroan 2025, the Company has not established a labor union [GRI belum memiliki serikat pekerja [GRI 2-30, 407-1], tetapi 2-30, 407-1]. Nevertheless, the Company ensures that every Perseroan tetap memastikan bahwa setiap karyawan employee has the right to express opinions and grievances memiliki hak untuk menyuarakan pendapat dan keluhan directly to management, upholding the principles of secara langsung kepada manajemen, menjunjung tinggi respect and openness in internal communication. prinsip kehormatan dan keterbukaan dalam komunikasi internal. Tenaga Kerja Anak dan Karyawan Child Labor and Forced Labor Paksa [OJK F19] [GRI 408-1, 409-1] [OJK F19] [GRI 408-1, 409-1] Perseroan memperhatikan batas usia minimal karyawan The Company observes the minimum working age untuk memastikan bahwa tidak ada karyawan anak requirement to ensure that no child labor exists within di lingkungan Perseroan. Di samping itu, Perseroan its operations. In addition, the Company strictly prohibits menerapkan kebijakan melarang kerja paksa, yaitu forced labor, defined as any work or service exacted from semua karyawan atau jasa yang dipaksakan pada setiap any person under the threat of penalty and not offered orang dengan ancaman hukuman apapun karena orang voluntarily. tersebut tidak menyediakan diri secara sukarela. PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 241
Page 242
Laporan Keberlanjutan Positioned for
Sustainability Report Profitable Growth
Kesejahteraan Karyawan [GRI 401-3] Employee Welfare [GRI 401-3]
Pegawai Perseroan menerima paket kompensasi yang The Company provides a comprehensive compensation
komprehensif, mencakup gaji pokok, berbagai tunjangan, package, including base salary, various allowances,
bonus kinerja, dan hak cuti tahunan. Skema bonus yang performance bonuses, and annual leave entitlements.
diterapkan oleh Perseroan dirancang untuk memberikan The bonus scheme is designed to reward employees in
penghargaan kepada karyawan sesuai dengan kinerja accordance with their performance during the assessment
mereka selama tahun penilaian. year.
Fasilitas kesehatan untuk seluruh pegawai Perseroan Health facilities for all employees are covered through
ditanggung melalui asuransi kesehatan swasta dan BPJS private health insurance and the national healthcare
Kesehatan, menunjukkan perhatian Perseroan terhadap program (BPJS Kesehatan), reflecting the Company’s
kesejahteraan dan keamanan karyawan. Perseroan commitment to employee welfare and security. The
juga memberikan Jaminan Sosial Tenaga Kerja (BPJS Company also provides social security coverage through
Ketenagakerjaan) sesuai dengan peraturan yang berlaku. BPJS Ketenagakerjaan in accordance with prevailing
regulations.
Rasio Upah Dasar [OJK F20] Basic Wage Ratio [OJK F20]
Upah yang diterima oleh karyawan Perseroan telah Employee wages have been aligned with the applicable
disesuaikan dengan Upah Minimum Provinsi (UMP) atau Provincial Minimum Wage (UMP) or Municipal/Regency
Upah Minimum Kota/Kabupaten (UMK) yang berlaku, Minimum Wage (UMK), reflecting the Company’s
mencerminkan komitmen Perseroan untuk memberikan commitment to providing compensation in accordance
kompensasi yang sesuai dengan standar dan peraturan with local standards and regulations.
yang berlaku di wilayah setempat.
Berikut adalah perbandingan nilai upah minimum dan The following is a comparison between the applicable
gaji dasar (karyawan level terendah) di beberapa kantor minimum wage and the basic salary (entry-level
cabang Perseroan pada tahun 2025: employees) at several of the Company’s branch offices
in 2025:
Ratio
No. Branch UMP Basesalary
(Rp) (%)
1 Pusat 5.396.800 5.396.800 0 0,00%
2 Balikpapan 3.701.600 3.701.600 0 0,00%
3 Banda aceh 3.898.900 3.898.900 0 0,00%
4 Bandarl ampung 3.305.400 3.305.400 0 0,00%
5 Bandung 4.483.000 4.483.000 0 0,00%
6 Banjarmasin 3.599.200 3.599.200 0 0,00%
7 Batam 4.989.600 4.989.600 0 0,00%
8 Bekasi 5.690.800 5.690.800 0 0,00%
9 Bogor 5.126.900 5.126.900 0 0,00%
10 Cirebon 2.697.700 2.697.700 0 0,00%
11 Denpasar 3.298.200 3.298.200 0 0,00%
12 Jakarta 1 5.396.800 5.396.800 0 0,00%
13 Jakarta 2 5.396.800 5.396.800 0 0,00%
14 Jambi 3.607.300 3.607.300 0 0,00%
15 Jember 2.838.700 2.838.700 0 0,00%
16 Kediri 2.572.400 2.572.400 0 0,00%
17 Makassar 3.880.200 3.880.200 0 0,00%
18 Malang 3.553.600 3.553.600 0 0,00%
19 Manado 3.824.300 3.824.300 0 0,00%
20 Mataram 2.859.700 2.859.700 0 0,00%
21 Medan 4.014.100 4.014.100 0 0,00%
242 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 243
Positioned for
Profitable Growth
Ratio
No. Branch UMP Basesalary
(Rp) (%)
22 Padang 2.994.200 2.994.200 0 0,00%
23 Palembang 3.916.700 3.916.700 0 0,00%
24 Palu 3.386.600 3.386.600 0 0,00%
25 Pekanbaru 3.676.000 3.676.000 0 0,00%
26 Pontianak 3.024.900 3.024.900 0 0,00%
27 Purwakarta 4.792.300 4.792.300 0 0,00%
28 Purwokerto 2.338.500 2.338.500 0 0,00%
29 Samarinda 3.724.500 3.724.500 0 0,00%
30 Semarang 3.454.900 3.454.900 0 0,00%
31 Siantar 2.992.600 2.992.600 0 0,00%
32 Sidoarjo 4.870.600 4.870.600 0 0,00%
33 Solo 2.416.600 2.416.600 0 0,00%
34 Surabaya 4.961.800 4.961.800 0 0,00%
35 Tangerang 5.069.800 5.069.800 0 0,00%
36 Tasikmalaya 2.802.000 2.802.000 0 0,00%
37 Tegal 2.376.700 2.376.700 0 0,00%
38 Yogyakarta 2.655.100 2.655.100 0 0,00%
Lingkungan Bekerja yang Decent and Safe Working
Layak dan Aman [OJK F21] Environment [OJK F21]
Berkaitan dengan penciptaan tempat kerja yang layak In relation to the creation of a decent and safe workplace,
dan aman, Perseroan secara konsisten berupaya untuk the Company consistently strives to establish a proper
menciptakan lingkungan kerja yang layak dan aman and safe working environment in accordance with
sesuai prinsip Keselamatan dan Kesehatan Kerja (K3). Occupational Health and Safety (OHS/K3) principles. OHS
Manajemen K3 di Perseroan dimulai dengan identifikasi management within the Company begins with hazard
bahaya pada setiap aktivitas atau area kerja, termasuk identification in every activity or work area, including
area gudang dan distribusi. Hasil dari identifikasi bahaya warehouse and distribution areas. The results of hazard
dan penilaian risiko ini dicatat dalam dokumen Identifikasi identification and risk assessment are documented in the
Bahaya dan Penilaian Risiko (IBPR), menjadi landasan Hazard Identification and Risk Assessment (HIRA) records,
dalam menentukan langkah mitigasi. which serve as the basis for determining mitigation
measures.
Sebagai upaya dalam kesiapsiagaan menghadapi As part of emergency preparedness efforts, the Company
kondisi darurat, Perseroan menyediakan peralatan provides emergency response equipment and instruments
dan instrumen tanggap darurat di seluruh area kerja. across all work areas. Internal socialization related to
Sosialisasi internal terkait K3 senantiasa dilakukan secara OHS is conducted regularly to ensure that all employees
berkala agar seluruh karyawan mengerti, memahami understand and properly implement the established safety
dan menerapkannya. procedures.
Kinerja K3 [OJK F.21] [GRI 403-1, 403-3] OHS Performance [OJK F.21] [GRI 403-1, 403-3]
Dalam mengupayakan target zero accident, Perseroan In pursuing a zero-accident target, the Company actively
terlibat secara aktif dalam evaluasi menyeluruh terhadap conducts comprehensive evaluations of the accident
program pencegahan kecelakaan yang telah diterapkan. prevention programs that have been implemented. The
Perseroan tidak hanya berfokus pada aspek fisik dan Company focuses not only on physical and technical
teknis, melainkan juga pada peningkatan kesadaran aspects, but also on enhancing awareness and fostering
dan budaya keselamatan di seluruh lapisan Perseroan. a strong safety culture at all organizational levels.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 243
Page 244
Laporan Keberlanjutan Positioned for
Sustainability Report Profitable Growth
Pada tahun 2025, Perseroan mencatatkan 5 (lima) insiden In 2025, the Company recorded 5 (five) workplace
kecelakaan kerja. Atas kejadian tersebut, Perseroan accident incidents. In response, the Company ensured
memastikan penanganan dan pendampingan optimal proper handling and support for the affected employees,
bagi karyawan terdampak, serta melakukan evaluasi dan while also conducting evaluations and implementing
langkah perbaikan guna mencegah terulangnya insiden corrective measures to prevent similar incidents from
serupa di masa mendatang. recurring in the future.
Program Pendidikan dan Education and Training
Pelatihan [OJK F22] [GRI 403-5] Programs [OJK F22] [GRI 403-5]
Perseroan memandang penguatan kompetensi The Company regards competency enhancement
sebagai fondasi untuk menjaga kualitas layanan dan as a foundation for maintaining service quality and
meningkatkan produktivitas. Pada tahun buku 2025, improving productivity. In fiscal year 2025, training and
pelatihan dan pengembangan kompetensi diarahkan competency development initiatives were directed
untuk memperkuat kemampuan teknis sesuai fungsi kerja, toward strengthening technical capabilities in line with
meningkatkan pemahaman atas standar operasional, job functions, enhancing understanding of operational
serta menumbuhkan budaya kerja yang adaptif dan standards, and fostering an adaptive and professional
profesional. work culture.
Program pelatihan dilaksanakan melalui kombinasi Training programs were delivered through a combination
metode, antara lain pelatihan internal, pelatihan eksternal, of methods, including internal training sessions, external
pembelajaran berbasis sistem/digital (apabila tersedia), training programs, system-based/digital learning (where
serta on-the-job training. Perseroan juga mendorong available), and on-the-job training. The Company also
peningkatan kompetensi yang relevan dengan kebutuhan encouraged competency development aligned with
organisasi, termasuk aspek kepatuhan, etika kerja, dan organizational needs, including compliance, work ethics,
kualitas layanan. and service quality aspects.
Sepanjang tahun 2025, Perseroan secara aktif Throughout 2025, the Company actively conducted
melaksanakan berbagai program peningkatan various competency development programs, such as
kompetensi, seperti sertifikasi, seminar, lokakarya, dan certifications, seminars, workshops, and skills-based
pelatihan berfokus pada pengembangan keterampilan training sessions. A total of 108 skills training sessions, 25
karyawan. Sebanyak 108 kali pelatihan, 25 sertifikasi, 16 certifications, 16 workshops/seminars, and 14 occupational
workshop/seminar, dan 14 kali pelatihan mengenai K3 health and safety (OHS) training sessions were provided
telah diberikan kepada karyawan. to employees.
Total anggaran yang diperuntukkan untuk pengembangan The total budget allocated for human capital development
SDM pada tahun ini mencapai Rp287.623.854 meningkat during the year amounted to Rp 287,623,854, representing
dari periode sebelumnya sebesar Rp210.234.860. an increase compared to the previous period of Rp
Keberhasilan program ini tercermin dalam partisipasi 210,234,860. The effectiveness of these programs was
aktif dari karyawan yang mengikuti pelatihan, dengan reflected in active employee participation, with an average
rata-rata 4,7 jam pelatihan per karyawan, meningkat of 4.7 training hours per employee, increasing compared
dibandingkan periode 2024 yang tercatat rata-rata 1,2 to 2024, which recorded an average of 1.2 training hours
jam pelatihan per karyawan. per employee.
244 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 245
Positioned for
Profitable Growth
ASPEK MASYARAKAT COMMUNITY ASPECT
Dampak Operasi terhadap Impact of Operations on Surrounding
Masyarakat Sekitar [OJK F.23, F.4] Communities [OJK F.23, F.4]
Perseroan menyadari bahwa aktivitas perkantoran, The Company recognizes that its office, warehouse,
pergudangan, dan distribusi dapat menimbulkan and distribution activities may generate impacts on
dampak bagi masyarakat di sekitar wilayah operasional, communities surrounding its operational areas, both
baik positif maupun negatif. Dampak positif terutama positive and negative. Positive impacts are primarily
tercermin melalui dukungan Perseroan terhadap reflected in the Company’s support for the availability of
ketersediaan layanan distribusi produk kesehatan yang reliable health product distribution services, the creation
andal, penciptaan kesempatan kerja, serta kontribusi of employment opportunities, and social contributions
sosial melalui program TJSL di wilayah operasional. Di through Corporate Social and Environmental Responsibility
sisi lain, potensi dampak negatif yang dikelola Perseroan (TJSL) programs within its operational areas. On the
pada umumnya berkaitan dengan aktivitas logistik dan other hand, potential negative impacts managed by
operasional fasilitas, seperti mobilitas kendaraan distribusi, the Company generally relate to logistics and facility
kebisingan, serta aspek keselamatan di sekitar area keluar- operations, such as the mobility of distribution vehicles,
masuk fasilitas. Perseroan melakukan pengendalian noise, and safety aspects around facility entry and
melalui pengaturan operasional, penerapan prosedur exit points. The Company mitigates these impacts
keselamatan, pemeliharaan fasilitas, serta pengelolaan through operational arrangements, implementation
limbah domestik agar tidak menimbulkan gangguan of safety procedures, facility maintenance, and proper
terhadap lingkungan sekitar. Sepanjang tahun buku 2025, management of domestic waste to prevent disturbances
Perseroan mencatat tidak ada aduan masyarakat terkait to the surrounding environment. Throughout fiscal year
dampak operasional. 2025, the Company recorded no public complaints related
to operational impacts.
Pengaduan Masyarakat [OJK F.24] Public Complaints [OJK F.24]
Operasional bisnis Perseroan pada dasarnya tidak The Company’s business operations fundamentally do
memiliki potensi dampak negatif yang signifikan terhadap not pose significant negative impacts on surrounding
masyarakat maupun lingkungan sekitar. Risiko sosial communities or the environment. Potential social risks
yang mungkin timbul lebih terkait pada kelancaran are primarily related to the reliability of distribution
sistem distribusi dan pengelolaan obat. Oleh karena itu, systems and pharmaceutical management. Therefore,
Perseroan memperkuat keandalan distribusi melalui the Company strengthens distribution reliability through
kolaborasi dengan entitas anak PT Digital Pharma Andalan collaboration with its subsidiary, PT Digital Pharma Andalan
Indonesia dengan pemanfaatan platform digital order Indonesia, by utilizing the digital order management
management (OLIN) untuk mendukung skema B2B dan platform (OLIN) to support B2B schemes and ensure
menjaga kontinuitas distribusi. Perseroan menyediakan distribution continuity. The Company provides various
berbagai kanal pengaduan masyarakat, meliputi telepon, public complaint channels, including telephone, facsimile,
faksimile, SMS, email, situs web, serta formulir pelaporan SMS, email, website, online reporting forms (QR), as well
online (QR) maupun pelaporan langsung ke kantor as direct reporting to operational offices. Throughout
operasional. Sepanjang tahun 2025, Perseroan tidak 2025, the Company did not receive any public complaints
menerima pengaduan masyarakat yang mencerminkan indicating violations of ethics, integrity, norms, or alleged
pelanggaran etika, integritas, norma, maupun dugaan regulatory breaches.
pelanggaran peraturan.
Tanggung Jawab Sosial terhadap Social Responsibility for the
Masyarakat [OJK F.25] Community [OJK F.25]
Program Tanggung Jawab Sosial dan Lingkungan The Corporate Social and Environmental Responsibility
(TJSL) merupakan upaya pemberdayaan masyarakat (TJSL) program represents the Company’s community
yang dirancang selaras dengan kebutuhan sosial di empowerment initiative, designed to align with social
sekitar wilayah operasional, sekaligus mendukung needs in areas surrounding its operations while supporting
keberlangsungan bisnis Perseroan sebagai perusahaan the sustainability of its business as a pharmaceutical
distribusi farmasi dan alat kesehatan. Melalui TJSL, and medical device distribution company. Through TJSL,
Perseroan mendorong terciptanya hubungan yang the Company fosters harmonious relationships with
harmonis dengan masyarakat, memperkuat ketahanan communities, strengthens social resilience, and builds a
sosial, serta membangun lingkungan pendukung yang supportive environment conducive to reliable operational
kondusif bagi operasional dan layanan distribusi yang and distribution services.
andal.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 245
Page 246
Laporan Keberlanjutan Positioned for
Sustainability Report Profitable Growth
Dalam perencanaan program, Perseroan mengaitkan In planning its programs, the Company aligns TJSL
kegiatan TJSL dengan Tujuan Pembangunan Berkelanjutan initiatives with the Sustainable Development Goals (SDGs)
(TPB/SDGs) di Indonesia dan menetapkan prioritas tujuan in Indonesia and determines priority goals that are most
yang paling relevan dengan strategi serta karakteristik relevant to its strategy and business characteristics. These
kegiatan usaha. Prioritas tersebut difokuskan pada tujuan priorities focus on goals directly related to improving
yang berkaitan langsung dengan peningkatan kualitas health quality, strengthening community capacity, and
kesehatan, penguatan kapasitas masyarakat, serta enhancing the socio-economic conditions of communities
penguatan kondisi sosial-ekonomi komunitas di sekitar in operational areas.
area operasional.
Pelaksanaan TJSL dilakukan melalui mekanisme yang TJSL implementation follows a structured mechanism,
mencakup identifikasi kebutuhan masyarakat, penetapan including community needs identification, program
program dan mitra pelaksana, pelaksanaan kegiatan, and implementing partner determination, activity
serta evaluasi untuk memastikan program memberi execution, and evaluation to ensure that programs
manfaat yang terukur. Ke depan, Perseroan akan deliver measurable benefits. Going forward, the Company
memperkuat kualitas TJSL melalui penajaman program will further enhance the quality of its TJSL initiatives by
pemberdayaan, penguatan indikator capaian (output sharpening empowerment programs, strengthening
dan outcome), serta perluasan kolaborasi agar kontribusi output and outcome indicators, and expanding
sosial semakin relevan dengan kebutuhan masyarakat collaboration to ensure that social contributions remain
sekaligus memperkuat nilai jangka panjang bagi relevant to community needs while reinforcing long-term
Perseroan. value for the Company.
Hingga akhir tahun 2025, Perseroan telah merealisasikan As of the end of 2025, the Company has realized a CSR/TJSL
anggaran CSR/TJSL sebesar Rp301.050.000. Adapun budget of Rp301,050,000. The details of the implemented
rincian program yang telah dilaksanakan, sebagai berikut: programs are as follows:
Program/Kegiatan TJSL Lokasi Bentuk Dukungan SDG Terkait
TJSL Program/Activity Location Form of Support Related SDG
MPI Berbagi: Donasi ke lebih dari
10 panti asuhan di 10 1 Tanpa Kemiskinan
500 anak yatim piatu di 10 Panti Uang tunai dan paket sembako
kota berbeda 2 Tanpa Kelaparan
Asuhan Cash donations and basic food
10 orphanages in 10 1 No Poverty
MPI Shares: Donation to more than packages
different cities 2 Zero Hunger
500 orphans in 10 orphanages
Donor Darah secara sukarela dari
Donor Darah MPI Semarang karyawan Perseroan kantor cabang 3 Kehidupan Sehat dan
Kantor cabang
– Bekerjasama dengan PMI Semarang, rutin setiap 3 bulan sekali. Sejahtera
Semarang
Semarang Voluntary blood donation by 3 Good Health and Well-
Semarang Branch
MPI Blood Donation Semarang – In employees of the Company’s Being
Office
collaboration with PMI Semarang Semarang branch office, conducted
regularly every 3 months
13 Penanganan
Pulau Pramuka &
Perubahan Iklim
Hutan Lindung Muara
MPI X OLIN Peduli Mangrove – 14 Ekosistem Laut
Angke Penanaman 750 bibit pohon
Bekerjasama dengan LEVA 15 Ekosistem Daratan
Pramuka Island mangrove
MPI X OLIN Mangrove Care – In 13 Climate Action
& Muara Angke Planting of 750 mangrove seedlings
collaboration with LEVA 14 Life Below Water
Protected Forest
15 Life on Land
Kantor cabang
Mataram, Pematang 3 ekor sapi.
Siantar dan Daging hasil sembelihan di bagikan 1 Tanpa Kemiskinan
MPI Berqurban Purwakarta kepada masyarakat sekitar 2 Tanpa Kelaparan
MPI Qurban Program Mataram, Pematang 3 cows. The meat from the sacrifice 1 No Poverty
Siantar, and was distributed to the surrounding 2 Zero Hunger
Purwakarta Branch communities
Offices
3 Kehidupan Sehat dan
MPI Tanam TOGA (Tanaman Obat Sejahtera
Keluarga) – Bekerjasama dengan Penanaman TOGA dan edukasi 15 Ekosistem Daratan
Desa Cihanjawar,
Mahasiswa Poltekes Kemenkes kepada masyarakat sekitar 4 Pendidikan yang
Purwakarta
Jakarta III Planting of TOGA plants and Berkualitas
Cihanjawar Village,
MPI TOGA Planting – In education for the surrounding 3 Good Health and Well-
Purwakarta
collaboration with students of community Being
Poltekkes Kemenkes Jakarta III 15 Life on Land
4 Quality Education
246 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 247
Positioned for
Profitable Growth
ASPEK TANGGUNG JAWAB SUSTAINABLE PRODUCT/SERVICE
PENGEMBANGAN PRODUK/ DEVELOPMENT RESPONSIBILITY ASPECT
JASA BERKELANJUTAN
Komitmen untuk Memberikan Layanan Commitment to Providing Equal
atas Produk dan/atau Jasa yang Product and/or Service Access
Setara kepada Konsumen [OJK F17] to Consumers [OJK F17]
Perseroan terus berkomitmen dalam mengembangkan The Company remains committed to continuously
pelayanannya, memperhatikan produk-produk yang enhancing its services and ensuring that distributed
didistribusikan dengan merespons kebutuhan dari products respond to the needs of various consumer
berbagai segmen konsumen. Upaya ini dilakukan dengan segments. These efforts are undertaken by considering
memperhatikan tren pasar, analisis kebutuhan pelanggan, market trends, customer needs analysis, and product
dan inovasi produk, yang kini juga dioptimalkan melalui innovation, which are further optimized through integrated
sistem pemesanan terintegrasi seperti aplikasi OLIN. ordering systems such as the OLIN application. Through
Dengan demikian, Perseroan dapat mendistribusikan this approach, the Company is able to distribute products
produk yang sesuai dengan harapan dan kebutuhan that meet customer expectations and needs across
pelanggan dari berbagai lapisan masyarakat secara different segments of society in a more efficient and real-
lebih efisien dan real-time. time manner.
Untuk memastikan kualitas dan mutu produk yang To ensure the quality and integrity of the products
didistribusikan, Perseroan senantiasa terbuka terhadap distributed, the Company remains open to suggestions
saran dan masukan dari pelanggan. Perseroan and feedback from customers. The Company has
memiliki sistem tanggapan dan penanganan keluhan established an effective customer complaint response and
pelanggan yang efektif sesuai dengan pedoman handling system in accordance with service guidelines.
layanan. Hal ini bertujuan untuk memastikan bahwa This mechanism ensures that every customer complaint is
setiap keluhan pelanggan ditanggapi dengan baik dan addressed appropriately and constructively, contributing
solutif, menciptakan tingkat kepuasan pelanggan yang to a customer satisfaction level of 98.2% in 2025.
mencapai 98,2% pada tahun 2025.
In addition, the Company upholds the principle of
Selain itu, Perseroan menjunjung tinggi prinsip transparency. Information provided regarding products
transparansi. Informasi yang disertakan mengenai and services is presented with a high degree of accuracy.
produk dan jasa selalu dihadirkan dengan akurasi yang This is intended to provide assurance and build customer
tinggi. Hal ini bertujuan untuk memberikan kepastian dan trust in the products and services they choose.
kepercayaan kepada pelanggan terkait dengan produk
dan jasa yang mereka pilih.
Inovasi dan Pengembangan Produk/ Innovation and Sustainable Product/
Jasa Berkelanjutan [OJK F.26] Service Development [OJK F.26]
Pada tahun buku 2025, Perseroan memperkuat inovasi In fiscal year 2025, the Company strengthened service
layanan untuk meningkatkan keandalan distribusi, mutu innovation to enhance distribution reliability, service
layanan, dan pengalaman pelanggan. Pengembangan quality, and customer experience. Development initiatives
diarahkan pada peningkatan kualitas proses layanan were directed toward improving service process efficiency,
yang lebih efisien, peningkatan visibilitas rantai pasok, increasing supply chain visibility, and strengthening
serta penguatan tata kelola mutu distribusi sesuai distribution quality governance in accordance with the
karakteristik produk farmasi dan alat kesehatan. Inisiatif characteristics of pharmaceutical and medical device
pengembangan pada tahun buku 2025 mencakup, products. Development initiatives undertaken in fiscal
antara lain peluncuran sistem barcoding APEX untuk year 2025 included, among others, the launch of the APEX
mendukung manajemen gudang dan pencatatan barcoding system to support warehouse management
data master item secara real-time, termasuk pada and real-time recording of item master data, including
proses penerimaan dan pengeluaran barang melalui during the receipt and issuance of goods via barcode
pemindaian barcode. Penerapan sistem ini ditujukan scanning. The implementation of this system is intended
untuk meningkatkan akurasi dan kecepatan pencatatan to improve the accuracy and speed of inventory recording,
persediaan, meminimalkan kesalahan input manual, minimize manual input errors, and strengthen the
serta memperkuat transparansi, ketertelusuran stok, dan Company’s transparency, inventory traceability, and
pengendalian internal Perseroan. internal controls.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 247
Page 248
Laporan Keberlanjutan Positioned for
Sustainability Report Profitable Growth
Evaluasi Keamanan Produk Product Safety Evaluation
bagi Pelanggan [OJK F.27] for Customers [OJK F.27]
Perseroan senantiasa berupaya untuk memberikan The Company consistently strives to provide the best
pelayanan terbaik antara lain menjamin kualitas dan service, including ensuring that product quality and
keamanan produk tetap terjaga. Produk-produk yang safety are well maintained. The products distributed by
didistribusikan oleh Perseroan berasal dari pabrikasi yang the Company originate from manufacturers that comply
menjalani standar keselamatan dan kesehatan yang with strict health and safety standards. All stages—ranging
ketat. Seluruh tahapan, mulai dari perizinan, sertifikasi, from licensing, certification, manufacturing processes, to
proses pabrikasi, hingga distribusi, telah dilaksanakan distribution—are carried out diligently to ensure optimal
dengan cermat untuk memastikan tingkat keamanan safety levels for customers.
yang optimal bagi para pelanggan.
Pengawasan yang ketat secara prosedural telah mengikuti Procedural supervision is conducted in accordance
pedoman, proses, dan pemeriksaan yang teliti. Perseroan with established guidelines, processes, and thorough
melakukan seleksi setiap calon Prinsipal yang akan inspections. The Company performs a selection process
bekerjasama dengan perseroan dengan memastikan for every prospective Principal prior to entering into
kepatuhan principal tersebut atas setiap reguasi yang cooperation, ensuring that the Principal complies with
berlaku sehingga meyakinkan perseroan bahwa setiap all applicable regulations. This provides assurance that
langkah yang dilakukan oleh para principal dalam each step undertaken by the Principal in the production
produksi produk dijalankan sesuai dengan standar yang process adheres to established standards and meets
telah ditetapkan, sehingga dapat memenuhi harapan customer expectations in terms of safety and quality.
pelanggan dalam hal keamanan dan kualitas.
Perseroan memastikan bahwa setiap produk dan layanan The Company ensures that every product and
yang disediakan tidak hanya mencakup kebutuhan service provided not only fulfills community needs
masyarakat secara menyeluruh, tetapi juga memberikan comprehensively but also guarantees fairness and safety
keadilan dan keamanan dalam setiap transaksi dan in every transaction and business interaction. The review
interaksi bisnisnya. Proses dan pemeriksaan yang teliti, and assessment processes include the following:
yaitu:
1. Kesesuaian produk dengan visi dan misi Perseroan. 1. Alignment of products with the Company’s vision and
mission.
2. Kesesuaian produk dan layanan dengan kebutuhan 2. Alignment of products and services with customer
dan kemampuan pelanggan. needs and capabilities.
3. Mempertimbangkan isu lingkungan, seperti upaya 3. Consideration of environmental issues, such as
pelestarian alam, pengelolaan risiko lingkungan environmental preservation efforts and environmental
(contohnya, pembuangan limbah, pengelolaan polusi risk management (e.g., waste disposal, pollution
dan lainnya). Perseroan menetapkan syarat tertentu management, and others). The Company establishes
terkait risiko lingkungan, yang wajib dicantumkan oleh specific environmental risk requirements that must
Unit Bisnis dalam prosedur pemberian produk dan jasa. be incorporated by Business Units into product and
4. Mempertimbangkan isu sosial, seperti kegiatan TJSL. service procedures.
5. Menyampaikan informasi berdasarkan asas 4. Consideration of social aspects, including TJSL
transparansi. Setiap produk dan layanan yang initiatives.
ditawarkan Perseroan kepada pelanggan, disampaikan 5. Provision of information based on the principle of
melalui ringkasan informasi mengenai produk transparency. Every product and service offered to
tersebut saat penawaran dan/ atau kesepakatan customers is accompanied by a product information
penandatanganan perjanjian. Ketentuan ringkasan summary at the time of offering and/or agreement
produk yang disampaikan Perseroan mengacu pada signing. The product summary provisions comply with
ketentuan yang berlaku. applicable regulations.
6. Memastikan bahwa setiap produk telah melalui 6. Ensuring that each product has undergone thorough
pemeriksaan yang teliti: assessment, including:
a. Kajian risiko, terkait delapan jenis risiko: risiko kredit, a. Risk assessment covering eight risk types: credit risk,
risiko pasar, risiko likuiditas, risiko operasional, risiko market risk, liquidity risk, operational risk, strategic
strategis, risiko kepatuhan, risiko reputasi, dan risiko risk, compliance risk, reputational risk, and legal risk.
hukum
b. Kajian uji kepatuhan. b. Compliance testing review.
c. Kajian operasional. c. Operational review.
d. Kajian keuangan. d. Financial review.
e. Kajian IT. e. IT review.
248 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 249
Positioned for
Profitable Growth
f.Serta kajian unit kerja pendukung lainnya yang f. Reviews by other relevant supporting units.
terkait.
7. Memastikan bahwa seluruh produk telah mendapatkan 7. Ensuring that all products have obtained approval
persetujuan dari pihak terkait sebagaimana diatur from relevant parties as stipulated in the Company’s
dalam Kebijakan Produk Perseroan, didukung oleh Product Policy, supported by adequate procedures
standar prosedur serta infrastruktur yang memadai, and infrastructure, including certified human resources
termasuk SDM yang telah memiliki sertifikat yang and the availability of a Business Continuity Plan (BCP).
disyaratkan, serta adanya Business Continuity Plan
(BCP). 8. For products requiring regulatory approval, the
8. Untuk produk-produk yang membutuhkan persetujuan Company ensures that such products are distributed
dari regulator, Perseroan memastikan bahwa only after obtaining approval from the relevant
produk tersebut hanya akan didistribusikan setelah regulator.
mendapatkan persetujuan dari regulator.
Komitmen Perseroan terhadap kualitas dan keamanan The Company’s commitment to product quality and safety
produk telah memberikan hasil yang baik, dengan tidak has yielded positive results, as evidenced by the absence
adanya tuntutan atas ketidakpatuhan Perseroan terhadap of legal claims related to non-compliance with laws and
undang-undang dan peraturan di bidang ekonomi dan regulations in the economic and social sectors.
sosial.
Penilaian dan Pengendalian Product Impact Assessment
Dampak Produk [OJK F.28] and Control [OJK F.28]
Dalam rangka menjaga keamanan dan mutu, Perseroan
melakukan penilaian menyeluruh atas produk yang In order to maintain product safety and quality, the
didistribusikan dan dijual kepada pelanggan. Perseroan Company conducts comprehensive assessments of
memastikan setiap kemasan produk principal yang products distributed and sold to customers. The Company
didistribusikan telah disertai informasi yang memadai, ensures that each principal product package distributed
antara lain manfaat, komposisi, serta potensi efek is accompanied by adequate information, including
samping, dan dikomunikasikan secara jelas untuk benefits, composition, and potential side effects, which
membangun kepercayaan pelanggan. are communicated clearly to build customer trust.
Untuk mendukung tata kelola produk/jasa, Perseroan To support product/service governance, the Company
memastikan setiap produk melalui penelaahan yang ensures that each product undergoes thorough review
mencakup (antara lain) kajian manajemen risiko, processes, including (among others) risk management
kepatuhan, operasional, keuangan, kajian IT, serta assessment, compliance review, operational review,
kajian unit pendukung terkait; memastikan pemenuhan financial review, IT review, and reviews by relevant
persetujuan internal sesuai Kebijakan Produk; kesiapan supporting units. The Company also ensures fulfillment
prosedur, infrastruktur, SDM tersertifikasi yang disyaratkan, of internal approvals in accordance with the Product Policy,
serta Business Continuity Plan (BCP); dan memastikan readiness of procedures and infrastructure, availability of
produk yang memerlukan persetujuan regulator hanya certified human resources as required, and the existence
didistribusikan setelah mendapatkan persetujuan of a Business Continuity Plan (BCP). Furthermore, products
dimaksud. requiring regulatory approval are distributed only after
obtaining the necessary approvals from the relevant
authorities.
Kepatuhan atas Regulasi Produk dan Compliance with Product Regulations
Perlindungan Konsumen [OJK F.29] and Consumer Protection [OJK F.29]
Perseroan menjaga kesehatan dan keselamatan The Company maintains the health and safety of
pelanggan dengan mematuhi peraturan perundang- customers by complying with applicable laws and
undangan yang berlaku, termasuk memastikan setiap regulations, including ensuring that every product
produk yang didistribusikan dilengkapi informasi yang distributed is equipped with sufficient information and
mencukupi serta dilakukan evaluasi berkala atas periodic evaluations of safety and quality standards.
keamanan dan standar mutu. Sepanjang tahun buku Throughout the 2025 financial year, there will be no
2025, tidak terdapat tuntutan terkait ketidakpatuhan demands related to non-compliance with regulations in
terhadap peraturan di bidang ekonomi dan sosial. the economic and social fields.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 249
Page 250
Laporan Keberlanjutan Positioned for
Sustainability Report Profitable Growth
Kepuasan Pelanggan [OJK F.30] Customer Satisfaction [OJK F.30]
Perseroan memandang kepuasan pelanggan sebagai The Company views customer satisfaction as a key
indikator penting untuk memastikan konsistensi kualitas indicator in ensuring consistent service quality, effective
layanan, efektivitas penanganan umpan balik, serta handling of feedback, and the relevance of continuous
relevansi peningkatan proses layanan dari waktu ke service process improvements. In 2024, the customer
waktu. Pada tahun 2024, tingkat kepuasan pelanggan satisfaction level for the Company’s products and services
atas layanan produk dan jasa Perseroan tercatat 98,1%, was recorded at 98.1%, and in 2025, the Company recorded
dan pada tahun 2025 Perseroan mencatat kepuasan an increase in customer satisfaction to 98.2%.
pelanggan meningkat menjadi 98,2%.
PRIVASI PELANGGAN DAN CUSTOMER PRIVACY AND
KEAMANAN DATA [GRI 418-1] DATA SECURITY [GRI 418-1]
Sepanjang tahun 2025, Perseroan tidak menerima Throughout 2025, the Company did not receive any
pengaduan yang berdasar terkait pelanggaran privasi substantiated complaints concerning breaches of
pelanggan maupun kehilangan data pelanggan. customer privacy or losses of customer data. The
Perseroan tetap menjaga pengendalian akses data dan Company continues to maintain data access controls
keamanan informasi untuk mendukung perlindungan and information security to support data protection in
data dalam kegiatan operasiona its operations.
Verifikasi Tertulis dari Pihak Independen [OJK G.1] [GRI 2-5]
Written Verification from Independent Parties
Laporan Keberlanjutan PT Millennium Pharmacon This 2025 Sustainability Report of PT Millennium Pharmacon
Internasional Tbk tahun 2025 ini belum menggunakan jasa Internasional Tbk has not been subject to an assurance
penjamin (assurance). Namun, Perseroan menjalankan engagement. However, the Company has conducted an
tahapan verifikasi internal untuk menjamin kredibilitas internal verification process to ensure the credibility and
dan kualitas informasi yang tercantum dalam Laporan ini. quality of the information contained in this Report.
250 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 251
Positioned for
Profitable Growth
Lembar Umpan Balik [OJK G.2]
Feedback Sheet
Kami mohon kesediaan para pemangku kepentingan We kindly invite stakeholders to provide feedback
untuk memberikan umpan balik setelah membaca after reading the Sustainability Report of PT Millennium
Laporan Keberlanjutan PT Millennium Pharmacon Pharmacon International Tbk by sending an email or
International Tbk dengan mengirim email atau mengirim submitting this form via fax or mail.
formulir ini melalui fax/pos.
Profil Anda (Mohon diisi bila berkenan)
Your Profile (Please fill in if you wish)
Nama
: ……………………………………………………
Name
Institusi/Perusahaan
: ……………………………………………………
Institution/Company
Email
: ……………………………………………………
Email
Telepon/HP
: ……………………………………………………
Phone/Mobile
Golongan Pemangku Kepentingan
Stakeholder Category
Pemegang saham/investor Konsumen
Karyawan / Employees
Shareholders/Investors Consumers
Perguruan Tinggi Media Mitra Usaha
Universities Media Business Partners
Lainnya, sebutkan
Organisasi Masyarakat/NGO Pemerintah/OJK
Others, please specify:
Community Organizations/NGOs Government/OJK
____________________
Bagaimana penilaian Anda mengenai Kurang Sangat
Tidak
penulisan laporan ini? Setuju Tidak Tahu Setuju Setuju
Setuju
What is your assessment of the writing of Slightly Don't know Agree Strongly
Disagree
this report? Disagree Agree
Laporan ini mudah dimengerti
This report is easy to understand
Laporan ini bermanfaat
This report is useful
Laporan ini sudah menggambarkan kinerja
Perusahaan dalam pembangunan berkelanjutan
This report reflects the Company’s performance in
sustainable development.
Mohon berikan saran, usul, atau komentar Anda atas Please provide your suggestions, recommendations, or
laporan ini: comments on this report:
................................................................................................................................................................................................................................................................................................................
................................................................................................................................................................................................................................................................................................................
................................................................................................................................................................................................................................................................................................................
................................................................................................................................................................................................................................................................................................................
................................................................................................................................................................................................................................................................................................................
................................................................................................................................................................................................................................................................................................................
................................................................................................................................................................................................................................................................................................................
................................................................................................................................................................................................................................................................................................................
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 251
Page 252
Positioned for
Profitable Growth
Tanggapan Terhadap Umpan Balik
Laporan Tahun Sebelumnya [OJK G.3]
Response to Feedback Seet the Prior Year
Selama tahun 2025, Perseroan tidak menerima tanggapan Throughout 2024, The Company Did Not Receive A
atas Laporan Keberlanjutan tahun 2024. Kendati demikian, Response To The 2023 Sustainability Report. However, The
Perusahaan berupaya untuk senantiasa meningkatkan Company Strives To Continually Improve The Quality Of
kualitas Laporan Keberlanjutan Perusahaan untuk dapat The Company’s Sustainability Report To Be Able To Comply
memenuhi pedoman GRI Universal Standards 2021 dan With The 2021 GRI Universal Standards Guidelines And
POJK No.51/POJK.03/2017 tentang Penerapan Keuangan Pojk No.51/Pojk.03/2017 Concerning The Implementation
Berkelanjutan bagi Lembaga Jasa Keuangan, Emiten dan Of Sustainable Finance For Financial Service Institutions,
Perusahaan Publik. Issuers And Public Companies.
252 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 253
Positioned for
Profitable Growth
Daftar Pengungkapan Sesuai Peraturan Otoritas
Jasa Keuangan No. 51/POJK.03/2017 Tentang
Penerapan Keuangan Berkelanjutan Bagi Lembaga
Jasa Keuangan, Emiten dan Perusahaan Publik [OJK G.4]
List of Disclosures in Accordance with Financial Services Authority
Regulation No. 51/POJK.03/2017 Regarding the Implementation
of Sustainable Finance for Financial Services Institutions, Issuers,
and Public Companies
No.
Indeks Nama Indeks Halaman
Index Index Name Page
Number
Strategi Keberlanjutan
A. 214-215
Sustainability Strategy
Penjelasan Strategi Keberlanjutan
A.1 214-215
Explanation on Sustainability Strategy
Ikhtisar Kinerja Aspek Keberlanjutan
B. 15
Sustainability Performance Highlights
Aspek Ekonomi
B.1 15
Economic Aspect
Kuantitas produksi atau jasa yang dijual
B.1.a 15
Sales quantity of production or services
Pendapatan atau penjualan
B.1.b 15
Revenue or sales
Laba atau rugi bersih
B.1.c 15
Net profit or loss
Produk ramah lingkungan
B.1.d 15, 247-249
Environmentally friendly products
Pelibatan pihak lokal yang berkaitan dengan proses bisnis Keuangan Berkelanjutan
B.1.e 15
Local parties involved in business process of Sustainable Finance
Aspek Lingkungan Hidup
B.2 15
Environmental Aspects
Penggunaan energi
B.2.a 15, 232-233
Energy use
Pengurangan emisi yang dihasilkan
B.2.b 238
Lowering generated emissions
Pengurangan limbah dan efluen
B.2.c 238-239
Lowering waste and effluent
Pelestarian keanekaragaman hayati
B.2.d 235
Preserving biodiversity
Aspek sosial
B.3 15, 240-250
Social aspect
Dampak positif dan negatif penerapan Keuangan Berkelanjutan bagi masyarakat dan lingkungan
(termasuk orang, daerah, dan dana)
The positive and negative impacts of the implementation of Sustainable Finance on society and the
environment (including people, regions, and funds)
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 253
Page 254
Positioned for
Profitable Growth
No.
Indeks Nama Indeks Halaman
Index Index Name Page
Number
Profil Perusahaan
C. 55-66, 86
Company Profile
Visi, Misi, dan Nilai Keberlanjutan
C.1 55
Vision, Mission, and Value of Sustainability
Alamat Perusahaan
C.2 64-65
Company’s Address
Skala Usaha
C.3 62, 86
Business Scale
Total aset atau kapitalisasi aset dan total kewajiban
C.3.a 10-12
Total assets or capitalization of assets and liabilities
Jumlah karyawan menurut jenis kelamin, jabatan, usia, pendidikan, dan status ketenagakerjaan
C.3.b 86-87
Number of employees according to gender, position, age, education, and employment status
Nama pemegang saham dan persentase kepemilikan saham
C.3.c 94-95
Name of shareholder and percentage of share ownership
Wilayah operasional
C.3.d 62-63
Operational area
Produk, Layanan, dan Kegiatan Usaha yang Dijalankan
C.4 57-61
Current Products, Services, and Business Activities
Keanggotaan pada Asosiasi
C.5 66
Membership in the Association
Perubahan Emiten dan Perusahaan Publik yang Bersifat Signifikan
C.6 61
Significant Changes of Issuers and Public Companies
Penjelasan Direksi
D. 214-215
Directors Statement
Kebijakan untuk merespon tantangan dalam pemenuhan strategi keberlanjutan
D.1.a 214-215
Responding to challenges in fulfilling the sustainability strategy
Penerapan Keuangan Berkelanjutan
D.1.b 214-215
Implementation of Sustainable Finance
Strategi pencapaian target
D.1.c 215
Target achievement strategy
Tata Kelola Keberlanjutan
E. 218-225
Sustainability Governance
Penanggung Jawab Penerapan Keuangan Berkelanjutan
E.1 218-220
Management of Sustainable Finance Implementation
Pengembangan Kompetensi Terkait Keuangan Berkelanjutan
E.2 220
Competency Development on Sustainable Finance
Penilaian Risiko Atas Penerapan Keuangan Berkelanjutan
E.3 220-221
Risk Assessment for Sustainable Finance Implementation
Hubungan Dengan Pemangku Kepentingan
E.4 223-224
Stakeholder Engagement
Permasalahan Terhadap Penerapan Keuangan Berkelanjutan
E.5 225
Challenges of Sustainable Financial Implementation
Kinerja Keberlanjutan
F. 216-250
Sustainability Performance
Kegiatan Membangun Budaya Keberlanjutan
F.1 216-217
Building a Culture of Sustainability
Kinerja Ekonomi
Economic Performance
Perbandingan Target dan Kinerja Produksi, Portofolio, Target Pembiayaan, atau Investasi,
Pendapatan dan Laba Rugi
F.2 226-227
Comparison of Performance Targets and Production, Portfolios, Financial Targets, or Investment,
Revenue and Profit and Loss
254 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 255
Positioned for
Profitable Growth
No.
Indeks Nama Indeks Halaman
Index Index Name Page
Number
Perbandingan Target dan Kinerja Portofolio, Target Pembiayaan, atau Investasi pada Instrumen
Keuangan atau Proyek yang Sejalan dengan Keuangan Berkelanjutan
F.3 228-229
Comparison of Performance Targets and Production, Portfolios, Financial Targets, or Investment on
Financial Instruments or Projects in Line with Sustainable Finance Implementation
Kinerja Lingkungan Hidup
Environmental Performance
Biaya Lingkungan Hidup
F.4 231, 245
Environmental Costs
Penggunaan Material yang Ramah Lingkungan
F.5 231-232
The Use of Environmentally Friendly Materials
Jumlah dan Intensitas Energi yang Digunakan
F.6 232-233
The Number and the Intensity of Energy Use
Upaya dan Pencapaian Efisiensi Energi dan Penggunaan Energi Terbarukan
F.7 233-234
The Efforts and Achievements of Energy Efficiency Including the Use of Renewable Energy Sources
Penggunaan Air
F.8 234
Water Consumption
Dampak dari Wilayah Operasional yang Dekat atau Berada di Daerah Konservasi atau Memiliki
F.9 Keanekaragaman Hayati 235
The Impact of Operational Areas Near or in the Area of Conservation or Biodiversity
Usaha Konservasi Keanekaragaman Hayati
F.10 235
Biodiversity Conservation Efforts
Jumlah dan Intensitas Emisi yang Dihasilkan Berdasarkan Jenisnya
F.11 236-238
The Number and Intensity of Emissions Produced by Type
Upaya dan Pencapaian Pengurangan Emisi yang Dilakukan
F.12 238
The Efforts and Achievement of Emission Reductions Undertaken
Jumlah Limbah dan Efluen yang Dihasilkan Berdasarkan Jenis
F.13 238-239
The Amount of Waste and Effluent Generated by Type
Mekanisme Pengelolaan Limbah dan Efluen
F.14 238-239
Waste and Effluent Management Mechanism
Tumpahan yang Terjadi (jika ada)
F.15 239-240
Spill that Occurred (if any)
Jumlah dan Materi Pengaduan Lingkungan Hidup yang Diterima dan Diselesaikan
F.16 231
The Number and Material Environmental Complaints Received and Resolved
Kinerja Sosial
Social Performance
Komitmen untuk Memberikan Layanan atas Produk dan/atau Jasa yang Setara kepada Konsumen
F.17 247
Commitment to Provide Equal Services on Products and/or Services to Customers
Kesetaraan Kesempatan Bekerja
F.18 240-241
Equality of Employment Opportunities
Tenaga Kerja Anak dan Tenaga Kerja Paksa
F.19 241
Child Labor and Forced Labor
Upah Minimum Regional
F.20 242-243
The Minimum Regional Wage
Lingkungan Bekerja yang Layak dan Aman
F.21 243-244
Decent and Safe Working Environment
Pelatihan dan Pengembangan Kemampuan Pegawai
F.22 244
Training and Competency Development for Employees
Dampak Operasi Terhadap Masyarakat Sekitar
F.23 245
Operational Impacts to Local Communities
Pengaduan Masyarakat
F.24 245
Public Complaints
Kegiatan Tanggung Jawab Sosial Lingkungan (TJSL)
F.25 245-246
Social and Environmental Responsibility Activities
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 255
Page 256
Positioned for
Profitable Growth
No.
Indeks Nama Indeks Halaman
Index Index Name Page
Number
Inovasi dan Pengembangan Produk/Jasa Keuangan Berkelanjutan
F.26 247
Innovation and development of Sustainable Finance products and/or services
Produk/Jasa yang Sudah Dievaluasi Keamanannya bagi Pelanggan
F.27 248-249
Customer Safety
Dampak Produk/Jasa
F.28 249
Impact of Products/Services
Jumlah Produk yang Ditarik Kembali
F.29 249
The Number of Products Recalled
Survei Kepuasan Pelanggan Terhadap Produk dan/atau Jasa Keuangan Berkelanjutan
F.30 250
Survey of Customer Satisfaction
Lainnya
Others
Verifikasi Tertulis dari Pihak Independen (jika ada)
G.1 250
Written Verification from an Independent Party (if Any)
Lembar Umpan Balik
G.2 251
Feedback Form
Tanggapan Terhadap Umpan Balik Laporan Keberlanjutan Tahun Sebelumnya
G.3 252
Response to Feedback from the Prior Year
Daftar Pengungkapan Sesuai Peraturan Otoritas Jasa Keuangan Nomor 51/2017
G.4 List of Disclosures in accordance with POJK 51/2017 regarding the Implementation of Sustainable 253-256
Finance for Financial Service Institutions, Issuers and Public Companies
256 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 257
Positioned for
Profitable Growth
Indeks Standar GRI
GRI Standards Index
PT Millennium Pharmacon International Tbk telah menyampaikan informasi yang tercantum dalam
Pernyataan
Indeks Standar GRI ini untuk periode pelaporan 1 Januari 2025 sampai dengan 31 Desember 2025
Penggunaan
dengan mengacu pada Standar GRI.
Statement of
PT Millennium Pharmacon International Tbk has reported the information cited in this GRI Standards Index
Use
for the reporting period from 1 January 2025 to 31 December 2025 with reference to the GRI Standards.
GRI 1: LANDASAN 2021
GRI 1:
GRI 1: FOUNDATION 2021
GRI
Pengungkapan Halaman
Standard
Disclosure Page
GRI Standard
GRI 2: PENGUNGKAPAN UMUM 2021
GRI 2: GENERAL DISCLOSURES 2021
Organisasi dan Praktik Pelaporan
Organization and Reporting Practices
Detail organisasi
2-1 52-64
Organizational details
Entitas yang termasuk dalam pelaporan keberlanjutan
2-2 203
Entities included in the organization’s sustainability reporting
Periode pelaporan, frekuensi dan titik kontak
2-3 204
Reporting period, frequency, and contact point
Informasi tentang penyajian kembali
2-4 204
Restatements of information
Asurans eksternal
2-5 250
External assurance
Aktivitas dan Pekerja
Activities and Workers
Aktivitas, rantai pasok, dan relasi bisnis lainnya
2-6 57-61
Activities, value chain, and other business relationships
Karyawan
2-7 86-87
Employees
Pekerja yang bukan karyawan
2-8 86
Workers who are not employees
Tata Kelola
Governance
Struktur dan komposisi tata kelola
2-9 132-169, 218-220
Governance structure and composition
Nominasi dan pemilihan badan tata kelola tertinggi
2-10 138-139, 166-169
Nomination and selection of the highest governance body
Ketua badan tata kelola tertinggi
2-11 218
Chair of the highest governance body
Peran badan tata kelola tertinggi dalam mengawasi pengelolaan dampak
2-12 Role of the highest governance body in overseeing the management of 218
impacts
Pendelegasian tanggung jawab untuk mengelola dampak
2-13 218
Delegation of responsibility for managing impacts
Peran badan tata kelola tertinggi dalam pelaporan keberlanjutan
2-14 218, 220
Role of the highest governance body in sustainability reporting
Benturan kepentingan
2-15 128-129, 192-194
Conflicts of interest
Komunikasi kepedulian terhadap permasalahan kritikal
2-16 192-193, 218-219
Communication of critical concerns
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 257
Page 258
Positioned for
Profitable Growth
PT Millennium Pharmacon International Tbk telah menyampaikan informasi yang tercantum dalam
Pernyataan
Indeks Standar GRI ini untuk periode pelaporan 1 Januari 2025 sampai dengan 31 Desember 2025
Penggunaan
dengan mengacu pada Standar GRI.
Statement of
PT Millennium Pharmacon International Tbk has reported the information cited in this GRI Standards Index
Use
for the reporting period from 1 January 2025 to 31 December 2025 with reference to the GRI Standards.
GRI 1: LANDASAN 2021
GRI 1:
GRI 1: FOUNDATION 2021
GRI
Pengungkapan Halaman
Standard
Disclosure Page
GRI Standard
Pengetahuan kolektif dari badan tata kelola tertinggi
2-17 220
Collective knowledge of the highest governance body
Evaluasi kinerja badan tata kelola tertinggi
2-18 154-155
Evaluation of the performance of the highest governance body
Kebijakan remunerasi
2-19 153
Remuneration policies
Proses untuk menentukan remunerasi
2-20 153
Process to determine remuneration
Rasio kompensasi total tahunan
2-21 -
Annual total compensation ratio
Strategi, Kebijakan, dan Praktik
Strategy, Policy, and Practice
Pernyataan tentang strategi pembangunan berkelanjutan
2-22 214-215
Statement on sustainable development strategy
Komitmen kebijakan
2-23 221-222
Policy commitments
Menanamkan komitmen kebijakan
2-24 221-222
Embedding policy commitments
Proses untuk memulihkan dampak negatif
2-25 222
Processes to remediate negative impacts
Mekanisme pemberian umpan balik/saran dan menyampaikan kekhawatiran
2-26 192-193, 245
Mechanisms for seeking advice and raising concerns
Kepatuhan terhadap hukum dan peraturan
2-27 194, 218-219
Compliance with laws and regulations
Keanggotaan asosiasi
2-28 66
Membership associations
Keterlibatan Pemangku Kepentingan
Stakeholder Engagement
Pendekatan keterlibatan pemangku kepentingan
2-29 223-224
Approach to stakeholder engagement
Perjanjian kerja bersama
2-30 241
Collective bargaining agreements
GRI 3: TOPIK MATERIAL 2021
GRI 3: MATERIAL TOPICS 2021
Proses menentukan topik material
3-1 205-210
Process to determine material topics
Daftar topik material
3-2 212-213
List of material topics
Pengelolaan topik material
3-3 214-250
Management of material topics
TOPIK EKONOMI
ECONOMIC TOPICS
GRI 205: ANTI KORUPSI 2016
GRI 205: ANTI-CORRUPTION 2016
Manajemen topik material
3-3 194
Management of material topics
Komunikasi dan pelatihan tentang kebijakan dan prosedur anti-korupsi
205-2 194
Communication and training about anti-corruption policies and procedures
258 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 259
Positioned for
Profitable Growth
PT Millennium Pharmacon International Tbk telah menyampaikan informasi yang tercantum dalam
Pernyataan
Indeks Standar GRI ini untuk periode pelaporan 1 Januari 2025 sampai dengan 31 Desember 2025
Penggunaan
dengan mengacu pada Standar GRI.
Statement of
PT Millennium Pharmacon International Tbk has reported the information cited in this GRI Standards Index
Use
for the reporting period from 1 January 2025 to 31 December 2025 with reference to the GRI Standards.
GRI 1: LANDASAN 2021
GRI 1:
GRI 1: FOUNDATION 2021
GRI
Pengungkapan Halaman
Standard
Disclosure Page
GRI Standard
Insiden korupsi yang terbukti dan tindakan yang diambil
205-3 193-194
Confirmed incidents of corruption and actions taken
PRAKTIK PENGADAAN
PROCUREMENT PRACTICES
GRI 204: PRAKTIK PENGADAAN 2016
GRI 204: PROCUREMENT PRACTICES 2016
Manajemen topik material
3-3 15
Management of material topics
Proporsi pengeluaran untuk pemasok lokal
204-1 15
Proportion of spending on local suppliers
TOPIK SOSIAL
SOCIAL TOPICS
GRI 401: KEPEGAWAIAN 2016
GRI 401: EMPLOYMENT 2016
Manajemen topik material
3-3 240-242
Management of material topics
Perekrutan karyawan baru dan pergantian karyawan
401-1 15, 86-87, 240-241
New employee hires and employee turnover
Tunjangan yang diberikan kepada karyawan purnawaktu yang tidak diberikan
kepada karyawan pada kurun waktu tertentu atau paruh waktu
401-2 242
Benefits provided to full-time employees that are not provided to temporary or
part-time employees
Cuti melahirkan
401-3 242
Parental leave
KESEHATAN DAN KESELAMATAN KERJA
OCCUPATIONAL HEALTH AND SAFETY
GRI 403: KESEHATAN DAN KESELAMATAN KERJA 2018
GRI 403: OCCUPATIONAL HEALTH AND SAFETY 2018
Manajemen topik material
3-3 243-244
Management of material topics
Sistem manajemen keselamatan dan kesehatan kerja
403-1 243
Occupational health and safety management system
Pengidentifikasian bahaya, penilaian risiko, dan investigasi insiden
403-2 243
Hazard identification, risk assessment, and incident investigation
Pelatihan pekerja mengenai keselamatan dan kesehatan kerja
403-5 244
Worker training on occupational health and safety
Kecelakaan kerja
403-9 15, 244
Work-related injuries
PELATIHAN DAN PENDIDIKAN
TRAINING AND EDUCATION
GRI 404: PENDIDIKAN DAN PELATIHAN 2016
GRI 404: TRAINING AND EDUCATION 2016
Manajemen topik material
3-3 244
Management of material topics
Rata-rata jam pelatihan per tahun per karyawan
404-1 244
Average hours of training per year per employee
Program untuk meningkatkan keterampilan karyawan dan program bantuan
404-2 peralihan 244
Programs for upgrading employee skills and transition assistance programs
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 259
Page 260
Positioned for
Profitable Growth
PT Millennium Pharmacon International Tbk telah menyampaikan informasi yang tercantum dalam
Pernyataan
Indeks Standar GRI ini untuk periode pelaporan 1 Januari 2025 sampai dengan 31 Desember 2025
Penggunaan
dengan mengacu pada Standar GRI.
Statement of
PT Millennium Pharmacon International Tbk has reported the information cited in this GRI Standards Index
Use
for the reporting period from 1 January 2025 to 31 December 2025 with reference to the GRI Standards.
GRI 1: LANDASAN 2021
GRI 1:
GRI 1: FOUNDATION 2021
GRI
Pengungkapan Halaman
Standard
Disclosure Page
GRI Standard
KESEHATAN DAN KESELAMATAN PELANGGAN
CUSTOMER HEALTH AND SAFETY
GRI 416: KESEHATAN DAN KESELAMATAN PELANGGAN 2016
GRI 416: CUSTOMER HEALTH AND SAFETY 2016
Manajemen topik material
3-3 248-249
Management of material topics
Penilaian dampak kesehatan dan keselamatan dari berbagai kategori produk
dan jasa
416-1 248-249
Assessment of the health and safety impacts of product and service
categories
Insiden ketidakpatuhan sehubungan dengan dampak kesehatan dan
keselamatan dari produk dan jasa
416-2 249
Incidents of non-compliance concerning the health and safety impacts of
products and services
PEMASARAN DAN PELABELAN
MARKETING AND LABELING
GRI 417: PEMASARAN DAN PELABELAN 2016
GRI 417: MARKETING AND LABELING 2016
Manajemen topik material
3-3 247-249
Management of material topics
Persyaratan untuk pelabelan dan informasi produk dan jasa
417-1 247-249
Requirements for product and service information and labeling
PRIVASI PELANGGAN
CUSTOMER PRIVACY
GRI 418: PRIVASI PELANGGAN 2016
GRI 418: CUSTOMER PRIVACY 2016
Manajemen topik material
3-3 250
Management of material topics
Pengaduan yang berdasar mengenai pelanggaran terhadap privasi
pelanggan dan hilangnya data pelanggan
418-1 250
Substantiated complaints concerning breaches of customer privacy and
losses of customer data
260 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 261
Positioned for
Profitable Growth
Halaman ini sengaja dikosongkan
This page is intentionally left blank
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 261
Page 262
Positioned for
Profitable Growth
07
Laporan
Keuangan
Financial Report
262 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 263
Positioned for Profitable Growth PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 263
Page 264
Laporan Keuangan Positioned for
Financial Report Profitable Growth
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK/AND ITS SUBSIDIARY
LAPORAN KEUANGAN KONSOLIDASIAN/
CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025/
FOR THE YEAR ENDED 31 DECEMBER 2025
DAN/AND
LAPORAN AUDITOR INDEPENDEN/
INDEPENDENT AUDITORS’ REPORT
264 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 265
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
LAPORAN KEUANGAN KONSOLIDASIAN CONSOLIDATED FINANCIAL STATEMENT
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
DAFTAR ISI CONTENTS
Pernyataan Direksi Directors’ Statement
Laporan Auditor Independen Independent Auditors’ Report
Ekshibit/
Exhibit
Laporan Auditor Independen Independent Auditors’ Report
Laporan Posisi Keuangan Konsolidasian A Consolidated Statement of Financial Position
Laporan Laba Rugi dan Penghasilan Komprehensif Consolidated Statement of Profit or Loss
Lain Konsolidasian B And Other Comprehensive Income
Laporan Perubahan Ekuitas Konsolidasian C Consolidated Statement of Changes in Equity
Laporan Arus Kas Konsolidasian D Consolidated Statement of Cash Flows
Catatan atas Laporan Keuangan Konsolidasian E Notes to the Consolidated Financial Statements
Lampiran/
Appendix
Laporan Keuangan Tersendiri 1-5 The Separate Financial Statements
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 265
Page 266
Laporan Keuangan Positioned for
Financial Report Profitable Growth
266 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 267
Positioned for
Profitable Growth
Tel : +62-21 5795 7300 Tanubrata Sutanto Fahmi Bambang & Rekan
Fax : +62-21 5795 7301 Certified Public Accountant
www.bdo.co.id Licence No. 622/KM.1/2016
Head Office
Prudential Tower, 17th Floor
Jl. Jend. Sudirman Kav. 79
Jakarta 12910 - Indonesia
This report is originally issued in Indonesian language
No. : 00138/2.1068/AU.1/05/1249-5/1/III/2026 No. : 00138/2.1068/AU.1/05/1249-5/1/III/2026
Laporan Auditor Independen Independent Auditors’ Report
Pemegang Saham, Dewan Komisaris The Shareholders, Board of Commissioners
dan Direksi and Directors
PT Millennium Pharmacon International Tbk PT Millennium Pharmacon International Tbk
Jakarta Jakarta
Opini Opinion
Kami telah mengaudit laporan keuangan konsolidasian We have audited the consolidated financial statements
PT Millennium Pharmacon International Tbk dan entitas of PT Millennium Pharmacon International Tbk and its
anaknya (“Grup”), yang terdiri dari laporan posisi subsidiary (the “Group”), which comprise the
keuangan konsolidasian tanggal 31 Desember 2025, consolidated statement of financial position as of
serta laporan laba rugi dan penghasilan komprehensif 31 December 2025, and the consolidated statement of
lain konsolidasian, laporan perubahan ekuitas profit or loss and other comprehensive income,
konsolidasian dan laporan arus kas konsolidasian untuk consolidated statement of changes in equity and
tahun yang berakhir pada tanggal tersebut, serta consolidated statement of cash flows for the year then
catatan atas laporan keuangan konsolidasian, termasuk ended, and notes to the consolidated financial
informasi kebijakan akuntansi material. statements, including material accounting policy
information.
Menurut opini kami, laporan keuangan konsolidasian In our opinion, the accompanying consolidated
terlampir menyajikan secara wajar, dalam semua hal financial statements present fairly, in all material
yang material, posisi keuangan konsolidasian Grup respects, the consolidated financial position of the
tanggal 31 Desember 2025, serta kinerja keuangan dan Group as of 31 December 2025, and its consolidated
arus kas konsolidasiannya untuk tahun yang berakhir financial performance and cash flows for the year then
pada tanggal tersebut, sesuai dengan Standar Akuntansi ended, in accordance with Indonesian Financial
Keuangan di Indonesia. Accounting Standards.
Basis Opini Basis for Opinion
Kami melaksanakan audit kami berdasarkan Standar We conducted our audit in accordance with Standards
Audit yang ditetapkan oleh Institut Akuntan Publik on Auditing established by Indonesian Institute of
Indonesia. Tanggung jawab kami menurut standar Certified Public Accountants. Our responsibilities
tersebut diuraikan lebih lanjut dalam paragraf under those standards are further described in the
Tanggung Jawab Auditor terhadap Audit atas Laporan Auditors’ Responsibilities for the Audit of the
Keuangan Konsolidasian pada laporan kami. Kami Consolidated Financial Statements paragraph of our
independen terhadap Grup berdasarkan ketentuan report. We are independent of the Group in
etika yang relevan dalam audit kami atas laporan accordance with the ethical requirement that are
keuangan konsolidasian di Indonesia, dan kami telah relevant to our Audit of the consolidated financial
memenuhi tanggung jawab etika lainnya berdasarkan statements in Indonesia, and we have fulfilled our
ketentuan tersebut. Kami yakin bahwa bukti audit yang ethical responsibilities in accordance with these
telah kami peroleh adalah cukup dan tepat untuk requirements. We believe that the audit evidence we
menyediakan suatu basis bagi opini audit kami. have obtained is sufficient and appropriate to provide
a basis for our opinion.
TANUBRATA SUTANTO FAHMI BAMBANG & REKAN
Tanubrata Sutanto Fahmi Bambang & Rekan (Certified Public Accountant), an Indonesian partnership, is a member of BDO International Limited, a UK
company limited by guarantee, and forms part of the international BDO network of independent member firms.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 267
Page 268
Laporan Keuangan Positioned for
Financial Report Profitable Growth
Halaman 2 Page 2
Hal Audit Utama Key Audit Matters
Hal audit utama adalah hal-hal yang, menurut Key audit matters are those matters that, in our
pertimbangan profesional kami, merupakan hal yang professional judgment, were of most significance in
paling signifikan dalam audit kami atas laporan our audit of the financial statements of the current
keuangan periode kini. Hal-hal tersebut disampaikan period. These matters were addressed in the context
dalam konteks audit kami atas laporan keuangan secara of our audit of the financial statements as a whole,
keseluruhan, dan dalam merumuskan opini kami atas and in forming our opinion thereon, and we do not
laporan keuangan terkait, kami tidak menyatakan suatu provide a separate opinion on these matters.
opini terpisah atas hal audit utama tersebut.
Hal Audit Utama yang teridentifikasi dalam Audit kami The Key Audit Matters identified in our audit are
diuraikan sebagai berikut: outlined as follows:
1. Perubahan nilai wajar investasi pada instrumen 1. Changes in the fair value of investments in
ekuitas equity instruments
Sebagaimana diungkapkan pada Catatan 7 atas As disclosed in Note 7 regarding Investment in
Penyertaan dalam bentuk saham atas laporan shares in the consolidated financial statements. On
keuangan konsolidasian. Pada tanggal 31 Desember 31 December 2025, the carrying value of
2025, nilai tercatat investasi pada instrumen investments in equity instruments amounted to
ekuitas adalah sebesar Rp 18.586.000.000. Pada Rp 18,586,000,000. In the current year, the Group
tahun berjalan, Grup mengakui penurunan nilai recognized impairment in the fair value of
wajar investasi sebesar Rp 3.922.000.000 yang investments amounting to Rp 3,922,000,000 which
dicatat pada penghasilan komprehensif lain were recorded in consolidated other comprehensive
konsolidasian. income.
Grup telah menetapkan investasi pada instrumen The Group has determined investment in equity
ekuitas untuk diukur pada nilai wajar melalui instruments to be measured at fair value through
penghasilan komprehensif lain. Kami fokus pada other comprehensive income. We focus on the
jumlah terpulihkan investasi pada instrumen recoverable amount of investments in financial
keuangan yang ditentukan berdasarkan pendekatan instruments, which is determined based on a
tertimbang probabilitas untuk menentukan arus kas probability-weighted approach to determining
yang diharapkan, memerlukan pertimbangan expected cash flows that requires management's
manajemen atas estimasi kinerja keuangan masa judgment of estimates of future financial
depan dengan menggunakan suku bunga pasar dan performance using market interest rates and risk
premi risiko yang spesifik atas efek yang tidak premiums specific to non-traded securities and key
diperdagangkan dan asumsi utama yang digunakan, assumptions. used, in particular sales growth,
khususnya pertumbuhan penjualan, tingkat terminal growth rate and discount rate.
pertumbuhan terminal dan tingkat diskonto.
Dalam merespon hal audit utama yang In responding to the identified key audit matters,
teridentifikasi, kami melakukan prosedur audit we performed the following audit procedures:
sebagai berikut:
• Menilai keandalan anggaran yang disetujui • • Assessed the reliability of approved budget by
dengan membandingkan anggaran yang disetujui comparing their previous years’ approved
pada tahun-tahun sebelumnya dengan tren hasil budget against past trends of actual results;
aktual di masa lalu;
• Melibatkan pakar penilai kami untuk menilai • • Involved our valuation expert to assess the
tingkat diskonto dan model penurunan nilai discount rates and certain impairment models
tertentu yang digunakan dalam menentukan used in determining the recoverable amounts of
jumlah terpulihkan dari Unit Penghasil Kas; dan the Cash Generating Unit (CGUs); and
• Memeriksa kesesuaian analisis sensitivitas yang • • Checked the appropriateness of sensitivity
dilakukan oleh manajemen, termasuk analysis performed by management, including
pengungkapan, terhadap kemungkinan disclosures, to possible reasonable changes in
perubahan wajar dalam asumsi-asumsi utama key assumptions and the corresponding effect
dan dampaknya terhadap jumlah terpulihkan. on the recoverable amounts.
TANUBRATA SUTANTO FAHMI BAMBANG & REKAN
Tanubrata Sutanto Fahmi Bambang & Rekan (Certified Public Accountant), an Indonesian partnership, is a member of BDO International Limited, a UK
company limited by guarantee, and forms part of the international BDO network of independent member firms.
268 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 269
Positioned for
Profitable Growth
Halaman 3 Page 3
Hal Audit Utama (Lanjutan) Key Audit Matters (Continued)
2. Cadangan penurunan nilai piutang usaha 2. Allowance for impairment trade receivables
Grup memiliki piutang usaha (Catatan 5) yang The Company has trade receivables (Note 5) that
dipertimbangkan mengalami penurunan nilai. are considered impaired. Total trade
Jumlah piutang usaha pada tanggal 31 Desember receivables as of 31 December 2025 amounted
2025 sebesar Rp 838.490.427.704, di mana to Rp 838,490,427,704, which experienced an
mengalami penurunan nilai sebesar impairment of Rp 26,488,926,436 as of
Rp 26.488.926.436 pada tanggal 31 Desember 2025. 31 December 2025.
Pada tanggal 31 Desember 2025, Grup telah As of 31 December 2025, the Group provided
membentuk cadangan penurunan nilai atas piutang allowance for impairment of trade receivables
usaha sebesar Rp 3.021.492.300. amounting to Rp 3,021,492,300.
Grup menerapkan PSAK 109 untuk mengukur The Group applies PSAK 109 to measure expected
kerugian kredit ekspektasian (KKE) dengan credit losses (ECL) using a lifetime allowance for
menggunakan penyisihan KKE sepanjang masa untuk ECL for these financial assets. The calculation of
aset keuangan tersebut. Perhitungan cadangan the allowance for impairment of financial assets
penurunan nilai aset keuangan juga melibatkan also involved estimates and assumptions from the
estimasi dan asumsi manajemen Grup. Grup Group's management. The Group uses the collective
menggunakan metode kolektif dengan method by considering information indicating that
mempertimbangkan informasi yang mengindikasikan a significant increase in credit risk has occurred.
peningkatan risiko kredit secara signifikan telah For the purpose of determining significant
terjadi. Untuk tujuan menentukan peningkatan increases in credit risk and collectively recognizing
risiko kredit secara signifikan dan mengakui allowance for possible losses, the Group classifies
penyisihan kerugian secara kolektif, Grup trade receivables based on similar credit risk
mengelompokkan piutang usaha berdasarkan characteristics in order to facilitate analysis
kesamaan karakteristik risiko kredit dengan tujuan designed to enable significant increases in credit
untuk memfasilitasi analisis yang didesain untuk risk to be identified in a timely manner.
memungkinkan peningkatan risiko kredit secara
signifikan dapat diidentifikasi tepat waktu.
Dalam merespon hal audit utama yang In responding to the identified key audit matters,
teridentifikasi, kami melakukan prosedur audit we performed the following audit procedures:
sebagai berikut:
• Kami telah menguji keakuratan model • • We have tested the computation accuracy of the
perhitungan KKE berdasarkan persyaratan dalam ECL model applied with the requirements in
PSAK 109; PSAK 109;
• Kami menguji perhitungan cadangan penurunan • • We examined the calculation of the allowance
nilai aset keuangan yang dihitung menggunakan for impairment of financial assets which was
metode kolektif berdasarkan kesamaan calculated using collective method based on
karakteristik risiko kredit; similar credit risk characteristics;
• Kami telah menilai ketepatan asumsi-asumsi • • We have assessed the appropriateness of
manejemen yang digunakan dalam perhitungan management’s assumptions used in the
cadangan penurunan nilai aset keuangan yaitu calculation of the allowance for impairment of
estimasi arus kas masa depan dan asumsi kondisi financial assets, such as estimated future cash
ekonomi masa depan; flows and forward-looking economic conditions;
• Kami berdiskusi dengan manajemen Grup • • We inquired with the Group’s management
mengenai usaha-usaha yang telah dilakukan regarding efforts that have been made to
untuk memulihkan aset keuangan tersebut recover these financial assets during the year
selama tahun berjalan yang berakhir pada ended 31 December 2025.
tanggal 31 Desember 2025.
TANUBRATA SUTANTO FAHMI BAMBANG & REKAN
Tanubrata Sutanto Fahmi Bambang & Rekan (Certified Public Accountant), an Indonesian partnership, is a member of BDO International Limited, a UK
company limited by guarantee, and forms part of the international BDO network of independent member firms.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 269
Page 270
Laporan Keuangan Positioned for
Financial Report Profitable Growth
Halaman 4 Page 4
Hal Lain Other Matter
Audit kami atas laporan keuangan konsolidasian Grup Our audit of the accompanying consolidated financial
tanggal 31 Desember 2025 dan untuk tahun yang statements of Group as of 31 December 2025 and for
berakhir pada tanggal tersebut terlampir, dilaksanakan the year then ended, was performed for the purpose of
dengan tujuan untuk merumuskan suatu opini atas forming an opinion on such consolidated financial
laporan keuangan konsolidasian tersebut secara statements taken as a whole. The accompanying
keseluruhan. Informasi keuangan PT Millennium financial information of PT Millennium Pharmacon
Pharmacon International Tbk (entitas induk) terlampir, International Tbk (parent entity), which comprises the
yang terdiri dari laporan posisi keuangan tanggal statement of financial position as of 31 December 2025
31 Desember 2025 serta laporan laba rugi dan and the statement of profit or loss and other
penghasilan komprehensif lain, laporan perubahan comprehensive income, statement of changes in equity
ekuitas dan laporan arus kas untuk tahun yang berakhir and statement of cash flows for the year then ended
pada tanggal tersebut (secara kolektif disebut sebagai (collectively referred to as the "Parent Entity Financial
“Informasi Keuangan Entitas Induk”), yang disajikan Information"), which is presented as supplementary
sebagai informasi tambahan terhadap laporan keuangan information to the accompanying consolidated
konsolidasian terlampir, disajikan untuk tujuan analisis financial statements, is presented for the purposes of
tambahan dan bukan merupakan bagian dari laporan additional analysis and is not a required part of the
keuangan konsolidasian terlampir yang diharuskan accompanying consolidated financial statements under
menurut Standar Akuntansi Keuangan di Indonesia. Indonesian Financial Accounting Standards. The Parent
Informasi Keuangan Entitas Induk merupakan tanggung Entity Financial Information is the responsibility of
jawab manajemen serta dihasilkan dari dan berkaitan management and was derived from and relates directly
secara langsung dengan catatan akuntansi dan catatan to the underlying accounting and other records used to
lainnya yang mendasarinya yang digunakan untuk prepare the accompanying consolidated financial
menyusun laporan keuangan konsolidasian terlampir. statements. The Parent Entity Financial Information
Informasi Keuangan Entitas Induk telah menjadi objek has been subjected to the auditing procedures applied
prosedur audit yang diterapkan dalam audit atas in the audit of the accompanying consolidated
laporan keuangan konsolidasian terlampir berdasarkan financial statements in accordance with Standards on
Standar Audit yang ditetapkan oleh Institut Akuntan Auditing established by the Indonesian Institute of
Publik Indonesia. Menurut opini kami, Informasi Certified Public Accountants. In our opinion, the
Keuangan Entitas Induk disajikan secara wajar, dalam Parent Entity Financial Information is fairly stated, in
semua hal yang material, berkaitan dengan laporan all material respects, in relation to the accompanying
keuangan konsolidasian terlampir secara keseluruhan. consolidated financial statements taken as a whole.
Informasi Lain Other Information
Manajemen bertanggung jawab atas informasi lain. Management is responsible for the other information.
Informasi lain terdiri dari informasi yang tercantum The other information comprises the information
dalam laporan tahunan, tetap tidak termasuk laporan included in the annual report, but does not include the
keuangan konsolidasian dan laporan auditor kami. consolidated financial statements and our auditors’
Laporan tahunan diharapkan akan tersedia bagi kami report thereon. The annual report is expected to be
setelah tanggal laporan auditor ini. made available to us after the date of this auditors’
report.
Opini kami atas laporan keuangan konsolidasian tidak Our opinion on the consolidated financial statements
mencakup informasi lain, dan oleh karena itu, kami does not cover the other information and we will not
tidak menyatakan bentuk keyakinan apapun atas express any form of assurance conclusion thereon.
informasi lain tersebut.
Sehubungan dengan audit kami atas laporan keuangan In connection in our audit of the consolidated financial
konsolidasian, tanggung jawab kami adalah untuk statements, our responsibility, is to read the other
membaca informasi lain yang teridentifikasi di atas, information identified above when it becomes
jika tersedia dan, dalam melaksanakannya, available and, in doing so, consider whether the other
mempertimbangkan apakah informasi lain mengandung information is materially inconsistent with the
ketidakkonsistensian material dengan laporan keuangan consolidated financial statements or our knowledge
konsolidasian atau pemahaman yang kami peroleh obtained in the audit, or otherwise appears to be
selama audit, atau mengandung kesalahan penyajian materially misstated.
material.
TANUBRATA SUTANTO FAHMI BAMBANG & REKAN
Tanubrata Sutanto Fahmi Bambang & Rekan (Certified Public Accountant), an Indonesian partnership, is a member of BDO International Limited, a UK
company limited by guarantee, and forms part of the international BDO network of independent member firms.
270 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 271
Positioned for
Profitable Growth
Halaman 5 Page 5
Informasi Lain (Lanjutan) Other Information (Continued)
Ketika kami membaca laporan tahunan, jika kami When we read the annual report, if we conclude that
menyimpulkan bahwa terdapat suatu kesalahan there is a material misstatement therein, we are
penyajian material di dalamnya, kami diharuskan required to communicate the matter to those charged
mengomunikasikan hal tersebut kepada pihak yang with governance and take appropriate actions in
bertanggung jawab atas tata kelola dan mengambil accordance with Standards on Auditing established by
tindakan tepat berdasarkan Standar Audit yang the Indonesian Institute of Certified Public
ditetapkan oleh Institut Akuntan Publik Indonesia. Accountants.
Tanggung Jawab Manajemen dan Pihak yang Responsibilities of Management and Those Charged
Bertanggung Jawab atas Tata Kelola terhadap with Governance for the Consolidated Financial
Laporan Keuangan Konsolidasian Statements
Manajemen bertanggung jawab atas penyusunan dan Management is responsible for the preparation
penyajian wajar laporan keuangan konsolidasian and fair presentation of these consolidated financial
tersebut sesuai dengan Standar Akuntansi Keuangan di statements in accordance with Indonesian Financial
Indonesia, dan atas pengendalian internal yang Accounting Standards, and for such internal control as
dianggap perlu oleh manajemen untuk memungkinkan management determines is necessary to enable the
penyusunan laporan keuangan konsolidasian yang bebas preparation of consolidated financial statements that
dari kesalahan penyajian material, baik yang are free from material misstatement, whether due to
disebabkan oleh kecurangan maupun kesalahan. fraud or error.
Dalam penyusunan laporan keuangan konsolidasian, In preparing the consolidated financial statements,
manajemen bertanggung jawab untuk menilai management is responsible for assessing the Group's
kemampuan Grup dalam mempertahankan ability to continue as going concern, disclosing, as
kelangsungan usahanya, mengungkapkan, sesuai dengan applicable, matters related to going concern and using
kondisinya, hal-hal yang berkaitan dengan the going concern basis of accounting unless
kelangsungan usaha, dan menggunakan basis akuntansi management either intends to liquidate the Group or
kelangsungan usaha, kecuali manajemen memiliki to cease operations, or has no realistic alternative but
intensi untuk melikuidasi Grup atau menghentikan to do so.
operasi, atau tidak memiliki alternatif yang realistis
selain melaksanakannya.
Pihak yang bertanggung jawab atas tata kelola Those charged with governance are responsible
bertanggung jawab untuk mengawasi proses pelaporan for overseeing the Group's financial reporting process.
keuangan Grup.
Tanggung Jawab Auditor terhadap Audit atas Laporan Auditors’ Responsibilities for the Audit of the
Keuangan Konsolidasian Consolidated Financial Statements
Tujuan kami adalah untuk memperoleh keyakinan Our objectives are to obtain reasonable assurance
memadai tentang apakah laporan keuangan about whether the consolidated financial statements
konsolidasian secara keseluruhan bebas dari kesalahan as a whole are free from material misstatement,
penyajian material, baik yang disebabkan oleh whether due to fraud or error, and to issue an
kecurangan maupun kesalahan, dan untuk menerbitkan auditors' report that includes our opinion. Reasonable
laporan auditor yang mencakup opini kami. Keyakinan assurance is a high level of assurance, but is not a
memadai merupakan suatu tingkat keyakinan tinggi, guarantee that an audit conducted in accordance with
namun bukan merupakan suatu jaminan bahwa audit Standards on Auditing will always detect a material
yang dilaksanakan berdasarkan Standar Audit akan misstatement when it exists. Misstatements can arise
selalu mendeteksi kesalahan penyajian material ketika from fraud or error and are considered material if,
hal tersebut ada. Kesalahan penyajian dapat individually or in the aggregate, they could reasonably
disebabkan oleh kecurangan maupun kesalahan dan be expected to influence the economic decisions of
dianggap material jika, baik secara individual maupun users taken on the basis of these consolidated financial
secara agregat, dapat diekspektasikan secara wajar statements.
akan mempengaruhi keputusan ekonomi yang diambil
oleh pengguna berdasarkan laporan keuangan
konsolidasian tersebut.
TANUBRATA SUTANTO FAHMI BAMBANG & REKAN
Tanubrata Sutanto Fahmi Bambang & Rekan (Certified Public Accountant), an Indonesian partnership, is a member of BDO International Limited, a UK
company limited by guarantee, and forms part of the international BDO network of independent member firms.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 271
Page 272
Laporan Keuangan Positioned for
Financial Report Profitable Growth
Halaman 6 Page 6
Tanggung Jawab Auditor terhadap Audit atas Laporan Auditors’ Responsibilities for the Audit of the
Keuangan Konsolidasian (Lanjutan) Consolidated Financial Statements (Continued)
Sebagai bagian dari suatu audit berdasarkan Standar As part of an audit in accordance with Standards on
Audit, kami menerapkan pertimbangan profesional dan Auditing, we exercise professional judgment and
mempertahankan skeptisisme profesional selama Audit. maintain professional skepticism throughout the audit.
Kami juga: We also:
• Mengidentifikasi dan menilai risiko kesalahan • Identify and assess the risks of material
penyajian material dalam laporan keuangan misstatement of the consolidated financial
konsolidasian, baik yang disebabkan oleh statements, whether due to fraud or error,
kecurangan maupun kesalahan, mendesain dan design and perform audit procedures responsive
melaksanakan prosedur audit yang responsif to those risks, and obtain audit evidence that is
terhadap risiko tersebut, serta memperoleh bukti sufficient and appropriate to provide a basis for
audit yang cukup dan tepat untuk menyediakan our opinion. The risk of not detecting a material
basis bagi opini kami. Risiko tidak terdeteksinya misstatement resulting from fraud is higher than
kesalahan penyajian material yang disebabkan for one resulting from error, as fraud may involve
oleh kecurangan lebih tinggi dari yang disebabkan collusion, forgery, intentional omissions,
oleh kesalahan, karena kecurangan dapat misrepresentations, or the override of internal
melibatkan kolusi, pemalsuan, penghilangan control.
secara sengaja, pernyataan salah, atau
pengabaian pengendalian internal.
• Memperoleh suatu pemahaman tentang • Obtain an understanding of internal control
pengendalian internal yang relevan dengan audit relevant to the audit in order to design audit
untuk mendesain prosedur audit yang tepat sesuai procedures that are appropriate in the
dengan kondisinya, tetapi bukan untuk tujuan circumstances, but not for the purpose of
menyatakan opini atas keefektivitasan expressing an opinion on the effectiveness of the
pengendalian internal Grup. Group’s internal control.
• Mengevaluasi ketepatan kebijakan akuntansi yang • Evaluate the appropriateness of accounting
digunakan serta kewajaran estimasi akuntansi dan policies used and the reasonableness of
pengungkapan terkait yang dibuat oleh accounting estimates and related disclosures
manajemen. made by management.
• Menyimpulkan ketepatan penggunaan basis • Conclude on the appropriateness of
akuntansi kelangsungan usaha oleh manajemen management's use of the going concern basis
dan berdasarkan bukti audit yang diperoleh, of accounting and, based on the audit evidence
apakah terdapat suatu ketidakpastian material obtained, whether a material uncertainty
yang terkait dengan peristiwa atau kondisi yang exists related to events or conditions that
dapat menyebabkan keraguan signifikan atas may cast significant doubt on the Group's ability
kemampuan Grup untuk mempertahankan to continue as a going concern. If we conclude
kelangsungan usahanya. Ketika kami that a material uncertainty exists, we are
menyimpulkan bahwa terdapat suatu required to draw attention in our auditors' report
ketidakpastian material, kami diharuskan untuk to the related disclosures in the consolidated
menarik perhatian dalam laporan auditor kami ke financial statements or, if such disclosures are
pengungkapan terkait dalam laporan keuangan inadequate, to modify our opinion. Our
konsolidasian atau, jika pengungkapan tersebut conclusions are based on the audit evidence
tidak memadai, harus menentukan apakah perlu obtained up to the date of our auditors' report.
untuk memodifikasi opini kami. Kesimpulan kami However, future events or conditions may cause
didasarkan pada bukti audit yang diperoleh hingga the Group to cease to continue as a going
tanggal laporan auditor kami. Namun, peristiwa concern.
atau kondisi masa depan dapat menyebabkan
Grup tidak dapat mempertahankan kelangsungan
usaha.
• Mengevaluasi penyajian, struktur, dan isi laporan • Evaluate the overall presentation, structure and
keuangan konsolidasian secara keseluruhan, content of the consolidated financial statements,
termasuk pengungkapannya, dan apakah laporan including the disclosures, and whether the
keuangan konsolidasian mencerminkan transaksi consolidated financial statements represent the
dan peristiwa yang mendasarinya dengan suatu underlying transactions and events in a manner
cara yang mencapai penyajian wajar. that achieves fair presentation.
TANUBRATA SUTANTO FAHMI BAMBANG & REKAN
Tanubrata Sutanto Fahmi Bambang & Rekan (Certified Public Accountant), an Indonesian partnership, is a member of BDO International Limited, a UK
company limited by guarantee, and forms part of the international BDO network of independent member firms.
272 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 273
Positioned for
Profitable Growth
Halaman 7 Page 7
Tanggung Jawab Auditor terhadap Audit atas Laporan Auditors’ Responsibilities for the Audit of the
Keuangan Konsolidasian (Lanjutan) Consolidated Financial Statements (Continued)
• Memperoleh bukti audit yang cukup dan tepat • Obtain sufficient and appropriate audit evidence
terkait informasi keuangan Grup atau aktivitas regarding the financial information of the Group or
bisnis dalam Grup untuk menyatakan opini atas business activities within the Group to express an
laporan keuangan konsolidasian. Kami opinion on the consolidated financial statements.
bertanggung jawab atas arahan, supervisi, dan We are responsible for the direction, supervision
pelaksanaan audit Grup. Kami tetap bertanggung and performance of the audit Group. We remain
jawab sepenuhnya atas opini audit kami. solely responsible for our audit opinion.
Kami mengkomunikasikan kepada pihak yang We communicate with those charged with governance
bertanggung jawab atas tata kelola mengenai, antara regarding, among other matters, the planned scope
lain, ruang lingkup dan saat yang direncanakan atas and timing of the audit and significant audit findings,
audit, serta temuan audit signifikan, termasuk setiap including any significant deficiencies in internal
defisiensi signifikan dalam pengendalian internal yang control that we identify during our audit.
teridentifikasi oleh kami selama audit.
Kami juga memberikan suatu pernyataan kepada pihak We also provide those charged with governance with a
yang bertanggung jawab atas tata kelola bahwa kami statement that we have complied with relevant
telah mematuhi ketentuan etika yang relevan mengenai ethical requirements regarding independence, and to
independensi, dan mengkomunikasikan seluruh communicate with them all relationships and
hubungan, serta hal-hal lain yang dianggap secara other matters that may reasonably be thought to bear
wajar berpengaruh terhadap independensi kami, dan on our independence, and where applicable, related
jika relevan, pengamanan terkait. safeguards.
Dari hal-hal yang dikomunikasikan kepada pihak yang From the matters communicated with those charged
bertanggung jawab atas tata kelola, kami menentukan with governance, we determine those matters that
hal-hal tersebut yang paling signifikan dalam audit atas were of most significance in the audit of the financial
laporan keuangan periode kini dan oleh karenanya statements of the current period and are therefore the
menjadi hal audit utama. Kami menguraikan hal audit key audit matters. We describe these matters in our
utama dalam laporan auditor kami, kecuali peraturan auditor's report unless law or regulation precludes
perundang-undangan melarang pengungkapan publik public disclosure about the matter or when, in
tentang hal tersebut atau ketika, dalam kondisi sangat extremely rare circumstances, we determine that a
jarang terjadi, kami menentukan bahwa suatu hal tidak matter should not be communicated in our report
boleh dikomunikasikan dalam laporan kami karena because the adverse consequences of doing so would
konsekuensi merugikan dari mengomunikasikan hal reasonably be expected to outweigh the public interest
tersebut akan diekspektasikan secara wajar melebihi benefits of such communication.
manfaat kepentingan publik atas komunikasi tersebut.
Kantor Akuntan Publik
TANUBRATA SUTANTO FAHMI BAMBANG & Rekan
Nanda Priyatna Harahap, SE, Ak, M.Ak., CPA, CA, ASEAN CPA
NIAP AP.1249/
License No. AP.1249
30 Maret 2026/ 30 March 2026
TANUBRATA SUTANTO FAHMI BAMBANG & REKAN
Tanubrata Sutanto Fahmi Bambang & Rekan (Certified Public Accountant), an Indonesian partnership, is a member of BDO International Limited, a UK
company limited by guarantee, and forms part of the international BDO network of independent member firms.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 273
Page 274
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit A Exhibit A
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
LAPORAN POSISI KEUANGAN KONSOLIDASIAN CONSOLIDATED STATEMENT OF FINANCIAL POSITION
31 DESEMBER 2025 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
31 Desember/ 31 Desember/
Catatan/ December December
Notes 2025 2024
ASET ASSETS
Aset Lancar Current Assets
Kas dan bank 4 62.842.729.716 53.472.920.923 Cash and banks
Piutang usaha – pihak ketiga 5 812.001.501.268 731.939.823.034 Trade receivables - third parties
Piutang lain-lain Other receivables
Pihak ketiga 16.459.921.609 4.804.626.429 Third parties
Pihak berelasi 27 5.280.793.152 4.849.036.337 Related party
Persediaan 6 609.092.307.483 567.732.385.118 Inventories
Pajak dibayar di muka 13a 206.049.665.570 193.132.912.605 Prepaid taxes
Biaya dibayar di muka 4.085.372.130 5.301.218.978 Prepaid expenses
Uang muka 3.129.340.923 2.561.293.991 Advance payment
Jumlah Aset Lancar 1.718.941.631.851 1.563.794.217.415 Total Current Assets
Aset Tidak Lancar Non-Current Assets
Piutang lain–lain - pihak berelasi 27 11.100.000.000 14.400.000.000 Other receivables - related party
Penyertaan dalam bentuk saham 7 18.586.000.000 22.508.000.000 Investment in shares of stock
Aset tetap 8 109.084.754.345 80.865.592.238 Property and equipment
Aset takberwujud 9 6.995.340.719 7.778.722.243 Intangible assets
Aset hak-guna 10 29.443.646.297 30.551.291.312 Right–of–use assets
Taksiran tagihan restitusi pajak Estimated claims for income
penghasilan 13b 34.326.073.242 31.112.017.785 tax refund
Aset pajak tangguhan 13e 27.353.988.319 17.055.771.330 Deferred tax assets
Aset tidak lancar lainnya 4.888.420.362 3.791.217.078 Other non-current assets
Jumlah Aset Tidak Lancar 241.778.223.284 208.062.611.986 Total Non-Current Assets
JUMLAH ASET 1.960.719.855.135 1.771.856.829.401 TOTAL ASSETS
Lihat Catatan atas Laporan Keuangan Konsolidasian pada See accompanying Notes to the Consolidated Financial Statements
Ekshibit E terlampir yang merupakan bagian yang tidak terpisahkan on Exhibit E which are an integral part of
dari Laporan Keuangan Konsolidasian secara keseluruhan the Consolidated Financial Statements taken as a whole
274 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 275
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit A/2 Exhibit A/2
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
LAPORAN POSISI KEUANGAN KONSOLIDASIAN CONSOLIDATED STATEMENT OF FINANCIAL POSITION
31 DESEMBER 2025 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
31 Desember/ 31 Desember/
Catatan/ December December
Notes 2025 2024
LIABILITAS DAN EKUITAS LIABILITIES AND EQUITY
Liabilitas Jangka Pendek Current Liabilities
Utang bank 11 749.562.430.208 798.202.277.720 Bank loans
Utang usaha Trade payables
Pihak ketiga 12 688.589.046.187 518.378.583.738 Third parties
Pihak berelasi 12,27 5.860.014.025 9.211.162.935 Related party
Utang lain-lain Other payables
Pihak ketiga 4.150.814.297 3.937.630.119 Third parties
Pihak berelasi 27 76.098.618.599 55.959.841.458 Related party
Utang pajak 13c 240.460.045 114.467.541 Tax payables
Beban akrual 14 19.083.982.341 18.365.850.154 Accrued expenses
Liabilitas imbalan kerja jangka pendek 15 5.402.258.913 4.238.362.326 Short-term employee benefit liability
Bagian liabilitas jangka panjang yang Long-term liabilities due
akan jatuh tempo dalam satu tahun: within one year:
Utang bank 11 6.424.407.576 5.008.888.896 Bank loan
Hire purchase 458.700.899 - Hire purchase
Jumlah Liabilitas Jangka Pendek 1.555.870.733.090 1.413.417.064.887 Total Current Liabilities
Liabilitas Jangka Panjang Non-Current Liabilities
Liabilitas jangka panjang
setelah dikurangi bagian yang jatuh Long-term liabilities net
tempo dalam waktu satu tahun: of current maturities:
Utang bank 11 53.296.039.526 43.311.111.104 Bank loans
Liabilitas imbalan kerja jangka panjang 16 36.089.872.387 32.631.733.401 Long-term employee benefit liability
Hire purchase 59.963.200 - Hire purchase
Jumlah Liabilitas Jangka Panjang 89.445.875.113 75.942.844.505 Total Non-Current Liabilities
JUMLAH LIABILITAS 1.645.316.608.203 1.489.359.909.392 TOTAL LIABILITIES
EKUITAS EQUITY
Ekuitas yang diatribusikan Equity attributable
kepada pemilik entitas induk to the owners of the parent
Modal saham – nilai nominal Share capital – of par value
Rp 100 per saham Rp 100 per share
Modal dasar – Authorized capital –
2.184.000.000 saham 2,184,000,000 shares
Modal Ditempatkan dan disetor Issued and fully-paid-up capital -
penuh – 1.274.000.000 saham 17 127.400.000.000 127.400.000.000 1,274,000,000 shares
Tambahan modal disetor 18 2.309.683.922 2.309.683.922 Additional paid-in capital
Surplus revaluasi 32 4.202.572.171 4.202.572.171 Revaluation surplus
Perubahan nilai wajar investasi 32 ( 27.622.920.000 ) ( 24.563.760.000 ) Change fair value in investment
Saldo laba Retained earnings
Telah ditentukan penggunaannya 14.332.500.000 11.784.500.000 Appropriated
Belum ditentukan penggunaannya 194.802.645.122 161.382.497.408 Unappropriated
Ekuitas yang diatribusikan kepada Equity attributable to the
pemilik entitas induk 315.424.481.215 282.515.493.501 owners of the parent
Kepentingan non–pengendali ( 21.234.283 ) ( 18.573.492 ) Non–controlling interest
JUMLAH EKUITAS 315.403.246.932 282.496.920.009 TOTAL EQUITY
JUMLAH LIABILITAS DAN EKUITAS 1.960.719.855.135 1.771.856.829.401 TOTAL LIABILITIES AND EQUITY
Lihat Catatan atas Laporan Keuangan Konsolidasian pada See accompanying Notes to the Consolidated Financial Statements
Ekshibit E terlampir yang merupakan bagian yang tidak terpisahkan on Exhibit E which are an integral part of
dari Laporan Keuangan Konsolidasian secara keseluruhan the Consolidated Financial Statements taken as a whole
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 275
Page 276
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit B Exhibit B
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
LAPORAN LABA RUGI DAN PENGHASILAN CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER
KOMPREHENSIF LAIN KONSOLIDASIAN COMPREHENSIVE INCOME
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
31 Desember/ 31 Desember/
Catatan/ December December
Notes 2025 2024
PENDAPATAN 20 4.109.810.339.016 3.916.863.878.530 REVENUES
BEBAN POKOK PENDAPATAN 21 ( 3.747.451.408.783 ) ( 3.582.486.836.953 ) COST OF REVENUES
LABA KOTOR 362.358.930.233 334.377.041.577 GROSS PROFIT
BEBAN USAHA OPERATING EXPENSES
Beban penjualan 22 ( 65.590.708.237 ) ( 65.548.217.684 ) Selling expenses
Beban umum dan administrasi 23 ( 169.304.420.742 ) ( 160.642.697.924 ) General and administrative expenses
Pendapatan operasi lain 1.255.661.044 3.711.571.405 Other operating income
Beban operasi lain ( 15.182.421.127 ) ( 15.463.988.795 ) Other operating expenses
Jumlah Beban Usaha ( 248.821.889.062 ) ( 237.943.332.998 ) Total Operating Expenses
LABA USAHA 113.537.041.171 96.433.708.579 OPERATING PROFIT
Pendapatan keuangan 290.090.283 59.006.191 Finance income
Beban keuangan 24 ( 64.930.209.553 ) ( 68.791.412.181 ) Finance expenses
Beban Keuangan - Bersih ( 64.640.119.270 ) ( 68.732.405.990 ) Finance Expenses – Net
LABA SEBELUM PAJAK PROFIT BEFORE INCOME
PENGHASILAN 48.896.921.901 27.701.302.589 TAX
PAJAK PENGHASILAN INCOME TAX
Kini 13d ( 19.879.370.569 ) ( 8.743.488.816 ) Current
Tangguhan 13d,e 9.448.699.865 ( 2.043.681.651 ) Deferred
Beban Pajak Penghasilan ( 10.430.670.704 ) ( 10.787.170.467 ) Income Tax Expenses
LABA TAHUN BERJALAN 38.466.251.197 16.914.132.122 PROFIT FOR THE YEAR
PENGHASILAN KOMPREHENSIF LAIN OTHER COMPREHENSIVE INCOME
Pos-pos yang tidak akan Items that will not be reclassified
direklasifikasi ke laba rugi: to profit or loss:
Perubahan nilai wajar investasi 7 ( 3.922.000.000 ) ( 10.792.000.000 ) Change fair value in investment
Pengukuran kembali imbalan Remeasurement of employee
kerja 15 60.558.602 ( 676.717.542 ) benefits
Pajak penghasilan yang terkait Tax relating to items that
pos-pos yang tidak akan will not be reclassified
direklasifikasi ke laba rugi: to profit or loss:
Perubahan nilai wajar investasi 13e 862.840.000 2.374.240.000 Change fair value in investment
Pengukuran kembali imbalan 13e Remeasurement of employee
kerja ( 13.322.876 ) 148.877.863 benefits
Kerugian komprehensif lain Other comprehensive loss
tahun berjalan ( 3.011.924.274 ) ( 8.945.599.679 ) for the year
JUMLAH LABA KOMPREHENSIF TOTAL COMPREHENSIVE INCOME
TAHUN BERJALAN 35.454.326.923 7.968.532.443 FOR THE YEAR
Lihat Catatan atas Laporan Keuangan Konsolidasian pada See accompanying Notes to the Consolidated Financial Statements
Ekshibit E terlampir yang merupakan bagian yang tidak terpisahkan on Exhibit E which are an integral part of
dari Laporan Keuangan Konsolidasian secara keseluruhan the Consolidated Financial Statements taken as a whole
276 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 277
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit B/2 Exhibit B/2
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
LAPORAN LABA RUGI DAN PENGHASILAN CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER
KOMPREHENSIF LAIN KONSOLIDASIAN COMPREHENSIVE INCOME
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
31 Desember/ 31 Desember/
Catatan/ December December
Notes 2025 2024
LABA TAHUN BERJALAN YANG PROFIT FOR THE YEAR
DAPAT DIATRIBUSIKAN KEPADA: ATTRIBUTABLE TO:
Pemilik entitas induk 38.468.911.988 16.928.878.936 Owners of the parent entity
Kepentingan non-pengendali ( 2.660.791 ) ( 14.746.814 ) Non-controlling interests
JUMLAH 38.466.251.197 16.914.132.122 TOTAL
PENGHASILAN KOMPREHENSIF YANG COMPREHENSIVE INCOME
DIATRIBUSIKAN KEPADA: ATTRIBUTABLE TO:
Pemilik entitas induk 35.456.987.714 7.983.279.257 Owners of the parent entity
Kepentingan non-pengendali ( 2.660.791 ) ( 14.746.814 ) Non-controlling interests
JUMLAH 35.454.326.923 7.968.532.443 TOTAL
LABA PER SAHAM 25 30,20 13,29 EARNINGS PER SHARE
Lihat Catatan atas Laporan Keuangan Konsolidasian pada See accompanying Notes to the Consolidated Financial Statements
Ekshibit E terlampir yang merupakan bagian yang tidak terpisahkan on Exhibit E which are an integral part of
dari Laporan Keuangan Konsolidasian secara keseluruhan the Consolidated Financial Statements taken as a whole
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 277
Page 278
Positioned for
Profitable Growth
2025
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Laporan Tahunan & Laporan Keberlanjutan
Ekshibit C Exhibit C
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk DAN ENTITAS ANAK PT MILLENNIUM PHARMACON INTERNATIONAL Tbk AND ITS SUBSIDIARY
LAPORAN PERUBAHAN EKUITAS KONSOLIDASIAN CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
Ekuitas yang
diatribusikan
Tambahan Perubahan kepada pemilik Kepentingan
modal nilai wajar Saldo Laba/ Retained Earnings entitas induk/ non-
disetor/ Surplus Investasi/ Telah Belum Equity pengendali/
Additional Revaluasi/ Change ditentukan ditentukan attributable to Non-
Catatan/ Modal saham/ paid-in Revaluation fair value penggunaannya/ penggunaannya/ the owners of controlling Jumlah Ekuitas/
Notes Share capital capital Surplus in investment Appropriated Unappropriated the parent entity interests Total Equity
Balance at
Saldo 1 Januari 2024 127.400.000.000 2.309.683.922 4.202.572.171 ( 16.146.000.000 ) 8.599.500.000 151.351.458.151 277.717.214.244 ( 3.826.678 ) 277.713.387.566 1 January 2024
Deklarasi dividen 19 - - - - - ( 3.185.000.000 ) ( 3.185.000.000 ) - ( 3.185.000.000 ) Declaration of dividen
Pencadangan saldo Appropriation of
laba 19 - - - - 3.185.000.000 ( 3.185.000.000 ) - - - retained earnings
Penghasilan komprehensif Other comprehensive
lain tahun berjalan - - - ( 8.417.760.000 ) - 16.401.039.257 7.983.279.257 ( 14.746.814 ) 7.968.532.443 income for the year
Laporan Keuangan
Financial Report
Balance at
Saldo 31 Desember 2024 127.400.000.000 2.309.683.922 4.202.572.171 ( 24.563.760.000 ) 11.784.500.000 161.382.497.408 282.515.493.501 ( 18.573.492 ) 282.496.920.009 31 December 2024
Deklarasi dividen 19 - - - - - ( 2.548.000.000 ) ( 2.548.000.000 ) - ( 2.548.000.000 ) Declaration of dividen
PT Millennium Pharmacon International Tbk
Pencadangan saldo Appropriation of
laba 19 - - - - 2.548.000.000 ( 2.548.000.000 ) - - - retained earnings
Penghasilan komprehensif Other comprehensive
lain tahun berjalan - - - ( 3.059.160.000 ) - 38.516.147.714 35.456.987.714 ( 2.660.791 ) 35.454.326.923 income for the year
Balance at
Saldo 31 Desember 2025 127.400.000.000 2.309.683.922 4.202.572.171 ( 27.622.920.000 ) 14.332.500.000 194.802.645.122 315.424.481.215 ( 21.234.283 ) 315.403.246.932 31 December 2025
Catatan 17/ Catatan 18/ Catatan 32/ Catatan 32/
Note 17 Note 18 Note 32 Note 32
Lihat Catatan atas Laporan Keuangan Konsolidasian pada See accompanying Notes to the Consolidated Financial Statements
Ekshibit E terlampir yang merupakan bagian yang tidak on Exhibit E which are an integral part of
terpisahkan dari Laporan Keuangan Konsolidasian secara keseluruhan the Consolidated Financial Statements taken as a whole
278
Page 279
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit D Exhibit D
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
LAPORAN ARUS KAS KONSOLIDASIAN CONSOLIDATED STATEMENT OF CASH FLOWS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
31 Desember/ 31 Desember/
Catatan/ December December
Notes 2025 2024
ARUS KAS DARI AKTIVITAS CASH FLOWS FROM
OPERASI OPERATING ACTIVITES
Penerimaan kas dari pelanggan 4.026.727.168.482 3.839.343.073.215 Cash received from customers
Pembayaran kepada pemasok dan
karyawan ( 3.841.698.207.698 ) ( 3.878.053.492.468 ) Payment to suppliers and employees
Pembayaran pajak penghasilan 13 ( 23.093.426.024 ) ( 21.164.130.031 ) Income tax payments
Penerimaan bunga 290.090.283 59.006.190 Interest received
Pembayaran biaya keuangan ( 74.129.529.191 ) ( 65.635.249.549 ) Interest payments
Arus kas neto yang diperoleh dari Net cash flows provided by (used for)
(digunakan untuk) aktivitas operasi 88.096.095.852 ( 125.450.792.643 ) operating activities
ARUS KAS DARI AKTIVITAS CASH FLOWS FROM
INVESTASI INVESTING ACTIVITIES
Proceed from the sale of property
Penerimaan dari penjualan aset tetap 8 221.984.781 237.909.911 and equipment
Acquisition of property
Perolehan aset tetap 8 ( 37.760.116.988 ) ( 14.158.567.273 ) and equipment
Perolehan aset hak-guna 10 ( 11.339.633.332 ) - Acquisition of right-of-use assets
Perolehan aset lain-lain ( 1.097.203.288 ) - Acquisition of other assets
Arus kas neto yang digunakan untuk Net cash flows used for
aktivitas investasi ( 49.974.968.827 ) ( 13.920.657.362 ) investing activities
ARUS KAS DARI AKTIVITAS CASH FLOWS FROM
PENDANAAN FINANCING ACTIVITIES
Penerimaan utang bank 11 2.397.602.895.454 2.682.459.318.856 Cash received from bank loans
Penerimaan dari pihak berelasi 11.028.844.907 7.346.684.426 Received from related parties
Pembayaran utang bank 11 ( 2.434.842.295.865 ) ( 2.544.996.471.646 ) Payments of bank loans
Pembayaran liabilitas sewa - ( 7.679.694.443 ) Payments of lease liabilities
Pembayaran dividen ( 2.540.762.728 ) ( 3.185.000.000 ) Payment of dividend
Arus kas neto yang (digunakan untuk) Net cash flows (used for) provided by
diperoleh dari aktivitas pendanaan ( 28.751.318.232 ) 133.944.837.193 financing activities
KENAIKAN (PENURUNAN) BERSIH KAS NET INCREASE (DECREASE) IN CASH
DAN BANK 9.369.808.793 ( 5.426.612.812 ) AND BANKS
KAS DAN BANK PADA AWAL CASH AND BANKS AT
TAHUN 4 53.472.920.923 58.899.533.735 BEGINNING OF THE YEAR
KAS DAN BANK PADA AKHIR CASH AND BANKS AT
TAHUN 4 62.842.729.716 53.472.920.923 END OF THE YEAR
Lihat Catatan atas Laporan Keuangan Konsolidasian pada Ekshibit E See accompanying Notes to Consolidated Financial Statements on
terlampir yang merupakan bagian yang tidak terpisahkan Exhibit E which are an integral part of
dari Laporan Keuangan Konsolidasian secara keseluruhan the Consolidated Financial Statements taken as a whole
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 279
Page 280
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E Exhibit E
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
1. INFORMASI UMUM 1. GENERAL INFORMATION
a. Pendirian dan Informasi Umum a. Establishment and General Information
PT Millennium Pharmacon International Tbk PT Millennium Pharmacon International Tbk
(“Perusahaan”) didirikan di Jakarta dengan nama (the “Company”) was established in Jakarta under
N.V. Perusahaan Dagang Soedarpo Corporation the name of N.V. Perusahaan Dagang Soedarpo
berdasarkan Akta Notaris Rd. Mr. Soewandi, S.H., Corporation based on Notarial Deed No. 32 of
No. 32 tanggal 20 Oktober 1952. Akta pendirian ini Rd. Mr. Soewandi, S.H., dated 20 October 1952.
telah disahkan oleh Menteri Kehakiman Republik The deed of establishment was approved by the
Indonesia dalam Surat Keputusan No. J.A.5/43/20 Ministry of Justice of the Republic of Indonesia in
tanggal 27 Mei 1953 serta diumumkan dalam Berita its Decision Letter No. J.A.5/43/20 dated 27 May
Negara Republik Indonesia No. 56, Tambahan 1953 and was published in Supplement No. 421 to
No. 421 tanggal 14 Juli 1953. Anggaran dasar the State Gazette of the Republic of Indonesia
Perusahaan telah mengalami beberapa kali No. 56 dated 14 July 1953. The Company’s articles
perubahan, terakhir dengan Akta Notaris No. 32 of association have been amended several times,
tanggal 14 Januari 2026 dari Dini Lastari must recently based on notarial deed No. 32
Siburian S.H., berkedudukan di Jakarta Selatan dated 14 January 2026 of Dini Lastari
mengenai perubahan direksi dan komisaris. Siburian S.H., Notary in South Jakarta. The
Perubahan tersebut telah memperoleh Company approved change in boards of directors
persetujuan dari Menteri Hukum dan Hak and commissioners. This change had been
Asasi Manusia Republik Indonesia dalam approved by the Minister of Law and Human Right
Surat Keputusan No. AHU.AH.01.09-0098971 of the Republic of Indonesia through letter
tanggal 24 Februari 2026. No. AHU.AH.01.09-0098971 dated 24 February
2026.
Sesuai dengan pasal 3 anggaran dasar Perusahaan, In accordance with article 3 of the Company’s
lingkup kegiatan Perusahaan meliputi bidang usaha articles of association, the scope of its activities
perdagangan besar farmasi, obat tradisional, consists of wholesaler of pharmaceutical,
kosmetik dan alat kesehatan. Pada saat ini, traditional medicine, cosmetics and medical
kegiatan usaha yang dilakukan Perusahaan adalah devices. Currently, the Company is engaged in
di bidang distribusi obat resep, obat non-resep dan distribution and trading of prescription medicine,
alat kesehatan. Perusahaan beroperasi secara non-prescription medicine and medical devices.
komersial pada tanggal 20 Oktober 1952. The Company started its commercial operations on
20 October 1952.
Perusahaan berkedudukan di Jakarta dengan The Company is domiciled in Jakarta with
37 kantor cabang di beberapa kota besar di Pulau 37 branches located in several big cities in
Sumatera, Jawa, Bali, Kalimantan dan Sulawesi. Sumatera, Java, Bali, Kalimantan and Sulawesi.
Saat ini, kantor Pusat Perusahaan beralamat di Currently, the Company’s head office is located at
Crown Bungur Arteri, Jalan Sultan Iskandar Muda Crown Bungur Arteri, Jalan Sultan Iskandar Muda
No. 18, Kebayoran Lama, Jakarta Selatan. No. 18, Kebayoran Lama, South Jakarta.
Pharmaniaga International Corporation Sdn. Bhd. Pharmaniaga International Corporation Sdn. Bhd.
adalah entitas induk langsung Perusahaan. is the parent Company of the Company. Boustead
Boustead Holdings Bhd. adalah entitas induk utama Holdings Bhd. is the ultimate parent Company of
Perusahaan. the Company.
b. Penawaran Umum Efek Perusahaan b. The Company’s Public Offering
Perusahaan melakukan penawaran umum perdana The Company conducted an initial public offering
kepada masyarakat sejumlah 2.600.000 saham of 2,600,000 shares through the stock exchange in
melalui bursa efek di Indonesia pada tahun 1990 Indonesia in 1990 based on Letter from the
sesuai dengan Surat dari Menteri Keuangan Ministry of Finance of the Republic of Indonesia
Republik Indonesia No. SI-090/SHM/MK.10/1990 No. SI-090/ SHM/MK.10/1990 dated 22 March
tanggal 22 Maret 1990. Pada tanggal 7 Mei 1990, 1990. On 7 May 1990, the Company listed its
Perusahaan telah mencatatkan sebanyak 3,500,000 shares (consisting of 2,600,000 new
3.500.000 saham Perusahaan (2.600.000 saham shares and 900,000 current shares owned by
merupakan saham baru yang dikeluarkan dari existing shareholders) on the Stock Exchange in
portepel dan 900.000 saham milik pemegang Indonesia (Surabaya Stock Exchange and Jakarta
saham lama) pada Bursa Efek di Indonesia (Bursa Stock Exchange).
Efek Surabaya dan Bursa Efek Jakarta).
280 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 281
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/2 Exhibit E/2
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
1. INFORMASI UMUM (Lanjutan) 1. GENERAL INFORMATION (Continued)
b. Penawaran Umum Efek Perusahaan (Lanjutan) b. The Company’s Public Offering (Continued)
Perusahaan melakukan pemecahan nilai nominal The Company conducted stock split through
saham dari Rp 1.000 per saham menjadi Rp 500 per reduction of par value per share from Rp 1,000 to
saham sesuai Surat dari Bursa Efek Jakarta Rp 500 based on the Letter from Jakarta Stock
No. Peng-32/BEJ-2.4/0299 tanggal 2 Februari Exchange No. Peng-32/BEJ-2.4/0299 dated
1999. Pada tanggal 3 Februari 1999, pemecahan 2 February 1999. On 3 February 1999, the stock
saham tersebut telah dicatatkan pada Bursa Efek split was listed on the Jakarta Stock Exchange.
Jakarta.
Pada tanggal 7 Juni 2000, Perusahaan memperoleh On 7 June 2000, the Company obtained an
pernyataan efektif dari Ketua Badan Pengawas effective statement from the Chairman of the
Pasar Modal (Bapepam) berdasarkan Surat Capital Market Supervisory Agency (Bapepam)
No. S-1345/PM/2000 untuk melakukan Penawaran under its Letter No. S-1345/PM/2000 to conduct
Umum Terbatas (PUT) I kepada para pemegang Limited Public Offering (LPO) I to its shareholders
saham dalam rangka penerbitan Hak Memesan Efek with Pre-emptive Rights of 72,800,000 shares
Terlebih Dahulu (HMETD) sejumlah 72.800.000 with a par value and an offering price of Rp 500
saham dengan nominal dan harga penawaran per share. On 4 July 2000, these shares were
masing-masing sebesar Rp 500 per saham. Pada listed on the Jakarta Stock Exchange.
tanggal 4 Juli 2000, saham tersebut telah
dicatatkan pada Bursa Efek Jakarta.
Perusahaan melakukan pemecahan nilai nominal The Company conducted stock split through
saham dari Rp 500 per saham menjadi Rp 100 per reduction of par value per share from Rp 500 to
saham sesuai Surat dari Bursa Efek Jakarta Rp 100 based on the Letter from Jakarta Stock
No. Peng-171/BEJ.EEM/08-2001 tanggal 31 Agustus Exchange No. Peng-171/BEJ.EEM/08-2001 dated
2001. Pada tanggal 3 September 2001, pemecahan 31 August 2001. On 3 September 2001, the stock
saham tersebut telah dicatatkan pada Bursa Efek split was listed on the Jakarta Stock Exchange.
Jakarta.
Pada tanggal 21 Juni 2002, Perusahaan On 21 June 2002, the Company obtained an
memperoleh pernyataan efektif dari Ketua effective statement from the Chairman of
Bapepam berdasarkan Surat No. S-1362/PM/2002 Bapepam under its Letter No. S-1362/PM/2002 to
untuk melakukan PUT II kepada para pemegang conduct LPO II for its shareholders with Pre-
saham dalam rangka penerbitan HMETD sejumlah emptive Rights of 182,000,000 shares with a par
182.000.000 saham dengan nominal dan harga value and an offering price of Rp 100 per share.
penawaran masing-masing sebesar Rp 100 per On 17 July 2002, these shares were listed on the
saham. Pada tanggal 17 Juli 2002, saham tersebut Jakarta Stock Exchange.
telah dicatatkan pada Bursa Efek Jakarta.
Pada tanggal 17 November 2017, Perusahaan On 17 November 2017, the Company obtained an
memperoleh pernyataan efektif dari Kepala effective statement from the Chief Executive of
Eksekutif Pengawas Pasar Modal Otoritas Jasa the Capital Market Supervisory of Financial
Keuangan berdasarkan Surat No. S-443/D.04/2017 Services Authority under its Letter
untuk melakukan PUT III kepada para pemegang No. S-443/D.04/2017 to conduct LPO III for its
saham dalam rangka penerbitan HMETD sejumlah shareholders with Pre-emptive Rights of
546.000.000 juta saham dengan nilai nominal 546,000,000 shares with a par value of Rp 100 per
sebesar Rp 100 per saham dan harga penawaran share and an offering price of Rp 110 per share.
sebesar Rp 110 per saham. Pada tanggal On 15 December 2017, these shares were listed on
15 Desember 2017, saham tersebut telah the Indonesia Stock Exchange.
dicatatkan pada Bursa Efek Indonesia.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 281
Page 282
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/3 Exhibit E/3
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
1. INFORMASI UMUM (Lanjutan) 1. GENERAL INFORMATION (Continued)
b. Penawaran Umum Efek Perusahaan (Lanjutan) b. The Company’s Public Offering (Continued)
Jumlah saham Perusahaan yang dicatat sejak The Company’s number of shares listed since the
penawaran umum perdana saham sampai dengan initial public offering until 31 December 2025 is
tanggal 31 Desember 2025 adalah sebagai berikut: as follows:
Jumlah saham
Tanggal/ Total shares
Keterangan Date (Lembar / Share) Description
Penawaran umum perdana saham dan Initial public offering and partial
pencatatan sebagian saham listing of the Company’s shares
Perusahaan pada Bursa Efek in the Indonesia Stock Exchange
Indonesia (Bursa Efek Surabaya dan 7 Mei/ in (Surabaya Stock Exchange and
Bursa Efek Jakarta) May 1990 3.500.000 Jakarta Stock Exchange)
17 Februari/
Pembagian saham bonus February 1994 4.550.000 Distribution of bonus shares
Pencatatan tambahan saham 16 Desember/ Listing of the Company’s
Perusahaan December 1994 5.600.000 additional shares
Perubahan nilai nominal saham dari Change in nominal value of shares
Rp 1.000 menjadi Rp 500 3 Februari/ From Rp 1,000 to Rp 500
per saham (stock split) February 1999 13.650.000 per share (stock split)
25 Februari/
Pembagian saham bonus February 1999 4.550.000 Distribution of bonus shares
17 Juni/
Pembagian saham bonus June 1999 4.550.000 Distribution of bonus shares
4 Juli/
Penawaran Umum Terbatas I July 2000 72.800.000 Limited Public Offering I
Perubahan nilai nominal saham dari Change in nominal value of shares
Rp 500 menjadi Rp 100 3 September/ From Rp 500 to Rp 100
per saham (stock split) September 2001 436.800.000 per share (stock split)
17 Juli/
Penawaran Umum Terbatas II July 2002 182.000.000 Limited Public Offering II
15 Desember/
Penawaran Umum Terbatas III December 2017 546.000.000 Limited Public Offering III
Jumlah 1.274.000.000 Total
282 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 283
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/4 Exhibit E/4
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
1. INFORMASI UMUM (Lanjutan) 1. GENERAL INFORMATION (Continued)
c. Dewan Komisaris dan Direksi, Komite Audit, c. Boards of Commissioners and Directors, Audit
Kepala Audit Internal, Sekretaris Perusahaan Committee, Head of Internal Audit, Corporate
dan Karyawan Secretary and Employees
Susunan Dewan Komisaris dan Direksi Perusahaan The composition of the Company’s Boards of
pada tanggal 31 Desember 2025 dan 2024 adalah Commissioners and Directors as of 31 December
sebagai berikut: 2025 and 2024 are as follows:
Dewan Komisaris Board of Commissioners
Komisaris Utama : Joefly Joesoef Bahroeny* : President Commissioner
Komisaris : Zulkifli bin Jafar : Commissioner
Komisaris Independen : Sarah Azreen binti Abdul Samat : Independent Commissioner
Komisaris Independen : Prof. Aman Bhakti Pulungan : Independent Commissioner
Komisaris Independen : Dr.Imam Fathorrahman MM. : Independent Commissioner
Dewan Direksi Board of Directors
Direktur Utama : Ahmad bin Abu Bakar : President Director
Direktur : Mohamad Fazly bin Hassan : Director
*) Merangkap Komisaris Independent/ Concurrently Independent Commissioner
Berdasarkan Surat Keputusan Sirkuler sebagai Based on the Circular Decision in Lieu of the Board
Pengganti Rapat Dewan Komisaris tanggal of Commissioners’ Letter dated 25 May 2023, the
25 Mei 2023, susunan Komite Audit Perusahaan composition of the Company’s Audit Committee as
pada tanggal 31 Desember 2025 dan 2024 adalah of 31 December 2025 and 2024 is as follows:
sebagai berikut:
Ketua : Sarah Azreen binti Abdul Samat : Chairman
Anggota : Zulkifli bin Jafar : Member
Anggota : Ary Gunawan : Member
Anggota : Dr.Imam Fathorrahman MM. : Member
Berdasarkan Surat Keputusan Direksi, Kepala Audit Based on the Board of Directors’ Decision Letter,
Internal Perusahaan pada tanggal 31 Desember the Company’s Head of Internal Audit as of
2025 adalah Aris Sulistyanto. 31 December 2025 is Aris Sulistyanto.
Berdasarkan Surat Keputusan Direksi, sekretaris Based on the Board of Directors’ Decision Letter,
perusahaan pada tanggal 31 Desember 2025 adalah the Company’s corporate secretary as of
Olga Indria Bolang. 31 December 2025 is Olga Indria Bolang.
Manajemen kunci terdiri dari Dewan Komisaris dan Key management comprises the Boards of
Direksi. Commissioners and Directors.
Pada tanggal 31 Desember 2025 dan 2024, jumlah As of 31 December 2025 and 2024, the Group had
karyawan Grup masing-masing adalah sejumlah S 1,197 and 1,181 employees (unaudited),
1.197 dan 1.181 karyawan (tidak diaudit). respectively.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 283
Page 284
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/5 Exhibit E/5
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
1. INFORMASI UMUM (Lanjutan) 1. GENERAL INFORMATION (Continued)
d. Struktur Perusahaan dan Entitas Anak d. Corporate Structure and Subsidiary
Berdasarkan Akta No. 13 tanggal 9 Mei 2023 dari Based on Deed No. 13 dated 9 May 2023 from
notaris Dini Lastari Siburian S.H., di Jakarta, notary Dini Lastari Siburian S.H., in Jakarta, the
Perusahaan mendirikan dan memiliki penyertaan Company established and owns shares in
saham pada PT Digital Pharma Andalan Indonesia PT Digital Pharma Andalan Indonesia (DPAI) of
(DPAI) sebesar 99,99% dari modal disetor sebesar 99.99% of the paid-in capital of Rp 247,500,000.
Rp 247.500.000. Selanjutnya Perusahaan dan Hereinafter The Company and its subsidiary are
entitas anak disebut Grup. called Group.
Berdasarkan Akta No. 48 tanggal 22 Mei 2024, dari Based on Deed No. 48 dated 22 May 2024, from
notaris Desty Haninditia Puri S.H.,MKn. di Jakarta, notary Desty Haninditia Puri S.H., MKn, in
Perusahaan memiliki penyertaan saham pada DPAI Jakarta, the Company own a share in DPAI of
sebesar 99,94% dari modal ditempatkan dan disetor 99.94% of the share issued and paid-in capital of
atau sebesar Rp 4.097.500.000. Dengan demikian Rp 4,097,500,000. Accordingly, the Company
kepemilikan Perusahaan di entitas anak menurun ownership in subsidiary decreased from 99.99% to
dari 99.99% menjadi 99,94% dan penyertaan saham 99.94% and paid-in capital in subsidiary from
di entitas anak dari Rp 247.500.000 menjadi Rp 247,500,000 to Rp 4,097,500,000.
Rp 4.097.500.000.
Pada tanggal 31 Desember 2025 dan 2024, rincian As of 31 December 2025 dan 2024 the details of
entitas anak Perusahaan adalah sebagai berikut: the Company’s subsidiary are as follows:
Tahun
Persentase (%) operasi
Pemilikan/ komersial/
Percentage (%) of Year of Jumlah aset sebelum eliminasi/
Entitas anak/ Domisili/ Bidang usaha/ ownership commercial Total assets before elimination
Subsidiaries Domicile Business 2025 2024 operation 2025 2024
PT Digital Pharma Jakarta, Perdagangan dan 99,94% 99,94% 2023 1.302.823.315 2.214.645.443
Andalan Indonesia Indonesia pengembangan
software/Trade and
software equipment
e. Penerbitan Laporan Keuangan Konsolidasian e. Issuance of The Consolidated Financial
Statements
Direksi Perusahaan bertanggung jawab terhadap The Board of Directors are responsible for the
penyusunan dan penyajian laporan keuangan preparation and presentation of the consolidated
konsolidasian, yang telah diselesaikan dan financial statements, which were completed and
diotorisasi untuk diterbitkan pada tanggal authorized for issuance on 30 March 2026.
30 Maret 2026.
2. INFORMASI KEBIJAKAN AKUNTANSI MATERIAL 2. MATERIAL ACCOUNTING POLICY INFORMATIONS
a. Dasar Penyusunan a. Basis of Preparation
Prinsip kebijakan akuntansi yang diadopsi dalam The principal accounting policies adopted in the
penyusunan laporan keuangan konsolidasian preparation of the consolidated financial
dinyatakan dalam Catatan ini. Kebijakan tersebut statements are set out in this Note. The policies
telah diterapkan secara konsisten untuk setiap have been consistently applied to all the years
tahun penyajian, kecuali dinyatakan lain. presented, unless otherwise stated.
284 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 285
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/6 Exhibit E/6
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. INFORMASI KEBIJAKAN AKUNTANSI MATERIAL 2. MATERIAL ACCOUNTING POLICY INFORMATIONS
(Lanjutan) (Continued)
a. Dasar Penyusunan (Lanjutan) a. Basis of Preparation (Continued)
Laporan keuangan konsolidasian disusun The consolidated financial statements have been
berdasarkan Standar Akuntansi (“SAK”) yang prepared in accordance with Indonesian Financial
mencakup Pernyataan Standar Akuntansi Keuangan Accounting Standard (“SAK”), which comprise the
(PSAK) dan Interpretasi Standar Akuntansi Statement of Financial Accounting Standards
Keuangan (ISAK) yang diterbitkan oleh Dewan (“PSAK”) and Interpretations of Statement of
Standar Akuntansi Keuangan Ikatan Akuntan Financial Accounting Standard (“ISAK”) issued by
Indonesia (DSAK) serta Peraturan No. VIII.G.7 the Financial Accounting Standard Board of the
Lampiran keputusan Ketua BAPEPAM No. KEP- Indonesian Institute of Accountant (“DSAK”) and
347/BL/2012 tanggal 25 Juni 2012 yang terdapat di Rule No. VIII.G.7 Attachment of Chairman of
dalam Peraturan dan Pedoman Penyajian dan BAPEPAM’s Decision No. KEP-347/BL/2012 dated
Pengungkapan Laporan Keuangan yang diterbitkan 25 June 2012 on the Regulations and the
oleh Badan Pengawas Pasar Modal dan Lembaga Guidelines on Financial Statement Presentation
Keuangan (BAPEPAM-LK, yang fungsinya dialihkan and Disclosures issued by Capital Market and
kepada OJK sejak tanggal 1 Januari 2013). Financial Institution Supervisory Agency
(BAPEPAM-LK, which function has been
transferred to OJK starting on 1 January 2013).
Laporan keuangan konsolidasian disajikan dalam The consolidated financial statements are
mata uang Rupiah (Rp), yang juga merupakan mata presented in Rupiah (Rp), which is also the
uang fungsional Grup. Group’s functional currency.
Laporan keuangan konsolidasi disusun berdasarkan The consolidated financial statement have been
konsep akrual, kecuali laporan arus kas prepared on the accrual basis, except for the
konsolidasian yang disusun dengan menggunakan consolidated statement of cash flows is prepared
metode langsung dengan mengelompokkan arus kas based on the direct method by classifying cash
dalam aktivitas operasi, investasi dan pendanaan. flow on the basis of operating, investing and
financing activities.
Penyusunan laporan keuangan konsolidasian The preparation of the consolidated financial
berdasarkan SAK mensyaratkan penggunaan statements in compliance with SAK requires the
estimasi akuntansi kritikal tertentu. Penyusunan use of certain critical accounting estimates. The
laporan keuangan konsolidasian juga mensyaratkan preparation of the consolidated financial
manajemen Grup untuk menggunakan statements also requires Group management to
pertimbangan dalam menerapkan kebijakan exercise judgement in applying the Group’s
akuntansi Grup. Area di mana pertimbangan dan accounting policies. The areas where significant
estimasi yang signifikan telah dibuat dalam judgements and estimates have been made in
penyusunan laporan keuangan beserta dampaknya preparing the financial statements and their
diungkapkan dalam Catatan 3. effect are disclosed in Note 3.
Laporan keuangan konsolidasian telah disusun The consolidated financial statement has been
berdasarkan biaya historis, kecuali untuk pos-pos prepared using historical cost, except for the
berikut (lihat kebijakan akuntansi terkait untuk following items (refer to related accounting
penjelasan lebih rinci): policies for further explanation):
- Instrumen keuangan – yang dinilai wajar melalui - Financial instruments – fair value through
laporan laba rugi profit or loss
- Instrumen keuangan – yang dinilai wajar melalui - Financial instruments – fair value through
penghasilan komprehensif lain other comprehensive income
- Imbalan kontinjensi - Contingency consideration
- Properti investasi - Investment property
- Revaluasi aset tetap - Revalued property, plant and equipment
- Liabilitas imbalan pasti bersih - Net defined benefit liability
- Liabilitas pembayaran berbasis saham yang - Cash settled share-based payment liabilities
diselesaikan dengan kas
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 285
Page 286
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/7 Exhibit E/7
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. INFORMASI KEBIJAKAN AKUNTANSI MATERIAL 2. MATERIAL ACCOUNTING POLICY INFORMATIONS
(Lanjutan) (Continued)
b. Perubahan pada Pernyataan Standar Akuntansi b. Changes to the Statements of Financial
Keuangan dan Interpretasi Pernyataan Standar Accounting Standards and Interpretations of
Akuntansi Keuangan Statement of Financial Accounting Standards
Penerapan dari revisi standar berikut yang berlaku The adoption of these amended standards, which
efektif mulai 1 Januari 2025 tidak menimbulkan are effective beginning 1 January 2025 did not
perubahan substansial terhadap kebijakan result in substantial changes to the Group’s
akuntansi Grup dan pengaruh yang material atas accounting policies and had no material impact
jumlah yang dilaporkan atas tahun berjalan atau on the amounts reported for the current or prior
tahun sebelumnya. financial years.
- Amendemen PSAK 221 “Pengaruh Perubahan - Amendment of PSAK 221 “The Effects of
Kurs Valuta Asing” – Kekurangan Changes in Foreign Exchange Rates” – Lack
Ketertukaran of Exchangeability
Amandemen PSAK 221, ‘Pengaruh Perubahan Amendment of PSAK 221 “The Effects of
Kurs Valuta Asing', memperjelas pengaturan Changes in Foreign Exchange Rates” clarifies
terkait kondisi ketika suatu mata uang tidak the requirements concerning the conditions
tertukarkan serta pengungkapannya. under which a currency is non-exchangeable
and its disclosure.
- PSAK 117 “Kontrak Asuransi” - PSAK 117 “Insurance Contract”
PSAK 117 mengatur relaksasi beberapa PSAK 117 regulates the relaxation of several
ketentuan antara lain berupa penambahan provisions, including the addition of scope
pengecualian ruang lingkup, penyesuaian exceptions, adjustments to the presentation
penyajian laporan keuangan, penerapan opsi of financial statements, application of risk
mitigasi risiko dan beberapa modifikasi pada mitigation options and some modifications to
ketentuan transisi. PSAK 117 juga transitional provisions. PSAK 117 also requires
mensyaratkan pemisahan yang jelas antara a clear separation between income generated
pendapatan yang dihasilkan dari bisnis asuransi from the insurance business and from
dengan yang berasal dari kegiatan investasi. investment activities.
Penerapan dari revisi standar berikut yang berlaku The adoption of these amended standards, which
efektif mulai 1 Januari 2026 tidak menimbulkan are effective beginning 1 January 2026 did not
perubahan substansial terhadap kebijakan result in substantial changes to the Groups’s
akuntansi Grup dan pengaruh yang material atas accounting policies and had no material impact
jumlah yang dilaporkan atas tahun berjalan atau on the amounts reported for the current or prior
tahun sebelumnya. financial years.
- Amendemen PSAK 109 dan PSAK 107 - Amendment of PSAK 109 and PSAK 107
“Pengungkapan tentang Klasifikasi dan “Classification and Measurement of
Pengukuran Instrumen Keuangan” Financial Instruments”
Amendemen PSAK 109 ini menambahkan dan The amendment adds and clarifies provisions
mengklarifikasi ketentuan dalam PSAK 109 in PSAK 109 regarding the derecognition of
terkait penghentian pengakuan liabilitas financial liabilities and clarifies the
keuangan, serta mengklarifikasi penilaian assessment of cash flow characteristics for
karakteristik arus kas untuk aset keuangan financial assets with environmental, social
dengan fitur ESG-linked, aset keuangan dengan and governance (ESG)-linked features,
fitur non-recourse, dan instrumen yang terikat financial assets with non-recourse features
secara kontraktual seperti tranche. and contractually linked instruments such as
Amendemen ini juga mengubah ketentuan tranches. The amendment also modifies
dalam PSAK 107 terkait persyaratan provisions in PSAK 107 related to disclosure
pengungkapan investasi pada instrumen ekuitas requirements for investments in equity
yang diukur pada nilai wajar melalui instruments measured at fair value through
penghasilan komprehensif lain dan menambah other comprehensive income and adds
ketentuan terkait instrumen keuangan dengan provisions related to financial instruments
persyaratan kontraktual yang mengubah waktu with contractual terms that alter the timing
atau jumlah arus kas kontraktual. or amount of contractual cashflow.
286 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 287
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/8 Exhibit E/8
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. INFORMASI KEBIJAKAN AKUNTANSI MATERIAL 2. MATERIAL ACCOUNTING POLICY INFORMATIONS
(Lanjutan) (Continued)
b. Perubahan pada Pernyataan Standar Akuntansi b. Changes to the Statements of Financial
Keuangan dan Interpretasi Pernyataan Standar Accounting Standards and Interpretations of
Akuntansi Keuangan (Lanjutan) Statement of Financial Accounting Standards
(Continued)
Penerapan dari revisi standar berikut yang The adoption of these amended standards, which
berlaku efektif mulai 1 Januari 2026 tidak are effective beginning 1 January 2026 did not
menimbulkan perubahan substansial terhadap result in substantial changes to the Groups’s
kebijakan akuntansi Grup dan pengaruh yang accounting policies and had no material impact
material atas jumlah yang dilaporkan atas tahun on the amounts reported for the current or prior
berjalan atau tahun sebelumnya. (Lanjutan) financial years. (Continued)
- Amendemen PSAK 109 dan PSAK 107 terkait - Amendments to PSAK 109 and PSAK 107 of
Kontrak yang Mengacu pada Listrik Contracts Referencing Nature-dependent
Bergantung Alam Electricity.
Amandemen ini mengubah persyaratan The amendment modifies the 'own use' and
‘pengunaan sendiri' dan akuntansi lindung nilai hedge accounting requirements of PSAK 109
dalam PSAK 109 serta memperkenalkan and introduce specific disclosure
persyaratan pengungkapan khusus untuk PSAK requirements for PSAK 107. They apply only to
107. Ketentuan ini hanya berlaku untuk contracts that involve variability in electricity
kontrak yang melibatkan variabilitas dalam generation due to uncontrollable natural
pembangkit listrik yang disebabkan oleh conditions, like weather. These are known as
kondisi alam yang tidak dapat dikendalikan, 'contracts referencing nature-dependent
seperti cuaca. Kontrak-kontrak ini dikenal electricity’.
sebagai 'kontrak dengan referensi listrik yang
bergantung pada alam'.
Penerapan dari standar baru berikut berlaku The adoption of the new standard is effective
efektif mulai 1 Januari 2027. Penerapan 1 January 2027. Retrospective application is
retrospektif diwajibkan, sehingga informasi required, and so the comparative information for
komparatif untuk tahun keuangan yang berakhir the financial year ending 31 December 2026 will
pada 31 Desember 2026 akan disajikan ulang be restated in accordance with this standard.
sesuai dengan standar ini.
- PSAK 118 “Penyajian dan Pengungkapan - PSAK 118 “Presentation and Disclosure in
dalam Laporan Keuangan” Financial Statements”
PSAK 118 menggantikan PSAK 201, PSAK 118 supersedes PSAK 201, retaining many
mempertahankan banyak prinsip yang ada existing principles but significantly changing
tetapi secara signifikan mengubah cara entitas how entities report “operating profit or loss.”
melaporkan “laba atau rugi operasional.” PSAK It establishes a defined structure for the
ini menetapkan struktur yang jelas untuk statement of profit or loss, categorising items
laporan laba rugi dengan mengelompokkan into operating, investing, financing, income
pos-pos ke dalam kategori operasi, investasi, taxes and discontinued operations. The
pembiayaan, pajak penghasilan, dan operasi standard mandates specific disclosures,
yang dihentikan. Standar ini mewajibkan including management-defined performance
pengungkapan tertentu, termasuk ukuran measures (MPMs), allowing investors to
kinerja tetapan manajemen (UKTM), yang understand management's view of the
memungkinkan investor memahami bagaimana company's financial performance and how
pandangan manajemen atas kinerja keuangan these measures compare to those defined in
perusahaan dan bagaimana ukuran tersebut PSAK 118.
dibandingkan dengan ukuran yang didefinisikan
dalam PSAK 118.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 287
Page 288
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/9 Exhibit E/9
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. INFORMASI KEBIJAKAN AKUNTANSI MATERIAL 2. MATERIAL ACCOUNTING POLICY INFORMATIONS
(Lanjutan) (Continued)
b. Perubahan pada Pernyataan Standar Akuntansi b. Changes to the Statements of Financial
Keuangan dan Interpretasi Pernyataan Standar Accounting Standards and Interpretations of
Akuntansi Keuangan (Lanjutan) Statement of Financial Accounting Standards
(Continued)
- PSAK 118 “Penyajian dan Pengungkapan - PSAK 118 “Presentation and Disclosure in
dalam Laporan Keuangan” (Lanjutan) Financial Statements” (Continued)
Meskipun PSAK 118 tidak memengaruhi Even though PSAK 118 will not impact the
pengakuan atau pengukuran pos-pos dalam recognition or measurement of items in the
laporan keuangan, dampaknya terhadap financial statements, its impacts on
penyajian dan pengungkapan diperkirakan presentation and disclosure are expected to be
akan sangat luas, terutama yang berkaitan pervasive, in particular those related to the
dengan laporan kinerja keuangan dan statement of financial performance and
penyediaan UKTM dalam laporan keuangan. providing MPM within the financial
statements.
Manajemen saat ini sedang menilai secara rinci Management is currently assessing the
implikasi penerapan standar baru ini pada detailed implications of applying the new
laporan keuangan konsolidasian Grup. Dari standard on the Group’s consolidated financial
penilaian awal, secara garis besar, dampak statements. From the high-level preliminary
potensial berikut telah diidentifikasi: assessment performed, the following
potential impacts have been identified:
1. Meskipun adopsi PSAK 118 tidak akan 1. Although the adoption of PSAK 118 will
berpengaruh pada laba bersih Perusahaan, have no impact on the Company’s net
Perusahaan mengharapkan pengelompokan profit, the Company expects that Grouping
pos pendapatan dan beban dalam laporan items of income and expenses in the
laba rugi ke dalam kategori baru akan statement of profit or loss into the new
memengaruhi cara perhitungan dan categories will impact how operating profit
pelaporan laba operasi. Dari penilaian is calculated and reported. From the high-
dampak garis besar yang dilakukan level impact assessment that the Company
Perusahaan, pos-pos berikut mungkin has performed, the following items might
berpotensi memengaruhi laba operasi: potentially impact operating profit:
a. Perbedaan nilai tukar yang saat ini a. Foreign exchange differences currently
digabungkan dalam pos ‘pendapatan lain aggregated in the line item ‘other
dan keuntungan/ (kerugian) lain – neto’ income and other gains/(losses) – net’ in
dalam laba operasi mungkin perlu operating profit might need to be
dipisahkan, dengan beberapa disaggregated, with some foreign
keuntungan atau kerugian dari nilai exchange gains or losses presented
tukar disajikan di bawah laba operasi. below operating profit.
b. PSAK 118 memiliki persyaratan khusus b. PSAK 118 has specific requirements on
mengenai kategori di mana keuntungan the category in which derivative gains or
atau kerugian derivatif diakui – yaitu losses are recognised – which is thesame
kategori yang sama dengan pendapatan category as the income and expenses
dan beban yang dipengaruhi oleh risiko affected by the risk that the derivative
yang dikelola oleh derivatif tersebut. is used to manage. Although the
Meskipun Perusahaan saat ini mengakui Company currently recognises some
beberapa keuntungan atau kerugian gains or losses in operating profit and
dalam laba operasi dan lainnya dalam others in finance costs, there might be a
biaya keuangan, mungkin akan terjadi change to where these gains or losses
perubahan mengenai tempat di mana are recognised, and the Company is
keuntungan atau kerugian tersebut currently evaluating the need for
diakui, dan Perusahaan saat ini sedang change.
mengevaluasi kebutuhan untuk
melakukan perubahan.
288 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 289
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/10 Exhibit E/10
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. INFORMASI KEBIJAKAN AKUNTANSI MATERIAL 2. MATERIAL ACCOUNTING POLICY INFORMATIONS
(Lanjutan) (Continued)
b. Perubahan pada Pernyataan Standar Akuntansi b. Changes to the Statements of Financial
Keuangan dan Interpretasi Pernyataan Standar Accounting Standards and Interpretations of
Akuntansi Keuangan (Lanjutan) Statement of Financial Accounting Standards
(Continued)
- PSAK 118 “Penyajian dan Pengungkapan dalam - PSAK 118 “Presentation and Disclosure in
Laporan Keuangan” (Lanjutan) Financial Statements” (Continued)
Manajemen saat ini sedang menilai secara rinci Management is currently assessing the detailed
implikasi penerapan standar baru ini pada implications of applying the new standard on the
laporan keuangan konsolidasian Grup. Dari Group’s consolidated financial statements. From
penilaian awal, secara garis besar, dampak the high-level preliminary assessment
potensial berikut telah diidentifikasi: (Lanjutan) performed, the following potential impacts have
been identified: (Continued)
2. Pos-pos yang disajikan dalam laporan 2. The line items presented on the primary
keuangan utama mungkin akan berubah akibat financial statements might change as a result
penerapan konsep ‘ringkasan terstruktur yang of the application of the concept of ‘useful
berguna’ dan prinsip yang ditingkatkan structured summary’ and the enhanced
mengenai agregasi dan disaggregasi. Selain principles on aggregation and disaggregation.
itu, karena goodwill akan disajikan secara In addition, since goodwill will be required to
terpisah dalam laporan posisi keuangan, be separately presented in the statement of
Perusahaan akan memisahkan goodwill dan financial position, the Company will
aset tidak berwujud lainnya serta disaggregate goodwill and other intangible
menyajikannya secara terpisah dalam laporan assets and present them separately in the
posisi keuangan. statement of financial position.
3. Perusahaan tidak mengharapkan adanya 3. The Company does not expect there to be a
perubahan signifikan dalam informasi yang significant change in the information that is
saat ini diungkapkan dalam catatan, karena currently disclosed in the notes because the
persyaratan untuk mengungkapkan informasi requirement to disclose material information
material etap tidak berubah; namun, cara remains unchanged; however, the way in
pengelompokan informasi tersebut mungkin which the information is Grouped might
berubah sebagai akibat dari prinsip change as a result of the aggregation/
agregasi/disaggregasi. Selain itu, akan ada disaggregation principles. In addition, there
pengungkapan baru yang signifikan yang will be significant new disclosures required
diwajibkan untuk: for:
- ukuran kinerja tetapan manajemen (UKTM); - management-defined performance measures
(MPM);
- rincian jenis beban untuk pos-pos yang - a break-down of the nature of expenses for
disajikan berdasarkan fungsi dalam kategori line items presented by function in the
operasi laporan laba rugi – rincian ini hanya operating category of the statement of
diperlukan untuk beberapa jenis beban profit or loss – this break-down is only
tertentu; dan required for certain nature expenses; and
- untuk periode tahunan pertama penerapan - for the first annual period of application of
PSAK 118, rekonsiliasi untuk setiap pos PSAK 118, a reconciliation for each line item
dalam laporan laba rugi antara angka yang in the statement of profit or loss between
telah disajikan ulang berdasarkan the restated amounts presented by applying
penerapan PSAK 118 dan angka yang PSAK 118 and the amounts previously
sebelumnya disajikan berdasarkan PSAK presented applying PSAK 201.
201.
- Dari perspektif laporan arus kas, akan ada - From a cash flow statement perspective,
perubahan cara penyajian bunga diterima there will be changes to how interest
dan bunga dibayar. Bunga dibayar akan received and interest paid are presented.
disajikan sebagai arus kas pendanaan dan Interest paid will be presented as financing
bunga diterima akan disajikan sebagai arus cash flows and interest received as investing
kas investasi, yang merupakan perubahan cash flows, which is a change from current
dari penyajian saat ini sebagai bagian dari presentation as part of operating cash flows.
arus kas operasi.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 289
Page 290
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/11 Exhibit E/11
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. INFORMASI KEBIJAKAN AKUNTANSI MATERIAL 2. MATERIAL ACCOUNTING POLICY INFORMATIONS
(Lanjutan) (Continued)
c. Dasar Konsolidasian c. Basis of Consolidation
Apabila entitas mengendalikan investee, maka hal Where an entity has control over an investee, it
tersebut diklasifikasikan sebagai Entitas Anak. is classified as a Subsidiary. The entity controls
Entitas mengendalikan investee jika tiga elemen an investee if all three of the following elements
berikut terpenuhi: pengendalian atas investee, are present: power over the investee, exposure to
eksposur atas hak imbal hasil variabel dari variable returns from the investee, and the
keterlibatannya dengan investee, dan kemampuan ability of the investor to use its power to affect
untuk menggunakan pengendalian nya atas those variable returns. Control is reassessed
investee untuk mempengaruhi jumlah imbal hasil whenever facts and circumstances indicate that
variable dari investor. Pengendalian dapat dikaji there may be a change in any of these elements
kembali ketika fakta dan kondisi mengindikasikan of control.
bahwa terdapat kemungkinan adanya perubahan
pada elemen pengendalian tersebut.
Pengendalian defacto terjadi pada situasi dimana De-facto control exists in situations where the
Perusahaan memiliki kemampuan praktis untuk company has the practical ability to direct the
mengarahkan aktivitas relevan atas investee tanpa relevant activities of the investee without
memiliki hak suara mayoritas. Untuk menentukan holding the majority of the voting rights. In
apakah pengendalian defacto terjadi, maka determining whether de-facto control exists the
Perusahaan mempertimbangkan beberapa fakta company considers all relevant facts and
dan keadaan berikut ini: circumstances, including:
- Ukuran kepemilikan hak suara entitas relatif - The size of the company’s voting rights
terhadap ukuran dan penyebaran kepemilikan relative to both the size and dispersion of
pemilik suara lain; other parties who hold voting rights;
- Hak suara potensial substantif yang dimiliki - Substantive potential voting rights held by
oleh Perusahaan dan para pihak lain; the company and by other parties;
- Pengaturan kontraktual lain; - Other contractual arrangements;
- Pola historis dalam penggunaan hak suara. - Historic patterns in voting attendance.
c.
Laporan keuangan konsolidasian menyajikan hasil d. The consolidated financial statements present
Perusahaan dan entitas anaknya (“Grup”) seolah- the results of The Company and its subsidiaries
olah merupakan satu entitas. Transaksi antar (“the Group”) as if they formed a single entity.
entitas dan saldo antara Grup oleh karena itu Intercompany transactions and balances between
dieliminasi secara penuh. Group companies are therefore eliminated in full.
Laporan keuangan konsolidasian menggabungkan The consolidated financial statements incorporate
hasil kombinasi bisnis dengan menggunakan the results of business combinations using the
metode akuisisi. DaIam laporan posisi keuangan, acquisition method. In the statement of financial
aset dan liabilitas teridentifikasi, dan liabilitas position, the acquiree's identifiable assets,
kontinjensi pada awalnya diakui pada nilai wajar liabilities and contingent liabilities are initially
pada tanggal akuisisi. Hasil tersebut dimasukkan recognised at their fair values at the acquisition
dalam laporan penghasilan komprehensif date. The results of acquired operations are
konsolidasian sejak tanggal pengendalian included in the consolidated statement of
diperoleh. Hasil tersebut tidak dikonsolidasi sejak comprehensive income from the date on which
dari tanggal pengendalian hilang. control is obtained. They are deconsolidated from
the date on which control ceases.
290 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 291
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/12 Exhibit E/12
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. INFORMASI KEBIJAKAN AKUNTANSI MATERIAL 2. MATERIAL ACCOUNTING POLICY INFORMATIONS
(Lanjutan) (Continued)
d. Kepentingan Non-Pengendali d. Non-Controlling Interests
Grup mengakui kepentingan non-pengendali pada The Group recognises any non-controlling interest
pihak yang diakuisisi baik sebesar nilai wajar atau in the acquiree on an acquisition-by-acquisition
sebesar bagian proporsional kepentingan basis, either at fair value or at the non-
nonpengendali atas aset neto pihak yang controlling interest’s proportionate share of the
diakuisisi. Kepentingan non-pengendali disajikan acquiree’s net assets. Non-controlling interest is
di ekuitas dalam laporan posisi keuangan reported as equity in the consolidated statement
konsolidasian, terpisah dari ekuitas pemilik of financial position, separate from the owner of
entitas induk. Komponen lain kepentingan non- the parent’s equity. Other components of non-
pengendali seperti opsi saham beredar secara controlling interest such as outstanding share
umum diakui pada nilai wajar. options are generally measured at fair value.
Selisih lebih imbalan yang dialihkan, jumlah setiap The excess of the consideration transferred the
kepentingan non-pengendali pada pihak diakuisisi amount of any non-controlling interest in the
dan nilai wajar pada tanggal akuisisi kepentingan acquiree and the acquisition-date fair value of
ekuitas sebelumnya dimiliki oleh pihak any previous equity interest in the acquiree over
pengakuisisi pada pihak diakuisisi atas nilai wajar the fair value of the net identifiable assets
aset bersih teridentifikasi yang diperoleh dicatat acquired is recorded as goodwill. If those amounts
sebagai goodwill. Jika jumlah tersebut lebih are less than the fair value of the net identifiable
rendah dari nilai wajar aset bersih teridentifikasi assets of the business acquired, in the case of a
atas bisnis yang diakuisisi dalam kasus pembelian bargain purchase, the difference is recognised
dengan diskon, selisihnya diakui dalam laporan directly in the income statement.
laba rugi.
e. Transaksi dan Saldo dalam Mata Uang Asing e. Foreign Currency Transactions and Balances
Transaksi-transaksi dalam mata uang asing dicatat Transaction recorded at the exchange rates
berdasarkan kurs yang berlaku pada saat transaksi prevailing at the time of transactions are made.
dilakukan. Pada setiap akhir tahun pelaporan, aset At the end of each reporting year, monetary
dan liabilitas moneter dalam mata uang asing assets and liabilities denominated in foreign
dijabarkan ke dalam Rupiah Indonesia dengan currencies are translated to Indonesian Rupiah
menggunakan kurs tengah tanggal transaksi using the middle exchange rates at the last bank
perbankan terakhir yang dipublikasikan oleh Bank transaction date as published by Bank Indonesia.
Indonesia.
Laba atau rugi atas selisih kurs yang timbul dari Exchange rate gains or losses arising from the
transaksi dalam mata uang asing dan penjabaran foreign currency transactions and from the
aset dan liabilitas moneter dalam mata uang asing translation of monetary assets and liabilities
diakui pada usaha tahun berjalan. denominated in foreign currencies are recognized
in the current year operations.
Pada tanggal 31 Desember 2025 dan 2024, kurs As of 31 December 2025 dan 2024, the exchange
yang digunakan adalah sebagai berikut: rates used were as follows:
2025 2024
1 Dolar Amerika Serikat 16.782 16.162 1 United States Dollar
1 Ringgit Malaysia 4.144 3.616 1 Malaysian Ringgit
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 291
Page 292
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/13 Exhibit E/13
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. INFORMASI KEBIJAKAN AKUNTANSI MATERIAL 2. MATERIAL ACCOUNTING POLICY INFORMATIONS
(Lanjutan) (Continued)
f. Transaksi dengan Pihak Berelasi f. Transaction with Related Parties
Grup melakukan transaksi dengan pihak berelasi The Group have transactions with related parties
sesuai dengan definisi yang diuraikan pada as defined in PSAK 224: Disclosure of Related
PSAK 224: Pengungkapan Pihak-Pihak Berelasi. Parties.
i. Orang atau anggota keluarga dekatnya i. A person or a close member of that person’s
mempunyai relasi dengan entitas pelapor jika family is related to a reporting entity if that
orang tersebut: person:
a. Memiliki pengendalian atau pengendalian a. Has control or joint control over the
bersama atas entitas pelapor; reporting entity;
b. Memiliki pengaruh signifikan atas entitas b. Has significant influence over the reporting
pelapor; atau entity; or
c. Merupakan personil manajemen kunci c. Is a member of the key management
entitas pelapor atau entitas induk dari personnel of the reporting entity or a
entitas pelapor. parent of the reporting entity.
ii. Suatu entitas berelasi dengan entitas pelapor ii. An entity is related to a reporting entity if any
jika memenuhi salah satu dari kondisi berikut: of the following condition applies:
a. Entitas dan entitas pelapor adalah anggota a. The entity and the reporting entity are
dari kelompok usaha yang sama (artinya members of the same group (which means
Perusahaan berikutnya saling berelasi that each parent, subsidiary, and fellow
dengan entitas lain); subsidiary is related to the others);
b. Satu entitas adalah entitas asosiasi atau b. One entity is an associate or joint venture
ventura bersama dari entitas lain (atau of the other entity (or an associate or joint
entitas asosiasi atau ventura bersama yang venture of a member of a group of which
merupakan anggota suatu kelompok usaha, the other entity is a member);
yang mana entitas lain tersebut adalah
anggotanya);
c. Kedua entitas tersebut adalah ventura c. Both entities are joint ventures of the
bersama dari pihak ketiga yang sama; same third party;
d. Satu entitas adalah ventura bersama dari d. One entity is joint venture of a third entity
entitas ketiga dan entitas yang lain adalah and the other entity is an associate of the
entitas asosiasi dari entitas ketiga; third entity;
e. Entitas tersebut adalah suatu program e. The entity is a post- employment defined
imbalan pasca kerja untuk imbalan kerja benefit plan for the benefit of employees
dari salah satu entitas pelapor atau entitas of either the reporting entity or an entity
yang terkait dengan entitas pelapor. related to the reporting entity. If the
Apabila entitas pelapor adalah entitas yang reporting entity is running itself such a
menyelenggarakan program tersebut, plan, the sponsoring employers are also
maka entitas sponsor juga berelasi dengan related to the reporting entity;
entitas pelapor;
f. Entitas dikendalikan atau dikendalikan f. The entity is controlled or jointly
bersama oleh orang yang diidentifikasi controlled by a person identified in (i);
dalam huruf (i);
g. Orang yang diidentifikasi dalam huruf (i)(a) g. Person that identified in (i)(a) which have
memiliki pengaruh signifikan atas entitas significant influence over the entity or key
atau merupakan personil manajemen kunci management personnel of the entity (or
entitas (atau entitas induk dari entitas); parent entity from entity);
h. Entitas, atau anggota dari kelompok h. Entity, or member of a group where
dimana entitas merupakan bagian dari entity was part of a group, provide key
kelompok tersebut, menyediakan jasa management services to the reporting
personil manajemen kunci kepada entitas entity or parent entity from reporting
pelapor atau kepada entitas induk dari entity.
entitas pelapor.
292 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 293
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/14 Exhibit E/14
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. INFORMASI KEBIJAKAN AKUNTANSI MATERIAL 2. MATERIAL ACCOUNTING POLICY INFORMATIONS
(Lanjutan) (Continued)
g. Aset Keuangan g. Financial Assets
Grup mengklasifikasikan aset keuangannya ke The Group classified its financial assets into one
dalam salah satu kategori yang dijelaskan di of the categories discussed below, depending on
bawah ini, tergantung pada tujuan pengakuisisian the purpose for which the asset was acquired.
aset.
Selain daripada aset keuangan yang memenuhi Other than financial assets in a qualifying hedging
kualifikasi hubungan lindung nilai, kebijakan relationship, the Group’s accounting policy for
akuntansi Grup dikategorikan sebagai berikut: each category is as follows:
Nilai wajar melalui laba atau rugi Fair value through profit or loss
Kategori ini meliputi hanya derivative in-the- This category comprises only in-the-money
money (lihat bagian “liabilitas keuangan” untuk derivatives (see "financial liabilities" section for
derivative out of the money). Derivatif tersebut out of money derivatives). They are carried in the
dicatat dalam laporan posisi keuangan pada nilai statement of financial position at fair value with
wajar dengan perubahan nilai wajar diakui dalam changes in fair value recognized in the statement
laporan laba rugi dan penghasilan komprehensif of comprehensive income in the finance income or
lain pada bagian pendapatan atau beban expense line. Other than derivative financial
keuangan. Selain daripada instrumen keuangan instruments which are not designated as hedging
derivatif yang digunakan sebagai instrumen instruments, the Group does not have any assets
lindung nilai, Grup tidak memiliki aset yang held for trading nor does it voluntarily classify
dimiliki untuk dijual maupun secara sukarela any financial assets as being at fair value through
mengklasifikasikan aset keuangan pada nilai wajar profit or loss.
melalui laporan laba rugi.
Biaya perolehan diamortisasi Amortised cost
Aset ini terutama muncul dari penyediaan barang These assets arise principally from the provision
dan jasa kepada pelanggan (sebagai contoh of goods and services to customers (e.g., trade
piutang usaha), tetapi juga menggabungkan jenis receivables), but also incorporate other types of
aset keuangan lainnya di mana tujuannya adalah financial assets where the objective is to hold
untuk memiliki aset-aset tersebut dengan tujuan these assets in order to collect contractual cash
untuk mengumpulkan arus kas kontraktual dan flows and the contractual cash flows are solely
arus kas kontraktual adalah semata-mata payments of principal and interest. They are
pembayaran pokok dan bunga. Aset tersebut pada initially recognised at fair value plus transaction
awalnya diakui pada nilai wajar ditambah biaya costs that are directly attributable to their
transaksi yang dapat diatribusikan secara langsung acquisition or issue, and are subsequently carried
dengan perolehan atau penerbitannya, dan at amortised cost using the effective interest rate
selanjutnya dicatat pada biaya perolehan method, less provision for impairment.
diamortisasi menggunakan metode suku bunga
efektif, dikurangi penyisihan penurunan nilai.
Penyisihan penurunan nilai untuk piutang usaha Impairment provisions for current and non-
lancar dan tidak lancar diakui berdasarkan current trade receivables are recognised based on
pendekatan yang disederhanakan dalam PSAK 109 the simplified approach within PSAK 109 using a
menggunakan matriks provisi dalam penentuan provision matrix in the determination of the
kerugian kredit ekspektasian sepanjang masa. lifetime expected credit losses. During this
Selama proses ini, probabilitas non-pembayaran process the probability of the non-payment of the
piutang usaha dinilai. Probabilitas ini kemudian trade receivables is assessed. This probability is
dikalikan jumlah kerugian yang diharapkan yang then multiplied by the amount of the expected
timbul dari wanprestasi untuk menentukan loss arising from default to determine the
perkiraan kerugian kredit ekpektasian sepanjang lifetime expected credit loss for the trade
masa untuk piutang usaha. Untuk piutang usaha, receivables. Trade receivables, which are
yang dilaporkan bersih, provisi tersebut dicatat reported net, such provisions are recorded in a
dalam akun provisi terpisah dengan kerugian separate provision account with the loss being
diakui dalam beban pokok penjualan dalam recognised within cost of sales in the statement
laporan laba rugi komprehensif. of comprehensive income.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 293
Page 294
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/15 Exhibit E/15
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. INFORMASI KEBIJAKAN AKUNTANSI MATERIAL 2. MATERIAL ACCOUNTING POLICY INFORMATIONS
(Lanjutan) (Continued)
g. Aset Keuangan (Lanjutan) g. Financial Assets (Continued)
Biaya perolehan diamortisasi (Lanjutan) Amortised cost (Continued)
Pada konfirmasi bahwa piutang usaha tidak akan On confirmation that the trade receivable will not
dapat ditagih, nilai tercatat bruto aset dihapuskan be collectable, the gross carrying value of the
terhadap ketentuan terkait. asset is written off against the associated
provision.
Ketentuan penurunan nilai piutang dari pihak- Impairment provisions for receivables from
pihak berelasi dan transaksi kepada pihak-pihak related parties and transactions to related parties
berelasi diakui berdasarkan model kerugian kredit are recognised based on a forward looking
ekspektasian. Metodologi yang digunakan untuk expected credit loss model. The methodology
menentukan jumlah provisi didasarkan pada used to determine the amount of the provision is
apakah telah ada peningkatan risiko kredit yang based on whether there has been a significant
signifikan sejak pengakuan awal aset keuangan. increase in credit risk since initial recognition of
Bagi mereka yang risiko kreditnya tidak meningkat the financial asset. For those where the credit
secara signifikan sejak pengakuan awal aset risk has not increased significantly since initial
keuangan, kerugian kredit ekspektasian dua belas recognition of the financial asset, twelve month
bulan bersama dengan pendapatan bunga kotor expected credit losses along with gross interest
diakui. Bagi mereka yang memiliki risiko kredit income are recognised. For those for which credit
telah meningkat secara signifikan, kerugian kredit risk has increased significantly, lifetime expected
ekspektasian sepanjang masa bersama dengan credit losses along with the gross interest income
pendapatan bunga kotor diakui. Untuk mereka are recognised. For those that are determined to
yang dianggap mengalami penurunan nilai kredit, be credit impaired, lifetime expected credit
kerugian kredit ekspektasian sepanjang masa losses along with interest income on a net basis
serta pendapatan bunga secara bersih diakui. are recognised.
Dari waktu ke waktu, Grup memilih untuk From time to time, the Group elects to
menegosiasikan kembali persyaratan jatuh tempo renegotiate the terms of trade receivables due
piutang usaha dari pelanggan yang memiliki from customers with which it has previously had
transaksi historis yang baik negosiasi ulang seperti a good trading history. Such renegotiations will
ini dapat mengubah jangka waktu pembayaran lead to changes in the timing of payments rather
daripada perubahan jumlah terutang dan, sebagai than changes to the amounts owed and, in
akibatnya, arus kas baru yang diharapkan consequence, the new expected cash flows are
terdiskonto pada tingkat suku bunga efektif awal discounted at the original effective interest rate
dan perbedaan yang dihasilkan terhadap nilai and any resulting difference to the carrying value
tercatat diakui dalam laporan penghasilan is recognised in the statement of comprehensive
komprehensif (laba operasi). income (operating profit).
Aset keuangan Grup yang diukur pada biaya The Group's financial assets measured at
perolehan diamortisasi terdiri dari piutang usaha amortised cost comprise trade and other
dan piutang lain-lain dan kas dan setara kas dalam receivables and cash and cash equivalents in the
laporan posisi keuangan. statement of financial position.
294 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 295
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/16 Exhibit E/16
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. INFORMASI KEBIJAKAN AKUNTANSI MATERIAL 2. MATERIAL ACCOUNTING POLICY INFORMATIONS
(Lanjutan) (Continued)
g. Aset Keuangan (Lanjutan) g. Financial Assets (Continued)
Nilai wajar melalui penghasilan komprehensif lain Fair value through other comprehensive income
Perusahaan memiliki sejumlah investasi strategis The Company has a number of strategic
pada entitas publik dan entitas bukan publik yang investments in listed and unlisted entities which
tidak dicatat sebagai entitas anak, entitas are not accounted for as subsidiaries, associates
asosiasi, atau entitas yang dikendalikan bersama. or jointly controlled entities. For those
Untuk investasi tersebut, Perusahaan telah investments, the Company has made an
membuat pemilihan yang tidak dapat dibatalkan irrevocable election to classify the investments at
untuk mengklasifikasikan investasi pada nilai fair value through other comprehensive income
wajar melalui penghasilan komprehensif lain rather than through profit or loss as the Company
daripada melalui laba rugi karena Perusahaan considers this measurement to be the most
menganggap pengukuran ini sebagai yang paling representative of the business model for these
representatif dari model bisnis untuk aset ini. assets. They are carried at fair value with
Nilai tersebut dicatat pada nilai wajar dengan changes in fair value recognised in other
perubahan nilai wajar diakui dalam penghasilan comprehensive income and accumulated in the
komprehensif lain dan diakumulasikan dalam nilai fair value through other comprehensive income
wajar melalui cadangan penghasilan komprehensif reserve. Upon disposal any balance within fair
lain. Pada saat pelepasan, saldo dalam nilai wajar value through other comprehensive income
melalui cadangan penghasilan komprehensif lain reserve is reclassified directly to retained
direklasifikasi langsung ke laba ditahan dan tidak earnings and is not reclassified to profit or loss.
direklasifikasi ke laba rugi.
Pembelian dan penjualan aset keuangan yang Purchases and sales of financial assets measured
diukur pada nilai wajar melalui penghasilan at fair value through other comprehensive income
komprehensif lain diakui pada tanggal are recognised on settlement date with any
penyelesaian dengan perubahan nilai wajar antara change in fair value between trade date and
tanggal perdagangan dan tanggal penyelesaian settlement date being recognised in the fair value
diakui pada cadangan yang diukur pada nilai wajar through other comprehensive income reserve.
penghasilan komprehensif lain.
Penurunan nilai aset keuangan Impairment of financial assets
Setiap akhir periode pelaporan, Perusahaan The Company assesses at the end of each
mengevaluasi apakah terdapat bukti yang objektif reporting period whether there is any objective
bahwa aset keuangan atau kelompok aset evidence that a financial asset or a Company of
keuangan mengalami penurunan nilai. financial assets is impaired.
Aset keuangan atau kelompok aset keuangan A financial asset or a group of financial assets is
diturunkan nilainya dan kerugian penurunan nilai deemed to be impaired if, and only if, there is
telah terjadi jika, dan hanya jika, terdapat bukti objective evidence of impairment as a result of
yang objektif mengenai penurunan nilai tersebut one or more events that has occurred after the
sebagai akibat dari satu atau lebih peristiwa yang initial recognition of the asset (an incurred ‘loss
terjadi setelah pengakuan awal aset tersebut event’) and that loss event has an impact on the
(peristiwa yang merugikan), dan peristiwa yang estimated future cash flows of the financial
merugikan tersebut berdampak pada estimasi assets or the Company of financial assets that can
arus kas masa depan atas aset keuangan atau be reliably estimated.
kelompok aset keuangan yang dapat diestimasi
secara andal.
Untuk aset keuangan yang dicatat pada biaya For financial assets carried at amortized cost, the
perolehan diamortisasi, Perusahaan pertama kali Company first assesses whether objective
menentukan apakah terdapat bukti objektif evidence of impairment exists individually for
mengenai adanya penurunan nilai secara financial assets that are individually significant,
individual atas aset keuangan yang signifikan or collectively for financial assets that are not
secara individual atau untuk aset keuangan yang individually significant.
tidak signifikan secara individual terdapat bukti
penurunan nilai secara kolektif.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 295
Page 296
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/17 Exhibit E/17
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. INFORMASI KEBIJAKAN AKUNTANSI MATERIAL 2. MATERIAL ACCOUNTING POLICY INFORMATIONS
(Lanjutan) (Continued)
g. Aset Keuangan (Lanjutan) g. Financial Assets (Continued)
Penurunan nilai aset keuangan (Lanjutan) Impairment of financial assets (Continued)
Jika Perusahaan menentukan tidak terdapat bukti If the Company determines that no objective
objektif mengenai adanya penurunan nilai atas evidence of impairment exists for an individually
aset keuangan yang dinilai secara individual, assessed financial asset, whether significant or
terlepas aset keuangan tersebut signifikan atau not, it includes the asset in a group of financial
tidak, maka Perusahaan memasukkan aset assets with similar credit risk characteristics and
tersebut ke dalam kelompok aset keuangan yang collectively assesses them for impairment. Assets
memiliki karakteristik risiko kredit yang sejenis that are individually assessed for impairment and
dan menilai penurunan nilai kelompok tersebut for which an impairment loss is, or continues to
secara kolektif. Aset yang penurunan nilainya be, recognized are not included in a collective
dinilai secara individual, dan untuk itu kerugian assessment of impairment.
penurunan nilai diakui atau tetap diakui, tidak
termasuk dalam penilaian penurunan nilai secara
kolektif.
Jika terdapat bukti objektif bahwa kerugian If there is objective evidence that an impairment
penurunan nilai telah terjadi, jumlah kerugian loss has occurred, the amount of the loss is
tersebut diukur sebagai selisih antara nilai measured as the difference between the assets
tercatat aset dengan nilai kini estimasi arus kas carrying amount and the present value of
masa datang (tidak termasuk ekspektasi kerugian estimated future cash flows (excluding future
kredit masa mendatang yang belum terjadi). Nilai expected credit losses that have not yet been
kini estimasi arus kas masa mendatang didiskonto incurred). The present value of the estimated
menggunakan suku bunga efektif awal dari aset future cash flows is discounted at the financial
keuangan tersebut. assets original effective interest rate.
Ketika aset tidak tertagih, nilai tercatat atas aset When the asset becomes uncollectible, the
keuangan yang telah diturunkan nilainya dikurangi carrying amount of the financial assets is reduced
secara langsung atau jika ada suatu jumlah telah directly or if an amount was charged to the
dibebankan ke akun cadangan penurunan nilai allowance account, the amounts charged to the
jumlah tersebut dihapusbukukan terhadap nilai allowance account are written off against the
tercatat aset keuangan tersebut. carrying value of the financial assetss.
Jika, pada periode berikutnya, jumlah kerugian If, in a subsequent period, the amount of the
penurunan nilai berkurang dan penurunan nilai impairment loss decreases and the impairment
tersebut diakui, maka kerugian penurunan nilai was recognized, the previously recognized
yang sebelumnya diakui dipulihkan, sepanjang impairment loss is reversed to the extent that the
nilai tercatat aset tidak melebihi biaya perolehan carrying amount of the asset does not exceed its
diamortisasi pada tanggal pemulihan dengan amortized cost at the reversal date by adjusting
menyesuaikan akun cadangan. Jumlah pemulihan the allowance account. The amount of the
aset keuangan diakui pada laba rugi. reversal is recognized in profit or loss.
Penerimaan kemudian atas piutang yang telah Subsequent recoveries of previously written off
dihapusbukukan sebelumnya, jika pada periode receivables, if in the current period, are credited
berjalan dikreditkan dengan menyesuaikan pada to the allowance accounts, but if after the
akun cadangan penurunan nilai, sedangkan jika reporting period, are credited to other operating
setelah akhir periode pelaporan dikreditkan income.
sebagai pendapatan operasional lainnya.
296 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 297
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/18 Exhibit E/18
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. INFORMASI KEBIJAKAN AKUNTANSI MATERIAL 2. MATERIAL ACCOUNTING POLICY INFORMATIONS
(Lanjutan) (Continued)
g. Aset Keuangan (Lanjutan) g. Financial Assets (Continued)
Penghentian pengakuan Derecognition
Suatu aset keuangan, atau mana yang berlaku, A financial assets, or where applicable a part of
bagian dari aset keuangan atau bagian dari a financial asset or part of a group of similar
kelompok aset keuangan sejenis, dihentikan financial assets, is derecognized when:
pengakuannya pada saat:
a. Hak kontraktual atas arus kas yang berasal a. The contractual rights to receive cash flows
dari aset keuangan tersebut berakhir; atau from the financial assets have expired; or
b. Perusahaan mentransfer hak kontraktual b. The company has transferred its contractual
untuk menerima arus kas yang berasal dari rights to receive cash flows from the financial
aset keuangan atau menanggung kewajiban asset or has assumed an obligation to pay
untuk membayar arus kas yang diterima tanpa them in full without material delay to a third
penundaan yang signifikan kepada pihak party under a “pass-through” arrangement
ketiga melalui suatu kesepakatan penyerahan and either (i) has transferred substantially all
dan (i) secara substansial mentransfer seluruh the risks and rewards of the financial assets,
risiko dan manfaat atas kepemilikan aset or (ii) has neither transferred nor retained
keuangan tersebut, atau (ii) secara substantially all the risks and rewards of the
substansial tidak mentransfer dan tidak financial assets, but has transferred control of
memiliki seluruh risiko dan manfaat atas the financial assets.
kepemilikan aset keuangan tersebut, namun
telah mentransfer pengendalian atas aset
keuangan tersebut.
h. Liabilitas Keuangan h. Financial Liabilities
Grup mengklasifikasikan liabilitas keuangan ke The Group’s classifies its financial liabilities into
dalam satu atau dua kategori, tergantung pada one of two categories, depending on the purpose
tujuan liabilitas tersebut diakuisisi. for which the liability was acquired.
Selain daripada liabilitas keuangan untuk tujuan Other than financial liabilities in a qualifying
lindung nilai (lihat penjelasan di bawah ini), hedging relationship (see below), the Group's
kebijakan akuntansi milik Perusahaan untuk setiap accounting policy for each category is as follows:
kategori dijelaskan sebagai berikut:
Nilai wajar melalui laporan laba rugi Fair value through profit or loss
Kategori ini hanya terdiri dari instrumen derivatif This category comprises only out-of-the-money
out-of-the-money (lihat ‘Aset keuangan’ in-the derivatives (see "Financial assets" for in the
money). Instrumen tersebut dinilai di dalam money derivatives). They are carried in the
laporan posisi keuangan pada nilai wajar dengan statement of financial position at fair value with
perubahan nilai wajar yang diakui di dalam changes in fair value recognised in the statement
laporan penghasilan komprehensif. Perusahaan of comprehensive income. The Company does not
tidak mempunyai atau mengeluarkan instrumen hold or issue derivative instruments for
derivatif untuk tujuan spekulasi melainkan untuk speculative purposes, but for hedging purposes.
tujuan lindung nilai. Selain instrumen derivatif Other than these derivative financial
tersebut, Grup tidak memiliki liabilitas untuk instruments, the Group does not have any
diperdagangkan maupun ditujukan bagi semua liabilities held for trading nor has it designated
liabilitas keuangan yang dikelompokkan sebagai any financial liabilities as being at fair value
nilai wajar melalui laporan laba rugi. through profit or loss.
Grup tidak mempunyai atau mengeluarkan The Group does not hold or issue derivative
instrumen derivatif untuk tujuan spekulasi instruments for speculative purposes, but for
melainkan untuk tujuan lindung nilai. Selain hedging purposes. Other than these derivative
instrumen derivatif tersebut, Grup tidak memiliki financial instruments, the Group does not have
liabilitas untuk diperdagangkan maupun ditujukan any liabilities held for trading nor has it
bagi semua liabilitas keuangan yang designated any financial liabilities as being at fair
dikelompokkan sebagai nilai wajar melalui laporan value through profit or loss.
laba rugi.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 297
Page 298
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/19 Exhibit E/19
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. INFORMASI KEBIJAKAN AKUNTANSI MATERIAL 2. MATERIAL ACCOUNTING POLICY INFORMATIONS
(Lanjutan) (Continued)
h. Liabilitas Keuangan (Lanjutan) h. Financial Liabilities (Continued)
Liabilitas keuangan lain Other financial liabilities
Liabilitas keuangan lain termasuk hal-hal berikut: Other financial liabilities include the following
items:
- Pinjaman bank dan perpetual preference - Bank borrowings and the Company's perpetual
share Perusahaan pada awalnya diakui pada preference shares are initially recognised at
nilai wajar dikurangi biaya transaksi yang fair value net of any transaction costs directly
dapat diatribusikan secara langsung pada saat attributable to the issue of the instrument.
penerbitan instrumen. Liabilitas dengan bunga Such interest bearing liabilities are
seperti itu selanjutnya diukur pada biaya subsequently measured at amortised cost
perolehan diamortisasi dengan menggunakan using the effective interest rate method,
metode tingkat suku bunga efektif, yang which ensures that any interest expense over
memastikan bahwa beban bunga selama the period to repayment is at a constant rate
periode sampai dengan pembayaran kembali on the balance of the liability carried in the
menggunakan kurs konstan pada saldo statement of financial position. For the
liabilitas yang dicatat dalam laporan posisi purposes of each financial liability, interest
keuangan. Untuk tujuan dari setiap liabilitas expense includes initial transaction costs and
keuangan, beban bunga termasuk biaya any premium payable on redemption, as well
transaksi awal dan premi terutang pada saat as any interest or coupon payable while the
penebusan, serta bunga atau kupon terutang liability is outstanding.
pada saat liabilitas masih belum diselesaikan.
- Utang usaha dan liabilitas moneter jangka - - Trade payables and other short-term
pendek lain yang pada saat pengukuran awal monetary liabilities, which are initially
diakui pada nilai wajar dan selanjutnya dicatat recognised at fair value and subsequently
pada biaya perolehan diamortisasi dengan carried at amortised cost using the effective
menggunakan metode suku bunga efektif. interest method.
i. Kas dan Bank f. i. Cash and Banks
Kas dan bank disajikan di laporan posisi keuangan. g. Cash and banks presented in the statement of
Di laporan arus kas mencakup kas dan simpanan financial position. In the statement of cash flows
yang sewaktu-waktu bisa dicairkan dan tidak include cash in hand and deposits held at call with
dijaminkan serta tidak dibatasi penggunaannya. banks and they are not being pledged as collateral
for borrowings and not restricted to use.
j. Biaya Dibayar di Muka h. j. Prepaid Expenses
Biaya dibayar di muka diamortisasi sesuai dengan i. Prepaid expenses are amortized over the periods
masa manfaat masing-masing biaya dengan benefited using the straight-line method.
menggunakan metode garis lurus.
k. Persediaan j. k. Inventories
f.
Persediaan dinyatakan berdasarkan nilai terendah Inventories are stated at the lower of cost or net
antara biaya perolehan atau nilai realisasi neto. realizable value. Cost is determined using the
Biaya perolehan ditentukan dengan menggunakan Weighted Average method.
metode rata-rata tertimbang.
Penyisihan kerugian penurunan nilai persediaan Allowance for impairment losses on inventories is
ditentukan untuk menurunkan nilai tercatat determined to reduce the carrying value of
persediaan ke nilai realisasi neto. inventories to their net realizable value.
298 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 299
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/20 Exhibit E/20
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. INFORMASI KEBIJAKAN AKUNTANSI MATERIAL 2. MATERIAL ACCOUNTING POLICY INFORMATIONS
(Lanjutan) (Continued)
l. Aset Tetap l. Property and Equipment
Grup memilih model biaya sebagai kebijakan The Group’s has chosen to use the cost model as
akuntansi pengukuran aset tetapnya. the accounting policy for measurement of its
property and equipment.
Seluruh aset tetap awalnya diakui sebesar biaya All property and equipment are initially
perolehan, yang terdiri atas harga perolehan dan recognized at cost, which comprises its
biaya-biaya tambahan yang dapat diatribusikan acquisition price and any costs directly
langsung untuk membawa aset ke lokasi dan attributable in bringing the asset to the location
kondisi yang diinginkan supaya aset tersebut siap and condition necessary for it to be capable of
digunakan sesuai dengan maksud manajemen. operating in the manner intended by
management.
Setelah pengakuan awal, aset tetap, kecuali hak Subsequent to initial recognition, property and
atas tanah, dinyatakan sebesar biaya perolehan equipment, except landrights, are carried at cost
dikurangi akumulasi penyusutan dan rugi less accumulated depreciation and impairment
penurunan nilai, jika ada. losses, if any.
Penyusutan aset tetap tertentu dihitung dengan Depreciation of certain property and equipment
menggunakan metode saldo menurun ganda, is computed using the double-declining-balance
kecuali penyusutan bangunan menggunakan method, except for depreciation of buildings
metode garis lurus berdasarkan masa manfaat using the straight-line method based on the
ekonomis aset tetap sebagai berikut: estimated useful lives of the assets as follows:
Masa manfaat/
Tarif Penyusutan/ Useful Lives
Depreciation Rate (Tahun/Years)
Bangunan 5% 20 Buildings
Renovasi bangunan 50% 4 Buildings renovation
Perbaikan sewa 50% 4 Leasehold improvements
Kendaraan 50% 4 Vehicles
Peralatan kantor 25% 8 Office equipments
Peralatan teknik 25% 8 Technical equipments
Grup melakukan perubahan kebijakan akuntansi Group changed their accounting policy of property
atas aset tetap dari model biaya menjadi model and equipment from cost basis to revaluation
revaluasi sejak tanggal 31 Desember 2023 untuk basis as of 31 December 2023 for property and
aset tetap hak atas tanah dan bangunan. Aset equipment of land and building. Property and
tetap selanjutnya dicatat pada nilai wajar, equipment are subsequently carried at fair value,
berdasarkan penilaian periodik yang dihitung oleh based on periodic valuations by a professionally
penilai profesional. qualified valuer.
Biaya legal awal untuk mendapatkan hak legal Initial legal costs incurred to obtain legal rights
diakui sebagai bagian biaya akuisisi hak atas are recognised as part of the acquisition cost of
tanah, biaya-biaya tersebut tidak didepresiasikan. the landrights, and these costs are not
Biaya terkait dengan pembaruan hak atas tanah depreciated. Costs related to renewal of
diakui sebagai aset takberwujud dan diamortisasi landrights are recognised as intangible assets and
sepanjang umur hak atas tanah. amortised during the period of the landrights.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 299
Page 300
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/21 Exhibit E/21
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. INFORMASI KEBIJAKAN AKUNTANSI MATERIAL 2. MATERIAL ACCOUNTING POLICY INFORMATIONS
(Lanjutan) (Continued)
l. Aset Tetap (Lanjutan) l. Property and Equipment (Continued)
Pada tanggal revaluasi, akumulasi penyusutan At the date of revaluation, the accumulated
atas aset tetap yang direvaluasi dieliminasi depreciation on the revalued property and
terhadap jumlah tercatat bruto dari aset dan equipment are eliminated against the gross
jumlah neto disajikan kembali terhadap jumlah carrying amount of the asset and the net amount
revaluasi aset. is restated to the revalued amount of the asset.
Revaluasi ini dilakukan dengan tingkat These revaluations are made with sufficient
keteraturan yang memadai untuk menjamin regularity to ensure that the carrying amount
bahwa jumlah tercatat tidak berbeda secara does not differ materially from that which would
material dari nilai wajar yang ditentukan pada be determined using fair value at the end of the
periode pelaporan. Perubahan pada nilai wajar reporting period. Changes in fair value are
diakui dalam penghasilan komprehensif lain dan recognized in other comprehensive income and
diakumulasi dalam cadangan revaluasi kecuali accumulated in the revaluation reserve except to
untuk penurunan nilai yang melebihi saldo kredit the extent that any decrease in value in excess of
pada cadangan revaluasi, atau pembalikan untuk the credit balance on the revaluation reserve, or
transaksi tersebut, diakui dalam laporan laba rugi. reversal of such a transaction, is recognized in
profit or loss.
Frekuensi revaluasi bergantung pada perubahan The frequency of revaluation depends on changes
nilai wajar dari aset tetap yang direvaluasi. Jika in the fair value of the revalued property and
nilai wajar dari aset yang direvaluasi berbeda equipment. If fair value of revaluation of
secara material dengan jumlah tercatatnya, maka property and equipment differs materially by its
revaluasi lanjutan disyaratkan. Beberapa aset carrying amount, a further revaluation is
tetap mengalami perubahan nilai wajar secara required. Some property and equipment are
signifikan dan fluktuatif, sehingga perlu subject to significant changes in their fair value
direvaluasi secara tahunan. Revaluasi tahunan and fluctuate, so they need to be revalued on an
tersebut tidak perlu dilakukan untuk aset tetap annual basis. The annual revaluation is not
yang perubahan nilai wajarnya tidak signifikan. necessary for property and equipment whose
Sebaliknya, aset tetap tersebut mungkin perlu changes in fair value are insignificant. On the
direvaluasi setiap tiga atau lima tahun sekali. other hand, the property and equipment may
need to be revalued every three or five years.
Penilaian aset tetap dilakukan atas penurunan dan The carrying amounts of property and equipment
kemungkinan penurunan nilai wajar aset jika are reviewed for impairment when events or
terjadi peristiwa atau perubahan keadaan yang changes in circumstances indicate that the
mengindikasikan bahwa nilai tercatat mungkin carrying values may not be fully recoverable.
tidak dapat seluruhnya terealisasi.
Jumlah tercatat aset tetap dihentikan An item of property and equipment is
pengakuannya pada saat dilepaskan atau saat derecognized upon disposal or when no future
tidak ada manfaat ekonomis masa depan yang economic benefits are expected from its use or
diharapkan dari penggunaan atau pelepasannya. disposal.
Laba atau rugi yang timbul dari penghentian Any gain or loss arising on derecognition of the
pengakuan aset (dihitung sebagai perbedaan asset (calculated as the difference between the
antara jumlah neto hasil pelepasan dan jumlah net disposal proceeds and the carrying amount of
tercatat dari aset) dikreditkan atau dibebankan the asset) is included in profit or loss in the year
pada operasi tahun aset tersebut dihentikan the asset is derecognized.
pengakuannya.
300 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 301
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/22 Exhibit E/22
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. INFORMASI KEBIJAKAN AKUNTANSI MATERIAL 2. MATERIAL ACCOUNTING POLICY INFORMATIONS
(Lanjutan) (Continued)
l. Aset Tetap (Lanjutan) l. Property and Equipment (Continued)
Beban pemeliharaan dan perbaikan dibebankan Repairs and maintenance are taken to profit or
pada operasi pada saat terjadinya. Beban loss when incurred. The cost of major renovation
pemugaran dan penambahan dalam jumlah besar and restoration is included in the carrying amount
dikapitalisasi kepada jumlah tercatat aset tetap of the related property and equipment when it
terkait bila besar kemungkinan bagi Perusahaan is probable that future economic benefits in
manfaat ekonomi masa depan menjadi lebih besar excess of the originally assessed standard
dari standar kinerja awal yang ditetapkan performance of the existing asset will flow to the
sebelumnya dan disusutkan sepanjang sisa masa Company, and is depreciated over the remaining
manfaat aset tetap terkait. useful life of the related assets.
Nilai residu dari aset tetap adalah estimasi jumlah The residual value of a property and equipment is
yang dapat diperoleh Perusahaan saat ini dari the estimated amount that can be acquired by the
pelepasan aset tetap, setelah dikurangi estimasi Company at this time of disposal of property and
biaya pelepasan, jika aset tetap telah mencapai equipment, net of estimated costs of disposal, if
umur dan kondisi yang diperkirakan pada akhir the fixed asset has reached the age and condition
umur manfaat ekonomisnya. expected at the end of its useful life.
Pada setiap akhir tahun pelaporan, nilai residu, The residual values, useful lives and methods of
manfaat ekonomis dan metode penyusutan depreciation of assets are reviewed, and adjusted
dievaluasi, dan jika sesuai keadaan, disesuaikan prospectively, if appropriate, at the end of each
secara prospektif. reporting year.
Aset dalam penyelesaian dinyatakan sebesar biaya Construction in progress is stated at cost and is
perolehan dan disajikan sebagai bagian dari aset presented as part of property and equipment. The
tetap. Akumulasi biaya perolehan aset dalam accumulated costs are reclassified to the
penyelesaian dipindahkan ke masing-masing aset appropriate property and equipment account
tetap yang bersangkutan pada saat aset tersebut when the construction is substantially completed
selesai dikerjakan dan siap digunakan sesuai and the constructed asset is ready for its
dengan tujuannya. Aset dalam penyelesaian tidak intended use. Constructions in progress are not
disusutkan karena belum tersedia untuk depreciated as these are not yet available for use.
digunakan.
m. Aset Takberwujud m. Intangible assets
Piranti lunak komputer Computer software
Biaya pengembangan yang dapat secara langsung Development costs that are directly attributable
diatribusikan kepada desain dan pengujian produk to the design and testing of identifiable and
piranti lunak yang dapat diidentifikasi dan unik unique software products controlled by the
yang dikendalikan oleh Perusahaan diakui sebagai Company are recognised as intangible assets and
aset takberwujud dan diamortisasi selama amortised over their estimated useful lives of 8
estimasi masa manfaat yaitu 8 tahun. years.
Biaya yang dapat diatribusikan secara langsung Directly atributable costs that are capitalized as
dikapitalisasi sebagai bagian produk piranti lunak part of the software product include the software
mencakup beban pekerja pengembang piranti development employee costs and an appropriate
lunak dan bagian overhead yang relevan. portion of relevant overheads.
Pengeluaran pengembangan yang lain yang tidak Other development expenditures that do not
memenuhi kriteria ini diakui sebagai beban pada meet these criteria are recognised as an expense
saat terjadinya. Biaya pengembangan yang as incurred. Development costs previously
sebelumnya diakui sebagai beban tidak dapat recognised as an expense are not recognised as an
diakui sebagai aset pada periode berikutnya. asset in a subsequent period.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 301
Page 302
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/23 Exhibit E/23
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. INFORMASI KEBIJAKAN AKUNTANSI MATERIAL 2. MATERIAL ACCOUNTING POLICY INFORMATIONS
(Lanjutan) (Continued)
n. Sewa n. Lease
Mengidentifikasi Sewa Identifying Leases
Grup memperhitungkan suatu kontrak, atau The Group’s accounts for a contract, or a portion
bagian dari suatu kontrak, sebagai suatu sewa of a contract, as a lease when it conveys the right
ketika Perusahaan memberikan hak untuk to use an asset for a period of time in exchange
menggunakan aset selama suatu jangka waktu for consideration. Leases are those contracts that
untuk dipertukarkan dengan imbalan. Sewa adalah satisfy the following criteria:
kontrak yang memenuhi kriteria berikut:
- Terdapat aset identifikasian; - There is an identified asset;
- Perusahaan memperoleh secara substansial - The Company obtains substantially all the
semua manfaat ekonomis dari penggunaan economic benefits from use of the asset; and
aset; dan
- Perusahaan memiliki hak untuk mengarahkan - The Company has the right to direct use of the
penggunaan aset. asset.
Grup mempertimbangkan apakah pemasok The Group considers whether the supplier has
memiliki hak substitusi substantif. Jika pemasok substantive substitution rights. If the supplier
memang memiliki hak-hak tersebut, kontrak tidak does have those rights, the contract is not
diidentifikasi sebagai penyebab timbulnya sewa. identified as giving rise to a lease.
Dalam menentukan apakah Grup mendapatkan In determining whether the Group obtains
secara substantial seluruh manfaat ekonomik dari substantially all the economic benefits from use
penggunaan aset selama periode penggunaan, of the asset, the Group considers only the
Grup hanya mempertimbangkan manfaat ekonomi economic benefits that arise use of the asset, not
yang timbul dari penggunaan aset, bukan manfaat those incidentals to legal ownership or other
yang terkait dengan kepemilikan legal atau potential benefits.
manfaat potensial lainnya.
Dalam menentukan apakah Grup memiliki hak In determining whether the Group has the right
untuk mengarahkan penggunaan aset, Grup to direct use of the asset, the Group considers
mempertimbangkan apakah Grup mengarahkan whether it directs how and for what purpose the
bagaimana dan untuk tujuan apa aset tersebut asset is used throughout the period of use.
digunakan selama periode penggunaan.
Jika tidak ada keputusan signifikan yang harus If there are no significant decisions to be made
dibuat karena sifat aset tersebut, Grup akan because they are pre-determined due to the
mempertimbangkan apakah Grup terlibat dalam nature of the asset, the Group considers whether
desain aset dengan cara menetapkan sebelumnya it was involved in the design of the asset in a way
bagaimana dan untuk tujuan apa aset akan that predetermines how and for what purpose the
digunakan selama periode penggunaan, jika tidak asset will be used throughout the period of use. If
ada keputusan signifikan yang harus dibuat karena the contract or portion of a contract does not
sifat aset tersebut. Jika kontrak atau bagian dari satisfy these criteria, the Company applies other
kontrak tidak memenuhi kriteria ini, Grup applicable PSAK rather than PSAK 116.
menerapkan PSAK lain yang berlaku, daripada
PSAK 116.
Semua sewa dicatat dengan mengakui aset hak- All leases are accounted by recognising a right-of-
guna dan liabilitas sewa kecuali untuk : use asset and a lease liability except for:
- Sewa aset bernilai rendah; dan - Leases of low value assets; and
- Sewa dengan durasi 12 bulan atau kurang. - Leases with a duration of 12 months or less.
302 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 303
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/24 Exhibit E/24
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. INFORMASI KEBIJAKAN AKUNTANSI MATERIAL 2. MATERIAL ACCOUNTING POLICY INFORMATIONS
(Lanjutan) (Continued)
n. Sewa (Lanjutan) n. Lease (Continued)
Liabilitas sewa diukur pada nilai kini dari Lease liabilities are measured at the present
pembayaran kontraktual terutang kepada value of the contractual payments due to the
penyewa selama masa sewa, dengan tingkat lessor over the lease term, with the discount rate
diskonto yang ditentukan mengacu pada tarif determined by reference to the rate inherent in
dalam sewa kecuali dapat ditentukan dengan the lease unless readily determinable, in which
mudah untuk menentukan suku bunga pinjaman case the Company’s incremental borrowing rate
inkremental Perusahaan pada saat dimulainya on commencement of the lease is used.
sewa
Pembayaran sewa variabel hanya termasuk dalam Variable lease payments are only included in the
pengukuran liabilitas sewa jika mereka measurement of the lease liability if they depend
bergantung pada indeks atau tarif. Dalam kasus on an index or rate. In such cases, the initial
seperti itu, pengukuran awal dari liabilitas sewa measurement of the lease liability assumes the
mengasumsikan elemen variabel akan tetap tidak variable element will remain unchanged
berubah selama masa sewa. Pembayaran sewa throughout the lease term. Other variable lease
variabel lain-lain dibebankan pada periode yang payments are expensed in the period to which
terkait. they relate
Pada pengakuan awal, nilai tercatat liabilitas sewa On initial recognition, the carrying value of the
juga mencakup: lease liability also includes:
- jumlah yang diharapkan dibayarkan - amounts expected to be payable under any
berdasarkan jaminan nilai residual; residual value guarantee;
- harga eksekusi setiap opsi pembelian yang - the exercise price of any purchase option
diberikan untuk Perusahaan jika terdapat granted in for the Company if it is reasonably
kepastian yang memadai untuk menilai opsi certain to assess that option; and
itu; dan
- penalti yang harus dibayar untuk mengakhiri - any penalties payable for terminating the
sewa, jika jangka waktu sewa telah diestimasi lease, if the term of the lease has been
berdasarkan opsi terminasi akan dilakukan. estimated on the basis of termination option
being exercised.
Aset hak-guna pada awalnya diukur sebesar Right-of-use assets are initially measured at the
jumlah liabilitas sewa, dikurangi untuk setiap amount of the lease liability, reduced for any
insentif sewa yang diterima, dan ditambah untuk: lease incentives received, and increased for:
- pembayaran sewa yang dilakukan pada atau - lease payments made at or before
sebelum dimulainya sewa; dan commencement of the lease; and
- biaya langsung awal yang dikeluarkan. - initial direct costs incurred.
Setelah pengukuran awal, liabilitas sewa Subsequent to initial measurement lease
meningkat sebagai akibat dari bunga yang liabilities increase as a result of interest charged
dibebankan pada tingkat konstan pada saldo at a constant rate on the balance outstanding and
terutang dan dikurangi untuk pembayaran sewa. are reduced for lease payments made. Right-of-
Aset hak-guna diamortisasi secara garis lurus use assets are depreciated on a straight-line basis
selama sisa masa sewa atau selama umur ekonomis over the remaining term of the lease or over the
aset yang tersisa, jika dinilai lebih pendek remaining economic life of the asset if, rarely,
daripada masa sewa tersebut. this is judged to be shorter than the lease term.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 303
Page 304
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/25 Exhibit E/25
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. INFORMASI KEBIJAKAN AKUNTANSI MATERIAL 2. MATERIAL ACCOUNTING POLICY INFORMATIONS
(Lanjutan) (Continued)
o. Penurunan Nilai Aset Non-Keuangan o. Impairment of Non-Financial Assets
Pada setiap akhir tahun pelaporan, Grup menilai The Group assesses at the end of each reporting
apakah terdapat indikasi suatu aset mengalami year whether there is an indication that an asset
penurunan nilai. Jika terdapat indikasi tersebut, may be impaired. If any such indication exists,
maka Perusahaan akan membuat estimasi atas the Company makes an estimate of the asset’s
jumlah terpulihkan aset tersebut. recoverable amount.
Jumlah terpulihkan yang ditentukan untuk aset An asset’s recoverable amount is the higher of an
individual adalah jumlah yang lebih tinggi antara assets or cash-generating unit’s (CGU) fair value
nilai wajar aset atau unit penghasil kas (UPK) less costs to sell and its value in use, and is
dikurangi biaya untuk menjual dengan nilai determined for an individual asset, unless the
pakainya, kecuali aset tersebut tidak menghasilkan asset does not generate cash inflows that are
arus kas masuk yang sebagian besar independen largely independent of those from other assets or
dari aset atau kelompok aset lain. Jika nilai Company of assets. Where the carrying amount of
tercatat aset lebih besar daripada nilai an asset exceeds its recoverable amount, the
terpulihkannya, maka aset tersebut asset is considered impaired and is written down
dipertimbangkan mengalami penurunan nilai dan to its recoverable amount.
nilai tercatat aset diturunkan nilai menjadi sebesar
nilai terpulihkannya.
Penilaian dilakukan pada setiap akhir tahun An assessment is made at the end of each
pelaporan apakah terdapat indikasi bahwa rugi reporting year as to whether there is any
penurunan nilai yang telah diakui dalam tahun indication that previously recognized impairment
sebelumnya untuk suatu aset mungkin tidak ada losses for an asset may no longer exist or may
lagi atau mungkin telah menurun. Jika indikasi have decreased. If such indication exists, the
tersebut ada, maka entitas mengestimasi jumlah recoverable amount is estimated.
terpulihkan aset tersebut.
Kerugian penurunan nilai yang telah diakui dalam A previously recognized impairment loss for an
tahun sebelumnya untuk suatu aset dibalik hanya asset is reversed only if there has been a change
jika terdapat perubahan asumsi-asumsi yang in the assumptions used to determine the asset’s
digunakan untuk menentukan jumlah terpulihkan recoverable amount since the last impairment
aset tersebut sejak rugi penurunan nilai terakhir loss was recognized.
diakui.
Pembalikan tersebut dibatasi sehingga jumlah The reversal is limited so that the carrying
tercatat aset tidak melebihi jumlah terpulihkannya amount of the assets does not exceed its
maupun jumlah tercatat, neto setelah penyusutan, recoverable amount, nor exceed the carrying
seandainya tidak ada rugi yang telah diakui untuk amount that would have been determined, net of
aset tersebut pada tahun sebelumnya. depreciation, had no impairment loss been
recognized for the asset in prior years.
Pembalikan rugi penurunan nilai diakui dalam laba The reversal of an impairment loss is recognized
rugi. Setelah pembalikan tersebut diakui, in profit or loss. After such reversal, the
penyusutan aset tersebut disesuaikan di tahun depreciation charged is adjusted in future years
mendatang untuk mengalokasikan jumlah tercatat to allocate the asset’s revised carrying amount,
aset yang direvisi, dikurangi nilai sisanya, dengan less any residual value, on a systematic basis over
dasar yang sistematis selama sisa umur its remaining useful life.
manfaatnya.
304 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 305
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/26 Exhibit E/26
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. INFORMASI KEBIJAKAN AKUNTANSI MATERIAL 2. MATERIAL ACCOUNTING POLICY INFORMATIONS
(Lanjutan) (Continued)
p. Program Imbalan Pasti p. Defined benefit schemes
Surplus dan defisit program imbalan pasti diukur Defined benefit scheme surpluses and deficits are
sebesar: measured at:
- Nilai wajar dari aset yang direncanakan pada - The fair value of plan assets at the reporting
tanggal pelaporan; dikurangi date; less
- Liabilitas yang direncanakan dihitung dengan - Planned liabilities calculated using the
menggunakan metode projected unit credit projected unit credit method discounted to
yang didiskonto ke nilai kini dengan its present value using yields available on
menggunakan imbal hasil obligasi perusahaan high quality corporate bonds that have
yang berkualitas tinggi yang tersedia yang maturity dates approximating to the terms of
memiliki tanggal jatuh tempo yang mendekati the liabilities; plus
persyaratan liabilitas; ditambah
- Biaya jasa lalu yang tidak diakui; dikurangi - Unrecognized past service costs; less
- Dampak persyaratan pendanaan minimum yang - The effect of minimum funding requirements
disetujui dengan skema perwakilan. agreed with scheme trustees.
Pengukuran kembali kewajiban pasti neto diakui Remeasurements of the net defined obligation
langsung dalam ekuitas. Pengukuran Kembali are recognised directly within equity. The
tersebut termasuk: remeasurements include:
- Keuntungan dan kerugian aktuaris. - Actuarial gains and losses.
- Imbalan atas aset program (tidak termasuk - Return on plan assets (interest exclusive).
bunga).
- Dampak batas tertinggi aset (tidak termasuk - Any asset ceiling effects (interest exclusive).
bunga).
Biaya jasa diakui dalam laporan laba rugi, dan Service costs are recognised in profit or loss, and
termasuk biaya jasa kini dan masa lalu, serta include current and past service costs as well as
keuntungan dan kerugian kurtailmen. gains and losses on curtailments.
Beban bunga neto (pendapatan) diakui dalam Net interest expense (income) is recognised in
laporan laba rugi dan dihitung dengan menerapkan profit or loss, and is calculated by applying the
tingkat diskonto untuk mengukur kewajiban discount rate used to measure the defined
imbalan pasti (aset) pada awal periode tahunan benefit obligation (asset) at the beginning of the
hingga saldo kewajiban imbalan pasti bersih (aset), annual period to the balance of the net defined
dengan mempertimbangkan dampak dari benefit obligation (asset), considering the
pembayaran iuran dan manfaat selama periode. effects of contributions and benefit payments
during the period.
Keuntungan atau kerugian yang timbul dari Gains or losses arising from changes to scheme
perubahan manfaat program atau kurtailmen benefits or scheme curtailment are recognised
diakui secara langsung dalam laporan laba rugi. immediately in profit or loss.
Penyelesaian program imbalan pasti diakui dalam Settlements of defined benefit schemes are
periode di mana penyelesaian tersebut terjadi. recognised in the period in which the settlement
occurs.
q. Provisi q. Provision
Provisi diakui jika Grup mempunyai kewajiban kini Provisions are recognized when the Group has
(hukum maupun konstruktif) sebagai akibat present obligation (legal or constructive) as a
peristiwa masa lalu, yang memungkinkan Grup result of a past event, it is probable that the
harus menyelesaikan kewajiban tersebut dan Group will be required to settle the obligation
estimasi yang andal mengenai jumlah kewajiban and a reliable estimate can be made of the
tersebut dapat dibuat. amount of the obligation.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 305
Page 306
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/27 Exhibit E/27
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. INFORMASI KEBIJAKAN AKUNTANSI MATERIAL 2. MATERIAL ACCOUNTING POLICY INFORMATIONS
(Lanjutan) (Continued)
q. Provisi (Lanjutan) q. Provision (Continued)
Jumlah yang diakui sebagai provisi adalah hasil The amount recognized as a provision is the best
estimasi terbaik pengeluaran yang diperlukan estimate of the consideration required to settle
untuk menyelesaikan kewajiban kini pada tanggal the obligation at the reporting date, taking into
pelaporan, dengan mempertimbangkan risiko dan account the risks and uncertainties surrounding
ketidakpastian terkait kewajiban tersebut. the obligation.
Ketika provisi diukur menggunakan estimasi arus Where a provision is measured using the cash
kas untuk menyelesaikan kewajiban kini, maka flows estimated to settle the present obligation,
nilai tercatat provisi adalah nilai kini arus kas its carrying amount is the present value of those
tersebut. cash flows.
Jika sebagian atau seluruh pengeluaran untuk When some or all of the economic benefits
menyelesaikan provisi diganti oleh pihak ketiga, required to settle a provision are expected to be
maka penggantian itu diakui hanya pada saat recovered from a third party, the receivable is
timbul keyakinan bahwa penggantian pasti akan recognized as an asset if it is virtually certain
diterima dan jumlah penggantian dapat diukur that reimbursement will be received and the
dengan andal. amount of the receivable can be measured
reliably.
r. Perpajakan r. Taxation
Beban pajak terdiri dari pajak kini dan pajak The tax expense comprises current and deferred
tangguhan. Pajak diakui dalam laba rugi, kecuali tax. Tax is recognized in profit or loss, except to
jika berkaitan dengan item yang diakui dalam the extent that it relates to items recognized in
penghasilan komprehensif lain atau secara other comprehensive income or directly in
langsung dalam ekuitas. Dalam kasus ini, pajak equity. In this case, the tax is also recognized in
diakui dalam penghasilan komprehensif lain atau other comprehensive income or directly in
langsung dalam ekuitas. equity, respectively.
Pajak Kini Current Tax
Beban pajak penghasilan kini dihitung dengan dasar The current income tax charge is calculated on
hukum pajak yang berlaku atau yang secara the basis of the tax laws enacted or substantively
substantive berlaku pada akhir pelaporan. Aset enacted at the end of the reporting period.
atau liabilitas pajak penghasilan kini terdiri dari Current income tax assets and/or liabilities
kewajiban kepada atau klaim dari otoritas pajak comprise those liabilities to, or claim from, tax
yang berhubungan dengan periode pelaporan kini authorities relating to the current or prior
atau sebelumnya, yang belum dibayar pada akhir reporting period, that are unpaid at the end of
periode tanggal pelaporan. Berdasarkan laba kena each reporting period date. Based on the taxable
pajak untuk periode tersebut. Seluruh perubahan profit for the period. All changes to current tax
pada aset atau liabilitas pajak kini diakui sebagai assets or liabilities are recognized as a
komponen biaya pajak penghasilan dalam laba atau component of income tax expense in profit or
rugi. loss.
306 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 307
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/28 Exhibit E/28
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. INFORMASI KEBIJAKAN AKUNTANSI MATERIAL 2. MATERIAL ACCOUNTING POLICY INFORMATIONS
(Lanjutan) (Continued)
r. Perpajakan (Lanjutan) r. Taxation (Continued)
Pajak Tangguhan Deferred Tax
Aset dan liabilitas pajak tangguhan diakui ketika Deferred tax assets and liabilities are recognized
jumlah tercatat dari aset atau liabilitas dalam where the carrying amount of an asset or liability
laporan posisi keuangan berbeda dari dasar in the statement of financial position differs
perpajakannya, kecuali jika perbedaan itu terjadi from its tax base, except for differences arising
karena: on:
- Pengakuan awal goodwill; - The initial recognition of goodwill;
- Pengakuan awal aset atau liabilitas pada saat - The initial recognition of an asset or liability
transaksi yang bukan merupakan bisnis in a transaction which is not a business
kombinasi dan pada saat transaksi terjadi tidak combination and at the time of the
mempengaruhi akuntansi atau laba kena pajak; transaction affects neither accounting or
dan; taxable profit; and;
- Perusahaan mampu mengendalikan waktu - The Company is able to control the timing of
pembalikan perbedaan dan kemungkinan besar the reversal of the difference and it is
bahwa perbedaan tersebut tidak akan dibalik probable that the difference will not reverse
pada masa yang akan datang. in the foreseeable future.
Pengakuan dari aset pajak tangguhan terbatas Recognition of deferred tax assets is restricted to
pada saat dimana terdapat kemungkinan besar those instances where it is probable that taxable
bahwa laba kena pajak akan tersedia terhadap profit will be available against which the
perbedaan yang dapat digunakan. difference can be utilised.
Jumlah aset atau liabilitas ditentukan dengan The amount of the asset or liability is determined
menggunakan tarif pajak yang berlaku pada akhir using tax rates that have been enacted or
periode pelaporan dan diharapkan akan digunakan substantively enacted by the end of reporting
ketika liabilitas pajak tangguhan/ aset telah period and are expected to apply when the
diselesaikan/ dipulihkan. deferred tax liabilities/ assets are settled/
recovered.
Perusahaan melakukan saling hapus aset pajak The Company Deferred tax assets and liabilities
tangguhan dan lliabilitas pajak tangguhan jika dan are offset when the Company:
hanya jika:
a. Perusahaan memiliki hak yang dapat a. The Company has a legally enforceable right
dipaksakan secara hukum untuk melakukan to offset current tax assets and liabilities;
saling hapus aset pajak kini terhadap liabilitas and
pajak kini; dan
b. Aset pajak tangguhan dan liabilitas pajak b. The deferred tax assets and Liabilities relate
tangguhan terkait dengan pajak penghasilan to taxes levied by the same tax authority on
yang dikenakan oleh otoritas pepajakan yang either:
sama atas:
i. Perusahaan kena pajak yang sama; atau i. The same taxable the Company; or
ii. Perusahaan kena pajak yang berbeda yang ii. The Company which intend either to settle
memiliki itensi untuk memulihkan current tax assets and liabilities on a net
aset dan liabilitas pajak kini dengan basis, or to realise the assets and settle
dasar neto, atau merealisasikan aset the liabilities simultaneously, in each
dan menyelesaikan liabilitas secara future period in which significant amounts
bersamaan, pada setiap periode masa of deferred tax assets or liabilities are
depan dimana jumlah signifikan atas aset expected to be settled or recovered.
atau liabilitas pajak tangguhan diharapkan
untuk diselesaikan atau dipulihkan.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 307
Page 308
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/29 Exhibit E/29
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. INFORMASI KEBIJAKAN AKUNTANSI MATERIAL 2.1. MATERIAL ACCOUNTING POLICY INFORMATIONS
(Lanjutan) (Continued)
r. Perpajakan (Lanjutan) 3. r. Taxation (Continued)
Pajak Pertambahan Nilai (PPN) Value Added Tax (VAT)
Pendapatan, beban dan aset diakui neto atas Revenue, expenses and assets are recognized net
jumlah PPN kecuali: of the amount of VAT except:
i. PPN yang muncul dari pembelian aset atau i. Where the VAT incurred on a purchase of
jasa yang tidak dapat dikreditkan, yang dalam assets or services is not recoverable, in
hal ini PPN diakui sebagai bagian dari biaya which case the VAT is recognized as part of
perolehan aset atau sebagai bagian dari item the cost of acquisition of the asset or as part
beban-beban yang terkait; dan of the expense item as applicable; and
ii. Piutang dan utang yang disajikan termasuk ii. Receivables and payables that are stated
dengan jumlah PPN. with the amount of VAT included.
Jumlah PPN neto yang diajukan untuk direstitusi, The net amount of VAT which is claimed for
atau terutang kepada, kantor pajak termasuk restitution from, or payable to, the taxation
sebagai bagian dari aset atau liabilitas pada authorities is included as part of assets or
laporan posisi keuangan konsolidasian. liabilities in the consolidated statement of
financial position.
Pajak Final Final Tax
Sesuai peraturan perpajakan di Indonesia, pajak In accordance with the tax regulation in
final dikenakan atas nilai bruto transaksi, dan tetap Indonesia, final tax is applied to the gross value
dikenakan walaupun atas transaksi tersebut pelaku of transactions, even when the parties carrying
transaksi mengalami kerugian. the transaction recognizing losses.
Pajak final tidak termasuk dalam lingkup yang Final tax is scoped out from PSAK 212: Income
diatur oleh PSAK 212: Pajak Penghasilan. Tax.
s. Modal Saham s. Share Capital
Instrumen keuangan yang diterbitkan oleh Financial instruments issued by the Company are
Perusahaan diklasifikasikan sebagai ekuitas hanya classified as equity only to the extent that they
sebatas ketika instrumen keuangan tersebut tidak do not meet the definition of a financial liability
memenuhi definisi liabilitas keuangan atau aset or financial asset.
keuangan.
Saham biasa Perusahaan diklasifikasikan sebagai The Company’s ordinary shares are classified as
instrumen ekuitas. equity instruments.
t. Pengakuan Pendapatan dan Beban t. Revenue and Expense Recognition
Pengakuan pendapatan harus memenuhi lima Revenue recognition to fulfill five steps of
langkah analisa sebagai berikut: assessment:
1. Identifikasi kontrak dengan pelanggan; 1. Identify contract(s) with a customer;
2. Identifikasi kewajiban pelaksanaan dalam 2. Identify the performance obligations in the
kontrak. Kewajiban pelaksanaan merupakan contract. Performance obligations are
janji-janji dalam kontrak untuk menyerahkan promises in a contract to transfer to a
barang atau jasa yang memiliki karakteristik customer goods or services that are distinct;
berbeda ke pelanggan;
308 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 309
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/30 Exhibit E/30
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. INFORMASI KEBIJAKAN AKUNTANSI MATERIAL 2. MATERIAL ACCOUNTING POLICY INFORMATIONS
(Lanjutan) (Continued)
t. Pengakuan Pendapatan dan Beban (Lanjutan) t. Revenue and Expenses Recognition (Continued)
Pengakuan pendapatan harus memenuhi lima Revenue recognition to fulfill five steps of
langkah analisa sebagai berikut: (Lanjutan) assessment: (Continued)
3. Penetapan harga transaksi. Harga transaksi 3. Determine the transaction price. Transaction
merupakan jumlah imbalan yang berhak price is the amount of consideration to which
diperoleh suatu entitas sebagai kompensasi an entity expects to be entitled in exchange
atas diserahkannya barang atau jasa yang for transferring promised goods or services to
dijanjikan ke pelanggan. Jika imbalan yang a customer. If the consideration promised in
dijanjikan di kontrak mengandung suatu a contract includes a variable amount, the
jumlah yang bersifat variabel, maka Grup Group estimates the amount of consideration
membuat estimasi jumlah imbalan tersebut to which it expects to be entitled in exchange
sebesar jumlah yang diharapkan berhak for transferring the promised goods or
diterima atas diserahkannya barang atau jasa services to a customer less the estimated
yang dijanjikan ke pelanggan dikurangi dengan amount of service level guarantee which will
estimasi jumlah jaminan kinerja jasa yang akan be paid during the contract period;
dibayarkan selama periode kontrak;
4. Alokasi harga transaksi ke setiap kewajiban 4. Allocate the transaction price to each
pelaksanaan dengan menggunakan dasar harga performance obligation on the basis of the
jual berdiri sendiri relatif dari setiap barang relative stand-alone selling prices of each
atau jasa berbeda yang dijanjikan di kontrak. distinct goods or services promised in the
Ketika tidak dapat diamati secara langsung, contract. Where these are not directly
harga jual berdiri sendiri relatif diperkirakan observable, the relative stand-alone selling
berdasarkan biaya yang diharapkan ditambah prices are estimated based on expected cost-
marjin; plus margin;
5. Pengakuan pendapatan ketika kewajiban 5. Recognise revenue when the performance
pelaksanaan telah dipenuhi dengan obligation is satisfied by transferring a
menyerahkan barang atau jasa yang dijanjikan promised goods or services to a customer
ke pelanggan (ketika pelanggan telah memiliki (which is when the customer obtains control
kendali atas barang atau jasa tersebut). of that goods or services).
Untuk penjualan barang, kewajiban pelaksanaan For sale of goods, performance obligation is
umumnya terpenuhi, dan pendapatan diakui, pada typically satisfied, and revenue is recognized,
saat pengendalian atas barang telah berpindah when the control of goods has been transferred
kepada pelanggan (pada suatu waktu). to the customer (a point of time).
Beban diakui pada saat terjadinya dengan Expenses are recognized when incurred
menggunakan dasar akrual. on an accrual basis.
u. Biaya Emisi Saham u. Share Issuance Cost
Biaya yang terjadi sehubungan dengan penerbitan Costs incurred in connection with the Company’s
saham Perusahaan melalui penawaran umum issuance of new share through limited public
terbatas dikurangkan langsung dengan hasil emisi offering were offset directly with the proceeds
dan disajikan sebagai pengurang akun tambahan and presented as deduction to additional paid-in
modal disetor dalam laporan posisi keuangan. capital account in the statement of financial
position.
v. Dividen v. Dividend
Pembagian dividen kepada para pemegang saham Dividend distribution to the shareholders is
diakui sebagai liabilitas dalam laporan posisi recognized as a liability in the statement of
keuangan pada tahun ketika dividen tersebut financial position in the years in which the
disetujui atau dideklarasikan oleh para pemegang dividends are approved or declared by the
saham. shareholders.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 309
Page 310
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/31 Exhibit E/31
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. INFORMASI KEBIJAKAN AKUNTANSI MATERIAL 2. MATERIAL ACCOUNTING POLICY INFORMATIONS
(Lanjutan) (Continued)
w. Laba per Saham w. Earnings per Shares
Laba per saham dihitung dengan membagi laba Earnings per share are computed by dividing the
tahun berjalan dengan rata-rata tertimbang profit for the year by the weighted average
jumlah saham yang beredar dan disetor penuh number of issued and fully paid shares during the
selama tahun yang bersangkutan. Jumlah rata-rata year. The weighted average number of shares is
saham adalah sejumlah 1.274.000.000 saham 1,274,000,000 shares as of and 31 December 2025
masing-masing pada tanggal 31 Desember 2025 dan and 2024, respectively.
2024.
Perusahaan tidak mempunyai efek berpotensi The Company does not have dilutive potential
saham biasa yang bersifat dilutif pada tanggal ordinary shares as of 31 December 2025 and 2024,
31 Desember 2025 dan 2024, oleh karenanya laba therefore diluted earnings per share are not
per saham dilusian tidak dihitung dan disajikan calculated and presented in the statements of
pada laporan laba rugi dan penghasilan profit or loss and other comprehensive income.
komprehensif lain.
x. Informasi Segmen x. Segment Information
Segmen operasi adalah suatu komponen dari An operating segment is a component of an
entitas: entity:
a. yang terlibat dalam aktivitas bisnis yang mana a. that engages in business activities from which
memperoleh pendapatan dan menimbulkan it may earn revenues and incur expenses
beban (termasuk pendapatan dan beban terkait (including revenues and expenses relating to
dengan transaksi dengan komponen lain dari transactions with other components of the
entitas yang sama); same entity);
b. hasil operasinya dikaji ulang secara reguler b. whose operating results are reviewed
oleh pengambil keputusan operasional untuk regularly by the entity’s chief operating
membuat keputusan tentang sumber daya yang decision maker to make decisions about
dialokasikan pada segmen tersebut dan menilai resources to be allocated to the segment and
kinerjanya; dan assess its performance; and
c. tersedia informasi keuangan yang dapat c. for which discrete financial information is
dipisahkan. available.
Setiap unsur segmen yang dilaporkan merupakan The amount of each segment item reported is the
ukuran yang dilaporkan kepada pengambil measure reported to the operations decision
keputusan operasional untuk tujuan maker for the purposes of making decisions about
mengalokasikan sumber daya kepada segmen dan allocating resources to the segment and assessing
menilai kinerjanya. its performance.
Perusahaan menyajikan segmen operasi The Company presents operating segment based
berdasarkan laporan internal yang disajikan on internal reports that are presented to the
kepada pengambil keputusan operasional yaitu operations decision maker which is the Board of
Direksi. Directors.
Perusahaan mengungkapkan segmen The Company discloses its operating segments
operasionalnya berdasarkan segmen usaha yang based on business segments that consist of
meliputi obat resep, obat non-resep dan alat prescription medicine, non-prescription
kesehatan. medicine and medical devices.
Segmen geografis meliputi penyediaan barang di A geographical segment is engaged in providing
dalam lingkungan ekonomi tertentu yang memiliki products within a particular economic
risiko serta tingkat pengembalian yang berbeda environment that is subject to risks and returns
dengan segmen operasi lainnya yang berada dalam that are different from those of segments
lingkungan ekonomi lain. Segmen geografis operating in other economic environments. The
Perusahaan meliputi area Jawa, Sumatera, Company’s geographical segments cover Java,
Kalimantan, Sulawesi dan Bali. Sumatera, Kalimantan, Sulawesi and Bali.
310 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 311
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/32 Exhibit E/32
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. INFORMASI KEBIJAKAN AKUNTANSI MATERIAL 2. MATERIAL ACCOUNTING POLICY INFORMATIONS
(Lanjutan) (Continued)
y. Kontinjensi y. Contingencies
Liabilitas kontinjensi tidak diakui dalam laporan Contingent liabilities are not recognized in the
keuangan tetapi diungkapkan dalam catatan atas financial statements but are disclosed in the
laporan keuangan kecuali jika kemungkinan arus notes to the financial statements unless the
keluar sumber daya yang mewujudkan manfaat possibility of an outflow of resources embodying
ekonomi sangat kecil. Aset kontinjensi tidak diakui economic benefits is remote. Contingent assets
dalam laporan keuangan tetapi diungkapkan dalam are not recognized in the financial statements
catatan atas laporan keuangan ketika arus masuk but are disclosed in the notes to the financial
manfaat ekonomi memungkinkan. statements when an inflow of economic benefits
is probable.
z. Peristiwa Setelah Periode Pelaporan z. Events After the Reporting Date
Peristiwa setelah periode pelaporan menyajikan Events after the reporting date that provide
bukti kondisi yang terjadi pada akhir periode evidence of conditions that existed at the end of
pelaporan (peristiwa penyesuaian) yang the reporting period (adjusting events) are
dicerminkan di dalam laporan keuangan. reflected in the financial statements.
Peristiwa setelah periode pelaporan yang bukan Events after the reporting date that are not
merupakan peristiwa penyesuaian, diungkapkan di adjusting events are disclosed in the notes to
dalam catatan laporan keuangan bila material. financial statements when material.
3. PERTIMBANGAN, ESTIMASI DAN ASUMSI AKUNTANSI 3. CRITICAL ACCOUNTING JUDGEMENTS, ESTIMATES
YANG SIGNIFIKAN AND ASSUMPTIONS
Penyusunan laporan keuangan Grup mengharuskan The preparation of the Group’s financial statements
manajemen untuk membuat pertimbangan, estimasi requires management to make judgments, estimates
dan asumsi yang mempengaruhi jumlah yang dilaporkan and assumptions that affect the reported amounts of
dari pendapatan, beban, aset dan liabilitas, dan revenues, expenses, assets and liabilities, and the
pengungkapan atas liabilitas kontinjensi, pada akhir disclosure of contingent liabilities, at the end of the
tahun pelaporan. Ketidakpastian mengenai asumsi dan reporting year. Uncertainty about these assumptions
estimasi tersebut dapat mengakibatkan penyesuaian and estimates could result in outcomes that require a
material terhadap nilai tercatat aset dan liabilitas material adjustment to the carrying amount of the
dalam tahun pelaporan berikutnya. asset and liability affected in future years.
Pertimbangan Judgments
Pertimbangan berikut ini dibuat oleh manajemen dalam The following judgments are made by management in
rangka penerapan kebijakan akuntansi Grup yang the process of applying the Group’s accounting
memiliki pengaruh paling signifikan atas jumlah yang policies that have the most significant effects on the
diakui dalam laporan keuangan Grup: amounts recognized in the Group’s financial
statements:
Klasifikasi instrumen keuangan Classification of financial instruments
Perusahaan menetapkan klasifikasi atas aset dan The Group determines the classifications of certain
liabilitas tertentu sebagai aset keuangan dan liabilitas assets and liabilities as financial assets and
keuangan dengan mempertimbangkan bila definisi yang financial liabilities by judging if they meet the
ditetapkan PSAK 109 dipenuhi. Dengan demikian, aset definition set forth in PSAK 109. Accordingly, the
keuangan dan liabilitas keuangan diakui sesuai dengan financial assets and financial liabilities are
kebijakan akuntansi Grup seperti diungkapkan pada accounted for in accordance with the Group’s
Catatan 2g dan 2h. accounting policies disclosed in Notes 2g and 2h.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 311
Page 312
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/33 Exhibit E/33
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
3. PERTIMBANGAN, ESTIMASI DAN ASUMSI AKUNTANSI 3. CRITICAL ACCOUNTING JUDGEMENTS, ESTIMATES
YANG SIGNIFIKAN (Lanjutan) AND ASSUMPTIONS (Continued)
Pertimbangan (Lanjutan) Judgments (Continued)
Investasi pada entitas anak Investment in subsidiaries
Grup menetapkan bahwa Grup memiliki kendali atas The Group determined that it has control over its
entitas anaknya (Catatan 1d) dengan subsidiaries (Note 1d) by considering, among others,
mempertimbangkan, antara lain, kekuasaan atas its power over the investee, exposure or rights to
investee, eksposur, atau hak atas imbal hasil variabel variable returns from its involvement with the
dari keterlibatannya dengan investee, dan kemampuan investee, and the ability to use its power over the
untuk menggunakan kekuasaannya atas investee yang investee to affect its returns. The following were also
mempengaruhi jumlah imbal hasil. Hal-hal considered:
pertimbangan:
- Pengaturan kontraktual dengan pemilik hak suara - The contractual arrangement with the other vote
lainnya dari investee, holders of the investee,
- Hak yang timbul atas pengaturan kontraktual lain, - Rights arising from other contractual
dan arrangements, and
- Hak suara dan hak suara potensial yang dimiliki - The Group’s voting rights and potential voting
Grup. rights.
Penentuan mata uang fungsional Determination of functional currency
Mata uang fungsional adalah mata uang dari lingkungan The functional currency is the currency of the primary
ekonomi primer dimana entitas beroperasi. Mata uang economic environment in which entity operates. It is
tersebut adalah mata uang yang mempengaruhi the currency that mainly influences the revenue and
pendapatan dan beban dari jasa yang diberikan. cost of rendering services. Based on the economic
Berdasarkan substansi ekonomi dari kondisi mendasari substance of the relevant underlying circumstances,
yang relevan, mata uang fungsional dan penyajian Grup the functional and presentation currency of the
adalah Rupiah Indonesia. Group’s is the Indonesian Rupiah.
Estimasi dan Asumsi Estimates and Assumptions
Asumsi utama masa depan dan sumber utama estimasi The key assumptions concerning the future and other
ketidakpastian lain pada tanggal pelaporan yang key sources of estimation uncertainty at the reporting
memiliki risiko signifikan bagi penyesuaian yang date that have a significant risk of causing a material
material terhadap nilai tercatat aset dan liabilitas adjustment to the carrying amounts of assets and
untuk tahun berikutnya, diungkapkan di bawah ini. liabilities within the next financial years are
Perusahaan menyusun asumsi dan estimasi pada disclosed below. The Company bases its assumptions
parameter yang tersedia pada saat laporan keuangan and estimates on parameters available when the
Grup disusun. Asumsi dan situasi mengenai Group’s financial statements were prepared. Existing
perkembangan masa depan, mungkin berubah akibat circumstances and assumptions about future
perubahan pasar atau situasi di luar kendali Grup. developments may change due to market changes or
Perubahan tersebut dicerminkan dalam asumsi terkait circumstances arising beyond the control of the
pada saat terjadinya. Group’s. Such changes are reflected in the
assumptions when they occur.
Cadangan kerugian penurunan nilai piutang usaha Allowance for impairment losses on trade receivables
Grup menggunakan matriks provisi untuk menghitung The Group’s uses a provision matrix to calculate
kerugian kredit ekspektasian piutang usaha. Tingkat expected credit losses (“ECL”) for trade receivables.
provisi adalah berdasarkan hari jatuh tempo atas The provision rates are based on days past due for
kelompok segmen pelanggan yang mempunyai Companyings of various customer segments that have
karakteristik risiko kredit yang serupa (misalnya similar credit risk characteristics (e.g., by geography,
berdasarkan geografi, tipe produk, tipe dan/atau product type, customer type and/or rating, coverage
peringkat pelanggan, nilai pertanggungan dari letter of by letters of credit and others).
credit dan lain-lain).
312 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 313
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/34 Exhibit E/34
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
3. PERTIMBANGAN, ESTIMASI DAN ASUMSI AKUNTANSI 3. CRITICAL ACCOUNTING JUDGEMENTS, ESTIMATES
YANG SIGNIFIKAN (Lanjutan) AND ASSUMPTIONS (Continued)
Estimasi dan Asumsi (Lanjutan) Estimates and Assumptions (Continued)
Matriks provisi pada mulanya didasarkan pada tingkat The provision matrix is initially based on the
gagal bayar historis Perusahaan yang diobservasi. Grup Company’s historical observed default rates. The
akan memperbaharui matriks untuk menyesuaikan Group’s will calibrate the matrix to adjust the
pengalaman kerugian kredit historis dengan informasi historical credit loss experience with forward-looking
forward-looking. Sebagai contoh, jika perkiraan atas information. For instance, if forecast economic
kondisi ekonomi diperkirakan memburuk pada tahun conditions are expected to deteriorate over the next
depan, yang dapat menyebabkan meningkatnya jumlah year, which can lead to an increased number of
gagal bayar, tingkat gagal bayar historis disesuaikan. defaults, the historical default rates are adjusted.
Cadangan kerugian penurunan nilai piutang usaha Allowance for impairment losses on trade receivables
Pada setiap tanggal pelaporan, tingkat gagal bayar At each of reporting date, the historical observed
historis diperbaharui dan perubahan estimasi forward- default rates are updated and changes in the forward-
looking dianalisis. Penilaian atas korelasi antara tingkat looking estimates are analysed. The assessment of the
gagal bayar historis yang diobservasi, perkiraan atas correlation between historical observed default
kondisi ekonomi dan kerugian kredit ekspektasian rates, and forecast economic conditions and ECLs is a
merupakan estimasi yang signifikan. Jumlah kerugian significant estimate. The amount of ECLs is sensitive
kredit ekspektasian dapat dipengaruhi oleh perubahan to changes in circumstances and of forecast economic
keadaan dan perkiraan kondisi ekonomi. Pengalaman conditions. The Group’s historical credit loss
kerugian kredit historis Grup dan perkiraan kondisi experience and forecast of economic conditions may
ekonomi juga mungkin tidak menggambarkan gagal also not be representative of a customer’s actual
bayar aktual pelanggan di masa yang akan datang. default in the future.
Cadangan Kerugian Penurunan Nilai Persediaan Allowance for Impairment Losses on Inventories
Cadangan kerugian penurunan nilai persediaan Allowance for impairment losses on inventories is
diestimasi berdasarkan fakta dan keadaan yang estimated based on the best available facts and
tersedia, termasuk namun tidak terbatas kepada, circumstances, including but not limited to, the
kondisi fisik persediaan yang dimiliki, harga jual pasar inventories’ own physical conditions, their market
dan estimasi biaya yang timbul untuk penjualan. selling prices and their estimated costs to sell. The
Penyisihan dievaluasi kembali dan disesuaikan jika provisions are re-evaluated and adjusted as
terdapat tambahan informasi yang mempengaruhi additional information received affects the amount
jumlah yang diestimasi. estimated.
Estimasi umur manfaat ekonomis aset tetap Estimated useful life of property and equipment
Grup mengestimasi umur manfaat ekonomis dari aset The Group estimates the useful lives of its property
tetap berdasarkan utilisasi dari aset yang dapat and equipment based on expected asset utilization as
dimanfaatkan untuk mendukung rencana dan strategi anchored on business plans and strategies that also
usaha yang juga mempertimbangkan perkembangan consider expected future technological developments
teknologi di masa depan dan perilaku pasar. Estimasi and market behavior. The estimation of the useful
dari umur manfaat ekonomis aset tetap adalah live of property and equipment is based on the
berdasarkan penelaahan Grup secara kolektif terhadap Group’s collective assessment on industry practice,
praktek industri, evaluasi teknis internal dan internal technical evaluation and experience with
pengalaman untuk aset yang setara. similar assets.
Estimasi umur manfaat ekonomis aset tetap ditelaah The estimated useful lives of its property and
paling sedikit setiap akhir tahun pelaporan dan equipment are reviewed at least each of end financial
diperbarui jika ekspektasi berbeda dari estimasi reporting and are updated if expectations differ from
sebelumnya dikarenakan pemakaian dan kerusakan previous estimates due to physical wear and tear,
fisik, keusangan secara teknis atau komersial dan technical or commercial obsolescence and legal or
hukum atau pembatasan lain atas penggunaan dari aset other limitations on the use of the assets.
tersebut.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 313
Page 314
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/35 Exhibit E/35
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
3. PERTIMBANGAN, ESTIMASI DAN ASUMSI AKUNTANSI 3. CRITICAL ACCOUNTING JUDGEMENTS, ESTIMATES
YANG SIGNIFIKAN (Lanjutan) AND ASSUMPTIONS (Continued)
Estimasi dan Asumsi (Lanjutan) Estimates and Assumptions (Continued)
Estimasi umur manfaat ekonomis aset tetap (Lanjutan) Estimated useful life of property and equipment
(Continued)
Tetapi adalah mungkin, hasil di masa depan dari operasi It is possible, however, that future results of
dapat dipengaruhi secara material oleh perubahan- operations can be materially affected by changes in
perubahan dalam estimasi yang diakibatkan oleh the estimates brought about by changes in the factors
perubahan faktor-faktor yang disebutkan di atas. mentioned above. The amounts and timing of
Jumlah dan waktu dari beban yang dicatat untuk setiap recorded expenses for any period are affected
tahun akan terpengaruh oleh perubahan atas faktor- by changes in these factors and circumstances.
faktor dan situasi tersebut. Pengurangan dalam A reduction in the estimated useful lives of the
estimasi umur manfaat ekonomis dari aset tetap Group Group’s property and equipment will increase the
akan meningkatkan beban umum dan administrasi dan recorded of general and administrative expenses and
menurunkan nilai buku neto aset tetap yang dicatat. decrease net book value of respective property and
equipment.
Liabilitas imbalan kerja Employee benefits liability
Penentuan liabilitas imbalan kerja Grup bergantung The determination of the Group’s employee benefits
pada pemilihan asumsi yang digunakan oleh aktuaris liability is dependent on its selection of certain
independen dalam menghitung jumlah-jumlah assumptions used by the independent actuary in
tersebut. calculating such amounts.
Asumsi tersebut termasuk antara lain, tingkat diskonto, Those assumptions include discount rates, future
tingkat kenaikan gaji tahunan, tingkat pengunduran diri annual salary increase, annual employee turn-over
karyawan tahunan, tingkat kecacatan, umur pensiun rate, disability rate, retirement ages and mortality
dan tingkat kematian. Seperti dijelaskan pada Catatan rate. As disclosed in Note 2p, actual results that differ
2p, hasil aktual yang berbeda dari asumsi Grup diakui from the Group’s assumptions are recognized as other
sebagai penghasilan komprehensif lain. Dikarenakan comprehensive income. Due to the complexity of the
kompleksitas dari penilaian, asumsi dan periode jangka valuation, the underlying assumptions and their long-
panjang, kewajiban imbalan pasti sangat sensitif term nature, a defined benefit obligation is highly
terhadap perubahan asumsi. sensitive to changes in assumptions.
Grup berkeyakinan bahwa asumsi yang ditetapkan While the Group’s believes that its assumptions are
adalah memadai dan tepat, perbedaan signifikan dalam reasonable and appropriate, significant differences in
pengalaman aktual Grup atau perubahan signifikan the Group’s actual experiences or significant changes
dalam asumsi dapat mempengaruhi secara material in its assumptions may materially affect its
beban dan liabilitas imbalan kerja. Semua asumsi employee benefits liability and expense. All
ditelaah pada setiap tanggal pelaporan. assumptions are reviewed at each reporting date.
Pajak Penghasilan Income Tax
Estimasi signifikan dilakukan dalam menentukan provisi Significant estimate is involved in determining the
atas pajak penghasilan badan. Terdapat transaksi dan provision for corporate income tax. There are certain
perhitungan tertentu yang penentuan pajak akhirnya transactions and computation for which the ultimate
adalah tidak pasti dalam kegiatan usaha bisnis yang tax determination is uncertain during the ordinary
normal. course of business.
Grup mengakui liabilitas atas pajak penghasilan badan The Group’s recognizes liabilities for expected
berdasarkan estimasi apakah akan terdapat tambahan corporate income tax issues based on estimates of
pajak penghasilan badan. Apabila keputusan final atas whether additional corporate income tax will be due.
pajak tersebut berbeda dari jumlah yang pada awalnya Where the final tax outcome of those matters is
dicatat, perbedaan tersebut akan dicatat pada laporan different from the amounts that were initially
laba rugi dan penghasilan komprehensif lain pada tahun recorded, such differences will be recorded at the
dimana ketetapan pajak tersebut dikeluarkan. statement of profit or loss and other comprehensive
income in the year in which such final tax assessment
is made.
314 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 315
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/36 Exhibit E/36
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
3. PERTIMBANGAN, ESTIMASI DAN ASUMSI AKUNTANSI 3. CRITICAL ACCOUNTING JUDGEMENTS, ESTIMATES
YANG SIGNIFIKAN (Lanjutan) AND ASSUMPTIONS (Continued)
Estimasi dan Asumsi (Lanjutan) Estimates and Assumptions (Continued)
Aset pajak tangguhan Deferred Tax Assets
Aset pajak tangguhan diakui atas seluruh perbedaan Deferred tax assets are recognized for all deductible
temporer yang dapat dikurangkan, sepanjang besar temporary differences, to the extent that it is
kemungkinannya bahwa penghasilan kena pajak akan probable that taxable profit will be available against
tersedia sehingga perbedaan temporer tersebut dapat which the deductible temporary differences.
digunakan. Estimasi signifikan oleh manajemen Significant management estimates are required to
disyaratkan dalam menentukan jumlah aset pajak determine the amount of deferred tax assets that can
tangguhan yang dapat diakui, berdasarkan saat be recognized, based upon the likely timing and the
penggunaan dan tingkat penghasilan kena pajak serta level of the future taxable profits together with
strategi perencanaan pajak masa depan. future tax planning strategies.
4. KAS DAN BANK 4. CASH AND BANKS
2025 2024
Kas 236.102.897 228.575.234 Cash on hand
Bank Cash in banks
Rupiah Rupiah
PT Bank CIMB Niaga Tbk 23.605.248.747 24.720.360.069 PT Bank CIMB Niaga Tbk
PT Bank Central Asia Tbk 20.276.764.414 14.900.732.125 PT Bank Central Asia Tbk
PT Bank Pembangunan Daerah Jambi 6.615.923.814 590.375.662 PT Bank Pembangunan Daerah Jambi
PT Bank Pembangunan Daerah Papua 3.278.217.174 492.297.164 PT Bank Pembangunan Daerah Papua
PT Bank Pembangunan Daerah PT Bank Pembangunan Daerah
Jawa Timur Tbk 2.179.074.017 37.387.538 Jawa Timur Tbk
PT Bank Nagari (d/h PT Bank PT Bank Nagari (formerly PT Bank
Pembangunan Daerah Sumatera Pembangunan Daerah Sumatera
Barat) 1.327.069.341 709.593.613 Barat)
PT Bank Negara Indonesia (Persero)
Tbk 1.068.920.116 2.105.583.441 PT Bank Negara Indonesia (Persero) Tbk
PT Bank Mandiri (Persero) Tbk 892.237.023 417.751.681 PT Bank Mandiri (Persero) Tbk
PT Bank UOB Indonesia 786.719.368 2.016.400.849 PT Bank UOB Indonesia
PT Bank Pembangunan Daerah PT Bank Pembangunan Daerah
Jawa Tengah 571.086.160 353.287.718 Jawa Tengah
PT Bank Pembangunan Daerah PT Bank Pembangunan Daerah Sulawesi
Sulawesi Selatan dan Sulawesi Barat 472.556.845 178.455.864 Selatan dan Sulawesi Barat
PT Bank Sulawesi Utara dan Gorontalo PT Bank Sulawesi Utara dan Gorontalo
(d/h PT Bank Pembangunan Daerah (formerly PT Bank Pembangunan Daerah
Sulawesi Utara) 454.876.542 357.620.014 Sulawesi Utara)
PT Bank NTB Syariah 428.983.685 44.668.058 PT Bank NTB Syariah
PT Bank Pembangunan Daerah Jawa PT Bank Pembangunan Daerah Jawa
Barat dan Banten Tbk 296.615.539 366.068.978 Barat dan Banten Tbk
PT Bank Rakyat Indonesia (Persero) PT Bank Rakyat Indonesia (Persero) Tbk
Tbk 233.903.027 5.334.045.272
PT Bank Syariah Indonesia Tbk 67.485.922 580.874.501 PT Bank Syariah Indonesia Tbk
PT Bank Pembangunan Daerah Sleman 1.546.285 1.672.270 PT Bank Pembangunan Daerah Sleman
PT Bank OCBC NISP Tbk 1.403.534 8.767.783 PT Bank OCBC NISP Tbk
PT Bank Mega Tbk 1.166.270 1.247.696 PT Bank Mega Tbk
Dolar Amerika Serikat United States Dollar
PT Bank CIMB Niaga Tbk 26.721.475 26.934.943 PT Bank CIMB Niaga Tbk
PT Bank UOB Indonesia 20.107.521 220.450 PT Bank UOB Indonesia
62.606.626.819 53.244.345.689
Jumlah 62.842.729.716 53.472.920.923 Total
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 315
Page 316
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/37 Exhibit E/37
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
4. KAS DAN BANK (Lanjutan) 4. CASH AND BANKS (Continued)
Semua rekening bank ditempatkan pada bank pihak All cash in banks are placed with third party banks.
ketiga.
Pada tanggal 31 Desember 2025 dan 2024, tidak As of 31 December 2025 and 2024, there is no cash and
terdapat saldo kas dan bank yang dijaminkan atau banks which are pledged for collateral and restricted
dibatasi penggunaannya. in use.
5. PIUTANG USAHA 5. TRADE RECEIVABLES
Piutang usaha berdasarkan jenis pelanggan adalah: Details of trade receivable by customers type are as
follows:
2025 2024
Pihak ketiga Third parties
Rumah Sakit 568.672.176.821 511.157.002.193 Hospital
Apotik 189.431.217.310 162.447.314.285 Pharmacy
Supermarket 15.465.244.207 27.095.061.032 Supermarket
Lain-lain 64.921.789.366 54.707.879.660 Others
838.490.427.704 755.407.257.170
Dikurangi: Penyisihan kerugian Less: Allowance
penurunan nilai ( 26.488.926.436 ) ( 23.467.434.136 ) for impairment losses
Jumlah 812.001.501.268 731.939.823.034 Total
Piutang usaha berdasarkan geografis adalah: Details of trade receivable by geographical are as
follows:
2025 2024
Jawa 427.707.107.249 383.171.221.494 Jawa
Sumatera 220.669.754.522 191.196.609.772 Sumatera
Kalimantan 71.900.801.759 64.170.696.909 Kalimantan
Sulawesi 69.275.914.262 66.843.812.177 Sulawesi
Bali 29.572.737.660 28.220.139.144 Bali
Lombok 19.364.112.252 21.804.777.674 Lombok
838.490.427.704 755.407.257.170
Dikurangi: Penyisihan kerugian Less: Allowance
penurunan nilai ( 26.488.926.436 ) ( 23.467.434.136 ) for impairment losses
Jumlah 812.001.501.268 731.939.823.034 Total
Jumlah piutang usaha berdasarkan umur (hari) adalah Total trade receivables by age (days) are as follows:
sebagai berikut:
2025 2024
Belum jatuh tempo 619.014.825.458 561.126.367.894 Not yet due
Sudah jatuh tempo: Over due:
1 – 30 hari 86.160.643.851 66.948.032.648 1 – 30 days
31 – 60 hari 38.167.183.575 35.758.144.010 31 – 60 days
61 – 90 hari 19.688.703.699 20.180.093.805 61 – 90 days
91 – 120 hari 14.337.321.560 12.795.692.173 91 – 120 days
Lewat 120 hari 61.121.749.561 58.598.926.640 More than 120 days
( (
838.490.427.704 755.407.257.170
Dikurangi: Penyisihan kerugian Less: Allowance
penurunan nilai ( 26.488.926.436 ) ( 23.467.434.136 ) for impairment losses
Jumlah 812.001.501.268 731.939.823.034 Total
316 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 317
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/38 Exhibit E/38
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
5. PIUTANG USAHA (Lanjutan) 5. TRADE RECEIVABLES (Continued)
Mutasi saldo penyisihan atas penurunan nilai selama The movements of allowance for impairment loss
tahun berjalan adalah sebagai berikut: during the year are as follows:
2025 2024
Saldo awal 23.467.434.136 23.732.219.428 Beginning balance
Penambahan cadangan selama Additional during of allowance
tahun berjalan (Catatan 23) 3.021.492.300 5.000.000.000 the year (Note 23)
Penghapusan selama tahun
berjalan - ( 5.264.785.292 ) Write-off during the year
Saldo akhir 26.488.926.436 23.467.434.136 Ending balance
Grup telah menerapkan metode yang disederhanakan The Group applies the simplified approach to provide
untuk menghitung kerugian kredit ekspektasian sesuai for expected credit losses as prescribed by
dengan PSAK 109 yang mengizinkan penggunaan PSAK 109, which permits the use of the lifetime
cadangan kerugian ekspektasian seumur hidup untuk expected loss allowance for all trade receivables. To
seluruh piutang usaha. Untuk mengukur kerugian measure the expected credit losses, trade receivables
kredit ekspektasian, piutang usaha telah have been categorized based on shared credit risk
dikelompokkan berdasarkan karakteristik risiko kredit characteristics and the days past due.
dan waktu jatuh tempo yang serupa.
Seluruh piutang usaha Grup dalam mata uang Rupiah All of the Group’s trade receivables are denominated
Indonesia. in Indonesian Rupiah currency.
Pada tanggal 31 Desember 2025 dan 2024, tidak As of 31 December 2025 and 2024, there are no trade
terdapat piutang usaha yang dijaminkan. receivables pledged as collateral.
Manajemen berkeyakinan bahwa cadangan kerugian Management believes that allowance for impairment
penurunan nilai piutang usaha adalah cukup untuk losses on trade receivables is adequate to cover
menutupi kemungkinan kerugian atas tidak possible losses that may arise from uncollected trade
tertagihnya piutang usaha. Manajemen juga receivables. Management believes that there are no
berkeyakinan bahwa tidak terdapat risiko yang significant concentrations of risk on trade receivables.
terkonsentrasi secara signifikan atas piutang usaha.
6. PERSEDIAAN 6. INVENTORIES
2025 2024
Obat resep 423.338.835.004 394.288.671.014 Prescription medicines
Alat kesehatan 159.779.848.116 146.139.359.562 Medical equipment
Obat non-resep 30.483.992.482 32.408.573.062 Non - prescription medicines
Lain-lain 33.436.500 60.113.000 Others
613.636.112.102 572.896.716.638
Dikurangi: Penyisihan kerugian Less: Allowance
penurunan nilai ( 4.543.804.619 ) ( 5.164.331.520 ) for impairment losses
Jumlah 609.092.307.483 567.732.385.118 Total
Mutasi cadangan kerugian penurunan nilai persediaan The movements in the allowance for impairment loss
adalah sebagai berikut: on inventories are as follows:
2025 2024
Saldo awal 5.164.331.520 3.643.482.852 Beginning balance
Penambahan cadangan selama Additional during of allowance
tahun berjalan (Catatan 23) 3.400.000.000 4.905.141.665 the year (Note 23)
Penghapusan selama tahun
berjalan ( 4.020.526.901 ) ( 3.384.292.997 ) Write-off during the year
Saldo akhir 4.543.804.619 5.164.331.520 Ending balance
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 317
Page 318
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/39 Exhibit E/39
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
6. PERSEDIAAN (Lanjutan) 6. INVENTORIES (Continued)
Jumlah persediaan yang dibebankan sebagai The inventories charged to cost of good sold for the
pokok penjualan masing-masing untuk tahun yang years ended 31 December 2025 and 2024 are amounted
berkahir 31 Desember 2025 dan 2024 adalah sebesar to Rp 3,747,451,408,783 and Rp 3,582,486,836,953,
Rp 3.747.451.408.783 dan Rp 3.582.486.836.953 respectively (Note 21).
(Catatan 21).
Pada tanggal 31 Desember 2025 dan 2024 persediaan As of 31 December 2025 and 2024, inventories are
diasuransikan terhadap risiko kebakaran, pencurian insured against fire, theft and other possible risks by
dan risiko lainnya pada pihak ketiga, dengan a third party, with a total insured coverage of
nilai pertanggungan masing-masing sebesar Rp 701,124,154,646 and Rp 728,276,713,878.
Rp 701.124.154.646 dan Rp 728.276.713.878.
Manajemen berkeyakinan bahwa nilai pertanggungan Management believes that the insurance coverage is
tersebut adalah memadai untuk menutup kemungkinan adequate to cover possible losses on the insured
kerugian persediaan yang diasuransikan. inventories.
Persediaan tidak digunakan sebagai jaminan atas Inventories are not used as collateral by the Company.
pinjaman bank yang diperoleh Perusahaan.
Berdasarkan hasil penelaahan terhadap nilai realisasi Based on the review result of physical condition and
neto dan kondisi fisik dari persediaan pada tanggal net realizable of inventories at the reporting date,
pelaporan, manajemen berkeyakinan bahwa cadangan management believes that allowance for impairment
kerugian penurunan nilai persediaan adalah cukup losses on inventories is adequate to cover any possible
untuk menutupi kemungkinan kerugian penurunan nilai impairment losses that may arise.
yang mungkin timbul.
7. PENYERTAAN DALAM BENTUK SAHAM 7. INVESTMENT IN SHARES OF STOCK
Akun ini merupakan penyertaan dalam bentuk saham This account represents an investment in shares of
pada PT Errita Pharma (“Errita”) dengan persentase stock of PT Errita Pharma (“Errita”) with an ownership
kepemilikan sebesar 15% dengan harga perolehan percentage of 15% and an acquisition cost of
sebesar Rp 54.000.000.000. Rp 54,000,000,000.
Pembelian saham Errita tersebut di atas sesuai dengan The acquisition of Errita’s shares is in compliance with
rencana penggunaan dana atas hasil Penawaran Umum the use of proceeds plan under Limited Public Offering
Terbatas III Perusahaan yang telah disetujui oleh Rapat III as resolved by the Company's Extraordinary General
Umum Pemegang Saham Luar Biasa Perusahaan tanggal Meeting of Shareholders dated 11 September 2017, as
11 September 2017, yang dinyatakan dalam Akta covered by Notarial Deed No. 52 of Dr. Irawan
Notaris Dr. Irawan Soerodjo, S.H., M.Si. No. 52 pada Soerodjo, S.H., M.Si. on the same date.
tanggal yang sama.
Sesuai ketentuan PSAK 109, Perusahaan In accordance with provision of PSAK 109, the
mengklasifikasikan penyertaan dalam bentuk saham Company classified the investment in shares of stock
tersebut sebagai aset keuangan yang diukur pada nilai as financial asset measured at fair value through other
wajar melalui penghasilan komprehensif lain. comprehensive income.
2025 2024
Biaya perolehan 54.000.000.000 54.000.000.000 Acquisition cost
Perubahan pada nilai wajar melalui Change in fair value through
penghasilan komprehensif lain ( 35.414.000.000 ) ( 31.492.000.000 ) other comprehensive income
Nilai tercatat 18.586.000.000 22.508.000.000 Carrying amount
318 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 319
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/40 Exhibit E/40
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
7. PENYERTAAN DALAM BENTUK SAHAM (Lanjutan) 7. INVESTMENT IN SHARES OF STOCK (Continued)
Mutasi perubahan nilai wajar melalui penghasilan The movements change in fair value through other
komprehensif lain adalah sebagai berikut: comprehensive income are as follows:
2025 2024
Saldo awal 31.492.000.000 20.700.000.000 Beginning balance
Perubahan nilai wajar Change in fair value in
pada tahun berjalan 3.922.000.000 10.792.000.000 current year
Saldo akhir 35.414.000.000 31.492.000.000 Ending balance
Investasi dalam bentuk saham ini diukur pada nilai Investments in shares are measured at fair value
wajar melalui penghasilan komprehensif lain karena through other comprehensive income because these
investasi ini merupakan efek yang tidak investments are non-traded securities. As of
diperdagangkan. Pada tanggal 31 Desember 2025 dan 31 December 2025 and 2024, the Company assessed
2024 Perusahaan menilai nilai wajar investasi di Errita the fair value of its investment in Errita using
dengan menggunakan arus kas yang didiskontokan discounted cash flows using market interest rates and
dengan menggunakan suku bunga pasar dan premi a specific risk premium for non-traded securities.
risiko yang spesfifik atas efek yang tidak
diperdagangkan.
8. ASET TETAP 8. PROPERTY AND EQUIPMENT
Saldo awal/ Penambahan/ Pengurangan/ Reklasifikasi/ Saldo akhir/
31 Desember 2025 Beginning balance Additions Disposals Reclassifications Ending balance 31 December 2025
Biaya perolehan Acquisition cost
Pemilikan langsung Direct ownership
Hak atas tanah 47.966.800.002 - - - 47.966.800.002 Landrights
Bangunan 3.886.574.828 262.432.000 - 8.775.000.000 12.924.006.828 Buildings
Renovasi bangunan 6.628.314.362 138.190.000 - - 6.766.504.362 Buildings renovation
Perbaikan sewa 21.454.773.995 315.065.134 ( 7.571.300) 3.209.949.780 24.972.217.609 Leasehold improvements
Kendaraan 12.446.718.333 929.485.616 ( 1.279.000.033) - 12.097.203.916 Vehicles
Peralatan kantor 27.773.722.539 2.226.882.053 ( 1.656.905.678) - 28.343.698.914 Office equipment
Peralatan teknik 7.015.805.562 1.471.791.155 ( 411.915.466) - 8.075.681.251 Technical equipment
Aset dalam penyelesaian Contruction in progress
Bangunan 12.393.287.499 32.416.271.030 - ( 11.984.949.780) 32.824.608.749 Buildings
Jumlah 139.565.997.120 37.760.116.988 ( 3.355.392.477) - 173.970.721.631 Total
Akumulasi penyusutan Accumulated depreciation
Pemilikan langsung Direct ownership
Bangunan 734.689.687 847.969.520 - - 1.582.659.207 Buildings
Renovasi bangunan 4.089.986.996 1.309.430.908 - - 5.399.417.904 Buildings renovation
Perbaikan sewa 15.447.892.376 4.060.670.775 ( 1.892.825) - 19.506.670.326 Leasehold improvements
Kendaraan 11.645.983.107 565.159.695 ( 1.278.962.275) - 10.932.180.527 Vehicles
Peralatan kantor 22.520.639.643 1.831.131.210 ( 1.645.368.047) - 22.706.402.806 Office equipment
Peralatan teknik 4.261.213.073 900.530.221 ( 403.106.778) - 4.758.636.516 Technical equipment
Jumlah 58.700.404.882 9.514.892.329 ( 3.329.329.925) - 64.885.967.286 Total
Jumlah Tercatat 80.865.592.238 109.084.754.345 Carrying Amount
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 319
Page 320
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/41 Exhibit E/41
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
8. ASET TETAP (Lanjutan) 8. PROPERTY AND EQUIPMENT (Continued)
Saldo awal/ Penambahan/ Pengurangan/ Reklasifikasi/ Saldo akhir/
31 Desember 2024 Beginning balance Additions Disposals Reclassifications Ending balance 31 December 2024
Biaya perolehan Acquisition cost
Pemilikan langsung Direct ownership
Hak atas tanah 47.966.800.002 - - - 47.966.800.002 Landrights
Bangunan 3.886.574.828 - - - 3.886.574.828 Buildings
Renovasi bangunan 2.391.114.582 672.169.025 - 3.565.030.755 6.628.314.362 Buildings renovation
Perbaikan sewa 16.090.069.022 2.557.625.518 - 2.807.079.455 21.454.773.995 Leasehold improvements
Kendaraan 12.496.212.797 513.355.536 ( 562.850.000) - 12.446.718.333 Vehicles
Peralatan kantor 27.530.605.966 1.848.211.099 ( 1.605.094.526) - 27.773.722.539 Office equipment
Peralatan teknik 5.655.363.531 1.477.636.545 ( 260.775.314) 143.580.800 7.015.805.562 Technical equipment
Aset dalam penyelesaian Contruction in progress
Bangunan 11.819.408.959 7.089.569.550 - ( 6.515.691.010) 12.393.287.499 Buildings
Jumlah 127.836.149.687 14.158.567.273 ( 2.428.719.840) - 139.565.997.120 Total
Akumulasi penyusutan Accumulated depreciation
Pemilikan langsung Direct ownership
Bangunan - 734.689.687 - - 734.689.687 Buildings
Renovasi bangunan 1.672.903.075 2.417.083.921 - - 4.089.986.996 Buildings renovation
Perbaikan sewa 11.023.310.791 4.424.581.585 - - 15.447.892.376 Leasehold improvements
Kendaraan 11.858.173.267 350.659.840 ( 562.850.000) - 11.645.983.107 Vehicles
Peralatan kantor 22.288.691.182 1.837.042.987 ( 1.605.094.526) - 22.520.639.643 Office equipment
Peralatan teknik 3.745.116.128 776.872.259 ( 260.775.314) - 4.261.213.073 Technical equipment
Jumlah 50.588.194.443 10.540.930.279 ( 2.428.719.840) - 58.700.404.882 Total
Jumlah Tercatat 77.247.955.244 80.865.592.238 Carrying Amount
Rincian laba penjualan aset tetap adalah sebagai The details of gain on80.865.592.238
sale of property and equipment
berikut: are as follows:
2025 2024
Penjualan aset tetap 221.984.781 237.909.911 Sales of property and equipment
Carrying amount of property
Jumlah tercatat aset tetap ( 26.062.552) - and equipment
Laba penjualan aset tetap 195.922.229 237.909.911 Gain on sales of property and equipment
Penyusutan yang dibebankan sebagai beban umum dan Depreciation charged to general and administrative
administrasi untuk tahun yang berakhir pada tanggal expenses for the years ended 31 December 2025
31 Desember 2025 dan 2024 adalah sebesar and 2024 amounted to Rp 9,514,892,329 and
Rp 9.514.892.329 dan Rp 10.540.930.279 (Catatan Rp 10,540,930,279, respectively (Note 23).
23).
Pada tanggal 31 Desember 2025 dan 2024, nilai As of 31 December 2025 and 2024, the costs of the
perolehan aset tetap Perusahaan yang telah disusutkan Company’s property and equipment that
penuh namun masih digunakan masing-masing adalah had been fully depreciated but were still being
sebesar Rp 37.013.630.977 dan Rp 35.169.803.711. utilized amounted to Rp 37,013,630,977 and
Rp 35,169,803,711, respectively.
Perusahaan memiliki beberapa bidang tanah dengan The Company owns parcels of landrights with Building
Hak Guna Bangunan (HGB) di Bekasi dan Bandar Use Rights (HGB) in Bekasi and Bandar Lampung, with
Lampung, dengan luas keseluruhan sejumlah 1.276 a total covering area of 1,276 square meters, which
meter persegi, yang masing-masing akan berakhir 2033 will expire in 2033 for Bekasi and 2036 for Bandar
untuk Bekasi dan 2036 untuk Bandar Lampung. Lampung. Management believes that there will be no
Manajemen berkeyakinan bahwa tidak terdapat difficulty in the extension of landrights since all of the
masalah dengan perpanjangan hak atas tanah karena landrights were acquired legally and supported with
seluruh tanah diperoleh secara sah dan didukung appropriate ownership evidence.
dengan bukti pemilikan yang memadai.
320 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 321
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/42 Exhibit E/42
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
8. ASET TETAP (Lanjutan) 8. PROPERTY AND EQUIPMENT (Continued)
Pada tanggal 31 Desember 2025 dan 2024, seluruh aset As of 31 December 2025 and 2024, all property and
tetap, kecuali hak atas tanah dan perbaikan sewa, equipment, except for landrights and leasehold
diasuransikan terhadap risiko kebakaran, pencurian improvements, are insured against fire, theft and
dan risiko lainnya dengan jumlah pertanggungan other possible risks with a total coverage
masing-masing sebesar Rp 113.649.023.864 dan of Rp 113,649,023,864 and Rp 58,742,321,115,
Rp 58.742.321.115. Manajemen berkeyakinan bahwa respectively. Management believes that the insurance
nilai pertanggungan tersebut adalah memadai untuk coverage is adequate to cover possible losses on the
menutup kemungkinan kerugian aset tetap yang insured property and equipment.
diasuransikan.
Pada tanggal 31 Desember 2023, Perusahaan membeli As of 31 December 2023, the Company purchased land
aset tetap tanah seluas 9.436 m2 di Bintarajaya, of 9,436 m2 in Bintarajaya, Bekasi, West Java which
Bekasi, Jawa Barat yang digunakan sebagai jaminan was used as collateral and contractual commitments
dan komitmen kontratual kepada PT Bank Central to PT Bank Central Asia Tbk (Note 11a).
Asia Tbk (Catatan 11a).
Pada tanggal 31 Desember 2025 dan 2024, tidak ada As of 31 December 2025 and 2024, there are no
aset tetap yang tidak dipakai sementara atau property and equipment that are temporarily out of
dihentikan dari penggunaan aktif dan tidak use or retired from use but are not classified as being
diklasifikasikan sebagai tersedia untuk dijual. held for sale.
Pada tanggal 31 Desember 2025 dan 2024, berdasarkan As of 31 December 2025 and 2024, based on a review
penelaahan atas estimasi umur manfaat, nilai residu on estimated useful lives, residual values and methods
dan metode penyusutan aset tetap, manajemen of depreciation of property and equipment.
berkeyakinan bahwa tidak terdapat perubahan atas Management believes that there are no changes in the
estimasi masa manfaat, nilai residu dan metode useful lives, residual values and method of
penyusutan aset tetap. depreciation of property and equipment.
Pada 31 Desember 2025 dan 2024, tidak terdapat As of 31 December 2025 and 2024, there is no
perbedaan signifikan antara nilai wajar dengan nilai significant difference between fair value and carrying
tercatat untuk kelompok aset tetap tanah dan value for the land and buildings.
bangunan.
Metode dan asumsi yang digunakan dalam The methods and assumptions used in estimating the
mengestimasi nilai wajar aset tetap dengan fair value of property and equipment use the cost
menggunakan pendekatan biaya dan dilakukan approach and are based on existing market conditions
berdasarkan kondisi pasar yang ada pada tanggal at the date of valuation of the property and
penilaian aset tetap. equipment.
Penilaian kembali aset tetap hanya untuk tujuan Revaluation of property and equipment is only for
akuntansi sesuai dengan PSAK 216 tentang “Aset accounting purposes in accordance with PSAK 216
Tetap” dan tidak untuk tujuan pajak. regarding “Property, plant and equipment” and not
for tax purposes.
Berdasarkan penelaahan manajemen, tidak terdapat Based on management’s assessment, there are no
kejadian atau perubahan keadaan yang events or changes in circumstances that may indicate
mengindikasikan adanya penurunan nilai aset tetap impairment in the value of property and equipment as
pada tanggal 31 Desember 2025 dan 2024. of 31 December 2025 and 2024.
Aset dalam penyelesaian diperkirakan selesai pada Construction in progress is estimated to be completed
tahun 2027. Pada tanggal 31 Desember 2025 in 2027. As of 31 December 2025, the work progress
persentase progres pekerjaan sudah mencapai 85,3%. percentage has reached 85.3%.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 321
Page 322
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/43 Exhibit E/43
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
9. ASET TAKBERWUJUD 9. INTANGIBLE ASSETS
Saldo awal/ Saldo akhir/
Beginning Penambahan/ Pengurangan/ Ending
31 Desember 2025 balance Additions Deductions balance 31 December 20255
Biaya perolehan Acquisition cost
Perangkat lunak 10.905.927.194 654.900.000 - 11.560.827.194 Software
Akumulasi amortisasi Accumulated amortization
Perangkat lunak 3.127.204.951 1.438.281.524 - 4.565.486.475 Software
Jumlah Tercatat 7.778.722.243 6.995.340.719 Carrying Amount
Saldo awal/ Saldo akhir/
Beginning Penambahan/ Pengurangan/ Ending
31 Desember 2024 balance Additions Deductions balance 31 December 20244
Biaya perolehan Acquisition cost
Perangkat lunak 10.905.927.194 - - 10.905.927.194 Software
Akumulasi amortisasi Accumulated amortization
Perangkat lunak 1.763.964.052 1.363.240.899 - 3.127.204.951 Software
Jumlah Tercatat 9.141.963.142 7.778.722.243 Carrying Amount
Amortisasi dibebankan sebagai beban umum dan Amortization charged to general and administrative
administrasi untuk tahun yang berakhir pada tanggal expenses for the years ended 31 December 2025
31 Desember 2025 dan 2024 adalah sebesar and 2024 amounted to Rp 1,438,281,524 and
Rp 1.438.281.524 dan Rp 1.363.240.899 (Catatan 23). Rp 1,363,240,899 respectively (Note 23).
10. ASET HAK-GUNA 10. RIGHT-OF-USE ASSETS
Saldo awal/ Saldo akhir/
Beginning Penambahan/ Pengurangan/ Ending
31 Desember 2025 balance Additions Deductions balance 31 December 20255
Biaya perolehan Acquisition cost
Bangunan 69.275.776.616 11.339.633.332 - 80.615.409.948 Buildings
Akumulasi amortisasi Accumulated amortization
Bangunan 38.724.485.304 12.447.278.347 - 51.171.763.651 Buildings
Jumlah Tercatat 30.551.291.312 29.443.646.297 Carrying Amount
Saldo awal/ Saldo akhir/
Beginning Penambahan/ Pengurangan/ Ending
31 Desember 2024 balance Additions Deductions balance 31 December 20244
Biaya perolehan Acquisition cost
Bangunan 74.880.565.650 7.890.805.553 ( 13.495.594.587 ) 69.275.776.616 Buildings
Akumulasi amortisasi Accumulated amortization
Bangunan 39.534.989.061 11.667.705.569 ( 12.478.209.326 ) 38.724.485.304 Buildings
Jumlah Tercatat 35.345.576.589 30.551.291.312 Carrying Amount
Penyusutan yang dibebankan sebagai beban umum dan Depreciation charged to general and administrative
administrasi untuk tahun yang berakhir pada expenses for the years ended 31 December 2025
tanggal 31 Desember 2025 dan 2024 adalah sebesar and 2024 amounting to Rp 12,447,278,347 and
Rp 12.447.278.347 dan Rp 11.667.705.569 (Catatan Rp 11,667,705,569 (Note 23).
23).
322 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 323
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/44 Exhibit E/44
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
11. UTANG BANK 11. BANK LOANS
2025 2024
Utang bank jangka pendek Short-term bank loans
Fasilitas Kredit Jangka Pendek: Short-term Loan Facilities:
PT Bank Central Asia Tbk (a) 291.950.214.961 246.875.665.045 PT Bank Central Asia Tbk (a)
PT Bank CIMB Niaga Tbk (b) 287.986.117.835 270.835.824.504 PT Bank CIMB Niaga Tbk (b)
PT Bank UOB Indonesia (c) 169.626.097.412 280.490.788.171 PT Bank UOB Indonesia (c)
Jumlah 749.562.430.208 798.202.277.720 Total
Utang bank jangka panjang Long-term bank loan
Fasilitas Kredit Investasi: Investment Credit Facilities:
PT Bank Central Asia Tbk (a) 59.720.447.102 48.320.000.000 PT Bank Central Asia Tbk (a)
Jatuh tempo dalam satu tahun ( 6.424.407.576 ) ( 5.008.888.896 ) Current maturities
Bagian jangka panjang 53.296.039.526 43.311.111.104 Long-term maturities
a. PT Bank Central Asia Tbk (“BCA”) a. PT Bank Central Asia Tbk (“BCA”)
Berdasarkan Surat Pemberitahuan Pemberian Based on the Credit Grant Notification Letter
Kredit No 005/SPPK/BCA-W08/2024 tanggal No. 005/SPPK/BCA-W08/2024 dated 27 March
27 Maret 2024, Perusahaan memperoleh fasilitas 2024, the Company obtained a Multi Facility
Kredit Multi Fasilitas (KMF) dari BCA sebesar Credit (KMF) facility from BCA amounted to
Rp 305.000.000.000 dengan rincian sebagai Rp 305,000,000,000 with the following details:
berikut:
- Fasilitas Kredit Lokal (“KL”) sebesar - Local Credit Facility (“KL”) amounting to
Rp 25.000.000.000. Rp 25,000,000,000.
- Fasilitas Time Loan Revolving (“TL Rev”) - Time Loan Revolving (“TL Rev”) facility of
sebesar Rp 280.000.000.000. Rp 280,000,000,000.
- Fasilitas Bank Garansi sebesar - Bank Guarantee facility of Rp 20,000,000,000.
Rp 20.000.000.000.
Tingkat suku bunga fasilitas kredit yang The credit facility interest rates charged to the
dibebankan kepada Perusahaan adalah sebagai Company are as follows:
berikut:
- Fasilitas Kredit Lokal (“KL”): 8% p.a, fixed - Local Credit Facility (“KL”): 8% p.a, fixed up
sampai dengan 9 Agustus 2024. to 9 August 2024.
- Fasilitas Time Loan Revolving (“TL Rev”): 8% - Time Loan Revolving Facility (“TL Rev”): 8%
p.a, fixed 1 (satu) tahun. p.a, fixed 1 (one) year.
- Bank Garansi : 1% p.a - Bank Guarantee: 1% p.a
Fasilitas-fasilitas kredit tersebut berlaku sampai The credit facilities are valid until 28 March 2025.
dengan tanggal 28 Maret 2025.
Berdasarkan Surat Pemberitahuan Penyesuaian Based on Credit Interest Rate Adjustment
Suku Bunga Kredit No. 398/SRT/SBK-W08/2024 Notification Letter No. 398/SRT/SBK-W08/2024
tanggal 8 Agustus 2024 dengan ketentuan sebagai dated 8 August 2024 are as follows:
berikut:
- Fasilitas Kredit Lokal (“KL”): 8,25% p.a, fixed - Local Credit Facility (“KL”): 8.25% p.a, fixed
1 (satu) tahun. 1 (one) year.
- Fasilitas Time Loan Revolving (“TL Rev”): - Time Loan Revolving Facility (“TL Rev”):
8,25% p.a, fixed 1 (satu) tahun. 8.25% p.a, fixed 1 (one) year.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 323
Page 324
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/45 Exhibit E/45
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
11. UTANG BANK (Lanjutan) 11. BANK LOANS (Continued)
a. PT Bank Central Asia Tbk (“BCA”) (Lanjutan) a. PT Bank Central Asia Tbk (“BCA”) (Continued)
Berdasarkan Surat Pemberitahuan Pemberian Based on the Credit Grant Notification Letter
Kredit No. 00954/SLK-KOM/2025 tanggal 22 April No. 00954/SLK-KOM/2025 dated 22 April 2025,
2025, Perusahaan memperoleh fasilitas Kredit the Company obtained a Multi Facility Credit
Multi Fasilitas (KMF) dari BCA sebesar (KMF) facility from BCA amounted to
Rp 335.000.000.000 dengan rincian sebagai Rp 335,000,000,000 with the following details:
berikut:
- Fasilitas Kredit Lokal (“KL”) sebesar - Local Credit Facility (“KL”) amounting to
Rp 25.000.000.000. Rp 25,000,000,000.
- Fasilitas Time Loan Revolving (“TL Rev”) - Time Loan Revolving (“TL Rev”) facility of
sebesar Rp 310.000.000.000. Rp 310,000,000,000.
- Fasilitas Bank Garansi sebesar - Bank Guarantee facility of Rp 20,000,000,000.
Rp 20.000.000.000.
Tingkat suku bunga fasilitas kredit yang The credit facility interest rates charged to the
dibebankan kepada Perusahaan adalah sebagai Company are as follows:
berikut:
- Fasilitas Kredit Lokal (“KL”) dan Time Loan - Local Credit Facility (“KL) and Time Loan
Revolving (“TL Rev”): 8,25% p.a, fixed 1 (satu) Revolving Facility (“TL Rev”): 8,25% p.a, fixed
tahun. 1 (one) year.
- Bank Garansi : 0,25% p.a - Bank Guarantee: 0,25% p.a
Fasilitas-fasilitas kredit tersebut berlaku sampai The credit facilities are valid until 28 March 2026.
dengan tanggal 28 Maret 2026.
Pada tanggal 31 Desember 2025 dan 2024, fasilitas As of 31 December 2025 and 2024, TL Rev facility
TL Rev yang digunakan Perusahaan adalah sebesar used by the Company amounts to
Rp 291.950.214.961 dan Rp 246.875.665.045, Rp 291,950,214,961 and Rp 246,875,665,045,
sedangkan fasilitas bank garansi yang digunakan while the bank guarantee facility used by the
oleh Perusahaan sehubungan dengan jaminan Company in connection with purchase guarantees
pembelian untuk pemasok masing-masing adalah for suppliers amounts to Rp 10,000,000,000.
sebesar Rp 10.000.000.000.
Berdasarkan perjanjian kredit, Perusahaan Under the respective credit agreement, the
diwajibkan untuk memberikan letter of comfort Company is required to provide a letter of
dari Pharmaniaga Berhad kepada BCA serta comfort from Pharmaniaga Berhad to BCA and
mematuhi pembatasan tertentu yang berkaitan comply with certain restrictions related to the
dengan kegiatan usaha Perusahaan dan memenuhi Company's business activities and meet financial
rasio keuangan seperti current ratio dan debt ratios such as current ratio and debt service
service coverage ratio dengan batas minimum coverage ratio with a minimum limit of 110% and
masing-masing 110% dan 125% dan interest bearing 125%, respectively, and interest-bearing debt to
debt to equity ratio dengan batas maksimum equity ratio with a maximum limit of 330%.
330%.
Fasilitas kredit investasi Investment Credit Facility
Berdasarkan Surat Pemberitahuan Pemberian Based on the Credit Grant Notification Letter
Kredit No 45/SPPK/BCA-W08/2023 tanggal No. 45/SPPK/BCA-W08/2023 dated 20 December
20 Desember 2023, Perusahaan memperoleh 2023, the Company obtained an investment Credit
fasilitas Kredit Investasi (“Baru”) dari BCA sebesar (“Baru”) facility from BCA amounting to
Rp 44.000.000.000, jangka waktu 10 (sepuluh) Rp 44,000,000,000, 10 (ten) year term including
tahun termasuk Grace period 1 tahun dengan 1 year Grace period with an interest rate of 7.75%
tingkat suku bunga 7.75% p.a. fixed 1 (satu) p.a. fixed 1 (one) year.
tahun.
Per 31 Desember 2025 dan 2024, tingkat suku As of 31 December 2025 and 2024, the interest
bunga fasilitas kredit investasi adalah 8%. rate of investment credit facility is 8%.
324 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 325
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/46 Exhibit E/46
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
11. UTANG BANK (Lanjutan) 11. BANK LOANS (Continued)
a. PT Bank Central Asia Tbk (“BCA”) (Lanjutan) a. PT Bank Central Asia Tbk (“BCA”) (Continued)
Fasilitas kredit investasi (Lanjutan) Investment Credit Facility (Continued)
Berdasarkan Surat Pemberitahuan Pemberian Based on the Credit Grant Notification Letter
Kredit No 005/SPPK/BCA-W08/2024 tanggal No. 005/SPPK/BCA-W08/2024 dated 27 March
27 Maret 2024, Perusahaan memperoleh fasilitas 2024, the Company obtained an investment Credit
Kredit Investasi 2 (“Baru”) dari BCA sebesar 2 (“Baru”) facility from BCA amounting to
Rp 21.400.000.000, jangka waktu 10 (sepuluh) Rp 21,400,000,000, 10 (ten) year term including 1
tahun termasuk Grace period 1 tahun dengan year Grace period with an interest rate of 7,75%
tingkat suku bunga 7.75% p.a. fixed 1 (satu) p.a. fixed for 1 (one) year.
tahun.
Berdasarkan Surat Pemberitahuan Pemberian Based on the Credit Grant Notification Letter
Kredit No 00954/SLK-KOM/2025 tanggal No. 00954/SLK-KOM/2025 dated 22 April 2025,
22 April 2025, Fasilitas Kredit Investasi 2 dari BCA Investment Credit Facility 2 from BCA is divided
dibagi menjadi 2 yaitu Kredit Investasi 2 dan into 2, namely Investment Credit 2 and
Kredit Investasi 3 (“Baru”) dengan total Investment Credit 3 (“Baru”), amounting to
Rp 21.400.000.000. Rp 21,400,000,000.
Per 31 Desember 2025 dan 2024, tingkat suku As of 31 December 2025 and 2024, the interest
bunga Kredit Investasi - 2 dan Kredit Investasi - 3 rate of Investment Credit - 2 and Investment
sebesar 8.25%. Credit - 3 is 8,25%.
Jaminan Kredit Credit Guarantee
Berdasarkan Fasilitas Kredit Investasi tersebut, Based on the Investment Credit Facilities, the
jaminan kreditnya adalah tanah di Bintara Jaya credit guarantee is the Land in Bintara Jaya with
dengan detail sebagai berikut the details are as follows:
- SHGB NIB. 10.26.000022185.0 - HGB NIB. 10.26.000022185.0
- SHGB NIB. 10.26.000024986.0 - SHGB NIB. 10.26.000024986.0
- SHGB NIB. 10.26.000022077.0 - SHGB NIB. 10.26.000022077.0
b. PT Bank CIMB Niaga Tbk (“CIMB Niaga”) b. PT Bank CIMB Niaga Tbk (“CIMB Niaga”)
Berdasarkan Akta Perjanjian Kredit No. 55 tanggal Based on Deed of Credit Agreement No. 55 dated
27 Oktober 2020 yang dibuat di hadapan Veronica 27 October 2020 as covered by Veronica
Nataadmaja, S.H., M.Corp.Admin., M.Com., Nataadmaja, S.H., M.Corp.Admin., M.Com.,
Notaris di Jakarta, Perusahaan memperoleh Notary in Jakarta, the Company obtained credit
fasilitas kredit dari CIMB Niaga dan perjanjian facilities from CIMB Niaga and the credit
kredit telah diperpanjang dengan rincian sebagai agreement has been extended with the following
berikut: details:
Perusahaan telah memperpanjang perjanjian The Company has extended the credit agreement
kredit dengan surat No. 032/ERW/CBTIV/XI/2023 with letter No. 032/ERW/CBTIV/XI/2023 dated
tanggal 13 November 2023. Fasilitas kredit 13 November 2023. The credit facilities are valid
tersebut berlaku sampai dengan tanggal until 27 October 2024.
27 Oktober 2024.
- Fasilitas Pinjaman Transaksi Khusus Trade - “Pinjaman Transaksi Khusus” Trade Account
Account Payables (“PTK-TAP”) sebesar Payables (“PTK-AP”) facility amounting to
Rp 300.000.000.000. Rp 300,000,000,000.
- Fasilitas Pinjaman Rekening Koran (“PRK”) - “Pinjaman Rekening Koran” (“PRK”) facility
sebesar Rp 10.000.000.000. amounting to Rp 10,000,000,000.
- Fasilitas Bank Garansi sebesar - Bank Guarantee facility amounting to
Rp 50.000.000.000. Rp 50,000,000,000.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 325
Page 326
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/47 Exhibit E/47
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
11. UTANG BANK (Lanjutan) 11. BANK LOANS (Continued)
b. PT Bank CIMB Niaga Tbk (“CIMB Niaga”) (Lanjutan) b. PT Bank CIMB Niaga Tbk (“CIMB Niaga”)
(Continued)
Tingkat suku bunga fasilitas kredit yang The interest rates on credit facilities charged to
dibebankan kepada Perusahaan adalah sebagai the Company are as follows:
berikut:
- Fasilitas PTK-AP: cost of fund ditambah 2% per - PTK-AP facility: cost of fund plus 2% per
tahun. annum.
- Fasilitas PRK: 12% per tahun (suku bunga - PRK facility: 12% per annum (floating rate).
mengambang).
Perusahaan telah memperpanjang perjanjian The Company has extended the credit agreement
kredit dengan surat No. 001/ERW/CBTIV/I/2025 with letter No. 001/ERW/CBTIV/I/2025 dated
tanggal 6 Januari 2025. Fasilitas kredit tersebut 6 January 2025. The credit facilities are valid
berlaku sampai dengan tanggal 27 Oktober 2025. until 27 October 2025.
- Fasilitas Pinjaman Transaksi Khusus Trade - “Pinjaman Transaksi Khusus” Trade Account
Account Payables (“PTK-TAP”) sebesar Payables (“PTK-AP”) facility amounting to
Rp 300.000.000.000. Rp 300,000,000,000.
- Fasilitas Pinjaman Rekening Koran (“PRK”) - “Pinjaman Rekening Koran” (“PRK”) facility
sebesar Rp 10.000.000.000. amounting to Rp 10,000,000,000.
- Fasilitas Bank Garansi sebesar - Bank Guarantee facility amounting to
Rp 50.000.000.000. Rp 50,000,000,000.
Tingkat suku bunga fasilitas kredit yang The interest rates on credit facilities charged to
dibebankan kepada Perusahaan adalah sebagai the Company are as follows:
berikut:
- Fasilitas PTK-AP: cost of fund ditambah 2% per - PTK-AP facility: cost of fund plus 2% per
tahun. annum.
- Fasilitas PRK: 11% per tahun (suku bunga - PRK facility: 11% per annum (floating rate).
mengambang).
Perusahaan telah memperpanjang perjanjian The Company has extended the credit agreement
kredit dengan surat No.52/ZF/CBTIV/IX/2025 with letter No. 001/ERW/CBTIV/I/2025 dated
tanggal 8 Desember 2025. Fasilitas kredit tersebut 8 December 2025. The credit facilities are valid
berlaku sampai dengan tanggal 27 Oktober 2026. until 27 October 2026.
- Fasilitas Pinjaman Transaksi Khusus Trade - “Pinjaman Transaksi Khusus” Trade Account
Account Payables (“PTK-TAP”) sebesar Payables (“PTK-AP”) facility amounting to
Rp 300.000.000.000. Rp 300,000,000,000.
- Fasilitas Pinjaman Rekening Koran (“PRK”) - “Pinjaman Rekening Koran” (“PRK”) facility
sebesar Rp 10.000.000.000. amounting to Rp 10,000,000,000.
- Fasilitas Bank Garansi sebesar - Bank Guarantee facility amounting to
Rp 50.000.000.000. Rp 50,000,000,000.
Tingkat suku bunga fasilitas kredit yang The interest rates on credit facilities charged to
dibebankan kepada Perusahaan adalah sebagai the Company are as follows:
berikut:
- Fasilitas PTK-AP: cost of fund ditambah 2% per - PTK-AP facility: cost of fund plus 2% per
tahun. annum.
- Fasilitas PRK: 11% per tahun (suku bunga - PRK facility: 11% per annum (floating rate).
mengambang).
326 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 327
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/48 Exhibit E/48
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
11. UTANG BANK (Lanjutan) 11. BANK LOANS (Continued)
b. PT Bank CIMB Niaga Tbk (“CIMB Niaga”) (Lanjutan) b. PT Bank CIMB Niaga Tbk (“CIMB Niaga”)
(Continued)
Berdasarkan perjanjian kredit, Perusahaan Under the respective credit agreement, the
diwajibkan untuk memberikan letter of comfort Company is required to provide a letter of
dari Pharmaniaga Berhad kepada CIMB Niaga serta comfort from Pharmaniaga Berhad to CIMB Niaga
mematuhi pembatasan tertentu yang berkaitan and comply with certain restrictions related to
dengan kegiatan usaha Perusahaan dan memenuhi the Company's business activities and meet
rasio keuangan seperti current ratio dan debt financial ratios such as the current ratio and debt
service coverage ratio dengan batas minimum service coverage ratio with a minimum limit of
masing-masing 110% dan 125% dan interest 110% and 125%, respectively, and interest-bearing
bearing debt to equity ratio dengan batas debt to equity ratio with a maximum limit of
maksimum 330%. Perjanjian kredit juga 330%. The credit agreement also requires a loan
mensyaratkan adanya pinjaman dari pemegang from the shareholder with a minimum amount of
saham dengan jumlah minimum sebesar Rp 65,000,000,000 and the repayment of these
Rp 65.000.000.000 dan pembayaran kembali loan shall be subject to CIMB Niaga approval
pinjaman tersebut harus memperoleh persetujuan (Note 27).
CIMB Niaga (Catatan 27).
Berdasarkan Letter of Consent tanggal 21 Mei Based on the Letter of Consent dated 21 May 2021
2021 dari CIMB Niaga sehubungan dengan from CIMB Niaga in connection with the approval
persetujuan pembayaran kembali pinjaman of loan repayment to shareholders.
kepada pemegang saham.
Berdasarkan Surat Pemberitahuan Penyesuaian Based on Credit Interest Rate Adjustment
Suku Bunga Kredit No. 044/ERW/CBTHIV/X/2025 Notification Letter No. 044/ERW/CBTHIV/X/2025
tanggal 8 Oktober 2025 terdapat penyesuaian suku dated 8 October 2025 the interest rate has been
bunga 8,25% menjadi 8,10% per September 2025. adjusted from 8.25% to 8.10% as of September
2025.
Pada tanggal 31 Desember 2025 dan 2024, fasilitas As of 31 December 2025 and 2024, PTK-AP loan
PTK-AP yang digunakan Perusahaan adalah facility used by the Company amount to
sebesar Rp 287.986.117.835 dan Rp 287,986,117,835 and Rp 270,835,824,504,
Rp 270.835.824.504, sedangkan fasilitas bank while the bank guarantee facility used by the
garansi yang digunakan oleh Perusahaan Company in connection with purchase guarantees
sehubungan dengan jaminan pembelian untuk for suppliers amounts to Rp 33,480,000,000.
pemasok adalah sebesar Rp 33.480.000.000.
c. PT Bank UOB Indonesia (“UOB”) c. PT Bank UOB Indonesia (“UOB”)
Pada tanggal 17 November 2022, Perusahaan On 17 November 2022, the Company obtained
memperoleh surat perjanjian kredit dengan credit facilities Letter No. 1577/11/2022. The
No. 1577/11/2022. Perusahaan, PT Errita Pharma Company, PT Errita Pharma (Errita) and UOB have
(Errita) dan UOB telah menandatangani signed the Amendment III to Amendment and
Amandemen III terhadap Perubahan dan Reaffirmation of the Credit Agreement
Penegasan kembali perjanjian Kredit No. 1273/10/2021 dated 19 October 2022.
No. 1273/10/2021 tanggal 19 Oktober 2021.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 327
Page 328
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/49 Exhibit E/49
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
11. UTANG BANK (Lanjutan) 11. BANK LOANS (Continued)
c. PT Bank UOB Indonesia (“UOB”) (Lanjutan) c. PT Bank UOB Indonesia (“UOB”) (Continued)
Berikut perubahan mengenai Jenis dan Limit Following are changes regarding the types and
Fasilitas Kredit: limits of Credit Facility:
1. Fasilitas Multi Option Trade (“MOT”) sebesar 1. Multi Option Trade (“MOT”) facility
Rp 425.000.000.000 dengan sublimit sebagai amounting to Rp 425,000,000,000 which
berikut: consists of below sublimits:
- Fasilitas Letter of Credit (L/C) atau Surat - Letter of Credit (L/C) or Surat Kredit
Kredit Berdokumen Dalam Negeri (SKBDN) Berdokumen Dalam Negeri (SKBDN)
sebesar Rp 100.000.000.000 untuk facility amounting to Rp 100,000,000,000
Perusahaan dan Rp 10.000.000.000 untuk for the Company and Rp 10,000,000,000
Errita. for Errita.
- Fasilitas Trust Receipts (TR) sebesar - Trust Receipts (TR) facility amounting to
Rp 100.000.000.000 untuk Perusahaan Rp 100,000,000,000 for the Company and
dan Rp 10.000.000.000 untuk Errita. Rp 10,000,000,000 for Errita.
- Fasilitas Clean Trust Receipts (CTR) - Clean Trust Receipts (CTR) facility
sebesar Rp 370.000.000.000 untuk amounting to Rp 370,000,000,000 for the
Perusahaan dan Rp 55.000.000.000 untuk Company and Rp 55,000,000,000 for
Errita. Errita.
- Fasilitas Bank Guarantee (BG) sebesar - Bank Guarantee (BG) facility amounting
Rp 150.000.000.000 untuk Perusahaan to Rp 150,000,000,000 for the Company
dan Rp 10.000.000.000 untuk Errita. and Rp 10,000,000,000 for Errita.
- Fasilitas Revolving Credit Facility (RCF) - Revolving Credit (RCF) facility amounting
sebesar Rp 50.000.000.000 untuk to Rp 50,000,000,000 for the Company
Perusahaan dan Rp 15.000.000.000 untuk and Rp 15,000,000,000 for Errita.
Errita.
2. Fasilitas Foreign Exchange (FX) sebesar 2. Foreign Exchange (FX) facility amounting to
US$ 25.000.000 untuk Perusahaan dan US$ 25,000,000 for the Company and
US$ 2.500.000 untuk Errita. US$ 2,500,000 for Errita.
Jumlah pemakaian fasilitas kredit MOT yang The total aggregate outstanding of MOT facility
terdiri dari fasilitas L/C atau SKBDN, TR, CTR, BG, which consists of L/C or SKBDN, TR, CTR, BG, RCF
RCF dan BEPS secara bersama-sama dari waktu ke and BEPS facilities shall not exceed
waktu tidak boleh melebihi Rp 425.000.000.000, Rp 425,000,000,000 at any point in time, with an
dengan alokasi masing-masing sebesar allocation of Rp 370,000,000,000 for the Company
Rp 370.000.000.000 untuk Perusahaan dan and Rp 55,000,000,000 for Errita, respectively.
Rp 55.000.000.000 untuk Errita.
Berdasarkan perjanjian kredit, Perusahaan dan Under the respective credit agreement, the
Errita wajib bertanggung jawab secara tanggung Company and Errita shall be jointly responsible
renteng atas kewajiban pembayaran dan for the repayment obligation to settle and repay
pembayaran kembali saldo yang terutang kepada the outstanding balance to UOB.
UOB.
328 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 329
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/50 Exhibit E/50
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
11. UTANG BANK (Lanjutan) 11. BANK LOANS (Continued)
c. PT Bank UOB Indonesia (“UOB”) (Lanjutan) c. PT Bank UOB Indonesia (“UOB”) (Continued)
Perubahan tingkat suku bunga atas fasilitas kredit Amandement to the interest rates on credit
yang diperoleh Perusahaan adalah sebagai facilities obtained by the Company are as follows:
berikut:
- Fasilitas TR dan CTR: JIBOR ditambah 2,25% - TR and CTR facilities: JIBOR plus 2.25% per
per tahun untuk saldo dalam mata uang Rupiah annum for outstanding loan balance in
Indonesia dan LIBOR ditambah 1,25% per tahun Indonesian Rupiah and LIBOR plus 1.25% per
untuk saldo dalam mata uang Dolar Amerika annum for outstanding loan balance in United
Serikat. States Dollar.
- Fasilitas RCF: JIBOR ditambah 3% per tahun. - RCF facility: JIBOR plus 3% per annum.
Fasilitas-fasilitas kredit tersebut berlaku sampai The credit facilities are valid until 29 January
dengan tanggal 29 Januari 2024. 2024.
Pada tanggal 27 November 2023, Perusahaan On 27 November 2023, the Company obtained
memperoleh surat perjanjian kredit dengan credit facilities Letter No. 1577/11/2023. The
No. 1444/11/2023. Perusahaan, PT Errita Pharma Company, PT Errita Pharma Errita and UOB have
(Errita) dan UOB telah menandatangani signed the Amendment IV to Amendment and
Amandemen IV terhadap Perubahan dan Reaffirmation of the Credit Agreement
Penegasan kembali perjanjian Kredit No. 1273/10/2022 dated 19 October 2022. In the
No. 1577/11/2022 tanggal 17 November 2022. credit agreement there are no changes to the
Dalam surat perjanjian kredit tersebut tidak ada facility and interest rate.
perubahan pada fasilitas dan tingkat suku bunga.
Fasilitas-fasilitas kredit tersebut berlaku sampai The credit facilities are valid until 29 January
dengan tanggal 29 Januari 2025. 2025.
Pada tanggal 24 Januari 2025, Perusahaan, On 24 January 2025, the Company, PT Errita
PT Errita Pharma dan UOB telah menandatangani Pharma, and UOB signed an amendment and
perubahan dan penegasan kembali terhadap restatement to the credit agreement No.
perjanjian kredit No. 111/01/2025 dan Perubahan 111/01/2025, as well as Amendment V to the
V terhadap perjanjian fasilitas valuta asing foreign exchange facility agreement No.
No.112/01/2025. Dalam surat tersebut, 112/01/2025. In the letter, the Company and the
Perusahaan dan Bank menyetujui perubahan Bank agreed to amend certain terms and
syarat dan ketentuan tertentu dari Perjanjian conditions of the Credit Agreement. The facility
Kredit. Fasilitas tersebut di perpanjang sampai was extended until 29 January 2026.
dengan tanggal 29 Januari 2026.
Pada tanggal 31 Desember 2025 dan 2024, As of 31 December 2025 dan 2024, the CTR facility
fasilitas CTR yang digunakan oleh Perusahaan used by the Company amounted to
masing-masing adalah sebesar Rp 169.626.097.412 Rp 169,626,097,412 and Rp 280,490,788,171.
dan Rp 280.490.788.171.
Pada tanggal 31 Desember 2025 dan 31 Desember As of 31 December 2025 and 31 December 2024,
2024, Errita menyatakan bahwa tidak terdapat Errita stated that there are no principal and
tunggakan pokok dan bunga serta telah mematuhi interest arrears and has complied with the loan
seluruh ketentuan pembatasan pinjaman (loan covenants as determined in the loan agreement.
covenants) yang ditetapkan dalam perjanjian
pinjaman.
Menjaga kewajiban keuangan, yang meliputi: Maintain financial covenant, which include:
a. Current Ratio Minimal 1,1 kali untuk a. Current Ratio minimum 1.1 times for the
Perusahaan Company
b. Interest Bearing Debt/Equity Maksimal 3 kali b. Interest Bearing Debt/Equity maximum
untuk Perusahaan dan Errita 3 times for the Company and Errita
c. Debt Service Coverage Ratio minimal 1,25 kali c. Debt Service Coverage Ratio minimum 1.25
untuk Perusahaan. times for the Company.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 329
Page 330
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/51 Exhibit E/51
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
11. UTANG BANK (Lanjutan) 11. BANK LOANS (Continued)
c. PT Bank UOB Indonesia (“UOB”) (Lanjutan) c. PT Bank UOB Indonesia (“UOB”) (Continued)
Kewajiban Keuangan Bank Covenant
Berdasarkan penilaian manajemen terhadap Based on management's assessment on financial
laporan keuangan periode 31 Desember 2024, year 31 December 2024, Errita has not complied
Errita belum memenuhi batas minimum kewajiban with the minimum financial covenant for Interest
keuangan Interest Bearing Debt/Equity Bearing Debt/Equity, so with the issuance of
sehingga dikeluarkannya surat No. 2025/CFS/LTR/ letter No. 2025/CFS/LTR/CBK/0061 dated
CBK/0061 tanggal 14 Februari 2025 dari UOB, 14 February 2025 from UOB, Errita has obtained
Errita telah memperoleh persetujuan approval for the waiver of these financial
pengesampingan atas pemenuhan batasan covenants.
tersebut.
Berdasarkan penilaian manajemen terhadap Based on management's assessment on financial
laporan keuangan periode 31 Desember 2025, year 31 December 2025, Errita has not complied
Errita belum memenuhi batas minimum kewajiban with the minimum financial covenant for Interest
keuangan Interest Bearing Debt/Equity sehingga Bearing Debt/Equity, so that with the issuance
dikeluarkannya surat No. 2026/CS/LTR/CBK/0134 of letter No. 2026/CS/LTR/CBK/0134 dated
tanggal 2 Februari 2026 dari UOB, Errita telah 2 February 2026 from UOB, Errita has obtained
memperoleh persetujuan pengesampingan atas approval for the waiver of these financial
pemenuhan batasan tersebut. covenants.
Kewajiban Keuangan Bank Covenant
Menjaga kewajiban keuangan, yang meliputi: Maintain financial covenant, which include:
a. Current Ratio Minimal 1,1 kali untuk a. Current Ratio minimum 1.1 times for the
Perusahaan. Company.
b. Interest Bearing Debt/Equity Maksimal 3 kali b. Intereset earing Debt/Equity Maximum
untuk Perusahaan termasuk modal disetor, 3 times for the Company including paid-in
laba ditahan dan pinjaman subordinasi capital, retained earnings and subordinated
pemegang saham dan Errita termasuk modal shareholder loan and Errita including paid-in
disetor, laba ditahan, pinjaman subordinasi capital, retained earnings, subordinated loan
dari pemegang saham dan pinjaman dengan from shareholders and loan with an equivalent
nilai yang setara sebesar Rp 15.550.000.000 value of Rp 15,550,000,000 from Pharmaniaga
dari Pharmaniaga Logistics Sdn. Bhd. Logistics Sdn. Bhd.
12. UTANG USAHA 12. TRADE PAYABLES
Komposisi utang usaha berdasarkan kategori adalah Trade payables composition based on category as
sebagai berikut: follow:
2025 2024
Pihak ketiga Third parties
Obat resep 379.167.713.258 280.943.299.640 Prescription medicine
Alat kesehatan 279.548.189.126 211.545.392.847 Medical equipment
Obat non-resep 29.873.143.803 25.889.891.251 Non-prescription medicine
688.589.046.187 518.378.583.738
Pihak berelasi (Catatan 27) Related party (Note 27)
Alat kesehatan 5.860.014.025 9.211.162.935 Medical equipment
Jumlah 694.449.060.212 527.589.746.673 Total
330 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 331
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/52 Exhibit E/52
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
12. UTANG USAHA (Lanjutan) 12. TRADE PAYABLES (Continued)
Komposisi utang usaha berdasarkan umur adalah Trade payables composition based on aging as follow:
sebagai berikut:
2025 2024
Belum jatuh tempo 577.193.150.864 526.135.172.636 Not yet due
Sudah jatuh tempo Overdue:
1 – 30 hari 117.255.909.348 1.454.574.037 1 – 30 days
Jumlah 694.449.060.212 527.589.746.673 Total
Pada tanggal laporan posisi keuangan konsolidasian, As at consolidated statements of financial position’s
seluruh utang usaha adalah dalam mata uang Rupiah. date, all trade payables are denominated in Rupiah
currency.
Pada tanggal 31 Desember 2025 dan 2024, fasilitas As of 31 December 2025 and 2024, the bank guarantees
bank garansi yang digunakan oleh Perusahaan facility used by the Company in connection with the
sehubungan dengan pembelian persediaan purchase of merchandise inventories amounted to
masing-masing adalah sebesar Rp 43.480.000.000 Rp 43,480,000,000, respectively (Note 11).
(Catatan 11).
Rincian transaksi dan saldo dengan pihak berelasi The details of transactions and balances with related
diungkapkan dalam Catatan 27. party are disclosed in Note 27.
13. PERPAJAKAN 13. TAXATION
a. Pajak dibayar di muka a. Prepaid tax
2025 2024
Pajak Pertambahan Nilai 205.575.575.298 193.109.030.048 Value Added Tax
Pajak Penghasilan: Income Tax:
Pasal 21 474.090.272 23.882.557 Article 21
Jumlah 206.049.665.570 193.132.912.605 Total
Pada tanggal 8 Juni 2020, Perusahaan mengajukan On 8 June 2020, the Company submitted an
permohonan pemindahbukuan atas sebagian application for transfer of some details of
rincian kompensasi utang pajak melalui SPMKP compensation for tax payable through SPMKP
No. 00432A tanggal 27 April 2020 untuk masa pajak No. 00432A dated 27 April 2020 for VAT period of
PPN Februari 2015 sebesar Rp 502.357.590, namun February 2015 amounting to Rp 502,357,590, but
pengajuan tersebut ditolak oleh DJP. Oleh karena the submission was rejected by DJP. Therefore,
itu Perusahaan telah mencatat sebagai beban di the Company was recorded as tax expenses in
2024. 2024.
Pada bulan Mei 2024, atas klaim PPN Masa In May 2024, based on the claim of VAT
Desember 2022 sebesar Rp 63.257.815.079, period December 2022 amounting to
Perusahaan menerima Surat Ketetapan Pajak Rp 63,257,815,079, the Company received the Tax
Lebih Bayar (SKPLB) No. 00012/407/22/054/24 Overpayment Assessment Letter (SKPLB)
tanggal 1 April 2024 dari Direktorat Jenderal No. 00012/407/22/054/24 dated 1 April 2024 from
Pajak. Jumlah pembayaran PPN diterima Directorate General of Taxation. The amount of
Perusahaan berdasarkan Surat Perintah Membayar payment of VAT tax received by the Company
Kelebihan Pajak (SPMKP) No. 00304A tanggal 2 Mei pursuat to SPMKP No. 00304A dated 2 May 2024
2024 adalah sebesar Rp 54.359.184.123 dan amounting to Rp 54,359,184,123 and the
sisanya sebesar Rp 8.898.630.956 sedang dalam remaining amount of Rp 8,898,630,956 is
proses keberatan. currently in the tax objection process.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 331
Page 332
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/53 Exhibit E/53
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
13. PERPAJAKAN (Lanjutan) 13. TAXATION (Continued)
a. Pajak dibayar di muka (Lanjutan) a. Prepaid tax (Continued)
Pada bulan Januari 2026, Direktorat Jenderal In January 2026, the Directorate General of Taxes
Pajak mengabulkan permohonan pengurangan (DGT) granted the Company’s request, dated
atau pembatalan Surat Tagihan Pajak (STP) yang October 6, 2025, for the reduction or cancellation
tidak benar dalam surat permohonan Perusahaan of incorrect Tax Collection Letters (STP).
tanggal 6 Oktober 2025. DJP membatalkan STP Consequently, the DGT annulled the 2022
PPN tahun pajak 2022 sebesar Rp 1.744.387.306. Value Added Tax (VAT) STP amounting to
Selisih sebesar Rp 7.154.243.650 yang sebelumnya Rp 1,744,387,306. The remaining balance of
diajukan keberatan oleh Perusahaan dicatat Rp 7,154,243,650, for which the Company had
sebagai beban pajak. previously filed an objection, has been recognized
as a tax expense.
Pada bulan Februari 2025, atas klaim PPN Masa In February 2025, based on the claim of VAT
Desember 2023 sebesar Rp 74.378.836.728, period December 2023 amounting to
Perusahaan menerima Surat Ketetapan Pajak Rp 74,378,836,728, the Company received the Tax
Lebih Bayar (SKPLB) No. 00004/407/23/054/25 Overpayment Assessment Letter (SKPLB)
tanggal 3 Februari 2025 dari Direktorat Jenderal No. 00004/407/23/054/25 dated 3 February 2025
Pajak. Jumlah pembayaran PPN diterima from Directorate General of Taxation. The
Perusahaan berdasarkan Surat Perintah amount of payment of VAT tax received by the
Membayar Kelebihan Pajak (SPMKP) No. 00165A Company pursuant to SPMKP No. 00165A dated
tanggal 26 Februari 2025 adalah sebesar 26 February 2025 amounting to Rp 73,896,911,158
Rp 73.896.911.158 dan sisanya sebesar and the remaining amount of Rp 481,925,570 was
Rp 481.925.570 dicatat sebagai beban pajak pada recorded as tax expenses in 2024.
tahun 2024.
Pada tanggal 3 Februari 2025, Perusahaan On 3 February 2025, the Company received Tax
menerima Surat Ketetapan Pajak Kurang Bayar Underpayment Assessment Letter (SKPKB)
(SKPKB) No. 00010/207/23/054/25 sampai No. 00010/207/23/054/25 until No. 00020/207/
dengan No. 00020/207/23/054/25 untuk Pajak 23/054/25 for Value Added Tax period January –
Pertambahan Nilai masa Januari – November 2023 November 2023 amounting to Rp 258,506,584.
sebesar Rp 258.506.584.
Pada tanggal 3 Februari 2025, Perusahaan On 3 February 2025, the Company received Tax
menerima Surat Tagihan Pajak (STP) No. 00009/ Bill (STP) No. 00009/107/23/054/25 until
107/23/054/25 sampai dengan No. 00020/107/ No. 00020/107/23/054/25 for Value Added Tax
23/054/25 untuk Pajak Pertambahan Nilai masa period January – December 2023 amounting to
Januari – Desember 2023 sebesar Rp 10.440.051. Rp 10,440,051.
Pada bulan Februari 2025, atas restitusi Pajak In February 2025, based on restitution of Value
Pertambahan Nilai (PPN) masa Desember 2023 Added Tax (VAT) for the period of December 2023
sebesar Rp 74.378.836.728, Perusahaan telah amounting to Rp 74,378,836,728, the Company
menerima Surat Ketetapan Pajak Lebih Bayar has received the Tax Overpayment Assessment
(SKPLB) No. 00004/407/23/054/25 tanggal Letter (SKPLB) No. 00004/407/23/054/25 dated
3 Februari 2025 dari Direktorat Jenderal Pajak 3 February 2025 from the Directorate General of
sebesar Rp 74.287.536.052. Restitusi pajak bersih Taxation amounting to Rp 74,287,536,052. Net
setelah dikurangkan dengan beban pajak diterima refund for the overpayment, after deduction of
oleh Perusahaan seluruhnya berdasarkan Surat tax expense has been received by the Company
Perintah Membayar Kelebihan Pajak (SPMKP) based on the Tax Overpayment Refund Order
Nomor: 00165A tanggal 26 Februari 2025 adalah (SPMKP) Number: 00165A dated 26 February 2025
sebesar Rp 73.896.911.158. amounting to Rp 73,896,911,158.
332 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 333
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/54 Exhibit E/54
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
13. PERPAJAKAN (Lanjutan) 13. TAXATION (Continued)
b. Taksiran tagihan restitusi pajak penghasilan b. Estimated claim for income tax refund
2025 2024
Pajak Penghasilan – Pasal 28A Income Tax – Article 28A:
2025 7.010.357.046 - 2025
2024 12.420.641.216 12.420.641.216 2024
2023 3.678.944.787 7.475.246.376 2023
2022 11.216.130.193 11.216.130.193 2022
Jumlah 34.326.073.242 31.112.017.785 Total
Tahun 2023 Year 2023
Taksiran tagihan restitusi pajak penghasilan untuk The estimated claim for an income tax refund for
tahun 2023 sebesar Rp 7.475.246.376. 2023 is Rp 7,475,246,376.
Pada tanggal 12 Maret 2025, Perusahaan menerima On 12 March 2025, the Company received a
Surat Pemberitahuan Hasil Pemeriksaan (SPHP) Notification of Tax Audit Findings (SPHP) for
Pajak Penghasilan Badan untuk masa pajak tahun corporate income tax for the 2023 tax year
2023 No. S-80/RIKSIS/KPP.0708/2025. No. S-80/RIKSIS/KPP.0708/2025.
Pada tanggal 25 April 2025 Perusahaan menerima On 25 April 2025 the Company received an
Surat Ketetapan Pajak Lebih Bayar (SKPLB) Pajak overpaid tax assessment (SKPLB) for corporate
Penghasilan Badan untuk masa pajak tahun 2023 income tax for the 2021 tax year No.
No. 00040/406/23/054/25 dengan nilai sebesar 00040/406/23/054/25 with a value of Rp
Rp 3.678.944.787, dibandingkan dengan lebih 3,678,944,787, compared to the overpayment
bayar yang dilaporkan oleh Perusahaan sebesar reported by the Company of
Rp 7.475.246.376. Selisih antara tagihan restitusi Rp 7,475,246,376. The difference between claims
dan pengembalian pajak penghasilan sebesar for refund and refund of income tax amounted to
Rp 3.796.301.589 dicatat sebagai beban pajak kini Rp 3,796,301,589 recorded as current tax expense
– tahun lalu (Catatan 13d). - previous year (Note 13d).
Kelebihan pembayaran pajak sebesar Tax overpayment amounting to Rp 3,678,944,787
Rp 3.678.944.787 dikompensasikan untuk was offset against the Company’s 2022 tax
dibayarkan ke sejumlah utang pajak 2022. Pada liabilities. On 6 October 2025, the Company
tanggal 6 Oktober 2025, Perusahaan mengajukan formally contested the underlying 2022 Tax
permohonan pengurangan atau pembatalan SKP Assessment Letter (SKP) by submitting an
yang tidak benar atas pajak tahun 2022. Sampai application for its reduction or cancellation. As of
saat ini, belum ada keputusan atas permohonan the current date, a formal decision from the
tersebut. Directorate General of Taxes (DGT) remains
pending.
Tahun 2022 Year 2022
Taksiran tagihan restitusi pajak penghasilan untuk The estimated claim for an income tax refund for
tahun 2022 sebesar Rp 11.216.130.193. 2022 is Rp 11,216,130,193.
Pada tanggal 1 April 2024, Perusahaan menerima On 1 April 2024, the Company received an
Surat Ketetapan Pajak Kurang Bayar (SKPKB) Pajak underpaid tax assessment (SKPKB) for corporate
Penghasilan Badan untuk masa pajak tahun income tax for the 2022 tax year No. 00002/
2022 No. 00002/206/22/054/24. Pada saat ini 206/22/054/24. At this time, the Company is
Perusahaan sedang mengajukan keberatan atas submitting the objection letter for the SKPKB.
Surat Ketetapan Pajak Kurang Bayar (SKPKB)
tersebut.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 333
Page 334
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/55 Exhibit E/55
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
13. PERPAJAKAN (Lanjutan) 13. TAXATION (Continued)
c. Utang Pajak c. Tax Payables
2025 2024
Pajak Penghasilan: Income Taxes:
Pasal 21 - 5.562.652 Article 21
Pasal 23 97.330.408 86.598.034 Article 23
Pasal 4(2) 143.129.637 22.306.855 Article 4(2)
Jumlah 240.460.045 114.467.541 Total
d. Pajak Penghasilan d. Income Tax
Rincian (beban) manfaat pajak penghasilan adalah The details of income tax (expense) benefit are as
sebagai berikut: follows:
2025 2024
Pajak kini ( 16.083.068.980 ) ( 8.743.488.816 ) Current tax
Pajak kini – tahun sebelumnya ( 3.796.301.589 ) - Current tax – previous year
Jumlah pajak kini ( 19.879.370.569 ) ( 8.743.488.816) Total current tax
Pajak tangguhan 9.448.699.865 ( 2.043.681.651) Deferred tax
Jumlah ( 10.430.670.704 ) ( 10.787.170.467) Total
Rekonsiliasi antara (beban) manfaat pajak The reconciliation between consolidation income
penghasilan konsolidasian dan hal perhitungan tax benefit and the calculation profit before
laba sebelum pajak penghasilan konsolidasian consolidation income tax is as follows:
adalah sebagai berikut:
2025 2024
Laba konsolidasian sebelum Consolidated profit before
pajak penghasilan 48.896.921.901 27.701.302.589 income tax
Rugi entitas anak 4.363.697.421 4.662.337.444 Loss of the subsidiary
Laba sebelum pajak
Perusahaan 53.260.619.322 32.363.640.033 The Company’s income before tax
Beban pajak penghasilan dengan Income tax expense at the
tarif yang berlaku 11.717.336.250 7.120.000.807 applicable tax rate
Pengaruh pajak atas beda tetap 2.625.314.835 611.766.270 Tax effect on permanent differences
Penyesuaian atas pajak Adjustment of the previous period
tangguhan periode sebelumnya ( 7.708.281.970) 3.055.403.390 deffered tax income
Pajak kini – tahun sebelumnya 3.796.301.589 - Current tax – previous year
Beban pajak penghasilan 10.430.670.704 10.787.170.467 Income tax expense
334 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 335
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/56 Exhibit E/56
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
13. PERPAJAKAN (Lanjutan) 13. TAXATION (Continued)
d. Pajak Penghasilan (Lanjutan) d. Income Tax (Continued)
Rekonsiliasi antara laba sebelum pajak The reconciliation between profit before invoice
penghasilan Perusahaan dengan laba kena pajak tax of the Company ended the Company’s taxable
perusahaan untuk tahun yang berakhir pada profit for the year ended 31 December 2025 and
31 Desember 2025 dan 2024 adalah sebagai 2024 are as follows:
berikut:
2025 2024
Laba konsolidasian sebelum 48.896.921.901 27.701.302.589 Consolidated profit before
pajak penghasilan income tax
Rugi entitas anak 4.363.697.421 4.662.337.444 Loss of the subsidiary
Laba sebelum pajak Perusahaan 53.260.619.322 32.363.640.033 The Company’s income before tax
Beda tetap: Permanent differences:
Beban yang bukan merupakan
pengurang pajak 12.223.339.534 2.839.761.968 Non – deductible expense
Pendapatan keuangan yang telah Financing income subjected
dikenakan pajak bersifat final ( 290.090.283) ( 59.006.191 ) to final tax
Jumlah beda tetap 11.933.249.251 2.780.755.777 Total permanent difference
Beda temporer: Temporary differences:
Imbalan kerja 3.518.697.422 1.728.361.012 Employee benefits
Bonus 1.427.510.244 202.334.231 Bonus
Depreciation of property
Penyusutan aset tetap 200.008.889 200.008.889 and equipment
Cadangan kerugian penurunan Allowance for impairment
nilai piutang 3.021.492.300 264.785.291 losses of trade receivables
Cadangan kerugian penurunan Allowance for impairment
nilai persediaan ( 620.526.901) 1.520.848.668 losses of inventories
Aset hak-guna 363.808.434 682.397.365 Right-of-use assets
Jumlah beda temporer 7.910.990.388 4.598.735.456 Total temporary differences
Taksiran laba kena pajak 73.104.859.961 39.743.131.266 Estimated taxable income
Pembulatan 73.104.859.000 39.743.131.000 Rounding
Beban pajak kini, tarif 22% 16.083.068.980 8.743.488.816 Current income tax, rate 22%
Dikurangi: kredit
pajak penghasilan Less: income tax credit
Pasal 22 23.038.333.242 21.142.696.858 Article 22
Pasal 23 55.092.782 21.433.174 Article 23
23.093.426.024 21.164.130.032
Taksiran klaim pajak Estimated claim tax
penghasilan 7.010.357.046 12.420.641.216 refund
Surat pemberitahuan (“SPT”) Tahunan Pajak The Annual Corporate Income Tax Return (“SPT”)
Penghasilan Badan untuk tahun pajak 2025 belum for fiscal year 2025 has not yet been submitted.
dilaporkan. Laba kena pajak hasil rekonsiliasi The taxable income that resulted from
untuk tahun yang berakhir pada tanggal reconciliation for the year ended 31 December
31 Desember 2025 akan digunakan sebagai dasar 2025 will be used as the basis for annual corporate
dalam pengisian SPT Tahunan Pajak Penghasilan income tax filing of the Company.
Badan Perusahaan.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 335
Page 336
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/57 Exhibit E/57
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
13. PERPAJAKAN (Lanjutan) 13. TAXATION (Continued)
e. Aset Pajak Tangguhan e. Deferred tax Assets
Pajak tangguhan dihitung berdasarkan pengaruh Deferred tax is computed based on the effect of
dari perbedaan temporer antara jumlah tercatat temporary differences between the carrying
aset dan liabilitas menurut laporan keuangan amount of assets and liabilities in the financial
dengan dasar pengenaan pajak aset dan liabilitas. statements with the tax bases of assets and
liabilities.
Rincian aset pajak tangguhan pada tanggal The details of deferred tax assets as of
31 Desember 2025 dan 2024 adalah sebagai 31 December 2025 and 2024 are as follows:
berikut:
Dikreditkan
(dibebankan)
ke penghasilan
Dikreditkan komprehensif
(dibebankan) lain/ Credited
ke laba rugi/ (Charged) to
31 Desember/ Credited other 31 Desember/
December (charged) to comprehensive December
2024 profit or loss income 2025
Liabilitas imbalan kerja 7.140.153.058 812.941.743 ( 13.322.876 ) 7.939.771.925 Employee benefits liabilities
Bonus 932.439.712 1.290.342.586 - 2.222.782.298 Bonus
Depreciation of property and
Penyusutan aset tetap 180.869.202 44.001.956 - 224.871.158 equipment
Cadangan kerugian Allowance for impairment
penurunan nilai piutang 5.162.835.510 664.728.306 - 5.827.563.816 losses of trade receivables
Cadangan kerugian
penurunan nilai Allowance for impairment
persediaan 1.136.152.934 ( 136.515.918) - 999.637.016 losses of inventories
Aset hak-guna ( 3.239.578.217 ) 6.773.201.192 - 3.533.622.975 Right-of-use assets
Perubahan nilai wajar Change fair value in
investasi 6.928.240.000 - 862.840.000 7.791.080.000 Investment
Surplus revaluasi ( 1.185.340.869 ) - - ( 1.185.340.869 ) Revaluation surplus
Aset Pajak Tangguhan Deferred Tax Asset
- Bersih 17.055.771.330 9.448.699.865 849.517.124 27.353.988.319 – Net
Dikreditkan
ke penghasilan
(Dibebankan) komprehensif
Dikreditkan lain/
ke laba rugi/ Credited to
31 Desember/ (Charged) other 31 Desember/
December Credited to comprehensive December
2023 profit or loss income 2024
Liabilitas imbalan kerja 6.611.035.776 380.239.419 148.877.863 7.140.153.058 Employee benefits liabilities
Bonus 887.926.181 44.513.531 - 932.439.712 Bonus
Depreciation of property and
Penyusutan aset tetap 136.867.246 44.001.956 - 180.869.202 equipment
Cadangan kerugian Allowance for impairment
penurunan nilai piutang 5.221.088.274 ( 58.252.764 ) - 5.162.835.510 losses of trade receivables
Cadangan kerugian
penurunan nilai Allowance for impairment
persediaan 801.566.228 334.586.706 - 1.136.152.934 losses of inventories
Aset hak-guna ( 450.807.718 ) ( 2.788.770.499 ) - ( 3.239.578.217 ) Right-of-use assets
Perubahan nilai wajar Change fair value in
investasi 4.554.000.000 - 2.374.240.000 6.928.240.000 Investment
Surplus revaluasi ( 1.185.340.869 ) - - ( 1.185.340.869 ) Revaluation surplus
Aset Pajak Tangguhan Deferred Tax Asset
- Bersih 16.576.335.118 ( 2.043.681.651 ) 2.523.117.863 17.055.771.330 – Net
336 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 337
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/58 Exhibit E/58
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
13. PERPAJAKAN (Lanjutan) 13. TAXATION (Continued)
Berdasarkan Undang-Undang No. 7 Tahun 2021 tentang Based on Law No. 7 Year 2021 concerning
"Harmonisasi Peraturan Perpajakan", yang merubah UU "Harmonization of Tax Regulations", which amends
No. 7 Tahun 1983 tentang "Pajak Penghasilan" dan Law No. 7 Year 1983 concerning "Income Tax" and the
Pemerintah menetapkan tarif tunggal pajak Government set the single rate of corporate income
penghasilan badan menjadi 22% mulai Tahun Pajak tax to be 22% from the 2022 Fiscal Year onwards. In
2022 dan seterusnya. Selain itu, UU tersebut addition, the Act amends Law No. 6 Year 1983
mengubah UU No. 6 Tahun 1983 tentang "Ketentuan concerning "General Provisions and Tax Procedures"
Umum dan Tata Cara Perpajakan" dan UU No. 8 Tahun and Law No. 8 Year 1983 concerning "Value Added Tax
1983 tentang "Pajak Pertambahan Nilai Barang dan on Goods and Services and Sales Tax on Luxury Goods"
Jasa dan Pajak Penjualan atas Barang Mewah" dan and provisions related to carbon tax.
ketentuan terkait dengan pajak karbon.
14. BEBAN AKRUAL 14. ACCRUED EXPENSES
2025 2024
Bunga 2.979.778.463 12.179.098.101 Interest
Lain - lain 16.104.203.878 6.186.752.053 Others
Jumlah 19.083.982.341 18.365.850.154 Total
Beban akrual - lain-lain terutama merupakan akrual Accrued expenses others mainly represents accruals of
atas pengiriman, pengangkutan dan jasa profesional. freight, expedition and professional fees.
15. LIABILITAS IMBALAN KERJA JANGKA PENDEK 15. SHORT-TERM EMPLOYEE BENEFITS LIABILITY
Rincian liabilitas imbalan kerja jangka pendek adalah The details of short-term employee benefits liability
sebagai berikut: are as follows:
2025 2024
Cadangan bonus karyawan 5.402.258.913 4.238.362.326 Provision for employee bonus
Cadangan bonus karyawan merupakan estimasi Provision for employees’ bonus represents estimated
cadangan bonus akan yang diberikan kepada karyawan. bonus provision that will be paid to the employees.
16. LIABILITAS IMBALAN KERJA JANGKA PANJANG 16. LONG-TERM EMPLOYEE BENEFITS LIABILITY
Liabilitas imbalan kerja jangka panjang Perusahaan The Company’s long-term employee benefits liability
hanya berhubungan dengan liabilitas imbalan kerja. relates only to post-employment benefits. The
Perusahaan memberikan imbalan kerja kepada Company provides post-employment benefits for its
karyawan berdasarkan UU Cipta Kerja No. 6/2023 dan employees based on Cipta Kerja Law No. 6/2023 and
Peraturan Pemerintah No. 35/2021. Imbalan kerja Government Regulation No. 35/2021. The benefits are
tersebut tidak didanai. unfunded.
Tabel berikut ini merangkum komponen-komponen The following tables summarize the components of
atas beban imbalan kerja yang diakui di laporan laba post-employment benefits expense recognized in the
rugi dan penghasilan komprehensif lain dan liabilitas statement of profit or loss and other comprehensive
imbalan kerja jangka panjang yang diakui di laporan income and long-term employee benefits liability
posisi keuangan 31 Desember 2025 dan 2024 recognized in the statement of financial position
berdasarkan penilaian aktuaria yang dilakukan oleh 31 December 2025 and 2024, as determined by
aktuaris independen, dengan menggunakan metode independent actuary, by using the projected unit
projected unit credit. credit method.
a. Liabilitas Imbalan Kerja Jangka Panjang a. Long-term Employee Benefits Liability
2025 2024
Nilai kini kewajiban 36.089.872.387 32.631.733.401 Present value of obligation
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 337
Page 338
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/59 Exhibit E/59
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
16. LIABILITAS IMBALAN KERJA JANGKA PANJANG 16. LONG-TERM EMPLOYEE BENEFITS LIABILITY
(Lanjutan) (Continued)
b. Beban Imbalan kerja b. Employee Benefits Expense
2025 2024
Biaya jasa kini 3.948.362.809 3.573.166.361 Current service cost
Biaya bunga 2.131.865.814 2.073.461.221 Interest cost
Jumlah 6.080.228.623 5.646.627.582 Total
c. Perubahan liabilitas imbalan kerja jangka panjang c. Changes in long-term employee benefits liability
selama tahun berjalan adalah sebagai berikut: during the year are as follows:
2025 2024
Saldo awal tahun 32.631.733.401 30.050.162.619 Balance beginning of the year
Beban imbalan kerja Employee benefits expense
(Catatan 23) 6.080.228.623 5.646.627.582 (Note 23)
Pembayaran manfaat ( 2.561.531.035 ) ( 3.741.774.342) Benefit payment
(Keuntungan) kerugian aktuarial ( 60.558.602 ) 676.717.542 Actuarial (gain) loss
Saldo akhir tahun 36.089.872.387 32.631.733.401 Balance at end of year
d. Keuntungan aktuaria kumulatif yang diakui dalam d. The cumulative actuarial gains recognized in
penghasilan komprehensif lain adalah sebagai other comprehensive income are as follows:
berikut:
2025 2024
Saldo awal tahun 588.339.514 ( 88.378.028 ) Balance beginning of the year
(Keuntungan) kerugian aktuaria Actuarial (gain) loss during the
tahun berjalan ( 60.558.602 ) 676.717.542 year
Saldo akhir tahun 527.780.912 588.339.514 Balance at the end of year
e. Asumsi-asumsi dasar yang digunakan dalam e. The principal assumptions used in determining
menentukan liabilitas imbalan kerja jangka long-term employee benefits liability as follows:
panjang sebagai berikut:
2025 2024
Tingkat diskonto 6,51% 7,25% Discount rate
Tingkat kenaikan gaji 6,00% 5,00% Future salary increase
Tabel mortalita TMI-IV 2019 TMI-IV 2019 Mortality table
Tingkat cacat 10% 1% Disability rate
Tingkat penguduran diri 10% dari usia 18 5% dari usia 20 Resignation rate
kemudian menurun kemudian menurun
linier 0% di usia 53/ linier 0% di usia 55/
10% of age 18 then 5% of age 20 then
decreasing linearly decreasing linearly
into 0% at age 53 into 0% at age 55
Usia pensiun normal 55 tahun/years 55 tahun/years Normal pension age
338 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 339
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/60 Exhibit E/60
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
16. LIABILITAS IMBALAN KERJA JANGKA PANJANG 16. LONG-TERM EMPLOYEE BENEFITS LIABILITY
(Lanjutan) (Continued)
f. Sensitivitas liabiltas imbalan kerja untuk perubahan f. The sensitivity of the employee benefit liabilities to
asumsi aktuaria pokok sebagai berikut: changes in the principal actuarial assumption are as
follows:
2025
Dampak terhadap liabilitas
imbalan pasti/
Impact on defined
benefit obligation
Perubahan Kenaikan Penurunan
Asumsi/ Asumsi/ Asumsi/
Change in Increase in Derease in
assumptions assumption assumption
Tingkat diskonto 1% ( 2.977.267.595 ) 3.455.738.390 Discount rate
Tingkat kenaikan upah 1% 3.443.610.626 ( 3.021.315.988) Salary increase rate
2024
Dampak terhadap liabilitas
imbalan pasti/
Impact on defined
benefit obligation
Perubahan Kenaikan Penurunan
Asumsi/ Asumsi/ Asumsi/
Change in Increase in Derease in
assumptions assumption assumption
Tingkat diskonto 1% ( 2.305.278.888 ) 2.608.357.795 Discount rate
Tingkat kenaikan upah 1% 2.399.597.380 ( 2.165.525.684 ) Salary increase rate
Analisa sensitivitas diatas didasarkan pada perubahan The above sensitivity analysis is based on a change in
atas suatu asumsi aktuaria dimana semua asumsi an assumption while holding all other assumptions
lainnya dianggap konstan. Dalam prakteknya, hal ini constant. In practice, this is unlikely to occur and
jarang terjadi dan perubahan beberapa asumsi changes in some of the assumptions may be
mungkin saling berkorelasi. Dalam perhitungan correlated. When calculating the sensitivity of
sensitivitas liabilitas imbalan kerja atas asumsi employment benefit liabilities to significant
aktuaria utama, metode yang sama (projected unit actuarial assumptions, the same method (projected
credit) telah diterapkan seperti perhitungan unit credit) has been applied when calculating the
liabilitas imbalan kerja yang diakui dalam laporan employment benefit liabilities recognized within the
posisi keuangan. statements of financial position.
17. MODAL SAHAM 17. SHARE CAPITAL
Sesuai dengan daftar pemegang saham yang dikeluarkan Based on the shareholders list issued by the Share
oleh Biro Administrasi Efek Perusahaan (PT Raya Saham Administrator Bureau of the Company (PT Raya Saham
Registra), susunan pemegang saham dan komposisi Registra), the Company’s shareholders and its ownership
kepemilikan saham pada tanggal 31 Desember 2025 dan composition as of 31 December 2025 and 2024 are as
2024 adalah sebagai berikut: follows:
Jumlah lembar Jumlah saham/ Jumlah/
saham/Number Total shares Total
of shares (Lembar/Shares) (%)
Pemegang Saham Shareholders
Pharmaniaga International Pharmaniaga International
Corp. Sdn. Bhd., Malaysia 935.541.534 93.554.153.400 73,43 Corp. Sdn. Bhd., Malaysia
PT Danpac Pharma 123.844.020 12.384.402.000 9,72 PT Danpac Pharma
PT Indolife Pensiontama 42.762.830 4.276.283.000 3,36 PT Indolife Pensiontama
PT Ngrumat Bondo Utama 23.731.000 2.373.100.000 1,86 PT Ngrumat Bondo Utama
Masyarakat 148.120.616 14.812.061.600 11,63 Public
Jumlah 1.274.000.000 127.400.000.000 100 Total
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 339
Page 340
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/61 Exhibit E/61
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
17. MODAL SAHAM (Lanjutan) 17. SHARE CAPITAL (Continued)
Berdasarkan pencatatan Biro Administrasi Efek, tidak Based on the Share Administrator Bureau’s records,
ada anggota Dewan Komisaris dan Direksi Perusahaan there are no members of the Boards of Commissioners
yang memiliki saham Perusahaan yang telah and Directors who own the Company’s shares of stock
diterbitkan pada tanggal 31 Desember 2025 dan 2024. as of 31 December 2025 and 2024.
18. TAMBAHAN MODAL DISETOR 18. ADDITIONAL PAID-IN CAPITAL
Tambahan modal disetor merupakan selisih antara Additional paid-in capital represents the difference
jumlah harga penawaran saham dengan jumlah nilai between the offering share price and the par values
nominal saham yang ditawarkan dalam penawaran of the shares offered in the Company’s limited public
umum terbatas Perusahaan setelah dikurangi dari offering after being deducted from the total costs
seluruh beban yang berhubungan dengan penawaran incurred in connection with the limited public
umum terbatas tersebut. Rincian akun ini pada tanggal offering. The details of this account as of
31 Desember 2025 dan 2024 adalah sebagai berikut: 31 December 2025 and 2024 are as follows:
Jumlah/
Total
Tambahan modal disetor dari penerbitan
Saham baru sebelum Penawaran Umum Additional paid-in capital from issuance of
Terbatas III 1.300.000.000 new shares before Limited Public Offering III
Selisih lebih harga penawarn saham di atas
nilai nominal saham ( 1.750.725.142 ) Excess of offering price over par value of shares
Sub-jumlah ( 450.725.142 ) Sub-total
Tambahan modal disetor dari penerbitan
Saham baru sebelum Penawaran Umum Additional paid-in capital from issuance of
Terbatas III 5.460.000.000 new shares before Limited Public Offering III
Selisih lebih harga penawarn saham di atas
nilai nominal saham ( 2.699.590.936 ) Excess of offering price over par value of shares
Sub-jumlah 2.760.409.064 Sub-total
Jumlah 2.309.683.922 Total
19. DIVIDEN KAS DAN SALDO LABA YANG TELAH 19. CASH DIVIDENDS AND APPROPRIATED RETAINED
DITENTUKAN PENGGUNAANNYA EARNINGS
Berdasarkan Keputusan Rapat Umum Pemegang Saham Based on the Resolution of the Annual General Meeting
Tahunan Perusahaan tanggal 28 Mei 2025 yang of the Company’s Shareholders dated 28 May 2025 as
dinyatakan dalam Akta No. 75 Notaris Dini Lastari covered by Deed No. 75 of Dini Lastari Siburian, S.H.,
Siburian, S.H., Notaris di Jakarta, pada tanggal yang Notary in Jakarta, on the same date, the Company’s
sama, para pemegang saham Perusahaan memutuskan shareholders resolved to approve the appropriation of
untuk menyetujui pencadangan saldo laba sebesar retained earnings amounting to Rp 2,548,000,000 as a
Rp 2.548.000.000 sebagai dana cadangan dan reserve fund and the declaration of dividends
pembagian dividen kas sebesar Rp 2.548.000.000. amounting to Rp 2,548,000,000. The dividend was fully
Dividen ini sudah dibayarkan pada tanggal 1 dan 2 Juli paid on 1 and 2 July 2025.
2025.
Berdasarkan Keputusan Rapat Umum Pemegang Saham Based on the Resolution of the Annual General Meeting
Tahunan Perusahaan tanggal 31 Mei 2024 yang of the Company’s Shareholders dated 31 May 2024 as
dinyatakan dalam Akta No. 66 Notaris Dini Lastari covered by Deed No. 66 of Dini Lastari Siburian, S.H.,
Siburian, S.H., Notaris di Jakarta, pada tanggal yang Notary in Jakarta, on the same date, the Company’s
sama, para pemegang saham Perusahaan memutuskan shareholders resolved to approve the appropriation of
untuk menyetujui pencadangan saldo laba sebesar retained earnings amounting to Rp 3,185,000,000 as a
Rp 3.185.000.000 sebagai dana cadangan dan reserve fund and the declaration of dividends
pembagian dividen kas sebesar Rp 3.185.000.000 atau amounting to Rp 3,185,000,000 or Rp 2.5 per share.
sebesar Rp 2,5 per saham. Dividen ini sudah dibayarkan The dividend was fully paid on 3 July 2024.
secara penuh pada tanggal 3 Juli 2024.
340 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 341
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/62 Exhibit E/62
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
20. PENDAPATAN 20. REVENUES
2025 2024
Obat resep 2.887.792.388.490 2.761.106.651.046 Prescription medicines
Alat kesehatan 1.078.183.045.113 949.673.112.885 Medical equipment
Obat non-resep 143.452.403.742 205.936.532.821 Non-prescription medicines
Lainnya 382.501.671 147.581.778 Others
Jumlah 4.109.810.339.016 3.916.863.878.530 Total
Seluruh penjualan dilakukan dengan pihak ketiga dan All sales are made to third parties and there are no
tidak terdapat penjualan kepada pelanggan yang sales to customers that individually exceeded 10% of
melebihi 10% dari jumlah penjualan neto. the net sales.
21. BEBAN POKOK PENDAPATAN 21. COST OF REVENUES
Rincian beban pokok pendapatan adalah sebagai The details of cost of revenue sold are as follows:
berikut:
2025 2024
Obat resep 2.643.013.016.206 2.504.956.572.042 Prescription medicines
Alat kesehatan 970.840.721.604 870.952.504.927 Medical equipment
Obat non-resep 133.560.076.662 206.536.174.984 Non-prescription medicines
Lainnya 37.594.311 41.585.000 Others
Jumlah 3.747.451.408.783 3.582.486.836.953 Total
Rincian pembelian persediaan yang melebihi 10% dari Purchases of inventories which individually represents
jumlah penjualan neto masing-masing pada more than 10% of the total net sales in
31 Desember 2025 dan 2024 adalah sebagai berikut: 31 December 2025 and 2024 are as follows:
2025 2024
PT Lapi Laboratories Indonesia 1.279.551.680.830 1.296.271.531.545 PT Lapi Laboratories Indonesia
PT Global Dispomedika 509.587.481.335 547.679.378.526 PT Global Dispomedika
PT Medi Hop 400.156.324.506 431.766.417.952 PT Medi Hop
PT Dipa Pharmalab Intersains 181.240.545.602 403.503.813.675 PT Dipa Pharmalab Intersains
Jumlah 2.370.536.032.273 2.679.221.141.698 Total
Pembelian persediaan dari pihak berelasi untuk tahun Purchases of inventories from related
31 Desember 2025 dan 2024 masing-masing adalah parties amounted to Rp 44,323,981,362 and
sebesar Rp 44.323.981.362 dan Rp 55.870.122.868 Rp 55,870,122,868 on 31 December 2025 and 2024,
(Catatan 27). respectively (Note 27).
22. BEBAN PENJUALAN 22. SELLING EXPENSES
2025 2024
Gaji, upah dan Salaries, wages and
tunjangan karyawan 34.068.533.489 34.491.908.490 allowances
Pengangkutan dan pengiriman 23.982.984.243 23.473.977.238 Freight and expedition
Perjalanan 3.912.917.874 4.094.744.926 Travelling
Iklan dan promosi 3.059.449.034 2.963.592.918 Advertising and promotion
Sumbangan dan representasi 566.823.597 523.994.112 Donation and representation
Jumlah 65.590.708.237 65.548.217.684 Total
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 341
Page 342
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/63 Exhibit E/63
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
23. BEBAN UMUM DAN ADMINISTRASI 23. GENERAL AND ADMINISTRATIVE EXPENSES
2025 2024
Gaji, upah dan Salaries, wages and
tunjangan karyawan 85.983.970.933 79.335.101.896 allowances
Penyusutan aset hak- Depreciation of right-of-use
guna (Catatan 10) 12.447.278.347 11.667.705.569 assets (Note 10)
Lisensi 11.091.434.491 6.836.921.835 Lisence
Jasa profesional 10.273.451.170 7.094.002.698 Professional fees
Penyusutan aset tetap Depreciation of property and
(Catatan 8) 9.514.892.329 10.540.930.279 equipment (Note 8)
Imbalan kerja (Catatan 16b) 6.080.228.623 5.646.627.582 Employee benefits (Note 16)
Beban kantor 5.364.476.877 6.071.237.841 Office expense
Listrik dan energi 4.582.441.145 4.540.909.853 Electricity and energy
Penyisihan kerugian penurunan Provision for impairment losses
nilai persediaan (Catatan 6) 3.400.000.000 4.905.141.665 on inventories (Note 6)
Penyisihan kerugian penurunan Provision for impairment losses
nilai piutang usaha (Catatan 5) 3.021.492.300 5.000.000.000 on trade receivables (Note 5)
Alat tulis dan barang cetakan 2.887.852.514 3.304.087.216 Office supplies and printing
Sewa dan pemeliharaan gedung 2.373.098.379 3.140.552.882 Office rental and maintenance
Perbaikan dan pemeliharaan 1.901.183.786 2.515.570.985 Repairs and maintenance
Perjalanan 1.742.799.826 2.272.629.753 Traveling
Pos dan komunikasi 1.568.671.002 1.553.360.558 Postage and communication
Pendidikan dan pelatihan 1.509.675.958 1.208.152.831 Training and educations
Asuransi 1.462.489.679 1.378.460.719 Insurance
Amortisasi aset takberwujud Amortization of intangibles assets
(Catatan 9) 1.438.281.524 1.363.240.899 (Note 9)
Sumbangan dan representasi 1.345.405.053 916.553.276 Donations and representation
Lain-lain 1.315.296.806 1.351.509.587 Others
Jumlah 169.304.420.742 160.642.697.924 Total
24. BIAYA KEUANGAN 24. FINANCE COSTS
2025 2024
Bunga atas utang bank 64.930.209.553 68.713.990.798 Interest on bank loans
Bunga atas liabilitas sewa - 77.421.383 Interest on lease liabilities
Jumlah 64.930.209.553 68.791.412.181 Total
25. LABA PER SAHAM 25. EARNINGS PER SHARE
Perhitungan laba per saham dasar adalah sebagai The calculation of earnings per share are as follow:
berikut:
2025 2024
Laba tahun berjalan yang dapat
diatribusikan kepada pemilik Profit for the year attributable
entitas induk 38.468.911.988 16.928.878.936 to the owners of parent entity
Jumlah rata-rata tertimbang Weighted average number of
saham yang beredar 1.274.000.000 1.274.000.000 shares outstanding
Jumlah 30,20 13,29 Total
Perusahaan tidak mempunyai efek berpotensi saham The Company has no potentially dilutive shares,
bersifat dilutif sehingga Perusahaan tidak menghitung accordingly, no diluted earnings per share was
laba per saham dilusian. calculated.
342 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 343
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/64 Exhibit E/64
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
26. INFORMASI SEGMEN 26. SEGMENT INFORMATION
Segmen Usaha Business Segment
Sesuai dengan PSAK 108: Segmen Usaha, informasi In accordance with PSAK 108: Business Segments, the
keuangan ini disajikan berdasarkan informasi yang following financial information is presented based on
digunakan manajemen dalam mengevaluasi kinerja the information used by management in evaluating the
tiap segmen dan menentukan pengalokasian sumber performance of each segment and in determining
daya. allocations of resources.
Struktur organisasi dan manajemen Perusahaan serta The organizational structure and management of the
pelaporan keuangan internal berdasarkan kelompok Company as well as its internal financial reporting
produk. Oleh sebab itu, untuk tujuan pelaporan system are based on group of products. Therefore,
manajemen, saat ini Perusahaan dibagi dalam tiga business segment information of the Company is
segmen berdasarkan pertimbangan risiko hasil terkait presented based on judgment of risk and results of
dengan produk yaitu obat resep, obat non-resep dan related products which are prescription medicine,
alat kesehatan. non-prescription medicine and medical devices.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 343
Page 344
Positioned for
Profitable Growth
2025
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Laporan Tahunan & Laporan Keberlanjutan
Ekshibit E/65 Exhibit E/65
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
26. INFORMASI SEGMEN (Lanjutan) 26. SEGMENT INFORMATION (Continued)
2025
Alat Obat
Obat Resep/ kesehatan/ Non-resep/
Prescription Medical Non -Prescription Lainnya/ Jumlah/
medicines equipment medicines Others Total
Penjualan neto 2.887.792.388.490 1.078.183.045.113 143.452.403.742 382.501.671 4.109.810.339.016 Net sales
Hasil segmen 244.779.372.284 107.342.323.509 9.892.327.080 344.907.360 362.358.930.233 Segment result
Beban usaha tidak dapat dialokasikan ( 248.821.889.062 ) Unallocated operating expenses
Laba usaha 113.537.041.171 Income for operations
Pendapatan keuangan 290.090.283 Finance incone
Biaya keuangan ( 64.930.209.553 ) Finance costs
Beban pajak penghasilan ( 10.430.670.704 ) Income tax expense
Laporan Keuangan
Laba tahun berjalan 38.466.251.197 Profit for the year
Financial Report
Kerugian komprehensif lain ( 3.011.924.274 ) Other comprehensive loss
Jumlah laba komprehensif tahun berjalan 35.454.326.923 Total comprehensive income for the year
ASET ASSET
PT Millennium Pharmacon International Tbk
Aset segmen 418.795.030.385 159.779.848.116 30.483.992.482 33.436.500 609.092.307.483 Segment assets
Aset tidak dapat dialokasi 1.351.627.547.652 Unallocated assets
Jumlah Aset 1.960.719.855.135 Total Assets
LIABILITAS LIABILITIES
Liabilitas segmen 379.167.713.258 285.408.203.151 29.873.143.803 - 694.449.060.212 Segment liabilities
Liabilitas tidak dapat dialokasi 950.867.547.991 Unallocated liabilities
Jumlah Liabilitas 1.645.316.608.203 Total Liabilities
344
Page 345
345
Annual Report & Sustainability Report
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/66 Exhibit E/66
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
26. INFORMASI SEGMEN (Lanjutan) 26. SEGMENT INFORMATION (Continued)
2024
Alat Obat
2025
Obat Resep/ kesehatan/ Non-resep/
Prescription Medical Non -Prescription Lainnya/ Jumlah/
medicines equipment medicines Others Total
Penjualan neto 2.761.106.651.046 949.673.112.885 205.936.532.821 147.581.778 3.916.863.878.530 Net sales
Hasil segmen 256.150.079.004 78.720.607.958 ( 599.642.163 ) 105.996.778 334.377.041.577 Segment result
Beban usaha tidak dapat dialokasikan ( 237.943.332.998 ) Unallocated operating expenses
Laba usaha 96.433.708.579 Income for operations
Pendapatan keuangan 59.006.191 Finance incone
Biaya keuangan ( 68.791.412.181 ) Finance costs
Beban pajak penghasilan ( 10.787.170.467 ) Income tax expense
Laba tahun berjalan 16.914.132.122 Profit for the year
Kerugian komprehensif lain ( 8.945.599.679 ) Other comprehensive loss
Jumlah laba komprehensif tahun berjalan 7.968.532.443 Total comprehensive income for the year
ASET ASSET
PT Millennium Pharmacon International Tbk
Aset segmen 389.124.339.494 146.139.359.562 32.408.573.062 60.113.000 567.732.385.118 Segment assets
Aset tidak dapat dialokasi 1.204.124.444.283 Unallocated assets
Jumlah Aset 1.771.856.829.401 Total Assets
LIABILITAS LIABILITIES
Liabilitas segmen 280.943.299.640 220.756.555.782 25.889.891.251 - 527.589.746.673 Segment liabilities
Liabilitas tidak dapat dialokasi 961.770.162.719 Unallocated liabilities
Jumlah Liabilitas 1.489.359.909.392 Total Liabilities
Profitable Growth
Positioned for
Page 346
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/67 Exhibit E/67
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
26. INFORMASI SEGMEN (Lanjutan) 26. SEGMENT INFORMATION (Continued)
Segmen Geografis (Lanjutan) Geographical Segments (Continued)
Perusahaan pada tanggal 31 Desember 2025 dan 2024 The Company has 37 and 36 branches as of
memiliki 37 dan 36 kantor cabang, yang beroperasi di 31 December 2025 and 2024, that operates in six areas
enam wilayah geografis yang menjangkau seluruh covering Indonesia. The Company’s merchandise
Indonesia. Produk Perusahaan seperti obat resep, obat inventories such as prescription medicine, non-
non-resep dan alat kesehatan didistribusikan ke pulau prescription medicine and medical equipment are
Jawa, Bali, Lombok, Sumatera, Kalimantan dan distributed to Java, Bali, Lombok, Sumatera,
Sulawesi. Kalimantan and Sulawesi islands.
Penjualan Perusahaan berdasarkan segmen geografis Sales by geographical segment of the Company are as
adalah sebagai berikut: follows:
2025 2024
Jawa 2.441.098.759.545 2.365.195.513.149 Jawa
Sumatera 903.426.029.399 846.075.215.543 Sumatera
Kalimantan 332.020.496.177 294.381.035.938 Kalimantan
Sulawesi 227.047.672.809 217.319.164.675 Sulawesi
Bali 145.302.884.817 135.600.323.255 Bali
Lombok 60.914.496.269 58.292.625.970 Lombok
Jumlah 4.109.810.339.016 3.916.863.878.530 Total
Informasi jumlah aset Perusahaan berdasarkan segmen Information on total assets by geographical segments
geografis adalah sebagai berikut: of the Company are as follows:
2025 2024
Jawa 1.256.806.463.351 1.100.741.720.217 Jawa
Sumatera 368.997.248.467 347.043.953.408 Sumatera
Kalimantan 131.980.792.583 134.178.088.649 Kalimantan
Sulawesi 119.398.009.243 110.299.220.964 Sulawesi
Bali 52.993.093.195 46.770.973.998 Bali
Lombok 30.544.248.296 32.822.872.165 Lombok
Jumlah 1.960.719.855.135 1.771.856.829.401 Total
Informasi jumlah penambahan aset tetap Perusahaan Information of acquisition of fixed assets by
berdasarkan segmen geografis adalah sebagai berikut: geographical segments of the Company are as follows:
2025 2024
Jawa 32.871.710.165 9.648.285.144 Jawa
Bali 3.305.153.506 1.642.080.045 Bali
Sulawesi 1.073.534.073 120.724.188 Sulawesi
Kalimantan 275.627.610 581.454.644 Kalimantan
Sumatera 221.206.634 2.100.322.702 Sumatera
Lombok 12.885.000 65.700.550 Lombok
Jumlah 37.760.116.988 14.158.567.273 Total
346 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 347
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/68 Exhibit E/68
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
27. SALDO DAN TRANSAKSI DENGAN PIHAK-PIHAK 27. BALANCE AND TRANSACTIONS WITH RELATED
BERELASI PARTIES
Rincian sifat hubungan dan jenis transaksi antara The summary of the nature of relationships and
Perusahaan dengan pihak-pihak berelasi adalah transactions between the Company and the related
sebagai berikut: parties are as follows:
Pihak-pihak berelasi/ Sifat dari hubungan/ Sifat dari transaksi/
Related parties Nature of relationship Nature of transaction
Pharmaniaga International Pemegang saham / Pinjaman dengan bunga/
Corporation Sdn. Bhd The shareholders Interest bearing loan
PT Danpac Pharma Pemegang saham / Pembelian persediaan/
The shareholders Purchase of inventories
Pharmaniaga Logistics Sdn. Bhd Entitas sepengendali/ Pembelian persediaan dan pinjaman dengan bunga/
Entity under common control Purchase of inventories and interest bearing loan
PT Errita Pharma Entitas sepengendali/ Pembelian persediaan, piutang lain-lain, penyertaan
Entity under common control dalam saham/ Purchase of inventories, other
receivables and investment in shares of stock
Pharmaniaga Berhad Entitas sepengendali/ Pembelian persediaan dan pinjaman dengan bunga/
Entity under common control Purchase of inventories and interest bearing loan
PT Mega Pharmaniaga Entitas sepengendali/ Pembelian persediaan/
Entity under common control Purchase of inventories
Pristine Pharma Sdn. Bhd Entitas sepengendali/ Pembelian persediaan/
Entity under common control Purchase of inventories
Pharmaniaga Marketing Sdn. Bhd Entitas sepengendali/ Pembelian persediaan/
Entity under common control Purchase of inventories
Personel manajemen kunci/ Dewan Komisaris dan Imbalan kerja jangka pendek/
Key management personnel Direktur/ Board of Short term employee benefits
Commissioners and Directors
Pembelian Persediaan dan Utang Usaha Purchase of Inventories and Trade Payables
Perusahaan membeli persediaan dari pihak berelasi. The Company purchased inventories from related
Pembelian dilakukan dengan tingkat harga dan syarat parties. Purchases were made at normal prices and
normal sebagaimana dilakukan dengan pihak ketiga. conditions as those made by third parties.
Piutang Lain-lain Other Receivable
Piutang lain-lain kepada PT Errita Pharma (“Errita”) Other receivable to PT Errita Pharma (“Errita”)
merupakan tagihan atas barang yang diretur sesuai represents receivable for returns of merchandise
kesepakatan bersama. Piutang tersebut akan inventories in accordance with the mutual agreement.
dibayarkan secara angsuran oleh Errita sampai tahun This receivable will be paid in installments by Errita
2029. until 2029.
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 347
Page 348
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/69 Exhibit E/69
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
27. SALDO DAN TRANSAKSI DENGAN PIHAK-PIHAK 27. BALANCE AND TRANSACTIONS WITH RELATED
BERELASI (Lanjutan) PARTIES (Continued)
Dalam kegiatan usaha normal, Perusahaan melakukan In the normal course of business, the Company
transaksi dengan pihak-pihak berelasi. Rincian saldo entered into transactions with related parties. The
dan transaksi dengan pihak-pihak berelasi adalah details of balances and transactions with related
sebagai berikut: parties are as follows:
2025 2024
Pembelian persediaan (Catatan 21) Purchases of inventories (Note 21)
PT Danpac Pharma 34.559.028.980 51.901.765.722 PT Danpac Pharma
PT Errita Pharma 9.764.952.382 3.968.357.146 PT Errita Pharma
Jumlah 44.323.981.362 55.870.122.868 Total
Persentase terhadap jumlah pembelian 0,95% 1,68% Percentage to total purchases
Piutang lain-lain Other receivables
Aset lancar Current asset
PT Errita Pharma 5.280.793.152 4.849.036.337 PT Errita Pharma
Aset tidak lancar Non-current asset
PT Errita Pharma 11.100.000.000 14.400.000.000 PT Errita Pharma
Jumlah 16.380.793.152 19.249.036.337 Total
Persentase terhadap jumlah aset 0,84% 1,09% Percentage to total assets
Utang usaha (Catatan 12) Trade payables (Note 12)
PT Danpac Pharma 5.860.014.025 9.211.162.935 PT Danpac Pharma
Utang lain-lain Other Payables
Pharmaniaga Logistics Sdn. Bhd 34.684.714.943 26.317.374.657 Pharmaniaga Logistics Sdn. Bhd
Pharmaniaga Berhad 28.587.217.826 18.229.768.227 Pharmaniaga Berhad
Pharmaniaga Marketing Sdn. Bhd 6.898.408.079 6.020.673.440 Pharmaniaga Marketing Sdn. Bhd
Pharmaniaga International Pharmaniaga International
Corporation Sdn. Bhd 5.240.624.215 4.573.821.477 Corporation Sdn. Bhd
Pristine Pharma Sdn. Bhd 619.321.831 540.521.271 Pristine Pharma Sdn. Bhd
PT Danpac Pharma 68.331.705 277.682.386 PT Danpac Pharma
Jumlah 76.098.618.599 55.959.841.458 Total
Persentase terhadap jumlah liabilitas 4,63% 3,76% Percentage to total liabilities
Kompensasi kepada Dewan Komisaris dan Direksi Compensation to the Board of Commissioners and
Directors
2025 2024
Imbalan kerja jangka pendek Short-term employee benefits
Dewan Komisaris 2.248.193.763 2.152.104.793 Board of Commissioners
Dewan Direksi 5.086.525.704 4.815.607.251 Board of Directors
Jumlah 7.334.719.467 6.967.712.044 Total
Persentase terhadap jumlah beban gaji, Percentage to total salaries, wages,
upah dan tunjangan karyawan 6,10% 7,95% and allowance expenses
Tidak ada kompensasi dalam bentuk imbalan kerja There are no compensation for other long-term
jangka Panjang, pesangon pemutusan kontrak kerja benefit, termination benefits and share-based
dan pembayaran berbasis saham kepada personel payment to key management of the Company.
manajemen kunci Perusahaan.
348 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 349
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/70 Exhibit E/70
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
28. PERJANJIAN PENTING 28. SIGNIFICANT AGREEMENT
a. Perjanjian Distribusi a. Distribution Agreements
Saat ini, Perusahaan telah melakukan perjanjian Currently, the Company has entered into
distribusi dengan PT Meiji Indonesia, distribution agreements with PT Meiji Indonesia,
PT Meprofarm, PT Guardian Pharmatama, PT Lapi PT Meprofarm, PT Guardian Pharmatama, PT Lapi
Laboratories Indonesia, PT Dipa Pharmalab Laboratories Indonesia, PT Dipa Pharmalab
Intersains, PT Gracia Pharmindo, PT Danpac Intersains, PT Gracia Pharmindo, PT Danpac
Pharma, PT Sarua Subur, PT Puspa Pharma, Pharma, PT Sarua Subur, PT Puspa Pharma,
PT Promedrahardjo Farmasi Industri, PT Simex PT Promedrahardjo Farmasi Industri, PT Simex
Pharmaceutical Indonesia, PT Nutrindo Graha Pharmaceutical Indonesia, PT Nutrindo Graha
Husada, PT Metiska Farma, PT Teguhsindo Husada, PT Metiska Farma, PT Teguhsindo
Lestaritama, PT Nulab Pharmaceutical Indonesia, Lestaritama, PT Nulab Pharmaceutical Indonesia,
PT Steril Medical Indonesia, PT Errita Pharma, PT Steril Medical Indonesia, PT Errita Pharma,
PT Medi Hop, PT Global Dispomedika, PT Global PT Medi Hop, PT Global Dispomedika, PT Global
Succes Chain, PT Nutrisains, PT Nutrifood Succes Chain, PT Nutrisains, PT Nutrifood
Indonesia, PT Meniti Jalan Surga, PT Dua Lima Indonesia, PT Sarua Subur, PT Starnegy, PT Meniti
Industries, PT Dion Pharma Abadi, PT Rama Jalan Surga, PT Dua Lima Industries, PT Dion
Emerald Multi Sukses, PT Pesona Bintang Utama, Pharma Abadi, PT Rama Emerald Multi Sukses,
PT Marketama Indah, PT Herbatama Indo Perkasa, PT Pesona Bintang Utama, PT Marketama Indah,
PT Bromo Pharmautical Industries, dan PT Herbatama Indo Perkasa, PT Bromo
PT Kino Indonesia, yang bergerak di bidang Pharmautical Industries, and PT Kino Indonesia,
produksi obat resep, obat non-resep dan alat which are engaged in the production of
kesehatan, untuk mendistribusikan dan menjual prescription medicine, non-prescription medicine
produk perusahaan-perusahaan tersebut sesuai and medical devices, to distribute and sell the
dengan syarat dan kondisi yang ditetapkan dalam products of such companies, in accordance with
perjanjian. Jangka waktu perjanjian berkisar terms and conditions as determined in the
antara 1 (satu) sampai 5 (lima) tahun dan dapat agreement. ranging between 1 (one) to 5 (five)
diperpanjang. years and can be extended.
b. Perjanjian Lisensi b. License Agreement
Perjanjian lisensi Oracle Fusion dilakukan oleh Oracle Fusion license agreement entered into by
Pharmaniaga Berhad dengan Oracle Corporation Pharmaniaga Berhad with Oracle Corporation
Malaysia Sdn. Bhd. Pembayaran beban lisensi Malaysia Sdn. Bhd. Payment of the license fee is
dilakukan oleh Pharmaniaga Berhad yang made by Pharmaniaga Berhad which is then billed
kemudian ditagihkan ke Perusahaan melalui Debit to the Company via a Debit Note.
Note.
Beban lisensi untuk tahun yang berakhir pada The license fees for the years ended
tanggal 31 Desember 2025 dan 2024 adalah 31 December 2025 and 2024 amounted to
sebesar Rp 11.091.434.491 dan Rp 6.836.921.835 Rp 11,091,434,491 and Rp 6,836,921,835 and are
dan disajikan sebagai “Beban Umum dan presented as “General and Administrative
Administrasi – Beban Kantor” pada laporan laba Expenses - Office Expenses” in the statements of
rugi dan penghasilan komprehensif lain profit or loss and other comprehensive income
(Catatan 23). (Note 23).
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 349
Page 350
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/71 Exhibit E/71
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
29. ASET DAN LIABILITAS MONETER DALAM MATA UANG 29. MONETARY ASSET AND LIABILITIES DENOMINATED IN
ASING FOREIGN CURRENCIES
Pada tanggal 31 Desember 2025 dan 2024, Perusahaan As of 31 December 2025 and 2024, the Company had
mempunyai aset dan liabilitas moneter dalam mata uang monetary asset and liabilities denominated in foreign
asing sebagai berikut: currencies as follows:
2025 2024
Mata uang asing/ Setara IDR/ Mata uang asing/ Setara IDR/
Foreign currency Equivalent IDR Foreign currency Equivalent IDR
Aset moneter Monetary assets
Bank USD 2.790 46.828.996 1.680 27.155.393 Cash in banks
Jumlah aset moneter 46.828.996 27.155.393 Total monetary assets
Liabilitas moneter
Utang lain-lain MYR 18.348.339 76.030.286.894 15.396.783 55.682.159.072 Other payables
Jumlah liabilitas Total monetary
moneter 76.030.286.894 55.682.159.072 liabilities
Liabilitas moneter Net monetary liabilities
dalam mata uang in foreign
asing - bersih 75.983.457.898 55.655.003.679 currencies
30. NILAI WAJAR INSTRUMEN KEUANGAN 30. FAIR VALUE OF FINANCIAL INSTRUMENTS
PSAK 113, “Pengukuran Nilai Wajar”, mensyaratkan PSAK 113, “Fair value measurement” requires disclosure
pengungkapan atas pengukuran nilai wajar dengan tingkat of fair value measurements by level of the following fair
hirarki nilai wajar sebagai berikut: value measurement hierarchy:
• Tingkat 1: harga kuotasian (tidak disesuaikan) dalam • Level 1: quoted prices (unadjusted) in active markets
pasar aktif untuk aset atau liabilitas yang identik; for identical assets or liabilities;
• Tingkat 2: input selain harga kuotasian yang • Level 2: inputs other than quoted prices included
termasuk dalam tingkat 1 yang dapat diobservasi within level 1 that are observable for the asset or
untuk aset atau liabilitas, baik secara langsung liability, either directly (as prices) or indirectly
(misalnya harga) atau secara tidak langsung (derived except from prices); and
(diperoleh selain dari harga); dan
• Tingkat 3: input untuk aset atau liabilitas yang bukan • Level 3: inputs for the asset or liability that are not
berdasarkan data pasar yang dapat diobservasi (input based on observable market data (unobservable
yang tidak dapat diobservasi). inputs).
Berikut ini adalah metode dan asumsi yang digunakan The following are the methods and assumptions used to
untuk memperkirakan nilai wajar setiap kelompok dari estimate the fair value of each class of the Group’s
instrumen keuangan Grup: financial instruments:
1. Kas dan bank, piutang usaha, piutang lain-lain, utang 1. Cash and banks, trade receivables, other
usaha, utang lain-lain, beban akrual dan liabilitas receivables, trade payables, other payables, accrued
imbalan kerja jangka pendek mendekati nilai expenses and short-term employee benefits liability
tercatatnya karena bersifat jangka pendek. approximate their carrying values due to their short-
term nature.
2. Nilai wajar penyertaan dalam bentuk saham yang 2. The fair values of investment in shares of stock
merupakan efek yang tidak diperdagangkan di bursa which not traded in stock exchange (unlisted
dihitung dari arus kas yang didiskontokan dengan securities) were calculated based on cash flows
menggunakan suku bunga pasar dan premi risiko yang discounted using a rate based on the market interest
spesifik atas efek yang tidak diperdagangkan rate and the risk premium specific to the unlisted
tersebut. securities.
3. Nilai wajar aset tidak lancar lainnya - setoran 3. The fair value of other non-current assets -security
jaminan diasumsikan sama dengan nilai terutangnya deposits are assumed to be the same as their original
karena tidak mempunyai persyaratan pembayaran principal amounts because they have no fixed
yang pasti walaupun tidak diharapkan untuk repayment terms although they are not expected to
dikembalikan dalam jangka waktu 12 (dua belas) be settled within 12 (twelve) months after the
bulan setelah tahun pelaporan. reporting year.
350 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 351
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/72 Exhibit E/72
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
30. NILAI WAJAR INSTRUMEN KEUANGAN (Lanjutan) 30. FAIR VALUE OF FINANCIAL INSTRUMENTS (Continued)
Berikut ini adalah metode dan asumsi yang digunakan The following are the methods and assumptions used to
untuk memperkirakan nilai wajar setiap kelompok dari estimate the fair value of each class of the Group’s
instrumen keuangan Grup: (Lanjutan) financial instruments: (Continued)
4. Nilai tercatat dari utang bank dan utang lainlain dari 4. The carrying values of bank loans and other payable
pihak berelasi mendekati nilai wajarnya disebabkan from a related party approximate its fair value due
oleh pemakaian suku bunga mengambang atas to the floating rate interests on these instruments
instrumen tersebut, dimana tingkat bunga tersebut which are subject to adjustments by the banks and
selalu disesuaikan dengan pasar oleh bank dan pihak respective related party.
berelasi.
5. Nilai wajar liabilitas sewa jangka panjang diestimasi 5. The fair value of long-term lease liabilities are
berdasarkan nilai diskonto dari arus kas masa datang estimated based on discounted value of future cash
yang disesuaikan untuk mencerminkan risiko kredit flows that are adjusted to reflect the Company’s
Perusahaan. own credit risk.
Tabel berikut menyajikan nilai wajar, yang mendekati The following tables set forth the fair values, which
nilai tercatat, atas aset keuangan dan liabilitas keuangan approximate their carrying amounts, of financial assets
Perusahaan pada tanggal 31 Desember 2025 dan 2024: and financial liabilities of the Company as of
31 December 2025 and 2024:
2025 2024
Aset keuangan Financial assets
Aset Keuangan Lancar Current Financial Assets
Kas dan bank 62.842.729.716 53.472.920.923 Cash and banks
Piutang usaha 812.001.501.268 731.939.823.034 Trade receivables
Piutang lain-lain 21.740.714.761 9.653.662.766 Other receivables
Jumlah Aset Keuangan Lancar 896.584.945.745 795.066.406.723 Total Current Financial Assets
Aset Keuangan Tidak Lancar Non-Current Financial Assets
Penyertaan dalam bentuk saham 18.586.000.000 22.508.000.000 Investment in shares of stock
Aset tidak lancar lainnya - Other non-current assets -
Piutang lain-lain 11.100.000.000 14.400.000.000 Other receivable
Setoran jaminan 294.124.416 279.124.416 Security deposits
Jumlah Aset Keuangan Tidak Lancar 29.980.124.416 37.187.124.416 Total Non-Current Financial Assets
Jumlah Aset Keuangan 926.565.070.161 832.253.531.139 Total Financial Assets
Liabilitas keuangan Financial liabilities
Liabilitas Keuangan Jangka Pendek Current Financial Liabilities
Utang bank 749.562.430.208 798.202.277.720 Bank loans
Utang usaha 694.449.060.212 527.589.746.673 Trade payables
Utang lain-lain 80.249.432.896 59.897.471.577 Other payables
Beban akrual 19.083.982.341 18.365.850.154 Accrued expenses
Liabilitas imbalan kerja jangka
pendek 5.402.258.913 4.238.362.326 Short-term employee benefits
Hire purchase 458.700.899 - Hire purchase
Bagian liabilitas jangka panjang
yang akan jatuh tempo Long-term liabilities due
dalam satu tahun: within one year:
Utang bank 6.424.407.576 5.008.888.896 Bank loan
Jumlah Liabilitas Keuangan Jangka
Pendek 1.555.630.273.045 1.413.302.597.346 Total Current Financial Liabilities
Liabilitas Keuangan Jangka Panjang Non-Current Financial Liabilities
Hire purchase 59.963.200 - Hire purchase
Liabilitas jangka panjang setelah
bagian yang jatuh tempo dalam Long-term liabilities due after
satu tahun: one year:
Utang bank 53.296.039.526 43.311.111.104 Bank loan
Jumlah Liabilitas Keuangan Jangka
Panjang 53.356.002.726 43.311.111.104 Total Non-Current Financial Liabilities
Jumlah Liabilitas Keuangan 1.608.986.275.771 1.456.613.708.450 Total Financial Liabilities
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 351
Page 352
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/73 Exhibit E/73
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
31. TUJUAN DAN KEBIJAKAN MANAJEMEN RISIKO 31. FINANCIAL RISK MANAGEMENT OBJECTIVES AND
KEUANGAN POLICIES
Manajemen Risiko Risk Management
Risiko utama yang timbul dari instrumen keuangan The main risks arising from the Company’s financial
Perusahaan adalah risiko kredit, risiko tingkat suku instruments are credit risk, interest rate risk and
bunga dan risiko likuiditas. Kepentingan untuk liquidity risk. The importance of managing these risks
mengelola risiko ini telah meningkat secara signifikan has significantly increased in light of the considerable
dengan mempertimbangkan perubahan dan volatilitas change and volatility in both Indonesian and
pasar keuangan baik di Indonesia maupun international financial markets. The Company’s Board
internasional. Direksi Perusahaan menelaah dan of Directors reviews and approves the policies for
menyetujui kebijakan untuk mengelola risiko-risiko managing these risks which are summarized below.
yang dirangkum di bawah ini.
a. Risiko kredit a. Credit risk
Risiko kredit adalah risiko jika pihak debitur tidak Credit risk is the risk that the counterparty will
memenuhi liabilitasnya yang menyebabkan not meet its obligations leading to a financial
kerugian keuangan. Risiko kredit yang dihadapi loss. The Company is exposed to credit risk arising
Perusahaan berasal dari kredit yang diberikan from the credit granted to its customers and
kepada pelanggan dan penempatan dana di placement in the bank’s current account. The
rekening koran bank. Perusahaan melakukan Company trades only with recognized and
hubungan usaha hanya dengan pihak ketiga yang creditworthy third parties. It is the Company’s
diakui dan kredibel. Perusahaan memiliki policy that all customers who wish to trade on
kebijakan untuk semua pelanggan yang akan credit terms are subject to credit verification
melakukan perdagangan secara kredit harus procedures.
melalui prosedur verifikasi kredit.
Sebagai tambahan, saldo piutang usaha dipantau In addition, trade receivables balances are
secara terus menerus untuk mengurangi risiko monitored on an ongoing basis to reduce the
piutang yang tidak tertagih. Nilai maksimal exposure to bad debts. The maximum exposure to
eksposur terhadap risiko kredit adalah sebesar credit risk is represented by the carrying amount
nilai tercatat piutang usaha sebagaimana of trade receivables as shown in Note 5. There is
diungkapkan pada Catatan 5. Tidak terdapat no concentration of credit risk as the Company has
konsentrasi risiko kredit karena Perusahaan a large number of customer without any
memiliki banyak pelanggan tanpa adanya significant individual customers.
pelanggan individu yang signifikan.
Sehubungan dengan risiko kredit yang timbul dari With respect to credit risk arising from the other
aset keuangan lainnya yang mencakup saldo kas di financial assets, which comprise cash in banks,
bank, risiko kredit yang dihadapi timbul karena the Company’s exposure to credit risk arises from
wanprestasi dari pihak terkait. Perusahaan default of the counterparty. The Company
mengelola risiko kredit yang terkait dengan manages credit risk exposures from its deposits
simpanan di bank dengan memonitor reputasi dan with bank by monitoring reputation and credit
peringkat kredit. Nilai maksimal eksposur ratings. The maximum exposure to this risk is
terhadap risiko ini adalah sebesar nilai tercatat equal to the carrying amounts of the above-
dari aset keuangan sebagaimana diungkapkan mentioned financial assets disclosed in Note 4.
pada Catatan 4.
Manajemen yakin terhadap kemampuan untuk Management is confident in its ability to continue
mengendalikan dan menjaga eksposur risiko kredit to control and sustain minimal exposure of credit
pada tingkat yang minimal. risk.
352 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 353
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/74 Exhibit E/74
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
31. TUJUAN DAN KEBIJAKAN MANAJEMEN RISIKO 31. FINANCIAL RISK MANAGEMENT OBJECTIVES AND
KEUANGAN (Lanjutan) POLICIES (Continued)
Manajemen Risiko (Lanjutan) Risk Management (Continued)
a. Risiko kredit (Lanjutan) a. Credit risk (Continued)
Tabel berikut menunjukkan eksposur maksimum The following table sets out the maximum exposure
risiko kredit yang disajikan sejumlah nilai buku aset of credit risk is presented by the carrying amount of
keuangan dikurangi cadangan kerugian penurunan the financial assets less any allowance for
nilai pada tanggal laporan posisi keuangan: impairment losses as of the date of statement of
financial position:
2025 2024
Bank 62.606.626.819 53.244.345.689 Cash in banks
Piutang usaha 812.001.501.268 731.939.823.034 Trade receivables
Piutang lain-lain 21.740.714.761 9.653.662.766 Other receivables
Jumlah 896.348.842.848 794.837.831.489 Total
Tabel di bawah ini menunjukkan analisa umur aset The tables below present the aging analysis of
keuangan Perusahaan pada tanggal 31 Desember 2025 the Company’s financial assets as of and
dan 2024: 31 December 2025 and 2024:
2025
Telah jatuh Telah jatuh
Lancar dan tidak tempo namun tempo dan/
mengalami tidak mengalami atau mengalami
penurunan nilai/ penurunan penurunan
Neither past nilai/ Past nilai/ Past
due not due but not due and/but Jumlah/
impaired impaired impaired Total
Bank 62.606.626.819 - - 62.606.626.819 Cash in banks
Piutang usaha 619.014.825.458 192.986.675.810 26.488.926.436 838.490.427.704 Trade receivables
Piutang lain-lain 21.740.714.761 - - 21.740.714.761 Other receivables
Jumlah 703.362.167.038 192.986.675.810 26.488.926.436 922.837.769.284 Total
Dikurangi: Less:
Cadangan kerugian Allowance for
penurunan nilai - - ( 26.488.926.436 ) ( 26.488.926.436 ) impairment losses
Neto 703.362.167.038 192.986.675.810 - 896.348.842.848 Net
2024
Telah jatuh Telah jatuh
Lancar dan tidak tempo namun tempo dan/
mengalami tidak mengalami atau mengalami
penurunan nilai/ penurunan penurunan
Neither past nilai/ Past nilai/ Past
due not due but not due and/but Jumlah/
impaired impaired impaired Total
Bank 53.244.345.689 - - 53.244.345.689 Cash in banks
Piutang usaha 561.126.367.894 170.813.455.140 23.467.434.136 755.407.257.170 Trade receivables
Piutang lain-lain 9.653.662.766 - - 9.653.662.766 Other receivables
Jumlah 624.024.376.349 170.813.455.140 23.467.434.136 818.305.265.625 Total
Dikurangi: Less:
Cadangan kerugian Allowance for
penurunan nilai - - ( 23.467.434.136 ) ( 23.467.434.136 ) impairment losses
Neto 624.024.376.349 170.813.455.140 - 794.837.831.489 Net
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 353
Page 354
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/75 Exhibit E/75
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
31. TUJUAN DAN KEBIJAKAN MANAJEMEN RISIKO 31. FINANCIAL RISK MANAGEMENT OBJECTIVES AND
KEUANGAN (Lanjutan) POLICIES (Continued)
Manajemen Risiko (Lanjutan) Risk Management (Continued)
b. Risiko tingkat suku bunga b. Interest rate risk
Risiko tingkat suku bunga adalah risiko dimana nilai Interest rate risk is the risk that the fair value or
wajar atau arus kas masa depan dari suatu instrumen future cash flows of a financial instrument will
keuangan akan berfluktuasi akibat perubahan suku fluctuate because of changes in market interest
bunga pasar. Eksposur Perusahaan terhadap risiko rates. The Company is exposed to the risk of changes
perubahan suku bunga pasar terutama terkait dengan in market interest rates relating primarily to its
utang bank jangka pendek dan utang lain-lain dari short-term bank loans and other payable from a
pihak berelasi. Fluktuasi suku bunga mempengaruhi related party. Interest rate fluctuations influence
biaya atas pinjaman baru dan bunga atas saldo utang the cost of new loans and the interest on the
Perusahaan yang dikenakan suku bunga outstanding variable rate loans of the Company.
mengambang.
Saat ini, Perusahaan tidak mempunyai kebijakan Currently, the Company does not have a formal
lindung nilai formal atas risiko suku bunga. Untuk hedging policy for interest rate exposures. For
pinjaman bank dan utang lain-lain dari pihak bank loans and other payable from a related party,
berelasi, Perusahaan berusaha mengurangi risiko the Company may seek to mitigate the interest rate
tingkat suku bunga dengan cara mendapatkan risk by obtaining loans structured with competitive
struktur pinjaman dengan suku bunga kompetitif. interest rate.
Tabel berikut ini menunjukkan sensitivitas The following table demonstrates the sensitivity to
kemungkinan perubahan tingkat suku bunga utang a reasonably possible change in interest rates on that
bank dan utang lain-lain dari pihak berelasi. Dengan portion of bank loans and other payable from a
asumsi variabel lain konstan, laba sebelum pajak related party. With all other variables held constant,
penghasilan dipengaruhi oleh tingkat suku bunga the income before income tax is affected through
mengambang sebagai berikut: the impact on floating rate loan as follows:
2025
Dampak terhadap
Kenaikan/penurunan laba sebelum
dalam satuan poin/ pajak penghasilan/
Increase/decrease in Effect on profit
basis point before income tax
Rupiah Indonesia +100 10.430.670.704 Rupiah Indonesia
Rupiah Indonesia -100 ( 10.430.670.704 ) Rupiah Indonesia
c. Risiko nilai tukar mata uang asing c. Foreign currency exchange rate risk
Mata uang pelaporan Perusahaan adalah Rupiah The Company’s reporting currency is Indonesian
Indonesia. Perusahaan menghadapi risiko nilai tukar Rupiah. The Company faces foreign exchange risk
mata uang asing terutama dari utang lain-lain dari mainly from other payable from a related party
pihak berelasi dalam mata uang Ringgit Malaysia. which denominated in Malaysian RInggit.
Perusahaan mengelola risiko nilai tukar mata uang The Company manages the risk of foreign exchange
asing dengan melakukan pengawasan terhadap rates by monitoring the fluctuations in foreign
fluktuasi nilai tukar mata uang asing secara terus exchange rate continuously so as to perform
menerus sehingga dapat melakukan tindakan yang appropriate actions to reduce the risk of foreign
tepat untuk mengurangi risiko nilai tukar mata uang currency exchange rates.
asing.
Jumlah aset dan liabilitas moneter Perusahaan dalam The company monetary asset and liabilities
mata uang asing pada tanggal 31 Desember 2025 dan denominated in foreign currencies as of
2024 disajikan pada Catatan 29. 31 December 2025 dan 2024 are presented in
Note 29.
354 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 355
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/76 Exhibit E/76
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
31. TUJUAN DAN KEBIJAKAN MANAJEMEN RISIKO 31. FINANCIAL RISK MANAGEMENT OBJECTIVES AND
KEUANGAN (Lanjutan) POLICIES (Continued)
Manajemen Risiko (Lanjutan) Risk Management (Continued)
d. Risiko likuiditas d. Liquidity risk
Dalam mengelola risiko likuiditas, Perusahaan In the management of liquidity risk, the Company
memantau dan menjaga tingkat kas dan bank yang monitors and maintains a level of cash and banks
dianggap memadai untuk membiayai operasi deemed adequate to finance the Company’s
Perusahaan dan untuk mengatasi dampak dari operations and to mitigate the effects of fluctuation
fluktuasi arus kas. Perusahaan juga secara rutin in cash flows. The Company also regularly evaluates
mengevaluasi proyeksi arus kas dan arus kas aktual, the projected and actual cash flows, including its
termasuk jadwal jatuh tempo utang bank dan utang bank loans and trade payables maturity profiles, and
usaha, dan terus menelaah kondisi pasar keuangan continuously assesses conditions in the financial
untuk memelihara fleksibilitas pendanaan dengan markets to maintain flexibility in funding by
cara menjaga ketersediaan komitmen fasilitas kredit. availability of credit facilities.
Tabel di bawah ini menggambarkan profil jatuh The table below summarizes the maturity profile of
tempo atas liabilitas keuangan Perusahaan the Company’s financial liabilities based on
berdasarkan pembayaran kontraktual yang tidak contractual undiscounted payments:
didiskontokan:
2025
Tidak
memiliki tanggal
jatuh tempo/ Lebih dari
No contractual Dalam 1 tahun/ 1 tahun/ More Jumlah/
maturity Within 1 year than 1 year Total
Utang bank - 755.986.837.784 53.296.039.526 809.282.877.310 Bank loans
Utang usaha - 694.449.060.212
- - 694.449.060.212 Trade payables
Beban akrual - 19.083.982.341 - 19.083.982.341 Accrued expenses
Liabilitas imbalan Employee benefit
kerja - 5.402.258.913 36.089.872.387 41.492.131.300 liability
Hire purchase - 458.700.899 59.963.200 518.664.099 Hire purchase
Utang lain-lain - 80.249.432.974 - 80.249.432.974 Other payables
Jumlah - 1.554.854.754.436 90.221.393.699 1.645.076.148.236 Total
2024
Tidak
memiliki tanggal
jatuh tempo/ Lebih dari
No contractual Dalam 1 tahun/ 1 tahun/ More Jumlah/
maturity Within 1 year than 1 year Total
Utang bank - 803.291.166.616 43.311.111.104 846.522.277.720 Bank loans
Utang usaha - 527.589.746.673
- - 527.589.746.673 Trade payables
Beban akrual - 18.365.850.154 - 18.365.850.154 Accrued expenses
Liabilitas imbalan Employee benefit
kerja - 4.238.362.326 - 4.238.362.326 liability
Hire purchase - - - - Hire purchase
Utang lain-lain - 59.897.471.577 - 59.897.471.577 Other payables
Jumlah - 1.413.382.597.346 43.311.111.104 1.456.693.708.450 Total
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 355
Page 356
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/77 Exhibit E/77
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
31. TUJUAN DAN KEBIJAKAN MANAJEMEN RISIKO 31. FINANCIAL RISK MANAGEMENT OBJECTIVES AND
KEUANGAN (Lanjutan) POLICIES (Continued)
Manajemen Modal Capital Management
Tujuan utama pengelolaan modal Perusahaan adalah The primary objective of the Company’s capital
untuk memastikan pemeliharaan rasio modal yang sehat management is to ensure that it maintains healthy
untuk mendukung usaha dan memaksimalkan imbalan bagi capital ratios in order to support its business and
pemegang saham. maximize shareholder value.
Selain itu, Perusahaan dipersyaratkan oleh Undang- In addition, the Company is also required by the
Undang Perseroan Terbatas efektif tanggal 16 Agustus Corporate Law effective on 16 August 2007 to contribute
2007 untuk mengkontribusikan sampai dengan 20% dari and to maintain a non-distributable reserve fund until
modal saham ditempatkan dan disetor penuh ke dalam the said reserve reaches 20% of the issued and fully paid
dana cadangan yang tidak boleh didistribusikan. share capital. These externally imposed capital
Persyaratan permodalan eksternal tersebut requirements are considered by the Company at the
dipertimbangkan oleh Perusahaan pada Rapat Umum Annual Shareholders’ General Meeting.
Pemegang Saham.
Perusahaan mengelola struktur permodalan dan The Company manages its capital structure and makes
melakukan penyesuaian terhadap perubahan kondisi adjustments to it, in light of changes in economic
ekonomi. Untuk memelihara dan menyesuaikan struktur conditions. To maintain or adjust the capital structure,
permodalan, Perusahaan dapat menyesuaikan the Company may adjust the dividend payment to
pembayaran dividen kepada pemegang saham atau shareholders or issue new shares. No changes were made
menerbitkan saham baru. Tidak ada perubahan atas in the objectives, policies or processes for managing
tujuan, kebijakan maupun proses pada 31 Desember 2025 capital in 31 December 2025 and 2024.
dan 2024.
Kebijakan Perusahaan adalah mempertahankan struktur The Company’s policy is to maintain a healthy capital
permodalan yang sehat untuk mengamankan akses structure in order to secure access to finance at a
terhadap pendanaan pada biaya yang wajar. reasonable cost.
32. PENGUNGKAPAN PENGARUH PAJAK TERKAIT SETIAP 32. DISCLOSURE OF TAX EFFECT RELATED TO OTHER
KOMPONEN PENGHASILAN KOMPREHENSIF LAIN COMPREHENSIVE INCOME
2025
Cadangan nilai wajar
Surplus revaluasi melalui penghasilan
asset tetap/ Surplus komprehensif lain/
on revaluation Fair value through
property and other comprehensive
equipment income
Pos-pos yang tidak akan Items that will not be reclassified
direklasifikasi ke laba rugi: to profit or loss:
Saldo awal tahun 4.202.572.171 ( 24.563.760.000 ) Beginning balance
Perubahan nilai wajar investasi - ( 3.922.000.000 ) Change fair value in investment
Pajak-pajak terkait pos-pos yang
tidak akan direklasifikasi Tax relating to items that not
ke dalam laporan laba be reclassified to profit or
rugi: (Catatan 13e) loss: (Note 13e)
Perubahan nilai wajar investasi - 862.840.000 Change fair value in investment
Saldo akhir 4.202.572.171 ( 27.622.920.000 ) Ending balance
356 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 357
Positioned for
Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/78 Exhibit E/78
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
32. PENGUNGKAPAN PENGARUH PAJAK TERKAIT SETIAP 32. DISCLOSURE OF TAX EFFECT RELATED TO OTHER
KOMPONEN PENGHASILAN KOMPREHENSIF LAIN COMPREHENSIVE INCOME (Continued)
(Lanjutan)
2024
Cadangan nilai wajar
Surplus revaluasi melalui penghasilan
asset tetap/ Surplus komprehensif lain/
on revaluation Fair value through
property and other comprehensive
equipment income
Pos-pos yang tidak akan Items that will not be reclassified
direklasifikasi ke laba rugi: to profit or loss:
Saldo awal tahun 4.202.572.171 ( 16.146.000.000 ) Beginning balance
Perubahan nilai wajar investasi - ( 10.792.000.000 ) Change fair value in investment
Pajak-pajak terkait pos-pos yang
tidak akan direklasifikasi Tax relating to items that not
ke dalam laporan laba be reclassified to profit or
rugi: (Catatan 13e) loss: (Note 13e)
Perubahan nilai wajar investasi - 2.374.240.000 Change fair value in investment
Saldo akhir 4.202.572.171 ( 24.563.760.000 ) Ending balance
33. INFORMASI ARUS KAS 33. CASH FLOW INFORMATION
Rekonsiliasi liabilitas yang timbul dari aktivitas Reconciliation of liabiliies arising from funding
pendanaan adalah sebagai berikut: activities are as follows:
Pergerakan non-kas/
Non-cash changes
Pergerakan
Pergerakan beban transaksi
valuta asing/ dan lain-lain/
Movement Changes in
1 Januari/ Arus kas/ in foreign transaction 31 Desember/
January 2025 Cash flows exchange cost and other December 2025
Utang bank 846.522.277.720 ( 37.239.400.410 ) - - 809.282.877.310 Bank loans
Utang pihak berelasi 55.959.841.458 11.028.844.907 9.109.932.234 - 76.098.618.599 Related parties payable
Jumlah liabilitas dari Total liabilities from
aktivitas pendanaan 902.482.119.178 ( 33.939.400.410 ) 9.109.932.234 - 885.381.495.909 financing activities
Pergerakan non-kas/
Non-cash changes
Pergerakan
Pergerakan beban transaksi
valuta asing/ dan lain-lain/
Movement Changes in
1 Januari/ Arus kas/ in foreign transaction 31 Desember/
January 2024 Cash flows exchange cost and other December 2024
Utang bank 709.059.430.510 137.462.847.210 - - 846.522.277.720 Bank loans
Utang pihak berelasi 47.556.701.887 7.346.684.426 1.056.455.145 - 55.959.841.458 Related parties payable
Liabilitas sewa 1.276.549.764 - - ( 1.276.549.764) - Lease liabilities
Jumlah liabilitas dari Total liabilities from
aktivitas pendanaan 757.892.682.161 144.809.531.636 1.056.455.145 ( 1.276.549.764 ) 902.482.119.178 financing activities
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 357
Page 358
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Consolidated Financial Statements are Originally
Issued in Indonesian Language
Ekshibit E/79 Exhibit E/79
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
DAN ENTITAS ANAK AND ITS SUBSIDIARY
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
34. PERISTIWA SETELAH PERIODE PELAPORAN 34. EVENTS AFTER REPORTING PERIOD
a. Perubahan dewan komisaris dan dewan direksi a. Changes the board of director and the board of
commissioners
Pada tanggal 14 Januari 2026, Perusahaan On 14 January 2026, the Company’s Articles of
mengalami perubahan anggaran dasar melalui Association were amended based on Notarial Deed
Akta Notaris No. 32 yang dibuat dihadapan No. 32 of Dini Lastari Siburian, S.H., M.Kn.,
Dini Lastari Siburian S.H., mengenai perubahan regarding changes the board of commissioners and
dewan komisaris dan direksi Perusahaan. the board of directors. The changes in
Perubahan direksi dan dewan komisaris composition of the Company’s Board of Directors
Perusahaan sebagai berikut: and Board of Commissioners were as follows:
Dewan Komisaris Board of Commissioners
Komisaris Utama : Joefly Joesoef Bahroeny* : President Commissioner
Komisaris : Zulkifli bin Jafar : Commissioner
Komisaris Independen : Sarah Azreen binti Abdul Samat : Independent Commissioner
Komisaris Independen : Prof. Aman Bhakti Pulungan : Independent Commissioner
Dewan Direksi Board of Directors
Direktur Utama : Dr. Imam Fathorrahman MM. : President Director
Direktur : Mohamad Fazly bin Hassan : Director
*) Merangkap Komisaris Independent/ Concurrently Independent Commissioner
b. Perjanjian signifikan b. Significant agreement
Pada tanggal 28 Januari 2026, Perusahaan, On 28 January 2026, the Company, PT Errita
PT Errita Pharma dan UOB telah menandatangani Pharma, and UOB signed an amendment and
perubahan dan penegasan Kembali terhadap restatement to the credit agreement
perjanjian kredit No. 038/01/2026 dan Perubahan No. 038/01/2026, as well as amendment VI to the
VI terhadap perjanjian fasilitas valuta asing foreign exchange facility agreement
No. 039/01/2026. Dalam surat tersebut, No. 039/01/2026. In the letter, the Company and
Perusahaan dan Bank menyetujui perubahan the Bank agreed to amend certain terms and
syarat dan ketentuan tertentu dari Perjanjian conditions of the Credit Agreement. The credit
Kredit. Fasilitas tersebut berlaku hingga tanggal facilities are valid until 29 January 2027.
29 Januari 2027.
35. INFORMASI LAPORAN KEUANGAN TERSENDIRI GRUP 35. FINANCIAL INFORMATION OF THE PARENT COMPANY
ONLY
Laporan keuangan tersendiri entitas induk merupakan The separate financial statements of the parent entity
informasi tambahan dalam laporan keuangan is presented as supplementary information to the
konsolidasian Grup, yang terdiri dari laporan posisi consolidated financial statements of the Group, that
keuangan, laporan laba rugi komprehensif, laporan consist of statement of financial position, statement
perubahan ekuitas dan laporan arus kas. of comprehensive income, statement of changes in
equity and statement of cash flows.
Laporan keuangan tersendiri entitas induk disajikan Financial statement of the parent Company was
dari lampiran 1 sampai dengan 5. presented on appendix 1 up to 5.
358 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 359
Positioned for
Profitable Growth
These Separate Financial Statements are Originally
Issued in Indonesian Language
Lampiran 1 Appendix 1
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
LAPORAN POSISI KEUANGAN TERSENDIRI SEPARATE STATEMENT OF FINANCIAL POSITION
ENTITAS INDUK 31 DESEMBER 2025 PARENT ENTITY 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
31 Desember/ 31 Desember/
Catatan/ December December
Notes 2025 2024
ASET ASSETS
Aset Lancar Current Assets
Kas dan bank 4 62.629.337.008 52.510.869.200 Cash and banks
Piutang usaha – pihak ketiga 5 812.001.501.268 731.939.823.033 Trade receivables-third parties
Piutang lain-lain Other receivables
Pihak ketiga 16.397.889.139 4.796.969.133 Third parties
Pihak berelasi 27 11.977.518.682 7.860.072.996 Related party
Persediaan 6 609.058.870.983 567.672.272.118 Inventories
Pajak dibayar di muka 13a 206.003.444.423 193.132.912.605 Prepaid taxes
Biaya dibayar di muka 4.085.372.130 5.301.218.978 Prepaid expenses
Uang muka 3.129.197.001 2.561.293.991 Advance payment
Jumlah Aset Lancar 1.725.283.130.634 1.565.775.432.054 Total Current Assets
Aset Tidak Lancar Non-Current Assets
Piutang lain–lain - pihak berelasi 27 11.100.000.000 14.400.000.000 Other receivables - related party
Penyertaan dalam bentuk saham 7 22.683.500.000 26.605.500.000 Investment in shares of stock
Aset tetap 8 109.071.832.783 80.865.592.258 Property and equipment
Aset takberwujud 9 6.139.832.461 6.778.621.041 Intangible assets
Aset hak-guna 10 29.364.479.627 30.366.569.090 Right–of–use assets
Taksiran tagihan restitusi pajak Estimated claims for income
penghasilan 13b 34.326.073.242 31.112.017.785 tax refund
Aset pajak tangguhan 13e 27.353.988.319 17.055.771.330 Deferred tax assets
Aset tidak lancar lainnya 4.888.420.362 3.791.217.059 Other non-current assets
Jumlah Aset Tidak Lancar 244.928.126.794 210.975.288.563 Total Non-Current Assets
JUMLAH ASET 1.970.211.257.428 1.776.750.720.617 TOTAL ASSETS
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 359
Page 360
Laporan Keuangan Positioned for
Financial Report Profitable Growth
These Separate Financial Statements are Originally
Issued in Indonesian Language
Lampiran 2 Appendix 2
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
LAPORAN POSISI KEUANGAN TERSENDIRI SEPARATE STATEMENT OF FINANCIAL POSITION
ENTITAS INDUK 31 DESEMBER 2025 PARENT ENTITY 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
31 Desember/ 31 Desember/
Catatan/ December December
Notes 2025 2024
LIABILITAS DAN EKUITAS LIABILITIES AND EQUITY
Liabilitas Jangka Pendek Current Liabilities
Utang bank 11 749.562.430.208 798.202.277.720 Bank loans
Utang usaha Trade payables
Pihak ketiga 12 688.589.046.187 518.378.583.738 Third parties
Pihak berelasi 12,27 5.860.014.025 9.211.162.935 Related party
Utang lain-lain Other payables
Pihak ketiga 4.105.721.522 3.736.676.396 Third parties
Pihak berelasi 27 76.098.618.599 55.959.841.458 Related party
Utang pajak 13c 240.043.615 117.449.513 Tax payables
Beban akrual 14 18.964.691.223 18.351.700.154 Accrued expenses
Liabilitas imbalan kerja jangka pendek 15 5.402.258.913 4.238.362.326 Short-term employee benefit liability
Bagian liabilitas jangka panjang yang Long-term liabilities due
akan jatuh tempo dalam satu tahun: within one year:
Utang bank 11 6.424.407.576 5.008.888.896 Bank loan
Hire purchase 458.700.899 - Hire purchase
Jumlah Liabilitas Jangka Pendek 1.555.705.932.767 1.413.194.943.136 Total Current Liabilities
Liabilitas Jangka Panjang Non-Current Liabilities
Liabilitas jangka panjang
setelah dikurangi bagian yang jatuh Long-term liabilities net
tempo dalam waktu satu tahun: of current maturities:
Utang bank 11 53.296.039.526 43.311.111.104 Bank loans
Liabilitas imbalan kerja jangka panjang 16 36.089.872.387 32.455.241.173 Long-term employee benefit liability
Hire purchase 59.963.200 - Hire purchase
Jumlah Liabilitas Jangka Panjang 89.445.875.113 75.766.352.277 Total Non-Current Liabilities
JUMLAH LIABILITAS 1.645.151.807.880 1.488.961.295.413 TOTAL LIABILITIES
EKUITAS EQUITY
Ekuitas yang diatribusikan Equity attributable
kepada pemilik entitas induk to the owners of the parent
Modal saham – nilai nominal Share capital – of par value
Rp 100 per saham Rp 100 per share
Modal dasar – Authorized capital –
2.184.000.000 saham 2,184,000,000 shares
Modal Ditempatkan dan disetor Issued and fully-paid-up capital -
penuh – 1.274.000.000 saham 17 127.400.000.000 127.400.000.000 1,274,000,000 shares
Tambahan modal disetor 18 2.309.683.922 2.309.683.922 Additional paid-in capital
Surplus revaluasi 32 4.202.572.171 4.202.572.171 Revaluation surplus
Perubahan nilai wajar investasi 32 ( 27.622.920.000 ) ( 24.563.760.000 ) Change fair value in investment
Saldo laba Retained earnings
Telah ditentukan penggunaannya 14.332.500.000 11.784.500.000 Appropriated
Belum ditentukan penggunaannya 204.437.613.455 166.656.429.1117 Unappropriated
JUMLAH EKUITAS 325.059.449.548 287.789.425.204 TOTAL EQUITY
JUMLAH LIABILITAS DAN EKUITAS 1.970.211.257.428 1.776.750.720.617 TOTAL LIABILITIES AND EQUITY
360 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 361
Positioned for
Profitable Growth
These Separate Financial Statements are Originally
Issued in Indonesian Language
Lampiran 3 Appendix 3
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
LAPORAN LABA RUGI DAN PENGHASILAN SEPARATE STATEMENT OF PROFIT OR LOSS AND OTHER
KOMPREHENSIF LAIN TERSENDIRI ENTITAS INDUK COMPREHENSIVE INCOME PARENT ENTITY
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
Catatan/
Notes 2025 2024
PENDAPATAN 20 4.109.427.837.346 3.916.716.296.752 REVENUES
BEBAN POKOK PENDAPATAN 21 ( 3.747.413.814.473 ) ( 3.582.445.251.953 ) COST OF REVENUES
LABA KOTOR 362.014.022.873 334.271.044.799 GROSS PROFIT
BEBAN USAHA OPERATING EXPENSES
Beban penjualan 22 ( 65.396.665.038 ) ( 65.409.833.326 ) Selling expenses
Beban umum dan administrasi 23 ( 164.760.633.044 ) ( 156.018.334.861 ) General and administrative expenses
Pendapatan operasi lain 1.223.171.786 3.709.860.811 Other operating income
Beban operasi lain ( 15.179.157.985 ) ( 15.456.691.400 ) Other operating expenses
Jumlah Beban Usaha ( 244.113.284.281 ) ( 233.174.998.776 ) Total Operating Expenses
LABA USAHA 117.900.738.592 101.096.046.023 OPERATING PROFIT
Pendapatan keuangan 290.090.283 59.006.191 Finance income
Beban keuangan 24 ( 64.930.209.553 ) ( 68.791.412.181 ) Finance expenses
Beban Keuangan - Bersih ( 64.640.119.270 ) ( 68.732.405.990 ) Finance Expenses – Net
LABA SEBELUM PAJAK PROFIT BEFORE INCOME
PENGHASILAN 53.260.619.322 32.363.640.033 TAX
PAJAK PENGHASILAN INCOME TAX
Kini 13d ( 19.879.370.569 ) ( 8.743.488.816 ) Current
Tangguhan 13d,e 9.448.699.865 ( 2.043.681.651 ) Deferred
Beban Pajak Penghasilan ( 10.430.670.704 ) ( 10.787.170.467 ) Income Tax Expenses
LABA TAHUN BERJALAN 42.829.948.618 21.576.469.566 PROFIT FOR THE YEAR
PENGHASILAN KOMPREHENSIF LAIN OTHER COMPREHENSIVE INCOME
Pos-pos yang tidak akan Items that will not be reclassified
direklasifikasi ke laba rugi: to profit or loss:
Perubahan nilai wajar investasi 7 ( 3.922.000.000 ) ( 10.792.000.000 ) Change fair value in investment
Pengukuran kembali imbalan Remeasurement of employee
kerja 15 60.558.602 ( 676.717.542 ) benefits
Pajak penghasilan yang terkait Tax relating to items that
pos-pos yang tidak akan will not be reclassified
direklasifikasi ke laba rugi: to profit or loss:
Perubahan nilai wajar investasi 13e 862.840.000 2.374.240.000 Change fair value in investment
Pengukuran kembali imbalan 13e Remeasurement of employee
kerja ( 13.322.876 ) 148.877.863 benefits
Kerugian komprehensif lain Other comprehensive loss
tahun berjalan ( 3.011.924.274 ) ( 8.945.599.679 ) for the year
JUMLAH LABA KOMPREHENSIF TOTAL COMPREHENSIVE INCOME
TAHUN BERJALAN 39.818.024.344 12.630.869.887 FOR THE YEAR
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 361
Page 362
362
These Separate Financial Statements are Originally
Issued in Indonesian Language
Lampiran 4 Appendix 4
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk AND ITS SUBSIDIARY
LAPORAN PERUBAHAN EKUITAS TERSENDIRI ENTITAS INDUK SEPARATE STATEMENT OF CHANGES IN EQUITY PARENT ENTITY
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
Tambahan Perubahan
modal nilai wajar Saldo Laba/ Retained Earnings
disetor/ Surplus Investasi/ Telah Belum
Additional Revaluasi/ Change ditentukan ditentukan
PT Millennium Pharmacon International Tbk
Catatan/ Modal saham/ paid-in Revaluation fair value penggunaannya/ penggunaannya/ Jumlah Ekuitas/
Notes Share capital capital Surplus in investment Appropriated Unappropriated Total Equity
Balance at
Saldo 1 Januari 2024 127.400.000.000 2.309.683.922 4.202.572.171 ( 16.146.000.000 ) 8.599.500.000 151.977.799.224 278.343.555.317 1 January 2024
Financial Report
Deklarasi dividen 19 - - - - - ( 3.185.000.000 ) ( 3.185.000.000 ) Declaration of dividen
Laporan Keuangan
Pencadangan saldo Appropriation of
laba 19 - - - - 3.185.000.000 ( 3.185.000.000 ) - retained earnings
Penghasilan komprehensif Other comprehensive
lain tahun berjalan - - - ( 8.417.760.000 ) - 21.048.629.887 12.630.869.887 income for the year
Balance at
Saldo 31 Desember 2024 127.400.000.000 2.309.683.922 4.202.572.171 ( 24.563.760.000 ) 11.784.500.000 166.656.429.111 287.789.425.204 31 December 2024
Deklarasi dividen 19 - - - - - ( 2.548.000.000 ) ( 2.548.000.000 ) Declaration of dividen
Pencadangan saldo Appropriation of
laba 19 - - - - 2.548.000.000 ( 2.548.000.000 ) - retained earnings
Penghasilan komprehensif Other comprehensive
lain tahun berjalan - - - ( 3.059.160.000 ) - 42.877.184.344 39.818.024.344 income for the year
Balance at
Saldo 31 Desember 2025 127.400.000.000 2.309.683.922 4.202.572.171 ( 27.622.920.000 ) 14.332.500.000 204.437.613.455 325.059.449.548 31 December 2025
Catatan 17/ Catatan 18/ Catatan 32/ Catatan 32/
Note 17 Note 18 Note 32 Note 32
Laporan Tahunan & Laporan Keberlanjutan
2025
Profitable Growth
Positioned for
Page 363
Positioned for
Profitable Growth
These Separate Financial Statements are Originally
Issued in Indonesian Language
Lampiran 5 Appendix 5
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk PT MILLENNIUM PHARMACON INTERNATIONAL Tbk
LAPORAN ARUS KAS TERSENDIRI ENTITAS INDUK SEPARATE STATEMENT OF CASH FLOWS PARENT ENTITY
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
Catatan/
Notes 2025 2024
ARUS KAS DARI AKTIVITAS CASH FLOWS FROM
OPERASI OPERATING ACTIVITES
Penerimaan kas dari pelanggan 4.026.344.666.811 3.839.192.991.438 Cash received from customers
Pembayaran kepada pemasok dan
karyawan ( 3.848.873.316.560 ) ( 3.877.367.221.708 ) Payment to suppliers and employees
Pembayaran pajak penghasilan 13 ( 23.093.426.024 ) ( 21.164.130.031 ) Income tax payments
Penerimaan bunga 290.090.283 42.384.245 Interest received
Pembayaran biaya keuangan ( 74.129.529.191 ) ( 65.635.249.547 ) Interest payments
Arus kas neto yang diperoleh dari Net cash flows provided by (used for)
(digunakan untuk) aktivitas operasi 80.538.485.319 ( 124.931.225.603 ) operating activities
ARUS KAS DARI AKTIVITAS CASH FLOWS FROM
INVESTASI INVESTING ACTIVITIES
Proceed from the sale of property
Penerimaan dari penjualan aset tetap 8 221.984.781 237.909.911 and equipment
Acquisition of property
Perolehan aset tetap 8 ( 37.746.333.988 ) ( 14.158.567.273 ) and equipment
Perolehan aset hak-guna ( 11.339.633.332 ) - Acquisition of right-of-use assets
Perolehan aset lain-lain ( 1.097.203.288 ) - Acquisition of other assets
Arus kas neto yang digunakan untuk Net cash flows used for
aktivitas investasi ( 49.961.185.827 ) ( 13.920.657.362 ) investing activities
ARUS KAS DARI AKTIVITAS CASH FLOWS FROM
PENDANAAN FINANCING ACTIVITIES
Penerimaan utang bank 11 2.397.602.895.454 2.682.459.318.856 Cash received from bank loans
Penerimaan dari pihak berelasi 19.321.331.455 5.884.072.457 Received from related parties
Pembayaran utang bank 11 ( 2.434.842.295.865 ) ( 2.544.996.471.646 ) Payments of bank loans
Pembayaran liabilitas sewa - ( 7.679.694.443 ) Payments of lease liabilities
Pembayaran dividen ( 2.540.762.728 ) ( 3.185.000.000 ) Payment of dividend
Arus kas neto yang (digunakan untuk) Net cash flows (used for) provided by
diperoleh dari aktivitas pendanaan ( 20.458.831.683 ) 132.482.225.224 financing activities
KENAIKAN (PENURUNAN) BERSIH KAS NET INCREASE (DECREASE) IN CASH
DAN BANK 10.118.467.808 ( 6.369.657.741 ) AND BANKS
KAS DAN BANK PADA AWAL CASH AND BANKS AT
TAHUN 4 52.510.869.200 58.880.526.941 BEGINNING OF THE YEAR
KAS DAN BANK PADA AKHIR CASH AND BANKS AT
TAHUN 4 62.629.337.008 52.510.869.200 END OF THE YEAR
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 363
Page 364
Laporan Keuangan Positioned for
Financial Report Profitable Growth
364 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Page 365
Positioned for
Profitable Growth
Halaman ini sengaja dikosongkan
This page is intentionally left blank
PT Millennium Pharmacon International Tbk 2025 Annual Report & Sustainability Report 365
Page 366
Laporan Keuangan Positioned for
Financial Report Profitable Growth
Laporan Tahunan & Laporan Keberlanjutan
2025 Annual Report & Sustainability Report
Positioned
for Profitable
Growth
PT Millennium Pharmacon International Tbk
Kantor Pusat
Crown Bungur Arteri Lantai 2-4
Jl. Sultan Iskandar Muda No 18/Jl. Bungur No. 1
Kel. Kebayoran Lama Selatan, Kec. Kebayoran Lama
Jakarta Selatan 12240
Telp : (62-21) 2708-5961, 64, 65, 66
Fax : (62-21) 2708-5958
www.mpi-indonesia.co.id
366 PT Millennium Pharmacon International Tbk Laporan Tahunan & Laporan Keberlanjutan 2025
Names mentioned 189 people and organisations named in the text · linked when the evidence is strong
unresolved
org
PT Millennium Pharmacon
p.3 ×7
unresolved
org
Millennium International Tbk
p.3 ×2
unresolved
org
Pharmacon International Tbk
p.3 ×2
unresolved
org
Financial Services Authority
p.3 ×5
unresolved
org
PT Millennium
p.3 ×2
unresolved
org
Kantor Akuntan Publik
p.6
unresolved
—
Authority Regulation No. 51/POJK.03/2017 Regarding
· Akuntan Publik
p.7
unresolved
org
POM RI CDOB
p.18
unresolved
org
POM RI CDAKB
p.18
unresolved
org
Departemen Risk Management
p.28
unresolved
person
Dr. Imam
· Anggota
p.29 ×4
unresolved
person
Fathorrahman
· Independent Commissioner
p.29 ×3
unresolved
person
Sarah Azreen binti Abdul Samat
· Independent Commissioner
p.30 ×15
unresolved
org
PT DPAI
p.41 ×4
unresolved
person
Ahmad bin Abu Bakar
p.44 ×10
unresolved
person
Mohamad Fazly bin Hassan Susunan
p.44
unresolved
person
Mohamad Fazly bin Hassan PENERAPAN ASPEK
p.44 ×3
unresolved
person
Minarsih
p.53
unresolved
person
Minarsih Soedarpo Soedarpo Sastrosatomo Wiranatakusumah
p.53 ×3
unresolved
org
N.V. N.V.
p.53
unresolved
org
Menteri Kehakiman Republik Indonesia
p.53 ×2
unresolved
person
Raharti Sudjardjati
· Notaris
p.53
unresolved
person
Sudjardjati
p.53
unresolved
org
Minister of Justice
p.53
unresolved
org
PT NVPD Soedarpo Corporation.
p.53 ×5
unresolved
org
PT NVPD Soedarpo Corporation. Langkah
p.53
unresolved
org
Indonesia Stock Exchange
p.53 ×2
unresolved
org
Soedarpo Corporation Tbk.
p.53 ×5
unresolved
org
Pharmaniaga International Corporation Sdn. Bhd.
p.53 ×3
unresolved
org
Corporation Sdn. Bhd.
p.53 ×4
unresolved
org
PT Errita Pharma.
p.54 ×6
unresolved
org
PT Errita Pharma. Innovation
p.54
unresolved
org
PT Digital Pharma Andalan Indonesia
p.54 ×7
unresolved
org
PT Digital Pharma Andalan Indonesia OLIN
p.54
unresolved
org
PT MEIJI
p.59
unresolved
org
PT DIPA PHARMA
p.59
unresolved
org
PT MENITI
p.59
unresolved
org
PT DUALIMA INDUSTRIES
p.59
unresolved
org
PT MEPROFARM
p.59
unresolved
org
PT EFES DERMACOS INDONESIA
p.59
unresolved
org
PT METISKA FARMA
p.59
unresolved
org
PT NULAB PHARMACEUTICAL INDONESIA
p.59
unresolved
org
PT GLOBAL DISPOMEDIKA
p.59
unresolved
org
PT NUTRIFOOD INDONESIA
p.59
unresolved
org
PT NUTRINDO
p.59
unresolved
org
PT GRACIA PH.
p.59
unresolved
org
PT PHAROS IND.
p.59
unresolved
org
PT GUARDIAN PH.
p.59
unresolved
org
PT PROMED
p.59
unresolved
org
PT KEMENANGAN VITA FARMA
p.59
unresolved
org
PT RAMA EMERALD MULTI SUKSES
p.59
unresolved
org
PT KINOCARE
p.59
unresolved
org
PT SIMEX
p.59
unresolved
org
PT LAPI LABORATORIES
p.59
unresolved
org
PT STERIL MEDICAL INDONESIA
p.59
unresolved
org
PT LAPI OTC
p.59
unresolved
org
PT TEGUHSINDO LESTARITAMA
p.59
unresolved
org
PT MARKETAMA INDAH
p.59
unresolved
org
PT BINTANG KENCANA ANUGERAH
p.59
unresolved
org
PT MEDI HOP
p.59
unresolved
org
Pharmaniaga International Corporation International Corporation Sdn. Bhd.
p.60
unresolved
org
PT Digital Pharma
p.60
unresolved
org
PT Linsea Selatan
p.64
unresolved
org
PT Citra
p.65
unresolved
person
Dr. Soejono
p.65
unresolved
person
Ir. Sutami
p.65
unresolved
person
Committee
· President Director
p.69 ×2
unresolved
person
Jafar
p.70
unresolved
person
Prof. Aman Bhakti Pulungan, MD, Paed Consultant., PhD.,
· Komisaris Independen
p.70 ×22
unresolved
—
FAAP., FRCPI (Hon.)
· Independent Commissioner
p.70 ×2
unresolved
—
Reappointed
· President Commissioner
p.71 ×4
unresolved
org
PT Satya Agung
p.71 ×2
unresolved
org
PT Sisirau
p.71 ×3
unresolved
org
PT Teumaron
p.71
unresolved
org
PT P Bahrun
p.71
unresolved
org
PT Bahruny
· President Commissioner and
p.71 ×2
unresolved
org
PT BAPCO
p.71
unresolved
org
PT Perkebunan Nusantara (Persero)
p.71
unresolved
org
PT Perkebunan Nusantara III (Persero)
p.71
unresolved
org
MPI Tbk
p.71 ×38
unresolved
org
PT Bapco Menjabat
· Komisaris
p.71
unresolved
org
PT Satya Agung Utama
p.71
unresolved
org
PT Pbahrun
p.71
unresolved
org
PT Teumaron Served
p.71
unresolved
org
Holdings Sdn Bhd
p.72
unresolved
org
Pharma Manufacturing Sdn Bhd
p.72
unresolved
org
Aladdin Group Sdn Bhd
p.72
unresolved
org
Era Universe Development Sdn Bhd
p.72
unresolved
org
Songa Offshore Malaysia Sdn Bhd
p.72
unresolved
org
MMA Resources Sdn Bhd
p.72
unresolved
org
Legal Counsel Aces Sdn Bhd
p.72
unresolved
—
Rangkap Jabatan Served
· Commissioner
p.72
unresolved
org
PT Digital Pharma Anda Ian Indonesia
p.72
unresolved
org
MMA Resource Sdn Bhd
p.72
unresolved
org
Marsland Development Sdn Bhd
p.72
unresolved
org
Era Universe Sdn Bhd
p.72
unresolved
person
Profitable Growth Dr. Imam Fathorrahman
p.73 ×3
unresolved
org
Independent Non-Executive Director Pharmaniaga Sdn Bhd
p.73 ×4
unresolved
org
PT Digital Pharma Andalan Indonesia Indonesian
p.73
unresolved
org
MPI Tbk Jakarta Hubungan Afiliasi Affiliation Menjabat
· Komisaris
p.73
unresolved
person
Aman B. Pulungan
p.74
unresolved
org
Kementerian Kesehatan Indonesia
p.74
unresolved
—
Served
· Commissioner
p.74 ×4
unresolved
org
Capital Advisers Sdn Bhd
p.75 ×2
unresolved
org
Bank Berhad
p.75 ×3
unresolved
org
KPMG Corporate Services Sdn Bhd
p.75
unresolved
org
Committee PT MPI Tbk Menjabat
· Komisaris
p.75
unresolved
—
setelah tahun buku 2025 hingga
· General Meeting of Shareholders on January 14, 2026. The
p.76 ×3
unresolved
—
ini diterbitkan pada April 2026:
· following is the composition of the Board of Directors after
p.76
unresolved
person
Position Direktur Utama Dr. Imam Fathorrahman
p.76 ×42
unresolved
org
Pharmaniaga Logistics Sdn Bhd
p.77 ×2
unresolved
org
Mico Pharmacy Sdn Bhd
p.77
unresolved
org
SMP Pharmaceuticals Sdn Bhd
p.77
unresolved
org
PT Errita Pharma Kewarganegaraan
p.77 ×2
unresolved
org
PT Errita Pharma Malaysian Hubungan Afiliasi Domisili
p.77
unresolved
org
PT MPI Tbk Menjabat
· Direktur Utama
p.78
unresolved
—
Affiliation Served
· President Director
p.78
unresolved
org
PT Proton Edar Indonesia
p.79
unresolved
org
PT Digital Pharma Andalan Indonesia Kewarganegaraan
p.79
unresolved
person
Operational General Manager
· Direktur
p.82
unresolved
person
Sekertaris
· Direktur Utama
p.83
unresolved
person
Mustafa
· Presiden Direktur
p.83
unresolved
org
Risk Management Sr. Manager
· Corporate Secretary
p.83
unresolved
org
PT Danpac Pharma Corporation Sdn Bhd
p.88
unresolved
org
PT Ngrumat
p.88
unresolved
org
Menteri Keuangan RI No. SI-
p.91
unresolved
org
Minister of Finance
p.91
unresolved
org
Bapepam
p.91 ×8
unresolved
org
Kantor Akuntan Publik Public Accountant
p.94
unresolved
org
TANUBRATA SUTANTO FAHMI BAMBANG & REKAN
· Kantor Akuntan Publik
p.94 ×3
unresolved
org
BDO International Limited
p.94 ×2
unresolved
org
Mahkamah Agung
p.95
unresolved
org
PT RAYA SAHAM REGISTRA Name
p.95
unresolved
org
PT Kustodian Sentral Efek Indonesia
p.95
unresolved
org
PT Kustodian Sentral Efek Indonesia Name
p.95
unresolved
—
Service Rendered
p.95
unresolved
org
Bank Indonesia
p.100 ×2
unresolved
org
Kementerian Perindustrian
p.101
unresolved
org
Ministry of Industry
p.101
unresolved
org
Kantor Akuntan Publik Tanubrata
p.105
unresolved
org
Public Sutanto Fahmi Bambang & Rekan
p.105
unresolved
org
PT Danpac Pharma Shareholders
p.118
unresolved
—
Entitas Sepengendali
p.118 ×2
unresolved
—
Entity under comon control
p.118 ×2
unresolved
org
PT Errita Pharma Entity
p.118
unresolved
org
Pharmaniaga Berhad Sdn. Bhd.
p.118
unresolved
org
PT Mega Pharmaniaga
p.118
unresolved
org
Pristine Pharma Sdn. Bhd.
p.118
unresolved
org
Pharmaniaga Marketing Sdn. Bhd
p.119
unresolved
—
baik perorangan maupun institusi,
p.132
unresolved
—
Undang-Undang Perseroan Terbatas dan Anggaran
p.132
unresolved
—
Dasar Perseroan. Hak-hak Pemegang Saham terutama
p.132
unresolved
—
sebagai organ tertinggi Perseroan, dengan kewenangan
p.132
unresolved
—
Selaras dengan prinsip kesetaraan, Perseroan menerapkan
p.132
unresolved
—
struktur kepemilikan saham secara transparan, termasuk
p.132
unresolved
—
dan/atau pengendali (apabila
p.132
unresolved
person
Dini Lastari Siburian
p.135 ×2
unresolved
person
H. Notary
p.135
unresolved
org
PT Raya Saham Registra Attendance
p.135
unresolved
org
PT Raya Saham Registra Parties Kantor Akuntan Publik
p.135
unresolved
org
Tanubrata Sutanto Fahmi Bambang & Partners
p.135
unresolved
person
PIAGAM
· KOMISARIS
p.138
unresolved
person
Consultant, PhD, FAAP,
· Independent Commissioner
p.140
unresolved
person
PROGRAM ORIENTASI
· KOMISARIS
p.142
unresolved
person
Independensi
· Komisaris
p.144
unresolved
person
Tabel Pernyataan Independensi
· Komisaris Independen
p.145
unresolved
person
Dr. Imam Pernyataan Independensi Joesoef
p.145
unresolved
org
Financial Services Authority Regulation
· Komisaris
p.146
Extraction attempts how the parser did, and what it refused
Nothing structured was extracted from this document — the attempts below say why.
No extraction attempted yet.